PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Giardiello, FM				Giardiello, FM			Genetic testing in hereditary colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; ADENOMATOUS POLYPOSIS; MUTATIONS; HOMOLOG; LOCUS; CHROMOSOME-5Q21; FAP		JOHNS HOPKINS UNIV HOSP,DEPT ONCOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins Medicine	Giardiello, FM (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT MED,BLALOCK 935,600 N WOLFE ST,BALTIMORE,MD 21218, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; *AM CANC SOC, 1996, AM CANC SOC PUBL; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CHUNG DC, 1995, GASTROENTEROLOGY, V109, P1685, DOI 10.1016/0016-5085(95)90660-6; Codori AM, 1996, ARCH PEDIAT ADOL MED, V150, P1131, DOI 10.1001/archpedi.1996.02170360021003; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; GIARDIELLO FM, 1995, GASTROINTESTINAL CAN; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Koreth J, 1996, J PATHOL, V178, P239, DOI 10.1002/(SICI)1096-9896(199603)178:3<239::AID-PATH506>3.0.CO;2-5; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1994, CANCER RES, V54, P4590; LYNCH HT, 1966, ARCH INTERN MED, V117, P206, DOI 10.1001/archinte.117.2.206; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Petersen G M, 1996, Oncology (Williston Park), V10, P89; Petersen G M, 1995, J Natl Cancer Inst Monogr, P67; PETERSEN GM, 1994, ANN MED, V26, P205, DOI 10.3109/07853899409147891; PETERSEN GM, 1995, SEMIN COLON RECTAL S, V6, P55; PETERSEN GM, 1996, ONCOLOGY, V10, P97; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SPIRIO L, 1992, AM J HUM GENET, V51, P92; VASEN HF, 1991, DIS COLON RECTUM, V34, P434; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	34	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1278	1281		10.1001/jama.278.15.1278	http://dx.doi.org/10.1001/jama.278.15.1278			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333271				2022-12-28	WOS:A1997XZ70900035
J	Lima, CD; Klein, MG; Hendrickson, WA				Lima, CD; Klein, MG; Hendrickson, WA			Structure-based analysis of catalysis and substrate definition in the HIT protein family	SCIENCE			English	Article							X-RAY STRUCTURE; TRANSITION-STATE ANALOG; NEUTRON-DIFFRACTION; CRYSTAL-STRUCTURES; URIDINE VANADATE; IDENTIFICATION; COMPLEX; URIDYLYLTRANSFERASE; PHOSPHOHISTIDINE; DICTYOSTELIUM	The histidine triad (HIT) protein family is among the most ubiquitous and highly conserved in nature, but a biological activity has not yet been identified for any member of the HIT family. Fragile histidine triad protein (FHIT) and protein kinase C interacting protein (PKCI) were used in a structure-based approach to elucidate characteristics of in vivo ligands and reactions. Crystallographic structures of ape, substrate analog, pentacovalent transition-state analog, and product slates of both enzymes reveal a catalytic mechanism and define substrate characteristics required for catalysis, thus unifying the HIT family as nucleotidyl hydrolases, transferases, or both. The approach described here may be useful in identifying structure-function relations between protein families identified through genomics.	HERBERT IRVING CANC CTR, NEW YORK, NY 10032 USA; INST HUMAN NUTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Lima, CD (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOL BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Lima, Christopher/0000-0002-9163-6092	NCI NIH HHS [T32CA09503] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FEINSTEINJAFFE I, 1985, ORGANOMETALLICS, V4, P1189, DOI 10.1021/om00126a009; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; Holm L, 1997, STRUCTURE, V5, P165, DOI 10.1016/S0969-2126(97)00176-7; Holm L, 1997, TRENDS BIOCHEM SCI, V22, P116, DOI 10.1016/S0968-0004(97)01021-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; LIMA CD, 1996, P NATL ACAD SCI USA, V93, P5355; LINDQVIST Y, 1994, EUR J BIOCHEM, V221, P139, DOI 10.1111/j.1432-1033.1994.tb18722.x; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; ROBINSON AK, 1993, BIOCHIM BIOPHYS ACTA, V1161, P139, DOI 10.1016/0167-4838(93)90207-8; ROBINSON K, 1994, BIOCHEM J, V304, P662, DOI 10.1042/bj3040662; ROSE ZB, 1982, METHOD ENZYMOL, V87, P42; SERAPHIN B, 1992, J DNA SEQUENCING MAP, V3, P177; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; THRALL SH, 1983, BIOCHEMISTRY-US, V32, P1803; Tse-Dinh Y.-C., 1980, J BIOL CHEM, V255, P5560; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; WEI YF, 1991, METHOD ENZYMOL, V200, P388; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; WESTBROOK ML, 1996, P IUCR COMPUTING SCH; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n	34	190	197	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					286	290		10.1126/science.278.5336.286	http://dx.doi.org/10.1126/science.278.5336.286			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323207				2022-12-28	WOS:A1997YA56400044
J	Moody, DB; Reinhold, BB; Guy, MR; Beckman, EM; Frederique, DE; Furlong, ST; Ye, S; Reinhold, VN; Sieling, PA; Modlin, RL; Besra, GS; Porcelli, SA				Moody, DB; Reinhold, BB; Guy, MR; Beckman, EM; Frederique, DE; Furlong, ST; Ye, S; Reinhold, VN; Sieling, PA; Modlin, RL; Besra, GS; Porcelli, SA			Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells	SCIENCE			English	Article							MYCOLIC ACIDS; CD1 FAMILY; MYCOBACTERIUM; IDENTIFICATION; RESTRICTS; GENES	The human CD1b protein presents lipid antigens to T cells, but the molecular mechanism is unknown. Identification of mycobacterial glucose monomycolate (GMM) as a CD1b-presented glycolipid allowed determination of the structural requirements for its recognition by T cells. Presentation of GMM to CD1b-restricted T cells was not affected by substantial variations in its lipid tails, but was extremely sensitive to chemical alterations in its carbohydrate or other polar substituents. These findings support the view that the recently demonstrated hydrophobic CD1 groove binds the acyl chains of lipid antigens relatively nonspecifically, thereby positioning the hydrophilic components for highly specific interactions with T cell antigen receptors.	BRIGHAM & WOMENS HOSP,DIV RHEUMATOL IMMUNOL & ALLERGY,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BOSTON UNIV,SCH MED,MASS SPECTROMETRY UNIT,BOSTON,MA 02118; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90033; UNIV CALIF LOS ANGELES,SCH MED,DEPT IMMUNOL & MICROBIOL,LOS ANGELES,CA 90033	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; Colorado State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X; Besra, Gurdyal/0000-0002-5605-0395	NCRR NIH HHS [RR10888] Funding Source: Medline; NIAMS NIH HHS [AR01988] Funding Source: Medline; NIGMS NIH HHS [GM54045] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001988] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12737; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1969, EUR J BIOCHEM, V13, P117; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; DATTA AK, 1991, CARBOHYD RES, V218, P95, DOI 10.1016/0008-6215(91)84089-W; EADS J, 1993, J BIOL CHEM, V268, P26375; KANEDA K, 1988, J GEN MICROBIOL, V134, P2213; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MINNIKIN DE, 1984, ARCH MICROBIOL, V139, P225, DOI 10.1007/BF00402005; NATSUHARA Y, 1990, CANCER IMMUNOL IMMUN, V31, P99, DOI 10.1007/BF01742373; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	20	376	379	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					283	286		10.1126/science.278.5336.283	http://dx.doi.org/10.1126/science.278.5336.283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323206				2022-12-28	WOS:A1997YA56400043
J	Andersen, SSL; Ashford, AJ; Tournebize, R; Gavet, O; Sobel, A; Hyman, AA; Karsenti, E				Andersen, SSL; Ashford, AJ; Tournebize, R; Gavet, O; Sobel, A; Hyman, AA; Karsenti, E			Mitotic chromatin regulates phosphorylation of Stathmin/Op18	NATURE			English	Article							MICROTUBULE DYNAMICS; EGG EXTRACTS; CELL CYCLE; PROTEIN; XENOPUS; CHROMOSOMES; KINASE; ONCOPROTEIN-18; ORGANIZATION; PHOSPHATASE	Meiotic and mitotic spindles are required for the even segregation of duplicated chromosomes to the two daughter cells. The mechanism of spindle assembly is not fully understood, but two have been proposed that are not mutually exclusive(1-3). The 'search and capture' model suggests that dynamic microtubules become progressively captured and stabilized by the kinetochores on chromosomes, leading to spindle assembly(3,4). The 'local stabilization' model proposes that chromosomes change the state of the cytoplasm around them, making it more favourable to microtubule polymerization(2,5-9). It has been shown(10,11) that Stathmin/Op18 inhibits microtubule polymerization in vitro by interaction with tubulin(12), and that overexpression in tissue culture cells of non-phosphorylatable mutants of Stathmin/Op18 prevents the assembly of mitotic spindles(13). We have used Xenopus egg extracts and magnetic chromatin beads(14) to show that mitotic chromatin induces phosphorylation of Stathmin/Op18. We have also shown the Stathmin/Op18 is one of the factors regulated by mitotic chromatin that governs preferential microtubule growth around chromosomes during spindle assembly.	EUROPEAN MOL BIOL LAB,CELL BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY; INSERM,U440,F-75005 PARIS,FRANCE	European Molecular Biology Laboratory (EMBL); Institut National de la Sante et de la Recherche Medicale (Inserm)			Andersen, Søren S. L./O-1915-2017; Tournebize, Regis/K-7847-2018; Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017	Andersen, Søren S. L./0000-0002-3625-1640; Tournebize, Regis/0000-0003-3718-3130; Hyman, Anthony A/0000-0003-3664-154X				ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; Belmont L, 1996, TRENDS BIOCHEM SCI, V21, P197, DOI 10.1016/S0968-0004(96)80013-2; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; CURMI PA, IN PRESS J BIOL CHEM; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FELIX MA, 1994, CELL CYCLE PRACTICAL, P253; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MAREK LF, 1978, CHROMOSOMA, V68, P367, DOI 10.1007/BF00327171; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MASSON D, 1995, J CELL BIOL, V131, P1015, DOI 10.1083/jcb.131.4.1015; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; SAMANTA A, 1995, P NATL ACAD SCI USA, V92, P6582, DOI 10.1073/pnas.92.14.6582; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; TOURNEBIZE R, IN PRESS EMBO J; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Waters JC, 1997, CURR OPIN CELL BIOL, V9, P37, DOI 10.1016/S0955-0674(97)80149-4; ZHANG DH, 1995, J CELL BIOL, V131, P1125, DOI 10.1083/jcb.131.5.1125; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287	30	112	115	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					640	643		10.1038/39382	http://dx.doi.org/10.1038/39382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335509				2022-12-28	WOS:A1997YA00800069
J	Fayers, PM; Hand, DJ				Fayers, PM; Hand, DJ			Generalisation from phase III clinical trials: survival, quality of life, and health economics	LANCET			English	Editorial Material							OF-LIFE; COST-EFFECTIVENESS; CANCER; CHEMOTHERAPY; CARE		OPEN UNIV,DEPT STAT,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND	Open University - UK	Fayers, PM (corresponding author), NORWEGIAN UNIV SCI & TECHNOL,FAC MED,UNIT EPIDEMIOL & CLIN RES,N-7005 TRONDHEIM,NORWAY.		Fayers, Peter M/A-5999-2010	Fayers, Peter/0000-0003-4778-1513				AASS N, 1991, J CLIN ONCOL, V9, P818, DOI 10.1200/JCO.1991.9.5.818; BAILEY KR, 1994, CONTROL CLIN TRIALS, V15, P15, DOI 10.1016/0197-2456(94)90024-8; BENNETT CL, 1995, J CLIN ONCOL, V13, P2457, DOI 10.1200/JCO.1995.13.9.2457; Bouchet C, 1996, J CLIN EPIDEMIOL, V49, P15, DOI 10.1016/0895-4356(95)00540-4; BOYD NF, 1990, MED DECIS MAKING, V10, P58, DOI 10.1177/0272989X9001000109; BRENNES RM, 1995, EUR J CANCER, V31, P1955; Brundage MD, 1997, J CLIN ONCOL, V15, P330, DOI 10.1200/JCO.1997.15.1.330; BUXTON MJ, 1955, MONOGR NCI, V19, P27; CUNNINGHAM WE, 1995, MED CARE, V33, pAS15; DAVIS CE, 1994, CONTROL CLIN TRIALS, V15, P11, DOI 10.1016/0197-2456(94)90023-X; DRUMMOND M, 1995, J RHEUMATOL, V22, P1403; DRUMMOND M, 1995, J RHEUMATOL, V22, P1418; FAYERS P, 1995, LANCET, V346, P445, DOI 10.1016/S0140-6736(95)92818-9; FREUND DA, 1995, MONOGR NCI, V19, P37; Gelber RD, 1996, JNCI-J NATL CANCER I, V88, P1039, DOI 10.1093/jnci/88.15.1039; GULATI SC, 1995, J CLIN ONCOL, V13, P2152, DOI 10.1200/JCO.1995.13.9.2152; HARDING MJ, 1993, LANCET, V341, P999, DOI 10.1016/0140-6736(93)91082-W; HAYS RD, 1996, QUALITY LIFE PHARMAC, P155; Horwitz RI, 1996, J CLIN EPIDEMIOL, V49, P395, DOI 10.1016/0895-4356(95)00058-5; OBRIEN BJ, 1994, MED CARE, V32, P150, DOI 10.1097/00005650-199402000-00006; OCONNOR AM, 1989, J CLIN EPIDEMIOL, V42, P119, DOI 10.1016/0895-4356(89)90085-1; RITTENHOUSE BE, 1996, QUALITY LIFE PHARMAC, P1215; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; RUBINS HB, 1994, CONTROL CLIN TRIALS, V15, P7, DOI 10.1016/0197-2456(94)90022-1; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Sorensen TIA, 1996, LANCET, V348, P351, DOI 10.1016/S0140-6736(05)64988-4; SPIEGELHALTER DJ, 1992, BRIT MED J, V305, P1205, DOI 10.1136/bmj.305.6863.1205; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; STILLER CA, 1989, BRIT MED J, V299, P1058, DOI 10.1136/bmj.299.6707.1058; Torrance GW, 1987, METHODS EC EVALUATIO; WITTES J, 1994, CONTROL CLIN TRIALS, V15, P5, DOI 10.1016/0197-2456(94)90021-3	31	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					1025	1027		10.1016/S0140-6736(97)03053-5	http://dx.doi.org/10.1016/S0140-6736(97)03053-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329528				2022-12-28	WOS:A1997XZ71000047
J	Sears, MR				Sears, MR			Epidemiology of childhood asthma	LANCET			English	Article							HOUSE-DUST MITE; RISK-FACTORS; AIRWAY RESPONSIVENESS; PARENTAL SMOKING; BRONCHIAL RESPONSIVENESS; ALLERGIC SENSITIZATION; RESPIRATORY-DISEASE; PULMONARY-FUNCTION; MATERNAL SMOKING; PASSIVE SMOKING		MCMASTER UNIV,DEPT MED,HAMILTON,ON L8S 4L8,CANADA	McMaster University	Sears, MR (corresponding author), ST JOSEPHS HOSP,ASTHMA RES GRP,HAMILTON,ON L8N 4A6,CANADA.							AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; ANDERSON ML, 1987, AM J ARCHAEOL, V91, P127, DOI 10.2307/505462; ANNESI I, 1995, AM J RESP CRIT CARE, V151, pA468; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barber K, 1996, ANN ALLERG ASTHMA IM, V76, P427, DOI 10.1016/S1081-1206(10)63459-X; BLAIR H, 1979, J ROY SOC MED, V72, P42, DOI 10.1177/014107687907200113; Busquets RM, 1996, EUR RESPIR J, V9, P2094, DOI 10.1183/09031936.96.09102094; Carey OJ, 1996, AM J RESP CRIT CARE, V154, P537, DOI 10.1164/ajrccm.154.2.8756835; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; CRANE J, 1989, NEW ZEAL MED J, V102, P36; GERRITSEN J, 1991, AM REV RESPIR DIS, V143, P1468, DOI 10.1164/ajrccm/143.6.1468; GERRITSEN J, 1990, J ALLERGY CLIN IMMUN, V85, P116, DOI 10.1016/0091-6749(90)90232-S; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GODFREY S, 1985, ARCH DIS CHILD, V60, P997, DOI 10.1136/adc.60.11.997; Goh DYT, 1996, ARCH DIS CHILD, V74, P131, DOI 10.1136/adc.74.2.131; Gustafsson D, 1996, ALLERGY, V51, P789, DOI 10.1111/j.1398-9995.1996.tb00024.x; HALKEN S, 1995, ALLERGY, V50, P97; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Harris JR, 1997, AM J RESP CRIT CARE, V156, P43, DOI 10.1164/ajrccm.156.1.9609094; Hodge L, 1996, MED J AUSTRALIA, V164, P137, DOI 10.5694/j.1326-5377.1996.tb122010.x; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; HOLT PG, 1996, EUR RESPIR J, V9, P85; INFANTERIVARD C, 1995, EPIDEMIOLOGY, V6, P178, DOI 10.1097/00001648-199503000-00016; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; Lai CKW, 1996, CLIN EXP ALLERGY, V26, P5, DOI 10.1111/j.1365-2222.1996.tb00050.x; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156, DOI 10.1164/ajrccm.155.1.9001305; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; MELLIS CM, 1994, J PAEDIATR CHILD H, V30, P387, DOI 10.1111/j.1440-1754.1994.tb00684.x; MURRAY AB, 1990, J ALLERGY CLIN IMMUN, V86, P732, DOI 10.1016/S0091-6749(05)80177-0; NEUSPIEL DR, 1989, AM J PUBLIC HEALTH, V79, P168, DOI 10.2105/AJPH.79.2.168; *NIH, 1995, NATL HEART LUNG BLOO, P6; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Oliveti JF, 1996, AM J EPIDEMIOL, V143, P570; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; PANHUYSEN CIM, 1995, ALLERGY, V50, P863, DOI 10.1111/j.1398-9995.1995.tb02491.x; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RYLANDER E, 1995, EPIDEMIOLOGY, V6, P289, DOI 10.1097/00001648-199505000-00017; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Schaubel D, 1996, J ASTHMA, V33, P255, DOI 10.3109/02770909609055366; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x; SEARS MR, 1994, BRIT MED J, V309, P72, DOI 10.1136/bmj.309.6947.72; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136, DOI 10.1164/ajrccm/145.5.1136; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; STODDARD JJ, 1995, AM J EPIDEMIOL, V141, P96, DOI 10.1093/oxfordjournals.aje.a117418; STRACHAN D, 1996, EUR RESPIR J, V9, P42; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; Ulrik CS, 1996, RESP MED, V90, P623, DOI 10.1016/S0954-6111(96)90021-9; ULRIK CS, 1995, RESP MED, V89, P574; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; vonMutius E, 1996, BRIT MED J, V312, P1448, DOI 10.1136/bmj.312.7044.1448; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Wilkinson J, 1996, THORAX, V51, P3, DOI 10.1136/thx.51.1.3; Woolcock AJ, 1996, MED J AUSTRALIA, V165, P358, DOI 10.5694/j.1326-5377.1996.tb125016.x; Wright AL, 1996, AM J RESP CRIT CARE, V153, P1259, DOI 10.1164/ajrccm.153.4.8616551	75	171	175	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					1015	1020		10.1016/S0140-6736(97)01468-2	http://dx.doi.org/10.1016/S0140-6736(97)01468-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329526				2022-12-28	WOS:A1997XZ71000045
J	Aparicio, OM; Weinstein, DM; Bell, SP				Aparicio, OM; Weinstein, DM; Bell, SP			Components and dynamics of DNA replication complexes in S-cerevisiae: Redistribution of MCM proteins and Cdc45p during S phase	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MINICHROMOSOME MAINTENANCE; CHROMOSOMAL REPLICATION; POLYMERASE-EPSILON; CDC6 PROTEIN; ARS ELEMENTS; XENOPUS; INITIATION	In S. cerevisiae, the chromatin structure of DNA replication origins changes as cells become competent for DNA replication, suggesting that G1 phase-specific association of replication factors with origin DNA regulates entry into S phase. We demonstrate that ORC, Cdc45p, and MCM proteins are components of prereplication complexes (pre-RC). The MOM-origin association is dependent upon ORC and Cdc6p. During S phase, MCM proteins and Cdc45p dissociate from origin DNA and associate with nonorigin DNA with similar kinetics as DNA Polymerase a, which is present at DNA replication forks. Our results identify protein components of the pre-RC and a novel replication complex appearing at the G1/S transition (the RC), and suggest that after initiation MCM proteins and Cdc45p move with eukaryotic replication forks.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)				Bell, Stephen/0000-0002-2876-610X; Aparicio, Oscar/0000-0002-5591-0277	NIGMS NIH HHS [GM52339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1992, DNA REPLICATION, P931; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DUTTA A, 1997, IN PRESS ANN REV CEL, V13; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MAINE GT, 1984, GENETICS, V106, P365; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MOIR D, 1982, GENETICS, V100, P547; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; NEWLON CS, 1991, GENETICS, V129, P343; NEWLON CS, 1991, GENETICS, V130, P235; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Shcherbakova PV, 1996, GENETICS, V142, P717; SIKORSKI RS, 1989, GENETICS, V122, P19; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZHU JG, 1992, MOL CELL BIOL, V12, P4733, DOI 10.1128/MCB.12.10.4733; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	50	624	634	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					59	69		10.1016/S0092-8674(01)80009-X	http://dx.doi.org/10.1016/S0092-8674(01)80009-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335335	Bronze			2022-12-28	WOS:A1997XZ80900009
J	Michaelis, C; Ciosk, R; Nasmyth, K				Michaelis, C; Ciosk, R; Nasmyth, K			Cohesins: Chromosomal proteins that prevent premature separation of sister chromatids	CELL			English	Article							STRAND-BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; DNA-REPLICATION; FISSION YEAST; TOPOISOMERASE-II; BUDDING YEAST; GENE; CONDENSATION; COMPLEX	Cohesion between sister chromatids opposes the splitting force exerted by microtubules, and loss of this cohesion is responsible for the subsequent separation of sister chromatids during anaphase. We describe three chromosmal proteins that prevent premature separation of sister chromatids in yeast. Two, Smc1p and Smc3p, are members of the SMC family, which are putative ATPases with coiled-coil domains. A third protein, which we call Scc1p, binds to chromosomes during S phase, dissociates from them at the metaphase-to-anaphase transition, and is degraded by the anaphase promoting complex. Association of Scc1p with chromatin depends on Smc1p. Proteins homologous to Scclp exist in a variety of eukaryotic organisms including humans. A common cohesion apparatus might be used by all eukaryotic cells during both mitosis and meiosis.	RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Ciosk, Rafal/L-7327-2013	Ciosk, Rafal/0000-0003-2234-6216; Nasmyth, Kim/0000-0001-7030-4403				AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BERENS C, 1992, J BIOL CHEM, V267, P1945; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Callan H.G, 1986, LAMPBRUSH CHROMOSOME; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLLOWAY SL, 1993, CELL, V73, P13093; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; McKay MJ, 1996, GENOMICS, V36, P305, DOI 10.1006/geno.1996.0466; MOLNAR M, 1995, GENETICS, V141, P61; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Rose M, 1990, LAB COURSE MANUAL ME; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V122, P19; SKIBBENS RV, 1993, J CELL BIOL, V80, P674; SPENCER F, 1990, GENETICS, V124, P237; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; YAMADA H, 1994, YEAST, V10, P883, DOI 10.1002/yea.320100704; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	41	1146	1165	2	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					35	45		10.1016/S0092-8674(01)80007-6	http://dx.doi.org/10.1016/S0092-8674(01)80007-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335333	Bronze			2022-12-28	WOS:A1997XZ80900007
J	Varnum, MD; Zagotta, WN				Varnum, MD; Zagotta, WN			Interdomain interactions underlying activation of cyclic nucleotide-gated channels	SCIENCE			English	Article							CATION CHANNEL; FUNCTIONAL EXPRESSION; SUBUNIT INTERACTIONS; MOLECULAR MECHANISM; POTASSIUM CHANNEL; COMPLEMENTARY-DNA; MODULATION; SHAKER; GENE; CALMODULIN	Cyclic nucleotide-gated (CNG) ion channels are multimeric proteins that activate in response to the binding of cyclic nucleotide to intracellular domains. Here, an intramolecular protein-protein interaction between the amino-terminal domain and the carboxylterminal ligand-binding domain of the rat olfactory CNG channel was shown to exert an autoexcitatory effect on channel activation. Calcium-calmodulin, which modulates CNG channel activity during odorant adaptation, blocked this interaction. A specific deletion within the amino-terminal domain disrupted the interdomain interaction in vitro and altered the gating properties and calmodulin sensitivity of expressed channels. Thus, the amino-terminal domain may promote channel opening by directly interacting with the carboxyl-terminal gating machinery; calmodulin regulates channel activity by targeting this interaction.	UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle					NATIONAL EYE INSTITUTE [R01EY010329] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010329, EY 10329] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Finn J. T., 1995, Biophysical Journal, V68, pA253; Fodor AA, 1997, J GEN PHYSIOL, V109, P3, DOI 10.1085/jgp.109.1.3; GORDON SE, 1995, J PHYSIOL-LONDON, V486, P533, DOI 10.1113/jphysiol.1995.sp020832; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; Gordon SE, 1996, BIOCHEMISTRY-US, V35, P3994, DOI 10.1021/bi952607b; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GORDON SE, 1995, NEURON, V14, P177; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; Grunwald M. E., 1997, Biophysical Journal, V72, pA335; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SHEN NV, 1993, NEURON, V11, P67; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; VARNUM MD, UNPUB; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZAGOTT AWN, 1996, ANN REV NEUROSCI, V19, P235; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	35	125	128	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					110	113		10.1126/science.278.5335.110	http://dx.doi.org/10.1126/science.278.5335.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311913				2022-12-28	WOS:A1997XZ12400049
J	Spraggon, G; Everse, SJ; Doolittle, RF				Spraggon, G; Everse, SJ; Doolittle, RF			Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin	NATURE			English	Article							ELECTRON-MICROSCOPY; GAMMA-CHAIN; PLASMINOGEN-ACTIVATOR; POLYMERIZATION; IDENTIFICATION; LOCALIZATION; SITES; REQUIREMENTS; ASSOCIATION; MOLECULES	In blood coagulation, units of the protein fibrinogen pack together to form a fibrin clot, but a crystal structure for fibrinogen is needed to understand how this is achieved. The structure of a cove fragment (fragment D) from human fibrinogen has now been determined to 2.9 Angstrom resolution. The 86K three-chained structure consists of a coiled-coil region and two homologous globular entities oriented at approximately 130 degrees to each other, Additionally, the covalently bound dimer of fragment D, known as 'doubte-D', was isolated from human fibrin, crystallized in the presence of a Gly-Pro-Arg-Pro-amide peptide ligand, which simulates the donor polymerization site, and its structure solved by molecular replacement with the model of fragment D.	UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bailey K, 1943, NATURE, V151, P716, DOI 10.1038/151716a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; COHEN C, 1961, J POLYM SCI, V49, P144; DANG CV, 1985, J BIOL CHEM, V260, P9713; DONAHUE JP, 1994, P NATL ACAD SCI USA, V91, P12178, DOI 10.1073/pnas.91.25.12178; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P1563, DOI 10.1002/pro.5560011204; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1710, DOI 10.1021/bi00627a029; EBERT RF, 1994, 1994 INDEX VARIANT H; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVERSE SJ, 1995, PROTEIN SCI, V4, P1013; FU YP, 1995, GENOMICS, V30, P71, DOI 10.1006/geno.1995.0010; FUREY W, IN PRESS METHODS ENZ; Gerloff DL, 1997, PROTEINS, V27, P279; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUDRYCLERGEON G, 1974, PATHOL BIOL, V22, P47; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, NEWSLETT PROTEIN CRY, V31, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIHALYI E, 1963, BIOCHIM BIOPHYS ACTA, V67, P90; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MOSESSON MW, 1995, J CLIN INVEST, V96, P1053, DOI 10.1172/JCI118091; MOSESSON MW, 1995, J STRUCT BIOL, V115, P88, DOI 10.1006/jsbi.1995.1033; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V748, P86, DOI 10.1016/0167-4838(83)90030-4; Okumura N, 1996, THROMB HAEMOSTASIS, V75, P887; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAN Y, 1992, P NATL ACAD SCI USA, V89, P2066, DOI 10.1073/pnas.89.6.2066; PIZZO SV, 1973, J BIOL CHEM, V248, P4574; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHIELEN WJG, 1991, BIOCHEM J, V276, P655, DOI 10.1042/bj2760655; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1993, J BIOL CHEM, V268, P26618; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	50	371	397	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					455	462		10.1038/38947	http://dx.doi.org/10.1038/38947			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333233				2022-12-28	WOS:A1997XY90900045
J	Chowienczyk, P; Ritter, J				Chowienczyk, P; Ritter, J			Arginine: NO more than a simple aminoacid?	LANCET			English	Editorial Material							NITRIC-OXIDE; HYPERCHOLESTEROLEMIC PATIENTS				Chowienczyk, P (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.			Chowienczyk, Phil/0000-0003-4507-038X				BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; CASINO PR, 1994, J AM COLL CARDIOL, V23, P844, DOI 10.1016/0735-1097(94)90628-9; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; MACALLISTER RJ, 1994, BRIT J PHARMACOL, V112, P43, DOI 10.1111/j.1476-5381.1994.tb13026.x; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510	10	26	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					901	902		10.1016/S0140-6736(05)63263-1	http://dx.doi.org/10.1016/S0140-6736(05)63263-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314865				2022-12-28	WOS:A1997XY67200005
J	Hautamaki, RD; Kobayashi, DK; Senior, RM; Shapiro, SD				Hautamaki, RD; Kobayashi, DK; Senior, RM; Shapiro, SD			Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice	SCIENCE			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; 1ST 2 CENTURIES; FUTURE-RESEARCH; METALLOPROTEINASES; METALLOELASTASE; EXPRESSION; LOCALIZATION; SUGGESTIONS; HAMSTERS; CLONING	To determine which proteinases are responsible for the lung destruction characteristic of pulmonary emphysema, macrophage elastase-deficient (MME-/-) mice were subjected to cigarette smoke. In contrast to wild-type mice, MME-/- mice did not have increased numbers of macrophages in their lungs and did not develop emphysema in response to long-term exposure to cigarette smoke. Smoke-exposed MME-/- mice that received monthly intratracheal instillations of monocyte chemoattractant protein-1 showed accumulation of alveolar macrophages but did not develop air space enlargement. Thus, macrophage elastase is probably sufficient for the development of emphysema that results from chronic inhalation of cigarette smoke.	WASHINGTON UNIV, SCH MED, BAMES JEWISH HOSP, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, BAMES JEWISH HOSP, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)								BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CHAPMAN HA, 1994, AM J RESP CRIT CARE, V150, pS155, DOI 10.1164/ajrccm/150.6_Pt_2.S155; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DUNNILL M. S., 1962, THORAX, V17, P320, DOI 10.1136/thx.17.4.320; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9, DOI 10.1164/ajrccm/140.3_Pt_2.S9; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312; HAUTAMAKI RD, UNPUB; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; MACKENZIE TD, 1994, NEW ENGL J MED, V330, P975, DOI 10.1056/NEJM199404073301406; MERCHANT RK, 1992, AM REV RESPIR DIS, V146, P448, DOI 10.1164/ajrccm/146.2.448; NAGAI A, 1994, AM J RESP CRIT CARE, V150, P1411, DOI 10.1164/ajrccm.150.5.7952569; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1334, DOI 10.1164/ajrccm/146.5_Pt_1.1334; SNIDER GL, 1984, AM REV RESPIR DIS, V129, P155; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1615, DOI 10.1164/ajrccm/146.6.1615; *US CDC, 1996, US NATL CENT HLTH ST, V44, P1; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WRIGHT JL, 1990, AM REV RESPIR DIS, V142, P1422, DOI 10.1164/ajrccm/142.6_Pt_1.1422	29	1101	1158	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					2002	2004		10.1126/science.277.5334.2002	http://dx.doi.org/10.1126/science.277.5334.2002			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302297				2022-12-28	WOS:A1997XX84900047
J	Stark, H; Rodnina, MV; RinkeAppel, J; Brimacombe, R; Wintermeyer, W; vanHeel, M				Stark, H; Rodnina, MV; RinkeAppel, J; Brimacombe, R; Wintermeyer, W; vanHeel, M			Visualization of elongation factor Tu on the Escherichia coli ribosome	NATURE			English	Article							AMINOACYL-TRANSFER-RNA; FACTOR EF-TU; CRYSTAL-STRUCTURE; PROTEIN-SYNTHESIS; TERNARY COMPLEX; GTP HYDROLYSIS; CROSS-LINKING; BINDING; REGION; SITE	The delivery of a specific amino acid to the translating ribosome is fundamental to protein synthesis. The binding of aminoacyl-transfer RNA to the ribosome is catalysed by the elongation factor Tu (EF-Tu). The elongation factor the aminoacyl-tRNA and GTP form a stable 'ternary' complex that binds to the ribosome. We have used electron cryomicroscopy and angular reconstitution(1) to visualize directly the kirromycin-stalled ternary complex in the A site of the 70S ribosome of Escherichia coli. Electron cryomicroscopy had previously given detailed ribosomal structures at 25 and 23 Angstrom (refs 2, 3) resolution, and was used to determine the position of tRNAs on the ribosome(4,5). In particular, the structures' of pre-translocational (tRNAs in A and P sites) and post-translocational ribosomes (P and E sites occupied) were both visualized at a resolution of similar to 20 Angstrom. Our three-dimensional reconstruction at 18 Angstrom resolution shows the ternary complex spanning the inter-subunit space with the acceptor domain of the tRNA reaching into the decoding centre. Domain I (the G domain) of the EF-Tu is bound both to the L7/L12 stalk and to the 50S body underneath the stalk, whereas domain 2 is oriented towards the S12 region on the 30S subunit.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; MAX PLANCK GESELL,FRITZ HABER INST,D-14195 BERLIN,GERMANY; UNIV WITTEN HERDECKE,INST MOL BIOL,D-58448 WITTEN,GERMANY; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY	Imperial College London; Max Planck Society; Fritz Haber Institute of the Max Planck Society; Witten Herdecke University; Max Planck Society			Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Holger, Stark/0000-0002-6161-1118				Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; Dey D, 1995, BIOCHIMIE, V77, P925, DOI 10.1016/0300-9084(95)80003-4; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; MESTERS JR, 1994, EMBO J, V13, P4877, DOI 10.1002/j.1460-2075.1994.tb06815.x; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MUELLER F, IN PRESS J MOL BIOL; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; POWERS T, 1993, P NATL ACAD SCI USA, V90, P1364, DOI 10.1073/pnas.90.4.1364; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; SANTER UV, 1995, RNA, V1, P89; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; TAPPRICH WE, 1990, EMBO J, V9, P2649, DOI 10.1002/j.1460-2075.1990.tb07447.x; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VANRYK DI, 1995, NUCLEIC ACIDS RES, V23, P3563, DOI 10.1093/nar/23.17.3563; WOLF H, 1977, EUR J BIOCHEM, V75, P67, DOI 10.1111/j.1432-1033.1977.tb11504.x	31	313	317	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					403	406		10.1038/38770	http://dx.doi.org/10.1038/38770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311785				2022-12-28	WOS:A1997XX67500058
J	Elliot, MJS				Elliot, MJS			Lower sodium for all	LANCET			English	Editorial Material							BLOOD-PRESSURE; HYPERTENSION; POPULATIONS; POTASSIUM; REDUCTION; SALT				Elliot, MJS (corresponding author), IMPERIAL COLL SCH MED,DEPT EPIDEMIOL & PUBL HLTH,ST MARYS CAMPUS,LONDON W2 1PG,ENGLAND.							APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1162, DOI 10.1001/archinte.152.6.1162; Cutler Jeffrey A., 1997, American Journal of Clinical Nutrition, V65, p643S, DOI 10.1093/ajcn/65.2.643S; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; GELEIJNSE JM, 1990, BMJ-BRIT MED J, V300, P899, DOI 10.1136/bmj.300.6729.899; Geleijnse JM, 1997, HYPERTENSION, V29, P913, DOI 10.1161/01.HYP.29.4.913; GELEIJNSE JM, 1994, BRIT MED J, V309, P436, DOI 10.1136/bmj.309.6952.436; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; *INT COOP RES GROU, 1988, BRIT MED J, V297, P319; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; WHELTON PK, 1996, CIRCULATION S1, V94, P178	10	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					825	826		10.1016/S0140-6736(05)62026-0	http://dx.doi.org/10.1016/S0140-6736(05)62026-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310596				2022-12-28	WOS:A1997XX40100004
J	Baxter, T; Milner, P; Wilson, K; Leaf, M; Nichol, J; Freeman, J; Cooper, N				Baxter, T; Milner, P; Wilson, K; Leaf, M; Nichol, J; Freeman, J; Cooper, N			A cost effective, community based heart health promotion project in England: Prospective comparative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRITISH FAMILY HEART; DISEASE; INTERVENTION; OXCHECK; CARE	Objective: To determine whether a community based coronary heart disease health promotion project, undertaken over four years, Was associated with changes in the prevalence in adults of lifestyle risk factors known to affect the development of coronary heart disease, and to estimate whether such an approach was cost effective. Design: Prospective, comparative study of the effects of a health promotion intervention on coronary heart disease lifestyle risk factors, assessed by postal questionnaire sent to a randomly chosen sample, both at baseline and after four years. Subjects: Intervention and control populations of adults aged 18-64 in Rotherham, both from areas with a high incidence of coronary heart disease and similar socioeconomic composition. Main outcome measures: Changes in prevalence of lifestyle risk factors between the control and intervention communities from 1991 to 1995. The effect of the intervention on certain lifestyle behaviours was evaluated using multiple logistic regression to model the proportion with a particular behaviour in the study communities as a function of age (18-40 or 41-64 years), sex, the year of observation (1991 or 1995), and area (intervention or control). Results: 6.9% fewer people smoked and 8.7% more drank low fat milk in the intervention area, but no other statistically significant changes between the areas were detected. The estimated cost per life year gained was pound 31. Conclusions: It is possible to have a cost effective impact on coronary heart disease lifestyle risk factors in a population of adults over four years using only modest resources.	ROTHERHAM HLTH AUTHORITIES, ROTHERHAM S65 2QU, S YORKSHIRE, ENGLAND; ROTHERHAM PRIOR HLTH SERV NHS TRUST, DONCASTER GATE HOSP, ROTHERHAM S65 1DW, S YORKSHIRE, ENGLAND; UNIV SHEFFIELD, SHEFFIELD SCH HLTH & RELATED RES, SHEFFIELD S1 4DA, S YORKSHIRE, ENGLAND	University of Sheffield			Nicholl, Jon/B-8257-2008					*AM CANC SOC, 1992, STAT B METR INS COMP, V73, P21; Baxter AP, 1997, PUBLIC HEALTH, V111, P231, DOI 10.1038/sj.ph.1900358; BURKE GL, 1989, INT J EPIDEMIOL, V18, pS73; Cartwright A, 1983, HLTH SURVEYS PRACTIC; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; *DEP HLTH, 1995, 2 DEP HLTH; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; FARQUHAR JW, 1978, AM J EPIDEMIOL, V108, P103, DOI 10.1093/oxfordjournals.aje.a112593; *HLTH ED AUTH OFF, 1990, HLTH LIF STYL SURV C; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; Langham S, 1996, BRIT MED J, V312, P1265, DOI 10.1136/bmj.312.7041.1265; Lessler JT, 1992, NONSAMPLING ERROR SU; Lindholm L, 1996, J EPIDEMIOL COMMUN H, V50, P190, DOI 10.1136/jech.50.2.190; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARTIN CA, 1989, AM J EPIDEMIOL, V129, P655, DOI 10.1093/oxfordjournals.aje.a115182; MAYNARD A, 1991, ECON J, V101, P1277, DOI 10.2307/2234443; NAIDOO J, 1994, HLTH PROMOTION F PRA; *OPCS, 1992, GEN HOUS SURV 1990; PEDERSEN TR, 1994, LANCET, V344, P1383; ROSE G, 1982, J EPIDEMIOL COMMUN H, V36, P102, DOI 10.1136/jech.36.2.102; ROSE G, 1986, LANCET, V1, P869; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1977, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6065.867; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SPACKMAN M, 1991, DISCOUNT RATES RETUR; TOLLEY K, 1993, HLTH PROMOTION MEASU; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; Wonderling D, 1996, BRIT MED J, V312, P1269, DOI 10.1136/bmj.312.7041.1269	30	29	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	1997	315	7108					582	585						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV717	9302957	Green Published			2022-12-28	WOS:A1997XV71700027
J	Lo, HJ; Kohler, JR; DiDomenico, B; Loebenberg, D; Cacciapuoti, A; Fink, GR				Lo, HJ; Kohler, JR; DiDomenico, B; Loebenberg, D; Cacciapuoti, A; Fink, GR			Nonfilamentous C-albicans mutants are avirulent	CELL			English	Article							CANDIDA-ALBICANS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; FILAMENTOUS GROWTH; HYPHAL FORMATION; GENE; PROTEIN; YEAST; HOMOLOG; MORPHOGENESIS	Candida albicans and Saccharomyces cerevisiae switch from a yeast to a filamentous form. In Saccharomyces, this switch is controlled by two regulatory proteins, Ste12p and Phd1p. Single-mutant strains, ste 12/ste12 or phd1/phd1, are partially defective, whereas the sfe12/ste12 phd1/phd1 double mutant is completely defective in filamentous growth and is noninvasive. The equivalent cph1/cph1 efg1/efg1 double mutant in Candida (Cph1p is the Ste12p homolog and Efg1p is the Phd1p homolog) is also defective in filamentous growth, unable to form hyphae or pseudohyphae in response to many stimuli, including serum or macrophages. This Candida cph1/cph1 efg1/efg1 double mutant, locked in the yeast form, is avirulent in a mouse model.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; CHILDRENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA; SCHERING PLOUGH RES INST, KENILWORTH, NJ 07033 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Merck & Company; Schering-Plough Research Institute			Lo, Hsiu-Jung/B-2658-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266, R01GM035010, R37GM035010] Funding Source: NIH RePORTER; NIAID NIH HHS [F32 AI009236] Funding Source: Medline; NIGMS NIH HHS [GM40266, GM35010] Funding Source: Medline; PHS HHS [F32A109236] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIRSE CE, 1993, INFECT IMMUN, V61, P3648, DOI 10.1128/IAI.61.9.3648-3655.1993; BOONE C, 1991, J BACTERIOL, V173, P6859, DOI 10.1128/jb.173.21.6859-6864.1991; BULLOCK WE, 1990, PRINCIPLES PRACTICE, P2340; CACCIAPUOTI A, 1992, ANTIMICROB AGENTS CH, V36, P64, DOI 10.1128/AAC.36.1.64; CANNON RD, 1992, MOL GEN GENET, V235, P453, DOI 10.1007/BF00279393; CHAPMAN SW, 1990, PRINCIPLES PRACTICE, P2353; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DABROWA N, 1981, J GEN MICROBIOL, V127, P391; DIAMOND RD, 1990, PRINCIPLES PRACTICE, P2331; Diener AC, 1996, GENETICS, V143, P769; EDWARDS JE, 1990, PRINCIPLES PRACTICE, P1943; FONZI WA, 1993, GENETICS, V134, P717; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; KIRKMANCORREIA C, 1993, MOL CELL BIOL, V13, P3765, DOI 10.1128/MCB.13.6.3765; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; LIU HP, 1995, SCIENCE, V267, P17; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; ODDS FC, 1985, CRC CR REV MICROBIOL, V12, P45, DOI 10.3109/10408418509104425; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; SHEPHERD MG, 1980, CAN J MICROBIOL, V26, P21, DOI 10.1139/m80-004; Sherman F., 1986, METHODS YEAST GENETI; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982	29	1418	1472	1	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					939	949		10.1016/S0092-8674(00)80358-X	http://dx.doi.org/10.1016/S0092-8674(00)80358-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298905	Bronze			2022-12-28	WOS:A1997XV56300014
J	Uhlenbeck, OC; Pardi, A; Feigon, J				Uhlenbeck, OC; Pardi, A; Feigon, J			RNA structure comes of age	CELL			English	Editorial Material							ELONGATION-FACTOR-G; CRYSTAL-STRUCTURE; HAMMERHEAD RIBOZYME; RIBOSOMAL-RNA; 3-DIMENSIONAL STRUCTURE; INTERNAL LOOP; BASE-PAIRS; COMPLEX; BINDING; HAIRPIN		UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Uhlenbeck, OC (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,CAMPUS BOX 215,BOULDER,CO 80309, USA.							Abramovitz DL, 1996, SCIENCE, V271, P1410, DOI 10.1126/science.271.5254.1410; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; Auffinger P, 1997, J MOL BIOL, V269, P326, DOI 10.1006/jmbi.1997.1022; BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; Baeyens KJ, 1996, P NATL ACAD SCI USA, V93, P12851, DOI 10.1073/pnas.93.23.12851; Bassi GS, 1996, RNA, V2, P756; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Beebe JA, 1996, BIOCHEMISTRY-US, V35, P10493, DOI 10.1021/bi960870m; BORER PN, 1995, BIOCHEMISTRY-US, V34, P6488, DOI 10.1021/bi00019a030; Butcher SE, 1997, J MOL BIOL, V268, P348, DOI 10.1006/jmbi.1997.0964; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Cohen SB, 1997, J AM CHEM SOC, V119, P6259, DOI 10.1021/ja9707421; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dieckmann T, 1996, RNA, V2, P628; Du ZH, 1996, BIOCHEMISTRY-US, V35, P4187, DOI 10.1021/bi9527350; Felden B, 1996, RNA, V2, P201; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Harada K, 1996, NATURE, V380, P175, DOI 10.1038/380175a0; Harris ME, 1997, RNA, V3, P561; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; Jiang F, 1996, NATURE, V382, P183, DOI 10.1038/382183a0; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; Kalurachchi K, 1997, P NATL ACAD SCI USA, V94, P2139, DOI 10.1073/pnas.94.6.2139; Kieft JS, 1997, STRUCTURE, V5, P713, DOI 10.1016/S0969-2126(97)00225-6; Kolk MH, 1997, EMBO J, V16, P3685, DOI 10.1093/emboj/16.12.3685; Laing LG, 1996, BIOCHEMISTRY-US, V35, P13586, DOI 10.1021/bi961310q; Leclerc F, 1997, FOLD DES, V2, P141, DOI 10.1016/S1359-0278(97)00019-9; LUKAVSKY P, 1997, IN PRESS P ACS S MOD; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; Menger M, 1996, BIOCHEMISTRY-US, V35, P14710, DOI 10.1021/bi960440w; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; Schweisguth DC, 1997, J MOL BIOL, V267, P505, DOI 10.1006/jmbi.1996.0903; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Sigurdsson ST, 1996, NUCLEIC ACIDS RES, V24, P3129, DOI 10.1093/nar/24.16.3129; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WANG YX, 1993, BIOCHEMISTRY-US, V32, P12279, DOI 10.1021/bi00097a002; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; Zimmermann GR, 1997, NAT STRUCT BIOL, V4, P644, DOI 10.1038/nsb0897-644; ZUKER M, 1995, NUCLEIC ACIDS RES, V23, P2791, DOI 10.1093/nar/23.14.2791	46	49	49	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					833	840		10.1016/S0092-8674(00)80348-7	http://dx.doi.org/10.1016/S0092-8674(00)80348-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298895	Bronze			2022-12-28	WOS:A1997XV56300004
J	Lee, A; Bateman, DN; Edwards, C; Smith, JM; Rawlins, MD				Lee, A; Bateman, DN; Edwards, C; Smith, JM; Rawlins, MD			Reporting of adverse drug reactions by hospital pharmacists: pilot scheme	BRITISH MEDICAL JOURNAL			English	Article								Spontaneous reporting of suspected adverse drug reactions is an important element of pharmacovigilance.(1) The yellow card scheme of the Committee on Safety of Medicines and the Medicines Control Agency registers reports from doctors, dentists, and coroners but not pharmacists. The value of including pharmacists has prerviously been proposed,(2-4) and we assessed the contributions of hospital pharmacists in a pilot scheme.	UNIV NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,YORKSHIRE REG DRUG & THERAPEUT CTR,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK								BOOTH NJ, 1988, PHARM J         1112, pR3; *COMM SAF MED, 1992, CURRENT PROBLEMS, V18, P4; *COMM SAF MED, 1985, REP ADV REACT WORK 2; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41; WINSTANLEY PA, 1989, BRIT J CLIN PHARMACO, V28, P113, DOI 10.1111/j.1365-2125.1989.tb03513.x	5	16	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					519	519		10.1136/bmj.315.7107.519	http://dx.doi.org/10.1136/bmj.315.7107.519			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329307	Green Published			2022-12-28	WOS:A1997XU50600019
J	PerezSchael, I; Guntinas, MJ; Perez, M; Pagone, V; Rojas, AM; Gonzalez, R; Cunto, W; Hoshino, Y; Kapikian, AZ				PerezSchael, I; Guntinas, MJ; Perez, M; Pagone, V; Rojas, AM; Gonzalez, R; Cunto, W; Hoshino, Y; Kapikian, AZ			Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOSORBENT-ASSAY; ESCHERICHIA-COLI; INFECTION; STRAINS; IMMUNOGENICITY; REACTOGENICITY; RESPONSES; SAFETY	Background Rotaviruses are the principal known etiologic agents of severe diarrhea among infants and young children worldwide. Although a rhesus rotavirus-based quadrivalent vaccine is highly effective in preventing severe diarrhea in developed countries, in developing countries its efficacy has been less impressive. We thus conducted a catchment study in Venezuela to assess the efficacy of the vaccine against dehydrating diarrhea. Methods In this randomized, double-blind, placebo-controlled trial, 2207 infants received three oral doses of the quadrivalent rotavirus vaccine (4x10(5) plaque-forming units per dose) or placebo at about two, three, and four months of age. During approximately 19 to 20 months of passive surveillance, episodes of gastroenteritis were evaluated at the hospital. Results The vaccine was safe, although 15 percent of the vaccinated infants had febrile episodes (rectal temperature, greater than or equal to 38.1 degrees C) during the six days after the first dose, as compared with 7 percent of the controls (P<0.001). However, the vaccine gave 88 percent protection against severe diarrhea caused by rotavirus and 75 percent protection against dehydration, and produced a 70 percent reduction in hospital admissions. Overall, the efficacy of the vaccine against a first episode of rotavirus diarrhea was 48 percent, Horizontal transmission of vaccine virus was demonstrated in 15 percent of the vaccine recipients and 13 percent of the placebo recipients with rotavirus-positive diarrhea. Conclusions In this study in a developing country, the quadrivalent rhesus rotavirus-based vaccine induced a high level of protection against severe diarrheal illness caused by rotavirus. (C) 1997, Massachusetts Medical Society.	CENT UNIV VENEZUELA, MINIST SANIDAD, INST BIOMED, SECC INVEST ENFERMEDADES ENTER, FUVESIN, CARACAS, VENEZUELA; INST BIOMED VENEZUELA, CARACAS, VENEZUELA; NIAID, INFECT DIS LAB, BETHESDA, MD 20892 USA	University of Central Venezuela; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NHLBI NIH HHS [BST5947-P-HI-4265] Funding Source: Medline; PHS HHS [87-I-113] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; BISHOP RF, 1983, NEW ENGL J MED, V309, P72, DOI 10.1056/NEJM198307143090203; BRANDT CD, 1981, J CLIN MICROBIOL, V13, P976, DOI 10.1128/JCM.13.5.976-981.1981; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; DAS BK, 1994, J CLIN MICROBIOL, V32, P1820, DOI 10.1128/JCM.32.7.1820-1822.1994; DAY NP, 1981, J CLIN MICROBIOL, V13, P596, DOI 10.1128/JCM.13.3.596-597.1981; FLORES J, 1982, VIROLOGY, V121, P288, DOI 10.1016/0042-6822(82)90168-4; FLORES J, 1993, J CLIN MICROBIOL, V31, P2439, DOI 10.1128/JCM.31.9.2439-2445.1993; GLASS RI, 1994, SCIENCE, V265, P1389, DOI 10.1126/science.8073280; Gonzalez R, 1997, J CLIN MICROBIOL, V35, P1103; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; GREEN KY, 1990, J INFECT DIS, V161, P667, DOI 10.1093/infdis/161.4.667; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; Hoshino Y, 1996, ARCH VIROL, P99; HOSHINO Y, 1984, J INFECT DIS, V149, P694, DOI 10.1093/infdis/149.5.694; *I MED, 1985, NEW VACC DEV EST PRI, V1, P410; KALICA AR, 1978, VIROLOGY, V87, P247, DOI 10.1016/0042-6822(78)90130-7; Kapikian AZ, 1996, J INFECT DIS, V174, pS65, DOI 10.1093/infdis/174.Supplement_1.S65; KELLY MT, 1985, MANUAL CLIN MICROBIO, P00263; Lanata CF, 1996, J INFECT DIS, V174, P268, DOI 10.1093/infdis/174.2.268; Linhares AC, 1996, B WORLD HEALTH ORGAN, V74, P491; LOSONSKY GA, 1988, PEDIATR INFECT DIS J, V7, P388, DOI 10.1097/00006454-198806000-00004; Mendez-Castellano H., 1986, VENEZUELAN ARCH CHIL, V49, P93; MORRIS SS, 1994, INT J EPIDEMIOL, V23, P617, DOI 10.1093/ije/23.3.617; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; ORSKOV F, 1984, METHOD MICROBIOL, V14, P43, DOI 10.1016/S0580-9517(08)70447-1; PEREZSCHAEL I, 1994, J MED VIROL, V42, P330, DOI 10.1002/jmv.1890420403; PEREZSCHAEL I, 1990, J MED VIROL, V30, P219, DOI 10.1002/jmv.1890300315; PEREZSCHAEL I, 1990, J CLIN MICROBIOL, V28, P553, DOI 10.1128/JCM.28.3.553-558.1990; PerezSchael I, 1996, J INFECT DIS, V174, pS19, DOI 10.1093/infdis/174.Supplement_1.S19; Rennels MB, 1996, PEDIATRICS, V97, P7; ROJAS AM, 1995, J MED VIROL, V47, P404, DOI 10.1002/jmv.1890470418; RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046; SHAW RD, 1985, J CLIN MICROBIOL, V22, P286, DOI 10.1128/JCM.22.2.286-291.1985; TANIGUCHI K, 1987, J INFECT DIS, V155, P1159, DOI 10.1093/infdis/155.6.1159; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; VESIKARI T, 1996, 2 SAT S 14 ANN M EUR; *WHO, 1990, MAN TREATM DIARRH US; [No title captured]; [No title captured]	40	252	270	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1181	1187		10.1056/NEJM199710233371701	http://dx.doi.org/10.1056/NEJM199710233371701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337376				2022-12-28	WOS:A1997YB71800001
J	Chen, WR; Midtgaard, J; Shepherd, GM				Chen, WR; Midtgaard, J; Shepherd, GM			Forward and backward propagation of dendritic impulses and their synaptic control in mitral cells	SCIENCE			English	Article							RAT OLFACTORY-BULB; PYRAMIDAL NEURONS; ACTION-POTENTIALS; INITIATION; RECORDINGS; SLICES; CA2+	The site of impulse initiation is crucial for the integrative actions of mammalian central neurons, but this question is currently controversial. Some recent studies support classical evidence that the impulse always arises in the soma-axon hillock region, with back-propagation through excitable dendrites, whereas others indicate that the dendrites are sufficiently excitable to initiate impulses that propagate forward along the dendrite to the soma-axon hillock. This issue has been addressed in the olfactory mitral cell, in which excitatory synaptic input is restricted to the distal tuft of a single primary dendrite. In rat olfactory bulb slices, dual whole cell recordings were made at or near the soma and from distal sites on the primary dendrite. The results show that the impulse can be initiated in either the soma-axon hillock or in the distal primary dendrite, and that the initiation site is controlled physiologically by the excitatory synaptic inputs to the distal tuft and inhibitory synaptic inputs near the soma.	UNIV COPENHAGEN,DEPT MED PHYSIOL,DK-2200 COPENHAGEN N,DENMARK	University of Copenhagen	Chen, WR (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.							BENARDO LS, 1982, J NEUROSCI, V2, P1614; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CALLAWAY JC, 1995, J NEUROSCI, V15, P2777; CHANG HT, 1952, COLD SPRING HARB SYM, V17, P189, DOI 10.1101/SQB.1952.017.01.019; Chen W., UNPUB; Chen WR, 1997, BRAIN RES, V745, P189, DOI 10.1016/S0006-8993(96)01150-X; CRAGG BG, 1955, J PHYSIOL-LONDON, V129, P608, DOI 10.1113/jphysiol.1955.sp005382; DEFELIPE J, 1992, PROG NEUROBIOL, V39, P563, DOI 10.1016/0301-0082(92)90015-7; Ennis M, 1996, NEUROREPORT, V7, P989, DOI 10.1097/00001756-199604100-00007; HAMILTON KA, 1989, BRAIN RES, V338, P181; HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3; HERRERAS O, 1990, J NEUROPHYSIOL, V64, P1429, DOI 10.1152/jn.1990.64.5.1429; HUGUENARD JR, 1989, P NATL ACAD SCI USA, V86, P2473, DOI 10.1073/pnas.86.7.2473; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JAHR CE, 1982, J PHYSIOL-LONDON, V326, P213, DOI 10.1113/jphysiol.1982.sp014187; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P695, DOI 10.1113/jphysiol.1974.sp010772; LEVETEAU J, 1965, SCIENCE, V175, P170; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; MORI K, 1982, J NEUROSCI, V2, P497; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORI K, 1975, BRAIN RES, V100, P685, DOI 10.1016/0006-8993(75)90170-5; Nickell WT, 1996, BRAIN RES BULL, V39, P57, DOI 10.1016/0361-9230(95)02042-X; RALL W, 1968, J NEUROPHYSIOL, V31, P884, DOI 10.1152/jn.1968.31.6.884; RALL W, 1966, EXP NEUROL, V14, P44, DOI 10.1016/0014-4886(66)90023-9; REGEHR WG, 1994, CURR BIOL, V4, P436, DOI 10.1016/S0960-9822(00)00096-8; SCOTT JW, 1987, NEUROBIOLOGY TASTE S, P151; Shepherd G. M., 1990, SYNAPTIC ORG BRAIN, P133; SHEPHERD GM, 1977, HDB PHYSL          1, V1, P945; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; Stuart G, 1997, TRENDS NEUROSCI, V20, P125, DOI 10.1016/S0166-2236(96)10075-8; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WELLIS DP, 1987, CHEM SENSES, V12, P707	38	195	204	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					463	467		10.1126/science.278.5337.463	http://dx.doi.org/10.1126/science.278.5337.463			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334305				2022-12-28	WOS:A1997YB35500045
J	Ellegren, H; Lindgren, G; Primmer, CR; Moller, AP				Ellegren, H; Lindgren, G; Primmer, CR; Moller, AP			Fitness loss and germline mutations in barn swallows breeding in Chernobyl	NATURE			English	Article							HIRUNDO-RUSTICA; MISMATCH REPAIR; DNA; RADIATION; EVOLUTION; ACCIDENT	The severe nuclear accident at Chernobyl in 1986 resulted in the worst reported accidental exposure of radioactive material to free-living organisms(1). Short-term effects on human populations inhabiting polluted areas include increased incidence of thyroid cancer(2), infant leukaemia(3), and congenital malformations in newborns(4). Two recent studies(5,6) have reported, although with some controversy(7,8), that germline mutation rates were increased in humans and voles living close to Chernobyl, but little is known about the viability of the organisms affected(9). Here we report an increased frequency of partial albinism, a morphological aberration associated with a loss of fitness, among barn swallows, Hirundo rustica, breeding close to Chernobyl. Heritability estimates indicate that mutations causing albinism were at least partly of germline origin. Furthermore, evidence for an increased germline mutation rate was obtained from segregation analysis at two hypervariable microsatellite loci, indicating that mutation events in barn swallows from Chernobyl were two-to tenfold higher than in birds from control areas in Ukraine and Italy.	UNIV PARIS 06,CNRS,URA 258,ECOL LAB,F-75252 PARIS 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Ellegren, H (corresponding author), SWEDISH UNIV AGR SCI,DEPT ANIM BREEDING & GENET,BOX 597,S-75124 UPPSALA,SWEDEN.		Primmer, Craig R/B-8179-2008; Moller, Anders/O-6665-2016	Primmer, Craig R/0000-0002-3687-8435; Moller, Anders/0000-0003-3739-4675				ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; Baker RJ, 1996, NATURE, V380, P707, DOI 10.1038/380707a0; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; Dubrova YE, 1996, NATURE, V383, P226, DOI 10.1038/383226b0; Dyck J., 1985, DICT BIRDS, P472; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; HANOTTE O, 1994, MOL ECOL, V3, P529, DOI 10.1111/j.1365-294X.1994.tb00133.x; Hillis DM, 1996, NATURE, V380, P665, DOI 10.1038/380665a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MOLLER AP, 1993, P ROY SOC B-BIOL SCI, V252, P51, DOI 10.1098/rspb.1993.0045; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petridou E, 1996, NATURE, V382, P352, DOI 10.1038/382352a0; Primmer CR, 1996, NAT GENET, V13, P391, DOI 10.1038/ng0896-391; Primmer CR, 1996, HEREDITAS, V124, P281, DOI 10.1111/j.1601-5223.1996.00281.x; PRIMMER CR, 1995, MOL ECOL, V4, P493, DOI 10.1111/j.1365-294X.1995.tb00243.x; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Saino N, 1997, EVOLUTION, V51, P562, DOI 10.1111/j.1558-5646.1997.tb02443.x; Satoh C, 1996, NATURE, V383, P226, DOI 10.1038/383226a0; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; [No title captured]	23	195	213	0	103	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					593	596		10.1038/39303	http://dx.doi.org/10.1038/39303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335497				2022-12-28	WOS:A1997YA00800057
J	Kessler, DA				Kessler, DA			The tobacco settlement	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Kessler, DA (corresponding author), YALE UNIV,SCH MED,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							Koop CE, 1997, FINAL REPORT ADVISOR; 1996, RICHMOND TIMES  0713	2	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1082	1083		10.1056/NEJM199710093371512	http://dx.doi.org/10.1056/NEJM199710093371512			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321540				2022-12-28	WOS:A1997XZ84400012
J	Rodriguez, I; Basler, K				Rodriguez, I; Basler, K			Control of compartmental affinity boundaries by hedgehog	NATURE			English	Article							DROSOPHILA IMAGINAL DISKS; PROTEIN KINASE-A; SIGNAL-TRANSDUCTION; ENGRAILED GENE; PATTERN; EXPRESSION; ENCODES	In Drosophila, each segmental primordium is subdivided into two cell populations, the anterior (A) and posterior (P) compartments by the selective activity of the transcription factor Engrailed (En) in P cells(1-4). Under En control, P cells secrete, but cannot respond to, the signalling protein Hedgehog (Hh)(5-7). In contrast, and by default, A cells are programmed to respond to Hh by expressing other signalling molecules, such as Decapentaplegic (Dpp) and Wingless (Wg), which organize growth and patterning in both compartments(5,7-9). Cells of the A and P compartments do not intermix, apparently as a consequence of their having distinct cell affinities that cause them to maximize contact with cells of the same compartment, while minimizing contact with cells from the other compartment(10). This failure to mix has previously been ascribed to an autonomous and direct role for En in specifying a P, as opposed to an A, cell affinity(3,11-13). However, an alternative hypothesis is that Hh secreted by P cells induces A cells to acquire a distinct cell affinity, ensuring that a stable 'affinity boundary' forms wherever P and A cells meet, Here we show that the affinity boundary that segregates A and P cells into adjacent but immiscible cell populations is to a large extent a consequence of local Hh signalling, rather than a reflection of an intrinsic affinity difference between A and P cells.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich			Rodriguez, Isabel/J-2636-2017	Rodriguez, Isabel/0000-0002-7322-4756; Basler, Konrad/0000-0003-3534-1529				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Burke R, 1996, DEVELOPMENT, V122, P2261; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; DUNINBORKOWSKI OM, 1995, DEV BIOL, V168, P689, DOI 10.1006/dbio.1995.1115; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; Lawrence P.A., 1986, P229; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	31	112	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	1997	389	6651					614	618		10.1038/39343	http://dx.doi.org/10.1038/39343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335503				2022-12-28	WOS:A1997YA00800063
J	Varmus, H; Satcher, D				Varmus, H; Satcher, D			Ethical complexities of conducting research in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CTR DIS CONTROL & PREVENT,ATLANTA,GA 30329	Centers for Disease Control & Prevention - USA	Varmus, H (corresponding author), NIH,BETHESDA,MD 20892, USA.							Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; *NAT COMM PROT HUM, 1988, 887809 GPO; *US DEP HHS, 1997, COND CLIN TRIALS MAT; *WHO, 1994, REC M MOTH TO INF TR; *WORLD MED ASS DEC, 1996, 18 WORLD MED ASS HEL	6	243	250	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					1003	1005		10.1056/NEJM199710023371411	http://dx.doi.org/10.1056/NEJM199710023371411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309109				2022-12-28	WOS:A1997XY42300011
J	Blum, RH				Blum, RH			Simplified vs complex adjuvant chemotherapy schedule for osteosarcoma	LANCET			English	Editorial Material											Blum, RH (corresponding author), ST VINCENTS COMPREHENS CANC CTR,NEW YORK,NY 10011, USA.							ROSEN G, 1982, CANCER-AM CANCER SOC, V49, P1221, DOI 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E	1	10	10	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					900	901		10.1016/S0140-6736(05)63262-X	http://dx.doi.org/10.1016/S0140-6736(05)63262-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314864				2022-12-28	WOS:A1997XY67200004
J	Mihic, SJ; Ye, Q; Wick, MJ; Koltchine, VV; Krasowski, MD; Finn, SE; Mascia, MP; Valenzuela, CF; Hanson, KK; Greenblatt, EP; Harris, RA; Harrison, NL				Mihic, SJ; Ye, Q; Wick, MJ; Koltchine, VV; Krasowski, MD; Finn, SE; Mascia, MP; Valenzuela, CF; Hanson, KK; Greenblatt, EP; Harris, RA; Harrison, NL			Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors	NATURE			English	Article							ACID TYPE-A; LONG-CHAIN ALCOHOLS; GENERAL-ANESTHETICS; CURRENTS; PROPOFOL; INHIBITION; MODULATION	Volatile anaesthetics have historically been considered to act in a nonspecific manner on the central nervous system(1,2). More recent studies, however, have revealed that the receptors for inhibitory neurotransmitters such as gamma-aminobutyric acid (GABA) and glycine are sensitive to clinically relevant concentrations of inhaled anaesthetics(3). The function of GABAA and glycine receptors is enhanced by a number of anaesthetics(4-9) and alcohols(10-12), whereas activity of the related(13) GABA rho 1 receptor is reduced(14). We have used this difference in pharmacology to investigate the molecular basis for modulation of these receptors by anaesthetics and alcohols. By using chimaeric receptor constructs, we have identified a region of 45 amino-acid residues that is both necessary and sufficient for the enhancement of receptor function. Within this region, two specific amino-acid residues in transmembrane domains 2 and 3 are critical for allosteric modulation of both GABA(A) and glycine receptors by alcohols and two volatile anaesthetics. These observations support the idea that anaesthetics exert a specific effect on these ion-channel proteins, and allow fbr the future testing of specific hypotheses of the action of anaesthetics.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Alcohol Res Ctr, Denver, CO 80262 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Denver Veteran Adm Med Ctr, Alcoholism Res Ctr, Denver, CO 80220 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Chicago; University of Chicago; University of Pennsylvania	Mihic, SJ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.		Krasowski, Matthew D/ABA-8590-2020	Krasowski, Matthew D/0000-0003-0856-8402; Hanson, Kirsten/0000-0002-0154-0979				DildyMayfield JE, 1996, BRIT J PHARMACOL, V118, P378, DOI 10.1111/j.1476-5381.1996.tb15413.x; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; JANOFF AS, 1981, BIOCHIM BIOPHYS ACTA, V649, P125, DOI 10.1016/0005-2736(81)90017-1; JONES MV, 1995, J PHARMACOL EXP THER, V274, P962; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339, DOI 10.1152/jn.1993.70.4.1339; Koltchine VV, 1996, NEUROPHARMACOLOGY, V35, P1445, DOI 10.1016/S0028-3908(96)00088-3; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LYON RC, 1981, J PHARMACOL EXP THER, V218, P669; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1996, MOL PHARMACOL, V50, P402; Mihic SJ, 1996, J PHARMACOL EXP THER, V277, P411; MIHIC SJ, 1994, EUR J PHARM-MOLEC PH, V268, P209; MIHIC SJ, 1994, MOL PHARMACOL, V46, P851; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SANNA E, 1995, MOL PHARMACOL, V47, P213; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SHOENBORN BP, 1967, NATURE, V214, P1120; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Yu DH, 1996, MOL PHARMACOL, V50, P1010; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934	27	1036	1057	6	82	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 25	1997	389	6649					385	389		10.1038/38738	http://dx.doi.org/10.1038/38738			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311780				2022-12-28	WOS:A1997XX67500053
J	Brandt, AM; Richmond, JB				Brandt, AM; Richmond, JB			Settling short on tobacco - Let the trials begin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Brandt, AM (corresponding author), HARVARD UNIV,SCH MED,DEPT SOCIAL MED,DIV MED ETH,641 HUNTINGTON AVE,BOSTON,MA 02115, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1028	1028		10.1001/jama.278.12.1028	http://dx.doi.org/10.1001/jama.278.12.1028			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307356	Green Submitted			2022-12-28	WOS:A1997XX01200039
J	TunstallPedoe, H; Woodward, M; Tavendale, R; Brook, RA; McCluskey, MK				TunstallPedoe, H; Woodward, M; Tavendale, R; Brook, RA; McCluskey, MK			Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; MYOCARDIAL-INFARCTION; LIFE-STYLE; ALCOHOL-CONSUMPTION; PLASMA-FIBRINOGEN; PASSIVE SMOKING; SERUM COTININE; BLOOD-PRESSURE; CASE-FATALITY; MORTALITY	Objective: To compare prediction by 27 different factors in men and women of coronary heart disease events, coronary deaths, and deaths from all causes. Design: Cohort study. Setting: Scottish population study. Subjects: In 1984-7 random sampling of residents aged 40-59 produced 11 629 men and women who generated survey clinic questionnaires, examination findings, and blood and urine specimens. Main outcome measures: Subsequent death, coronary artery surgery, and myocardial infarction. Risks were calculated for each category of factor or fifth of continuous variables. 27 factors were ranked by descending age adjusted hazard ratio of the top to bottom class in each factor, by sex and end point. Results: Follow up averaged; 7.6 years, during which the 5754 men had 404 coronary events, 159 coronary deaths, and 383 deaths and the 5875 women 177, 47, and 208 respectively The rankings for factors for the three end points were mainly similar in men and women, although hazard ratios were often higher in women. Classical risk factors ranked better for predicting coronary risk than newer ones. Yet strong prediction of coronary risk was no guarantee of significant prediction of all cause mortality. Findings included an anomalous coronary protective role for type A behaviour in women; raised plasma fibrinogen as a strong predictor of all end points; and an unexpectedly powerful protective relation of dietary potassium to all cause mortality. Conclusions: These initial unifactorial rankings and comparisons must be interpreted with caution until potential interaction, confounding, and problems of measurement and causation are further explored.			TunstallPedoe, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.		Woodward, Mark/D-8492-2015; Woodward, Mark/L-6817-2017	Woodward, Mark/0000-0001-9800-5296				BORTNER RW, 1969, J CHRON DIS, V22, P87, DOI 10.1016/0021-9681(69)90061-7; Collett D, 1994, MODELLING SURVIVAL D; CROMBIE I, 1990, HLTH ED J, V49, P71; CROMBIE IK, 1990, BRIT HEART J, V64, P199; CROMBIE IK, 1989, STATISTICIAN, V38, P25; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; HUGHES MD, 1993, BIOMETRICS, V49, P1056, DOI 10.2307/2532247; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KNOX SS, 1993, J PSYCHOSOM RES, P709; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LEE AJ, 1993, BRIT HEART J, V69, P338; LEE AJ, 1993, BRIT J HAEMATOL, V83, P616, DOI 10.1111/j.1365-2141.1993.tb04699.x; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; Morrison C, 1997, BMJ-BRIT MED J, V314, P541, DOI 10.1136/bmj.314.7080.541; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; Prineas R., 1982, MINNESOTA CODE MANUA; RICHEDWARDS JW, 1995, AM J EPIDEMIOL, V142, P909, DOI 10.1093/oxfordjournals.aje.a117738; ROSE G, 1980, LANCET, V1, P523; Rose G, 1982, CARDIOVASCULAR SURVE; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SMITH CB, 1992, EUR J CLIN NUTR, V46, P75; SMITH CB, 1992, EUR J CLIN NUTR, V46, P85; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH W C S, 1987, Health Bulletin (Edinburgh), V45, P211; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1990, BRIT HEART J, V64, P295; SWEETNAM PM, 1994, CIRCULATION, V90, P769, DOI 10.1161/01.CIR.90.2.769; TUNSTALL-PEDOE H, 1988, Journal of Clinical Epidemiology, V41, P105; TUNSTALLPEDOE H, 1995, J EPIDEMIOL COMMUN H, V49, P139, DOI 10.1136/jech.49.2.139; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TUNSTALLPEDOE H, 1991, J CLIN EPIDEMIOL, V44, P1411, DOI 10.1016/0895-4356(91)90102-F; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; *WHO, 1996, WORLD HLTH STAT ANN; *WHO MONICA PROJ, 1989, WORLD HLTH STAT ANN, P27; WHO MONICA Project, 1990, MONICA MAN; WOODWARD M, 1990, STATISTICIAN, V39, P319, DOI 10.2307/2349049; WOODWARD M, 1993, ADDICTION, V88, P821, DOI 10.1111/j.1360-0443.1993.tb02096.x; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, PREV MED, V21, P136, DOI 10.1016/0091-7435(92)90013-8; WOODWARD M, 1995, J EPIDEMIOL COMMUN H, V49, P354, DOI 10.1136/jech.49.4.354; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103	49	258	262	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					722	729		10.1136/bmj.315.7110.722	http://dx.doi.org/10.1136/bmj.315.7110.722			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314758	Green Published			2022-12-28	WOS:A1997XX67400024
J	Borowsky, SJ; Davis, MK; Goertz, C; Lurie, N				Borowsky, SJ; Davis, MK; Goertz, C; Lurie, N			Are all health plans created equal? The physician's view	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE; PROFESSIONAL SATISFACTION; QUALITY	Context.-The health care market is demanding increasing amounts of information regarding quality of care in health plans. Physicians are a potentially important but infrequently used source of such information. Objective.-To assess physicians' views on health plan practices that promote or impede delivery of high-quality care in health plans and to compare ratings between plans. Setting.-Minneapolis-St Paul, Minn. Participants.-One hundred physicians in each of 3 health plans. Each physician rated 1 health plan. Main Outcome Measures.-Likert-type items that assessed health plan practices that promote or impede delivery of high-quality care. Results.-A total of 249 physicians (84%) completed the survey. Fewer than 20% of all physicians gave plans the highest rating (excellent or strongly agree) for health plan practices that promote delivery of high-quality care (such as providing continuing medical education for physicians, identifying patients needing preventive care, and providing physicians feedback about practice patterns). Barriers to delivering high-quality care related to sufficiency of time to spend with patients, covered benefits and copayment structure, and utilization management practices. Ratings differed across health plans. For example, the percentage of physicians indicating that they would recommend the plan they rated to their own family was 64% for plan 1, 92% for plan 2, and 24% for plan 3 (P<.001 for all comparisons). Conclusions.-Physician surveys can highlight strengths and weaknesses in health plans, and their ratings differ across plans. Physician ratings of health plan practices that promote or impede delivery of high-quality care may be useful to consumers and purchasers of health care as a tool to evaluate health plans and promote quality improvement.	UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, INST HLTH SERV RES, MINNEAPOLIS, MN 55455 USA; HENNEPIN CTY MED CTR, MINNEAPOLIS, MN 55415 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center	Borowsky, SJ (corresponding author), VET AFFAIRS MED CTR, DEPT MED, 1 VET DR, MINNEAPOLIS, MN 55417 USA.			Goertz, Christine/0000-0002-4700-3669				BAKER LC, 1993, HEALTH AFFAIR, V12, P258, DOI 10.1377/hlthaff.12.suppl_1.258; Borowsky SJ, 1996, ANN INTERN MED, V125, P239, DOI 10.7326/0003-4819-125-3-199608010-00014; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; HAYS RD, 1994, JOINT COMM J QUAL IM, V20, P66, DOI 10.1016/S1070-3241(16)30045-1; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; KRAVITZ RL, 1990, MED CARE, V28, P502, DOI 10.1097/00005650-199006000-00003; LICHTENSTEIN R, 1984, MED CARE, V22, P56, DOI 10.1097/00005650-198401000-00005; Nelson E C, 1992, QRB Qual Rev Bull, V18, P284; REAMES HR, 1989, ARCH INTERN MED, V149, P1951, DOI 10.1001/archinte.149.9.1951; SCHULZ R, 1992, J FAM PRACTICE, V34, P298; SKOLNIK NS, 1993, J FAM PRACTICE, V37, P257	13	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					917	921		10.1001/jama.278.11.917	http://dx.doi.org/10.1001/jama.278.11.917			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV640	9302244				2022-12-28	WOS:A1997XV64000030
J	Strickberger, SA; Man, KC; Daoud, EG; Goyal, R; Brinkman, K; Knight, BP; Weiss, R; Bahu, M; Morady, F				Strickberger, SA; Man, KC; Daoud, EG; Goyal, R; Brinkman, K; Knight, BP; Weiss, R; Bahu, M; Morady, F			Adenosine-induced atrial arrhythmia: A prospective analysis	ANNALS OF INTERNAL MEDICINE			English	Article						atrial fibrillation; adenosine; tachycardia, supraventricular; electrophysiology; Wolff-Parkinson-White syndrome	PARKINSON-WHITE SYNDROME; INTRAVENOUS ADENOSINE; COMPLEX TACHYCARDIA; ACCESSORY PATHWAY; HEART-RATE; FIBRILLATION; FLUTTER; DIAGNOSIS; CONDUCTION; POTASSIUM	Background: Adenosine is considered safe and effective for paroxysmal supraventricular tachycardia (PSVT), but anecdotal experience suggests that adenosine can precipitate atrial arrhythmias. Objectives: To determine the frequency and mechanisms of adenosine-induced atrial arrhythmias. Setting: Clinical electrophysiology laboratory at a university medical center. Design: Prospective observational study. Patients: 200 consecutive patients with PSVT undergoing an electrophysiology procedure. Intervention: During PSVT, 12 mg of adenosine was administered centrally through the femoral vein. Measurements: Frequency of adenosine-induced atrial fibrillation. Results: Paroxysmal supraventricular tachycardia terminated after adenosine administration in 198 patients (99% [95% CI, 96% to 100%]). Adenosine led to atrial fibrillation (n = 22) or atrial fibrillation and atrial flutter (n = 2) in 24 patients (12% [CI, 7.5% to 16.5%]). An atrial premature complex occurred in all 24 patients who developed atrial fibrillation, atrial flutter, or both and in 102 of the 176 patients (58%) who did not (P < 0.001). The mean (+/-SD) time from the preceding atrial complex to the atrial premature complex was shorter when an atria[ arrhythmia occurred, and the mean ratio of this interval to the preceding atrial cycle length was also lower when atrial fibrillation developed (0.37 +/- 0.16 compared with 0.49 +/- 0.16; P = 0.002). Conclusions: The incidence of atrial fibrillation induced by 12 mg of adenosine administered through the femoral vein was 12%. Fibrillation seems to be associated with a ''long-short'' atrial sequence. If the mechanism of PSVT is unknown and the Wolff-Parkinson-White syndrome is possible, administration of adenosine should be limited to medical facilities that have emergency resuscitation equipment.			Strickberger, SA (corresponding author), UNIV MICHIGAN, MED CTR, 1500 E MED CTR DR, BOX 0022, ANN ARBOR, MI 48109 USA.							BELARDINELLI L, 1983, AM J PHYSIOL, V244, pH734, DOI 10.1152/ajpheart.1983.244.5.H734; BIAGGIONI I, 1986, LIFE SCI, V39, P2229, DOI 10.1016/0024-3205(86)90401-7; BRODSKY MA, 1995, AM HEART J, V130, P564, DOI 10.1016/0002-8703(95)90367-4; CONTI JB, 1995, AM J CARDIOL, V75, P952, DOI 10.1016/S0002-9149(99)80698-5; Cosio FG, 1996, J CARDIOVASC ELECTR, V7, P60, DOI 10.1111/j.1540-8167.1996.tb00461.x; DIMARCO JP, 1990, ANN INTERN MED, V113, P104, DOI 10.7326/0003-4819-113-2-104; DOMANOVITS H, 1994, EUR HEART J, V15, P589, DOI 10.1093/oxfordjournals.eurheartj.a060553; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2199; EXNER DV, 1995, ANN INTERN MED, V122, P351, DOI 10.7326/0003-4819-122-5-199503010-00005; FEDIDA D, 1989, AM J PHYSIOL, V256, pH1500, DOI 10.1152/ajpheart.1989.256.5.H1500; *FUJ US INC MEDC R, 1996, PACK INS AD; GARRATT CJ, 1994, AM J CARDIOL, V74, P401, DOI 10.1016/0002-9149(94)90415-4; GARRATT CJ, 1990, AM J CARDIOL, V65, P868, DOI 10.1016/0002-9149(90)91428-9; GARRATT CJ, 1991, CIRCULATION, V84, P1962, DOI 10.1161/01.CIR.84.5.1962; GRIFFITH MJ, 1988, LANCET, V1, P672; Herbert ME, 1997, ANN EMERG MED, V29, P172, DOI 10.1016/S0196-0644(97)70324-X; JOHNSON EA, 1956, NATURE, V178, P1174, DOI 10.1038/1781174a0; JOSEPHSON ME, 1993, CLIN CARDIAC ELECTRO, P181; Kim IB, 1996, CIRCULATION, V94, P2961, DOI 10.1161/01.CIR.94.11.2961; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; Lerman BB, 1996, J CARDIOVASC ELECTR, V7, P559, DOI 10.1111/j.1540-8167.1996.tb00563.x; LI HGG, 1994, J AM COLL CARDIOL, V24, P728, DOI 10.1016/0735-1097(94)90021-3; LOPEZ JA, 1994, TEX HEART I J, V21, P130; MORADY F, 1988, J AM COLL CARDIOL, V11, P1235, DOI 10.1016/0735-1097(88)90287-2; NUNAIN SO, 1992, CARDIOVASC RES, V26, P939, DOI 10.1093/cvr/26.10.939; ONUNAIN S, 1993, AM J CARDIOL, V71, P248, DOI 10.1016/0002-9149(93)90748-2; RANKIN AC, 1993, BRIT HEART J, V69, P263; RENSMA PL, 1988, CIRC RES, V62, P395, DOI 10.1161/01.RES.62.2.395; Silverman AJ, 1996, AM J EMERG MED, V14, P300, DOI 10.1016/S0735-6757(96)90182-5; SLADE AKB, 1993, BRIT HEART J, V70, P91; SMEETS JLRM, 1986, CIRC RES, V58, P96, DOI 10.1161/01.RES.58.1.96; Smith JR, 1997, PACE, V20, P743, DOI 10.1111/j.1540-8159.1997.tb03897.x; TEBBENJOHANNS J, 1995, PACE, V18, P743, DOI 10.1111/j.1540-8159.1995.tb04673.x; WALKER KW, 1995, PACE, V18, P441, DOI 10.1111/j.1540-8159.1995.tb02543.x; WELLS JL, 1978, PACE, V1, P426, DOI 10.1111/j.1540-8159.1978.tb03504.x; WEST GA, 1985, PFLUG ARCH EUR J PHY, V403, P75, DOI 10.1007/BF00583285; WHALLEY DW, 1995, PACE, V18, P1556, DOI 10.1111/j.1540-8159.1995.tb06742.x; WIENER N, 1946, Arch Inst Cardiol Mex, V16, P205	39	71	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					417	422		10.7326/0003-4819-127-6-199709150-00001	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9312997				2022-12-28	WOS:A1997XV77900001
J	Zuckerman, E; Zuckerman, T; Levine, AM; Douer, D; Gutekunst, K; Mizokami, M; Qian, DG; Velankar, M; Nathwani, BN; Fong, TL				Zuckerman, E; Zuckerman, T; Levine, AM; Douer, D; Gutekunst, K; Mizokami, M; Qian, DG; Velankar, M; Nathwani, BN; Fong, TL			Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma	ANNALS OF INTERNAL MEDICINE			English	Article							ESSENTIAL MIXED CRYOGLOBULINEMIA; NON-A; LYMPHOPROLIFERATIVE DISORDERS; PERIPHERAL-BLOOD; UNITED-STATES; RISK-FACTORS; HCV; ASSAY; DONORS; RNA	Background: Several studies from Europe have reported a high prevalence (9% to 32%) of chronic hepatitis C virus (HCV) infection in patients with B-cell non-Hodgkin lymphoma. It has been suggested that HCV plays a role in the pathogenesis of B-cell non-Hodgkin lymphoma. Objective: To determine the prevalence of HCV infection in patients with B-cell lymphoma in the United States. Design: Controlled, cross-sectional analysis. Setting: University medical center. Patients: 120 patients with B-cell lymphoma (78% were Hispanic, 9% were black, 7% were Asian, and 6% were white), 154 patients with other malignant hematologic conditions (control group 1), and 114 patients with nonmalignant conditions (control group 2). Measurements: Samples were tested for antibodies to HCV by enzyme-linked immunosorbent assay. Hepatitis C virus RNA was detected by reverse-transcription polymerase chain reaction. Genotyping for HCV was done with genotype-specific primers from the HCV core region. Results: infection with HCV was detected in 26 patients (22% [95% CI, 15% to 30%]) with B-cell lymphoma compared with 7 of 154 patients (4.5%) in control group 1 and 6 of 114 patients (5%) in control group 2 (P < 0.001). Risk factors for HCV infection were present in 15 patients (60%) with B-cell lymphoma and occurred a median of 15 years before diagnosis of lymphoma. Monocytoid B-cell lymphoma was the most common type of lymphoma found in HCV-positive patients (23% compared with 7% in HCV-negative patients) (P = 0.034). Conclusions: The prevalence of HCV infection was higher in patients with B-cell non-Hodgkin lymphoma than in controls. The possible role of HCV in the pathogenesis of B-cell lymphoma warrants further investigation.	UNIV SO CALIF, SCH MED, DIV HEMATOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA; ROCHE MOL SYST, SOMERVILLE, NJ 08876 USA; NAGOYA CITY UNIV, SCH MED, NAGOYA, AICHI 467, JAPAN	University of Southern California; University of Southern California; Roche Holding; Nagoya City University								AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COGLIATTI SB, 1990, J CLIN PATHOL, V43, P619, DOI 10.1136/jcp.43.8.619; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; ELLIS M, 1995, EUR J CLIN INVEST, V25, P833, DOI 10.1111/j.1365-2362.1995.tb01692.x; FERRI C, 1993, EUR J CLIN INVEST, V23, P399, DOI 10.1111/j.1365-2362.1993.tb00782.x; FERRI C, 1994, BRIT J HAEMATOL, V88, P392, DOI 10.1111/j.1365-2141.1994.tb05036.x; FERRI C, 1993, BLOOD, V82, P3701; FRANZIN F, 1995, BRIT J HAEMATOL, V90, P548, DOI 10.1111/j.1365-2141.1995.tb05582.x; Hanley J, 1996, LANCET, V347, P1339, DOI 10.1016/S0140-6736(96)90991-5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lau JYN, 1996, ANN INTERN MED, V124, P868, DOI 10.7326/0003-4819-124-10-199605150-00002; McColl MD, 1996, BRIT J HAEMATOL, V92, P771; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MONTALTO G, 1995, HEPATOLOGY, V22, P1409; MONTEVERDE A, 1988, ACTA HAEMATOL-BASEL, V79, P20, DOI 10.1159/000205684; MONTEVRDE A, 1994, P M HCV CRYOGLOBULIN, P34; MUSSINI C, 1995, BLOOD, V85, P1144, DOI 10.1182/blood.V85.4.1144.bloodjournal8541144; NATHWANI BN, 1992, HUM PATHOL, V23, P1061, DOI 10.1016/0046-8177(92)90270-D; NATHWANI BN, 1992, NEOPLASTIC HEMATOPAT, P555; NGAN BY, 1991, HUM PATHOL, V22, P409, DOI 10.1016/0046-8177(91)90125-9; NOLTE FS, 1995, J CLIN MICROBIOL, V33, P1775, DOI 10.1128/JCM.33.7.1775-1778.1995; Ohno T, 1997, J CLIN MICROBIOL, V35, P201, DOI 10.1128/JCM.35.1.201-207.1997; PAWLOTSKY JM, 1995, ANN INTERN MED, V122, P169, DOI 10.7326/0003-4819-122-3-199502010-00002; Pioltelli P, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91328-8; PORTER DD, 1986, PROG MED VIROL, V33, P42; ROSENBERG SA, 1982, CANCER, V49, P2112; SANTINI GF, 1993, BLOOD, V82, P2932; SAXENA S, 1995, LAB MED, V26, P682, DOI 10.1093/labmed/26.10.682; SHEIBANI K, 1988, CANCER, V62, P1531, DOI 10.1002/1097-0142(19881015)62:8<1531::AID-CNCR2820620814>3.0.CO;2-A; SHEIBANI K, 1986, AM J PATHOL, V124, P310; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Silvestri F, 1996, BLOOD, V87, P4296, DOI 10.1182/blood.V87.10.4296.bloodjournal87104296; VANDERPOEL C, 1991, TRANSFUSION, V31, P777; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X	39	348	352	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					423	428		10.7326/0003-4819-127-6-199709150-00002	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9312998				2022-12-28	WOS:A1997XV77900002
J	Devendra, D; Walker, A; MacFarlane, IA; Williams, G				Devendra, D; Walker, A; MacFarlane, IA; Williams, G			Confusion after visiting the radiology department	LANCET			English	Article							WATER	A 32-year-old woman came to hospital as an emergency in October, 1996, with worsening confusion for 24 h. On admission, she was unconscious (Glasgow coma score [GCS] of 5) with a pulse rate of 54 beats per minute, blood pressure of 84/56 mm Hg, and rectal temperature of 34 degrees C. There had been no history of trauma or bleeding. There were no focal neurological abnormalities. Laboratory blood glucose concentration was less than 1 mmol/L. She was given intravenous 10% glucose (1250 mL) but remained unconscious even when normoglycaemia was restored. Her bladder was catheterised, but was empty. Biochemistry screening showed a plasma sodium of 117 mmol/L, potassium 4.3 mmol/L, urea 4.9 mmol/L. Arterial blood analysis showed a mild metabolic acidosis (pH 7.25, base excess -12 mmol/L).			Devendra, D (corresponding author), FAZAKERLEY DIST GEN HOSP,DIABET & ENDOCRINOL CLIN RES GRP,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND.							BERL T, 1976, KIDNEY INT, V10, P117, DOI 10.1038/ki.1976.83; CHRISTENSON LL, 1985, POSTGRAD MED, V77, P161, DOI 10.1080/00325481.1985.11698898; LEVY MS, 1946, J CLIN ENDOCR METAB, V6, P607, DOI 10.1210/jcem-6-9-607	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					780	780		10.1016/S0140-6736(97)06439-8	http://dx.doi.org/10.1016/S0140-6736(97)06439-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297999				2022-12-28	WOS:A1997XW28200014
J	Burt, RA				Burt, RA			The Supreme Court speaks - Not assisted suicide but a constitutional right to palliative care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Burt, RA (corresponding author), YALE UNIV,SCH LAW,NEW HAVEN,CT 06520, USA.							Cherny N I, 1994, J Palliat Care, V10, P31; *INST MED, 1997, APPR DEATH IMPR CAR, P10; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; Pisano DJ, 1996, J LAW MED ETHICS, V24, P310, DOI 10.1111/j.1748-720X.1996.tb01872.x; Portenoy RK, 1996, J LAW MED ETHICS, V24, P296, DOI 10.1111/j.1748-720X.1996.tb01871.x	5	125	125	3	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1234	1236		10.1056/NEJM199710233371712	http://dx.doi.org/10.1056/NEJM199710233371712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9337388				2022-12-28	WOS:A1997YB71800012
J	Levitt, MA; Hong, AR				Levitt, MA; Hong, AR			A little survivor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Levitt, MA (corresponding author), SCHNEIDER CHILDRENS HOSP,NEW HYDE PK,NY 11040, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1208	1208		10.1056/NEJM199710233371705	http://dx.doi.org/10.1056/NEJM199710233371705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337380				2022-12-28	WOS:A1997YB71800005
J	Boshoff, C; Endo, Y; Collins, PD; Takeuchi, Y; Reeves, JD; Schweickart, VL; Siani, MA; Sasaki, T; Williams, TJ; Gray, PW; Moore, PS; Chang, Y; Weiss, RA				Boshoff, C; Endo, Y; Collins, PD; Takeuchi, Y; Reeves, JD; Schweickart, VL; Siani, MA; Sasaki, T; Williams, TJ; Gray, PW; Moore, PS; Chang, Y; Weiss, RA			Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines	SCIENCE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; MULTICENTRIC CASTLEMANS DISEASE; KAPOSIS-SARCOMA; DNA-SEQUENCES; TAT PROTEIN; MOLECULAR-CLONING; GROWTH-FACTOR; C CHEMOKINE; CELLS; INFECTION	Unique among known human herpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) encodes chemokine-like proteins (vMIP-I and VMIP-II). VMIP-II was shown to block infection of human immunodeficiency virus-type 1 (HIV-1) on a CD4-positive cell line expressing CCR3 and to a lesser extent on one expressing CCR5, whereas both vMIP-I and VMIP-II partially inhibited HIV infection of peripheral blood mononuclear cells. Like eotaxin, VMIP-II activated and chemoattracted human eosinophils by way of CCR3. vMIP-I and VMIP-II, but not cellular MIP-1 alpha or RANTES, were highly angiogenic in the chorioallantoic assay, suggesting a possible pathogenic role in Kaposi's sarcoma.	KANAZAWA UNIV,DEPT EXPT THERAPEUT,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,DEV CTR MOL TARGET DRUGS,CANC RES INST,KANAZAWA,ISHIKAWA 920,JAPAN; NATL HEART & LUNG INST,IMPERIAL COLL SCH MED,DEPT APPL PHARMACOL,LONDON SW3 6LY,ENGLAND; ICOS,BOTHELL,WA 98021; GRYPHON SCI,SAN FRANCISCO,CA 94080; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL & EPIDEMIOL,NEW YORK,NY 10032	Kanazawa University; Kanazawa University; Imperial College London; Icos Corporation; Columbia University	Boshoff, C (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND.		ENDO, Yoshio/D-8428-2015; Moore, Patrick/GVR-8294-2022; Reeves, Jacqueline/I-5379-2012; Moore, Patrick S./F-3960-2011; Chang, Yuan/F-4146-2011	ENDO, Yoshio/0000-0003-0785-2006; Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041	NCI NIH HHS [CA 67391] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Angiolillo AL, 1996, ANN NY ACAD SCI, V795, P158, DOI 10.1111/j.1749-6632.1996.tb52664.x; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P761; BOSHOFF C, UNPUB; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Chadburn A, 1997, CANCER-AM CANCER SOC, V80, P788, DOI 10.1002/(SICI)1097-0142(19970815)80:4&lt;788::AID-CNCR18&gt;3.0.CO;2-P; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Danesi R, 1997, CLIN CANCER RES, V3, P265; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUPIN N, 1995, NEW ENGL J MED, V333, P798; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gessain A, 1996, BLOOD, V87, P414; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; KNIGHTON D, 1977, BRIT J CANCER, V35, P347, DOI 10.1038/bjc.1977.49; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOSER B, 1993, J BIOL CHEM, V268, P7125; Murphy PM, 1997, NATURE, V385, P296, DOI 10.1038/385296a0; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OIKAWA T, 1991, CANCER LETT, V59, P57, DOI 10.1016/0304-3835(91)90136-6; ORENSTEIN JM, 1997, J ACQ IMMUN DEF SYND, V11, P735; PARRAVICINI C, IN PRES AM J PATHOL; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; WAHMAN A, 1991, EPIDEMIOL REV, V13, P178, DOI 10.1093/oxfordjournals.epirev.a036068; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; YOSHIZAKI K, 1989, BLOOD, V74, P1360	59	395	423	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					290	294		10.1126/science.278.5336.290	http://dx.doi.org/10.1126/science.278.5336.290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323208				2022-12-28	WOS:A1997YA56400045
J	Howard, J				Howard, J			Molecular motors: structural adaptations to cellular functions	NATURE			English	Review							MICROTUBULE-ACTIVATED ATPASE; SINGLE KINESIN MOLECULES; SKINNED MUSCLE-FIBERS; MYOSIN POWER STROKE; ACTIN-FILAMENTS; CONTRACTING MUSCLE; IN-VITRO; SMOOTH-MUSCLE; ADP RELEASE; CRYOELECTRON MICROSCOPY	Molecular motors are protein machines whose directed movement along cytoskeletal filaments is driven by ATP hydrolysis. Eukaryotic cells contain motors that help to transport organelles to their correct cellular locations and to establish and alter cellular morphology during cell locomotion and division. The best-studied motors, myosin from skeletal muscle and conventional kinesin from brain, are remarkably similar in structure, yet have very different functions. These differences can be understood in terms of the 'duty ratio', the fraction of the time that a motor Is attached to its filament. Differences in duty ratio can explain the diversity of structures, speeds and oligomerization states of members of the large kinesin, myosin and dynein families of motors.			Howard, J (corresponding author), UNIV WASHINGTON, DEPT PHYSIOL & BIOPHYS, BOX 357290, SEATTLE, WA 98195 USA.		Howard, Jonathon/D-4229-2011; Howard, Jonathon/J-7492-2016	Howard, Jonathon/0000-0003-0086-1196; Howard, Jonathon/0000-0003-0086-1196				Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; Bahler M, 1996, CURR OPIN CELL BIOL, V8, P18, DOI 10.1016/S0955-0674(96)80043-3; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BLOCK SM, 1995, NATURE, V378, P132, DOI 10.1038/378132a0; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRENNEN C, 1977, ANNU REV FLUID MECH, V9, P339, DOI 10.1146/annurev.fl.09.010177.002011; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CHEN YD, 1993, P NATL ACAD SCI USA, V90, P5148, DOI 10.1073/pnas.90.11.5148; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; CREVEL IMT, IN PRESS J MOL BIOL; DILLON PF, 1982, CIRC RES, V50, P799, DOI 10.1161/01.RES.50.6.799; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FERENCZI MA, 1984, J PHYSIOL-LONDON, V350, P519, DOI 10.1113/jphysiol.1984.sp015216; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FORD LE, 1985, J PHYSIOL-LONDON, V361, P131, DOI 10.1113/jphysiol.1985.sp015637; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GIBBONS BH, 1994, MOL BIOL CELL, V5, P57, DOI 10.1091/mbc.5.1.57; GILLESPIE PG, 1995, CURR OPIN NEUROBIOL, V5, P449, DOI 10.1016/0959-4388(95)80004-2; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hamasaki T, 1995, BIOPHYS J, V69, P2569, DOI 10.1016/S0006-3495(95)80128-1; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HIGUCHI H, 1995, BIOPHYS J, V69, P1000, DOI 10.1016/S0006-3495(95)79975-1; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; Hille B., 1992, IONIC CHANNELS EXCIT; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Huxley AF, 1996, J MUSCLE RES CELL M, V17, P507, DOI 10.1007/BF00123366; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1994, BIOPHYS J, V67, P2411, DOI 10.1016/S0006-3495(94)80728-3; HUXLEY HE, 1965, SCI AM, V213, P18, DOI 10.1038/scientificamerican1265-18; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; KOJIMA H, 1994, P NATL ACAD SCI USA, V91, P12962, DOI 10.1073/pnas.91.26.12962; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Mehta AD, 1997, P NATL ACAD SCI USA, V94, P7927, DOI 10.1073/pnas.94.15.7927; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; MOLLOY JE, 1995, BIOPHYS J, V68, pS298; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RIVOLTA MN, 1995, BBA-BIOENERGETICS, V1232, P1, DOI 10.1016/0005-2728(95)00107-1; SANGER JM, 1990, CELL MOTIL CYTOSKE S, V2; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Suzuki N, 1996, BIOPHYS J, V70, P401, DOI 10.1016/S0006-3495(96)79583-8; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WADE RH, 1993, J STRUCT BIOL, V110, P1, DOI 10.1006/jsbi.1993.1001; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; YOKOTA E, 1994, J CELL SCI, V107, P353; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	88	435	438	2	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	1997	389	6651					561	567		10.1038/39247	http://dx.doi.org/10.1038/39247			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335494				2022-12-28	WOS:A1997YA00800048
J	Taddei, F; Hayakawa, H; Bouton, MF; Cirinesi, AM; Matic, I; Sekiguchi, M; Radman, M				Taddei, F; Hayakawa, H; Bouton, MF; Cirinesi, AM; Matic, I; Sekiguchi, M; Radman, M			Counteraction by MutT protein of transcriptional errors caused by oxidative damage	SCIENCE			English	Article							ESCHERICHIA-COLI; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; MUTATIONS; CLONING; CDNA; SUBSTITUTIONS; TRANSLATION; REPLICATION; ELIMINATION	Oxidized guanine (8-oxo-7,8-dihydroguanine; 8-oxo-G) is a potent mutagen because of its ambiguous pairing with cytosine and adenine. The Escherichia coli MutT protein specifically hydrolyzes both 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP) and 8-oxo-guanosine triphosphate (8-oxo-rGTP), which are otherwise incorporated in DNA and RNA opposite template A. In vivo, this cleaning of the nucleotide pools decreases both DNA replication and transcription errors. The effect of mutT mutation on transcription fidelity was shown to depend on oxidative metabolism Such control of transcriptional fidelity by the ubiquitous MutT function has implications for evolution of RNA-based life, phenotypic expression, adaptive mutagenesis, and functional maintenance of nondividing cells.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 812,JAPAN; FUKUOKA DENT COLL,DEPT BIOL,FUKUOKA 81401,JAPAN; INST JACQUES MONOD,F-75251 PARIS 05,FRANCE	Kyushu University; Fukuoka Dental College (FDC); UDICE-French Research Universities; Universite Paris Cite			; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0002-7034-4365; Radman, Miroslav/0000-0003-0216-3148				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES BA, 1995, NATURE, V375, P741, DOI 10.1038/375741a0; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; CUPPLES CG, 1988, GENETICS, V120, P637; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; Galitski T, 1996, GENETICS, V143, P645; GALLANT J, 1979, MECH AGEING DEV, V10, P27, DOI 10.1016/0047-6374(79)90068-X; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; HAYAKAWA H, 1997, UNPUB; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Miller J.H., 1972, EXPT MOL GENETICS; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; NINIO J, 1991, BIOCHIMIE, V73, P1517, DOI 10.1016/0300-9084(91)90186-5; NINIO J, 1991, GENETICS, V129, P957; ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517; RADMAN M, 1973, PHYSICOCHEMICAL PROP, V3, P161; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; TADDEI F, UNPUB; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	29	244	250	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					128	130		10.1126/science.278.5335.128	http://dx.doi.org/10.1126/science.278.5335.128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311918				2022-12-28	WOS:A1997XZ12400054
J	Yu, SP; Yeh, CH; Sensi, SL; Gwag, BJ; Canzoniero, LMT; Farhangrazi, ZS; Ying, HS; Tian, M; Dugan, LL; Choi, DW				Yu, SP; Yeh, CH; Sensi, SL; Gwag, BJ; Canzoniero, LMT; Farhangrazi, ZS; Ying, HS; Tian, M; Dugan, LL; Choi, DW			Mediation of neuronal apoptosis by enhancement of outward potassium current	SCIENCE			English	Article							IONOPHORE-INDUCED APOPTOSIS; CEREBELLAR GRANULE CELLS; RAT CORTICAL-NEURONS; INTRACELLULAR CALCIUM; K+-CHANNELS; HIPPOCAMPAL-NEURONS; DNA FRAGMENTATION; NERVOUS-SYSTEM; LYMPHOCYTE-T; CA2+ INFLUX	Apoptosis of mouse neocortical neurons induced by serum deprivation or by staurosporine was associated with an early enhancement of delayed rectifier (I-K) current and loss of total intracellular K+. This I-K augmentation was not seen in neurons undergoing excitotoxic necrosis or in older neurons resistant to staurosporine-induced apoptosis. Attenuating outward K+ current with tetraethylammonium or elevated extracellular K+, but not blockers of Ca2+, Cl-, or other K+ channels, reduced apoptosis, even if associated increases in intracellular Ca2+ concentration were prevented. Furthermore, exposure to the K+ ionophore valinomycin or the K+-channel opener cromakalim induced apoptosis. Enhanced K+ efflux may mediate certain forms of neuronal apoptosis.	WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR STUDY NERVOUS SYST INJURY, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; CANZONIERO, Lorella Maria Teresa/0000-0003-2255-5341	PHS HHS [30337] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams P R, 1986, Adv Neurol, V44, P137; ALLBRITTON NL, 1988, J EXP MED, V167, P514, DOI 10.1084/jem.167.2.514; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; BEHRENS MI, UNPUB; BENNETT MR, 1979, BRAIN RES, V173, P549, DOI 10.1016/0006-8993(79)90250-6; CHALAZONITIS A, 1980, DEV BIOL, V78, P173, DOI 10.1016/0012-1606(80)90327-9; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; COLLINS F, 1991, J NEUROSCI, V11, P2582; CONE CD, 1976, SCIENCE, V192, P155, DOI 10.1126/science.56781; DECKERS CLP, 1993, EXP CELL RES, V208, P362, DOI 10.1006/excr.1993.1257; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; deLuca A, 1996, J NEUROSCI, V16, P4174; DEUTSCH C, 1990, PROG CLIN BIOL RES, V334, P251; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; ENOKIDO Y, 1993, NEUROSCIENCE, V57, P965, DOI 10.1016/0306-4522(93)90041-D; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FRANKLIN JL, 1995, J NEUROSCI, V15, P643; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HILLE B, 1967, J GEN PHYSIOL, V50, P1287, DOI 10.1085/jgp.50.5.1287; JOHNSON EM, 1992, EXP NEUROL, V115, P163, DOI 10.1016/0014-4886(92)90242-I; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KONISHI T, 1989, J PHYSIOL-LONDON, V411, P115, DOI 10.1113/jphysiol.1989.sp017564; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LAMPE PA, 1995, J NEUROBIOL, V26, P205, DOI 10.1002/neu.480260205; LEE SC, 1986, J CELL BIOL, V102, P1200, DOI 10.1083/jcb.102.4.1200; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCDONALD JW, IN PRESS BRAIN RES; MURRELL RD, 1993, EUR J NEUROSCI, V5, P1261, DOI 10.1111/j.1460-9568.1993.tb00911.x; NEHER E, 1972, PFLUG ARCH EUR J PHY, V336, P87, DOI 10.1007/BF00592924; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; POLITI DMT, 1989, EUR J PHARMACOL, V168, P7, DOI 10.1016/0014-2999(89)90626-2; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; Rose Kamala, 1993, P46; ROUZAIREDUBOIS B, 1991, CELL SIGNAL, V3, P333, DOI 10.1016/0898-6568(91)90062-Y; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SANCHEZ DY, 1992, J GEN PHYSIOL, V100, P217, DOI 10.1085/jgp.100.2.217; SCOTT BS, 1970, EXP NEUROL, V27, P16, DOI 10.1016/0014-4886(70)90197-4; TAKEI N, 1994, BRAIN RES, V652, P65, DOI 10.1016/0006-8993(94)90317-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UCKER DS, 1991, NEW BIOL, V3, P103; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x	51	515	551	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					114	117		10.1126/science.278.5335.114	http://dx.doi.org/10.1126/science.278.5335.114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311914				2022-12-28	WOS:A1997XZ12400050
J	Jusczyk, PW; Hohne, EA				Jusczyk, PW; Hohne, EA			Infants' memory for spoken words	SCIENCE			English	Article							SPEECH-PERCEPTION; YOUNG INFANTS; SOUND PATTERNS; CATEGORIES; PREFERENCE; KNOWLEDGE; CUES	Infants' long-term retention of the sound patterns of words was explored by exposing them to recordings of three children's stories for 10 days during a 2-week period when they were 8 months old, After an interval of 2 weeks, the infants heard lists of words that either occurred frequently or did not occur in the stories. The infants listened significantly longer to the lists of story words. By comparison, a control group of infants who had not been exposed to the stories showed no such preference. The findings suggest that 8-month-olds are beginning to engage in long-term storage of words that occur frequently in speech, which is an important prerequisite for learning language.	JOHNS HOPKINS UNIV,DEPT COGNIT SCI,BALTIMORE,MD 21218	Johns Hopkins University	Jusczyk, PW (corresponding author), JOHNS HOPKINS UNIV,DEPT PSYCHOL,BALTIMORE,MD 21218, USA.				NICHD NIH HHS [HD15795] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASLIN RN, IN PRESS HDB CHILD P, V2; BAILLARGEON R, 1991, CHILD DEV, V62, P1227, DOI 10.2307/1130803; Best C. T., 1995, ADV INFANCY RES, P217; EIMAS PD, 1971, SCIENCE, V171, P303, DOI 10.1126/science.171.3968.303; EIMAS PD, 1975, PERCEPT PSYCHOPHYS, V18, P341, DOI 10.3758/BF03211210; EIMAS PD, 1994, CHILD DEV, V65, P903; EIMAS PD, 1974, PERCEPT PSYCHOPHYS, V16, P513, DOI 10.3758/BF03198580; EIMAS PD, 1980, SCIENCE, V209, P1140, DOI 10.1126/science.7403875; Halle PA, 1996, INFANT BEHAV DEV, V19, P463, DOI 10.1016/S0163-6383(96)90007-7; Jusczyk P., 1997, DISCOVERY SPOKEN LAN; JUSCZYK PW, 1993, CHILD DEV, V64, P675, DOI 10.2307/1131210; JUSCZYK PW, 1993, J MEM LANG, V32, P402, DOI 10.1006/jmla.1993.1022; JUSCZYK PW, 1995, COGNITIVE PSYCHOL, V29, P1, DOI 10.1006/cogp.1995.1010; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; KUHL PK, 1979, J ACOUST SOC AM, V66, P1668, DOI 10.1121/1.383639; MANDLER JM, 1993, COGNITIVE DEV, V8, P291, DOI 10.1016/S0885-2014(93)80003-C; MARLER P, 1990, DEV PSYCHOBIOL, V23, P557, DOI 10.1002/dev.420230703; Morgan JL, 1996, J MEM LANG, V35, P666, DOI 10.1006/jmla.1996.0035; NELSON DGK, 1995, INFANT BEHAV DEV, V18, P111; QUINN PC, 1993, PERCEPTION, V22, P463, DOI 10.1068/p220463; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; SPELKE E, 1994, COGNITION, V50, P431, DOI 10.1016/0010-0277(94)90039-6; SPELKE ES, 1992, PSYCHOL REV, V99, P605, DOI 10.1037/0033-295X.99.4.605; WERKER JF, 1984, INFANT BEHAV DEV, V7, P49, DOI 10.1016/S0163-6383(84)80022-3	24	136	137	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1984	1986		10.1126/science.277.5334.1984	http://dx.doi.org/10.1126/science.277.5334.1984			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XX849	9302291				2022-12-28	WOS:A1997XX84900041
J	Kuo, CT; Veselits, ML; Leiden, JM				Kuo, CT; Veselits, ML; Leiden, JM			LKLF: A transcriptional regulator of single-positive T cell quiescence and survival	SCIENCE			English	Article							KRUPPEL-LIKE FACTOR; ACTIVATION; GENE; FAMILY; EKLF; IDENTIFICATION; RESPONSES; GLOBIN; MICE; LYMPHOCYTES	Mature single-positive (SP) T lymphocytes enter a ''resting'' state in which they are proliferatively quiescent and relatively resistant to apoptosis. The molecular mechanisms regulating this quiescent phenotype were unknown, Here it was found that the expression of a Kruppel-like zinc finger transcription factor, lung Kruppel-like factor (LKLF), is developmentally induced during the maturation of SP quiescent T cells and rapidly extinguished after SP T cell activation, LKLF-deficient T cells produced by gene targeting had a spontaneously activated phenotype and died in the spleen and lymph nodes from Fas ligand-induced apoptosis. Thus, LKLF is required to program the quiescent state of SP T cells and to maintain their viability in the peripheral lymphoid organs and blood.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI029637] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29637] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BARTON K, UNPUB; Baunoch DA, 1996, INT J ONCOL, V8, P895; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BUDD RC, 1987, J IMMUNOL, V138, P3120; CHEN J, 1994, TRANSGENESIS TARGETE, P35; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREEN JM, 1994, IMMUNOL RES, V13, P234, DOI 10.1007/BF02935615; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNG TM, 1988, J IMMUNOL, V141, P4110; KUO CH, UNPUB; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN IL, 1994, CELL, V76, P207, DOI 10.1016/0092-8674(94)90329-8; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369	45	333	341	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1986	1990		10.1126/science.277.5334.1986	http://dx.doi.org/10.1126/science.277.5334.1986			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302292				2022-12-28	WOS:A1997XX84900042
J	Valdivia, RH; Falkow, S				Valdivia, RH; Falkow, S			Fluorescence-based isolation of bacterial genes expressed within host cells	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM VIRULENCE; ESCHERICHIA-COLI; IDENTIFICATION; SELECTION; SECRETION; MACROPHAGES; AVIRULENT; PROTEINS; MUTANTS; SURVIVE	A selection strategy was devised to identify bacterial genes preferentially expressed when a bacterium associates with its host cell. Fourteen Salmonella typhimurium genes, which were under the control of at least four independent regulatory circuits, were identified to be selectively induced in host macrophages. Four genes encode virulence factors, including a component of a type III secretory apparatus. This selection methodology should be generally applicable to the identification of genes from pathogenic organisms that are induced upon association with host cells or tissues.			Valdivia, RH (corresponding author), STANFORD UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, STANFORD, CA 94305 USA.		Valdivia, Raphael/R-5377-2019	Valdivia, Raphael/0000-0003-0961-073X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26195] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAOUI A, 1992, J BACTERIOL, V174, P7661, DOI 10.1128/JB.174.23.7661-7669.1992; ALLAOUI A, 1995, MOL MICROBIOL, V18, P343, DOI 10.1111/j.1365-2958.1995.mmi_18020343.x; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DELPORTILLO FG, 1992, MOL MICROBIOL, V6, P3289; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GIROLOMONI G, 1995, EUR J IMMUNOL, V25, P2163, DOI 10.1002/eji.1830250807; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; GULIG PA, 1987, INFECT IMMUN, V55, P2891, DOI 10.1128/IAI.55.12.2891-2901.1987; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; GULIG PA, 1996, ESCHERICHIA COLI SAL, V2, P2774; Hensel M, 1997, MOL MICROBIOL, V24, P155, DOI 10.1046/j.1365-2958.1997.3271699.x; HORWITZ MA, 1987, J EXP MED, V166, P1310, DOI 10.1084/jem.166.5.1310; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; Mahan MJ, 1996, ESCHERICHIA COLI SAL, P2803; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; RHEN M, 1988, MICROB PATHOGENESIS, V5, P275, DOI 10.1016/0882-4010(88)90100-3; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; VALDIVIA RH, UNPUB; Wang JY, 1996, P NATL ACAD SCI USA, V93, P10434, DOI 10.1073/pnas.93.19.10434; Wanner BL, 1996, ESCHERICHIA COLI SAL, P1357, DOI DOI 10.1007/978-3-642-75969-7_16	33	488	515	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					2007	2011		10.1126/science.277.5334.2007	http://dx.doi.org/10.1126/science.277.5334.2007			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302299				2022-12-28	WOS:A1997XX84900049
J	Khuroo, MS; Wani, NA; Javid, G; Khan, BA; Yattoo, GN; Shah, AH; Jeelani, SG				Khuroo, MS; Wani, NA; Javid, G; Khan, BA; Yattoo, GN; Shah, AH; Jeelani, SG			Percutaneous drainage compared with surgery for hepatic hydatid cysts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL-TREATMENT; LIVER CYSTS; ECHINOCOCCUS-GRANULOSUS; SCLEROSING CHOLANGITIS; SONOGRAPHIC GUIDANCE; ALCOHOL INJECTION; DISEASE; ASPIRATION; ALBENDAZOLE; MANAGEMENT	Background In recent years percutaneous drainage has been used successfully to treat the hepatic hydatid cysts of echinococcal disease. We performed a controlled trial to compare the safety and efficacy of percutaneous drainage with those of surgical cystectomy, the traditional treatment. Methods In a prospective study, we randomly assigned 50 patients with hepatic hydatidosis to treatment with percutaneous drainage (25 patients) or cystectomy (25). Albendazole (10 mg per kilogram of body weight per day for eight weeks) was administered to the patients who underwent percutaneous drainage. Serial assessments included clinical and biochemical examinations, ultrasonography, and serologic tests of echinococcal-antibody titers. Results The mean (+/-SD) hospital stay was 4.2+/-1.5 days in the drainage group and 12.7+/-6.5 days in the surgery group (P<0.001). Over a mean follow-up period of 17 months, the mean cyst diameter decreased from 8.0+/-3.0 to 1.4+/-3.5 cm (P<0.001) after percutaneous drainage and from 9.1+/-3.0 to 0.9+/-1.8 cm (P<0.001) after surgery. The final cyst diameter did not differ significantly between the two groups (P=0.20). The cysts disappeared in 22 patients (88 percent) in the drainage group and in 18 (72 percent) in the surgery group (P=0.29). After an initial rise, the echinococcal-antibody titers fell progressively and at the last follow-up were negative (<1:160) in 19 patients (76 percent) in the drainage group and 17 (68 percent) in the surgery group (P=0.74). There were procedure-related complications in 8 patients (32 percent) in the drainage group and 21 (84 percent) in the surgery group, 17 of whom had fever postoperatively (P<0.001). Conclusions Percutaneous drainage, combined with albendazole therapy, is an effective and safe alternative to surgery for the treatment of uncomplicated hydatid cysts of the liver and requires a shorter hospital stay. (C) 1997, Massachusetts Medical Society.	SHERI KASHMIR INST MED SCI, DEPT GASTROENTEROL, SRINAGAR, JAMMU & KASHMIR, INDIA; SHERI KASHMIR INST MED SCI, DEPT GEN SURG, SRINAGAR, JAMMU & KASHMIR, INDIA	Sher-i-Kashmir Institute of Medical Sciences; Sher-i-Kashmir Institute of Medical Sciences			Khuroo, Mohammad Sultan/N-3571-2014	Khuroo, Mohammad Sultan/0000-0003-2823-8814				ACUNAS B, 1992, RADIOLOGY, V182, P541, DOI 10.1148/radiology.182.2.1732977; Akhan O, 1996, RADIOLOGY, V198, P259, DOI 10.1148/radiology.198.1.8539390; ALKARAWI MA, 1991, ENDOSCOPY, V23, P278, DOI 10.1055/s-2007-1010686; Ammann RW, 1996, GASTROENTEROL CLIN N, V25, P655, DOI 10.1016/S0889-8553(05)70268-5; BASTID C, 1994, DIGEST DIS SCI, V39, P1576, DOI 10.1007/BF02088067; CASTELLANO G, 1994, HEPATO-GASTROENTEROL, V41, P458; EKRAMI Y, 1976, ARCH SURG-CHICAGO, V111, P1350; FILICE C, 1990, GASTROENTEROLOGY, V98, P1366, DOI 10.1016/0016-5085(90)90358-8; GARGOURI M, 1990, CARDIOVASC INTER RAD, V13, P169, DOI 10.1007/BF02575469; GILGRANDE LA, 1993, LANCET, V342, P1269, DOI 10.1016/0140-6736(93)92361-V; GILGRANDE LA, 1983, AM J GASTROENTEROL, V78, P584; GIORGIO A, 1992, RADIOLOGY, V184, P705, DOI 10.1148/radiology.184.3.1509053; GORI S, 1993, ACTA CYTOL, V37, P423; KARAVIAS DD, 1992, SURG GYNECOL OBSTET, V174, P176; KHUROO MS, 1993, GASTROENTEROLOGY, V104, P1452, DOI 10.1016/0016-5085(93)90355-G; KHUROO MS, 1991, RADIOLOGY, V180, P141, DOI 10.1148/radiology.180.1.2052682; LANGER JC, 1984, ANN SURG, V199, P412, DOI 10.1097/00000658-198404000-00007; MILICEVIC M, 1994, SURG LIVER BILIARY T, V2, P1121; MORRIS DL, 1985, JAMA-J AM MED ASSOC, V253, P2053, DOI 10.1001/jama.253.14.2053; MORRIS DL, 1994, GUT, V35, P1517, DOI 10.1136/gut.35.11.1517; Munro BH, 1986, STAT METHODS HLTH CA; PLACER C, 1991, GASTROENTEROLOGY, V100, P290, DOI 10.1016/0016-5085(91)90630-4; SAYEK I, 1980, ARCH SURG-CHICAGO, V115, P847; SCHILLER CF, 1966, J AMER MED ASSOC, V195, P220, DOI 10.1001/jama.195.3.220; SIMONETTI G, 1993, CARDIOVASC INTER RAD, V16, P81, DOI 10.1007/BF02602983; SMYTH JD, 1980, T ROY SOC TROP MED H, V74, P649, DOI 10.1016/0035-9203(80)90157-1; TEGGI A, 1993, ANTIMICROB AGENTS CH, V37, P1679, DOI 10.1128/AAC.37.8.1679; TSIMOYIANNIS EC, 1995, EUR J SURG, V161, P299; Vuitton DA, 1996, B WORLD HEALTH ORGAN, V74, P231; WATTAL C, 1986, J CLIN MICROBIOL, V24, P41, DOI 10.1128/JCM.24.1.41-46.1986; YALIN R, 1989, Journal of Medical Imaging, V3, P301; ZARGAR SA, 1992, GASTROINTEST RADIOL, V17, P41, DOI 10.1007/BF01888506	32	234	250	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					881	887		10.1056/NEJM199709253371303	http://dx.doi.org/10.1056/NEJM199709253371303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX302	9302302	Bronze			2022-12-28	WOS:A1997XX30200003
J	Seretakis, D; Lagiou, P; Lipworth, L; Signorello, LB; Rothman, KJ; Trichopoulos, D				Seretakis, D; Lagiou, P; Lipworth, L; Signorello, LB; Rothman, KJ; Trichopoulos, D			Changing seasonality of mortality from coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR MORTALITY; TEMPERATURE; DECLINE	Context.-Coronary heart disease is the major cause of mortality in the United States. Factors associated with coronary risk are important to identify, Coronary mortality is greater during the winter months. Objective.-To investigate whether declining coronary mortality has been accompanied by a change in the seasonal pattern and to investigate the hypothesis that diminishing exposures to environmental cold and heat have affected the seasonal pattern. Design.-We used published data on coronary mortality by year to evaluate the time trend in the seasonal pattern, We fit a sine curve to the monthly frequency of deaths in each year and examined the trend over time in the ratio of the peak to the trough of the curve. Setting.-We used monthly coronary deaths in the United States from 1937 through 1991. Deaths by cause and month were not available by geographic area within the United States, but we were able to examine total monthly deaths in 2 regions with contrasting climates, New England and the South. Outcome Measures.-We used the yearly peak-to-trough ratio as our primary outcome and assessed its trend over time by linear regression, We also depicted the time trends using polynomial smoothing. Results.-The peak-to-trough ratio diminished by about 2% per year until around 1970, when the trend reversed. In New England, the decline was steeper than in the South, as measured from all deaths. Conclusion.-Seasonal patterns in coronary mortality in the United States have changed with time, These changes are compatible with the gradual expansion of adequate heating and the subsequent increased use of air-conditioning. Microclimatic influences on coronary mortality could explain in part the socioeconomic gradient of cardiovascular mortality.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; BOSTON UNIV, MED CTR, DEPT EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, MED CTR, SECT PREVENT MED, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston University				Rothman, Kenneth/0000-0003-2398-1705				EDWARDS JH, 1961, ANN HUM GENET, V25, P83, DOI 10.1111/j.1469-1809.1961.tb01501.x; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HELLER RF, 1984, BRIT MED J, V288, P1409, DOI 10.1136/bmj.288.6428.1409; KATSOUYANNI K, 1988, LANCET, V2, P573; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; LLOYD OL, 1995, BRIT MED J, V310, P467, DOI 10.1136/bmj.310.6977.467; MARMOT MG, 1986, LANCET, V2, P274; *NAT CTR HLTH STAT, 1937, VIT STAT US; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; U. S. Bureau of the Census, 1996, STAT ABSTR US; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029	12	92	96	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1012	1014		10.1001/jama.278.12.1012	http://dx.doi.org/10.1001/jama.278.12.1012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307350				2022-12-28	WOS:A1997XX01200033
J	Kuo, JS				Kuo, JS			Swimming with the sharks - the MD, MBA	LANCET			English	Editorial Material											Kuo, JS (corresponding author), DISCOVERY LABS INC,509 MADISON AVE,14TH FLOOR,NEW YORK,NY 10022, USA.								0	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					828	828		10.1016/S0140-6736(05)62029-6	http://dx.doi.org/10.1016/S0140-6736(05)62029-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310599				2022-12-28	WOS:A1997XX40100007
J	Engel, MH; Macko, SA				Engel, MH; Macko, SA			Isotopic evidence for extraterrestrial non-racemic amino acids in the Murchison meteorite	NATURE			English	Article							ORGANIC-MOLECULES; MASS-SPECTROMETRY; CARBON; LIFE; HYDROCARBONS; ENANTIOMERS; EARTH; CHIRALITY; DELIVERY; ORIGINS	Many amino acids contain an asymmetric centre, occurring as laevorotatory, L, or dextrorotatory, D, compounds. It is generally assumed that abiotic synthesis of amino acids on the early Earth resulted in racemic mixtures (L-and D-enantiomers in equal abundance). But the origin of life required, owing to conformational constraints, the almost exclusive selection of either L-or D-enantiomers(1,2), and the question of why living-systems on the Earth consist of L-enantiomers rather than D-enantiomers is unresolved(3). A substantial fraction of the organic compounds on the early Earth may have been derived from comet and meteorite impacts(4-6). It has been reported previously that amino acids in the Murchison meteorite exhibit an excess of L-enantiomers(7), raising the possibility that a similar excess was present in the initial inventory of organic compounds on the Earth. The stable carbon isotope compositions of individual amino acids in Murchison support an extraterrestrial origin(8)-rather than a terrestrial overprint of biological amino acids-although reservations have persisted (see, for example, ref. 9). Here we show that individual amino-acid enantiomers from Murchison are enriched in N-15 relative to their terrestrial counterparts, so confirming an extraterrestrial source for an L-enantiomer excess in the Solar System that may predate the origin of life on the Earth.	UNIV VIRGINIA, DEPT ENVIRONM SCI, CHARLOTTESVILLE, VA 22903 USA	University of Virginia	Engel, MH (corresponding author), UNIV OKLAHOMA, SCH GEOL & GEOPHYS, NORMAN, OK 73019 USA.		Macko, Stephen/K-4588-2015					BONNER WA, 1991, ORIGINS LIFE EVOL B, V21, P59, DOI 10.1007/BF01809580; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; CHYBA CF, 1990, SCIENCE, V249, P366, DOI 10.1126/science.11538074; COHEN J, 1995, SCIENCE, V267, P1265, DOI 10.1126/science.7871419; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; ENGEL MH, 1994, P NATL ACAD SCI USA, V91, P10475, DOI 10.1073/pnas.91.22.10475; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; ENGEL MH, 1990, NATURE, V348, P47, DOI 10.1038/348047a0; ENGEL MH, 1993, ORGANIC GEOCHEMISTRY, P685; EPSTEIN S, 1987, NATURE, V326, P477, DOI 10.1038/326477a0; Fogel M.L., 1993, ORGANIC GEOCHEMISTRY, P73, DOI DOI 10.1007/978-1-4615-2890-6_3; GILMOUR I, 1992, METEORITICS, V27, P224; GOLDANSKII VI, 1991, NATURE, V352, P114, DOI 10.1038/352114a0; GRADY MM, 1988, GEOCHIM COSMOCHIM AC, V52, P2855, DOI 10.1016/0016-7037(88)90152-4; HARE PE, 1985, CHEM BIOCH AMINO ACI, P415; HOPPE P, 1995, GEOCHIM COSMOCHIM AC, V59, P4029, DOI 10.1016/0016-7037(95)00280-D; KIEFFER HH, 1992, MARS, P1; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; Macko SA, 1997, ANAL CHEM, V69, P926, DOI 10.1021/ac960956l; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MERRITT DA, 1994, J AM SOC MASS SPECTR, V5, P387, DOI 10.1016/1044-0305(94)85054-2; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; ORO J, 1961, NATURE, V190, P389, DOI 10.1038/190389a0; PIZZARELLO S, 1994, GEOCHIM COSMOCHIM AC, V58, P5579, DOI 10.1016/0016-7037(94)90251-8; PIZZARELLO S, 1991, GEOCHIM COSMOCHIM AC, V55, P905, DOI 10.1016/0016-7037(91)90350-E; SHOCK EL, 1990, GEOCHIM COSMOCHIM AC, V54, P3159, DOI 10.1016/0016-7037(90)90131-4; SILFER JA, 1991, ANAL CHEM, V63, P370, DOI 10.1021/ac00004a014; SILFER JA, 1994, ORG GEOCHEM, V21, P603, DOI 10.1016/0146-6380(94)90006-X; SILFER JA, 1991, THESIS U OKLAHOMA; VALLENTYNE JR, 1964, GEOCHIM COSMOCHIM AC, V28, P157, DOI 10.1016/0016-7037(64)90147-4; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0	32	386	391	4	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					265	268		10.1038/38460	http://dx.doi.org/10.1038/38460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305838				2022-12-28	WOS:A1997XW77200041
J	Polyak, K; Xia, Y; Zweier, JL; Kinzler, KW; Vogelstein, B				Polyak, K; Xia, Y; Zweier, JL; Kinzler, KW; Vogelstein, B			A model for p53-induced apoptosis	NATURE			English	Article							CELL-DEATH; GENE; P53; IDENTIFICATION; EXPRESSION	The inactivation of the p53 gene in a large proportion of human cancers has inspired an intense search for the encoded protein's physiological and biological properties. Expression of p53 induces either a stable growth arrest or programmed cell death (apoptosis). In human colorectal cancers, the growth arrest is dependent on the transcriptional induction of the protein p21(WAF1/CIP1) (ref. 1), but the mechanisms underlying the development of p53-dependent apoptosis are largely unknown(2). As the most well documented biochemical property of p53 is its ability to activate transcription of genes, we examined in detail the transcripts induced by p53 expression before the onset of apoptosis. Of 7,202 transcripts identified, only 14 (0.19%) were found to be markedly increased in p53-expressing cells compared with control cells. Strikingly, many of these genes were predicted to encode proteins that could generate or respond to oxidative stress, including one that is implicated in apoptosis in plant meristems, These observations stimulated additional biochemical and pharmacological experiments suggesting that p53 results in apoptosis through a three-step process: (1) the transcriptional induction of redox-related genes; (2) the formation of reactive oxygen species; and (3) the oxidative degradation of mitochondrial components, culminating in cell death.	JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; HOWARD HUGHES MED INST, BALTIMORE, MD 21231 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University			Pillay, Nischalan/F-9536-2012					BOREK C, 1987, British Journal of Cancer, V55, P74; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAULKNER K, 1993, FREE RADICAL BIO MED, V15, P447, DOI 10.1016/0891-5849(93)90044-U; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; HAYWARD DC, 1993, P NATL ACAD SCI USA, V90, P2979, DOI 10.1073/pnas.90.7.2979; HOLLAND PC, 1973, J BIOL CHEM, V248, P6050; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KREOMER G, 1997, IMMUNOL TODAY, V18, P45; Lehar SM, 1996, ONCOGENE, V12, P1181; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAO PV, 1992, J BIOL CHEM, V267, P96; RIENHOFF HY, 1990, MOL BIOL MED, V7, P287; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TAMM I, 1978, ADV VIRUS RES, V22, P188; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WALDMAN T, 1995, CANCER RES, V55, P5187; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	29	2174	2274	3	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					300	305		10.1038/38525	http://dx.doi.org/10.1038/38525			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305847				2022-12-28	WOS:A1997XW77200052
J	Feeney, M; Clegg, A; Winwood, P; Snook, J				Feeney, M; Clegg, A; Winwood, P; Snook, J			A case-control study of measles vaccination and inflammatory bowel disease	LANCET			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; RISK FACTOR; VIRUS; INFECTION; ABSENCE	Background The cause of inflammatory bowel disease (IBD) remains to be established. Evidence has linked measles infection in early childhood with the subsequent risk of developing IBD, particularly Crohn's disease. A cohort study raised the possibility that immunisation with live attenuated measles vaccine, which induces active immunity to measles infection, might also predispose to the later development of IBD, provoking concerns about the safety of the vaccine. Method We report a case-control study of 140 patients with IBD (including 83 with Crohn's disease) born in or after 1968, and 280 controls matched for age, sex acid general practitioner (GP) area, designed to assess the influence of measles vaccination on later development of IBD. Documentary evidence of childhood vaccination history was sought from GP and community health records. Findings Crude measles vaccination rates were 56.4% in patients with IBD and 57.1% among controls. Matched odds ratios for measles vaccination were 1.08 (95% CI in patients with Crohn's disease, 0.84 in patients with ulcerative colitis, and 0.97 (0.64-1.47) in all patients with IBD. Interpretation These findings provide no support for the hypothesis that measles vaccination in childhood predisposes to the later development of either IBD overall or Crohn's disease in particular.	POOLE HOSP,DEPT GASTROENTEROL,POOLE BH15 2JB,DORSET,ENGLAND; ROYAL BOURNEMOUTH HOSP,DEPT GASTROENTEROL,BOURNEMOUTH,DORSET,ENGLAND; UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND	Poole Hospital; University of York - UK			Snook, Jonathon/AAK-3541-2020					BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; BAXTER T, 1995, LANCET, V345, P1363; Breslow N, 1980, STATISTICAL METHODS, V32; CALMAN KC, 1995, COMMUNICATION   0428; Cosgrove M, 1996, ARCH DIS CHILD, V74, P460, DOI 10.1136/adc.74.5.460; *DEP HLTH STAT DIV, KORN DAT VACC IMM; Ekbom A, 1996, LANCET, V348, P515, DOI 10.1016/S0140-6736(96)04429-7; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; FARRINGTON P, 1995, LANCET, V345, P1362, DOI 10.1016/S0140-6736(95)92559-7; GENT AE, 1994, LANCET, V343, P766, DOI 10.1016/S0140-6736(94)91841-4; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; Haga Y, 1996, GUT, V38, P211, DOI 10.1136/gut.38.2.211; HERMONTAYLOR JM, 1995, LANCET, V345, P922, DOI 10.1016/S0140-6736(95)90033-0; Hills, 1993, STAT MODELS EPIDEMIO; IIZUKA M, 1995, LANCET, V345, P199; Jones P, 1997, LANCET, V349, P473, DOI 10.1016/S0140-6736(05)61184-1; LEWIN J, 1995, GUT, V36, P564, DOI 10.1136/gut.36.4.564; MACDONALD TT, 1995, LANCET, V345, P1363; MILLER C, 1987, BRIT MED J, V295, P22, DOI 10.1136/bmj.295.6589.22; PATRIARCA PA, 1995, LANCET, V345, P1062, DOI 10.1016/S0140-6736(95)90810-2; RIIS P, 1990, INFLAMMATORY BOWEL D; ROTHMANN K, 1986, MODERN EPIDEMIOLOGY; SALISBURY DM, 1996, IMMUNISATION INFECT, P125; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; THAYER WR, 1990, INFLAMMATORY BOWEL D; THOMPSON NP, 1995, EUR J GASTROEN HEPAT, V7, P385; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; Thompson NP, 1996, LANCET, V347, P263, DOI 10.1016/S0140-6736(96)90438-9; Wickramaratne P J, 1995, Stat Methods Med Res, V4, P311, DOI 10.1177/096228029500400404	29	83	84	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					764	766		10.1016/S0140-6736(97)03192-9	http://dx.doi.org/10.1016/S0140-6736(97)03192-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297995				2022-12-28	WOS:A1997XW28200010
J	David, RJ; Collins, JW				David, RJ; Collins, JW			Differing birth weight among infants of US-born blacks, African-born blacks, and US-born whites	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; PRETERM DELIVERY; RACIAL-DIFFERENCES; WOMEN; PREGNANCY; MORTALITY; HEALTH; RACE; OUTCOMES; AGE	Background In the United States, the birth weights of infants of black women are lower than those of infants of white women. The extent to which the lower birth weights among blacks are related to social or genetic factors is unclear. Methods We used vital records for 1980 through 1995 from Illinois to determine the distribution of birth weights among infants born to three groups of women - U.S.-born blacks, African-born blacks, and U.S.-born whites. Results The mean birth weight of 44,046 infants of U.S.-born white women was 3446 g, that of 3135 infants of African-born black women was 3333 g, and that of 43,322 infants of U.S.-born black women was 3089 g. The incidence of low birth weight (weight less than 2500 g) was 13.2 percent among infants of U.S.-born black women and 7.1 percent among infants of African-born black women, as compared with 4.3 percent among infants of U.S, born white women (relative risks, 3.1 and 1.6, respectively). Among the women at lowest risk (those 20 to 39 years old, with 12 years of education for themselves and their spouses, early prenatal care, gravida 2 or 3, and no previous fetal loss), the rate of low birth weight in infants of African-born black women (3.6 percent) was closer to the rate in infants of U.S, born white women (2.4 percent), and the rate in infants of U.S.-born black women remained high (7.5 percent). Conclusions The birth-weight patterns of infants of African-born black women and U.S.-born white women are more closely related to one another than to the birth weights of infants of U.S.-born black women. (C) 1997, Massachusetts Medical Society.	UNIV ILLINOIS,SCH MED,DEPT PEDIAT,CHICAGO,IL; CHILDRENS MEM HOSP,DIV NEONATOL,CHICAGO,IL 60614; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	David, RJ (corresponding author), COOK CTY CHILDRENS HOSP,DIV NEONATOL,700 S WOOD ST,CHICAGO,IL 60612, USA.							ADAMS J, 1973, SCIENCE, V180, P1137, DOI 10.1126/science.180.4091.1137; AMINI SB, 1994, OBSTET GYNECOL, V83, P342; *BUR CENS, 1993, CP215 BUR CENS; CABRAL H, 1990, AM J PUBLIC HEALTH, V80, P70, DOI 10.2105/AJPH.80.1.70; CHAKRABORTY R, 1991, Ethnicity and Disease, V1, P245; COLLINS JW, 1990, AM J PUBLIC HEALTH, V80, P679, DOI 10.2105/AJPH.80.6.679; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; DAVID R J, 1991, Ethnicity and Disease, V1, P236; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; FOX SH, 1994, AM J EPIDEMIOL, V139, P1008, DOI 10.1093/oxfordjournals.aje.a116940; Friedman Daniel J., 1993, Ethnicity and Disease, V3, P255; Geronimus Arline T., 1992, Ethnicity and Disease, V2, P207; GLASS B, 1953, AM J HUM GENET, V5, P11; GOLDENBERG RL, 1991, OBSTET GYNECOL, V78, P782; HULSEY TC, 1991, AM J OBSTET GYNECOL, V164, P1299, DOI 10.1016/0002-9378(91)90703-T; KLEBANOFF MA, 1989, JAMA-J AM MED ASSOC, V262, P511, DOI 10.1001/jama.262.4.511; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; KLEINMAN JC, 1991, AM J DIS CHILD, V145, P194, DOI 10.1001/archpedi.1991.02160020086023; KLEINMAN JC, 1987, NEW ENGL J MED, V317, P749, DOI 10.1056/NEJM198709173171207; KRIEGER N, 1993, AM J PREV MED, V9, P82, DOI 10.1016/S0749-3797(18)30666-4; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; LITTLE RE, 1987, AM J HUM GENET, V40, P512; MAGNUS P, 1984, CLIN GENET, V26, P289; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; NAYLOR AF, 1967, ANN HUM GENET, V31, P71, DOI 10.1111/j.1469-1809.1967.tb02021.x; Oliver Roland, 1988, SHORT HIST AFRICA; RAWLINGS JS, 1995, NEW ENGL J MED, V332, P69, DOI 10.1056/NEJM199501123320201; REED TE, 1969, SCIENCE, V165, P762, DOI 10.1126/science.165.3895.762; ROWLEY DL, 1993, AM J PREV MED, V9, P1; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHEEHAN TJ, 1995, NEW ENGL J MED, V333, P386; VALANIS BM, 1979, SOC BIOL, V26, P189; WASSE H, 1994, AM J PUBLIC HEALTH, V84, P1505, DOI 10.2105/AJPH.84.9.1505; WILCOX A, 1990, J PEDIATR-US, V116, P7, DOI 10.1016/S0022-3476(05)81638-5; WILCOX AJ, 1983, INT J EPIDEMIOL, V12, P314, DOI 10.1093/ije/12.3.314; Wildschut H I, 1991, Paediatr Perinat Epidemiol, V5, P363, DOI 10.1111/j.1365-3016.1991.tb00722.x; Witzig R, 1996, ANN INTERN MED, V125, P675, DOI 10.7326/0003-4819-125-8-199610150-00008	37	337	343	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1209	1214		10.1056/NEJM199710233371706	http://dx.doi.org/10.1056/NEJM199710233371706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337381				2022-12-28	WOS:A1997YB71800006
J	Rubinstein, WS				Rubinstein, WS			A 'normal' practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1216	1216						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333246				2022-12-28	WOS:A1997XZ70900001
J	Papavasiliou, F; Casellas, R; Suh, HY; Qin, XF; Besmer, E; Pelanda, R; Nemazee, D; Rajewsky, K; Nussenzweig, MC				Papavasiliou, F; Casellas, R; Suh, HY; Qin, XF; Besmer, E; Pelanda, R; Nemazee, D; Rajewsky, K; Nussenzweig, MC			V(D)J recombination in mature B cells: A mechanism for altering antibody responses	SCIENCE			English	Article							HEAVY-CHAIN GENE; GERMINAL-CENTERS; ALLELIC EXCLUSION; TRANSGENIC MICE; IMMUNE-RESPONSE; MATURATION; RAG-1; REARRANGEMENT; LYMPHOCYTES; GENERATION	The clonal selection theory states that B lymphocytes producing high-affinity immunoglobulins are selected from a pool of cells undergoing antibody gene mutation. Somatic hypermutation is a well-documented mechanism for achieving diversification of immune responses in mature B cells. Antibody genes were also found to be modified in such cells in germinal centers by recombination of the variable (V), diversity (D), and joining (J) segments. The ability to alter immunoglobulin expression by V(D)J recombination in the selective environment of the germinal center may be an additional mechanism for inactivation or diversification of immune responses.	ROCKEFELLER UNIV,MOL IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; INST IMMUNOL,D-79108 FREIBURG,GERMANY; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLOGNE,GENET INST,WAYERTAL,GERMANY	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Jewish Health; University of Cologne			Nussenzweig, Michel/AAE-7292-2019	QIN, FRANK XIAOFENG/0000-0002-5395-0304; Rajewsky, Klaus/0000-0002-6633-6370	NIAID NIH HHS [R01 AI033608, AI33890] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033890, R01AI033608, R29AI033890] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BURNET FM, 1959, CLONAL SELECTION THE; CASELLAS R, UNPUB; CEBRA JJ, 1966, J EXP MED, V123, P547, DOI 10.1084/jem.123.3.547; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Hikida M, 1997, J IMMUNOL, V158, P2509; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Kelsoe G, 1996, Semin Immunol, V8, P179, DOI 10.1006/smim.1996.0022; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Liu YJ, 1996, IMMUNITY, V4, P241, DOI 10.1016/S1074-7613(00)80432-X; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1994, IMMUNOL REV, V137, P173, DOI 10.1111/j.1600-065X.1994.tb00664.x; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PEARSE M, 1988, P NATL ACAD SCI USA, V85, P6082, DOI 10.1073/pnas.85.16.6082; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; TALMAGE DW, 1959, SCIENCE, V129, P1643, DOI 10.1126/science.129.3364.1643; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P825; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	44	208	213	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					298	301		10.1126/science.278.5336.298	http://dx.doi.org/10.1126/science.278.5336.298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323210				2022-12-28	WOS:A1997YA56400047
J	Prusiner, SB				Prusiner, SB			Prion diseases and the BSE crisis	SCIENCE			English	Review							CREUTZFELDT-JAKOB-DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; GERSTMANN-STRAUSSLER SYNDROME; TRANSMISSIBLE MINK ENCEPHALOPATHY; SCRAPIE-ASSOCIATED PROTEIN; MICE EXPRESSING HUMAN; TRANSGENIC MICE; STRAIN VARIATION; PRP GENE; INCUBATION-TIME	Bovine spongiform encephalopathy (BSE) and human Creutzfeldt-Jakob disease (CJD) are among the most notable central nervous system degenerative disorders caused by prions. CJD may present as a sporadic, genetic, or infectious illness. Prions are transmissible particles that are devoid of nucleic acid and seem to be composed exclusively of a modified protein (PrPSc). The normal, cellular prion protein (PrPC) is converted into PrPSc through a posttranslational process during which it acquires a high beta-sheet content. it is thought that BSE is a result of cannibalism in which faulty industrial practices produced prion-contaminated feed for cattle. There is now considerable concern that bovine prions may have been passed to humans, resulting in a new form of CJD.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Prusiner, SB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS014069, P01NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008967] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR01081] Funding Source: Medline; NIA NIH HHS [AG08967] Funding Source: Medline; NINDS NIH HHS [NS14069] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALPERS M, 1987, P451; ALPERS MP, 1968, CENTRAL NERVOUS SYST, P234; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; BAKER HF, 1993, VET REC, V132, P403, DOI 10.1136/vr.132.16.403; Bamborough P, 1996, COLD SPRING HARB SYM, V61, P495; BATEMAN D, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91828-0; BELT PBGM, 1995, J GEN VIROL, V76, P509, DOI 10.1099/0022-1317-76-3-509; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; BOBOWICK AR, 1973, AM J EPIDEMIOL, V98, P381, DOI 10.1093/oxfordjournals.aje.a121567; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BRITTON TC, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91827-2; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; BROWN P, 1993, DEV BIOL STAND, V80, P91; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE M, 1993, P 9 INT C VIR GLASG, P93; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; Carp RI, 1997, J GEN VIROL, V78, P283, DOI 10.1099/0022-1317-78-1-283; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHAPMAN J, 1994, NEUROLOGY, V44, P1683, DOI 10.1212/WNL.44.9.1683; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CLOUSCARD C, 1995, J GEN VIROL, V76, P2097, DOI 10.1099/0022-1317-76-8-2097; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773; DAWSON M, 1990, VET REC, V126, P112; DAWSON M, 1990, VET REC, V127, P338; Derkatch IL, 1996, GENETICS, V144, P1375; DEVILLEMEUR T, 1997, REPORT HUMAN GROWTH, V14, P1; deVillemeur TB, 1996, NEUROLOGY, V47, P690, DOI 10.1212/WNL.47.3.690; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DICKINSON AG, 1969, GENET RES, V13, P213, DOI 10.1017/S0016672300002895; DICKINSON AG, 1988, CIBA FDN S, V135; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; DONNE DG, IN PRESS P NATL ACAD; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; ESMONDE T, 1993, J NEUROL NEUROSUR PS, V56, P999, DOI 10.1136/jnnp.56.9.999; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1988, VET REC, V123, P472, DOI 10.1136/vr.123.18.472; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; GABIZON R, 1993, AM J HUM GENET, V53, P828; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Gerstmann J., 1936, Z NEUROL, V154, P736, DOI [10.1007/BF02865827, DOI 10.1007/BF02865827]; GLASSE R, 1967, T NEW YORK ACAD SCI, V29, P748, DOI 10.1111/j.2164-0947.1967.tb02298.x; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; GOLDMANN W, 1990, P 8 INT C VIR BERL A, P284; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Grathwohl KUD, 1997, J VIROL METHODS, V64, P205, DOI 10.1016/S0166-0934(97)02197-6; GROTH D, UNPUB; HADLOW WJ, 1982, J INFECT DIS, V146, P657, DOI 10.1093/infdis/146.5.657; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P1113, DOI 10.1136/jnnp.51.9.1113; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HOMABROOK RW, 1968, BRAIN, V91, P53; HOPE J, 1988, NATURE, V336, P390, DOI 10.1038/336390a0; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1991, NEW ENGL J MED, V324, P1091, DOI 10.1056/NEJM199104183241604; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; HUNTER G. D., 1963, RES VET SCI, V4, P543; Hunter N, 1997, VET REC, V140, P59, DOI 10.1136/vr.140.3.59; Hunter N, 1997, NATURE, V386, P137, DOI 10.1038/386137a0; HUNTER N, 1994, VET REC, V135, P400, DOI 10.1136/vr.135.17.400; HUNTER N, 1993, J GEN VIROL, V74, P1025, DOI 10.1099/0022-1317-74-6-1025; IKEDA T, 1995, J GEN VIROL, V76, P2577, DOI 10.1099/0022-1317-76-10-2577; Ironside JW, 1997, AMYLOID, V4, P66, DOI 10.3109/13506129708995272; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kimberlin R.H., 1990, SE VIROL, V1, P153; KIMBERLIN RH, 1982, TRENDS BIOCHEM SCI, V7, P392, DOI 10.1016/0968-0004(82)90182-7; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KIMBERLIN RH, 1996, BOVINE SPONGIFORM EN, P155; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Krakauer DC, 1996, NATURE, V380, P675, DOI 10.1038/380675a0; KRETZSCHMAR HA, 1991, LANCET, V337, P1160, DOI 10.1016/0140-6736(91)92826-N; LANE KL, 1994, NEUROSURGERY, V34, P737, DOI 10.1227/00006123-199404000-00026; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; MALMGREN R, 1979, SLOW TRANSMISSIBLE D, V1, P93; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MATHEWS JD, 1968, LANCET, V2, P449; Meggendorfer F, 1930, Z GESAMTE NEUROL PSY, V128, P337, DOI 10.1007/BF02864269; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; ORourke KI, 1997, J GEN VIROL, V78, P975, DOI 10.1099/0022-1317-78-4-975; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PARRY HB, 1962, HEREDITY, V17, P75, DOI 10.1038/hdy.1962.4; PARRY HB, 1983, SCRAPIE DIS SHEEP, P31; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PATTISON IH, 1968, RES VET SCI, V9, P408; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; PERETZ D, IN PRESS J MOL BIOL; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1993, J INFECT DIS, V167, P602, DOI 10.1093/infdis/167.3.602; PRUSINER SB, 1982, ANN NEUROL, V12, P1, DOI 10.1002/ana.410120102; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; RIDLEY RG, UNPUB; Ridley RM, 1996, NEURODEGENERATION, V5, P219, DOI 10.1006/neur.1996.0030; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROBINSON MM, 1995, J COMP PATHOL, V113, P241, DOI 10.1016/S0021-9975(05)80039-8; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; ROSENTHAL NP, 1976, ARCH NEUROL-CHICAGO, V33, P252, DOI 10.1001/archneur.1976.00500040036005; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT M, IN PRESS J VIROL; SCOTT MR, 1997, PROTEIN SCI S1, V6, P84; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; SPUDICH S, 1995, MOL MED, V1, P607, DOI 10.1007/BF03401601; Stekel DJ, 1996, NATURE, V381, P119, DOI 10.1038/381119a0; Stender A, 1930, Z GESAMTE NEUROL PSY, V128, P528, DOI 10.1007/BF02864285; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TATEISHI J, UNPUB; TAYLOR KC, 1991, VET REC, V129, P522; TELLING G, UNPUB; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; *US CDCP, 1996, MMWR-MORBID MORTAL W, V45, P665; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, 1994, GENE DEV, V8, P959, DOI 10.1101/gad.8.8.959; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; WILESMITH J, UNPUB; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; WILESMITH JW, 1991, SEMINARS VIROLOGY, V2, P239; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	181	793	848	4	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					245	251		10.1126/science.278.5336.245	http://dx.doi.org/10.1126/science.278.5336.245			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323196				2022-12-28	WOS:A1997YA56400033
J	Sames, D; Chen, XT; Danishefsky, SJ				Sames, D; Chen, XT; Danishefsky, SJ			Convergent total synthesis of a tumour-associated mucin motif	NATURE			English	Article							GLYCOSYL PHOSPHITES; OLIGOSACCHARIDES; CELLS; CARBOHYDRATE; RECOGNITION; LEUKOSIALIN; PHOSPHATES; VACCINES; ANTIGENS; GLYCANS	Synthetic glycoconjugates that mimic cell-surface tumour antigens (glycolipids or glycoproteins with unusual carbohydrate structural motifs) have been shown to trigger humoral responses in murine and human immune systems(1-3). This raises the exciting possibility of inducing active immunity with fully synthetic carbohydrate vaccines, particularly if vaccine compounds can be synthesized that resemble the surface environment of transformed cells even more closely. Glycopeptides seem particularly suitable for this purpose. In contrast to most glycolipids and the carbohydrates themselves, glycopeptides bind to major histocompatibility complex molecules, and, in favourable cases, can stimulate T cells and lead to the expression of receptors that recognize the carbohydrate part of a glycopeptide with high specificity(4-8). The preparation of glycopeptides and glycoproteins remains, however, a difficult challenge(9-12): earlier synthesis methods have been inefficient, and established cloning approaches that allow engineering of global glycopatterns produce only heterogeneous glycoproteins(13). Here we report an efficient strategy of the synthesis of tumour-associated mucin glycopeptides with clustered trisaccharide glycodomains corresponding to the (2,6)-sialyl T antigen. Our approach involves construction of the complete glycodomain in the first stage, followed by convergent coupling to amino acid residues and subsequent incorporation of the glycosyl amino acid units into a peptide chain. This general strategy allows the assembly of molecules in which selected glycoforms can be incorporated at any desired position of the peptide chain. The resultant fully synthetic O-linked glycopeptide clusters are the closest homogeneous mimics of cell-surface mucins at present available, and so are promising compounds for the development of anticancer vaccines.	MEM SLOAN KETTERING CANC CTR,BIOORGAN CHEM LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Memorial Sloan Kettering Cancer Center; Columbia University								Bill RM, 1996, CHEM BIOL, V3, P145, DOI 10.1016/S1074-5521(96)90255-0; BILODEAU MT, 1996, ANGEW CHEM INT EDIT, V35, P1381; Carlstedt I, 1997, BIOCHEM SOC T, V25, P214, DOI 10.1042/bst0250214; DECK B, 1995, J IMMUNOL, V155, P1074; Elofsson M, 1997, TETRAHEDRON, V53, P369, DOI 10.1016/S0040-4020(96)00992-1; FINN OJ, 1995, IMMUNOL REV, V145, P61, DOI 10.1111/j.1600-065X.1995.tb00077.x; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; IIJIMA H, 1989, CARBOHYD RES, V186, P95, DOI 10.1016/0008-6215(89)84008-X; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; JENSON T, 1997, J IMMUNOL, P3769; JIANG JJ, 1994, SYNTHETIC COMMUN, V24, P187, DOI 10.1080/00397919408013818; KONDO H, 1994, J ORG CHEM, V59, P864, DOI 10.1021/jo00083a032; KUNZ H, 1997, GLYCOPEPTIDES RELATE, P23; Liebe B, 1997, ANGEW CHEM INT EDIT, V36, P618, DOI 10.1002/anie.199706181; MARTIN TJ, 1993, GLYCOCONJUGATE J, V10, P16, DOI 10.1007/BF00731182; MOURITSEN S, 1994, EUR J IMMUNOL, V24, P1066, DOI 10.1002/eji.1830240509; NAKAHARA Y, 1994, ACS SYM SER, V560, P249; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; Paulsen H, 1997, J CHEM SOC PERK T 1, P281, DOI 10.1039/a604123j; PAULSEN H, 1988, LIEBIGS ANN CHEM, P75; Qui D., 1997, TETRAHEDRON LETT, V38, P45; Ragupathi G, 1997, ANGEW CHEM INT EDIT, V36, P125, DOI 10.1002/anie.199701251; SAITOH O, 1991, CANCER RES, V51, P2854; SCHMIDT RR, 1994, ADV CARBOHYD CHEM BI, V50, P84; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SIM MM, 1993, J AM CHEM SOC, V115, P2260, DOI 10.1021/ja00059a023; SZABO L, 1995, CARBOHYD RES, V274, P11, DOI 10.1016/0008-6215(95)00016-M; TOYOKUNI T, 1995, CHEM SOC REV, V24, P231, DOI 10.1039/cs9952400231; TSUDA T, 1996, J CHEM SOC CHEM COMM, P2779; Witte K, 1997, J AM CHEM SOC, V119, P2114, DOI 10.1021/ja961846z	31	102	105	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					587	591		10.1038/39292	http://dx.doi.org/10.1038/39292			5	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335496				2022-12-28	WOS:A1997YA00800055
J	Vallet, V; Chraibi, A; Gaeggeler, HP; Horisberger, JD; Rossier, BC				Vallet, V; Chraibi, A; Gaeggeler, HP; Horisberger, JD; Rossier, BC			An epithelial serine protease activates the amiloride-sensitive sodium channel	NATURE			English	Article							TOAD URINARY-BLADDER; SUBUNITS; CELLS; MUTATIONS	Sodium balance, and ultimately blood pressure and extracellular fluid volume, is maintained by precise regulation of the activity of the epithelial sodium channel (ENaC)(1-3). In a Xenopus kidney epithelial cell Line (A6), exposure of the apical membrane to the protease inhibitor aprotinin reduces transepithelial sodium transport. Sodium-channel activity can be restored by subsequent exposure to the nonspecific protease trypsin. Using A6 cells and a functional complementation assay to detect increases in ENaC activity, we have cloned a 329-residue protein belonging to the serine protease family. We show that coexpression of this protein with ENaC in Xenopus oocytes increases the activity of the sodium channel by two- to threefold. This channel-activating protease (CAP1) is expressed in kidney, gut, lung, skin and ovary. Sequence analysis predicts that CAP1 is a secreted and/or glycosylphosphatidylinositol-anchored protein: ENaC activity would thus be regulated by the activity of a protease expressed at the surface of the same cell. This previously undiscovered mechanism for autocrine regulation may apply to other ion channels, in particular to members of the ENaC family that are present in neurons and epithelial cells.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND	University of Lausanne			Horisberger, Jean-Daniel/A-2538-2009					CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHRAIBI A, UNPUB J GEN PHYSL; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HANDLER JS, 1979, P NATL ACAD SCI USA, V76, P4151, DOI 10.1073/pnas.76.8.4151; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; LEWIS SA, 1991, J MEMBRANE BIOL, V122, P77, DOI 10.1007/BF01872741; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; ORCE GG, 1980, AM J PHYSIOL, V239, pF459, DOI 10.1152/ajprenal.1980.239.5.F459; PUOTI A, 1995, AM J PHYSIOL, V38, pC188; ROSSIER BC, 1997, J AM SOC NEPHROL, V9, P980; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483	18	425	433	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					607	610		10.1038/39329	http://dx.doi.org/10.1038/39329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335501				2022-12-28	WOS:A1997YA00800061
J	OBrien, CP				OBrien, CP			A range of research-based pharmacotherapies for addiction	SCIENCE			English	Article							ALCOHOL DEPENDENCE; SMOKING CESSATION; OPIATE WITHDRAWAL; SUBSTANCE-ABUSE; NICOTINE PATCH; DOUBLE-BLIND; DETOXIFICATION; NALTREXONE; DISORDERS; COCAINE	Modern approaches to the treatment of addiction have been influenced by several important factors. These include advances in our understanding of the nature of addiction based on longitudinal studies, and progress in elucidating the biological underpinnings of addictive behavior. In addition, changes in the system for delivery of services have begun to shape the way that addiction is treated.			OBrien, CP (corresponding author), UNIV PENN, VA MED CTR, 3900 CHESTNUT ST, PHILADELPHIA, PA 19104 USA.				PHS HHS [P60-05186] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X; Ball J.C., 2012, EFFECTIVENESS METHAD; Bearn J, 1996, DRUG ALCOHOL DEPEN, V43, P87, DOI 10.1016/S0376-8716(96)01289-6; Bickel WK, 1995, EXP CLIN PSYCHOPHARM, V3, P477, DOI 10.1037/1064-1297.3.4.477; BOISMARE F, 1984, PHARMACOL BIOCHEM BE, V21, P787, DOI 10.1016/S0091-3057(84)80020-9; BROWN ME, 1988, BIOL PSYCHIAT, V23, P507, DOI 10.1016/0006-3223(88)90023-6; BROWN SA, 1995, AM J PSYCHIAT, V152, P45; CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; CORNISH JW, 1997, J SUBST ABUSE TREAT, V14, P1; DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304; DOLE VP, 1965, JAMA-J AM MED ASSOC, V193, P80; DROUNGAS A, 1995, ADDICT BEHAV, V20, P657, DOI 10.1016/0306-4603(95)00029-C; FERRY LH, 1992, CIRCULATIN, V86, P1671; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; First M.B., 1994, DIAGNOSTIC STAT MANU, V4; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Fox BS, 1996, NAT MED, V2, P1129, DOI 10.1038/nm1096-1129; FULCO CE, 1995, I MED DEV MED TREATM; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; Gerstein D. R., 1994, CALIFORNIA DEP ALCOH, VADP94-628; GERSTEIN DR, 1990, I MED TREATING DRUG, P154; GOLD MS, 1979, AM J PSYCHIAT, V136, P100; HOLDER HD, 1986, JAMA-J AM MED ASSOC, V256, P1456, DOI 10.1001/jama.256.11.1456; HOLDER HD, 1992, J STUD ALCOHOL, V53, P293, DOI 10.15288/jsa.1992.53.293; KEANE TM, 1984, J CLIN PSYCHOL, V40, P340, DOI 10.1002/1097-4679(198401)40:1<340::AID-JCLP2270400162>3.0.CO;2-J; Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; KILLIAN A, 1978, PHARMACOL BIOCHEM BE, V9, P347, DOI 10.1016/0091-3057(78)90295-2; KING A, IN PRESS ALCOHOLISM; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; KRANZLER H, IN PRESS P COLL PROB; KREEK MJ, 1992, RES P ARNMD, V70, P205; LEBLANC AE, 1969, J PHARMACOL EXP THER, V168, P244; MASON BJ, 1994, ALCOHOL CLIN EXP RES, V18, P1162, DOI 10.1111/j.1530-0277.1994.tb00098.x; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; NACE EP, 1997, SUBSTANCE ABUSE, P383; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; OBRIEN CP, 1977, SCIENCE, V195, P1000, DOI 10.1126/science.841320; OBrien CP, 1996, J CONSULT CLIN PSYCH, V64, P677; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OBRIEN CP, 1994, TREATMENT SUBSTANCE, P223; OBRIEN CP, 1995, PHARMACOL BASIS THER, P557; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; Putzke J, 1996, EUR J PHARMACOL, V317, P39, DOI 10.1016/S0014-2999(96)00696-6; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REISINE T, 1995, PHARMACOL BASIS THER, P21; RETTIG RA, 1995, FEDERAL REGULATION M, P77; ROSE JE, 1994, CLIN PHARMACOL THER, V56, P86, DOI 10.1038/clpt.1994.105; ROTHENBERG S, 1977, PSYCHOPHARMACOLOGY, V52, P299, DOI 10.1007/BF00426715; ROUNSAVILLE BJ, 1985, J NERV MENT DIS, V173, P103, DOI 10.1097/00005053-198502000-00007; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P1723; Schuckit MA, 1997, AM J PSYCHIAT, V154, P948; VICTOR M, MED DIAGNOSIS TREATM, P201; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; WOODY GE, 1984, AM J PSYCHIAT, V141, P1171	59	300	310	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					66	70		10.1126/science.278.5335.66	http://dx.doi.org/10.1126/science.278.5335.66			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311929				2022-12-28	WOS:A1997XZ12400034
J	Zakian, VA				Zakian, VA			Life and cancer without telomerase	CELL			English	Review							YEAST TELOMERE; CHROMOSOME; SENESCENCE; CELLS; GENE; RNA				Zakian, VA (corresponding author), PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544, USA.							BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BRYAN TM, 1995, EMBO J, V14, P4340; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GREIDER CW, 1995, TELOMERES, P35; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; WELLINGER RJ, 1996, CELL, V85, P5423	18	41	47	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					1	3		10.1016/S0092-8674(01)80001-5	http://dx.doi.org/10.1016/S0092-8674(01)80001-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335327	Bronze			2022-12-28	WOS:A1997XZ80900001
J	Bruce, ME; Will, RG; Ironside, JW; McConnell, I; Drummond, D; Suttie, A; McCardle, L; Chree, A; Hope, J; Birkett, C; Cousens, S; Fraser, H; Bostock, CJ				Bruce, ME; Will, RG; Ironside, JW; McConnell, I; Drummond, D; Suttie, A; McCardle, L; Chree, A; Hope, J; Birkett, C; Cousens, S; Fraser, H; Bostock, CJ			Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; SCRAPIE INCUBATION; DIFFERENT STRAINS; RODENTS; LINES; SHEEP	There are many strains of the agents that cause transmissible spongiform encephalopathies (TSEs) or 'prion' diseases, These strains are distinguishable by their disease characteristics in experimentally infected animals, in particular the incubation periods and neuropathology they produce in panels of inbred mouse strains(1-4). We have shown that the strain of agent from cattle affected by bovine spongiform encephalopathy (BSE) produces a characteristic pattern of disease in mice that is retained after experimental passage through a variety of intermediate species(5-7). This BSE 'signature' has also been identified in transmissions to mice of TSEs of domestic cats and two exotic species of ruminant(6,8), providing the first direct evidence for the accidental spread of a TSE between species, Twenty cases of a clinically and pathologically atypical form of Creutzfeldt-Jakob disease (CJD), referred to as 'new variant' CJD (vCJD)(9), have been recognized in unusually young people in the United Kingdom, and a further case has been reported in France(10). This has raised serious concerns that BSE may have spread to humans, putatively by dietary exposure, Here we report the interim results of transmissions of sporadic CJD and VJD to mice, Our data provide strong evidence that the same agent strain is involved in both BSE and vCJD.	WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; INST ANIM HLTH,NEWBURY RG20 7NN,BERKS,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND	University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of London; London School of Hygiene & Tropical Medicine	Bruce, ME (corresponding author), INST ANIM HLTH,BBSRC MRC NEUROPATHOGENESIS UNIT,W MAINS RD,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND.		Hope, James/C-4966-2011	Ironside, James/0000-0001-5869-2108				Bell JE, 1997, NEUROPATH APPL NEURO, V23, P26, DOI 10.1111/j.1365-2990.1997.tb01182.x; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; CARP RI, 1991, J GEN VIROL, V72, P293, DOI 10.1099/0022-1317-72-2-293; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1971, MOL GEN GENET, V112, P73, DOI 10.1007/BF00266934; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; FARQUHAR CF, 1994, TRANSMISSIBLE SPONGI, P301; Foster JD, 1996, VET REC, V138, P546, DOI 10.1136/vr.138.22.546; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; FRASER H, 1994, VET REC, V134, P449, DOI 10.1136/vr.134.17.449; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; Fraser H, 1996, BRAIN PATHOL, V6, P89, DOI 10.1111/j.1750-3639.1996.tb00788.x; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; Hill AF, 1997, LANCET, V350, P188, DOI 10.1016/S0140-6736(05)62356-2; Kirkwood B., 1988, BR K ESSENTIALS MED; Mardia K., 1979, MULTIVARIATE ANAL, V15, P518; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; Tateishi J, 1996, SEMIN VIROL, V7, P175, DOI 10.1006/smvy.1996.0022; TATEISHI J, 1979, ANN NEUROL, V5, P581, DOI 10.1002/ana.410050616; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	28	1586	1630	1	104	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					498	501		10.1038/39057	http://dx.doi.org/10.1038/39057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333239				2022-12-28	WOS:A1997XY90900057
J	Novacek, MJ; Rougier, GW; Wible, JR; McKenna, MC; Dashzeveg, D; Horovitz, I				Novacek, MJ; Rougier, GW; Wible, JR; McKenna, MC; Dashzeveg, D; Horovitz, I			Epipubic bones in eutherian mammals from the late Cretaceous of Mongolia	NATURE			English	Article							FLAMING CLIFFS; DINOSAUR	An important transformation in the evolution of mammals was the loss of the epipubic bones. These are elements projecting anteriorly from the pelvic girdle into the abdominal region in a variety of Mesozoic mammals, related tritylodonts, marsupials and monotremes but not in living eutherian (placental) mammals(1-3). Here we describe a new eutherian from the Late Cretaceous period of Mongolia, and report the first record of epipubic bones in two distinct eutherian lineages. The presence of epipubic bones and other primitive features suggests that these groups occupy a basal position in the Eutheria. It has been argued that the epipubic bones support the pouch in living mammals(1,3,4), but epipubic bones have since been related to locomotion and suspension of the litter mass of several attached, lactating offspring(5). The loss of the epipubic bones in eutherians can be related to the evolution of prolonged gestation, which would not require prolonged external attachment of altricial young. Thus the occurrence of epipubic bones in two Cretaceous eutherians suggests that the dramatic modifications connected with typical placental reproduction(3,6,7) may have been later events in the evolution of the Eutheria.	UNIV LOUISVILLE, SCH MED, DEPT ANAT SCI & NEUROBIOL, LOUISVILLE, KY 40292 USA; MONGOLIAN ACAD SCI, INST GEOL, ULAANBAATAR, MONGOLIA	University of Louisville; Mongolian Academy of Sciences	Novacek, MJ (corresponding author), AMER MUSEUM NAT HIST, DEPT VERTEBRATE PALEONTOL, NEW YORK, NY 10024 USA.							DASHZEVEG D, 1995, NATURE, V374, P446, DOI 10.1038/374446a0; FOURIE S, 1962, NAVORSINGE NASIONALE, V2, P7; GREGORY WILLIAM K., 1926, AMER MUS NOVITATES, V225, P1; JELLISON WL, 1945, J MAMMAL, V26, P146, DOI 10.2307/1375090; KIELAN-JAWOROWSKA Z, 1975, Palaeontologia Polonica, V33, P5; Kielan-Jaworowska Z, 1981, PALAEONTOLOGIA POLON, V42, P25; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KIELANJAWOROWSK.Z, 1977, PALAEONTOL POL, V37, P55; KIELANJAWOROWSKA Z, 1975, NATURE, V255, P698, DOI 10.1038/255698a0; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; LECHE W, 1891, BIOL FOREN FORHANDL, V3, P120; LILLEGRAVEN JA, 1987, BIOL J LINN SOC, V32, P281, DOI 10.1111/j.1095-8312.1987.tb00434.x; Lilligraven J. A., 1969, Paleontological Contributions University of Kansas, VNo. 50, P1; MACPHEE RDE, 1993, MAMMAL PHYLOGENY : PLACENTALS, P13; MARSHALL LG, 1979, ZOOL J LINN SOC-LOND, V66, P369, DOI 10.1111/j.1096-3642.1979.tb01914.x; McKenna M. C., 1975, PHYLOGENY PRIMATES, P21, DOI DOI 10.1007/978-1-4684-2166-8_2; NORELL MA, 1995, NATURE, V378, P774, DOI 10.1038/378774a0; NORELL MA, 1994, SCIENCE, V266, P779, DOI 10.1126/science.266.5186.779; NOVACEK MJ, 1986, B AM MUS NAT HIST, V183, P1; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; NOVACEK MJ, 1994, SCI AM, V271, P60, DOI 10.1038/scientificamerican1294-60; Reig O.A., 1987, P1; RENFREE MB, 1993, MAMMAL PHYLOGENY, P4; ROUGIER G. W., 1993, THESIS U BUENOS AIRE; Springer Mark S., 1997, P129; Tyndale-Biscoe CH, 1987, REPROD PHYSL MARSUPI; VAUGHN PETER PAUL, 1956, JOUR ELISHA MITCHELL SCI SOC, V72, P243; WHITE TD, 1989, J THEOR BIOL, V139, P343, DOI 10.1016/S0022-5193(89)80213-9	29	92	97	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					483	486		10.1038/39020	http://dx.doi.org/10.1038/39020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333234				2022-12-28	WOS:A1997XY90900052
J	Solomon, CG; Willett, WC; Carey, VJ; RichEdwards, J; Hunter, DJ; Colditz, GA; Stampfer, MJ; Speizer, FE; Spiegelman, D; Manson, JE				Solomon, CG; Willett, WC; Carey, VJ; RichEdwards, J; Hunter, DJ; Colditz, GA; Stampfer, MJ; Speizer, FE; Spiegelman, D; Manson, JE			A prospective study of pregravid determinants of gestational diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCOSE-TOLERANCE; PHYSICAL-ACTIVITY; INSULIN-SECRETION; CIGARETTE-SMOKING; RISK-FACTORS; WEIGHT-GAIN; WOMEN; PREVALENCE; POPULATION; CRITERIA	Context.-Gestational diabetes mellitus (GDM) affects 3% to 5% of pregnancies. Knowledge of risk factors for GDM is needed to identify possible preventive strategies. Objective.-To assess whether recognized determinants of non-insulin-dependent diabetes mellitus also may be markers for increased risk of GDM. Design.-Prospective cohort study. Setting.-The Nurses' Health Study II, which involves female US nurses aged 25 to 42 years at entry. Participants.-The analyses included 14 613 women without previous GDM or other known diabetes who reported a singleton pregnancy between 1990 and 1994. Of these women, 722 (4.9%) reported a new diagnosis of GDM. Main Outcome Measure: Self-report of GDM, validated by medical record review in a subset. Results.-In multivariate analyses including age, pregravid body mass index (BMI), and other GDM risk factors, the risk for GDM increased significantly with increasing maternal age (P for trend, <.01) and family history of diabetes mellitus (relative risk, 1.68; 95% confidence interval [CI], 1.39-2.04). Relative risks for GDM were 2.13 (95% CI, 1.65-2.74) for pregravid BMI of 25 to 29.9 kg/m(2) and 2.90 (95% CI, 2.15-3.91) for BMI of 30 kg/m(2) or more (vs BMI of <20 kg/m(2)). Risk for GDM increased with greater weight gain in early adulthood, and it also increased among nonwhite women. Pregravid current smokers had a relative risk for GDM of 1.43 (95% CI, 1.14-1.80), and pregravid vigorous exercise was associated with a nonsignificant reduction in GDM risk. Conclusions.-Advanced maternal age, family history of diabetes mellitus, nonwhite ethnicity, higher BMI, weight gain in early adulthood, and cigarette smoking predict increased GDM risk. These observations may facilitate the identification of women at particular risk for GDM and suggest potential strategies for reducing this risk even before a woman becomes pregnant, such as avoiding substantial weight gain and smoking.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV GEN MED,SECT CLIN EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, ENDOCRINE HYPERTENS DIV, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT MATERNAL & CHILD HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Solomon, CG (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA050385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50385] Funding Source: Medline; NIDDK NIH HHS [DK-36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAULIEU MD, 1992, CAN MED ASSOC J, V147, P435; BELL DSH, 1990, DIABETES CARE, V13, P1196, DOI 10.2337/diacare.13.11.1196; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; BUNG P, 1991, DIABETES, V40, P182, DOI 10.2337/diab.40.2.S182; CHARLES MA, 1993, DIABETES CARE, V16, P593, DOI 10.2337/diacare.16.4.593; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COX NJ, 1994, DIABETES, V43, P166, DOI 10.2337/diab.43.1.166; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; DOOLEY SL, 1991, INT J GYNECOL OBSTET, V35, P13, DOI 10.1016/0020-7292(91)90057-C; DORNHORST A, 1992, DIABETIC MED, V9, P820, DOI 10.1111/j.1464-5491.1992.tb01900.x; GOLDMAN JA, 1967, ISRAEL J MED SCI, V3, P561; GREEN JR, 1990, AM J OBSTET GYNECOL, V163, P86, DOI 10.1016/S0002-9378(11)90675-9; HARRIS MI, 1991, DIABETES CARE, V14, P639, DOI 10.2337/diacare.14.7.639; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Kanders B., 1991, CONNS CURRENT THERAP, P524; KJOS SL, 1990, AM J OBSTET GYNECOL, V163, P93, DOI 10.1016/S0002-9378(11)90676-0; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUHL C, 1991, DIABETES, V40, P18, DOI 10.2337/diab.40.2.S18; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MARTIN AO, 1985, AM J OBSTET GYNECOL, V151, P471, DOI 10.1016/0002-9378(85)90272-8; METZGER BE, 1993, DIABETES CARE, V16, P1598, DOI 10.2337/diacare.16.12.1598; OSULLIVAN JB, 1973, AM J OBSTET GYNECOL, V116, P895; OSULLIVAN JB, 1982, JAMA-J AM MED ASSOC, V248, P949, DOI 10.1001/jama.248.8.949; OSULLIVAN JB, 1984, CARBOHYD METABOL, P174; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; SIMMONS D, 1995, J INTERN MED, V237, P315, DOI 10.1111/j.1365-2796.1995.tb01181.x; Solomon CG, 1996, DIABETES CARE, V19, P12, DOI 10.2337/diacare.19.1.12; THOMAS F, 1994, DIABETES, V43, P63, DOI 10.2337/diabetes.43.1.63; TROY LM, 1995, INT J OBESITY, V19, P570; VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	36	537	546	1	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1078	1083		10.1001/jama.278.13.1078	http://dx.doi.org/10.1001/jama.278.13.1078			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315766				2022-12-28	WOS:A1997XX30300031
J	Baylin, SB				Baylin, SB			Tying it all together: Epigenetics, genetics, cell cycle, and cancer	SCIENCE			English	Editorial Material							DNA-METHYLTRANSFERASE ACTIVITY; EMBRYONIC STEM-CELLS; DE-NOVO METHYLATION; CPG ISLAND; NUCLEAR ANTIGEN; 5-METHYLCYTOSINE CONTENT; DEPENDENT KINASES; REPLICATION; MOUSE; PCNA		DEPT MED,BALTIMORE,MD 21231		Baylin, SB (corresponding author), JOHNS HOPKINS COMPREHENS CANC CTR,BALTIMORE,MD 21231, USA.							Ahuja N, 1997, CANCER RES, V57, P3370; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BAYLIN SB, IN PRESS ADV CANC RE; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FEINBERG AP, 1988, CANCER RES, V48, P1159; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KO IJ, 1996, GENE DEV, V10, P1054; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAIRD PW, 1994, HUM MOL GENET, V3; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092	61	160	169	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1948	1949		10.1126/science.277.5334.1948	http://dx.doi.org/10.1126/science.277.5334.1948			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9333948				2022-12-28	WOS:A1997XX84900028
J	Li, Y; Field, PM; Raisman, G				Li, Y; Field, PM; Raisman, G			Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells	SCIENCE			English	Article							SCHWANN-CELLS; SPINAL-CORD; AXONAL REGENERATION; SENSORY NEURONS; BULB; SYSTEM; GROWTH; MOTOR; MOUSE	The upper cervical corticospinal tract was transected on one side in adult rats. A suspension of ensheathing cells cultured from adult rat olfactory bulb was injected into the lesion site, This induced unbranched, elongative growth of the cut corticospinal axons, The axons grew through the transplant and continued to regenerate into the denervated caudal host tract, Rats with complete transections and no transplanted cells did not use the forepaw on the lesioned side for directed reaching, Rats in which the transplanted cells had formed a continuous bridge across the lesion exhibited directed forepaw reaching on the lesioned side.*			Li, Y (corresponding author), NATL INST MED RES,MRC,NORMAN & SADIE LEE RES CTR,DIV NEUROBIOL,LONDON NW7 1AA,ENGLAND.		Raisman, Geoffrey/B-3215-2009					BARBER PC, 1982, NEUROSCIENCE, V7, P3077, DOI 10.1016/0306-4522(82)90231-7; BARBER PC, 1978, BRAIN RES, V141, P57, DOI 10.1016/0006-8993(78)90616-9; DEVON R, 1992, BRAIN RES, V589, P175; Franceschini IA, 1996, DEV BIOL, V173, P327, DOI 10.1006/dbio.1996.0027; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; KUHLENGEL KR, 1990, J COMP NEUROL, V293, P74, DOI 10.1002/cne.902930107; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LI Y, 1994, J NEUROSCI, V14, P4050; MONTEROMENEI CN, 1992, BRAIN RES, V570, P198, DOI 10.1016/0006-8993(92)90582-T; MOULTON DG, 1974, ANN NY ACAD SCI, V237, P52, DOI 10.1111/j.1749-6632.1974.tb49843.x; NEUBERGER TJ, 1992, J COMP NEUROL, V315, P16, DOI 10.1002/cne.903150103; RAISMAN G, 1985, NEUROSCIENCE, V14, P237, DOI 10.1016/0306-4522(85)90176-9; RAMONCUETO A, 1995, GLIA, V14, P163, DOI 10.1002/glia.440140302; RAMONCUETO A, 1992, NEUROSCIENCE, V47, P213, DOI 10.1016/0306-4522(92)90134-N; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; WILSON KCP, 1981, BRAIN RES, V205, P245, DOI 10.1016/0006-8993(81)90336-X; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309	18	720	832	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					2000	2002		10.1126/science.277.5334.2000	http://dx.doi.org/10.1126/science.277.5334.2000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302296				2022-12-28	WOS:A1997XX84900046
J	Wilson, JM; Mark, EJ; Connolly, SA; Shannon, DC; Ryan, DP				Wilson, JM; Mark, EJ; Connolly, SA; Shannon, DC; Ryan, DP			A preterm newborn female triplet with diffuse cystic changes in the left lung - Pulmonary interstitial emphysema, localized, persistent.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BIRTH-WEIGHT INFANTS; ADENOMATOID MALFORMATION; NEONATAL-PERIOD; SEQUESTRATION; MANAGEMENT; BRONCHOPULMONARY; ANOMALIES; DIAGNOSIS; SPECTRUM		HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138	Harvard University	Wilson, JM (corresponding author), CHILDRENS HOSP,EXTRACORPOREAL MEMBRANE OXYGENAT PROGRAM,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							BAILEY PV, 1990, J THORAC CARDIOV SUR, V99, P597; BERMAN L, 1988, CLIN RADIOL, V39, P237, DOI 10.1016/S0009-9260(88)80377-5; BINSTADT DH, 1977, J CAN ASSOC RADIOL, V28, P297; Boyden EA., 1977, DEV LUNG, P3; BREWER LL, 1979, AM J PATHOL, V95, P171; BROOKS JG, 1977, J PEDIATR-US, V91, P648, DOI 10.1016/S0022-3476(77)80525-8; CHAMBERS HM, 1989, PATHOLOGY, V21, P79, DOI 10.3109/00313028909059539; CORRIN B, 1975, AM J PATHOL, V79, P348; Engle W A, 1984, Am J Perinatol, V1, P196, DOI 10.1055/s-2007-1000003; FITCH LB, 1961, AM J MED SCI, V242, P65, DOI 10.1097/00000441-196107000-00008; FLETCHER BD, 1974, PEDIATRICS, V54, P808; FRONSTIN MH, 1967, AM J DIS CHILD, V114, P330, DOI 10.1001/archpedi.1967.02090240144017; FUJIMURA M, 1989, ARCH DIS CHILD, V64, P1379, DOI 10.1136/adc.64.10_Spec_No.1379; GAYLORD MS, 1987, PEDIATRICS, V79, P915; GAYLORD MS, 1985, PEDIATRICS, V76, P219; GERAMI S, 1969, J THORAC CARDIOV SUR, V58, P432, DOI 10.1016/S0022-5223(19)42594-4; GERLE RD, 1968, NEW ENGL J MED, V278, P1413, DOI 10.1056/NEJM196806272782602; GREENOUGH A, 1984, ARCH DIS CHILD, V59, P1046, DOI 10.1136/adc.59.11.1046; HADDON MJ, 1991, RADIOL CLIN N AM, V29, P241; HALLER JA, 1979, ANN THORAC SURG, V28, P33, DOI 10.1016/S0003-4975(10)63389-9; HART SM, 1983, ARCH DIS CHILD, V58, P612, DOI 10.1136/adc.58.8.612; HILLMAN BC, 1993, PEDIATRIC RESPIRATOR, P457; HODGMAN JE, 1969, PEDIATRICS, V44, P179; HOEFFEL JC, 1986, RADIOLOGY, V160, P513, DOI 10.1148/radiology.160.2.3726134; KEELING JW, 1981, VIRCHOWS ARCH A, V394, P1, DOI 10.1007/BF00431662; Lagrew D C Jr, 1994, J Perinatol, V14, P316; Langham MR, 1996, CLIN PERINATOL, V23, P671, DOI 10.1016/S0095-5108(18)30201-X; LEAPE LL, 1970, PEDIATRICS, V46, P97; LEONIDAS JC, 1975, J PEDIATR-US, V87, P776, DOI 10.1016/S0022-3476(75)80308-8; MCCULLAGH M, 1994, ARCH DIS CHILD-FETAL, V71, pF111, DOI 10.1136/fn.71.2.F111; MURRAY GF, 1967, J THORAC CARDIOV SUR, V53, P886, DOI 10.1016/S0022-5223(19)43144-9; MURRAY J, 1986, NORMAL LUNG, P1; NAKAMURA Y, 1993, ACTA PATHOL JAPON, V43, P347; NEILSON IR, 1991, J PEDIATR SURG, V26, P975, DOI 10.1016/0022-3468(91)90846-L; NEWMAN BM, 1986, ARCH SURG-CHICAGO, V121, P813; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; OLIPHANT L, 1987, CHEST, V91, P500, DOI 10.1378/chest.91.4.500; PICCIONE W, 1990, CHEST, V97, P244, DOI 10.1378/chest.97.1.244; PINSKY WW, 1978, CIRCULATION, V57, P159, DOI 10.1161/01.CIR.57.1.159; PROSSER R, 1964, ARCH DIS CHILD, V39, P236, DOI 10.1136/adc.39.205.236; SAVIC B, 1979, THORAX, V34, P96, DOI 10.1136/thx.34.1.96; SCHNEIDER JR, 1985, J THORAC CARDIOV SUR, V89, P332; SHACKELFORD GD, 1989, J COMPUT ASSIST TOMO, V13, P612, DOI 10.1097/00004728-198907000-00010; SILVER GA, 1985, LANCET, V2, P1135; Stocker J T, 1978, Perspect Pediatr Pathol, V4, P93; STOCKER JT, 1977, PEDIATRICS, V59, P847; STOCKER JT, 1977, HUM PATHOL, V8, P155, DOI 10.1016/S0046-8177(77)80078-6; SWYER PR, 1965, PEDIATRICS, V36, P374; WARNER JO, 1982, BRIT J DIS CHEST, V76, P177, DOI 10.1016/S0007-0971(82)80056-9; WILSON MG, 1960, AMA J DIS CHILD, V99, P489, DOI 10.1001/archpedi.1960.02070030491011; WOLF SA, 1980, J PEDIATR SURG, V15, P925, DOI 10.1016/S0022-3468(80)80305-8; WOOD BP, 1982, AM J ROENTGENOL, V138, P809, DOI 10.2214/ajr.138.5.809; 1990, NEW ENGL J MED, V323, P398; 1996, NEW ENGL J MED, V334, P1726	54	16	16	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					916	924		10.1056/NEJM199709253371308	http://dx.doi.org/10.1056/NEJM199709253371308			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX302	9302307				2022-12-28	WOS:A1997XX30200008
J	Gardner, SG; Bingley, PJ; Sawtell, PA; Weeks, S; Gale, EAM; Bell, RAF; Dunger, DB; Mukhtar, A; OMalley, BP; Silk, BR; Smith, EH; Scott, RDM; Latham, PJ; Lakhani, PK; Paton, RC; Ackland, FM; Fox, CJ; Griffin, NK; Matthews, DR; Neil, HAW; Mann, NP; Simpson, HCR; Brown, RS; Knight, AH; Cowen, JM; Pearce, JC; Cheetham, CH; Gallen, IW; Sandler, L; Westcott, T				Gardner, SG; Bingley, PJ; Sawtell, PA; Weeks, S; Gale, EAM; Bell, RAF; Dunger, DB; Mukhtar, A; OMalley, BP; Silk, BR; Smith, EH; Scott, RDM; Latham, PJ; Lakhani, PK; Paton, RC; Ackland, FM; Fox, CJ; Griffin, NK; Matthews, DR; Neil, HAW; Mann, NP; Simpson, HCR; Brown, RS; Knight, AH; Cowen, JM; Pearce, JC; Cheetham, CH; Gallen, IW; Sandler, L; Westcott, T			Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD IDDM; MELLITUS; RISK; EUROPE; ONSET	Objectives: To monitor incidence of insulin dependent diabetes in children in Oxford health region since 1985, and to look for any evidence of disproportionate increase in children aged under 5, Design: Primary ascertainment of cases of childhood diabetes was by prospective registration of all patients with insulin dependent diabetes diagnosed before age 15 years between 1985 and 1996 and resident in Oxford region at time of diagnosis, This was supplemented by examination of centralised hospital discharge records and death certificates, Secondary case ascertainment was by postal surveys of general practitioners in 1987 and 1996, Setting: Area formerly administered by Oxford Regional Health Authority. Subjects: 1037 children presenting with insulin dependent diabetes under age of 15 years, Main outcome measures: Incidence of insulin dependent diabetes in children aged 0-4, 5-9, and 10-14 years during 1985-95, Results: Overall incidence of diabetes in children aged 0-15 was 18.6 cases/100 000/year and showed an annual increase of 4% from 1985 to 1996. This was mainly due to a rapid increase in children aged 0-4 years, in whom there was an annual increase of 11% (95% confidence interval 6% to 15%, P < 0.0001), while the annual increase in those aged 5-9 was 4% (0 to 7%, P = 0.05) and in those aged 10-14 was 1% (-2% to 4%, P = 0.55), Conclusions: Incidence of insulin dependent diabetes in children aged under 5 years has risen markedly in the Oxford region over the past decade, The cause of the increase is unknown, but environmental influences encountered before birth or in early postnatal life are likely to be responsible.	UNIV BRISTOL,SOUTHMEAD HOSP,DEPT MED,BRISTOL BS10 5NB,AVON,ENGLAND; HORTON GEN HOSP,BANBURY,OXON,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; KETTERING DIST HOSP,KETTERING,NORTHANTS,ENGLAND; KING EDWARD VII HOSP,WINDSOR,ENGLAND; MILTON KEYNES DIST GEN HOSP,MILTON KEYNES,BUCKS,ENGLAND; NORTHAMPTON GEN HOSP,NORTHAMPTON,ENGLAND; RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND; ROYAL BERKSHIRE HOSP,READING RG1 5AN,BERKS,ENGLAND; STOKE MANDEVILLE HOSP,AYLESBURY HP21 8AL,BUCKS,ENGLAND; WEXHAM PK HOSP,SLOUGH SL2 4HL,BERKS,ENGLAND; WYCOMBE GEN HOSP,HIGH WYCOMBE,BUCKS,ENGLAND	Southmead Hospital; University of Bristol; University of Oxford; Radcliffe Infirmary; Royal Berkshire Hospital								BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BINGLEY PJ, IN PRESS DIABETES; BLOM L, 1991, DIABETOLOGIA, V34, P176, DOI 10.1007/BF00418272; BLOOM A, 1975, BRIT MED J, V2, P580; BURDEN AC, 1989, DIABETIC MED, V6, P334; DAHLQUIST GG, 1995, DIABETES, V44, P408, DOI 10.2337/diabetes.44.4.408; DECKERT T, 1978, DIABETOLOGIA, V14, P363, DOI 10.1007/BF01228130; *DIAB EP RES INT G, 1990, DIABETES, V39, P858; Ellis TM, 1996, LANCET, V347, P1464, DOI 10.1016/S0140-6736(96)91690-6; GINSBERGFELLNER F, 1985, REV INFECT DIS, V7, P5170; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; GREEN A, 1985, DIABETOLOGIA, V28, P339; HENDERSON P, 1949, BRIT MED J, V1, P478, DOI 10.1136/bmj.1.4602.478; LEVYMARCHAL C, 1995, DIABETOLOGIA, V38, P823, DOI 10.1007/s001250050359; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; PINKNEY JH, 1994, DIABETOLOGIA, V37, P70; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; STAINES A, 1993, DIABETOLOGIA, V36, P1282, DOI 10.1007/BF00400806; TUOMILEHTO J, 1991, DIABETOLOGIA, V34, P282, DOI 10.1007/BF00405089; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984; VANDERAUWERA B, 1995, J CLIN ENDOCR METAB, V80, P2567, DOI 10.1210/jc.80.9.2567; WADSWORTH E, 1995, BRIT MED J, V310, P700, DOI 10.1136/bmj.310.6981.700	23	182	187	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					713	717		10.1136/bmj.315.7110.713	http://dx.doi.org/10.1136/bmj.315.7110.713			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314756	Green Published			2022-12-28	WOS:A1997XX67400022
J	Allikmets, R; Shroyer, NF; Singh, N; Seddon, JM; Lewis, RA; Bernstein, PS; Peiffer, A; Zabriskie, NA; Li, YX; Hutchinson, A; Dean, M; Lupski, JR; Leppert, M				Allikmets, R; Shroyer, NF; Singh, N; Seddon, JM; Lewis, RA; Bernstein, PS; Peiffer, A; Zabriskie, NA; Li, YX; Hutchinson, A; Dean, M; Lupski, JR; Leppert, M			Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration	SCIENCE			English	Article							BEAVER DAM EYE; FUNDUS FLAVIMACULATUS; MACULOPATHY; DYSTROPHY; FROG	Age-related macular degeneration (AMD) is the leading cause of severe central visual impairment among the elderly and is associated both with environmental factors such as smoking and with genetic factors. Here, 167 unrelated AMD patients were screened for alterations in ABCR, a gene that encodes a retinal rod photoreceptor protein and is defective in Stargardt disease, a common hereditary form of macular dystrophy. Thirteen different AMD-associated alterations, both deletions and amino acid substitutions, were found in one allele of ABCR in 26 patients (16%). Identification of ABCR alterations will permit presymptomatic testing of high-risk individuals and may lead to earlier diagnosis of AMD and to new strategies for prevention and therapy.	NCI, LAB GENOM DIVERS, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; NCI, INTRAMURAL RES SUPPORT PROGRAM, SAIC FREDERICK, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; UNIV UTAH, DEPT HUMAN GENET, ECCLED INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA; HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02114 USA; BAYLOR COLL MED, DEPT OPHTHALMOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; UNIV UTAH, MORAN EYE CTR, DEPT OPHTHALMOL, SALT LAKE CITY, UT 84132 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Utah System of Higher Education; University of Utah			Allikmets, Rando/ABD-4533-2021; Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012	Dean, Michael C/0000-0003-2234-0631				Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALLIKMETS R, UNPUB; ANDERSON KL, 1995, AM J HUM GENET, V57, P1351; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060; EGAN KM, 1993, PRINCIPLES PRACTICES, P109; Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054; FISHMAN GA, 1976, ARCH OPHTHALMOL-CHIC, V94, P2061, DOI 10.1001/archopht.1976.03910040721003; GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206; GERBER S, 1995, AM J HUM GENET, V56, P396; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; MartinezMir A, 1997, GENOMICS, V40, P142, DOI 10.1006/geno.1996.4528; *NAT EYE I, 1992, AG REL EYE DIS STUD; National Advisory Eye Council (U.S.), 1993, NIH PUBL; PAPERMASTER DS, 1976, EXP EYE RES, V23, P105, DOI 10.1016/0014-4835(76)90194-9; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0; SHUSTER TA, 1988, EXP EYE RES, V46, P475, DOI 10.1016/S0014-4835(88)80005-8; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SZUTS EZ, 1985, BIOCHEMISTRY-US, V24, P4176, DOI 10.1021/bi00336a054; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352	25	701	737	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1805	1807		10.1126/science.277.5333.1805	http://dx.doi.org/10.1126/science.277.5333.1805			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295268	Green Submitted			2022-12-28	WOS:A1997XX29800042
J	Nelson, JC; Saven, JG; Moore, JS; Wolynes, PG				Nelson, JC; Saven, JG; Moore, JS; Wolynes, PG			Solvophobically driven folding of nonbiological oligomers	SCIENCE			English	Article							SECONDARY STRUCTURE; PHENYLACETYLENE MACROCYCLES; MOLECULAR MECHANICS; HELIX-COIL; PRINCIPLES; ALANINE; CRYSTAL; DESIGN	In solution, biopolymers commonly fold into well-defined three-dimensional structures, but only recently has analogous behavior been explored in synthetic chain molecules. An aromatic hydrocarbon backbone is described that spontaneously acquires a stable helical conformation having a large cavity. The chain does not form intramolecular hydrogen bonds, and solvophobic interactions drive the folding transition, which is sensitive to chain length, solvent quality, and temperature.	UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801; UNIV ILLINOIS,DEPT MAT SCI & ENGN,URBANA,IL 61801; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,URBANA,IL 61801; UNIV ILLINOIS,SCH CHEM SCI,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NCRR NIH HHS [PHS 1 S10 RR10444-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Appella DH, 1996, J AM CHEM SOC, V118, P13071, DOI 10.1021/ja963290l; BIXON M, 1963, BIOPOLYMERS, V1, P419, DOI 10.1002/bip.360010503; BLOOMFIELD VA, 1974, PHYSICAL CHEM NUCLEI; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Cantor C.R., 1980, BIOPHYS CHEM; Creighton T.E., 1993, PROTEINS; DADO GP, 1994, J AM CHEM SOC, V116, P1054, DOI 10.1021/ja00082a029; DILL KA, 1995, PROTEIN SCI, V4, P561; DOLGIKH DA, 1996, MOL BIOL, V30, P1149; GO N, 1968, P NATL ACAD SCI USA, V59, P1030, DOI 10.1073/pnas.59.4.1030; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; Hamuro Y, 1996, J AM CHEM SOC, V118, P7529, DOI 10.1021/ja9539857; Honig B, 1996, FOLD DES, V1, pR17, DOI 10.1016/S1359-0278(96)00005-3; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LAWRENCE DS, 1995, CHEM REV, V95, P2229, DOI 10.1021/cr00038a018; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LOKEY RS, 1995, NATURE, V375, P303; LUTHEYSCHULTEN Z, 1995, J PHYS CHEM-US, V99, P2177, DOI 10.1021/j100007a057; MIRNY LA, 1996, FOLDING DESIGN, V1, P221; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Nelson JC, 1996, J ORG CHEM, V61, P8160, DOI 10.1021/jo961250u; OKUYAMA K, 1984, J PHYS CHEM-US, V88, P1711, DOI 10.1021/j150653a010; PADMANABHAN S, 1994, J MOL BIOL, V241, P706, DOI 10.1006/jmbi.1994.1545; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; Perkins S. J., 1982, BIOL MAGN RESON, V4, P193; POLAND D, 1970, THEORY HELIXCOLL TRA; Privalov Peter L., 1992, P83; Saven JG, 1996, J MOL BIOL, V257, P199, DOI 10.1006/jmbi.1996.0156; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; Seebach D, 1996, HELV CHIM ACTA, V79, P2043, DOI 10.1002/hlca.19960790802; Shetty AS, 1996, J AM CHEM SOC, V118, P1019, DOI 10.1021/ja9528893; SMITH AB, 1994, J AM CHEM SOC, V116, P9947, DOI 10.1021/ja00101a017; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; STILL WC, 1996, MACROMODEL, V5; VENKATAC.CM, 1969, ANNU REV BIOCHEM, V38, P45, DOI 10.1146/annurev.bi.38.070169.000401; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; YANG AS, 1995, J MOL BIOL, V252, P351, DOI 10.1006/jmbi.1995.0502; ZHANG JS, 1994, J AM CHEM SOC, V116, P4227, DOI 10.1021/ja00089a012	41	734	740	1	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1793	1796		10.1126/science.277.5333.1793	http://dx.doi.org/10.1126/science.277.5333.1793			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295264				2022-12-28	WOS:A1997XX29800038
J	Sleat, DE; Donnelly, RJ; Lackland, H; Liu, CG; Sohar, I; Pullarkat, RK; Lobel, P				Sleat, DE; Donnelly, RJ; Lackland, H; Liu, CG; Sohar, I; Pullarkat, RK; Lobel, P			Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis	SCIENCE			English	Article							MITOCHONDRIAL ATP SYNTHASE; SUBUNIT-C; GENE; GLYCOPROTEINS; THIOESTERASE; INHIBITORS; EXPRESSION; SEQUENCE; ENZYMES; DISEASE	Classical late-infantile neuronal ceroid lipofuscinosis (LINCL) is a fatal neurodegenerative disease whose defective gene has remained elusive. A molecular basis for LINCL was determined with an approach applicable to other lysosomal storage diseases. When the mannose 6-phosphate modification of newly synthesized lysosomal enzymes was used as an affinity marker, a single protein was identified that is absent in LINCL. Sequence comparisons suggest that this protein is a pepstatin-insensitive lysosomal peptidase, and a corresponding enzymatic activity was deficient in LINCL autopsy specimens. Mutations in the gene encoding this protein were identified in LINCL patients but not in normal controls.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT LAB MED & PATHOL,NEWARK,NJ 07103; NEW YORK STATE INST BASIC RES DEV DISABIL,STATEN ISL,NY 10314	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Institute for Basic Research in Developmental Disabilities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030147] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45992] Funding Source: Medline; NINDS NIH HHS [NS30147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOUSTANY RM, 1996, HDB CLIN NEUROLOGY, V66, P671; DE BERNARDO S, 1974, ARCH BIOCHEM BIOPHYS, V163, P390, DOI 10.1016/0003-9861(74)90490-1; Ezaki J, 1996, J NEUROCHEM, V67, P1677, DOI 10.1046/j.1471-4159.1996.67041677.x; *INT BATT DIS CONS, 1995, CELL, V82, P949; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; IVY GO, 1992, AM J MED GENET, V42, P555, DOI 10.1002/ajmg.1320420427; KORNFELD S, 1995, METABOLIC MOL BASES, V2; Oda K, 1996, J BIOCHEM, V120, P564; ODA K, 1994, J BIOL CHEM, V269, P26518; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; PALMER DN, 1989, J BIOL CHEM, V264, P5736; RIDER JA, 1992, AM J MED GENET, V42, P519, DOI 10.1002/ajmg.1320420419; SCHEER E, 1995, GENOMICS, V29, P269, DOI 10.1006/geno.1995.1243; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1997, BIOCHEM J, V324, P33, DOI 10.1042/bj3240033; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; SLEAT DE, UNPUB; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0	19	453	466	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1802	1805		10.1126/science.277.5333.1802	http://dx.doi.org/10.1126/science.277.5333.1802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295267				2022-12-28	WOS:A1997XX29800041
J	Kraaijeveld, AR; Godfray, HCJ				Kraaijeveld, AR; Godfray, HCJ			Trade-off between parasitoid resistance and larval competitive ability in Drosophila melanogaster	NATURE			English	Article							ENCAPSULATION ABILITY; ASOBARA-TABIDA; SELECTION; WASP	The extent to which an organism is selected to invest in defences against pathogens and parasites depends on the advantages that ensue should infection occur, but also on the, costs of maintaining defences in the absence of infection. the presence of heritable variation in resistance suggests that costs exist, but we know very little about the nature or magnitude of these costs in natural populations of animals(1). A powerful technique for identifying trade-offs between fitness components is the study of correlated responses to artificial selection(2,3). We have selected Drosophila melanogaster for improved resistance against an endoparasitoid, Asobara tabida. Endoparasitoids are insects whose larvae develop internally within the body of other insects, eventually killing them, although their hosts can sometimes survive attack by mounting a cellular immune response(4-6). We found that reduced larval competitive ability in unparasitized D. melanogaster is a correlated response to artificial selection for improved resistance against A. tabida. The strength of selection for competitive ability and parasitoid resistance is likely to vary temporally and spatially, which may explain the observed heritable variation in resistance.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,NERC,CTR POPULAT BIOL,ASCOT SL5 7PY,BERKS,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOL,ASCOT SL5 7PY,BERKS,ENGLAND	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); Imperial College London								ATKINSON WD, 1979, J ANIM ECOL, V48, P91, DOI 10.2307/4102; CARTON Y, 1991, ACTA OECOL, V12, P89; CARTON Y, 1985, DEV COMP IMMUNOL, V9, P211, DOI 10.1016/0145-305X(85)90112-0; Godfray H. C. J., 1994, PARASITOIDS BEHAV EV, DOI 10.1515/9780691207025; Gupta AP, 1985, COMPREHENSIVE INSECT, P85; HENTER HJ, 1995, EVOLUTION, V49, P427, DOI [10.1111/j.1558-5646.1995.tb02275.x, 10.2307/2410267]; Hughes K, 1996, J INSECT BEHAV, V9, P477, DOI 10.1007/BF02214024; KRAAIJEVELD AR, 1995, EVOL ECOL, V9, P10, DOI 10.1007/BF01237692; KRAAIJEVELD AR, 1994, ECOL ENTOMOL, V19, P221, DOI 10.1111/j.1365-2311.1994.tb00413.x; LEWONTIN RC, 1955, EVOLUTION, V9, P27, DOI 10.2307/2405355; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; PARTRIDGE L, 1992, EVOLUTION, V46, P76, DOI [10.2307/2409806, 10.1111/j.1558-5646.1992.tb01986.x]; Read A. F., 1995, P450, DOI 10.1017/CBO9780511629396.018; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; Salt G., 1970, CELLULAR DEFENCE REA; SANTOS M, 1992, HEREDITY, V69, P489, DOI 10.1038/hdy.1992.163; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335	17	562	571	1	216	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					278	280		10.1038/38483	http://dx.doi.org/10.1038/38483			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305840				2022-12-28	WOS:A1997XW77200045
J	Lurie, P; Wolfe, SM				Lurie, P; Wolfe, SM			Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ZIDOVUDINE TREATMENT; CLINICAL RESEARCH; HIV-INFECTION; INFANT; TYPE-1; ETHICS				Lurie, P (corresponding author), PUBL CITIZENS HLTH RES GRP,WASHINGTON,DC 20009, USA.							ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; ANNAS G, 1997, BOSTON GLOBE    0518, pC1; Bishop WP, 1996, S AFR MED J, V86, P458; BRENNAN TA, 1994, COMMUNICATION   1228; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper E., 1996, P57; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; HALSEY NA, 1997, COMMUNICATION   0506; HEIMLICH HJ, 1996, 11 INT C AIDS VANC J; LALLEMANT M, 1995, ZDV COURSE PREVENT P; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; MACHIN D, 1987, STAT TABLES DESIGN C, P35; *NIH, 1997, DRAFT TALK POINTS RE; ROUZIOUX C, 1993, AIDS, V7, pS49, DOI 10.1097/00002030-199311002-00011; Scarlatti G, 1996, LANCET, V348, P863, DOI 10.1016/S0140-6736(95)11030-5; SIMONDS RJ, 1996, 11 INT C AIDS VANC C; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; US Public Health Service, 1994, MMWR-MORBID MORTAL W, V43, P1; VARMUS H, 1997, TESTIMONY SUBCOMMITT; VARMUS H, 1996, M ADV COMM DIR NIH D; *WHO, 1994, REC M MOTH INF TRANS; WIKTOR SZ, RANDOMIZED PLACEBO B; World Health Organization, 1993, INT ETH GUID BIOM RE	25	457	474	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					853	856		10.1056/NEJM199709183371212	http://dx.doi.org/10.1056/NEJM199709183371212			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9295246				2022-12-28	WOS:A1997XW28300012
J	Sugarman, J; Kaalund, V; Kodish, E; Marshall, MF; Reisner, EG; Wilfond, BS; Wolpe, PR; Hage, ML; Kurtzberg, J; Olson, J; Capron, AM; Faden, RR; Powers, M; Harvath, L; Howe, CWS				Sugarman, J; Kaalund, V; Kodish, E; Marshall, MF; Reisner, EG; Wilfond, BS; Wolpe, PR; Hage, ML; Kurtzberg, J; Olson, J; Capron, AM; Faden, RR; Powers, M; Harvath, L; Howe, CWS			Ethical issues in umbilical cord blood banking	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMATOPOIETIC STEM-CELLS; PLACENTAL BLOOD; TRANSPLANTATION; CHILDREN; DISEASE	Objective.-Banking umbilical cord blood (UCB) to be used as a source of stem cells for transplantation is associated with a set of ethical issues. An examination of these issues is needed to inform public policy and to raise the awareness of prospective parents, clinicians, and investigators. Participants.-Individuals with expertise in anthropology, blood banking, bone marrow transplantation, ethics, law, obstetrics, pediatrics, and the social sciences were invited to join the Working Group on Ethical Issues in Umbilical Cord Blood Banking. Evidence.-Members were assigned topics to present to the Working Group. Following independent reviews, background materials were sent to the Working Group. Consensus Process.-Individual presentations of topics at a 2-day meeting were followed by extensive group discussions in which consensus emerged. A writing committee then drafted a document that was circulated to the entire Working Group. After 3 rounds of comments over several months, all but 1 member of the Working Group agreed with the presentation of our conclusions. Conclusions.-(1) Umbilical cord blood technology is promising although it has several investigational aspects; (2) during this investigational phase, secure linkage should be maintained of stored UCB to the identity of the donor; (3) UCB banking for autologous use is associated with even greater uncertainty than banking for allogeneic use; (4) marketing practices for UCB banking in the private sector need close attention; (5) more data are needed to ensure that recruitment for banking and use of UCB are equitable; and (6) the process of obtaining informed consent for collection of UCB should begin before labor and delivery.	UNIV N CAROLINA, AFRICAN & AFROAMER STUDIES, CHAPEL HILL, NC USA; CASE WESTERN RESERVE UNIV, SCH MED, CTR BIOMED ETH, CLEVELAND, OH 44106 USA; MED UNIV S CAROLINA, PROGRAM BIOETH, CHARLESTON, SC 29425 USA; UNIV ARIZONA, DEPT PEDIAT, TUCSON, AZ 85721 USA; UNIV PENN, CTR BIOETH, PHILADELPHIA, PA 19104 USA; UNIV SO CALIF, LOS ANGELES, CA 90089 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; GEORGETOWN UNIV, WASHINGTON, DC 20057 USA; US FDA, BETHESDA, MD 20014 USA; NATL MARROW DONOR PROGRAM, MINNEAPOLIS, MN USA; JOHNS HOPKINS SCH PUBL HLTH, BETHESDA, MD USA; PENN STATE UNIV, COLL MED, HERSHEY, PA USA; ALBERT EINSTEIN COLL MED, NEW YORK, NY USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; NHLBI, NIH, BETHESDA, MD 20892 USA; AMER RED CROSS, CHARLOTTE, NC USA	University of North Carolina; University of North Carolina Chapel Hill; Case Western Reserve University; Medical University of South Carolina; University of Arizona; University of Pennsylvania; Pennsylvania Medicine; University of Southern California; Johns Hopkins University; Georgetown University; US Food & Drug Administration (FDA); National Marrow Donor Program; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Yeshiva University; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); American Red Cross	Sugarman, J (corresponding author), DUKE UNIV, MED CTR, DIV GEN INTERNAL MED, CTR HLTH POLICY RES & EDUC, CTR STUDY AGING & HUMAN DEV, DURHAM, NC 27710 USA.		Wolpe, Paul/A-1032-2007	Sugarman, Jeremy/0000-0001-7022-8332				ALEXANDER B, 1996, SELF             AUG, P159; ALEXANDER B, 1996, SELF             AUG, P125; ALMICI C, 1995, HAEMATOLOGICA, V80, P473; ANDREINI L, 1996, USA TODAY       0712, pA12; [Anonymous], 1986, HIST THEORY INFORM C; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; CHRISTENSENSZALANSKI JJJ, 1984, MED DECIS MAKING, V4, P47, DOI 10.1177/0272989X8400400108; *CORD BLOOD REG, 1996, CORD BLOOD MAK INF C; DESPIN L, 1996, WALL STREET J   0618, pA22; *FDA, 1995, DRAFT DOC REG PLAC U; FDA, 1997, PROP APPR REG CELL T; GALE RP, 1995, NEW ENGL J MED, V332, P392, DOI 10.1056/NEJM199502093320612; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1993, BONE MARROW TRANSPL, V11, P199; GOLD M, 1986, CONSPIRACY CELLS ONE; Gurney JG, 1996, CANCER, V78, P532; HARBY K, 1996, ONCOLOGY TIMES, V1, P5; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; LIND SE, 1994, TRANSFUSION, V34, P828, DOI 10.1046/j.1537-2995.1994.34994378287.x; *NAT HEART LUNG BL, 1995, NHLBIHB9505; NEERGARD L, 1996, SUNDAY HERALD   0616, pA11; RUBIN R, 1996, US NEWS WORLD R 0729, P60; SPENCER RF, 1977, CULTURE DIS HEALING, P289; SUGARMAN J, 1995, JAMA-J AM MED ASSOC, V274, P1783, DOI 10.1001/jama.274.22.1783; Varadi G, 1995, Obstet Gynecol Surv, V50, P611, DOI 10.1097/00006254-199508000-00022; *VIACORD, 1995, DEC EXP PAR CHOIC CO, P7; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; Wagner JE, 1996, BLOOD, V88, P795; Washington Harriet, 1994, EMERGE           OCT, P29; 1996, USA TODAY       0712, pA12	30	76	76	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					938	943		10.1001/jama.278.11.938	http://dx.doi.org/10.1001/jama.278.11.938			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302248				2022-12-28	WOS:A1997XV64000034
J	Aboussouan, LS; Khan, SU; Meeker, DP; Stelmach, K; Mitsumoto, H				Aboussouan, LS; Khan, SU; Meeker, DP; Stelmach, K; Mitsumoto, H			Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis	ANNALS OF INTERNAL MEDICINE			English	Article							NASAL VENTILATION; NATURAL-HISTORY; PREDICTION; DISEASE	Background: Noninvasive positive-pressure ventilation may benefit patients with amyotrophic lateral sclerosis and respiratory insufficiency. Objective: To determine 1) whether patients tolerant of noninvasive positive-pressure ventilation have better survival than intolerant patients and 2) whether bulbar symptoms account for intolerance of noninvasive positive-pressure ventilation. Design: Observational cohort study. Setting: Tertiary care referral center. Patients: 39 patients with amyotrophic lateral sclerosis who were treated with noninvasive positive-pressure ventilation. Intervention: Noninvasive positive-pressure ventilation was started for patients with new orthopnea, new hypercapnia, or both. Patients were divided into two groups: those tolerant of and those intolerant of noninvasive positive-pressure ventilation. Results: The risk for death from onset of respiratory insufficiency was higher for intolerant patients than for tolerant patients. (relative risk, 3.1 [95% CI, 1.8 to 9.6]). Moderate or severe bulbar symptoms were more prevalent among intolerant patients than among tolerant patients (67% compared with 33%; P = 0.04). Conclusions: Among patients with amyotrophic lateral sclerosis, those who are tolerant of noninvasive positive-pressure ventilation have better survival than do those who are intolerant. Bulbar symptoms partially account for intolerance of noninvasive positive-pressure ventilation.	WAYNE STATE UNIV, SCH MED, DETROIT, MI 48201 USA; CLEVELAND CLIN FDN, DEPT PULM & CRIT CARE MED, CLEVELAND, OH 44195 USA; CLEVELAND CLIN FDN, DEPT NEUROL, CLEVELAND, OH 44195 USA	Wayne State University; Cleveland Clinic Foundation; Cleveland Clinic Foundation			Aboussouan, Loutfi/O-2317-2019	Aboussouan, Loutfi/0000-0003-2716-0904				BACH JR, 1993, CHEST, V104, P1553, DOI 10.1378/chest.104.5.1553; BACH JR, 1994, LANCET, V344, P752, DOI 10.1016/S0140-6736(94)92242-X; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; BROOKS BR, 1991, ADV NEUROL, V56, P521; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CROWLEY J, 1984, ANNU REV PUBL HEALTH, V5, P385; FALLAT RJ, 1979, ARCH NEUROL-CHICAGO, V36, P74, DOI 10.1001/archneur.1979.00500380044004; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; HILL NS, 1994, CHEST, V105, P337, DOI 10.1378/chest.105.2.337; HILLEL AD, 1989, NEUROEPIDEMIOLOGY, V8, P142, DOI 10.1159/000110176; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; JABLECKI CK, 1989, MUSCLE NERVE, V12, P833, DOI 10.1002/mus.880121008; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; Oppenheimer Edward Anthony, 1993, Palliative Medicine, V7, P49; RAPHAEL JC, 1994, LANCET, V343, P1600	16	254	260	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					450	453		10.7326/0003-4819-127-6-199709150-00006	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313002				2022-12-28	WOS:A1997XV77900006
J	Hanna, FWF; Scanlon, MF				Hanna, FWF; Scanlon, MF			Hyponatraemia, hypothyroidism, and role of arginine-vasopressin	LANCET			English	Editorial Material							MYXEDEMA; HYPONATREMIA				Hanna, FWF (corresponding author), UNIV WALES HOSP,DEPT DIABET ENDOCRINOL & METAB,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.			hanna, fahmy/0000-0001-5800-1442				ALLON M, 1990, J AM SOC NEPHROL, V1, P205; ARCHAMBEAUDMOUVEROUX F, 1987, ANN MED INTERNE, V138, P114; GILLUM DM, 1997, AM J PHYSIOL, V253, pF170; HOCHBERG Z, 1983, HORM RES, V17, P128, DOI 10.1159/000179687; IWASAKI Y, 1990, J CLIN ENDOCR METAB, V70, P534, DOI 10.1210/jcem-70-2-534; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; KOIDE Y, 1982, ENDOCRINOL JAPON, V29, P363; MCDONOUGH AA, 1988, AM J PHYSIOL, V254, pC323, DOI 10.1152/ajpcell.1988.254.2.C323; Montenegro J, 1996, AM J KIDNEY DIS, V27, P195, DOI 10.1016/S0272-6386(96)90539-9; OJAMAA K, 1993, ANN THORAC SURG, V56, pS61, DOI 10.1016/0003-4975(93)90556-W; Saito T, 1997, J CLIN ENDOCR METAB, V82, P1054, DOI 10.1210/jc.82.4.1054; SKOWSKY WR, 1978, AM J MED, V64, P613, DOI 10.1016/0002-9343(78)90581-8	12	74	80	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					755	756		10.1016/S0140-6736(05)62563-9	http://dx.doi.org/10.1016/S0140-6736(05)62563-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297992				2022-12-28	WOS:A1997XW28200007
J	GrahameSmith, DG				GrahameSmith, DG			Clinical academic medicine: a Socratic dialogue	BRITISH MEDICAL JOURNAL			English	Article							TRIALS; METAANALYSIS; QUALITY				GrahameSmith, DG (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND.							ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; EYSENCK HJ, 1995, SYSTEMATIC REV, P64, DOI DOI 10.1007/S11121-005-553-Y; GARNER P, 1995, COCHRANE COLLABORATI; Greenhalgh T., 1997, READ PAPER, P13; *IND TASK FORC, 1997, CLIN AC CAR; KNIPSCHILD P, 1993, LANCET, V341, P1135, DOI 10.1016/0140-6736(93)93140-V; KNIPSCHILD P, 1995, SYSTEMATIC REV, P9; KOUDSTAAL PJ, 1995, COCHRANE DATABASE SY; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; Oxman A, 1995, COCHRANE COLLABORATI; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; Thompson SG, 1995, SYSTEMATIC REV, P48; 1995, DRUG THER B, V33, P25	16	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					593	595						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV717	9302960				2022-12-28	WOS:A1997XV71700031
J	Cockburn, J; Pit, S				Cockburn, J; Pit, S			Prescribing behaviour in clinical practice: patients' expectations and doctor's perceptions of patients' expectations - a questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRESCRIPTIONS; PHYSICIANS	Objectives: To examine the effect of patients' expectations for medication and doctors' perceptions of patients' expectations on prescribing when patients present with new conditions. Design: Questionnaire study of practitioners and patients. Setting: General practice in Newcastle, Australia. Subjects: 22 non-randomly selected general practitioners and 336 of their patients with a newly diagnosed medical condition. Main outcome measures: Prescription of medication and expectation of it. Results: Medication was prescribed for 169 (50%) patients, After controlling for the presenting condition, patients who expected medication were nearly three times more likely to receive medication (odds ratio = 2.9, 95% confidence interval 1.3 to 6.3). When the general practitioner thought the patient expected medication the patient was 10 times more likely to receive it (odds ratio = 10.1, 5.3 to 19.6). A significant association existed between patients' expectation and doctors' perception of patients' expectation (chi(2) = 52.0, df = 4, P = 0.001). For all categories of patient expectation, however, patients were more likely to receive medication when the practitioner judged the patient to want medication than when the practitioner ascribed no expectation to the patient. Conclusions: Although patients brought expectations to the consultation regarding medication, the doctors' opinions about their expectations were the strongest determinants of prescribing.			Cockburn, J (corresponding author), UNIV NEWCASTLE,DISCIPLINE BEHAV SCI RELAT MED,LOCKED BAG 10,WALLSEND 2287,AUSTRALIA.			Achilova, Diyora/0000-0002-7645-9497				*AUD COMM, 1994, PRESCR IMPR RAT PRES; BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; BRADLEY CP, 1992, BRIT J GEN PRACT, V42, P454; Bridges-Webb Charles, 1992, Medical Journal of Australia, V157, pS1; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; BRITTEN N, 1994, FAM PRACT, V11, P62, DOI 10.1093/fampra/11.1.62; COCKBURN J, 1987, BRIT MED J, V295, P813; DENIG P, 1988, SOC SCI MED, V27, P1381, DOI 10.1016/0277-9536(88)90203-1; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; Lamberts H, 1990, INT CLASSIFICATION P; OHAGAN JJ, 1984, NEW ZEAL MED J, V97, P331; REDMAN S, 1991, J BEHAV MED, V14, P527, DOI 10.1007/BF00845109; RYDE D, 1981, PRACTITIONER, V225, P283; SANCHEZMENEGAY C, 1994, J GEN INTERN MED, V9, P404, DOI 10.1007/BF02629524; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; WEBB S, 1994, BRIT J GEN PRACT, V44, P165	16	349	355	0	30	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					520	523		10.1136/bmj.315.7107.520	http://dx.doi.org/10.1136/bmj.315.7107.520			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329308	Green Published			2022-12-28	WOS:A1997XU50600020
J	Nakao, A; Afrakhte, M; Moren, A; Nakayama, T; Christian, JL; Heuchel, R; Itoh, S; Kawabata, N; Heldin, NE; Heldin, CH; tenDijke, P				Nakao, A; Afrakhte, M; Moren, A; Nakayama, T; Christian, JL; Heuchel, R; Itoh, S; Kawabata, N; Heldin, NE; Heldin, CH; tenDijke, P			Identification of Smad7, a TGF beta-inducible antagonist of TGF-beta signalling	NATURE			English	Article							MESODERM INDUCTION; XENOPUS-EMBRYOS; EXPRESSION; PROTEINS	TGF-beta signals from the membrane to the nucleus through serine. threonine kinase receptors and their downstream effecters, termed SMAD proteins(1). The activated TGF-beta receptor induces phosphorylation of two such proteins, Smad2 and Smad3 (refs 2-6), which form hetero-oligomeric complex(es) with Smad4/DPC4 (refs 5-10) that translocate to the nucleus(2,4,5,7), where they then regulate transcriptional responses(11,12). However, the mechanisms by which the intracellular signals of TGF-beta are switched off are unclear. Here we report the identification of Smad7, which is related to Smad6 (ref. 13). Transfection of Smad7 blocks responses mediated by TGF-beta in mammalian cells, and injection of Smad7 RNA into Xenopus embryos blocks activin/TGF-beta signalling. Smad7 associates stably with the TGF-beta receptor complex, but is not phosphorylated upon TGF-beta stimulation. TGF beta-mediated phosphorylation of Smad2 and Smad3 is inhibited by Smad7, indicating that the antagonistic effect of Smad7 is exerted at this important regulatory step. TGF-beta rapidly induces expression of Smad7 mRNA, suggesting that Smad7 may participate in a negative feedback loop to control TGF-beta responses.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN; OREGON HLTH SCI UNIV,SCH MED,DEPT CELL & DEV BIOL,L215,PORTLAND,OR 97201; JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; JAPAN SOC PROMOT SCI,RES FUTURE PROGRAM,TOSHIMA KU,TOKYO 170,JAPAN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital; Oregon Health & Science University; Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science			Nakayama, Takuya/J-5812-2015; Dijke, Peter ten/AAG-4660-2021; Heuchel, Rainer/P-7875-2019	Nakayama, Takuya/0000-0002-5531-6710; Dijke, Peter ten/0000-0002-7234-342X; Heuchel, Rainer/0000-0002-2782-585X; Itoh, Susumu/0000-0002-7967-0730				Afrakhte M, 1996, INT J CANCER, V68, P802; Chang CB, 1997, DEVELOPMENT, V124, P827; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moon R. T., 1989, TECHNIQUE, V1, P76; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	29	1482	1594	4	67	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					631	635		10.1038/39369	http://dx.doi.org/10.1038/39369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335507				2022-12-28	WOS:A1997YA00800067
J	Call, KT; Lurie, N; Jonk, Y; Feldman, R; Finch, MD				Call, KT; Lurie, N; Jonk, Y; Feldman, R; Finch, MD			Who is still uninsured in Minnesota? Lessons from state reform efforts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-INSURANCE; CHILDREN	Objective.-To describe Minnesota's health care system reform efforts and their implications for other state and national reform initiatives, document the rate of uninsurance in 1990 and 1995 with special attention to childrens' access to health insurance, and examine the effectiveness of MinnesotaCare, a voluntary state-subsidized health care plan, in serving its target population, Design.-Three cross-sectional telephone surveys: 2-stage random samples of Minnesotans of all ages in 1990 and 1995 and a stratified random sample of MinnesotaCare enrollees in 1994. Participants.-For the 2 statewide surveys, 10 310 respondents participated in 1990 and 11 519 in 1995; more detailed information was collected on approximately 1600 respondents in each survey, Eight hundred MinnesotaCare enrollees participated in the third survey conducted in 1994. Main Outcome Measure.-Changes in rates of uninsurance. Results.-While the rate of uninsurance increased al the national level, the point-in-time Minnesota rate remained stable and low at 6% between 1990 and 1995. The proportion of children uninsured for 12 months or more decreased from 5.2% in 1990 to 3.1% in 1995, while the proportion of uninsured single adults remained stable at approximately 11%. There was no evidence that MinnesotaCare enrollees are gaming the program, or that the program has resulted in significant erosion from the private market. Conclusions.-MinnesotaCare has enabled the state to maintain a low rate of uninsurance and has reduced this rate among its primary target: children, The program has been less effective in enrolling single adults, although it may be too early to witness the effects of recent expansions targeting this group, Minnesota's experience suggests that other state and national reform efforts aimed at reducing uninsurance, particularly among children, are likely to be successful.	UNIV MINNESOTA,SCH MED,DIV GEN INTERNAL MED,MINNEAPOLIS,MN 55455; HENNEPIN CTY MED CTR,MINNEAPOLIS,MN 55415	University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center	Call, KT (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,INST HLTH SERV RES,BOX 729 MAYO,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.		Jonk, Yvonne/AAY-6750-2020; Finch, Michael/AAN-7772-2021	Jonk, Yvonne/0000-0003-3309-3445; Finch, Michael/0000-0001-7770-1102				*ALPH CTR, 1997, STAT IN HLTH CAR REF; *ALPH CTR, 1992, STAT IN HLTH CAR REF; CALL KT, 1996, MINNESOTA HLTH CARE; CARTLAND JDC, 1993, HEALTH AFFAIR, V12, P144, DOI 10.1377/hlthaff.12.1.144; CUNNINGHAM PJ, 1990, HEALTH AFFAIR, V9, P76, DOI 10.1377/hlthaff.9.4.76; DAVIDSON G, 1996, INT HLTH EC ASS MAY; FRONSTIN P, 1995, INQUIRY-J HEALTH CAR, V32, P353; HELMS WD, 1992, HEALTH AFFAIR, V11, P7, DOI 10.1377/hlthaff.11.2.7; MILES SH, 1992, NEW ENGL J MED, V327, P1092, DOI 10.1056/NEJM199210083271511; *MN DEP HLTH, 1995, MDH PUBL; *MN DEP HUM SERV, 1996, MINN AR ENR REF SHEE; NELSON K, 1994, JAMA-J AM MED ASSOC, V272, P746; *STATC, 1995, STAT STAT SOFTW REL; SWARTZ K, 1993, INQUIRY-J HEALTH CAR, V30, P64; THORPE KE, 1992, JAMA-J AM MED ASSOC, V267, P945, DOI 10.1001/jama.267.7.945; *US BUR CENS, 1995, CURR POP SURV; *US BUR CENS, 1990, CURR POP SURV; US Census Bureau, 1990, 1990 US CENS; *WILD RES CTR, 1994, MN STAT SURV PERS PE, V1; YAWN B, 1996, WORKING PAPER SERIES	20	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1191	1195		10.1001/jama.278.14.1191	http://dx.doi.org/10.1001/jama.278.14.1191			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY422	9326482				2022-12-28	WOS:A1997XY42200040
J	Hall, TMT; Porter, JA; Young, KE; Koonin, EV; Beachy, PA; Leahy, DJ				Hall, TMT; Porter, JA; Young, KE; Koonin, EV; Beachy, PA; Leahy, DJ			Crystal structure of a hedgehog autoprocessing domain: Homology between hedgehog and self-splicing proteins	CELL			English	Article							TERMINAL CLEAVAGE PRODUCT; SONIC HEDGEHOG; AUTOPROTEOLYTIC CLEAVAGE; CIRCULAR PERMUTATIONS; ANOMALOUS DIFFRACTION; PATTERNING ACTIVITY; XENOPUS-LAEVIS; INDUCTION; ALIGNMENT; SEQUENCE	The similar to 25 kDa carboxy-terminal domain of Drosophila Hedgehog protein (Hh-C) possesses an autoprocessing activity that results in an intramolecular cleavage of full-length Hedgehog protein and covalent attachment of a cholesterol moiety to the newly generated amino-terminal fragment. We have identified a 17 kDa fragment of Hh-C (Hh-C-17) active in the initiation of autoprocessing and report here its crystal structure. The Hh-C-17 structure comprises two homologous subdomains that appear to have arisen from tandem duplication of a primordial gene. Residues in the Hh-C-17 active site have been identified, and their role in Hedgehog autoprocessing probed by site-directed mutagenesis. Aspects of sequence, structure, and reaction mechanism are conserved between Hh-C-17 and the self-splicing regions of inteins, permitting reconstruction of a plausible evolutionary history of Hh-C and the inteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOL BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; NIH, NATL CTR BIOTECHNOL INFORMAT, NATL LIB MED, BETHESDA, MD 20894 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)			Hall, Traci/F-5849-2019	Hall, Traci/0000-0001-6166-3009				Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Burglin TR, 1996, CURR BIOL, V6, P1047, DOI 10.1016/S0960-9822(02)70659-3; BURNCROT DA, 1995, MOL CELL BIOL, V15, P2294; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; EKKER SC, 1995, DEVELOPMENT, V121, P2337; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HEINEMANN U, 1995, TRENDS BIOCHEM SCI, V20, P349, DOI 10.1016/S0968-0004(00)89073-8; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JONES DH, 1992, BIOTECHNIQUES, V12, P528; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P141, DOI 10.1016/S0968-0004(00)88989-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI CJ, 1995, DEVELOPMENT, V121, P2349; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; PIETROKOVSKI S, 1997, IN PRESS PROT SCI; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P777, DOI 10.1073/pnas.72.3.777; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	51	226	235	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	1997	91	1					85	97		10.1016/S0092-8674(01)80011-8	http://dx.doi.org/10.1016/S0092-8674(01)80011-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335337	hybrid			2022-12-28	WOS:A1997XZ80900011
J	Kim, U; SanchezVives, MV; McCormick, DA				Kim, U; SanchezVives, MV; McCormick, DA			Functional dynamics of GABAergic inhibition in the thalamus	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; CENTRAL-NERVOUS-SYSTEM; UNDERLYING SYNCHRONIZED OSCILLATIONS; IN-VITRO; POSTSYNAPTIC POTENTIALS; PERIGENICULATE NUCLEUS; ABSENCE SEIZURES; PYRAMIDAL CELLS; ELECTROPHYSIOLOGICAL PROPERTIES; THALAMOCORTICAL OSCILLATIONS	The inhibitory gamma-aminobutyric acid-containing (GABAergic) neurons of the thalamic reticular and perigeniculate nuclei are involved in the generation of normal and abnormal synchronized activity in thalamocortical networks. An important factor controlling the generation of activity in this system is the amplitude and duration of inhibitory postsynaptic potentials (IPSPs) in thalamocortical cells, which depend on the pattern of activity generated in thalamic reticular and perigeniculate cells. Activation of single ferret perigeniculate neurons generated three distinct patterns of GABAergic IPSPs in thalamocortical neurons of the dorsal lateral geniculate nucleus: Low-frequency tonic discharge resulted in small-amplitude IPSPs mediated by GABA(A) receptors, burst firing resulted in large-amplitude GABA(A) IPSPs, and prolonged burst firing activated IPSPs mediated by GABA(A) and GABA(B) receptors. These functional properties of GABAergic inhibition can reconfigure the operations of thalamocortical networks into patterns of activity associated with waking, slow-wave sleep, and generalized seizures.	YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA	Yale University			McCormick, David A/J-2649-2015; Kobelt, Liza/F-5926-2011; Sanchez-Vives, Maria/J-8526-2014	McCormick, David A/0000-0002-9803-8335; Sanchez-Vives, Maria/0000-0002-8437-9083				AVOLI M, 1983, J NEUROPHYSIOL, V50, P819, DOI 10.1152/jn.1983.50.4.819; Bal T, 1996, NEURON, V17, P297, DOI 10.1016/S0896-6273(00)80161-0; BAL T, 1995, J PHYSIOL-LONDON, V483, P641, DOI 10.1113/jphysiol.1995.sp020612; BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; BENARDO LS, 1994, J PHYSIOL-LONDON, V476, P203, DOI 10.1113/jphysiol.1994.sp020124; BERMAN NJ, 1992, PROG BRAIN RES, V90, P443; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUSCH C, 1990, COLD SH Q B, V55, P69; BUZSAKI G, 1991, NEUROSCIENCE, V41, P351, DOI 10.1016/0306-4522(91)90332-I; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; CONTRERAS D, 1993, J PHYSIOL-LONDON, V470, P273, DOI 10.1113/jphysiol.1993.sp019858; Cox C. L., 1996, Society for Neuroscience Abstracts, V22, P97; CRUNELLI V, 1991, TRENDS NEUROSCI, V14, P16, DOI 10.1016/0166-2236(91)90178-W; CUCCHIARO JB, 1991, J COMP NEUROL, V310, P316, DOI 10.1002/cne.903100304; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; DESTEXHE A, 1995, P NATL ACAD SCI USA, V92, P9515, DOI 10.1073/pnas.92.21.9515; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; Golomb D, 1996, J NEUROPHYSIOL, V75, P750, DOI 10.1152/jn.1996.75.2.750; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HUGUENARD JR, 1994, J NEUROSCI, V14, P5485; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; Jones EG, 1985, THALAMUS; KAWAGUCHI Y, 1995, J NEUROSCI, V15, P2638; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MILES R, 1990, J PHYSIOL-LONDON, V431, P659, DOI 10.1113/jphysiol.1990.sp018353; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OTIS TS, 1992, J NEUROPHYSIOL, V67, P227, DOI 10.1152/jn.1992.67.1.227; Peters A.J, 1985, CEREBRAL CORTEX CELL, V1, DOI [10.1086/414271, DOI 10.1086/414271]; SANCHEZVIVES MV, IN PRESS NEUROSCIENC; SNEAD OC, 1992, EUR J PHARMACOL, V213, P343, DOI 10.1016/0014-2999(92)90623-C; Sodickson DL, 1996, J NEUROSCI, V16, P6374; SOLTESZ I, 1992, PROG BRAIN RES, V90, P151; STERIADE M, 1986, J NEUROSCI, V6, P68; STERIADE M, 1985, J NEUROPHYSIOL, V54, P1473, DOI 10.1152/jn.1985.54.6.1473; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; SUGITA S, 1992, NEUROSCI LETT, V134, P207, DOI 10.1016/0304-3940(92)90518-C; THOMPSON SM, 1992, J PHYSIOL-LONDON, V451, P329, DOI 10.1113/jphysiol.1992.sp019167; THOMSON AM, 1988, NEUROSCIENCE, V25, P491, DOI 10.1016/0306-4522(88)90253-9; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; UHLRICH DJ, 1991, J NEUROPHYSIOL, V65, P1528, DOI 10.1152/jn.1991.65.6.1528; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; WARREN RA, 1994, J NEUROPHYSIOL, V72, P1993, DOI 10.1152/jn.1994.72.4.1993	50	259	263	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					130	134		10.1126/science.278.5335.130	http://dx.doi.org/10.1126/science.278.5335.130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311919				2022-12-28	WOS:A1997XZ12400055
J	Xu, J; Dodd, RL; Makino, CL; Simon, MI; Baylor, DA; Chen, J				Xu, J; Dodd, RL; Makino, CL; Simon, MI; Baylor, DA; Chen, J			Prolonged photoresponses in transgenic mouse rods lacking arrestin	NATURE			English	Article							PHOSPHODIESTERASE ACTIVATION; RETINAL RODS; IN-VIVO; RHODOPSIN; PROTEIN; BINDING; PHOTORECEPTORS; INACTIVATION; PHOTOTRANSDUCTION; PHOSPHORYLATION	Arrestins are soluble cytoplasmic proteins that bind to G-protein-coupled receptors, thus switching off activation of the G protein and terminating the signalling pathway that triggers the cellular response(1,2). Although visual arrestin has been shown to quench the catalytic activity of photoexcited, phosphorylated rhodopsin in a reconstituted system(3), its role in the intact rod cell remains unclear because phosphorylation alone reduces the catalytic activity of rhodopsin(4-6). Here we have recorded photocurrents of rods from transgenic mice in which one or both copies of the arrestin gene were disrupted, Photoresponses were unaffected when arrestin expression was halved, indicating that arrestin binding is not rate limiting for recovery of the rod photoresponse, as it is in Drosophila(7,8). With arrestin absent, the flash response displayed a rapid partial recovery followed by a prolonged final phase, This behaviour indicates that an arrestin-independent mechanism initiates the quench of rhodopsin's catalytic activity and that arrestin completes the quench, The intensity dependence of the photoresponse in rods lacking arrestin further suggests that, although arrestin is required for normal signal termination, it does not participate directly in light adaptation.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; CALTECH,DIV BIOL,PASADENA,CA 91125	Stanford University; California Institute of Technology			Makino, Clint Lawrence/H-8428-2019	Makino, Clint Lawrence/0000-0002-6005-9069				ADMUS G, 1997, INVEST OPHTH VIS SCI, V38, P283; AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1987, RETINAL PROTEINS, P497; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CONE RA, 1969, NATURE, V221, P820, DOI 10.1038/221820a0; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; EBREY TG, 1968, VISION RES, V8, P965, DOI 10.1016/0042-6989(68)90071-0; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LEE RH, EXP EYE RES, V51, P325; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NAKATANI K, 1991, J GEN PHYSIOL, V97, P413, DOI 10.1085/jgp.97.3.413; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; Palczewski K, 1996, EXP EYE RES, V63, P599, DOI 10.1006/exer.1996.0151; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PENN JS, 1986, EXP EYE RES, V43, P915, DOI 10.1016/0014-4835(86)90070-9; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RAPORT CJ, 1994, INVEST OPHTH VIS SCI, V35, P2932; SCHREMSER JL, 1995, EXP EYE RES, V61, P17, DOI 10.1016/S0014-4835(95)80054-9; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y	30	262	264	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					505	509		10.1038/39068	http://dx.doi.org/10.1038/39068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333241				2022-12-28	WOS:A1997XY90900059
J	Anderson, C				Anderson, C			Violence in television commercials during nonviolent programming - The 1996 major league baseball playoffs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To identify the frequency of violent television commercials aired during major league baseball playoffs, traditionally thought to be a family-oriented viewing time. Design and Setting.-All 6 World Series games televised on the Fox Television Network (Fox), all 5 American League Championship Series playoff games televised by the National Broadcasting Company (NBC), and 4 first-round playoff games televised by ESPN Sports Television Network (ESPN) were videotaped in October 1996. Results.-During the 15 televised games reviewed, 104 (6.8%) of the 1528 commercials contained violent content. Sixty-one commercials (10 per game) that included violent interactions were noted during the World Series, 30 (6 per game) during the American League Championship Series, and 13 (3 per game) during the 4 first-round playoff games for a total of 104. In these 104 violent commercials, 69 contained at least 1 violent act, 90 contained at least 1 violent threat, and 27 contained evidence of at least 1 violent consequence. Seventy (67.3%) of the violent commercials were promotions for television programs, 7 (6.7%) were cable television program advertisements, and 20 (19.2%) were big-screen movie promotions. Twenty (71.4%) of 28 big-screen movie promotions were violent. Twenty-two (21.2%) of the 104 violent commercials and 7 ''nonviolent'' commercials contained blood or other graphic content, all of which were televised during the Fox presentation of the World Series. Fox also accounted for all 24 violent commercials that used a knife. Guns were involved in 25 violent commercials on NBC (5.0 per game), in 20 on Fox (3.33 per game), and in 7 on ESPN (1.75 per game). Conclusion. Overt violent content in commercials during the 1996 major league playoffs was common and consisted mainly of promotions for television programs and big-screen movies. It is counterintuitive to find such commercials in nonviolent programming and makes it difficult for parents to avoid exposing their children to this form of violence.			Anderson, C (corresponding author), HENNEPIN CTY MED CTR,FAMILY MED CTR,DEPT FAMILY PRACTICE,5 W LAKE ST,MINNEAPOLIS,MN 55408, USA.							ANGLIN TM, 1996, NATL TELEVISION VIOL; CENTERWALL BS, 1992, JAMA-J AM MED ASSOC, V267, P3059; DONNER L, 1990, VIOLENT BEHAV, P151; *NAT ASS BROADC, 1990, VOL PROGR PRINC; RAJECKI DW, 1994, J APPL SOC PSYCHOL, V24, P1685, DOI 10.1111/j.1559-1816.1994.tb01569.x; SILVER M, 1993, US NEWS WORLD R 0201, P65	6	13	13	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1045	1046		10.1001/jama.278.13.1045	http://dx.doi.org/10.1001/jama.278.13.1045			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX303	9315746				2022-12-28	WOS:A1997XX30300001
J	Hoganson, CW; Babcock, GT				Hoganson, CW; Babcock, GT			A metalloradical mechanism for the generation of oxygen from water in photosynthesis	SCIENCE			English	Article							AMINO-ACID-RESIDUES; TYROSINE Y-Z; PHOTOSYSTEM-II; EVOLVING COMPLEX; MANGANESE CLUSTER; D1 POLYPEPTIDE; REDUCED DERIVATIVES; PROTON RELEASE; ACTIVE-SITE; MN CLUSTER	In plants and algae, photosystem II uses light energy to oxidize water to oxygen at a metalloradical site that comprises a tetranuclear manganese cluster and a tyrosyl radical, A model is proposed whereby the tyrosyl radical functions by abstracting hydrogen atoms from substrate water bound as terminal ligands to two of the four manganese ions. Molecular oxygen is produced in the final step in which hydrogen atom transfer and oxygen-oxygen bond formation occur together in a concerted reaction. This mechanism establishes clear analogies between photosynthetic water oxidation and amino acid radical function in other enzymatic reactions.	MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM-37300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babcock G. T., 1995, PHOTOSYNTHESIS LIGHT, V2, P209; Babcock GT, 1997, ACTA CHEM SCAND, V51, P533, DOI 10.3891/acta.chem.scand.51-0533; BABCOCK GT, 1976, FEBS LETT, V61, P286; BABCOCK GT, 1989, BIOCHEMISTRY-US, V28, P9557, DOI 10.1021/bi00451a001; Baldwin MJ, 1996, J AM CHEM SOC, V118, P11325, DOI 10.1021/ja9626906; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BLOMBERG MRA, IN PRESS J AM CHEM S; Bogershausen O, 1996, BER BUNSEN PHYS CHEM, V100, P1987; BOUSSAC A, 1992, BIOCHEMISTRY-US, V31, P1224, DOI 10.1021/bi00119a036; Britt R.D, 1996, ADV PHOTOSYNTHESIS O; BRUDVIG GW, 1986, P NATL ACAD SCI USA, V83, P4586, DOI 10.1073/pnas.83.13.4586; Caudle MT, 1997, J AM CHEM SOC, V119, P3415, DOI 10.1021/ja9641158; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; COLLINS TJ, 1990, J AM CHEM SOC, V112, P899, DOI 10.1021/ja00158a077; Cotton F. A., 1988, ADV INORG CHEM, P707; DAU H, 1995, BIOCHEMISTRY-US, V34, P5274, DOI 10.1021/bi00015a043; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V767, P1, DOI 10.1016/0005-2728(84)90073-2; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; GARDNER KA, 1995, SCIENCE, V269, P1849, DOI 10.1126/science.7569922; GILBERT JA, 1985, J AM CHEM SOC, V107, P3855, DOI 10.1021/ja00299a017; GILCHRIST ML, 1995, P NATL ACAD SCI USA, V92, P9545, DOI 10.1073/pnas.92.21.9545; GIRERD JJ, 1995, PHOTOSYNTHESIS LIGHT, V2, P217; GREENWOOD NN, 1984, CHEM ELEMENTS, P1228; HADDY A, 1992, BIOCHIM BIOPHYS ACTA, V1099, P25, DOI 10.1016/0304-4173(92)90004-X; HAUMANN M, 1994, BIOCHEMISTRY-US, V33, P864, DOI 10.1021/bi00170a003; Haumann M, 1996, BBA-BIOENERGETICS, V1273, P237, DOI 10.1016/0005-2728(95)00152-2; HAUMANN M, 1996, OXYGENIC PHOTOSYNTHE, P165; HOGANSON CW, 1994, MET IONS BIOL SYST, V30, P77; Hoganson CW, 1995, PHOTOSYNTH RES, V46, P177, DOI 10.1007/BF00020428; Ingold C. K., 1969, STRUCTURE MECHANISM, P457; Karge M, 1997, BIOCHEMISTRY-US, V36, P8904, DOI 10.1021/bi962342g; Karge M, 1996, FEBS LETT, V378, P140, DOI 10.1016/0014-5793(95)01433-0; KERR JA, 1996, HDB CHEM PHYSICS, P9; KHANGULOV S, 1993, BIOCHEMISTRY-US, V32, P4912, DOI 10.1021/bi00069a028; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KOIKE H, 1987, BIOCHIM BIOPHYS ACTA, V893, P524, DOI 10.1016/0005-2728(87)90104-6; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KRAMARZ KW, 1994, PROG INORG CHEM, V42, P1, DOI 10.1002/9780470166437.ch1; Kretschmann H, 1996, BBA-BIOENERGETICS, V1274, P1, DOI 10.1016/0005-2728(95)00150-6; KRISHTALIK LI, 1990, BIOELECTROCH BIOENER, V23, P249, DOI 10.1016/0302-4598(90)80014-A; LAVERGNE J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P175, DOI 10.1016/S0005-2728(09)91005-2; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; LINDBERG K, 1993, PHOTOSYNTH RES, V38, P401, DOI 10.1007/BF00046767; LYDAKISSIMANTIR.N, IN PRESS BIOCH BIOPH; LYDAKISSIMANTIR.N, 1995, PHOTOSYNTHESIS LIGHT, V2, P279; MANCHANDA R, 1995, COORDIN CHEM REV, V144, P1, DOI 10.1016/0010-8545(95)01147-H; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; MESSINGER J, 1995, PHOTOSYNTHESIS LIGHT, V2, P283; MESSINGER J, IN PRESS BIOCHEMISTR; NARUTA Y, 1994, ANGEW CHEM INT EDIT, V33, P1839, DOI 10.1002/anie.199418391; ONO T, 1992, SCIENCE, V258, P1335, DOI 10.1126/science.258.5086.1335; PECORARO VL, 1988, PHOTOCHEM PHOTOBIOL, V48, P249; PECORARO VL, 1992, MANGANESE REDOX ENZY, P197; PROSS A, 1995, THEORETICAL PHYSICAL; RANDALL DW, 1995, J AM CHEM SOC, V117, P11780, DOI 10.1021/ja00152a021; Razeghifard MR, 1997, BIOCHEMISTRY-US, V36, P86, DOI 10.1021/bi9614287; RENGER G, 1992, FEBS LETT, V299, P28, DOI 10.1016/0014-5793(92)80092-U; RIGGS PJ, 1992, J AM CHEM SOC, V114, P10650, DOI 10.1021/ja00052a079; RiggsGelasco PJ, 1996, J AM CHEM SOC, V118, P2387, DOI 10.1021/ja9504496; Roelofs TA, 1996, P NATL ACAD SCI USA, V93, P3335, DOI 10.1073/pnas.93.8.3335; ROTZINGER FP, 1987, J AM CHEM SOC, V109, P6619, DOI 10.1021/ja00256a010; Sawyer D. T, 1991, OXYGEN CHEM; SHANK M, 1994, BIOCHEMISTRY-US, V33, P15433, DOI 10.1021/bi00255a025; STERN MK, 1992, MANGANESE REDOX ENZY, P233; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; Tang XS, 1996, J AM CHEM SOC, V118, P7638, DOI 10.1021/ja9610592; TANG XS, 1994, P NATL ACAD SCI USA, V91, P704, DOI 10.1073/pnas.91.2.704; TIAN GC, 1994, BIOCHEMISTRY-US, V33, P226, DOI 10.1021/bi00167a030; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; TOMMOS C, IN PRESS ACCT CHEM R; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VINCENT JB, 1987, INORG CHIM A-BIOINOR, V136, pL41, DOI 10.1016/S0020-1693(00)81142-1; Wachter RM, 1996, J AM CHEM SOC, V118, P2782, DOI 10.1021/ja9519896; WALDO GS, 1992, J AM CHEM SOC, V114, P5869, DOI 10.1021/ja00040a064; Wincencjusz H, 1997, BIOCHEMISTRY-US, V36, P3663, DOI 10.1021/bi9626719; Witt HT, 1996, BER BUNSEN PHYS CHEM, V100, P1923, DOI 10.1002/bbpc.19961001202; Yachandra VK, 1996, CHEM REV, V96, P2927, DOI 10.1021/cr950052k; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; YOCUM CF, 1991, BIOCHIM BIOPHYS ACTA, V1059, P1, DOI 10.1016/S0005-2728(05)80182-3; [No title captured]	84	499	506	1	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1953	1956		10.1126/science.277.5334.1953	http://dx.doi.org/10.1126/science.277.5334.1953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302282				2022-12-28	WOS:A1997XX84900032
J	Kamohara, S; Burcelin, R; Halaas, JL; Friedman, JM; Charron, MJ				Kamohara, S; Burcelin, R; Halaas, JL; Friedman, JM; Charron, MJ			Acute stimulation of glucose metabolism in mice by leptin treatment	NATURE			English	Article							OBESE GENE; RAT HYPOTHALAMUS; MESSENGER-RNA; FOOD-INTAKE; OB PROTEIN; OB/OB MICE; EXPRESSION; INSULIN; RECEPTOR; IDENTIFICATION	Leptin is an adipocyte hormone that functions as an afferent signal in a negative feedback loop regulating body weight(1-4), and acts by interacting with a receptor in the hypothalamus and other tissues(5,6), Leptin treatment has potent effects on lipid metabolism, and leads to a large, specific reduction of adipose tissue mass after several days(1,4). Here we show that leptin also acts acutely to increase glucose metabolism, although studies of leptin's effect on glucose metabolism have typically been confounded by the weight-reducing actions of leptin treatment, which by itself could affect glucose homoeostasis(1-3). We have demonstrated acute in vivo effects of intravenous and intracerebroventricular administrations of leptin on glucose metabolism, A five-hour intravenous infusion of leptin into wild-type mice increased glucose turnover and glucose uptake, but decreased hepatic glycogen content, The plasma levels of insulin and glucose did not change. Similar effects were observed after both intravenous and intracerebroventricular infusion of leptin, suggesting that effects of leptin on glucose metabolism are mediated by the central nervous system (CNS), These data indicate that leptin induces a complex metabolic response with effects on glucose as well as lipid metabolism, This response is unique to leptin, which suggests that new efferent signals emanate from the CNS after leptin treatment.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10021	Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine				Kamohara, Seika/0000-0002-2482-6611				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Golden PL, 1997, J CLIN INVEST, V99, P14, DOI 10.1172/JCI119125; GosteliPeter MA, 1996, BIOCHEM BIOPH RES CO, V221, P521, DOI 10.1006/bbrc.1996.0629; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; LAUTALA P, 1981, ACTA ENDOCRINOL-COP, V98, P481, DOI 10.1530/acta.0.0980481; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEONG SF, 1984, BIOCHEM J, V218, P131, DOI 10.1042/bj2180131; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; Massillon D, 1995, AM J PHYSIOL-ENDOC M, V269, pE1037, DOI 10.1152/ajpendo.1995.269.6.E1037; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; MILES PDG, 1991, P NATL ACAD SCI USA, V88, P1296, DOI 10.1073/pnas.88.4.1296; NAGAI K, 1988, HORM METAB RES, V20, P37, DOI 10.1055/s-2007-1010743; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Satoh N, 1997, ENDOCRINOLOGY, V138, P947, DOI 10.1210/en.138.3.947; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VRANIC M, 1976, J CLIN INVEST, V57, P245, DOI 10.1172/JCI108275; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185	29	591	613	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					374	377		10.1038/38717	http://dx.doi.org/10.1038/38717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311777				2022-12-28	WOS:A1997XX67500050
J	Kanaoka, Y; Ago, H; Inagaki, E; Nanayama, T; Miyano, M; Kikuno, R; Fujii, Y; Eguchi, N; Toh, H; Urade, Y; Hayaishi, O				Kanaoka, Y; Ago, H; Inagaki, E; Nanayama, T; Miyano, M; Kikuno, R; Fujii, Y; Eguchi, N; Toh, H; Urade, Y; Hayaishi, O			Cloning and crystal structure of hematopoietic prostaglandin D synthase	CELL			English	Article							GLUTATHIONE-S-TRANSFERASE; RAY-DIFFRACTION DATA; 3-DIMENSIONAL STRUCTURE; D SYNTHETASE; MAST-CELLS; WEISSENBERG CAMERA; D-ISOMERASE; PROTEIN; ACID; 9-DEOXY-DELTA-9,DELTA-12-13,14-DIHYDROPROSTAGLANDIN-D2	Hematopoietic prostaglandin (PG) D synthase is the key enzyme for production of the D and J series of prostanoids in the immune system and mast cells. We isolated a cDNA for the rat enzyme, crystallized the recombinant enzyme, and determined the three-dimensional structure of the enzyme complexed with glutathione at 2.3 Angstrom resolution. The enzyme is the first member of the sigma class glutathione S-transferase (GST) from vertebrates and possesses a prominent cleft as the active site, which is never seen among other members of the GST family. The unique 3-D architecture of the cleft leads to the putative substrate binding made and its catalytic mechanism, responsible for the specific isomerization from PGH(2) to PGD(2).	OSAKA BIOSCI INST, DEPT MOL BEHAV BIOL, OSAKA 565, JAPAN; JAPAN TOBACCO INC, CENT PHARMACEUT RES INST, OSAKA 56911, JAPAN; BIOMOL ENGN RES INST, OSAKA 565, JAPAN; FUKUI MED SCH, DEPT CHEM, FUKUI 91011, JAPAN; JAPAN SCI & TECHNOL CORP, PRESTO, OSAKA 565, JAPAN	Japan Tobacco Inc.; University of Fukui; Japan Science & Technology Agency (JST)			Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175; Ago, Hideo/0000-0002-9040-488X; Fujii, Yutaka/0000-0001-6357-3795				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P373; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Felsenstein J, 1993, PHYLIP PHYLOGENY INT; FIELDS BA, 1992, J APPL CRYSTALLOGR, V25, P809, DOI 10.1107/S0021889892008410; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; KLEMM P, 1982, EUR J BIOCHEM, V124, P339; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SHELDRICK GM, 1985, CRYSTALLOGRAPHIC COM, V3, P184; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V264, P428, DOI 10.1016/0003-9861(88)90308-6; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V260, P521, DOI 10.1016/0003-9861(88)90477-8; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1990, J BIOL CHEM, V265, P371; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	51	219	231	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1085	1095		10.1016/S0092-8674(00)80374-8	http://dx.doi.org/10.1016/S0092-8674(00)80374-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323136	Bronze			2022-12-28	WOS:A1997XX76800014
J	Liu, Q; Fischer, U; Wang, F; Dreyfuss, G				Liu, Q; Fischer, U; Wang, F; Dreyfuss, G			The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins	CELL			English	Article							MOTOR-NEURON GENE; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; COILED BODY; MOLECULAR ANALYSIS; CDNA CLONING; SURVIVAL; BINDING; DELETIONS; CAP; IDENTIFICATION	Spinal muscular atrophy (SMA), one of the most common fatal autosomal recessive diseases, is characterized by degeneration of motor neurons and muscular atrophy. The SMA disease gene, termed Survival of Motor Neurons (SMN), is deleted or mutated in over 98% of SMA patients. The function of the SMN protein is unknown. We found that SMN is tightly associated with a novel protein, SIP1, and together they form a specific complex with several spliceosomal snRNP proteins. SMN interacts directly with several of the snRNP Sm core proteins, including B, D1-3, and E. Interestingly, SIP1 has significant sequence similarity with Brr1, a yeast protein critical for snRNP biogenesis. these findings suggest a role for SMN and SIP1 in spliceosomal snRNP biogenesis and function and provide a likely molecular mechanism for the cause of SMA.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013; Fischer, Utz/A-4090-2016; Fischer, Utz/AAT-8422-2020	Dreyfuss, Gideon/0000-0001-8129-8774; Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BOHMANN K, 1995, J CELL SCI S, V19, P107; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; CHANG JG, 1995, AM J HUM GENET, V57, P1503; CHOI YD, 1984, J CELL BIOL, V99, P1997; COBBEN JM, 1995, AM J HUM GENET, V57, P805; Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; CZEIZEI A, 1989, J MED GENET, V21, P761; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FEENEY RJ, 1989, J BIOL CHEM, V264, P5776; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISHER DE, 1985, CELL, V42, P751, DOI 10.1016/0092-8674(85)90271-5; GALL JG, 1995, DEV GENET, V16, P25, DOI 10.1002/dvg.1020160107; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HERRMANN H, 1995, EMBO J, V14, P2076; LATCHMAN D S, 1990, New Biologist, V2, P297; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Liu Q, 1996, COLD SPRING HARB SYM, V61, P689; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; Munsat TL., 1991, NEUROMUSCUL DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604	50	522	539	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1013	1021		10.1016/S0092-8674(00)80367-0	http://dx.doi.org/10.1016/S0092-8674(00)80367-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323129	hybrid			2022-12-28	WOS:A1997XX76800007
J	Fertleman, CR; Gallagher, A; Rossiter, MA				Fertleman, CR; Gallagher, A; Rossiter, MA			Evaluation of fast track admission policy for children with sickle cell crises: questionnaire survey of parents' preferences	BRITISH MEDICAL JOURNAL			English	Article									N MIDDLESEX HOSP,LONDON N18 1QX,ENGLAND									BLACK J, 1986, LIVING SICKLE CELL D, P112; FRANCEDAWSON M, 1994, NURS STAND, V45, P25; Oppenheim A. N., 1992, QUESTIONNAIRE DESIGN	3	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					650	650		10.1136/bmj.315.7109.650	http://dx.doi.org/10.1136/bmj.315.7109.650			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310567	Green Published			2022-12-28	WOS:A1997XW69400020
J	Neilson, JP				Neilson, JP			Assessment of fetal nuchal translucency test for Down's syndrome	LANCET			English	Editorial Material							FIRST-TRIMESTER; GENERAL-POPULATION; MATERNAL AGE; TRISOMY-21; THICKNESS; GESTATION; FETUSES				Neilson, JP (corresponding author), UNIV LIVERPOOL,DEPT OBSTET & GYNAECOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							ALFIREVIC Z, 1997, PREGNANCY CHILDBIRTH; Braithwaite JM, 1996, BRIT J OBSTET GYNAEC, V103, P1201, DOI 10.1111/j.1471-0528.1996.tb09629.x; Chaban FK, 1996, PRENATAL DIAG, V16, P537, DOI 10.1002/(SICI)1097-0223(199606)16:6<537::AID-PD911>3.0.CO;2-4; Hyett JA, 1996, ULTRASOUND OBST GYN, V7, P101, DOI 10.1046/j.1469-0705.1996.07020101.x; HYETT JA, 1995, AM J OBSTET GYNECOL, V172, P1411, DOI 10.1016/0002-9378(95)90470-0; Kornman LH, 1996, PRENATAL DIAG, V16, P797, DOI 10.1002/(SICI)1097-0223(199609)16:9<797::AID-PD948>3.3.CO;2-D; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; ROBERTS LJ, 1995, BRIT J OBSTET GYNAEC, V102, P381, DOI 10.1111/j.1471-0528.1995.tb11289.x; Sebire NJ, 1996, BRIT J OBSTET GYNAEC, V103, P999, DOI 10.1111/j.1471-0528.1996.tb09550.x; SZABO J, 1990, LANCET, V336, P1133, DOI 10.1016/0140-6736(90)92614-N	10	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					754	755		10.1016/S0140-6736(05)62562-7	http://dx.doi.org/10.1016/S0140-6736(05)62562-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297991				2022-12-28	WOS:A1997XW28200006
J	Yu, SJM; Conticello, VP; Zhang, GH; Kayser, C; Fournier, MJ; Mason, TL; Tirrell, DA				Yu, SJM; Conticello, VP; Zhang, GH; Kayser, C; Fournier, MJ; Mason, TL; Tirrell, DA			Smectic ordering in solutions and films of a rod-like polymer owing to monodispersity of chain length	NATURE			English	Article							SYSTEM; PHASES	Solutions and melts of stiff ('rod-like') macromolecules often exhibit nematic liquid crystalline phases characterized by orientational, but not positional, molecular order(1,2). Smectic phases, in which macromolecular rods are organized into layers roughly perpendicular to the direction of molecular orientation, are rare, owing at least in part to the polydisperse nature (distribution of chain lengths) of polymers prepared by conventional polymerization processes. Bacterial methods for polypeptide synthesis(3), in which artificial genes encoding the polymer are expressed in bacterial vectors, offer the opportunity to make macromolecules with very well defined chain lengths. Here we show that a monodisperse derivative of poly(gamma-benzyl alpha,L-glutamate) prepared in this way shows smectic ordering in solution and in films. This result suggests that methods for preparing monodisperse polymers might provide access to new smectic phases with layer spacings that are susceptible to precise control on the scale of tens of nanometres.	UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003; UNIV MASSACHUSETTS,DEPT BIOCHEM & MOL BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst			Yu, Michael S/A-3332-2010	Conticello, Vincent/0000-0001-6940-6947				ALBRECHT C, 1993, PROG COLL POL SCI S, V92, P111; BLOCK H, 1993, POLY GAMMA BENZYL L, P135; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; Chen JT, 1996, SCIENCE, V273, P343, DOI 10.1126/science.273.5273.343; Demus D., 1978, TEXTURES LIQUID CRYS; DUKE RW, 1976, J AM CHEM SOC, V98, P3094, DOI 10.1021/ja00427a006; DUPRE DB, 1979, LIQUID CRYSTALS 4TH, P203; FLORY PJ, 1956, PROC R SOC LON SER-A, V234, P73, DOI 10.1098/rspa.1956.0016; KRICHELDORF HR, 1987, ALPHA AMINOACID N CA, P170; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIVOLANT F, 1986, J PHYS-PARIS, V47, P1813, DOI 10.1051/jphys:0198600470100181300; PAPKOV SP, 1984, ADV POLYM SCI, V59, P75; PRESTON J, 1978, LIQUID CRYSTALLINE O, P141; RADZILOWSKI LH, 1994, MACROMOLECULES, V27, P7747, DOI 10.1021/ma00104a033; ROBINSON C, 1957, NATURE, V180, P1183, DOI 10.1038/1801183a0; SAMULSKI ET, 1967, NATURE, V216, P997, DOI 10.1038/216997a0; STROOBANTS A, 1987, PHYS REV A, V36, P2929, DOI 10.1103/PhysRevA.36.2929; STUPP SI, 1993, SCIENCE, V259, P59, DOI 10.1126/science.259.5091.59; WATANABE J, 1993, ORDERING MACROMOLECU, P99; WEE EL, 1990, NATURE, V346, P44; WEN X, 1989, PHYS REV LETT, V63, P2760, DOI 10.1103/PhysRevLett.63.2760; WULFMAN DS, 1988, SYNTHETIC COMMUN, V18, P2349, DOI 10.1080/00397918808082380; ZHANG GH, 1992, MACROMOLECULES, V25, P3601, DOI 10.1021/ma00039a048	23	187	195	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					167	170		10.1038/38254	http://dx.doi.org/10.1038/38254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296493				2022-12-28	WOS:A1997XV75700044
J	Zipkin, ID; Kindt, RM; Kenyon, CJ				Zipkin, ID; Kindt, RM; Kenyon, CJ			Role of a new Rho family member in cell migration and axon guidance in C-elegans	CELL			English	Article							GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; CAENORHABDITIS-ELEGANS; SMALL GTPASES; GENE; CDC42; RAC; SEQUENCE; PATHWAY; HOMOLOG	Rho family GTPases are thought to regulate actin-dependent processes, but their functions in vivo are still poorly understood. We have investigated the function of a new, widely expressed Rho family member in C. elegans by analyzing mutations in the endogenous gene. Activated and null alleles all inhibit cell migration, demonstrating that this protein is required for cell migration in vivo. Only a small subset of the migrations inhibited by activating mutations are inhibited by null mutations, suggesting that considerable functional redundancy exists within this system. Our findings support this conclusion and show that mig-2 functions redundantly with another pathway to regulate nuclear migration. Surprisingly, activated alleles also cause misguided axon growth, suggesting that Rho family GTPases may couple guidance cues to process outgrowth.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017924, R01GM037053] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01GM37053, 5F32GM17924-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; Chen WN, 1996, GENE, V180, P217, DOI 10.1016/S0378-1119(96)00414-3; CHEN WN, 1994, J BIOL CHEM, V269, P32394; CLARK DV, 1995, MOL GEN GENET, V247, P367, DOI 10.1007/BF00293205; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Forrester WC, 1997, DEVELOPMENT, V124, P1831; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Run JQ, 1996, GENETICS, V143, P225; RUVKUN G, 1989, GENETICS, V121, P501; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WILLIAMS BD, 1992, GENETICS, V131, P609	38	212	217	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					883	894		10.1016/S0092-8674(00)80353-0	http://dx.doi.org/10.1016/S0092-8674(00)80353-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298900	Bronze			2022-12-28	WOS:A1997XV56300009
J	Blatchford, O; Davidson, LA; Murray, WR; Blatchford, M; Pell, J				Blatchford, O; Davidson, LA; Murray, WR; Blatchford, M; Pell, J			Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI INFECTION; PEPTIC-ULCER; HEMORRHAGE; MORTALITY	Objectives: To determine the incidence and case fatality of acute upper gastrointestinal haemorrhage in the west of Scotland and to identify associated factors. Design: Case ascertainment study. Setting: All hospitals treating adults with acute upper gastrointestinal haemorrhage in the west of Scotland. Subjects: 1882 patients aged 15 years and over treated in hospitals for acute upper gastrointestinal haemorrhage during a six month period. Main outcome measures:Incidence of acute upper gastrointestinal haemorrhage per 100 000 population per year, and case fatality. Results: The annual incidence was 172 per 100 000 people aged 15 and over. The annual population mortality was 14.0 per 100 000. Both were higher among elderly people, men, and patients resident in areas of greater social deprivation. Overall case fatality nias 8.2%. This was higher-among those who bled as inpatients after admission for other reasons (42%) and those admitted as tertiary referrals (16%). Factors associated with increased case fatality were age, uraemia, pre-existing malignancy, hepatic failure, hypotension, cardiac failure, and frank haematemesis or a history of syncope at presentation. Social deprivation, sex, and anaemia sere not associated with increased case fatality after adjustment for other factors. Conclusions: The incidence of acute upper gastrointestinal haemorrhage was 67% greater than the highest previously reported incidence in the United Kingdom, which may be partially attributable to the greater social deprivation in the west of Scotland and may be related to the increased prevalence of Helicobacter pylori. Fatality after acute upper gastrointestinal haemorrhage was associated with age, comorbidity, hypotension, and raised blood urea concentrations on admission, Although deprivation tvas associated with Increased incidence, it was not related to the risk of fatality.	ROYAL COLL PHYS & SURG GLASGOW, GLASGOW G2 5RJ, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM NHS, GLASGOW G31 2ER, LANARK, SCOTLAND; EASTERHOUSE HLTH CTR, GLASGOW G34 9HQ, LANARK, SCOTLAND; GREATER GLASGOW HLTH BOARD, DEPT PUBL HLTH, GLASGOW G1 1ET, LANARK, SCOTLAND									ALLAN R, 1976, Q J MED, V45, P533; BROWN RC, 1976, BRIT MED J, V1, P35, DOI 10.1136/bmj.1.6000.35; CLASON AE, 1986, BRIT J SURG, V73, P985, DOI 10.1002/bjs.1800731213; FALAIYE JM, 1978, NIGERIAN MED J, V8, P526; HUNT PS, 1979, BRIT MED J, V1, P1238, DOI 10.1136/bmj.1.6173.1238; JOHNSTON SJ, 1973, BRIT MED J, V3, P655, DOI 10.1136/bmj.3.5882.655; JONES PF, 1973, BRIT MED J, V3, P660, DOI 10.1136/bmj.3.5882.660; KOHLI H S, 1992, Health Bulletin (Edinburgh), V50, P14; LENNARDJONES JE, 1992, J ROY COLL PHYS LOND, V26, P281; MACLEOD IA, 1982, BRIT J SURG, V69, P256, DOI 10.1002/bjs.1800690509; McLoone P., 1994, CARSTAIRS SCORES SCO; MORGAN AG, 1988, SCAND J GASTROENTERO, V23, P51; MORRIS R, 1991, DEPRIVATION HLTH SCO; OHMANN C, 1992, SCAND J GASTROENTERO, V27, P571, DOI 10.3109/00365529209000121; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; *SCOTT HLTH SERV C, 1978, WHAT HAS BEEN HAPP P; *SPSS, 1993, SPSS WIND; VANZANTEN SJOV, 1995, ALIMENT PHARM THERAP, V9, P41; VELLACOTT KD, 1982, BRIT MED J, V284, P548, DOI 10.1136/bmj.284.6315.548; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568	22	231	236	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	1997	315	7107					510	514		10.1136/bmj.315.7107.510	http://dx.doi.org/10.1136/bmj.315.7107.510			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329304	Green Published			2022-12-28	WOS:A1997XU50600016
J	Jack, RS; Fan, XL; Bernheiden, M; Rune, G; Ehlers, M; Weber, A; Kirsch, G; Mentel, R; Furll, B; Freudenberg, M; Schmitz, G; Stelter, F; Schutt, C				Jack, RS; Fan, XL; Bernheiden, M; Rune, G; Ehlers, M; Weber, A; Kirsch, G; Mentel, R; Furll, B; Freudenberg, M; Schmitz, G; Stelter, F; Schutt, C			Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection	NATURE			English	Article							FREE-FLOW ISOTACHOPHORESIS; CD14; ENDOTOXIN; MICE; LPS; LIPOPROTEINS; MONOCYTES; RECEPTOR; SHOCK	An invading pathogen must be held in check by the innate immune system until a specific immune response can be mounted. In the case of Gram-negative bacteria, the principal stimulator of the innate immune system is Lipopolysaccharide (LPS), a component of the bacterial outer membrane(1). In vitro, LPS is bound by lipopolysaccharide-binding protein (LBP)(2) and transferred to CD14-the LPS receptor on the macrophage surface(3,4)-or to high-density lipoprotein (HDL) particles(5,6). Transfer to CD14 triggers an inflammatory response which is crucial for keeping an infection under control. Here we investigate how LBP functions in vivo by using LBP-deficient mice. Surprisingly, we find that LBP is not required in vivo for the clearance of LPS from the circulation, but is essential for the rapid induction of an inflammatory response by small amounts of LPS or Gram-negative bacteria and for survival of an intraperitoneal Salmonella infection.	UNIV GREIFSWALD,INST ANAT,D-17489 GREIFSWALD,GERMANY; UNIV GREIFSWALD,NUKL MED KLIN & POLIKLIN,D-17489 GREIFSWALD,GERMANY; UNIV GREIFSWALD,INST MED MIKROBIOL,D-17489 GREIFSWALD,GERMANY; MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY; UNIV KLINIKUM REGENSBURG,KLIN CHEM & LAB MED,D-93042 REGENSBURG,GERMANY	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; University of Regensburg	Jack, RS (corresponding author), UNIV GREIFSWALD,INST IMMUNOL & TRANSFUS MED,SAUERBRUCHSTR,D-17489 GREIFSWALD,GERMANY.			Freudenberg, Marina Alexandra/0000-0001-5894-1805				FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GALLAY P, 1994, P NATL ACAD SCI USA, V91, P7922, DOI 10.1073/pnas.91.17.7922; Grunwald U, 1996, J IMMUNOL, V157, P4119; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; JACK RS, 1995, EUR J IMMUNOL, V25, P1436, DOI 10.1002/eji.1830250545; NOWICKA G, 1990, J LIPID RES, V31, P1947; NOWICKA G, 1990, J LIPID RES, V31, P1173; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHMITZ G, 1997, HDB LIPOPROTEIN TEST, P477; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schutt C, 1995, RES IMMUNOL, V146, P339, DOI 10.1016/0923-2494(96)81038-8; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1978, IMMUNOCHEMISTRY, V15, P157, DOI 10.1016/0161-5890(78)90144-X; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J IMMUNOL, V158, P3925; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025	18	283	297	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					742	745		10.1038/39622	http://dx.doi.org/10.1038/39622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338787				2022-12-28	WOS:A1997YA95900058
J	Dolan, RJ; Fink, GR; Rolls, E; Booth, M; Holmes, A; Frackowiak, RSJ; Friston, KJ				Dolan, RJ; Fink, GR; Rolls, E; Booth, M; Holmes, A; Frackowiak, RSJ; Friston, KJ			How the brain learns to see objects and faces in an impoverished context	NATURE			English	Article							INFERIOR TEMPORAL CORTEX; SELECTIVE ATTENTION; EXTRASTRIATE CORTEX; RECOGNITION MEMORY; NEURONS	A degraded image of an object or face, which appears meaningless when seen for the first time, is easily recognizable after viewing an undegraded version of the same image(1), The neural mechanisms by which this form of rapid perceptual learning facilitates perception are not well understood. Psychological theory suggests the involvement of systems for processing stimulus attributes, spatial attention and feature binding(2), as well as those involved in visual imagery(3). Here we investigate where and how this rapid perceptual learning is expressed in the human brain by using functional neuroimaging to measure brain activity during exposure to degraded images before and after exposure to the corresponding undegraded versions (Fig. 1), Perceptual learning of faces or objects enhanced the activity of inferior temporal regions known to be involved in face and object recognition respectively(4-6). In addition, both face and object learning led to increased activity in medial and lateral parietal regions that have been implicated in attention(7) and visual imagery(8). We observed a strong coupling between the temporal face area and the medial parietal cortex when, and only when, faces were perceived, This suggests that perceptual learning involves direct interactions between areas involved in face recognition and those involved in spatial attention, feature binding and memory recall.	ROYAL FREE HOSP,SCH MED,ACAD DEPT PSYCHIAT,LONDON NW3,ENGLAND; UNIV OXFORD,DEPT EXPT PSYCHOL,OXFORD OX1 3UD,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Oxford	Dolan, RJ (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,QUEEN SQ,LONDON W1N 3BG,ENGLAND.		Frackowiak, Richard/H-4383-2011; Fink, Gereon R./AFW-9377-2022; Friston, Karl/D-9230-2011; Frackowiak, Richard S/I-1809-2013; Fink, Gereon R./E-1616-2012	Frackowiak, Richard/0000-0002-3151-822X; Fink, Gereon R./0000-0002-8230-1856; Friston, Karl/0000-0001-7984-8909; Fink, Gereon R./0000-0002-8230-1856; Dolan, Ray/0000-0001-9356-761X; Rolls, Edmund/0000-0003-3025-1292	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Clark VP, 1996, NEUROIMAGE, V4, P1, DOI 10.1006/nimg.1996.0025; DESIMONE R, 1979, BRAIN RES, V178, P363, DOI 10.1016/0006-8993(79)90699-1; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; FLETCHER P, 1995, NEUROIMAGE, V2, P196; FRIEDMANHILL SR, 1995, SCIENCE, V269, P853, DOI 10.1126/science.7638604; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1997, HUM BRAIN MAPP, V5, P133, DOI 10.1002/(SICI)1097-0193(1997)5:2<133::AID-HBM7>3.0.CO;2-4; GROSS CG, 1979, NEUROPSYCHOLOGIA, V17, P215, DOI 10.1016/0028-3932(79)90012-5; GROSS CG, 1972, HDB SENSORY PHYSL, V7, P451; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; ISHAI A, 1995, SCIENCE, V268, P1772, DOI 10.1126/science.7792605; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kosslyn S. M., 1996, IMAGE BRAIN RESOLUTI; LI L, 1993, J NEUROPHYSIOL, V69, P1918, DOI 10.1152/jn.1993.69.6.1918; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAMACHANDRAN VS, 1994, ARTFUL EYE, P249; Roelfsema PR, 1997, NATURE, V385, P157, DOI 10.1038/385157a0; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SAKIA K, 1994, NEUROREPORT, V5, P829; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Talairach J., 1988, COPLANAR STEREOTAXIC; TANAKA K, 1986, J NEUROSCI, V6, P134; Tovee MJ, 1996, NEUROREPORT, V7, P2757, DOI 10.1097/00001756-199611040-00070; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549	30	295	296	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					596	599		10.1038/39309	http://dx.doi.org/10.1038/39309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335498	Green Submitted			2022-12-28	WOS:A1997YA00800058
J	Ducatman, BS				Ducatman, BS			Be careful what you wish for	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1130	1130						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326456				2022-12-28	WOS:A1997XY42200001
J	McLeod, PJ; Tamblyn, RM; Gayton, D; Grad, R; Snell, L; Berkson, L; Abrahamowicz, M				McLeod, PJ; Tamblyn, RM; Gayton, D; Grad, R; Snell, L; Berkson, L; Abrahamowicz, M			Use of standardized patients to assess between-physician variations in resource utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERAL-PRACTITIONERS; SIMULATED PATIENTS; INTERNAL-MEDICINE; FAMILY MEDICINE; CARE; OUTCOMES; PERFORMANCES; SPECIALTIES; BEHAVIOR; SYSTEMS	Context.-As medical costs are increasingly being scrutinized, there is heightened interest in defining variations in physician behavior in clinical settings. Objective.-To evaluate if standardized patient (SP) technology is a reliable and feasible method of studying interphysician variations in test ordering, referral requests, prescribing behavior, and visit costs, Design.-The study was conducted with blinded SP visits to family medicine and internal medicine residents, university-affiliated family physicians, and community-based family physicians, Resource utilization and visit costs were assessed using test requisitions, consult requests, and prescriptions that were collected by the SPs. Setting.-Physicians' offices in ambulatory care, hospital-based clinics and in the community, Participants.-Four persons (aged 57-77 years) trained to simulate having osteoarthritis of the hip. In one simulation, the patient had gastropathy due to nonsteroidal anti-inflammatory drug use, and in the other, the patient sought therapy for hip discomfort, Main Outcome Measures.-Reliability of cost estimates of physician services, tests, consultations, prescriptions, and total visits and test-ordering behavior for nonsteroidal anti-inflammatory gastropathy, Results.-Overall, 112 (63%) of the physicians who were sent invitations to the study agreed to participate, Of 312 total SP visits conducted over a I-year period, unblinding due to SP detection occurred on 36 occasions (11.5%), Reliable cost estimates of physician services, tests, and consultations, and moderately reliable estimates of total visit costs, were obtained with 4 visits per practicing physician and with 2 visits per resident. There were extreme variations in total visit costs generated by the study physicians. A small number of physicians had a major impact on this variability. Conclusion.-Standardized patient technology provides a reliable, feasible method to assess variations in resource utilization between physicians.	MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT PHARMACOL,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT FAMILY MED,MONTREAL,PQ H3A 2T5,CANADA	McGill University; McGill University; McGill University; McGill University			Tamblyn, Robyn/L-6010-2016	Abrahamowicz, Michal/0000-0002-3172-3952				Barrows H. S., 1987, SIMULATED STANDARDIZ; BENNETT MD, 1983, MED CARE, V21, P830, DOI 10.1097/00005650-198308000-00007; BUCKS RS, 1990, SOC SCI MED, V30, P537, DOI 10.1016/0277-9536(90)90152-I; CARNEY PA, 1993, ANN INTERN MED, V119, P129, DOI 10.7326/0003-4819-119-2-199307150-00007; CHERKIN DC, 1987, MED CARE, V25, P445; CLARK JA, 1991, SOC SCI MED, V32, P853, DOI 10.1016/0277-9536(91)90241-4; Conry C M, 1991, J Am Board Fam Pract, V4, P399; EISENBERG JM, 1981, MED CARE, V19, P297, DOI 10.1097/00005650-198103000-00005; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR, P1; FERGUSON JA, 1990, J SOCIAL ADM PHARM, V7, P34; GORDON JJ, 1992, J GEN INTERN MED, V7, P57, DOI 10.1007/BF02599104; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HEMENWAY D, 1985, MED CARE, V23, P344, DOI 10.1097/00005650-198504000-00006; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KOPELOW ML, 1992, ACAD MED, V67, pS19, DOI 10.1097/00001888-199210000-00026; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LINN LS, 1984, INQUIRY-J HEALTH CAR, V21, P266; MACDOWELL NM, 1992, J FAM PRACTICE, V34, P306; MAHEUX B, 1988, CAN MED ASSOC J, V139, P737; MAZZUCA SA, 1993, J RHEUMATOL, V20, P80; MELVILLE A, 1980, SOC SCI MED-MED SOC, V14, P495, DOI 10.1016/0160-7979(80)90050-8; MURRAY JP, 1992, MED CARE, V30, P252, DOI 10.1097/00005650-199203000-00007; NIGHTINGALE SD, 1988, MED CARE, V26, P84, DOI 10.1097/00005650-198801000-00009; NOREN J, 1980, NEW ENGL J MED, V302, P11, DOI 10.1056/NEJM198001033020103; NORMAN GR, 1985, J MED EDUC, V60, P925; PINEAULT R, 1976, MED CARE, V14, P121, DOI 10.1097/00005650-197602000-00002; PINEAULT R, 1977, MED CARE, V15, P52; RENAUD M, 1980, AM J PUBLIC HEALTH, V70, P1068, DOI 10.2105/AJPH.70.10.1068; RETHANS JJ, 1991, BRIT MED J, V303, P1377, DOI 10.1136/bmj.303.6814.1377; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P94; RHEE SO, 1977, J HEALTH SOC BEHAV, V18, P10, DOI 10.2307/2955391; ROBBINS JA, 1983, WESTERN J MED, V138, P118; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; STREINER DL, 1989, HLTH MEASUREMENT SCA, P79; TAMBLYN R, 1992, ACAD MED, V10, P522; TAMBLYN RM, 1991, MED EDUC, V25, P100, DOI 10.1111/j.1365-2923.1991.tb00035.x; VERHAAK PFM, 1986, SOC SCI MED, V23, P595, DOI 10.1016/0277-9536(86)90153-X; Vu NV., 1994, ED RES, V23, P23; WILLIAMS SV, 1986, J GEN INTERN MED, V1, P8, DOI 10.1007/BF02596318; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009; YOUNG MJ, 1987, HEALTH SERV RES, V22, P623	42	56	56	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1164	1168		10.1001/jama.278.14.1164	http://dx.doi.org/10.1001/jama.278.14.1164			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY422	9326476				2022-12-28	WOS:A1997XY42200034
J	Williams, PA; Fulop, V; Garman, EF; Saunders, NFW; Ferguson, SJ; Hajdu, J				Williams, PA; Fulop, V; Garman, EF; Saunders, NFW; Ferguson, SJ; Hajdu, J			Haem-ligand switching during catalysis in crystals of a nitrogen-cycle enzyme	NATURE			English	Article							NITRIC-OXIDE; THIOSPHAERA-PANTOTROPHA; ELECTRON-TRANSFER; CYTOCHROME CD(1); HEME-PROTEINS; REDUCTASE; PSEUDOAZURIN; BINDING; PROGRAM	Cytochrome cd(1) nitrite reductase catalyses the conversion of nitrite to nitric oxide in the nitrogen cycle(1,2). The crystal structure of the oxidized enzyme(3,4) shows that the d(1) haem iron of the active site is ligated by His/Tyr side chains, and the c haem iron is ligated by a His/His ligand pair. Here we show that both haems undergo re-ligation during catalysis, Upon reduction, the tyrosine ligand of the d(1) haem is released to allow substrate binding, Concomitantly, a refolding of the cytochrome c domain takes place, resulting in an unexpected change of the c haem iron coordination from His17/His69 to Met106/His69. This step is similar to the last steps in the folding of cytochrome c(5-8). The changes must affect the redox potential of the haems, and suggest a mechanism by which internal electron transfer is regulated, Structures of reaction intermediates show how nitric oxide is formed and expelled from the active-site iron, as well as how both haems return to their starting coordination. These results show how redox energy can be switched into conformational energy within a haem protein.	UNIV OXFORD,MOL BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QT,ENGLAND; UNIV UPPSALA,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN	University of Oxford; University of Oxford; University of Oxford; Uppsala University			Saunders, Neil/B-5325-2010; Fulop, Vilmos/AAZ-7720-2021	Saunders, Neil/0000-0003-2139-6107; Williams, Pamela/0000-0002-1257-2351; Garman, Elspeth/0000-0001-8329-5665	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BERGER H, 1980, BIOCHIM BIOPHYS ACTA, V622, P355, DOI 10.1016/0005-2795(80)90047-1; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; EDWARDS SL, 1988, BIOCHEMISTRY-US, V27, P8074, DOI 10.1021/bi00421a016; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; Harutyunyan EH, 1996, J MOL BIOL, V264, P152, DOI 10.1006/jmbi.1996.0630; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Pascher T, 1996, SCIENCE, V271, P1558, DOI 10.1126/science.271.5255.1558; PETTIGREW GW, 1987, CYTOCHROMES C BIOL A; PETTIGREW GW, 1987, CYTOCHROMES C EVOLUT; Poulos TL, 1996, NAT STRUCT BIOL, V3, P401, DOI 10.1038/nsb0596-401; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SILVESTRINI MC, 1982, BIOCHEM J, V203, P445, DOI 10.1042/bj2030445; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; WILLIAMS PA, 1996, THESIS OXFORD U; Wittung P, 1996, FEBS LETT, V388, P47, DOI 10.1016/0014-5793(96)00513-3; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51	31	258	262	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					406	412		10.1038/38775	http://dx.doi.org/10.1038/38775			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311786				2022-12-28	WOS:A1997XX67500059
J	Linde, K; Clausius, N; Ramirez, G; Melchart, D; Eitel, N; Hedges, LV; Jonas, WB				Linde, K; Clausius, N; Ramirez, G; Melchart, D; Eitel, N; Hedges, LV; Jonas, WB			Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials	LANCET			English	Review							HOMEOPATHIC PREPARATION; RHEUMATOID-ARTHRITIS; PUBLICATION BIAS; COMPLEMENTARY MEDICINE; GENERAL-PRACTITIONERS; ALTERNATIVE MEDICINE; SYSTEMATIC REVIEWS; GALPHIMIA GLAUCA; ARNICA-MONTANA; POLLINOSIS	Background Homoeopathy seems scientifically implausible, but has widespread use. We aimed to assess whether the clinical effect reported in randomised controlled trials of homoeopathic remedies is equivalent to that reported for placebo. Methods We sought studies from computerised bibliographies and contacts with researchers, institutions, manufacturers, individual collectors, homoeopathic conference proceedings, and books. We included all languages. Double-blind and/or randomised placebo-controlled trials of clinical conditions were considered. Our review of 186 trials identified 119 that met the inclusion criteria. 89 had adequate data for meta-analysis, and two sets of trial were used to assess reproducibility. Two reviewers assessed study quality with two scales and extracted data for information on clinical condition, homoeopathy type, dilution, ''remedy'', population, and outcomes. Findings The combined odds ratio for the 89 studies entered into the main meta-analysis was 2.45 (95% CI 2.05, 2.93) in favour of homoeopathy. The odds ratio for the 26 good-quality studies was 1.66 (1.33, 2.08), and that corrected for publication bias was 1.78 (1.03, 3.10). Four studies on the effects of a single remedy on seasonal allergies had a pooled odds ratio for ocular symptoms at 4 weeks of 2.03 (1.51, 2.74). Five studies on postoperative ileus had a pooled mean effect-size-difference of -0.22 standard deviations (95% CI -0.36, -0.09) for flatus, and -0.18 SDs (-0.33, -0.03) for stool (both p<0.05). Interpretation The results of our meta-analysis are not compatible with the hypothesis that the clinical effects of homoeopathy are completely due to placebo. However, we found insufficient evidence from these studies that homoeopathy is clearly efficacious for any single clinical condition. Further research on homoeopathy is warranted provided it is rigorous and systematic.	NIH,OFF ALTERNAT MED,BETHESDA,MD 20892; TECH UNIV MUNICH,MUNCHENER MODELL,CTR COMPLEMENTARY MED RES,D-8000 MUNICH,GERMANY; UNIV N TEXAS,HLTH SCI CTR,DEPT PUBL HLTH & PREVENT MED,FT WORTH,TX; UNIV MUNICH,CHIRURG KLIN & POLIKLIN INNENSTADT,MUNICH,GERMANY; UNIV CHICAGO,DEPT EDUC,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; Technical University of Munich; University of North Texas System; University of North Texas Health Science Center; University of Munich; University of Chicago				Linde, Klaus/0000-0002-2902-970X; Hedges, Larry/0000-0002-7531-0631				ALIBEU JP, 1990, PEDIATRIE, V45, P465; ALLBERTINI H, 1984, HOMEOPATHIE, V1, P47; ANDRADE LEC, 1991, SCAND J RHEUMATOL, V20, P204, DOI 10.3109/03009749109103022; [Anonymous], BIOLOGISCHE MEDIZIN; Aulagnier G, 1985, HOMEOPATHIE, V6, P42; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BEKKERING GM, 1993, HUISARTS WETENSCHAP, V36, P414; BENZECRI JP, 1991, CAHIERS ANAL DONNEES, V16, P389; BIGNAMINI M, 1991, BERL J RES HOM, V1, P286; BOHMER D, 1992, BIOL MED, V21, P260; Boissel JP, 1996, CRITICAL LIT REV EFF, V1996, P195; Bordes L., 1986, CAH OTORHINOLARINGOL, V21, P731; BOURGOIS JC, 1984, THESIS U PARIS NORD; Brigo B, 1991, BERL J RES HOM, V1, P98; Campbell A., 1976, BR HOMOEOPATH J, V65, P154; CAREY H, 1986, BR HOMOEOPATH RES GR, V15, P12; Carlini EA, 1987, REV ASSOC MED BRAS, V33, P83; CASANOVA P, 1981, UNPUB ESSAI CLIN PRO; Casanova P, 1992, BILAN 3 ANN ETUDES R, V1, P11; CHAPMAN EH, 1994, J AM I HOM, V87, P14; CHEVREL JP, 1984, PRESSE MED, V13, P883; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Consoli AM., 1987, BRIT HOM J, V76, P114; COUDERT M, 1981, THESIS U LIMOGES; DAVIES AE, 1971, BRIT HOMOEOPATHIC J, V60, P36; DAVIES AE, 1988, BR HOM RES GROUP COM, V18, P42; DEKLERK ESMD, 1994, BRIT MED J, V309, P1329; DELAUNAY M, 1985, MED DOUCE, V44, P34; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEXPERT M, 1987, HOMEOPATHIE FRANCAIS, V75, P353; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; Dorfman P, 1992, CAHIERS BIOTHERAP, V114, P33; DORFMAN P, 1987, CAHIERS BIOTHERAP, V94, P77; Dorfman P, 1988, CAHIERS BIOTHERAPI S, V98, P77; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ENDLER PC, 1994, VET HUM TOXICOL, V36, P56; ENDLER PC, 1994, ULTRA HIGH DILUTION; ERNST E, 1995, ARCH INTERN MED, V155, P2405, DOI 10.1001/archinte.155.22.2405; Ernst E., 1990, PHLEBOLOGY, V5, P157; ERNST E, 1996, COMPLEMENTARY MED OB; ESTRANGIN M, 1983, THESIS U GRENOBLE; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; Ferley JP, 1987, IMMUNOLOGIE MED, V20, P22; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; Fisher P, 1986, BR HOM J, V75, P142; Fleiss JL, 1981, STAT METHODS RATES P; Freitas LA, 1995, REV HOMEOPATIA, V60, P26; Gaucher C, 1994, BR HOM J, V83, P132; GAUTHIER JE, 1983, THESIS U BORDEAUX; GIBSON J, 1991, BR HOM RES GROUP COM, V21, P34; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; GOTZSCHE PC, 1993, LANCET, V341, P1533; *GRECHO ARC GREPA, 1987, PRESSE MED, V16, P192; HAHNEMANN S, 1982, ULTRA HIGH DILUTION; Haltenhof H, 1995, Gesundheitswesen, V57, P192; HARDY J, 1984, BR HOM RES GROUP COM, V11, P75; HARIVEAU E, 1987, HOMEOPATHIE, V5, P55; HARIVEAU E, 1992, HOMEOPATH FRANCAISE, V80, P17; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; Hedges LV, 1996, J EDUC BEHAV STAT, V21, P299, DOI 10.2307/1165338; Hedges LV, 1992, STAT SCI, V7, P246, DOI DOI 10.1214/SS/1177011364; HEDGES LV, 1994, HDB RES SYNTHESIS, P286; Heilmann A., 1992, BIOL MED, V21, P225; HILDEBRANDT G, 1983, 2 BEITR PHARM AD PRO; HILL M, 1993, SURFACES, V3, P4; HOFMEYR GJ, 1990, BRIT J CLIN PRACT, V44, P619; HOURST P, 1981, THESIS U P M CURIE; JACOBS J, 1994, PEDIATRICS, V93, P719; Jacobs J, 1993, BR HOM J, V82, P83; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JADAD AR, 1996, EDUC PSYCHOL MEAS, V17, P1; Jansen GRHJ, 1992, BR HOM J, V81, P132; KAZIRO GSN, 1984, BRIT J ORAL MAX SURG, V22, P42, DOI 10.1016/0266-4356(84)90007-X; KENNEDY CO, 1971, BRIT HOM J, V60, P120; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KNIPSCHILD P, 1990, SOC SCI MED, V31, P625, DOI 10.1016/0277-9536(90)90099-E; KOHLER T, 1991, KASSENARZT, V13, P48; KUBISTA E, 1986, Gynaekologische Rundschau, V26, P65; Kurz C, 1993, Gynakol Geburtshilfliche Rundsch, V33 Suppl 1, P330; LABRECQUE M, 1992, CAN MED ASSOC J, V146, P1749; LEAMAN AM, 1989, ARCH EMERG MED, V6, P259; LECOCQ P, 1985, CAHIERS BIOTHERAPIE, V87, P65; LEPAISANT C, 1994, THESIS U CAEN; Lewis D, 1984, MIDLANDS HOMOEOPATHY, V11, P49; LIGHT RJ, 1984, SUMMING UP SCI REV R; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; LINDE K, 1996, FORSCH KOMPLEMENTMED, V3, P148; LOKKEN P, 1995, BRIT MED J, V310, P1439, DOI 10.1136/bmj.310.6992.1439; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; Master F.J., 1987, P 42 C LMHI ARL VIRG, P330; MICHAUD J, 1981, THESIS U NANTES; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; MOKKAPATTI R, 1992, BR HOMEOPATH J, V81, P22; MOSSINGER P, 1982, ZLLG HOMOOPATH ZTG, V227, P89; MOSSINGER P, 1984, HOMOOPATHIE NATURWIS, P165; MOSSINGER P, 1976, ALLG HOMOOPATH ZTG, V221, P177; MOSSINGER P, 1976, ALLG HOMOOPATH ZTG, V221, P26; MOSSINGER P, 1985, KINDERARZT, V16, P581; MOSSINGER P, 1990, ALLG HOMOOPATH ZTG, V225, P22; NOLLEVAUX MA, 1994, UNPUB KLIN STUDIE MU; OKEEFFE D, 1986, LANCET, V2, P1106; Orwin RG, 1983, J ED STAT, V8, P157, DOI [DOI 10.2307/1164923, 10.3102/10769986008002157]; Paterson J, 1943, BR HOM J, V33, P1; Pinsent RJ, 1986, BRIT HOMEOPATHIC RES, V15, P3; PONTI M, 1986, RECHERCHES HOMEOPATH, P71; RAHLFS VW, 1979, DEUT MED WOCHENSCHR, V104, P140, DOI 10.1055/s-0028-1103859; RAHLFS WV, 1976, ARZNEIMITTEL-FORSCH, V26, P2230; REIL GH, 1985, Z KARDIOL, V74, P65; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; REILLY DT, 1986, LANCET, V2, P881; RITTER H, 1966, HIPPOKRATES, V12, P472; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SainteLaudy J, 1997, INFLAMM RES, V46, pS27, DOI 10.1007/s000110050035; SAMPSON A, 1995, ALT THER, V1, P48; SARUGGIA M, 1992, BR HOM J, V81, P86; Savage R.H., 1977, BRIT HOMOEOPATHIC J, V66, P207; Savage R.H., 1978, BR HOM J, V67, P210; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCHUPPEL R, 1994, FORTSCHR KOMPLEMENTA, V1, P177; SCHWAB G, 1990, LASST SICH WIRKUNG H; SHIPLEY M, 1983, LANCET, V1, P97; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SOMMER RG, 1987, THERAPEUTIKON, V1, P16; THIEL W, 1991, BIOL MED, V20, P506; TVEITEN D, 1991, Tidsskrift for den Norske Laegeforening, V111, P3630; USTIANOWSKI PA, 1974, BRIT HOMOEOPATHIC J, V63, P276; VALERO E, 1981, THESIS U MED GRENOBL; VEVEA JL, 1995, PSYCHOMETRIKA, V60, P419, DOI 10.1007/BF02294384; Walach H, 1997, CEPHALALGIA, V17, P119, DOI 10.1046/j.1468-2982.1997.1702119.x; Weiser M, 1994, FORSCH KOMPLEMENTMED, V1, P251, DOI 10.1159/000209924; WERK W, 1994, THERAPIEWOCHE, V44, P34; Whitmarsh TE, 1997, CEPHALALGIA, V17, P600, DOI 10.1046/j.1468-2982.1997.1705600.x; WHITMARSH TE, 1993, CEPHALAGIA, V13, P254; WIESENAUER M, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1745; WIESENAUER M, 1983, FORTSCHR MED, V101, P811; Wiesenauer M, 1995, PHYTOMEDICINE, V2, P3, DOI 10.1016/S0944-7113(11)80041-3; WIESENAUER M, 1989, ARZNEIMITTEL-FORSCH, V39-1, P620; WIESENAUER M, 1990, ALLERGOLOGIE, V13, P359; WIESENAUER M, 1991, AKTUEL RHEUMATOL, V16, P1, DOI 10.1055/s-2008-1047372; WIESENAUER M, 1996, KOMPLEMENTARMED, V3, P230; WIESENAUER M, 1992, 10 JAHR KARL VER CAR, P142; YAKIR M, 1994, P 8 GIRI M JER, P49; Zell J, 1988, Fortschr Med, V106, P96	145	602	616	6	207	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					834	843		10.1016/S0140-6736(97)02293-9	http://dx.doi.org/10.1016/S0140-6736(97)02293-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX401	9310601				2022-12-28	WOS:A1997XX40100009
J	Engel, J				Engel, J			Biochemistry - Versatile collagens in invertebrates	SCIENCE			English	Editorial Material							SEA HYDROTHERMAL VENTS; INTERSTITIAL COLLAGENS; MINI-COLLAGENS; CUTICLE				Engel, J (corresponding author), UNIV BASEL,BIOZENTRUM,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND.							BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; Coyne KJ, 1997, SCIENCE, V277, P1830, DOI 10.1126/science.277.5333.1830; GAILL F, 1991, J MOL BIOL, V221, P209, DOI 10.1016/0022-2836(91)80215-G; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; GARRONE R, 1993, CR SOC BIOL, V187, P114; HOLSTEIN TW, 1994, SCIENCE, V265, P402, DOI 10.1126/science.265.5170.402; KRAMER JM, 1994, FASEB J, V8, P329, DOI 10.1096/fasebj.8.3.8143939; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; TRAUB W, 1966, J MOL BIOL, V16, P404, DOI 10.1016/S0022-2836(66)80182-1; WANG WQ, 1995, GENE, V152, P195, DOI 10.1016/0378-1119(95)00644-L	11	61	64	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1785	1786		10.1126/science.277.5333.1785	http://dx.doi.org/10.1126/science.277.5333.1785			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324767				2022-12-28	WOS:A1997XX29800033
J	Sacchettini, JC; Poulter, CD				Sacchettini, JC; Poulter, CD			Biochemistry - Creating isoprenoid diversity	SCIENCE			English	Editorial Material									UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	Sacchettini, JC (corresponding author), TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843, USA.							Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820; SAITO A, 1981, ARCH BIOCHEM BIOPHYS, V208, P508, DOI 10.1016/0003-9861(81)90538-5; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811	5	409	436	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1788	1789		10.1126/science.277.5333.1788	http://dx.doi.org/10.1126/science.277.5333.1788			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324768				2022-12-28	WOS:A1997XX29800036
J	Legendre, C; CaillatZucman, S; Samuel, D; Morelon, S; Bismuth, H; Bach, JF; Kreis, H				Legendre, C; CaillatZucman, S; Samuel, D; Morelon, S; Bismuth, H; Bach, JF; Kreis, H			Transfer of symptomatic peanut allergy to the recipient of a combined liver-and-kidney transplant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; IGE; ATOPY; FOOD		HOP NECKER ENFANTS MALAD,INSERM,U25,F-75743 PARIS,FRANCE; HOP PAUL BROUSSE,CTR HEPATOBILIAIRE,VILLEJUIF,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP	Legendre, C (corresponding author), HOP NECKER ENFANTS MALAD,TRANSPLANTAT SERV,161 RUE SEVRES,F-75743 PARIS 15,FRANCE.			Caillat-Zucman, Sophie/0000-0002-4535-3550				AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; COLLINS RH, 1993, NEW ENGL J MED, V328, P762, DOI 10.1056/NEJM199303183281104; Ewan PW, 1996, BRIT MED J, V312, P1074; FRIEND PJ, 1990, NEW ENGL J MED, V323, P807, DOI 10.1056/NEJM199009203231207; HAMAOKA T, 1973, J EXP MED, V138, P538, DOI 10.1084/jem.138.3.538; LOZA C, 1995, CLIN EXP ALLERGY, V25, P493, DOI 10.1111/j.1365-2222.1995.tb01086.x; SAARINEN UM, 1984, J ALLERGY CLIN IMMUN, V74, P196, DOI 10.1016/0091-6749(84)90286-0; Sampson HA, 1996, BRIT MED J, V312, P1050; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; SUBERBIELLE C, 1994, LANCET, V343, P1468, DOI 10.1016/S0140-6736(94)92583-6; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; TUCKER J, 1985, BRIT MED J, V290, P116, DOI 10.1136/bmj.290.6462.116; WALKER SA, 1986, CLIN EXP IMMUNOL, V66, P633; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	15	130	132	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					822	824		10.1056/NEJM199709183371204	http://dx.doi.org/10.1056/NEJM199709183371204			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9297112				2022-12-28	WOS:A1997XW28300004
J	McIntyre, PB; Berkey, CS; King, SM; Schaad, UB; Kilpi, T; Kanra, GY; Perez, CMO				McIntyre, PB; Berkey, CS; King, SM; Schaad, UB; Kilpi, T; Kanra, GY; Perez, CMO			Dexamethasone as adjunctive therapy in bacterial meningitis - A meta-analysis of randomized clinical trials since 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RESISTANT STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL MENINGITIS; NEUROLOGIC SEQUELAE; CHILDREN; METAANALYSIS; MANAGEMENT; INFECTIONS; STEROIDS; RISK; CORTICOSTEROIDS	Objective.-To evaluate the effectiveness of dexamethasone in bacterial meningitis in the subcategories of causative organism and timing and nature of antibiotic therapy. Data Sources.-MEDLINE, HEALTHLINE, and AIDSLINE were searched with the Medical Subject Headings ''dexamethasone'' and ''meningitis'' in any language. Bibliographies, conference abstracts, and the authors of identified studies were consulted. Study Selection.-Randomized, concurrently controlled trials of dexamethasone therapy in childhood bacterial meningitis published from 1988 to November 1996 were selected. Of 16 studies identified, 5 were not eligible. Data Extraction.-Data were extracted by means of standard outcomes in a protocol sent to all principal authors. Data Synthesis.-Random-effects meta-analysis models were used to obtain summary estimates. As the incidence of severe hearing loss differed significantly by organism among control subjects, organism-specific estimates were used. In Haemophilus influenzae type b meningitis, dexamethasone reduced severe hearing loss overall (combined odds ratio [OR], 0.31; 95% confidence interval [CI], 0.14-0.69), Similar ORs were obtained after studies were stratified by the timing of administration of dexamethasone (before or with antibiotics vs rater) or by type of antibiotic (cefuroxime vs other). in pneumococcal meningitis, only studies in which dexamethasone was given early suggested protection, which was significant for severe hearing loss (combined OR, 0.09; 95% CI, 0.0-0.71) and approached significance for any neurological or hearing deficit (combined OR, 0.23; 95% CI, 0.04-1.05). For all organisms combined, the pooled OR suggested protection against neurological deficits other than hearing loss but was not significant (OR, 0.59; 95% CI, 0.34-1.02). Outcomes were similar in studies that used 2 vs more than 2 days of dexamethasone therapy, Adverse effects were not significantly increased with dexamethasone except for secondary fever. The incidence of gastrointestinal tract bleeding increased with longer duration of dexamethasone treatment (0.5% in controls, 0.8% with 2 days of treatment, 3.0% with 4 days of treatment). Conclusions.-The available evidence on adjunctive dexamethasone therapy confirms benefit for H influenzae type b meningitis and, if commenced with or before parenteral antibiotics, suggests benefit for pneumococcal meningitis in childhood, Limiting dexamethasone therapy to 2 days may be optimal.	ROYAL ALEXANDRA HOSP CHILDREN,SYDNEY,NSW,AUSTRALIA; CHANNING LABS,BOSTON,MA; HOSP SICK CHILDREN,TORONTO,ON M5G 1X8,CANADA; UNIV BASEL,BASEL,SWITZERLAND; UNIV HELSINKI,HELSINKI,FINLAND; HACETTEPE UNIV,ANKARA,TURKEY; HOSP NACL NINOS DR CARLOS SAENZ HERRERA,SAN JOSE,COSTA RICA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Basel; University of Helsinki; Hacettepe University			McIntyre, Peter/GNM-5277-2022	McIntyre, Peter/0000-0001-5808-7450				ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; *AM AC PED, 1994, 1994 RED BOOK REP CO, P558; *AM AC PED COMM IN, 1990, PEDIATRICS, V86, P130; BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008; BERGMAN I, 1987, J PEDIATR-US, V110, P705, DOI 10.1016/S0022-3476(87)80006-9; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; BHATT SM, 1995, PEDIATR INFECT DIS J, V14, P93, DOI 10.1097/00006454-199502000-00002; BRADLEY JS, 1994, PEDIATR INFECT DIS J, V13, P823, DOI 10.1097/00006454-199409000-00015; BRADY MT, 1981, J PEDIATR-US, V99, P924, DOI 10.1016/S0022-3476(81)80023-6; CIANA G, 1995, J TROP PEDIATRICS, V41, P164, DOI 10.1093/tropej/41.3.164; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; FORTNUM HM, 1992, ARCH DIS CHILD, V67, P1128, DOI 10.1136/adc.67.9.1128; FRIEDLAND IR, 1993, ANTIMICROB AGENTS CH, V37, P1630, DOI 10.1128/AAC.37.8.1630; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GABOR K, 1993, ORVOSI HETILAP, V134, P247; GEIMAN BJ, 1992, WESTERN J MED, V157, P27; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; GLAZIOU PP, 1995, BRIT MED J, V311, P1356; HARBIN GL, 1979, SOUTH MED J, V72, P977, DOI 10.1097/00007611-197908000-00024; HAVENS PL, 1992, WESTERN J MED, V157, P84; HAVENS PL, 1989, AM J DIS CHILD, V143, P1051, DOI 10.1001/archpedi.1989.02150210085023; *INF DIS IMM COMM, 1990, CAN MED ASSOC J, V142, P307; IOANNIDIS JPA, 1994, LANCET, V343, P792, DOI 10.1016/S0140-6736(94)91867-8; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; KANRA GY, 1995, PEDIATR INFECT DIS J, V14, P490, DOI 10.1097/00006454-199506000-00005; KAPLAN SL, 1989, AM J DIS CHILD, V143, P290, DOI 10.1001/archpedi.1989.02150150044014; KAPLAN SL, 1988, PEDIATR INFECT DIS J, V7, P140; KENNEDY WA, 1991, AM J DIS CHILD, V145, P1374, DOI 10.1001/archpedi.1991.02160120042016; KILPI T, 1995, PEDIATR INFECT DIS J, V14, P270, DOI 10.1097/00006454-199504000-00005; KING SM, 1994, CAN J INFECT DIS, V5, P1; KLUGMAN KP, 1995, ANTIMICROB AGENTS CH, V39, P1988, DOI 10.1128/AAC.39.9.1988; LACROIX J, 1992, CRIT CARE MED, V20, P35, DOI 10.1097/00003246-199201000-00013; LAU J, 1997, META ANAL VERSION 09; LEBEL MH, 1989, AM J DIS CHILD, V143, P301, DOI 10.1001/archpedi.1989.02150150055017; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LEPPER MH, 1958, ARCH INTERN MED, V104, P252; Macaluso A, 1996, ANN TROP PAEDIATR, V16, P193, DOI 10.1080/02724936.1996.11747825; MARGUET C, 1993, ARCH FR PEDIATR, V50, P111; MCCRACKEN GH, 1989, NEW ENGL J MED, V320, P465; MCGOWAN JE, 1992, J INFECT DIS, V165, P1, DOI 10.1093/infdis/165.1.1; MCINTYRE P, 1993, MED J AUSTRALIA, V159, P766, DOI 10.5694/j.1326-5377.1993.tb141344.x; *MEN WORK PART BRI, 1992, ARCH DIS CHILD, V67, P324; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; NIELSEN PE, 1995, ACTA PAEDIATR, V84, P342, DOI 10.1111/j.1651-2227.1995.tb13642.x; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; ODIO CM, 1994, AM SOC MICR 34 INT C; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402; PRASAD K, 1995, J NEUROL NEUROSUR PS, V59, P31, DOI 10.1136/jnnp.59.1.31; PROBER CG, 1995, PEDIATRICS, V95, P29; Qazi SA, 1996, ARCH DIS CHILD, V75, P482, DOI 10.1136/adc.75.6.482; SCHAAD UB, 1993, LANCET, V342, P457, DOI 10.1016/0140-6736(93)91592-A; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; SCHAAD UB, 1995, CLIN INFECT DIS, V20, P685, DOI 10.1093/clinids/20.3.685; SMITH AL, 1988, NEW ENGL J MED, V319, P1012, DOI 10.1056/NEJM198810133191510; SYROGIANNOPOULOS GA, 1994, J INFECT DIS, V169, P853, DOI 10.1093/infdis/169.4.853; VIENNY H, 1984, PEDIATRICS, V73, P579; WAAGNER DC, 1990, PEDIATR INFECT DIS J, V9, P922; WALD ER, 1995, PEDIATRICS, V95, P21	61	264	271	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					925	931		10.1001/jama.278.11.925	http://dx.doi.org/10.1001/jama.278.11.925			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302246				2022-12-28	WOS:A1997XV64000032
J	Bjorge, T; Dillner, J; Anttila, T; Engeland, A; Hakulinen, T; Jellum, E; Lehtinen, M; Luostarinen, T; Paavonen, J; Pukkala, E; Sapp, M; Schiller, J; Youngman, L; Thoresen, S				Bjorge, T; Dillner, J; Anttila, T; Engeland, A; Hakulinen, T; Jellum, E; Lehtinen, M; Luostarinen, T; Paavonen, J; Pukkala, E; Sapp, M; Schiller, J; Youngman, L; Thoresen, S			Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers	BRITISH MEDICAL JOURNAL			English	Article							ANAL EPIDERMOID CARCINOMA; SQUAMOUS-CELL CARCINOMA; INTRAEPITHELIAL NEOPLASIA; SERUM ANTIBODIES; UTERINE CERVIX; HPV DNA; TYPE-16; VULVA; INFECTION; EXPERIENCE	Objective: To evaluate the association between infection with the major oncogenic types of human papillomavirus and the risk of developing non-cervical anogenital cancers in a cohort followed up prospectively. Design: Data from two large serum banks to which about 700 000 people had donated serum samples were followed up for a mean of 8 years. People who developed non-cervical anogenital cancers during follow up were identified by registry linkage with the nationwide cancer registries in Finland and Norway Within this cohort a nested case-control study was conducted based on the serological diagnosis of infection with human papillomavirus types 16, 18, and 33. Subjects: 81 cases and 240 controls matched for sex, age, and storage time of serum samples. Main outcome measures: Odds ratios of developing non-cervical anogenital cancers in presence of IgG antibodies to specific micro-organisms. Results: Subjects seropositive far human. papillomavirus type 16 had an increased risk of developing non-cervical anogenital cancers (odds ratio 3.1 (95% confidence interval 1.4 to 6.9)). Subjects seropositive for type 33 also had an increased risk (odds ratio 2.8 (1.0 to 8.3)) but not significantly after adjustment for infection with type 16. Seropositivity for human papillomavirus type 16 was associated with an increased risk of developing vulvar and vaginal. cancers (odds ratio 4.5 (1.1 to 22)) and a strongly increased risk of developing preinvasive vulvar and vaginal lesions (odds ratio infinity (3.8 to infinity)). Seropositivity for human papillomavirus type 18 increased the risk of developing preinvasive lesions (odds ratio 12 (1.2 to 590)). High, but non-significant odds ratios for types 16 and 33 were seen for penile cancers. Conclusions: This study provides prospective seroepidemiological evidence that infection with human papillomavirus type 16 confers an increased risk of developing non-cervical genital cancers, particularly vulvar and vaginal cancers.	KAROLINSKA INST,MICROBIOL & TUMORBIOL CTR,S-17177 STOCKHOLM,SWEDEN; NATL PUBL HLTH INST,FIN-90101 OULU,FINLAND; KAROLINSKA INST,DEPT CANC EPIDEMIOL,S-17177 STOCKHOLM,SWEDEN; NORWEGIAN CANC SOC,JANUS COMM,N-0369 OSLO,NORWAY; NATL PUBL HLTH INST,DEPT INFECT DIS EPIDEMIOL,FIN-00300 HELSINKI,FINLAND; FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,FIN-00170 HELSINKI,FINLAND; UNIV HELSINKI HOSP,DEPT OBSTET & GYNECOL,FIN-00290 HELSINKI,FINLAND; UNIV TAMPERE,TAMPERE SCH PUBL HLTH,FIN-33101 TAMPERE,FINLAND; UNIV MAINZ,DEPT MED MICROBIOL,D-55101 MAINZ,GERMANY; NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; UNIV OXFORD,CLIN TRIALS SERV UNIT,OXFORD OX2 6HE,ENGLAND	Karolinska Institutet; Finland National Institute for Health & Welfare; Karolinska Institutet; Finland National Institute for Health & Welfare; Finnish Cancer Registry; University of Helsinki; Helsinki University Central Hospital; Tampere University; Johannes Gutenberg University of Mainz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oxford	Bjorge, T (corresponding author), CANC REGISTRY NORWAY,INST EPIDEMIOL CANC RES,N-0310 OSLO,NORWAY.		Engeland, Anders/AAG-7437-2021; Schiller, John/ABK-8287-2022	lehtinen, matti/0000-0002-9481-0535; van Tinteren, Harm/0000-0002-4626-8702; Bjorge, Tone/0000-0002-9096-5257; Paavonen, Jorma/0000-0003-4775-606X; Luostarinen, Tapio/0000-0003-3231-8550				AnderssonEllstrom A, 1996, SEX TRANSM DIS, V23, P234, DOI 10.1097/00007435-199605000-00013; ANDERSSONELLSTROM A, 1994, LANCET, V344, P1435, DOI 10.1016/S0140-6736(94)90601-7; ANSINK AC, 1994, GYNECOL ONCOL, V52, P180, DOI 10.1006/gyno.1994.1028; AYNAUD O, 1994, CANCER, V74, P1762, DOI 10.1002/1097-0142(19940915)74:6<1762::AID-CNCR2820740619>3.0.CO;2-1; BJORGE T, 1995, INT J CANCER, V62, P29, DOI 10.1002/ijc.2910620108; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1990, OBSTET GYNECOL, V75, P859; BRINTON LA, 1990, GYNECOL ONCOL, V38, P49, DOI 10.1016/0090-8258(90)90010-I; Cannistra SA, 1996, NEW ENGL J MED, V334, P1030, DOI 10.1056/NEJM199604183341606; CHENG G, 1995, J INFECT DIS, V172, P1584, DOI 10.1093/infdis/172.6.1584; Chua KL, 1996, INT J CANCER, V68, P54, DOI 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO;2-6; *CYT SOFTW CORP, 1993, LOGX TURB VERS 1 1, V1; Daling J R, 1992, IARC Sci Publ, P223; DILLNER J, 1995, CANCER J - FRANCE, V8, P264; Dillner J, 1996, J INFECT DIS, V173, P1394, DOI 10.1093/infdis/173.6.1394; DILLNER J, 1995, INT J CANCER, V60, P377; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; GRAHAM S, 1979, CANCER, V44, P1870, DOI 10.1002/1097-0142(197911)44:5<1870::AID-CNCR2820440546>3.0.CO;2-E; HEINO P, 1995, J NATL CANCER I, V87, P437, DOI 10.1093/jnci/87.6.437; HORDING U, 1994, GYNECOL ONCOL, V52, P241, DOI 10.1006/gyno.1994.1039; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; JELLUM E, 1995, ENVIRON HEALTH PERSP, V103, P85, DOI 10.2307/3432566; KIRNBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494, DOI 10.1093/jnci/86.7.494; Lehtinen M, 1996, BMJ-BRIT MED J, V312, P537, DOI 10.1136/bmj.312.7030.537; LI JY, 1982, JNCI-J NATL CANCER I, V69, P1063; MEHTA CR, 1995, STAT MED, V14, P2143, DOI 10.1002/sim.4780141908; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MESSING MJ, 1995, OBSTET GYNECOL, V86, P51, DOI 10.1016/0029-7844(95)00101-V; MILDELANGOSCH K, 1995, INT J CANCER, V63, P639, DOI 10.1002/ijc.2910630507; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; Trimble CL, 1996, OBSTET GYNECOL, V87, P59, DOI 10.1016/0029-7844(95)00351-7; WANG SP, 1970, AM J OPHTHALMOL, V70, P367, DOI 10.1016/0002-9394(70)90096-6; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	35	53	56	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					646	649		10.1136/bmj.315.7109.646	http://dx.doi.org/10.1136/bmj.315.7109.646			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310566	Green Published			2022-12-28	WOS:A1997XW69400019
J	Tramer, MR; Reynolds, DJM; Moore, RA; McQuay, HJ				Tramer, MR; Reynolds, DJM; Moore, RA; McQuay, HJ			Impact of covert duplicate publication on meta-analysis: a case study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTOPERATIVE NAUSEA; INTRAVENOUS ONDANSETRON; REDUNDANT PUBLICATION; MULTIPLE PUBLICATION; CONTROLLED TRIALS; PREVENTION; SURGERY; DROPERIDOL; PLACEBO; QUALITY	Objective: To quantify the impact of duplicate data on estimates of efficacy. Design: Systematic search for published full reports of randomised controlled trials investigating ondansetron's effect on postoperative emesis. Abstracts were not considered. Data sources: Eighty four-trials (11 980 patients receiving ondansetron) published between 1991 and September 1996. Main outcome measures: Percentage of duplicated trials and patient data. Estimation of antiemetic efficacy (prevention of emesis) of the most duplicated ondansetron regimen. Comparison between the efficacy of non-duplicated and duplicated data. Results: Data from nine trials had been published in 14 further reports, duplicating data from 3335 patients receiving ondansetron; none used a clear cross reference. Intravenous ondansetron 4 mg versus placebo was investigated in 16 reports not subject to duplicate publication three reports subject to duplicate publication, and six duplicates of those three reports. The number needed to treat to prevent vomiting within 24 hours was 9.5 (95% confidence interval 6.9 to 15) in the 16 non-duplicated reports and 3.9 (3.3 to 4.8) in the three reports which were duplicated (P < 0.00001). When these 19 were combined the number needed to treat was 6.4 (5.3 to 7.9). When all original and duplicate reports were combined (n = 25) the apparent number needed to treat improved to 4.9 (4.4 to 5.6). Conclusions: By searching systematically we found 17% of published full reports of randomised trials and 28% of the patient data were duplicated. Trials reporting greater treatment effect were significant more likely to be duplicated. Inclusion of duplicated data in meta-analysis led to a 23% overestimation of ondansetron's antiemetic efficacy.	JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND	University of Oxford	Tramer, MR (corresponding author), CHURCHILL HOSP, NUFFIELD DEPT ANAESTHET, OXFORD OX3 7LJ, ENGLAND.							ANGELL M, 1989, NEW ENGL J MED, V320, P1212, DOI 10.1056/NEJM198905043201812; [Anonymous], 1979, BMJ-BRIT MED J, V1, P532; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; Calamandrei M, 1994, Cah Anesthesiol, V42, P19; CALAMANDREI M, 1994, MINERVA ANESTESIO S1, V60, P37; Campbell C, 1995, AM J ANESTHESIOL, V22, P81; CLAYBON L, 1994, ANAESTHESIA, V49, P24, DOI 10.1111/j.1365-2044.1994.tb03579.x; Collini S., 1995, Acta Anaesthesiologica Italica, V46, P49; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DAVIS A, 1995, ANAESTH INTENS CARE, V23, P438, DOI 10.1177/0310057X9502300404; DERSHWITZ M, 1992, CLIN PHARMACOL THER, V52, P96, DOI 10.1038/clpt.1992.107; DERSHWITZ M, 1997, AMBULATORY ANESTHESI, P441; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIDONATO A, 1994, MINERVA ANESTHESI S1, V60, P61; Du Pen S, 1992, Eur J Anaesthesiol Suppl, V6, P55; DUPEYRON JP, 1993, ANAESTHESIA, V48, P214, DOI 10.1111/j.1365-2044.1993.tb06904.x; GIORGI L, 1994, MINERVA ANESTESIO S1, V60, P73; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HELMERS JH, 1992, EUROPEAN J ANAEST S6, V9, P49; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; KENNY GNC, 1992, BRIT J ANAESTH, V68, P466, DOI 10.1093/bja/68.5.466; KHALIL SN, 1994, ANESTH ANALG, V79, P845; Kovac A, 1992, Eur J Anaesthesiol Suppl, V6, P37; Kovac AL, 1996, J CLIN ANESTH, V8, P644, DOI 10.1016/S0952-8180(96)00173-0; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V270, P2495, DOI 10.1001/jama.1993.03510200101040; MARKHAM A, 1993, DRUGS, V45, P931, DOI 10.2165/00003495-199345060-00006; MCKENZIE R, 1993, J CLIN ANESTH, V5, P30, DOI 10.1016/0952-8180(93)90084-R; MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Melani A. M., 1995, Acta Anaesthesiologica Italica, V46, P37; PAECH MJ, 1995, ANAESTH INTENS CARE, V23, P548, DOI 10.1177/0310057X9502300503; PAXTON LD, 1995, ANAESTHESIA, V50, P403, DOI 10.1111/j.1365-2044.1995.tb05993.x; PEARMAN MH, 1994, ANAESTHESIA, V49, P11, DOI 10.1111/j.1365-2044.1994.tb03577.x; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCUDERI P, 1993, ANESTHESIOLOGY, V78, P15, DOI 10.1097/00000542-199301000-00004; Taddei F., 1995, Acta Anaesthesiologica Italica, V46, P43; Tramer M, 1997, BRIT J ANAESTH, V78, P247, DOI 10.1093/bja/78.3.247; Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088; TRAMER MR, IN PRESS ANESTHESIOL; VOLPE N, 1994, DRUG INVEST, V8, P67, DOI 10.1007/BF03257429; VOLPE N, 1994, MINERVA ANESTESIO S1, V60, P121; WATCHA MF, 1995, EUR J ANAESTH, V12, P18; Zideman DA, 1996, MONATSSCHR KINDERH, V144, P727; ZIDEMAN DA, 1994, BRIT MED J, V308, P1349	47	451	455	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	1997	315	7109					635	640		10.1136/bmj.315.7109.635	http://dx.doi.org/10.1136/bmj.315.7109.635			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310564	Green Published			2022-12-28	WOS:A1997XW69400017
J	Unger, VM; Hargrave, PA; Baldwin, JM; Schertler, GFX				Unger, VM; Hargrave, PA; Baldwin, JM; Schertler, GFX			Arrangement of rhodopsin transmembrane alpha-helices	NATURE			English	Article							PROJECTION STRUCTURE; BOVINE RHODOPSIN; ACTIVATION; RESOLUTION; RECEPTORS; PROTEIN; TRANSDUCIN; DOMAIN	Rhodopsins(1), the photoreceptors in rod cells, are G-protein-coupled receptors with seven hydrophobic segments containing characteristic conserved sequence patterns that define a large family(2,3). Members of the family are expected to share a conserved transmembrane structure. Direct evidence for the arrangement of seven alpha-helices was obtained from a 9 Angstrom projection map of bovine rhodopsin(4). Structural constraints inferred from a comparison of G-protein-coupled receptor sequences were used to assign the seven hydrophobic stretches in the sequence to features in the projection map(5), A low-resolution three-dimensional structure of bovine rhodopsin(6) and two projection structures of frog rhodopsin(7) confirmed the position of the three least tilted helices, 4, 6 and 7, A more elongated peak of density for helix 5 indicated that it is tilted or bent(6,7), but helices 1, 2 and 3 were not resolved, Here we have used electron micrographs of frozen-hydrated two-dimensional frog rhodopsin crystals to determine the structure of frog rhodopsin, Seven rods of density in the map are used to estimate tilt angles for the seven helices. Density visible on the extracellular side of the membrane suggests a folded domain, Density extends from helix 6 on the intracellular side, and a short connection between helices 1 and 2, and possibly a part of the carboxy terminus, are visible.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV FLORIDA,DEPT OPHTHALMOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT BIOCHEM & MOL BIOL,GAINESVILLE,FL 32610	MRC Laboratory Molecular Biology; State University System of Florida; University of Florida; State University System of Florida; University of Florida			Schertler, Gebhard/M-9512-2014	Schertler, Gebhard F.X./0000-0002-5846-6810				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HAN M, 1995, BIOPHYS CHEM, V56, P23, DOI 10.1016/0301-4622(95)00011-L; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HARGRAVE PA, 1993, INT REV CYTOL B, V137, P49; HAVELKA WA, 1995, J MOL BIOL, V247, P726, DOI 10.1006/jmbi.1995.0176; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; THURMOND RL, 1997, P NATL ACAD SCI USA, V94, P1713; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; ZHANG HZ, 1994, J AM CHEM SOC, V116, P10165, DOI 10.1021/ja00101a040	26	446	452	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					203	206		10.1038/38316	http://dx.doi.org/10.1038/38316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296501				2022-12-28	WOS:A1997XV75700054
J	Barker, A				Barker, A			ABC of mental health - Mental health and the law	BRITISH MEDICAL JOURNAL			English	Review											Barker, A (corresponding author), BRACTON CTR,OXLEAS NHS TRUST,BEXLEY,KENT,ENGLAND.							*BRIT MED ASS, 1992, RIGHTS RESP DOCT; British Medical Association, 1995, ASS MENT CAP GUID DO; DAVIES T, 1997, PSYCHIAT B, V21, P200; JONES R, 1996, MENTAL HLTH ACT MANU; 1997, DRUG THER B, V35, P41	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					590	592						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	9302959				2022-12-28	WOS:A1997XV71700030
J	Hickman, M; Sutcliffe, H; Sondhi, A; Stimson, GV				Hickman, M; Sutcliffe, H; Sondhi, A; Stimson, GV			Validation of a regional drug misuse database: implications for policy and surveillance of problem drug use in the UK	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Hickman, M (corresponding author), IMPERIAL COLL SCH MED, DEPT SOCIAL SCI & MED, CTR RES DRUGS & HLTH BEHAV, LONDON SW6 1RQ, ENGLAND.		Hickman, Matthew/Y-2400-2019	Hickman, Matthew/0000-0001-9864-459X; Sondhi, Arun/0000-0002-4748-5522				CRABBE T, 1995, INT J DRUG POLICY, V6, P31; DONMALL M, 1990, DRUG MISUSE DATABASE; Home Office, 1995, TACKLING DRUGS TOGET; STIMSON GV, 1995, SOC SCI MED, V41, P699, DOI 10.1016/0277-9536(94)00435-V; SUTTON M, 1993, ADDICTION, V88, P455, DOI 10.1111/j.1360-0443.1993.tb02051.x	5	12	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	1997	315	7108					581	581						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	9302956				2022-12-28	WOS:A1997XV71700026
J	Morrison, JH; Hof, PR				Morrison, JH; Hof, PR			Life and death of neurons in the aging brain	SCIENCE			English	Review							PAIRED HELICAL FILAMENTS; LONG-TERM POTENTIATION; AMYOTROPHIC-LATERAL-SCLEROSIS; UNBIASED STEREOLOGICAL ESTIMATION; AMYLOID PRECURSOR PROTEIN; MILD ALZHEIMERS-DISEASE; DENDRITIC SPINE DENSITY; MONKEY CEREBRAL-CORTEX; AGED FISCHER-344 RATS; NEUROFIBRILLARY TANGLES	Neurodegenerative disorders are characterized by extensive neuron death that leads to functional decline, but the neurobiological correlates of functional decline in normal aging ave less well defined. For decades, it has been a commonly held notion that widespread neuron death in the neocortex and hippocampus is an inevitable concomitant of brain aging, but recent quantitative studies suggest that neuron death is restricted in normal aging and unlikely to account for age-related impairment of neocortical and hippocampal functions, In this article, the qualitative and quantitative differences between aging and Alzheimer's disease with respect to neuron loss are discussed, and age-related changes in functional and biochemical attributes of hippocampal circuits that might mediate functional decline in the absence of neuron death are explored. When these data are viewed comprehensively, it appears that the primary neurobiological substrates for functional impairment in aging differ in important ways from those in neurodegenerative disorders such as Alzheimer's disease.	MT SINAI SCH MED, DEPT GERIATR & ADULT DEV, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Morrison, JH (corresponding author), MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEUROBIOL AGING LABS, NEW YORK, NY 10029 USA.		Morrison, John/F-9229-2012		NATIONAL INSTITUTE ON AGING [R01AG006647] Funding Source: NIH RePORTER; NIA NIH HHS [AG05138, AG06647] Funding Source: Medline; NIMH NIH HHS [MHDA52145] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Albert Marilyn S., 1996, P217; Albert MS, 1996, P NATL ACAD SCI USA, V93, P13547, DOI 10.1073/pnas.93.24.13547; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; ARRIAGADA PV, 1992, NEUROLOGY, V42, P1681, DOI 10.1212/WNL.42.9.1681; Asada T, 1996, J AM GERIATR SOC, V44, P151, DOI 10.1111/j.1532-5415.1996.tb02431.x; BACHEVALIER J, 1991, NEUROBIOL AGING, V12, P99, DOI 10.1016/0197-4580(91)90048-O; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; Barnes C.A., 1980, PSYCHOBIOLOGY AGING, P253; BARNES CA, 1994, TRENDS NEUROSCI, V17, P13, DOI 10.1016/0166-2236(94)90029-9; Barnes CA, 1997, NATURE, V388, P272, DOI 10.1038/40859; BARNES CA, 1990, HDB NEUROPSYCHOLOGY, V4, P169; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BERG L, 1993, ARCH NEUROL-CHICAGO, V50, P349, DOI 10.1001/archneur.1993.00540040011008; Berr C, 1996, P NATL ACAD SCI USA, V93, P13410, DOI 10.1073/pnas.93.23.13410; BIERER LM, 1995, ARCH NEUROL-CHICAGO, V52, P81, DOI 10.1001/archneur.1995.00540250089017; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BOURAS C, 1993, NEUROSCI LETT, V153, P131, DOI 10.1016/0304-3940(93)90305-5; BOURAS C, 1994, CEREB CORTEX, V4, P138, DOI 10.1093/cercor/4.2.138; BRAAK H, 1985, ACTA NEUROPATHOL, V68, P325, DOI 10.1007/BF00690836; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRION JP, 1991, BIOCHEM J, V279, P831, DOI 10.1042/bj2790831; BRODY H, 1955, J COMP NEUROL, V102, P511, DOI 10.1002/cne.901020206; CALLAHAN LM, 1995, NEUROBIOL AGING, V16, P311, DOI 10.1016/0197-4580(95)00035-D; CHANG FLF, 1991, NEUROBIOL AGING, V12, P517, DOI 10.1016/0197-4580(91)90082-U; COLEMAN PD, 1987, NEUROBIOL AGING, V8, P521, DOI 10.1016/0197-4580(87)90127-8; COLON EJ, 1972, PSYCHIAT NEUROL NEUR, V75, P261; Convit A, 1997, NEUROBIOL AGING, V18, P131, DOI 10.1016/S0197-4580(97)00001-8; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; CRYSTAL H, 1988, NEUROLOGY, V38, P1682, DOI 10.1212/WNL.38.11.1682; DalCanto MC, 1997, ACTA NEUROPATHOL, V93, P537; DAVIES P, 1976, LANCET, V2, P1403; DAYAN AD, 1970, ACTA NEUROPATHOL, V16, P85, DOI 10.1007/BF00687663; DELACOSTE MC, 1993, J COMP NEUROL, V14, P1; DELACOURTE A, 1990, ACTA NEUROPATHOL, V80, P111, DOI 10.1007/BF00308912; DELAERE P, 1993, NEUROBIOL AGING, V14, P191, DOI 10.1016/0197-4580(93)90096-T; DEUPREE DL, 1991, BRAIN RES, V554, P1, DOI 10.1016/0006-8993(91)90164-Q; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; DUYCKAERTS C, 1986, ACTA NEUROPATHOL, V70, P249, DOI 10.1007/BF00686079; Fama R, 1997, ARCH NEUROL-CHICAGO, V54, P719, DOI 10.1001/archneur.1997.00550180039010; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; FLOOD DG, 1987, BRAIN RES, V402, P205, DOI 10.1016/0006-8993(87)90027-8; FLOOD DG, 1988, NEUROBIOL AGING, V9, P453, DOI 10.1016/S0197-4580(88)80098-8; Gallagher M, 1997, ANNU REV PSYCHOL, V48, P339, DOI 10.1146/annurev.psych.48.1.339; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gazzaley AH, 1996, J NEUROSCI, V16, P6830; Gazzaley AH, 1996, P NATL ACAD SCI USA, V93, P3121, DOI 10.1073/pnas.93.7.3121; GAZZALEY AH, IN PRESS NEUROBIOL A; GEINISMAN Y, 1995, PROG NEUROBIOL, V45, P223, DOI 10.1016/0301-0082(94)00047-L; Geula Changiz, 1994, P263; GIANNAKOPOULOS P, 1995, ARCH NEUROL-CHICAGO, V52, P1150, DOI 10.1001/archneur.1995.00540360028012; Giannakopoulos P, 1996, J NEUROPATH EXP NEUR, V55, P1210, DOI 10.1097/00005072-199612000-00004; GIANNAKOPOULOS P, 1994, DEMENTIA, V5, P348, DOI 10.1159/000106745; GIANNAKOPOULOS P, 1993, ACTA NEUROPATHOL, V85, P602, DOI 10.1007/BF00334669; GIANNAKOPOULOS P, 1994, ACTA NEUROPATHOL, V87, P456; GIANNAKOPOULOS P, IN PRESS BRAIN RES R; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Good PF, 1996, AM J PATHOL, V149, P21; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GREENOUGH WT, 1978, SCIENCE, V202, P1096, DOI 10.1126/science.715459; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HAUG H, 1984, J HIRNFORSCH, V25, P353; HAUW JJ, 1986, REV NEUROL, V142, P107; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; Hof Patrick R., 1994, P197; Hof PR, 1997, EUR NEUROL, V37, P71, DOI 10.1159/000117414; HOF PR, 1992, ARCH NEUROL-CHICAGO, V49, P946, DOI 10.1001/archneur.1992.00530330070019; HOF PR, 1991, J NEUROPATH EXP NEUR, V50, P451, DOI 10.1097/00005072-199107000-00006; HOF PR, 1993, NEUROSCI LETT, V152, P145, DOI 10.1016/0304-3940(93)90504-E; HOF PR, 1991, EXP NEUROL, V111, P293, DOI 10.1016/0014-4886(91)90096-U; HOF PR, 1990, J COMP NEUROL, V301, P44, DOI 10.1002/cne.903010105; Hof PR, 1996, J AM GERIATR SOC, V44, P857, DOI 10.1111/j.1532-5415.1996.tb03748.x; HOF PR, 1990, J COMP NEUROL, V301, P55, DOI 10.1002/cne.903010106; HOF PR, IN PRESS CEREBRAL CO, V13; HUBBARD BM, 1990, NEUROPATH APPL NEURO, V16, P111, DOI 10.1111/j.1365-2990.1990.tb00940.x; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; HYMAN BT, 1990, NEUROLOGY, V40, P1721, DOI 10.1212/WNL.40.11.1721; Irizarry MC, 1997, J NEUROSCI, V17, P7053; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jack CR, 1997, NEUROLOGY, V49, P786, DOI 10.1212/WNL.49.3.786; Jucker M, 1997, BEHAV BRAIN RES, V85, P1, DOI 10.1016/S0166-4328(96)02243-7; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kim CBY, 1997, ANAT REC, V247, P119, DOI 10.1002/(SICI)1097-0185(199701)247:1<119::AID-AR14>3.0.CO;2-S; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KSIEZAKREDING H, 1987, P NATL ACAD SCI USA, V84, P3410, DOI 10.1073/pnas.84.10.3410; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEWIS DA, 1987, J NEUROSCI, V7, P1799; MASLIAH E, 1991, AM J PATHOL, V138, P235; MASLIAH E, 1993, NEUROLOGY, V43, P192, DOI 10.1212/WNL.43.1_Part_1.192; Masliah E, 1996, J NEUROSCI, V16, P5795; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; McIntosh LJ, 1997, FREE RADICAL BIO MED, V23, P183, DOI 10.1016/S0891-5849(96)00573-4; MEUNIER M, 1993, J NEUROSCI, V13, P5418, DOI 10.1523/JNEUROSCI.13-12-05418.1993; MILLER CCJ, 1986, EMBO J, V5, P269, DOI 10.1002/j.1460-2075.1986.tb04209.x; MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MIZUTANI T, 1992, J NEUROL SCI, V108, P168, DOI 10.1016/0022-510X(92)90047-O; MOORE CI, 1993, HIPPOCAMPUS, V3, P57, DOI 10.1002/hipo.450030106; MORRIS JC, 1991, NEUROLOGY, V41, P469, DOI 10.1212/WNL.41.4.469; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Morrison BM, 1996, J COMP NEUROL, V373, P619, DOI 10.1002/(SICI)1096-9861(19960930)373:4<619::AID-CNE9>3.0.CO;2-4; MORRISON JH, 1987, BRAIN RES, V416, P331, DOI 10.1016/0006-8993(87)90914-0; MORRISON JH, 1993, NEUROBIOL AGING, V14, P51, DOI 10.1016/0197-4580(93)90021-3; Mutrux S, 1947, MON PSYCHIATR NEUROL, V113, P100; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; Pakkenberg B, 1997, J COMP NEUROL, V384, P312, DOI 10.1002/(SICI)1096-9861(19970728)384:2<312::AID-CNE10>3.0.CO;2-K; PEARSON RCA, 1985, P NATL ACAD SCI USA, V82, P4531, DOI 10.1073/pnas.82.13.4531; PETERS A, 1994, CEREB CORTEX, V4, P621, DOI 10.1093/cercor/4.6.621; Peters A, 1996, J COMP NEUROL, V371, P153, DOI 10.1002/(SICI)1096-9861(19960715)371:1<153::AID-CNE9>3.0.CO;2-2; PETERS A, 1993, ANAT REC, V236, P721, DOI 10.1002/ar.1092360416; Peters A, 1996, J NEUROPATH EXP NEUR, V55, P861, DOI 10.1097/00005072-199608000-00001; PRICE JL, 1991, NEUROBIOL AGING, V12, P295, DOI 10.1016/0197-4580(91)90006-6; Rapp PR, 1997, NEUROREPORT, V8, P1923, DOI 10.1097/00001756-199705260-00026; Rapp PR, 1996, P NATL ACAD SCI USA, V93, P9926, DOI 10.1073/pnas.93.18.9926; RAPP PR, 1995, EMOTION MEMORY BEHAV, P197; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; RITCHIE K, 1995, LANCET, V346, P931, DOI 10.1016/S0140-6736(95)91556-7; Roberts JA, 1997, NEUROREPORT, V8, P2047, DOI 10.1097/00001756-199705260-00048; ROGERS J, 1985, J NEUROSCI, V5, P2801; Rosene D. L., 1987, CEREB CORTEX, V6, P345, DOI DOI 10.1007/978-1-4615-6616-8_9; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; SAITOH T, 1991, LAB INVEST, V64, P596; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; Sampson VL, 1997, EXP NEUROL, V145, P295, DOI 10.1006/exnr.1997.6433; SCHMIDT ML, 1990, AM J PATHOL, V136, P1069; Simic G, 1997, J COMP NEUROL, V379, P482, DOI 10.1002/(SICI)1096-9861(19970324)379:4<482::AID-CNE2>3.0.CO;2-Z; Smith MA, 1997, J NEUROSCI, V17, P2653; SMITH MA, 1994, AM J PATHOL, V145, P42; SOBEL E, 1995, NEUROLOGY, V45, P903, DOI 10.1212/WNL.45.5.903; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1988, TRENDS NEUROSCI, V11, P170, DOI 10.1016/0166-2236(88)90144-0; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; TANG M, 1997, NEUROLOGY S7, V48, pS1; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TIGGES J, 1990, NEUROBIOL AGING, V11, P201, DOI 10.1016/0197-4580(90)90546-C; TIGGES J, 1995, ACTA ANAT, V153, P39; Tigges J, 1996, ACTA ANAT, V157, P63; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; VICKERS JC, 1992, BRAIN RES, V594, P273, DOI 10.1016/0006-8993(92)91134-Z; VICKERS JC, 1994, NEUROSCIENCE, V62, P1, DOI 10.1016/0306-4522(94)90310-7; Vickers JC, 1996, EXP NEUROL, V141, P1, DOI 10.1006/exnr.1996.0133; Vickers JC, 1997, NEUROSCIENCE, V78, P629, DOI 10.1016/S0306-4522(96)00662-8; VICKERS JC, 1994, J NEUROSCI, V14, P5603; VINCENT SL, 1989, ANAT REC, V223, P329, DOI 10.1002/ar.1092230312; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; WILLIAMS RW, 1989, J COMP NEUROL, V281, P335; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; WINKER MA, 1995, LANCET, V346, P1486, DOI 10.1016/S0140-6736(95)92500-7; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; WITTER MP, 1989, J NEUROSCI, V9, P216; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	184	991	1029	1	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	1997	278	5337					412	419		10.1126/science.278.5337.412	http://dx.doi.org/10.1126/science.278.5337.412			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334292				2022-12-28	WOS:A1997YB35500032
J	Han, SH; Dillon, SR; Zheng, B; Shimoda, M; Schlissel, MS; Kelsoe, G				Han, SH; Dillon, SR; Zheng, B; Shimoda, M; Schlissel, MS; Kelsoe, G			V(D)J recombinase activity in a subset of germinal center B lymphocytes	SCIENCE			English	Article							PRIMARY IMMUNE-RESPONSE; LIGHT-CHAIN; IN-SITU; RECIPROCAL PARTNERS; GENE REARRANGEMENT; CELLS; MATURATION; SELECTION; MECHANISM; ANTIGEN	Reexpression of the V(D)J recombinase-activating genes RAG1 and RAG2 in germinal center B cells creates the potential for immunoglobulin gene rearrangement and the generation of new antigen receptor specificities. intermediate products of V(D)J recombination are abundant in a subset of germinal center B cells, demonstrating that the kappa immunoglobulin light-chain locus becomes a substrate for renewed V(D)J recombinase activity. This recombinationally active cell compartment contains many heavy-chain VDJ rearrangements that encode low-affinity or nonfunctional antibody. In germinal centers, secondary V(D)J recombination may be induced by diminished binding to antigen ligands, thereby limiting abrupt changes in receptor specificity to B cells that are usually eliminated from the germinal center reaction, This restriction preserves efficient antigen-driven selection in germinal centers while allowing for saltations in the somatic evolution of B cells.	UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOL & CELL BIOL,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024335, R01AI040227, R37AI040227] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48722] Funding Source: Medline; NIAID NIH HHS [AI40227, AI24335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLMAN DM, 1993, J IMMUNOL, V151, P4431; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; CERASOLI D, UNPUB; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; COICO RF, 1983, J IMMUNOL, V131, P2254; Constantinescu A, 1997, J EXP MED, V185, P609, DOI 10.1084/jem.185.4.609; Cornall RJ, 1995, CURR OPIN IMMUNOL, V7, P804, DOI 10.1016/0952-7915(95)80052-2; COTTER F, 1990, BLOOD, V76, P131; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Han S.-G., UNPUB; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; HAN SH, 1995, J IMMUNOL, V155, P556; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; Kelsoe G, 1995, ADV IMMUNOL, V60, P267, DOI 10.1016/S0065-2776(08)60587-8; Kimoto H, 1997, EUR J IMMUNOL, V27, P268, DOI 10.1002/eji.1830270140; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MILLER C, 1995, J IMMUNOL, V155, P3377; Miller Carla, 1994, Aging Immunology and Infectious Disease, V5, P249; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347	38	252	254	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					301	305		10.1126/science.278.5336.301	http://dx.doi.org/10.1126/science.278.5336.301			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323211				2022-12-28	WOS:A1997YA56400048
J	Rigotti, NA; DiFranza, JR; Chang, YC; Tisdale, T; Kemp, B; Singer, DE				Rigotti, NA; DiFranza, JR; Chang, YC; Tisdale, T; Kemp, B; Singer, DE			The effect of enforcing tobacco-sales laws on adolescents' access to tobacco and smoking behavior	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE SALES; YOUTH ACCESS; MINORS; ENFORCEMENT; PREVENTION	Background Enforcing laws banning tobacco sales to miners is widely advocated as a way to reduce young people's access to tobacco and tobacco use. Whether this approach is successful is not known. Methods In a two-year controlled study, we assessed sales of tobacco to miners and young people's access to and use of tobacco in six Massachusetts communities. Three communities (the intervention group) enforced tobacco-sales laws, whereas three matched communities (the control group) did not. To assess compliance with the law, miners working for the study investigators attempted to purchase tobacco from all retail vendors in each community every six months. Three annual anonymous surveys of a total of 22,021 students in grades 9 through 12 (response rate, 84 percent) measured access to tobacco and smoking behavior. Results At base line, 68 percent of 487 vendors sold tobacco to miners. Compliance with the law improved significantly faster in the intervention communities than in the controls (P<0.001). By the study's end, 82 percent of the merchants in the intervention communities complied with the law, as compared with 45 percent in the control communities (P<0.001). However, adolescents under 18 years old reported only a small drop in their ability to purchase tobacco and no decline in its use. Communities with and those without enforcement programs did not differ with respect to these outcomes. Conclusions Enforcing tobacco-sales laws improved merchants' compliance and reduced illegal sales to miners but did not alter adolescents' perceived access to tobacco or their smoking. Test purchases of tobacco do not accurately reflect adolescents' self-reported access to tobacco, and reducing illegal sales to less than 20 percent of attempts - the goal of a new federal law - may not decrease young people's access to or use of tobacco. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, TOBACCO RES & TREATMENT CTR, BOSTON, MA 02114 USA; UNIV MASSACHUSETTS, MED CTR, DEPT FAMILY & COMMUNITY MED, WORCESTER, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Worcester	Rigotti, NA (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED, GEN INTERNAL MED UNIT,50 STANIFORD ST, 9TH FL, BOSTON, MA 02114 USA.				NATIONAL CANCER INSTITUTE [K07CA001673] Funding Source: NIH RePORTER; NCI NIH HHS [CA01673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMAN DG, 1991, AM J PUBLIC HEALTH, V81, P891, DOI 10.2105/AJPH.81.7.891; ALTMAN DG, 1989, JAMA-J AM MED ASSOC, V261, P80, DOI 10.1001/jama.261.1.80; BIENER L, 1994, RESULTS 1993 MASSACH; *CDCP, 1996, CDC PUBL; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P125; CUMMINGS KM, 1992, TOB CONTROL, V1, P264; *DEP HLTH HUM SERV, 1991, DHHS PUBL PHS; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE; *DEP HLTH HUM SERV, 1989, DHHS PUBL CDC; DiFranza J.R., 1992, TOB CONTROL, V1, P58, DOI [10.1136/tc.1.1.58a, DOI 10.1136/TC.1.1.58A]; DiFranza J. R., 1994, TOB CONTROL, V3, P334, DOI DOI 10.1136/TC.3.4.334; DiFranza JR, 1996, AM J PUBLIC HEALTH, V86, P221, DOI 10.2105/AJPH.86.2.221; Erickson A D, 1993, J Community Health, V18, P213, DOI 10.1007/BF01324432; *FDA, 1996, FED REGISTER, V61, P44396; FEIGHERY E, 1991, JAMA-J AM MED ASSOC, V266, P3168; FORSTER J L, 1989, Health Education Research, V4, P45, DOI 10.1093/her/4.1.45; Glantz SA, 1996, AM J PUBLIC HEALTH, V86, P156, DOI 10.2105/AJPH.86.2.156; HILTS PJ, 1995, NY TIMES        0131, pA3; Jason L, 1996, J APPL BEHAV ANAL, V29, P333, DOI 10.1901/jaba.1996.29-333; Jason LA, 1996, EVAL HEALTH PROF, V19, P3, DOI 10.1177/016327879601900101; JASON LA, 1991, JAMA-J AM MED ASSOC, V266, P3159, DOI 10.1001/jama.266.22.3159; JOHNSON LD, 1996, NIH PUBLICATION NATL, V1; *OFF INSP GEN, 1995, STAT OV TOB SAL MIN; Pierce J.P, 1993, TOBACCO USE CALIFORN; Radecki Thomas E., 1993, TOB CONTROL, V2, P300, DOI DOI 10.1136/TC.2.4.300; SEVERSON H, 1989, PREV MED, V18, P267, DOI 10.1016/0091-7435(89)90074-1; *SUBST AB MENT HLT, 1993, FED REGISTER, V58, P45156; Substance Abuse and Mental Health Services Administration, 1996, FED REGISTER, V16, P1492; TTALBOT B, 1992, TOB CONTROL, V1, P294; WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554; 1989, FINDINGS STUDY TEENA, P1; 1996, MMWR-MORBID MORTAL W, V45, P1060; 1996, MMWR-MORBID MORTAL W, V45, P413; 1995, MMWR-MORBID MORTAL W, V44, P839; 1991, MMWR-MORBID MORTAL W, V40, P712; 1996, MMWR-MORBID MORTAL W, V45, P125; 1996, MMWR-MORBID MORTAL W, V45, P1036	37	190	191	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1044	1051		10.1056/NEJM199710093371505	http://dx.doi.org/10.1056/NEJM199710093371505			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XZ844	9321533				2022-12-28	WOS:A1997XZ84400005
J	Nestler, EJ; Aghajanian, GK				Nestler, EJ; Aghajanian, GK			Molecular and cellular basis of addiction	SCIENCE			English	Review							MU-OPIOID-RECEPTOR; MESOLIMBIC DOPAMINE SYSTEM; LOCUS-CERULEUS NEURONS; VENTRAL TEGMENTAL AREA; OPIATE-DEPENDENT RATS; CYCLIC-AMP SYSTEM; LONG-TERM-MEMORY; BEHAVIORAL SENSITIZATION; NUCLEUS-ACCUMBENS; G-PROTEIN	Drug addiction results from adaptations in specific brain neurons caused by repeated exposure to a drug of abuse. These adaptations combine to produce the complex behaviors that define an addicted slate. Progress is being made in identifying such time-dependent, drug-induced adaptations and relating them to specific behavioral features of addiction. Current research needs to understand the types of adaptations that underlie the particularly long-lived aspects of addiction, such as drug craving and relapse, and to identify specific genes that contribute to individual differences in vulnerability to addiction. Understanding the molecular and cellular basis of addictive states will lead to major changes in how addiction is viewed and ultimately treated.	YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06508 USA; CONNECTICUT MENTAL HLTH CTR, NEW HAVEN, CT 06508 USA	Yale University	Nestler, EJ (corresponding author), YALE UNIV, SCH MED, DEPT PSYCHIAT, LAB MOL PSYCHIAT, 34 PK ST, NEW HAVEN, CT 06508 USA.							AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; AKAOKA H, 1991, J NEUROSCI, V11, P3830; ALREJA M, 1994, BRAIN RES, V639, P320, DOI 10.1016/0006-8993(94)91746-9; ALREJA M, 1993, J NEUROSCI, V13, P3525; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ATTALI B, 1989, J NEUROCHEM, V53, P1636, DOI 10.1111/j.1471-4159.1989.tb08562.x; Berhow MT, 1996, J NEUROSCI, V16, P4707; Berhow MT, 1996, J NEUROSCI, V16, P8019; BERHOW MT, 1995, NEUROSCIENCE, V68, P969, DOI 10.1016/0306-4522(95)00207-Y; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; Bonci A, 1996, NEURON, V16, P631, DOI 10.1016/S0896-6273(00)80082-3; Bonci A, 1997, J NEUROSCI, V17, P796; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Carlezon WA, 1996, J NEUROSCI, V16, P3112; Chen J. S., 1997, Society for Neuroscience Abstracts, V23, P410; Chen JS, 1997, J NEUROSCI, V17, P4933; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Christie MJ, 1997, TRENDS PHARMACOL SCI, V18, P134, DOI 10.1016/S0165-6147(97)01045-6; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; Crain SM, 1996, NEUROCHEM RES, V21, P1347, DOI 10.1007/BF02532375; CUNNINGHAM ST, 1993, J NEUROSCI, V13, P2342, DOI 10.1523/JNEUROSCI.13-06-02342.1993; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRAGO J, 1996, NEURON, V17, P747; ELLIOTT K, 1995, NEUROPSYCHOPHARMACOL, V13, P347, DOI 10.1038/sj.npp.1380294; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gold SJ, 1997, J NEUROSCI, V17, P8024; HENRY DJ, 1995, J NEUROSCI, V15, P6287; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; JEZIORSKI M, 1994, SYNAPSE, V16, P137, DOI 10.1002/syn.890160207; Jolas T, 1997, BRAIN RES, V755, P229, DOI 10.1016/S0006-8993(97)00103-0; Jolas T., 1997, Society for Neuroscience Abstracts, V23, P124; KALIVAS PW, 1995, DRUG ALCOHOL DEPEN, V37, P95, DOI 10.1016/0376-8716(94)01063-Q; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; Kelley AE, 1997, SYNAPSE, V26, P46, DOI 10.1002/(SICI)1098-2396(199705)26:1<46::AID-SYN5>3.0.CO;2-E; KOGAN JH, 1992, EUR J PHARMACOL, V211, P47, DOI 10.1016/0014-2999(92)90261-2; Kolesnikov YA, 1997, P NATL ACAD SCI USA, V94, P8220, DOI 10.1073/pnas.94.15.8220; KOLESNIKOV YA, 1992, EUR J PHARMACOL, V221, P339; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A., 1997, Society for Neuroscience Abstracts, V23, P1769; Kreek MJ, 1996, MOL PSYCHIATR, V1, P232; Kuhar MJ, 1996, TRENDS PHARMACOL SCI, V17, P260, DOI 10.1016/S0165-6147(96)10024-9; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; Lu WX, 1997, SYNAPSE, V26, P269, DOI 10.1002/(SICI)1098-2396(199707)26:3<269::AID-SYN8>3.0.CO;2-5; Lucas JJ, 1997, MOL PHARMACOL, V51, P755, DOI 10.1124/mol.51.5.755; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; Maldonado R, 1997, NEUROSCI BIOBEHAV R, V21, P91, DOI 10.1016/0149-7634(95)00061-5; MALDONADO R, 1995, N-S ARCH PHARMACOL, V352, P565; Mandelzys A, 1997, J NEUROSCI, V17, P5407; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MATSUOKA I, 1994, EUR J PHARM-MOLEC PH, V268, P215, DOI 10.1016/0922-4106(94)90191-0; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MISERENDINO MJD, 1995, BRAIN RES, V674, P299, DOI 10.1016/0006-8993(95)00030-T; Moratalla R, 1996, NEURON, V17, P147, DOI 10.1016/S0896-6273(00)80288-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Nye HE, 1996, MOL PHARMACOL, V49, P636; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; ORTIZ J, 1996, NEUROPSYCHOPHARMACOL, V14, P393; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PEI G, 1995, MOL PHARMACOL, V48, P173; Phillips TJ, 1997, CRIT REV NEUROBIOL, V11, P21, DOI 10.1615/CritRevNeurobiol.v11.i1.20; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Pich EM, 1997, SCIENCE, V275, P83; PUNCH L, IN PRESS J NEUROSCI; RASMUSSEN K, 1989, BRAIN RES, V505, P346, DOI 10.1016/0006-8993(89)91466-2; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Schoffelmeer ANM, 1996, NEUROCHEM RES, V21, P1417, DOI 10.1007/BF02532383; SEIF DW, 1995, ANNU REV NEUROSCI, V18, P463; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; Shaham Y, 1996, J NEUROSCI, V16, P1957; Shaham Y, 1997, J NEUROSCI, V17, P2605; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; Sim LJ, 1996, J NEUROSCI, V16, P2684; SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202; Spanagel R, 1996, J NEUROENDOCRINOL, V8, P93, DOI 10.1111/j.1365-2826.1996.tb00828.x; Spangler R, 1996, MOL BRAIN RES, V38, P71, DOI 10.1016/0169-328X(95)00319-N; STEKETEE JD, 1991, BRAIN RES, V545, P287, DOI 10.1016/0006-8993(91)91299-G; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; STRIPLIN CD, 1993, SYNAPSE, V14, P10, DOI 10.1002/syn.890140103; TAO PL, 1993, N-S ARCH PHARMACOL, V348, P504; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; Tolliver BK, 1996, J PHARMACOL EXP THER, V278, P411; TRUJILLO KA, 1994, BRAIN RES, V633, P178, DOI 10.1016/0006-8993(94)91538-5; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Turgeon SM, 1997, BRAIN RES, V749, P120, DOI 10.1016/S0006-8993(96)01316-9; Uhl GR, 1997, P NATL ACAD SCI USA, V94, P2785, DOI 10.1073/pnas.94.7.2785; Uhl GR, 1996, CURR BIOL, V6, P935, DOI 10.1016/S0960-9822(02)00630-9; Unterwald EM, 1996, EUR J PHARMACOL, V318, P31, DOI 10.1016/S0014-2999(96)00841-2; Valverde O, 1996, EUR J NEUROSCI, V8, P2671, DOI 10.1111/j.1460-9568.1996.tb01562.x; VANVLIET BJ, 1993, EUR J PHARM-MOLEC PH, V245, P23, DOI 10.1016/0922-4106(93)90165-6; VAUPEL DB, 1995, NEUROPSYCHOPHARMACOL, V13, P315, DOI 10.1016/0893-133X(95)00138-4; Ventayol P, 1997, N-S ARCH PHARMACOL, V355, P491, DOI 10.1007/PL00004974; Wang XB, 1997, J NEUROSCI, V17, P5993; WERLING LL, 1989, P NATL ACAD SCI USA, V86, P6393, DOI 10.1073/pnas.86.16.6393; White F J, 1998, Adv Pharmacol, V42, P1006; WHITE FJ, 1995, J PHARMACOL EXP THER, V273, P445; Widnell KL, 1996, J PHARMACOL EXP THER, V276, P306; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1; ZAMANILLO D, 1995, NEUROSCI LETT, V188, P183, DOI 10.1016/0304-3940(95)11428-Y; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699	124	1042	1122	4	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					58	63		10.1126/science.278.5335.58	http://dx.doi.org/10.1126/science.278.5335.58			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311927				2022-12-28	WOS:A1997XZ12400032
J	Shinde, UP; Liu, JJ; Inouye, M				Shinde, UP; Liu, JJ; Inouye, M			Protein memory through altered folding mediated by intramolecular chaperones	NATURE			English	Article							SUBTILISIN BPN'; PRO-SEQUENCE; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; KINETIC-ANALYSIS; PROPEPTIDE; CATALYSIS; PATHWAY; INHIBITION; MECHANISM	The 77-residue propeptide of subtilisin acts as an intramolecular chaperone that organizes the correct folding of its own protease domain, Similar folding mechanisms are used by several prokaryotic and eukaryotic proteins, including prohormone-convertases. Here we show that the intramolecular chaperone of subtilisin facilitates folding by acting as a template for its protease domain, although it does not form part of that domain. Subtilisin E folded by an intramolecular chaperone with an Ile(-48)-to-Val mutation acquires an 'altered' enzymatically active conformation that differs from wild-type subtilisin E. Although both the altered and wild-type subtilisins have identical amino-acid sequences, as determined by amino-terminal sequencing and mass spectrometry, they bind their cognate intramolecular chaperones with 4.5-fold greater affinity than non-cognate intramolecular chaperones, when added in trans. The two subtilisins also have different secondary structures, thermostability and substrate specificities. Our results indicate that an identical polypeptide can fold into an altered conformation through a mutated intramolecular chaperone and maintains memory of the folding process. Such a phenomenon, which we term 'protein memory', map be important in investigations of protein folding.			Shinde, UP (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854, USA.							ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; BRYAN PN, 1995, INTRAMOLECULAR CHAPE, P85; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P13909, DOI 10.1021/bi00213a021; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KLIBANOV AM, 1995, NATURE, V374, P596, DOI 10.1038/374596a0; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LEE YC, 1992, FEMS MICROBIOL LETT, V92, P73, DOI 10.1016/0378-1097(92)90544-X; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; LONGSTAFF C, 1990, BIOCHEMISTRY-US, V29, P7339, DOI 10.1021/bi00483a025; MATHEWS BW, 1995, ADV PROTEIN CHEM, V462, P240; RICHO GR, 1994, J BIOL CHEM, V269, P14806; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; RUSSELL AJ, 1988, J BIOL CHEM, V263, P11624; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SILEN JL, 1989, NATURE, V341, P362; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WINTHER JR, 1994, J BIOL CHEM, V269, P7006; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	30	131	136	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					520	522		10.1038/39097	http://dx.doi.org/10.1038/39097			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333245				2022-12-28	WOS:A1997XY90900063
J	Tei, H; Okamura, H; Shigeyoshi, Y; Fukuhara, C; Ozawa, R; Hirose, M; Sakaki, Y				Tei, H; Okamura, H; Shigeyoshi, Y; Fukuhara, C; Ozawa, R; Hirose, M; Sakaki, Y			Circadian oscillation of a mammalian homologue of the Drosophila period gene	NATURE			English	Article							SUPRACHIASMATIC NUCLEUS; CLOCK GENE; MELANOGASTER; BEHAVIOR; PROTEIN; PRODUCT; LESIONS; SYSTEM	Many biochemical, physiological and behavioural processes in organisms ranging from microorganisms to vertebrates exhibit circadian rhythms(1). In Drosophila, the gene period (per) is required for the circadian rhythms of locomotor activity and eclosion behaviour(2). Oscillation in the levels of per mRNA and Period (dPer) protein in the fly brain is thought to be responsible for the rhythmicity(3,4). However, no per homologues in animals other than insects have been identified. Here we identify the human and mouse genes (hPER and mPer, respectively) encoding PAS-domain (PAS, a dimerization domain present in Per, Amt and Sim)-containing polypeptides that aro highly homologous to dPer. Besides this structural resemblance, mPer shows autonomous circadian oscillation in its expression in the suprachiasmatic nucleus, which is the primary circadian pacemaker in the mammalian brain(5,6). Clock, a mammalian clock gene encoding a PAS-containing polypeptide(7,8), has now been cloned: it is likely that the Per homologues dimerize with other molecule(s) such as Clock through PAS-PAS interaction in the circadian clock system.	KOBE UNIV, SCH MED, DEPT ANAT & BRAIN SCI, CHUO KU, KOBE, HYOGO 650, JAPAN; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Kobe University; Scripps Research Institute	Tei, H (corresponding author), UNIV TOKYO, INST MED SCI, CTR HUMAN GENOME, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Okamura, Hitoshi/0000-0002-3013-4881				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Ban Y, 1997, J NEUROSCI, V17, P3920; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; EDMUNDS LN, 1988, CELLULAR MOL BASIS B; GILLETTE MU, 1987, BRAIN RES BULL, V19, P135, DOI 10.1016/0361-9230(87)90176-6; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; ITO T, 1993, ELECTROPHORESIS, V14, P278, DOI 10.1002/elps.1150140149; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sambrook J., 1989, MOL CLONING; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131; ZERR DM, 1990, J NEUROSCI, V10, P2749	27	642	672	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					512	516		10.1038/39086	http://dx.doi.org/10.1038/39086			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333243				2022-12-28	WOS:A1997XY90900061
J	Miller, TE				Miller, TE			Managed care regulation - In the laboratory of the states	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FEE-FOR-SERVICE; NATIONAL SURVEY; MEDICAL-CARE; HEALTH-CARE; PHYSICIANS; PATIENT; PREPAID; QUALITY; PLANS; ARRANGEMENTS	In the wake of failed national health care system reform, the responsibility of crafting public policy to respond to changes in the health care system has fallen largely to state governments. Beginning in 1995, state policymakers focused intensively on managed care regulation, adopting policies on a broad array of issues with important implications for patients, physicians, and the physician-patient relationship. To a surprising degree, the regulatory activity in diverse health care markets across the nation has reflected a shared set of concerns about managed care practices and trends. An evaluation of the impact of these state policies will provide essential information about the most effective role for government in promoting the physician-patient relationship and the rights of patients and health care professionals in the era of managed care.			Miller, TE (corresponding author), CUNY MT SINAI SCH MED, DEPT HLTH POLICY, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.							Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; Blum JD, 1996, AM J LAW MED, V22, P173; Blumenthal D, 1996, HEALTH AFFAIR, V15, P170, DOI 10.1377/hlthaff.15.2.170; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; *COUNC ETH JUD AFF, 1990, COD MED ETH REP COUN, V1, P130; DALLEK G, 1995, CONSUMER PROTECTION; DAVIS K, 1995, HEALTH AFFAIR, V14, P99, DOI 10.1377/hlthaff.14.2.99; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; *FAM US FDN, 1996, HMO CONS RISK STAT R; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FURROW BR, 1995, HLTH LAW, V2, P53; *GEN ACC OFF, 1988, MED PHYS INC PAYM PR; GLASSON J, 1995, JAMA-J AM MED ASSOC, V273, P330, DOI 10.1001/jama.1995.03520280076044; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GORDIS L, 1973, NEW ENGL J MED, V289, P331, DOI 10.1056/NEJM197308162890701; GRAY P, 1996, TIME MAGAZINE   0108, P50; Hellinger FJ, 1996, JAMA-J AM MED ASSOC, V276, P1065, DOI 10.1001/jama.276.13.1065; Hibbard JH, 1996, HEALTH CARE FINANC R, V18, P95; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; HUTCHCRAFT C, 1996, CHICAGO TRIBUNE 1030, pA1; Isaacs SL, 1996, HEALTH AFFAIR, V15, P31, DOI 10.1377/hlthaff.15.4.31; JIMENEZ R, 1996, BOSTON GLOBE    0128; JOFFE MS, 1990, INSIDERS GUIDE MANAG, P42; JORDAN KA, 1996, YALE J REGUL, V13, P1; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; Katz J., 1984, SILENT WORLD DOCTOR; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; Mariner WK, 1996, NEW ENGL J MED, V335, P1986, DOI 10.1056/NEJM199612263352610; McGlynn EA, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.3.7; MCNEIL BJ, 1992, PHYSICIAN PAYMENT RE, V922, P46; Mechanic D, 1996, MILBANK Q, V74, P171, DOI 10.2307/3350245; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MECHANIC D, 1994, INQUIRY-J HEALTH CAR, V31, P124; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; *NAT COMM QUAL ASS, 1995, 2731 NAT COMM QUAL A; OLMOS D, 1996, LOS ANGELES TIM 0414, pA1; OLMOS DR, 1996, LOS ANGELES TIM 0202, pD1; *PC STUD ETH PROBL, 1982, MAKING HLTH CARE DEC; PEAR R, 1996, NY TIMES        0922, P4; Pear Robert, 1996, N Y Times Web, pA12; RODWIN MA, 1995, NEW ENGL J MED, V332, P604, DOI 10.1056/NEJM199503023320913; RODWIN MA, 1996, HOUSTON LAW REV, V32, P1321; ROSENBLATT RA, 1996, LA TIMES        0907, pA1; SHEAR CL, 1983, MED CARE, V21, P1204, DOI 10.1097/00005650-198312000-00007; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653; TAYLOR M, 1995, CHICAGO TRIBUNE 1119, pC1; TERRY K, 1994, MED EC          0523, P138; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; Weston B, 1996, NEW ENGL J MED, V334, P543, DOI 10.1056/NEJM199602223340818; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; Yelin EH, 1996, JAMA-J AM MED ASSOC, V276, P1048, DOI 10.1001/jama.276.13.1048	56	46	46	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1102	1109		10.1001/jama.278.13.1102	http://dx.doi.org/10.1001/jama.278.13.1102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX303	9315771				2022-12-28	WOS:A1997XX30300036
J	Sagoo, MS; Lagnado, L				Sagoo, MS; Lagnado, L			G-protein deactivation is rate-limiting for shut-off of the phototransduction cascade	NATURE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; LIGHT ADAPTATION; RETINAL RODS; SALAMANDER RODS; CALCIUM-CONCENTRATION; SATURATING FLASHES; RHODOPSIN; KINETICS; TRANSDUCTION	Photoreceptors detect light through a seven-helix receptor (rhodopsin) and heterotrimeric G protein (transducin) coupled to a cyclic GMP phosphodiesterase(1,2). Similar pathways are used to amplify responses to hormones, taste and smell(3-5). The amplification of phototransduction is reduced by a fall in cytoplasmic Ca2+ (refs 6-10), but it is not known how the deactivation of rhodopsin and transducin influence this response and hence the extent and duration of phosphodiesterase activity(11-14). Here we investigate this by recording the electrical response to flashes of light in truncated rod photoreceptors(10). By removing ATP to block the deactivation of rhodopsin by phosphorylation(15), we show that this reaction limits the amplitude of the response and begins within 3.2 s of a flash in a solution containing 1 mu M Ca2+, falling to 0.9 s in a zero-Ca2+ solution. In contrast, the activation and amplitude of the response were unaffected when transducin deactivation by GTP hydrolysis was blocked by replacing GTP with its nonhydrolysable analogue GTP-gamma S-11, demonstrating that there is little GTP hydrolysis occurring over the period in which photoexcited rhodopsin is quenched. The rapid deactivation of rhodopsin is therefore a Ca2+-sensitive step controlling the amplitude of the light response, whereas transducin deactivation is slower and controls recovery.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Sagoo, Mandeep/0000-0003-1530-3824				CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CORSON DW, 1994, VISUAL NEUROSCI, V11, P91, DOI 10.1017/S0952523800011135; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; Gold GH, 1997, NATURE, V385, P677, DOI 10.1038/385677a0; GrayKeller MP, 1996, NEURON, V17, P323, DOI 10.1016/S0896-6273(00)80163-4; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; JONES GJ, 1995, J PHYSIOL-LONDON, V487, P441, DOI 10.1113/jphysiol.1995.sp020891; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; Lyubarsky A, 1996, J GEN PHYSIOL, V107, P19, DOI 10.1085/jgp.107.1.19; Matthews HR, 1996, J PHYSIOL-LONDON, V490, P1; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; Murnick JG, 1996, J PHYSIOL-LONDON, V495, P1; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; Nikonov S. S., 1996, Investigative Ophthalmology and Visual Science, V37, pS5; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; PEPPERBERG DR, 1994, VISUAL NEUROSCI, V11, P53, DOI 10.1017/S095252380001110X; Sagoo Mandeep S., 1997, Investigative Ophthalmology and Visual Science, V38, pS614; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YOUNGER JP, 1992, INVEST OPHTH VIS SCI, V33, P1104	30	69	69	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					392	395		10.1038/38750	http://dx.doi.org/10.1038/38750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311782				2022-12-28	WOS:A1997XX67500055
J	Ford, CA; Millstein, SG; HalpernFelsher, BL; Irwin, CE				Ford, CA; Millstein, SG; HalpernFelsher, BL; Irwin, CE			Influence of physician confidentiality assurances on adolescents' willingness to disclose information and seek future health care - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Adolescents' concerns about privacy in clinical settings decrease their willingness to seek health care for sensitive problems and may inhibit their communication with physicians. Objective.-To investigate the influence of physicians' assurances of confidentiality on adolescents' willingness to disclose information and seek future health care. Design.-Randomized controlled trial. Setting.-Three suburban public high schools in California, Participants.-The 562 participating adolescents represented 92% or students in mandatory classes. Intervention.-After random assignment to 1 of 3 groups, the adolescents listened to a standardized audiotape depiction of an office visit during which they heard a physician who assured unconditional confidentiality, a physician who assured conditional confidentiality, or a physician who did not mention confidentiality. Main Outcome Measures.-Adolescents' willingness to disclose general information, willingness to disclose information about sensitive topics, intended honesty, and likelihood of return visits to the physician depicted in the scenario were assessed by anonymous written questionnaire. Results.-Assurances of confidentiality increased the number or adolescents willing to disclose sensitive information about sexuality, substance use, and mental health from 39% (68/175) to 46.5% (178/383) (beta=.10, P=.02) and increased the number willing to seek future health care from 53% (93/175) to 67% (259/386) (beta=.17, P<.001). When comparing the unconditional with the conditional groups, assurances of unconditional confidentiality increased the number of adolescents willing to return for a future visit by 10 percentage points, from 62% (122/196) to 72% (137/190) (beta=.14, P=.001). Conclusions.-Adolescents are more willing to communicate with and seek health care from physicians who assure confidentiality. Further investigation is needed to identify a confidentiality assurance statement that explains the legal and ethical limitations of confidentiality without decreasing adolescents' likelihood of seeking future health care for routine and nonreportable sensitive health concerns.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,DIV ADOLESCENT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								ADLER NE, 1990, J PEDIATR-US, V116, P463, DOI 10.1016/S0022-3476(05)82845-8; *AM AC PED, 1997, GUID HLTH SUP, V3; *AM MED ASS, 1994, AMA GUID AD PREV SER; CHAMIE M, 1982, FAM PLANN PERSPECT, V14, P126, DOI 10.2307/2134710; CHENG TL, 1993, JAMA-J AM MED ASSOC, V269, P1404, DOI 10.1001/jama.269.11.1404; *COUNC SCI AFF AM, 1993, JAMA-J AM MED ASSOC, V269, P1420; ENGLISH A, 1990, MED CLIN N AM, P1097; ENGLISH A, 1996, STATE MINOR CONSENT; Ford CA, 1997, ARCH PEDIAT ADOL MED, V151, P505, DOI 10.1001/archpedi.1997.02170420075013; GANS JE, 1993, POLICY COMPENDIUM CO; Green M, 1994, BRIGHT FUTURES GUIDE; Hulley S. B., 1988, DESIGNING CLIN RES; LEVENBERG P, 1995, GUIDELINES ADOLESCEN; MALUS M, 1987, J FAM PRACTICE, V25, P159; MARKS A, 1983, J PEDIATR-US, V102, P456, DOI 10.1016/S0022-3476(83)80677-5; MILLER LC, 1983, J PERS SOC PSYCHOL, V44, P1234, DOI 10.1037/0022-3514.44.6.1234; OZER EM, 1997, AM ADOLESCENTS ARE T; Purcell JS, 1997, J ADOLESCENT HEALTH, V20, P300, DOI 10.1016/S1054-139X(96)00284-4; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; ZABIN LS, 1991, J ADOLESCENT HEALTH, V12, P225, DOI 10.1016/0197-0070(91)90015-E	20	315	316	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1029	1034		10.1001/jama.278.12.1029	http://dx.doi.org/10.1001/jama.278.12.1029			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX012	9307357				2022-12-28	WOS:A1997XX01200040
J	Cappuccio, FP; Markandu, ND; Carney, C; Sagnella, GA; MacGregor, GA				Cappuccio, FP; Markandu, ND; Carney, C; Sagnella, GA; MacGregor, GA			Double-blind randomised trial of modest salt restriction in older people	LANCET			English	Article							BLOOD-PRESSURE; SODIUM RESTRICTION; FOOD-INDUSTRY; HYPERTENSION; REDUCTION; PREVENTION; TASTE	Background Stroke is directly related to blood pressure and treatment trials in older hypertensive individuals show a reduction in strokes. However, the majority of strokes occur in normotensive individuals in whom no attempt is made to lower blood pressure. We compared the effects of modest salt restriction on blood pressure in older hypertensive and normotensive people. Methods 47 untreated elderly people (24 men, age range 60-78 years; blood-pressure range 123-205 mm Hg systolic and 64-112 mm Hg diastolic) completed a 2-month double-blind randomised placebo-controlled crossover study of modest salt restriction with slow sodium and placebo to give a salt intake of either 10 g (equivalent to the normal amount for the UK population) or 5 g. Findings On the normal salt intake for the UK population, supine blood pressure was 163/90 (SD 21/10) mm Hg with urinary sodium excretion of 177 (49) mmol/day. With modest sodium restriction, blood pressure fell to 156/87 (22/9) mm Hg (p<0.001/0.004) with a urinary sodium excretion of 94 (50) mmol/day. A reduction in sodium intake of 83 mmol/day was associated with a reduction of 7.2/3.2 mm Hg. There was no significant difference in the blood-pressure fall between 18 normotensive and 29 hypertensive participants (8.2/3.9 vs 6.6/2.7 mm Hg). Interpretation A modest reduction in salt intake leads to a fall in blood pressure in both normotensive and hypertensive older people similar to that in outcome trials of thiazide-based treatment. Since the majority of strokes in older people occur below the current definition of hypertension, our results have important implications for the prevention of stroke.			Cappuccio, FP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT MED,BLOOD PRESSURE UNIT,LONDON SW17 0RE,ENGLAND.		Cappuccio, Francesco/D-3028-2009	Cappuccio, Francesco Paolo/0000-0002-7842-5493				ADAMS SO, 1995, J AM DIET ASSOC, V95, P447, DOI 10.1016/S0002-8223(95)00120-4; APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1162, DOI 10.1001/archinte.152.6.1162; BEAUCHAMP GK, 1983, ANN INTERN MED, V98, P763, DOI 10.7326/0003-4819-98-5-763; BERTINO M, 1982, AM J CLIN NUTR, V36, P1134, DOI 10.1093/ajcn/36.6.1134; Cappuccio FP, 1996, AM J CLIN NUTR, V63, P787; CAPPUCCIO FP, 1985, J HYPERTENS, V3, P243, DOI 10.1097/00004872-198506000-00008; FOTHERBY MD, 1993, J HYPERTENS, V11, P657, DOI 10.1097/00004872-199306000-00010; GELEIJNSE JM, 1994, BRIT MED J, V309, P436, DOI 10.1136/bmj.309.6952.436; Godlee F, 1996, BRIT MED J, V312, P1239, DOI 10.1136/bmj.312.7041.1239; GREENFIELD H, 1984, HUM NUTR-APPL NUTR, V38A, P203; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; KUMANYIKA SK, 1993, HYPERTENSION, V22, P502, DOI 10.1161/01.HYP.22.4.502; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; MacGregor GA, 1996, BRIT MED J, V312, P1287, DOI 10.1136/bmj.312.7041.1287; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; *PROSP STUD COLL, 1995, LANCET, V346, P1647; SWALES JD, 1995, GROWTH MED SCI LESSO, P1; SWALES JD, 1994, J HYPERTENS S10, V12, pS5; WHETON PK, 1996, CIRCULATION S1, V94, P78	20	128	130	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					850	854		10.1016/S0140-6736(97)02264-2	http://dx.doi.org/10.1016/S0140-6736(97)02264-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310603				2022-12-28	WOS:A1997XX40100011
J	Langman, MJS				Langman, MJS			Homoeopathy trials: reason for good ones but are they warranted?	LANCET			English	Editorial Material											Langman, MJS (corresponding author), UNIV BIRMINGHAM,SCH MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.								0	29	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					825	825		10.1016/S0140-6736(05)62025-9	http://dx.doi.org/10.1016/S0140-6736(05)62025-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310595				2022-12-28	WOS:A1997XX40100003
J	Neuberger, J				Neuberger, J			Primary biliary cirrhosis	LANCET			English	Article							URSODEOXYCHOLIC ACID; LIVER-TRANSPLANTATION; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; DISEASE; MODEL; AUTOANTIBODIES; AUTOIMMUNITY; POLYPEPTIDE; PROGNOSIS; SURVIVAL				Neuberger, J (corresponding author), QUEEN ELIZABETH HOSP, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND.		Neuberger, James/ABG-3010-2020					BACH N, 1994, J HEPATOL, V20, P698, DOI 10.1016/S0168-8278(05)80137-0; Bandin O, 1996, HEPATOLOGY, V23, P1020; Beuers U, 1997, FALK SYMP, V91B, P230; Carithers BL, 1996, GASTROENTEROLOGY, V110, pA1163; CHRISTENSEN E, 1980, GASTROENTEROLOGY, V78, P236; CHRISTENSEN E, 1993, GASTROENTEROLOGY, V105, P1865, DOI 10.1016/0016-5085(93)91086-W; CULP KS, 1982, MAYO CLIN PROC, V57, P365; Czaja AJ, 1996, ANN INTERN MED, V125, P588, DOI 10.7326/0003-4819-125-7-199610010-00009; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; Garrido MC, 1996, J CLIN PATHOL, V49, P556, DOI 10.1136/jcp.49.7.556; GERSHWIN ME, 1991, GASTROENTEROLOGY, V100, P822, DOI 10.1016/0016-5085(91)80033-6; HEATHCOTE EJ, 1997, GUT, V30, P440; HEATHCOTE EJ, 1996, GASTROENTEROLOGY, V110, pA1082; Invernizzi P, 1997, HEPATOLOGY, V25, P1090, DOI 10.1002/hep.510250507; Jones DEJ, 1996, CLIN SCI, V91, P551, DOI 10.1042/cs0910551; Jones EA, 1996, GUT, V38, P644, DOI 10.1136/gut.38.5.644; JOPLIN R, 1991, HEPATOLOGY, V14, P442, DOI 10.1016/0270-9139(91)90181-T; Kaplan MM, 1996, NEW ENGL J MED, V335, P1570, DOI 10.1056/NEJM199611213352107; Kilmurry MR, 1996, HEPATOLOGY, V23, P1148; KRAMS SM, 1989, HEPATOLOGY, V9, P411, DOI 10.1002/hep.1840090311; Leung PSC, 1996, J AUTOIMMUN, V9, P119, DOI 10.1006/jaut.1996.0015; LUDWIG J, 1987, SEMIN LIVER DIS, V7, P293, DOI 10.1055/s-2008-1040584; MADDREY WC, 1983, NEW ENGL J MED, V308, P588, DOI 10.1056/NEJM198303103081011; MAHL TC, 1994, J HEPATOL, V20, P707, DOI 10.1016/S0168-8278(05)80139-4; MANNS MP, 1994, GASTROENTEROLOGY, V106, P1676, DOI 10.1016/0016-5085(94)90427-8; MECDINA J, 1997, HEPATOLOGY, V25, P12; Metcalf JV, 1996, LANCET, V348, P1399, DOI 10.1016/S0140-6736(96)04410-8; Metcalf JV, 1996, BRIT MED J, V312, P1181; MYSZOR M, 1990, Q J MED, V75, P377; Navasa M, 1996, J HEPATOL, V25, P129, DOI 10.1016/S0168-8278(96)80064-X; Neuberger J, 1995, Liver Transpl Surg, V1, P109; NEUBERGER J, IN PRESS AUTOIMMUNE; NICKOWITZ RE, 1994, GASTROENTEROLOGY, V106, P193, DOI 10.1016/S0016-5085(94)95333-3; Pares A., 1997, Journal of Hepatology, V26, P166; Pasha TM, 1996, HEPATOLOGY, V24, P169; Pasha TM, 1996, GASTROENTEROLOGY, V110, pA1290; PATTS K, 1996, AM J GASTROENTEROL, V91, P2314; POTTER BJ, 1980, GASTROENTEROLOGY, V78, P1034; Ricci P, 1997, HEPATOLOGY, V25, P672, DOI 10.1002/hep.510250330; Romics L, 1996, CLIN CHIM ACTA, V255, P165, DOI 10.1016/0009-8981(96)06404-2; ROSEN H, 1995, HEPATOLOGY, V21, P253, DOI 10.1002/hep.1840210138; SHAPIRO JM, 1979, GUT, V20, P137, DOI 10.1136/gut.20.2.137; SORENSEN HT, 1997, J HEPATOL S1, V26, P101; Spengler U, 1997, J HEPATOL, V26, P31, DOI 10.1016/S0168-8278(97)80006-2; SWAIN MG, 1995, HEPATOLOGY, V22, P1560, DOI 10.1002/hep.1840220532; TSUNEYAMA K, 1995, HEPATOLOGY, V22, P1440, DOI 10.1016/0270-9139(95)90150-7; Van Hoogstraten H. J. F., 1997, Journal of Hepatology, V26, P169; VandeWater J, 1996, HEPATOLOGY, V24, P1079; WIESNER RH, 1992, HEPATOLOGY, V16, P1290, DOI 10.1002/hep.1840160527; Xu L., 1997, Journal of Hepatology, V26, P61	50	166	175	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					875	879		10.1016/S0140-6736(97)05419-6	http://dx.doi.org/10.1016/S0140-6736(97)05419-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310614				2022-12-28	WOS:A1997XX40100047
J	Nakajima, T; Uchida, C; Anderson, SF; Lee, CG; Hurwitz, J; Parvin, JD; Montminy, M				Nakajima, T; Uchida, C; Anderson, SF; Lee, CG; Hurwitz, J; Parvin, JD; Montminy, M			RNA helicase a mediates association of CBP with RNA polymerase II	CELL			English	Article							TRANSCRIPTION FACTOR CREB; GENE-TRANSCRIPTION; DOSAGE COMPENSATION; DEPENDENT ACTIVATOR; MOLECULAR-CLONING; MALELESS PROTEIN; COACTIVATOR CBP; BINDING PROTEIN; X-CHROMOSOME; COMPLEX	The coactivator CBP has been proposed to stimulate the expression of certain signal-dependent genes via its association with RNA polymerase II complexes. Here we show that complex formation between CBP and RNA polymerase II requires RNA helicase A (RHA), a nuclear DNA/RNA helicase that is related to the Drosophila male dosage compensation factor mle, In transient transfection assays, RHA was found to cooperate with CBP in mediating target gene activation via the CAMP responsive factor CREB. As a mutation in RHA that compromised its helicase activity correspondingly reduced CREB-dependent transcription, we propose that RHA may induce local changes in chromatin structure that promote engagement of the transcriptional apparatus on signal responsive promoters.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV MOL ONCOL,BOSTON,MA 02115; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Memorial Sloan Kettering Cancer Center			Parvin, Jeffrey D/C-8955-2009	jhangiry, parvin/0000-0003-1415-7212	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037828, R01GM053504, R01GM037828] Funding Source: NIH RePORTER; NCI NIH HHS [CA54418] Funding Source: Medline; NIGMS NIH HHS [GM37828, GM53504] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BHATTACHARYA S, 1996, NATURE, V383, P343; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CG, 1993, J BIOL CHEM, V268, P16822; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parker D, 1996, MOL CELL BIOL, V16, P694; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422	27	455	474	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1107	1112		10.1016/S0092-8674(00)80376-1	http://dx.doi.org/10.1016/S0092-8674(00)80376-1			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323138	Bronze			2022-12-28	WOS:A1997XX76800016
J	Neuberger, MS				Neuberger, MS			Antigen receptor signaling gives lymphocytes a long life	CELL			English	Review											Neuberger, MS (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BAHLER DW, 1992, P NATL ACAD SCI USA, V89, P6770, DOI 10.1073/pnas.89.15.6770; BURNET FM, 1959, CLONAL SELECTION THE; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; MONROE JG, 1989, J EXP MED, V169, P1059, DOI 10.1084/jem.169.3.1059; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865	8	61	61	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					971	973		10.1016/S0092-8674(00)80362-1	http://dx.doi.org/10.1016/S0092-8674(00)80362-1			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323124	Bronze			2022-12-28	WOS:A1997XX76800002
J	Sidrauski, C; Walter, P				Sidrauski, C; Walter, P			The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response	CELL			English	Article							TRANSFER-RNA LIGASE; KAR2 BIP GENE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; 2-5A-DEPENDENT RNASE; YEAST; PATHWAY; OLIGOMERIZATION; PHOSPHORYLATION; INTERFERON	The endoplasmic reticulum (ER) communicates with the nucleus through the unfolded protein response (UPR), which senses accumulation of unfolded proteins in the ER lumen and leads to increased transcription of genes encoding ER-resident chaperones. As a key regulatory step in this signaling pathway, the mRNA encoding the UPR-specific transcription factor Hac1p becomes spliced by a unique mechanism that requires tRNA ligase but not the spliceosome. Splicing is initiated upon activation of Ire1p, a transmembrane kinase that lies in the ER and/or inner nuclear membrane. We show that Ire1p is a bifunctional enzyme: in addition to being a kinase, it is a site-specific endoribonuclease that cleaves HAC1 mRNA specifically at both splice junctions. The addition of purified tRNA ligase completes splicing; we therefore have reconstituted HAC1 mRNA splicing in vitro from purified components.			Sidrauski, C (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; GREER CL, 1986, MOL CELL BIOL, V6, P635, DOI 10.1128/MCB.6.2.635; GREER CL, 1987, MOL CELL BIOL, V7, P76, DOI 10.1128/MCB.7.1.76; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; Moore M., 1993, RNA WORLD, P303; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; STERN S, 1988, METHOD ENZYMOL, V164, P481; SWEET DJ, 1993, CURR BIOL, V3, P622, DOI 10.1016/0960-9822(93)90014-F; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	33	629	660	0	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1031	1039		10.1016/S0092-8674(00)80369-4	http://dx.doi.org/10.1016/S0092-8674(00)80369-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323131	Bronze			2022-12-28	WOS:A1997XX76800009
J	Dokland, T; McKenna, R; Ilag, LL; Bowman, BR; Incardona, NL; Fane, BA; Rossmann, MG				Dokland, T; McKenna, R; Ilag, LL; Bowman, BR; Incardona, NL; Fane, BA; Rossmann, MG			Structure of a viral procapsid with molecular scaffolding	NATURE			English	Article							FUNCTIONAL IMPLICATIONS; ATOMIC-STRUCTURE; BACTERIOPHAGE-PHI-X174; PHI-X174; PROTEIN; VIRUS; PROHEAD; CAPSIDS	The assembly of a macromolecular structure proceeds along an ordered morphogenetic pathway, and is accomplished by the switching of proteins between discrete conformations as they are added to the nascent assembly(1-3). Scaffolding proteins often play a catalytic role in the assembly process(1,2,4), rather like molecular chaperones(5). Although macromolecular assembly processes are fundamental to all biological systems, they have been characterized most thoroughly in viral systems, such as the icosahedral Escherichia coli bacteriophage Phi X174 (refs 6, 7). The Phi X174 virion contains the proteins F, G, H and J(7,8). assembly, two scaffolding proteins B and D are required for formation of a 108S, 360-Angstrom-diameter procapsid from pentameric precursors containing the F, G and H protein(6,9). The procapsid contains 240 copies of protein D, forming an external scaffold, and 60 copies each of the internal scaffolding protein B, the capsid protein F, and the spike protein G(9,10). Maturation involves packaging of DNA and J proteins and loss of protein B, producing a 132S intermediate(6,7). Subsequent removal of the external scaffold yields the mature virion. Both the F and G proteins have the eight- stranded antiparallel beta-sandwich motifs(8,11) common to many plant and animal viruses(12,13). Here we describe the structure of a procapsid-like particle at 3.5-Angstrom resolution, showing how the scaffolding proteins coordinate assembly of the virus by interactions with the F and G proteins, and showing that the F protein undergoes conformational changes during capsid maturation.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA; UNIV ARKANSAS, DEPT BIOL SCI, FAYETTEVILLE, AR 72701 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Tennessee System; University of Tennessee Health Science Center; University of Arkansas System; University of Arkansas Fayetteville				Dokland, Terje/0000-0001-5655-4123				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Casjens S, 1988, BACTERIOPHAGES, P15; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; EKECHUKWU MC, 1995, GENETICS, V140, P1167; EKECHUKWU MC, 1995, J BACTERIOL, V177, P829, DOI 10.1128/jb.177.3.829-830.1995; FANE BA, 1993, GENETICS, V134, P1003; FARBER MB, 1976, J VIROL, V17, P1027, DOI 10.1128/JVI.17.3.1027-1037.1976; HARRISON SC, 1996, FIELDS VIROLOGY, V1, P59; HAYASHI M, 1978, SINGLE STRANDED DNA, P531; Hayashi M., 1988, BACTERIOPHAGES, V2, P1; ILAG LL, 1995, STRUCTURE, V3, P353, DOI 10.1016/S0969-2126(01)00167-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KING J, 1980, BIOL REGUL DEV, V2, P101; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; McKenna R, 1996, J MOL BIOL, V256, P736, DOI 10.1006/jmbi.1996.0121; MCKENNA R, 1994, J MOL BIOL, V237, P517, DOI 10.1006/jmbi.1994.1253; MUKAI R, 1979, P NATL ACAD SCI USA, V76, P4877, DOI 10.1073/pnas.76.10.4877; Oosawa F., 1975, THERMODYNAMICS POLYM; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PRESTON VG, 1994, J GEN VIROL, V75, P2355, DOI 10.1099/0022-1317-75-9-2355; ROSSMANN MG, 1992, J APPL CRYSTALLOGR, V25, P166, DOI 10.1107/S002188989101141X; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530	29	117	125	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					308	313		10.1038/38537	http://dx.doi.org/10.1038/38537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305849				2022-12-28	WOS:A1997XW77200054
J	Aitken, RJ; Nixon, SJ; Ruckley, CV				Aitken, RJ; Nixon, SJ; Ruckley, CV			Lothian Surgical Audit: A 15-year experience of improvement in surgical practice through regional computerised audit	LANCET			English	Review								For the past 15 years, general surgeons in Lothian, UK, have done a computerised audit. Lothian Surgical Audit (LSA) has two components: the first is educational, in the form of a weekly meeting and an annual report; the second is the accurate recording of surgical activity by use of a simple three-digit code. The main message from LSA is that changes in surgical practice typically occur over 3 to 4 years, and require repeated education. Changes attributable to LSA include the establishment of specialist units, improved results after large-bowel surgery, and the demise of outmoded techniques. Audits should have a clear educational commitment, and be carried out long enough to allow for reauditing. The LSA software has been developed at minimal cost and is networked throughout Lothian hospitals. LSA provides clear evidence that regional audit can significantly influence and improve surgical practice. Its success has resulted from its surgeon-driven development, its flexible use in everyday practice, and the confidence it inspires in local surgeons.	ROYAL INFIRM EDINBURGH NHS TRUST,LOTHIAN SURG AUDIT GRP,DEPT SURG,EDINBURGH,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh			Nixon, Sara Jo/L-1369-2014	Nixon, Sara Jo/0000-0003-1179-2851				AITKEN RJ, 1987, CHANGING SURG PRACTI; AITKEN RJ, 1995, LOTHIAN SURG AUDIT A; Allery LA, 1997, BMJ-BRIT MED J, V314, P870; BRADBURY AW, 1994, BRIT J SURG, V81, P373, DOI 10.1002/bjs.1800810316; CHOUDARI CP, 1994, GUT, V35, P608, DOI 10.1136/gut.35.5.608; Crofts TJ, 1997, BRIT MED J, V314, P891; *DEP HLTH, 1989, WORK PAT; Fulton RA, 1996, BRIT MED J, V312, P1103; GRUER R, 1986, LANCET, V1, P23; *LOTH BORD LARG BO, 1995, BRIT J SURG, V82, P888; MARSON LP, 1997, BR J SURG S, V84, P24; Milne A A, 1996, Ann R Coll Surg Engl, V78, P177; *PARL OFF SCI TECH, 1995, MIM ACC SURG; Potter M A, 1996, Ann R Coll Surg Engl, V78, P11; POTTER MA, 1995, ANN R COLL SURG EN S, V4, P191; Raine C, 1996, Ann R Coll Surg Engl, V78, P59; *ROYAL COLL SURG E, 1996, REP NAT CONF ENQ PER, P96; SELLU D, 1996, BRIT MED J, V312, P8; Waghorn A, 1997, BRIT J SURG, V84, P300; WIGMORE SJ, 1995, BRIT J SURG, V82, P27, DOI 10.1002/bjs.1800820110	20	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					800	804		10.1016/S0140-6736(97)01021-0	http://dx.doi.org/10.1016/S0140-6736(97)01021-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9298014				2022-12-28	WOS:A1997XW28200050
J	Stoddart, H; Noah, N				Stoddart, H; Noah, N			Usefulness of screening large numbers of contacts for tuberculosis: questionnaire based review	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT EPIDEMIOL & PUBL HLTH,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	Stoddart, H (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.							CAPEWELL S, 1986, BRIT J DIS CHEST, V80, P37, DOI 10.1016/0007-0971(86)90007-0; *JOINT TUB COMM BR, 1994, THORAX, V49, P1193; SCOTT E, 1990, COMMUNICAB DIS REP, V34, P3; SELBY CD, 1989, RESP MED, V83, P353, DOI 10.1016/S0954-6111(89)80212-4; VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R	5	5	5	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					651	651		10.1136/bmj.315.7109.651	http://dx.doi.org/10.1136/bmj.315.7109.651			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310568	Green Published			2022-12-28	WOS:A1997XW69400021
J	Offermanns, S; Toombs, CF; Hu, YH; Simon, MI				Offermanns, S; Toombs, CF; Hu, YH; Simon, MI			Defective platelet activation in G alpha(q)-deficient mice	NATURE			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C ISOZYMES; G-PROTEINS; THROMBOXANE A(2); BLOOD-PLATELETS; RECEPTORS; EXPRESSION; C-BETA-2; FAMILY	Platelets are small disc-shaped cell fragments which undergo a rapid transformation when they encounter vascular damage. They become more spherical and extrude pseudopodia, their fibrinogen receptors are activated, causing them to aggregate, they release their granule contents, and eventually form a plug which is responsible for primary haemostasis(1). Activation of platelets is also implicated in the pathogenesis of unstable angina, myocardial infarction and stroke(2,3). Here we show that platelets from mice deficient in the alpha-subunit of the heterotrimeric guanine-nucleotide-binding protein G(q) are unresponsive to a variety of physiological platelet activators. As a result, G alpha(q)-deficient mice have increased bleeding times and are protected from collagen and adrenaline-induced thromboembolism. We conclude that G alpha(q), is essential for the signalling processes used by different platelet activators and that it cannot be replaced by G alpha(i) or the beta gamma subunits of the heterotrimeric G proteins. G alpha(q) may thus be a new target for drugs designed to block the activation of platelets.	CALTECH,DIV BIOL 147 75,PASADENA,CA 91125; AMGEN INC,DEPT PHARMACOL,THOUSAND OAKS,CA 91320	California Institute of Technology; Amgen			Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				Banno Y, 1996, J BIOL CHEM, V271, P14989, DOI 10.1074/jbc.271.25.14989; BEARER EL, 1995, CELL MOTIL CYTOSKEL, V30, P50, DOI 10.1002/cm.970300107; BUHL AM, 1995, J BIOL CHEM, V270, P24731; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COLLER BS, 1992, HEART CARDIOVASCULAR, P219; DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOURANI SMO, 1991, PHARMACOL REV, V43, P243; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Johnson GJ, 1996, BIOCHEM J, V318, P1023, DOI 10.1042/bj3181023; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LAWRENCE WH, 1994, J PHARM SCI, V83, P222, DOI 10.1002/jps.2600830222; Lee SB, 1996, BLOOD, V88, P1684; MCMURRAY J, 1994, BMJ-BRIT MED J, V309, P1343, DOI 10.1136/bmj.309.6965.1343; MILLIGAN G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P208, DOI 10.1016/0167-4889(93)90143-D; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, UNPUB NEURON; PACKHAM MA, 1994, CAN J PHYSIOL PHARM, V72, P278, DOI 10.1139/y94-043; PARK DG, 1993, J BIOL CHEM, V268, P4573; ROSENBLUM WI, 1983, THROMB RES, V30, P347, DOI 10.1016/0049-3848(83)90226-8; SAGE SO, 1995, PLATELETS PRACTICAL, P67; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808	30	450	460	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					183	186		10.1038/38284	http://dx.doi.org/10.1038/38284			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296496				2022-12-28	WOS:A1997XV75700049
J	Jigjinni, VS; Stevenson, J; Flemming, AFS				Jigjinni, VS; Stevenson, J; Flemming, AFS			The beefburger injury: a retrospective survey	BRITISH MEDICAL JOURNAL			English	Article									UNIV ST ANDREWS,ESSEX CM12 0HB,ENGLAND; WITHINGTON HOSP,MANCHESTER M20 2LR,LANCS,ENGLAND; CROSSHOUSE HOSP,DEPT ACCID & EMERGENCY,KILMARNOCK KA2 0BE,SCOTLAND	University of St Andrews								ANGERMANN P, 1993, J HAND SURG B, V18, P624; CLARKSON PA, 1985, LETT MATH PHYS, V10, P297, DOI 10.1007/BF00420570; EVANS DM, 1991, J HAND SURG-BRIT EUR, V16B, P239, DOI 10.1016/0266-7681(91)90045-P; JOHNS AM, 1981, INJURY, V12, P417, DOI 10.1016/0020-1383(81)90015-2; 1986, LANCET, V2, P1076	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					580	580						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV717	9302955				2022-12-28	WOS:A1997XV71700025
J	Timms, P; Balazs, J				Timms, P; Balazs, J			ABC of mental health - Mental health on the margins	BRITISH MEDICAL JOURNAL			English	Review																		Craig T., 1996, BAD START LONGITUDIN; CRAIG TKJ, 1995, HOMELESS MENTALLY IL; Gill B, 1996, OPCS SURVEYS PSYCHIA; HAIGH R, 1990, BMJ-BRIT MED J, V301, P848, DOI 10.1136/bmj.301.6756.848; Lawrenson F, 1997, BRIT MED J, V314, P1064, DOI 10.1136/bmj.314.7087.1064; SHINER P, 1991, HLTH SERVICES J 1107, P21; WILLIAMS D, 1995, PEOPLE WHO ARE HOMEL	7	8	8	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					536	539		10.1136/bmj.315.7107.536	http://dx.doi.org/10.1136/bmj.315.7107.536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU506	9329311	Green Published			2022-12-28	WOS:A1997XU50600026
J	Izbicki, JR; Hosch, SB; Pichlmeier, U; Rehders, A; Busch, C; Niendorf, A; Passlick, B; Broelsch, CE; Pantel, K				Izbicki, JR; Hosch, SB; Pichlmeier, U; Rehders, A; Busch, C; Niendorf, A; Passlick, B; Broelsch, CE; Pantel, K			Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; BONE-MARROW; FOLLOW-UP; CARCINOMA; MICROMETASTASES; METASTASES; LUNG; ADENOCARCINOMA; ANTIBODIES; TISSUES	Background Current methods of disease staging often fail to detect small numbers of tumor cells in lymph nodes, Metastatic relapse may arise from these few cells. Methods We studied 1308 lymph nodes from 68 patients with esophageal cancer without overt metastases who had undergone radical en bloc esophagectomy. A total of 399 lymph nodes obtained from 68 patients were found to be free of tumor by routine histopathological analysis and were studied further for isolated tumor cells by immunohistochemical analysis with the monoclonal anti-epithelial-cell antibody Ber-EP4. This antibody did not stain lymph nodes from 24 control patients without carcinoma. Results Of the 399 ''tumor free'' lymph nodes, 67 (17 percent), obtained from 42 of the 68 patients, contained Ber-EP4-positive tumor cells. Fifteen of 30 patients who were considered free of lymph-node metastases by histopathological analysis had such cells in their lymph nodes, and 5 of the 15 had small primary tumors. Ber-EP4-positive cells found in ''tumor free'' nodes were independently predictive of significantly reduced relapse-free survival (P = 0.008) and overall survival (P=0.03). They predicted relapse both in patients without nodal metastases (P=0.01) and in those with regional lymph-node involvement (P=0.007). All 12 patients whose lymph nodes were negative on both histopathological and immunohistochemical analysis and who were available for follow-up survived without recurrence. The presence of micrometastatic tumor cells in bone marrow had no additional prognostic value. Conclusions Immunohistochemical examination of lymph nodes may improve the pathological staging of esophageal cancer. (C) 1997, Massachusetts Medical Society.	UNIV HAMBURG,ABT MATH MED,HAMBURG,GERMANY; UNIV HAMBURG,INST PATHOL,D-2000 HAMBURG,GERMANY; UNIV MUNICH,INST IMMUNOL,D-8000 MUNICH,GERMANY	University of Hamburg; University of Hamburg; University of Munich	Izbicki, JR (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,ALLGEMEINCHIRURG ABT,MARTINISTR 52,D-20246 HAMBURG,GERMANY.							ABE S, 1990, J THORAC CARDIOV SUR, V100, P287; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BUSSOLATI G, 1986, BRIT J CANCER, V54, P631, DOI 10.1038/bjc.1986.219; BYRNE J, 1987, EUR J SURG ONCOL, V13, P409; CASSON AG, 1994, ANN THORAC SURG, V58, P1569, DOI 10.1016/0003-4975(94)91986-0; CHEN MYM, 1995, J CLIN GASTROENTEROL, V21, P254, DOI 10.1097/00004836-199510000-00019; CHEN ZL, 1993, JNCI-J NATL CANCER I, V85, P493, DOI 10.1093/jnci/85.6.493; COX DR, 1972, J R STAT SOC B, V34, P187; Daly JM, 1996, CANCER, V78, P1820, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; EARLAM R, 1988, DIS ESOPHAGUS, P11; GOLDMINC M, 1993, BRIT J SURG, V80, P367, DOI 10.1002/bjs.1800800335; HENNESSY TPJ, 1994, WORLD J SURG, V18, P367, DOI 10.1007/BF00316816; Hermanek P, 1992, TNM CLASSIFICATION M; *INT LUDW BREAST C, 1990, LANCET, V335, P1565; Jauch K W, 1992, Eur J Surg Oncol, V18, P553; KASPER M, 1987, EUR J CANCER CLIN ON, V23, P137, DOI 10.1016/0277-5379(87)90007-1; LATZA U, 1990, J CLIN PATHOL, V43, P213, DOI 10.1136/jcp.43.3.213; LERUT T, 1992, ANN SURG, V216, P583, DOI 10.1097/00000658-199211000-00010; LERUT TE, 1994, WORLD J SURG, V18, P379, DOI 10.1007/BF00316818; MARTINI N, 1983, ANN SURG, V198, P386, DOI 10.1097/00000658-198309000-00015; MILLIKAN KW, 1995, ARCH SURG-CHICAGO, V130, P617; MOMBURG F, 1987, CANCER RES, V47, P2883; MORITA M, 1994, SURGERY, V116, P1; OSULLIVAN GC, 1995, GASTROENTEROLOGY, V109, P1535, DOI 10.1016/0016-5085(95)90641-X; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; RAYMOND WA, 1989, PATHOLOGY, V21, P11, DOI 10.3109/00313028909059522; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SIEWERT JR, 1992, CHIRURG, V63, P693; Thorban S, 1996, JNCI-J NATL CANCER I, V88, P1222, DOI 10.1093/jnci/88.17.1222; VOGEL SB, 1995, ANN SURG, V221, P685, DOI 10.1097/00000658-199506000-00008; WATANABE H, 1992, CHIRURG, V63, P689	34	306	333	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1188	1194		10.1056/NEJM199710233371702	http://dx.doi.org/10.1056/NEJM199710233371702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337377	Bronze			2022-12-28	WOS:A1997YB71800002
J	WyssCoray, T; Masliah, E; Mallory, M; McConlogue, L; JohnsonWood, K; Lin, C; Mucke, L				WyssCoray, T; Masliah, E; Mallory, M; McConlogue, L; JohnsonWood, K; Lin, C; Mucke, L			Amyloidogenic role of cytokine TGF-beta 1 in transgenic mice and in Alzheimer's disease	NATURE			English	Article							GROWTH-FACTOR-BETA; E EPSILON-4 ALLELE; APOLIPOPROTEIN-E; EXTRACELLULAR-MATRIX; PRECURSOR PROTEIN; HEAD-INJURY; ANGIOPATHY; PLAQUES; DEPOSITION; BRAINS	Deposition of amyloid-beta peptide in the central nervous system is a hallmark of Alzheimer's disease and a possible cause of neurodegeneration(1-3). The factors that initiate or promote deposition of amyloid-beta peptide are not known. The transforming growth factor TGF-beta 1 plays a central role in the response of the brain to injury(4,5), and increased TGF-beta 1 has been found in the central nervous system of patients with Alzheimer's disease(6-8). Here we report that TGF-beta 1 induces amyloid-beta deposition in cerebral blood vessels and meninges of aged transgenic mice overexpressing this cytokine from astrocytes. Co-expression of TGF-beta 1 in transgenic mice overexpressing amyloid-precursor protein, which develop Alzheimer's like patholog(9-11), accelerated the deposition of amyloid-beta peptide. More TGF-beta 1 messenger RNA was present in post-mortem brain tissue of Alzheimer's patients than in controls, the levels correlating strongly with amyloid-beta deposition in the damaged cerebral blood vessels of patients with cerebral amyloid angiopathy, These results indicate that overexpression of TGF-beta 1 may initiate or promote amyloidogenesis in Alzheimer's disease and in experimental models and so may be a risk factor for developing Alzheimer's disease.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,NEUROSCI PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego	WyssCoray, T (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE MOL NEUROBIOL PROGRAM,SAN FRANCISCO,CA 94141, USA.		Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831; Mucke, Lennart/0000-0001-6256-9559				CHAO CC, 1994, CLIN DIAGN LAB IMMUN, V1, P109, DOI 10.1128/CDLI.1.1.109-110.1994; FILLIT H, 1995, LAB INVEST, V72, P249; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAAN J, 1994, DEMENTIA, V5, P210, DOI 10.1159/000106725; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; ITOH Y, 1993, J NEUROL SCI, V116, P135, DOI 10.1016/0022-510X(93)90317-R; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; PERESS NS, 1995, J NEUROPATH EXP NEUR, V54, P802, DOI 10.1097/00005072-199511000-00007; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Terry Robert D., 1994, P179; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WYSSCORAY T, 1995, AM J PATHOL, V147, P53	30	337	353	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					603	606		10.1038/39321	http://dx.doi.org/10.1038/39321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335500				2022-12-28	WOS:A1997YA00800060
J	Davidson, RC; Lewis, EL				Davidson, RC; Lewis, EL			Affirmative action and other special consideration admissions at the University of California, Davis, School of Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRADITIONAL PREDICTORS; PERFORMANCE	Context.-The use of race as a criterion for admission to medical schools and other professional schools has become increasingly controversial. This study documents the experience of students at one medical school, admitted through a special admissions process that included race as one consideration. Objective.-To examine the medical school, postgraduate training, and career experiences of students admitted by a special consideration admission program that included traditional affirmative action admissions. Design.-Twenty-year, retrospective, matched-cohort study. Setting.-A public medical school, Study Population.-All affirmative action and other special consideration admissions between 1968 and 1987 (20 years). Main Outcome Measures.-Academic progress, national board examination scores, graduation, residency evaluations, and practice characteristics. Results.-During the study period, 20% of students were special consideration admissions (range, 10%-45% per year). Of special consideration admissions, 53.5% were minority students, while 19% of regular admissions were minority students. When only underrepresented minority groups are analyzed, 42.7% of special consideration admissions and 4.0% of regular admissions were minorities. Of special consideration admissions, 94% graduated vs 97% of regular admissions. Regular admission students were more likely to receive honors or an A grade on core basic and clinical science courses. There was no difference in failure rates of core courses. Regular admission students had higher scores on Parts I and II of the National Board of Medical Examiners examination, and special consideration students were more likely to repeat the examination to receive a passing grade. Following graduation, the experience of the special consideration admission students was very similar to that of regular admission students. There was no difference in completion of residency training or evaluation of performance by residency directors. Both populations selected primary care disciplines at the same rate. The practice characteristics of the 2 populations were remarkably similar. Conclusions.-Criteria other than undergraduate grade point average and Medical College Admission Test scores can be used in predicting success in medical school. An admissions process that allows for ethnicity and other special characteristics to be used heavily in admission decisions yields powerful effects on the diversity of the student population and shows no evidence of diluting the quality of the graduates.	UNIV CALIF DAVIS,CTR HLTH SERV RES PRIMARY CARE,SACRAMENTO,CA 95817; UNIV CALIF DAVIS,OFF ASSOCIATE DEAN STUDENT AFFAIRS,SACRAMENTO,CA 95817; UNIV CALIF DAVIS,SCH MED,DEPT UROL,SACRAMENTO,CA 95817	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Davidson, RC (corresponding author), UNIV CALIF DAVIS,MED CTR,DEPT FAMILY & COMMUNITY MED,2221 STOCKTON BLVD,PCC2124,SACRAMENTO,CA 95817, USA.							*ASS AM MED COLL, 1992, AM MED ED I PROGR IS, P9; *COUNC GRAD MED ED, 1990, DHHS PUBL; DAVIDSON RC, 1987, WESTERN J MED, V146, P114; HALL FR, 1991, ACAD MED, V67, P121; HALL ML, 1995, ACAD MED, V70, P230, DOI 10.1097/00001888-199503000-00015; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; MELECA CB, 1995, ACAD MED, V70, P59, DOI 10.1097/00001888-199501000-00015; MITCHELL KJ, 1990, ACAD MED, V65, P149, DOI 10.1097/00001888-199003000-00005; MOY E, 1995, JAMA-J AM MED ASSOC, V273, P1515, DOI 10.1001/jama.273.19.1515	9	79	80	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1153	1158		10.1001/jama.278.14.1153	http://dx.doi.org/10.1001/jama.278.14.1153			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326474				2022-12-28	WOS:A1997XY42200032
J	Cox, GA; Lutz, CM; Yang, CL; Biemesderfer, D; Bronson, RT; Fu, A; Aronson, PS; Noebels, JL; Frankel, WN				Cox, GA; Lutz, CM; Yang, CL; Biemesderfer, D; Bronson, RT; Fu, A; Aronson, PS; Noebels, JL; Frankel, WN			Sodium/hydrogen exchanger gene defect in slow-wave epilepsy mutant mice	CELL			English	Article							RAT NA/H EXCHANGER; NA+/H+ ANTIPORTER; MOLECULAR-CLONING; ABSENCE SEIZURES; PH REGULATION; MOUSE; EXPRESSION; ISOFORM; NHE-1; CELLS	The ''housekeeping'' sodium/hydrogen exchanger, NHE1, mediates the electroneutral 1:1 exchange of Na+ and H+ across the plasma membrane. NHE1 is ubiquitous and is studied extensively for regulation of pH(i), cell volume, and response to growth factors. We describe a spontaneous mouse mutant, slow-wave epilepsy, (swe), with a neurological syndrome including ataxia and a unique epilepsy phenotype consisting of 3/sec absence and tonic-clonic seizures. swe was fine-mapped on Chromosome 4 and identified as a null allele of Nhe1. Mutants show selective neuronal death in the cerebellum and brainstem but otherwise are healthy. This first example of a disease-causing mutation in an Nhe gene provides a new tool for studying the delicate balance of neuroexcitability and cell survival within the CNS.	JACKSON LAB, BAR HARBOR, ME 04609 USA; YALE UNIV, SCH MED, NEW HAVEN, CT 06520 USA; TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA; BAYLOR COLL MED, INST MOL GENET, DEPT NEUROL, DIV NEUROSCI, HOUSTON, TX 77030 USA	Jackson Laboratory; Yale University; Tufts University; United States Department of Agriculture (USDA); Baylor College of Medicine				Noebels, Jeffrey/0000-0002-2887-0839	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031348, R01NS033396, R01NS031348] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31348, NS29702, NS33396] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS DJ, 1981, NEUROLOGY, V31, P1175, DOI 10.1212/WNL.31.9.1175; ANDERSON VE, 1991, EPILEPSY RES, P89; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bartolomei F, 1997, EUR NEUROL, V37, P169, DOI 10.1159/000117429; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; DOOSE H, 1973, EPILEPSIA, V14, P57, DOI 10.1111/j.1528-1157.1973.tb03942.x; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANKEL WN, 1995, MAMM GENOME, V6, P830, DOI 10.1007/BF00292431; HILDEBRANDT F, 1991, BIOCHIM BIOPHYS ACTA, V1129, P105, DOI 10.1016/0167-4781(91)90221-7; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; KAUSHIK N, 1994, MAMM GENOME, V5, P688, DOI 10.1007/BF00426074; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LENNOX WG, 1951, JAMA-J AM MED ASSOC, V146, P529, DOI 10.1001/jama.1951.03670060005002; LOISEAU P, 1995, EPILEPSIA, V36, P1182, DOI 10.1111/j.1528-1157.1995.tb01060.x; Ma E, 1997, NEUROSCIENCE, V79, P591, DOI 10.1016/S0306-4522(96)00674-4; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Maricich SM, 1997, J NEUROSCI, V17, P3675; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Neufeld MY, 1996, MOVEMENT DISORD, V11, P283, DOI 10.1002/mds.870110312; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Noebels JL, 1996, NEURON, V16, P241, DOI 10.1016/S0896-6273(00)80042-2; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Ottman R, 1997, AM J HUM GENET, V60, P667; Pasternack M, 1996, NEUROPHARMACOLOGY, V35, P1279, DOI 10.1016/S0028-3908(96)00075-5; PATEL VM, 1987, J CLIN NEUROPHYSIOL, V4, P101, DOI 10.1097/00004691-198704000-00001; Pathak BG, 1996, GENOMICS, V31, P261, DOI 10.1006/geno.1996.0045; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Pizzonia JH, 1996, J NEUROSCI RES, V44, P191, DOI 10.1002/(SICI)1097-4547(19960415)44:2<191::AID-JNR12>3.0.CO;2-9; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; RUTHERFORD PA, 1997, IN PRESS EXP NEPHROL; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHWARTZ WJ, 1978, J COMP NEUROL, V177, P335, DOI 10.1002/cne.901770210; SPRING J, 1994, GENOMICS, V21, P597, DOI 10.1006/geno.1994.1319; STERIADE M, 1995, J NEUROSCI, V15, P623; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Tombaugh GC, 1997, J NEUROPHYSIOL, V77, P639, DOI 10.1152/jn.1997.77.2.639; Trapp S, 1996, J PHYSIOL-LONDON, V496, P695, DOI 10.1113/jphysiol.1996.sp021720; TSE CM, 1992, J BIOL CHEM, V267, P9340; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WYLLIE E, 1993, TREATMENT EPILEPSY P	63	227	230	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	1997	91	1					139	148		10.1016/S0092-8674(01)80016-7	http://dx.doi.org/10.1016/S0092-8674(01)80016-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335342	hybrid			2022-12-28	WOS:A1997XZ80900016
J	Shibata, H; Toyama, K; Shioya, H; Ito, M; Hirota, M; Hasegawa, S; Matsumoto, H; Takano, H; Akiyama, T; Toyoshima, K; Kanamaru, R; Kanegae, Y; Saito, I; Nakamura, Y; Shiba, K; Noda, H				Shibata, H; Toyama, K; Shioya, H; Ito, M; Hirota, M; Hasegawa, S; Matsumoto, H; Takano, H; Akiyama, T; Toyoshima, K; Kanamaru, R; Kanegae, Y; Saito, I; Nakamura, Y; Shiba, K; Noda, H			Rapid colorectal adenoma formation initiated by conditional targeting of the APC gene	SCIENCE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; MOUSE; MUTATION; TUMORS; CELLS; DELETION; PROTEIN; MICE; FAP	Familial adenomatous polyposis coli (FAP) is a disease characterized by the development of multiple colorectal adenomas, and affected individuals carry germline mutations in the APC gene. With the use of a conditional gene targeting system, a mouse model of FAP was created that circumvents the embryonic lethality of Apc deficiency and directs Apc inactivation specifically to the colorectal epithelium, loxP sites were inserted into the introns around Ape exon 14, and the resultant mutant allele (Apc(580S)) was introduced into the mouse germline. Mice homozygous for Apc0(580S) were normal; however, upon infection of the colorectal region with an adenovirus encoding the Cre recombinase, the mice developed adenomas within 4 weeks, The adenomas showed deletion of Apc exon 14, indicating that the loss of Apc function was caused by Cre-loxP-mediated recombination.	INST CANC RES, DEPT CELL BIOL, TOSHIMA KU, TOKYO 170, JAPAN; JAPAN SCI & TECHNOL CORP, CREST, TOKYO, JAPAN; OSAKA UNIV, INST MICROBIAL DIS, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN; CTR ADULT DIS, OSAKA 537, JAPAN; TOHOKU UNIV, INST DEV AGING & CANC, DEPT CLIN ONCOL, SENDAI, MIYAGI 980, JAPAN; UNIV TOKYO, INST MED SCI, MOL GENET LAB, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, MOL MED LAB, MINATO KU, TOKYO 108, JAPAN	Japan Science & Technology Agency (JST); Osaka University; Tohoku University; University of Tokyo; University of Tokyo			hasegawa, sumitaka/A-4020-2012; Shiba, Kiyotaka/I-9588-2014	Shiba, Kiyotaka/0000-0001-6459-0204; Hirota, Morihisa/0000-0001-5682-0911; Shibata, Hiroyuki/0000-0003-3581-3506				BRODY SL, 1994, ANN NY ACAD SCI, V716, P90, DOI 10.1111/j.1749-6632.1994.tb21705.x; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; ICHII S, 1993, ONCOGENE, V8, P2399; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; LUONGO C, 1994, CANCER RES, V54, P5947; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHIBATA H, UNPUB; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TOYAMA K, UNPUB	21	446	456	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					120	123		10.1126/science.278.5335.120	http://dx.doi.org/10.1126/science.278.5335.120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311916				2022-12-28	WOS:A1997XZ12400052
J	Tamura, Y; Peng, P; Liu, K; Daou, M; Srivastava, PK				Tamura, Y; Peng, P; Liu, K; Daou, M; Srivastava, PK			Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations	SCIENCE			English	Article							IN-VIVO; T-CELLS; ANTIGEN; PEPTIDES; SARCOMAS; IMMUNITY; CANCER; GP96	Immunotherapy of mice with preexisting cancers with heat shock protein preparations derived from autologous cancer resulted in retarded progression of the primary cancer, a reduced metastatic load, and prolongation of life-span. Treatment with heat shock protein preparations derived from cancers other than the autologous cancer did not provide significant protection. Spontaneous cancers (lung cancer and melanoma), chemically induced cancers (fibrosarcoma and colon carcinoma), and an ultraviolet radiation-induced spindle cell cacinoma were tested, and the results support the efficacy of autologous cancer-derived heat shock protein-peptide complexes in immunotherapy of cancers without the need to identify specific tumor antigenic epitopes.	UNIV CONNECTICUT, SCH MED, CTR IMMUNOTHERAPY CANC & INFECT DIS, FARMINGTON, CT 06030 USA	University of Connecticut					NCI NIH HHS [CA64394, CA44786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044786, R01CA064394, R01CA044786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; BASOMBRIO MA, 1970, CANCER RES, V30, P2458; BLACHERE NE, 1993, J IMMUNOTHER, V14, P351; BLACHERE NE, IN PRESS J EXP MED; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CHANDAWARKAR RY, UNPUB; DAOU M, 1996, C R I CANC VACCINES; FELDWEG AM, 1995, INT J CANCER, V63, P310, DOI 10.1002/ijc.2910630227; GLOBERSON A, 1964, J NATL CANCER I, V32, P1229, DOI 10.1093/jnci/32.6.1229; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; JANETZKI S, UNPUB; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; MANDELBOIM O, 1995, NAT MED, V1, P1179, DOI 10.1038/nm1195-1179; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; PALLADINO MA, 1987, CANCER RES, V47, P5074; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; Peng P, 1997, J IMMUNOL METHODS, V204, P13, DOI 10.1016/S0022-1759(97)00017-3; RAMARATHINAM L, 1995, J IMMUNOL, V155, P5323; Roman E, 1996, IMMUNOLOGY, V88, P487, DOI 10.1046/j.1365-2567.1996.d01-697.x; Skeen MJ, 1996, J IMMUNOL, V156, P1196; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; Srivastava P K, 1996, Semin Immunol, V8, P295, DOI 10.1006/smim.1996.0038; SRIVASTAVA PK, 1984, INT J CANCER, V33, P417, DOI 10.1002/ijc.2910330321; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1993, ADV CANCER RES, V62, P153, DOI 10.1016/S0065-230X(08)60318-8; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SUGIURA K, 1955, CANCER RES, V15, P38; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Yuui, UNPUB; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391	32	580	739	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					117	120		10.1126/science.278.5335.117	http://dx.doi.org/10.1126/science.278.5335.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311915				2022-12-28	WOS:A1997XZ12400051
J	Ragaz, J; Jackson, SM; Le, N; Plenderleith, IH; Spinelli, JJ; Basco, VE; Wilson, KS; Knowling, MA; Coppin, CML; Paradis, M; Coldman, AJ; Olivotto, IA				Ragaz, J; Jackson, SM; Le, N; Plenderleith, IH; Spinelli, JJ; Basco, VE; Wilson, KS; Knowling, MA; Coppin, CML; Paradis, M; Coldman, AJ; Olivotto, IA			Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; RADIATION-THERAPY; FOLLOW-UP; L-PAM; IRRADIATION; MASTECTOMY; CYCLOPHOSPHAMIDE; MORTALITY; SURGERY; COMBINATION	Background Radiotherapy after mastectomy to treat early breast cancer has been known since the 1940s to reduce rates of local relapse. However, the routine use of postoperative radiotherapy began to decline in the 1980s because it failed to improve overall survival. We prospectively tested the efficacy of combining radiotherapy with chemotherapy, Methods From 1978 through 1986, 318 premenopausal women with node-positive breast cancer were randomly assigned, after modified radical mastectomy, to receive chemotherapy plus radiotherapy or chemotherapy alone. Radiotherapy was given to the chest wall and locoregional lymph nodes between the fourth and fifth cycles of cyclophosphamide, methotrexate, and fluorouracil. Results After 15 years of follow-up, the women assigned to chemotherapy plus radiotherapy had a 33 percent reduction in the rate of recurrence (relative risk, 0.67; 95 percent confidence interval, 0.50 to 0.90) and a 29 percent reduction in mortality from breast cancer (relative risk, 0.71; 95 percent confidence interval, 0.51 to 0.99), as compared with the women treated with chemotherapy alone. Conclusions Radiotherapy combined with chemotherapy after modified radical mastectomy decreases rates of locoregional and systemic relapse and reduces mortality from breast cancer. (C) 1997, Massachusetts Medical Society.	BRITISH COLUMBIA CANC AGCY, DEPT RADIAT ONCOL, VANCOUVER, BC V5Z 4E6, CANADA; BRITISH COLUMBIA CANC AGCY, CANC CONTROL RES UNIT, VANCOUVER, BC V5Z 4E6, CANADA; BRITISH COLUMBIA CANC AGCY, CANC CONTROL STRATEGY PROC, VANCOUVER, BC V5Z 4E6, CANADA; UNIV BRITISH COLUMBIA, DEPT HLTH CARE & EPIDEMIOL, VANCOUVER, BC V6T 1W5, CANADA; ST PAULS HOSP, HLTH RES CTR, VANCOUVER, BC V6Z 1Y6, CANADA	British Columbia Cancer Agency; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia; St. Paul's Hospital; University of Saskatchewan	Ragaz, J (corresponding author), BRITISH COLUMBIA CANC AGCY, DEPT MED ONCOL, 600 W 10TH AVE, VANCOUVER, BC V5Z 4E6, CANADA.		Spinelli, John J./B-6210-2013	Spinelli, John J./0000-0002-9119-3287				ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1996, NEW ENGL J MED, V334, P1003; ARRIAGADA R, 1995, J CLIN ONCOL, V13, P2869, DOI 10.1200/JCO.1995.13.12.2869; BLOMQVIST C, 1992, BRIT J CANCER, V66, P1171, DOI 10.1038/bjc.1992.430; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BUZDAR AU, 1984, CANCER, V53, P384, DOI 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G; CLARK RM, 1992, JNCI-J NATL CANCER I, V84, P683, DOI 10.1093/jnci/84.9.683; COX DR, 1972, J R STAT SOC B, V34, P187; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; DIAB SG, 1997, P ASCO, V16, pA130; DURAND RE, 1986, JNCI-J NATL CANCER I, V77, P247; Fisher B, 1992, J Natl Cancer Inst Monogr, P7; FISHER B, 1975, NEW ENGL J MED, V292, P117, DOI 10.1056/NEJM197501162920301; FU KK, 1985, CANCER, V55, P2123, DOI 10.1002/1097-0142(19850501)55:9+<2123::AID-CNCR2820551415>3.0.CO;2-O; FULLER SA, 1992, RADIOTHER ONCOL, V25, P19, DOI 10.1016/0167-8140(92)90190-6; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; GRIEM KL, 1987, J CLIN ONCOL, V5, P1546, DOI 10.1200/JCO.1987.5.10.1546; HAYBITTLE JL, 1989, BRIT MED J, V298, P1611, DOI 10.1136/bmj.298.6688.1611; HERMANN RE, 1993, SURG GYNECOL OBSTET, V177, P247; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MARKS LB, 1992, INT J RADIAT ONCOL, V23, P1021, DOI 10.1016/0360-3016(92)90908-Z; MCARDLE CS, 1986, BRIT J SURG, V73, P264, DOI 10.1002/bjs.1800730407; MEAKIN JW, 1979, CAN MED ASSOC J, V120, P1221; MUSS HB, 1991, BREAST CANCER RES TR, V19, P77, DOI 10.1007/BF01980937; NISSENMEYER R, 1978, CANCER, V41, P2088, DOI 10.1002/1097-0142(197806)41:6<2088::AID-CNCR2820410604>3.0.CO;2-J; OVERGAARD M, 1994, EJC SUPPL, V30, pS28; RUTQVIST LE, 1992, INT J RADIAT ONCOL, V22, P887, DOI 10.1016/0360-3016(92)90784-F; SCHABEL FM, 1976, AM J ROENTGENOL, V126, P500, DOI 10.2214/ajr.126.3.500; SKIPPER HE, 1970, CANCER CHEMOTH REP 1, V54, P431; STJERNSWARD J, 1977, INT J RADIAT ONCOL, V2, P1171, DOI 10.1016/0360-3016(77)90128-6; TUBIANA M, 1985, CANCER, V55, P2131, DOI 10.1002/1097-0142(19850501)55:9+<2131::AID-CNCR2820551416>3.0.CO;2-Q; VELEZGARCIA E, 1992, EUR J CANCER, V28A, P1833, DOI 10.1016/0959-8049(92)90015-T; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; VOKES, 1990, J CLIN ONCOL, V8, P1447, DOI 10.1200/JCO.1990.8.8.1447	34	1330	1359	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					956	962		10.1056/NEJM199710023371402	http://dx.doi.org/10.1056/NEJM199710023371402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309100				2022-12-28	WOS:A1997XY42300002
J	Gershon, D				Gershon, D			Bioinformatics in a post-genomics age	NATURE			English	Article																			0	12	13	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					417	418		10.1038/38796	http://dx.doi.org/10.1038/38796			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9324648				2022-12-28	WOS:A1997XX67500065
J	Steinbach, OC; Wolffe, AP; Rupp, RAW				Steinbach, OC; Wolffe, AP; Rupp, RAW			Somatic linker histones cause loss of mesodermal competence in Xenopus	NATURE			English	Article							GENE-TRANSCRIPTION; MYOD EXPRESSION; EARLY RESPONSE; IN-VIVO; EMBRYOS; INDUCTION; LAEVIS; PROTEIN; CELLS; EMBRYOGENESIS	In Xenopus, cells from the animal hemisphere are competent to form mesodermal tissues from the morula through to the blastula stage(1). Loss of mesodermal competence at early gastrula is programmed cell-autonomously, and occurs even in single cells at the appropriate stage(2). To determine the mechanism by which this occurs, we have been investigating a concomitant, global change in expression of H1 linker histone subtypes. H1 histones are usually considered to be general repressors of transcription(3), but in Xenopus they are increasingly thought to have selective functions in transcriptional regulation(4-6). Xenopus eggs and embryos at stages before the midblastula transition(7) are deficient in histone H1 protein, but contain an oocyte-specific variant called histone B4 or H1M. After the midblastula transition, histone B4 is progressively substituted by three somatic histone H1 variants, and replacement is complete by early neurula(8,9). Here we report that accumulation of somatic H1 protein is rate limiting for the loss of mesodermal competence. This involves selective transcriptional silencing of regulatory genes required for mesodermal differentiation pathways, like muscle, by somatic, but not maternal, H1 protein.	MAX PLANCK GESELL, FRIEDRICH MIESCHER LAB, D-72076 TUBINGEN, GERMANY; NICHHD, MOL EMBRYOL LAB, NIH, BETHESDA, MD 20892 USA	Eberhard Karls University of Tubingen; Max Planck Society; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				rupp, ralph/0000-0002-8068-9957				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1987, DEVELOPMENT, V99, P527; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; DWORKINRASTL E, 1994, DEV BIOL, V161, P425, DOI 10.1006/dbio.1994.1042; FRANK D, 1991, DEVELOPMENT, V113, P1387; GRAINGER RM, 1989, P NATL ACAD SCI USA, V86, P1900, DOI 10.1073/pnas.86.6.1900; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JONES EA, 1987, DEVELOPMENT, V101, P557; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Patterton D, 1996, DEV BIOL, V173, P2, DOI 10.1006/dbio.1996.0002; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SMITH JC, 1995, CURR OPIN CELL BIOL, V7, P856, DOI 10.1016/0955-0674(95)80070-0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; SYMES K, 1987, DEVELOPMENT, V101, P339; TSUDA T, 1986, FEBS LETT, V208, P39, DOI 10.1016/0014-5793(86)81527-7	29	158	163	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					395	399		10.1038/38755	http://dx.doi.org/10.1038/38755			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311783				2022-12-28	WOS:A1997XX67500056
J	Vainio, S; Muller, U				Vainio, S; Muller, U			Inductive tissue interactions, cell signaling, and the control of kidney organogenesis	CELL			English	Review							MESENCHYME; MORPHOGENESIS; PROTEOGLYCAN; EXPRESSION; GROWTH		UNIV OULU,DEPT BIOCHEM,FIN-90570 OULU,FINLAND; FRIEDRICH MIESCHER INST,CH-4058 BASEL,SWITZERLAND	Finland National Institute for Health & Welfare; University of Oulu; Friedrich Miescher Institute for Biomedical Research	Vainio, S (corresponding author), UNIV OULU,BIOCTR,FIN-90570 OULU,FINLAND.			Vainio, Seppo/0000-0001-9319-3566				Binari RC, 1997, DEVELOPMENT, V124, P2623; DAVIES J, 1995, DEVELOPMENT, V121, P1507; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Karavanova ID, 1996, DEVELOPMENT, V122, P4159; Kispert A, 1996, DEVELOPMENT, V122, P3627; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Liu ZZ, 1996, DEV BIOL, V178, P133, DOI 10.1006/dbio.1996.0204; Miyamoto N, 1997, DEVELOPMENT, V124, P1653; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; Robertson K, 1997, TRENDS GENET, V13, P1, DOI 10.1016/S0168-9525(96)30113-3; Saxen L., 1987, ORGANOGENESIS KIDNEY; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SPEMANN H, 1901, ARCH ENTW MECH ORG, V12, P244; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Torres M, 1995, DEVELOPMENT, V121, P4057; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021	19	108	111	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					975	978		10.1016/S0092-8674(00)80363-3	http://dx.doi.org/10.1016/S0092-8674(00)80363-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323125	Bronze			2022-12-28	WOS:A1997XX76800003
J	Cohen, LG; Celnik, P; PascualLeone, A; Corwell, B; Faiz, L; Dambrosia, J; Honda, M; Sadato, N; Gerloff, C; Catala, MD; Hallett, M				Cohen, LG; Celnik, P; PascualLeone, A; Corwell, B; Faiz, L; Dambrosia, J; Honda, M; Sadato, N; Gerloff, C; Catala, MD; Hallett, M			Functional relevance of cross-modal plasticity in blind humans	NATURE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; VISUAL-CORTEX; OCCIPITAL CORTEX; COIL SUPPRESSION; PERCEPTION; DISCRIMINATION; ACTIVATION	Functional imaging studies of people who were blind from an early age have revealed that their primary visual cortex can be activated by Braille reading and other tactile discrimination task(1). Other studies have also shown that visual cortical areas can be activated by somatosensory input in blind subjects but not those with sight(2-7). The significance of this cross-modal plasticity is unclear, however, as it is not known whether the visual cortex can process somatosensory information in a functionally relevant way. To address this issue, we used transcranial magnetic stimulation to disrupt the function of different cortical areas in people who were blind from an early age as they identified Braille or embossed Roman letters, Transient stimulation of the occipital (visual) cortex induced errors in both tasks and distorted the tactile perceptions of blind subjects, In contrast, occipital stimu lation had no effect on tactile performance in normal-sighted subjects, whereas similar stimulation is known to disrupt their visual performance. We conclude that blindness from an early age can cause the visual cortex to be recruited to a role in somatosensory processing. We propose that this cross-modal plasticity may account in part for the superior tactile perceptual abilities of blind subjects.	NINCDS,BIOMETRY & FIELD STUDIES BRANCH,NIH,BETHESDA,MD 20892; UNIV BUENOS AIRES,DEPT NEUROL REHABIL,FDN LUCHA ENFERMEDADES NEUROL INFANTILES,RA-1053 BUENOS AIRES,DF,ARGENTINA; BETH ISRAEL DEACONESS MED CTR,LAB MAGNET BRAIN STIMULAT,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV VALENCIA,INST CAJAL,VALENCIA,SPAIN; FUKUI MED SCH,BIOMED IMAGING RES CTR,MATUOKA,FUKUI 91011,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Buenos Aires; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); University of Valencia; University of Fukui	Cohen, LG (corresponding author), NINCDS,HUMAN CORT PHYSIOL UNIT,NIH,BLDG 36,RM 4D04,BETHESDA,MD 20892, USA.		Pascual-Leone, Alvaro/G-6566-2011; HONDA, Manabu/AAO-1202-2020; Pascual-Leone, Alvaro/AAC-5101-2019	Pascual-Leone, Alvaro/0000-0001-8975-0382; Sadato, Norihiro/0000-0002-9786-3907				AMASSIAN VE, 1989, ELECTROEN CLIN NEURO, V74, P458, DOI 10.1016/0168-5597(89)90036-1; ANDERSON JA, 1972, BIOMETRIKA, V59, P19, DOI 10.2307/2334611; BARKER AT, 1985, LANCET, V1, P1106; BRIDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; CHEN R, IN PRESS ELECTROENCE; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; COHEN LG, 1991, ELECTROEN CLIN NEURO, V81, P366, DOI 10.1016/0168-5597(91)90026-T; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P247, DOI 10.1097/00004691-199605000-00009; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P242, DOI 10.1097/00004691-199605000-00008; HENDERSON DC, 1979, T AM SOC ART INT ORG, V25, P367; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; Homser DW, 1989, APPL LOGISTIC REGRES; KUJALA T, 1995, NEUROSCI LETT, V183, P143, DOI 10.1016/0304-3940(94)11135-6; Luders H, 1987, SURG TREATMENT EPILE, P297; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; PASCUALLEONE A, 1991, NEUROLOGY, V41, P697, DOI 10.1212/WNL.41.5.697; PASCUALLEONE A, 1993, ANN NEUROL, V34, P33, DOI 10.1002/ana.410340108; PascualLeone A, 1996, EXP BRAIN RES, V107, P479; Penfield W., 1959, SPEECH BRAIN MECHANI; Pons T, 1996, NATURE, V380, P479; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; Rushton D. N., 1978, Frontiers in Visual Science, P574; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507; UHL F, 1993, NEUROSCI LETT, V150, P162, DOI 10.1016/0304-3940(93)90526-Q; UHL F, 1991, NEUROSCI LETT, V124, P256, DOI 10.1016/0304-3940(91)90107-5; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7; WASSERMANN EM, IN PRESS ELECTROENCE; [No title captured]	30	650	665	3	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					180	183		10.1038/38278	http://dx.doi.org/10.1038/38278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296495				2022-12-28	WOS:A1997XV75700048
J	Spencer, TE; Jenster, G; Burcin, MM; Allis, CD; Zhou, JX; Mizzen, CA; McKenna, NJ; Onate, SA; Tsai, SY; Tsai, MJ; OMalley, BW				Spencer, TE; Jenster, G; Burcin, MM; Allis, CD; Zhou, JX; Mizzen, CA; McKenna, NJ; Onate, SA; Tsai, SY; Tsai, MJ; OMalley, BW			Steroid receptor coactivator-1 is a histone acetyltransferase	NATURE			English	Article							THYROID-HORMONE RECEPTOR; MMTV PROMOTER; TRANSCRIPTION; ACTIVATION; GENE; CBP; DEACETYLASE; NUCLEOSOME; REGULATOR; COMPLEX	Steroid receptors and coactivator proteins are thought to stimulate gene expression by facilitating the assembly of basal transcription factors into a stable preinitiation complex(1). That is not clear, however, is how these transcription factors gain access to transcriptionally repressed chromatin to modulate the transactivation of specific gene networks in vitro. The available evidence indicates that acetylation of chromatin in vivo is coupled to transcription and that specific histone acetyltransferases (HATs) target histones bound to DNA and overcome the inhibitory effect of chromatin on gene expression(2-4). The steroid-receptor coactivator SRC-1 is a coactivator for many members of the steroid-hormone receptor superfamily of Ligand-inducible transcription factors(5), Here we show that SRC-1 possesses intrinsic histone acetyltransferase activity and that it also interacts with another HAT, p300/CBP-associate factor (PCAF). The HAT activity of SRC-1 maps to its carboxy-terminal region and is primarily specific for histones H3 and H4, Acetylation by SRC-1 and PCAF of histones bound at specific promoters may result from ligand binding to steroid receptors and could be a mechanism by which the activation functions of steroid receptors and associated coactivators enhance formation of a stable preinitiation complex, thereby increasing transcription of specific genes from transcriptionally repressed chromatin templates.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	Baylor College of Medicine; University of Rochester			Spencer, Thomas/AAD-6434-2020	Spencer, Thomas/0000-0003-2815-766X; McKenna, Neil/0000-0001-6689-0104				ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; IENSTET G, 1997, P NATL ACAD SCI USA, V94, P7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KINGSTON RE, 1996, GENE DEV, V10, P950; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WONG J, 1997, EMBO J, V11, P3158; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	26	1030	1046	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					194	198		10.1038/38304	http://dx.doi.org/10.1038/38304			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296499				2022-12-28	WOS:A1997XV75700052
J	Wutz, A; Smrzka, OW; Schweifer, N; Schellander, K; Wagner, EF; Barlow, DP				Wutz, A; Smrzka, OW; Schweifer, N; Schellander, K; Wagner, EF; Barlow, DP			Imprinted expression of the Igf2r gene depends on an intronic CpG island	NATURE			English	Article							H19 GENE; METHYLATION; MOUSE; CHROMOSOME; REPLICATION; CREATION; PATTERNS; REGIONS; MICE; DNA	Gametic imprinting is a developmental process that induces parental-specific expression or repression of autosomal and X-chromosome-linked genes(1,2). The mouse Igf2r gene (encoding the receptor for insulin-like growth factor type-2) is imprinted and is expressed from the maternal allele after embryonic implantation(3). We previously proposed that methylation of region 2, a region rich in cytosine-guanine doublets (a 'CpG island') in the second intron of Igf2r, is the imprinting signal that maintains expression of the maternal allele(4). Here we use mouse transgenes to test the role of region 2 and the influence of chromosome location on Igf2r imprinting, Yeast artificial chromosome transgenes successfully reproduced the imprinted methylation and expression pattern of the endogenous Igf2r gene; deletion of region 2 from these transgenes caused a loss of imprinting and restored biallelic Igf2r expression, These results define a primary role for region 2 and a negligible role for chromosomal location in Igf2r imprinting; they also show that methylation imprints can maintain allelic expression, Short transgenes containing only region 2 and yeast artificial chromosome transgenes with an inactive Igf2r promoter do not attract parental-specific methylation. All transgenes showing paternal-specific repression of Igf2r produced an antisense RNA whose transcription was dependent on region 2, The production of an antisense RNA by the repressed parental allele is reminiscent of the imprinting of the Igf2/H19 gene pair(5) and may indicate that expression competition could play a general role in imprinting.	NETHERLANDS CANC INST,NL-1066 CX AMSTERDAM,NETHERLANDS; INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; BOEHRINGER INGELHEIM R&D,A-1121 VIENNA,AUSTRIA; UNIV BONN,D-53115 BONN,GERMANY	Netherlands Cancer Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim; University of Bonn				Wagner, Erwin F/0000-0001-7872-0196				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BICKMORE WA, 1995, J CELL SCI, V108, P2801; BIRD AP, 1993, CURR BIOL, V3, P275, DOI 10.1016/0960-9822(93)90177-P; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Dittrich B, 1996, NAT GENET, V14, P163, DOI 10.1038/ng1096-163; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; Hogan B, 1994, MANIPULATING MOUSE E; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; Leighton PA, 1996, BIOL REPROD, V54, P273, DOI 10.1095/biolreprod54.2.273; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LERCHNER WL, 1996, MECH DEVELOP, V61, P1; LEWIS BC, 1992, GENET ANAL-BIOMOL E, V9, P86, DOI 10.1016/1050-3862(92)90003-N; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; PALDI A, 1995, CURR BIOL, V5, P1030, DOI 10.1016/S0960-9822(95)00207-7; Pfeifer K, 1996, P NATL ACAD SCI USA, V93, P13876, DOI 10.1073/pnas.93.24.13876; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; Sambrook J., 1989, MOL CLONING LABORATO, P743; Schweifer N, 1997, GENOMICS, V43, P285, DOI 10.1006/geno.1997.4816; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; VILLAR AJ, 1994, NAT GENET, V8, P373, DOI 10.1038/ng1294-373	27	478	494	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					745	749		10.1038/39631	http://dx.doi.org/10.1038/39631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338788				2022-12-28	WOS:A1997YA95900059
J	Annas, GJ				Annas, GJ			The bell tolls for a constitutional right to physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; *NY STAT TASK FORC, 1997, DEATH IS SOUGHT ASS; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785	4	16	16	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1098	1103		10.1056/NEJM199710093371523	http://dx.doi.org/10.1056/NEJM199710093371523			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321541	Green Published			2022-12-28	WOS:A1997XZ84400032
J	Tan, S; Hall, IP; Dewar, J; Dow, E; Lipworth, B				Tan, S; Hall, IP; Dewar, J; Dow, E; Lipworth, B			Association between beta(2)-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics	LANCET			English	Article							SALMETEROL; RECEPTOR; SUBSENSITIVITY; EFORMOTEROL	Background In-vitro studies have suggested that polymorphisms of the beta(2)-adrenoceptor may influence the desensitisation induced by beta(2)-agonists. We investigated the influence of beta(2)-AR polymorphism on the development of bronchodilator desensitisation in asthma patients. Methods We carried out an analysis of 22 moderately severe stable asthmatics, mean age 38 years, FEV1 63% of predicted and FEF25-75 38% of predicted, who received a median inhaled corticosteroid dose of 1000 mu g/day. Patients were randomly assigned inhaled placebo or inhaled formoterol 24 mu g bid for 4 weeks each in a crossover study. Bronchodilator dose-response curves were made at the end of each treatment period by use of cumulative doses of formoterol (6-108 mu g) with FEV1 and FEF25-75 measured 30 min after each dose, and up to 6 h after the last dose. We calculated the degree of bronchodilator desensitisation by comparing the dose-response (for maximum and 6 h) after placebo with that after formoterol, and expressed this degree as percentage of placebo response. Patients were divided into groups according to genotype at codon 16: homozygous Arg 16 (n=4), heterozygous Arg 16/Gly 16 (n=8), and homozygous Gly 16 (n=10). At codon 27: homozygous Gin 27 (n=5), heterozygous Gin 27/Glu 27 (n=11), and homozygous Glu 27 (n=6). Findings We found a significantly (p<0.05) greater degree of bronchodilator desensitisation with homozygous Gly 16 than with homozygous Arg 16 for maximal FEV1 response: -8% (Arg 16) vs 46% (Gly 16); and for maximal FEF25-75 response: -32% (Arg 16) vs 74% (Gly 16; 95% CI 15-92% and 49-164%, respectively). Bronchodilator responses at 6 h were also significantly (p<0.05) different for FEV1 and FEF25-75 when Arg 16 and Gly 16 were compared and values for heterozygous Arg 16/Gly 16 were intermediate. There was significantly greater desensitisation with Glu 27 than with Gin 27 for maximal FEF25-75 response: -7% (Gin 27) vs 68% (Glu 27), p=0.05; and for 6 h FEF25-75 response: 43% (Gin 27) vs 93% (Glu 27), p<0.05 (95% CI 2-147% and 5-94%, respectively). All patients who were homozygous Glu 27 were also homozygous Gly 16. Interpretation We have found preliminary evidence that beta(2)-adrenoceptor polymorphism is associated with altered beta(2)-adrenoceptor expression in asthma patients. The homozygous Gly-16 form was significantly more prone to bronchodilator desensitisation than Arg 16, with the influence of Gly 16 dominating over any putative protective effects of Glu 27.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL & THERAPEUT,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND; UNIV NOTTINGHAM HOSP,DEPT MED,DIV THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	University of Dundee; University of Dundee; University of Nottingham			Dow, Eleanor/A-7927-2012					Booth H, 1996, THORAX, V51, P1100, DOI 10.1136/thx.51.11.1100; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; CLARK CE, 1993, RESP MED, V87, P277; DEWAR J, 1996, AM J RESP CRIT CAR S, V153, P413; FINKELSTEIN FN, 1994, NEW ENGL J MED, V331, P1314; Green SA, 1995, PULM PHARMACOL, V8, P1, DOI 10.1006/pulp.1995.1001; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P414; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; Hall IP, 1996, THORAX, V51, P351, DOI 10.1136/thx.51.4.351; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; HOLROYD KJ, 1995, AM J RESP CRIT CAR S, V151, P673; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; RAMAGE L, 1994, RESPIR MED, V88, P353; Tan KS, 1997, AM J RESP CRIT CARE, V156, P28, DOI 10.1164/ajrccm.156.1.9610113; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; TURKI J, 1995, AM J PHYSIOL-LUNG C, V269, pL709, DOI 10.1152/ajplung.1995.269.5.L709; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603, DOI 10.1164/ajrccm.154.6.8970342; 1995, THORAX S1, V52, pS1	23	274	297	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					995	999		10.1016/S0140-6736(97)03211-X	http://dx.doi.org/10.1016/S0140-6736(97)03211-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329515				2022-12-28	WOS:A1997XZ71000011
J	deMuizon, C; Cifelli, RL; Paz, RC				deMuizon, C; Cifelli, RL; Paz, RC			The origin of the dog-like borhyaenoid marsupials of South America	NATURE			English	Article							MAMMALS	Dog-like marsupials (superfamily Borhyaenoidea) were the largest predacious mammals during the Tertiary period in South America(1). They are critical to our understanding of marsupial origin, phylogeny and palaeobiogeography because they have been related to various marsupial lineages of several continents: didelphoids(2) (mainly New World, but also Europe, Asia and Africa), pediomyrid(3), stagodontids(4) (North America), dasyuroids(5) (Australia) and deltatheroidans(6) (predominantly Asian). These relationships, based mainly on dental morphology, have been discussed and rejected several times(2,3,7,8). Here we report the discovery of exceptionally well preserved skulls and skeletons, referrable to the didelphoid Andinodelphys, which shed new light on the phylogenetic and palaeobiogeographic origin of dog-like marsupials. The skulls of Mayulestes (boryhyaenoid)(9), Andinodelphys and Pucadelphys (didelphoids)(10,11) from the early Palaeocene epoch of Bolivia are the oldest known for American marsupials. Comparison of their basicranial anatomy suggests that dog-like marsupials are closely related to an early didelphimorphian radiation in South America, rather than to Asiatic (deltatheroidan), North American (stagodontid), or Australian(dasyuroid) lineages.	UNIV OKLAHOMA,OKLAHOMA MUSEUM NAT HIST,NORMAN,OK 73019; UNIV MAYOR SAN SIMON,MUSEO ARQUEOL,COCHABAMBA,BOLIVIA	University of Oklahoma System; University of Oklahoma - Norman	deMuizon, C (corresponding author), MUSEUM NATL HIST NAT,CNRS,URA 12,PALEONTOL LAB,8 RUE BUFFON,F-75005 PARIS,FRANCE.		De Muizon, Christian/Q-7986-2019; De Muizon, Christian/P-4335-2017	De Muizon, Christian/0000-0002-1247-8867; De Muizon, Christian/0000-0002-1247-8867				Aplin K.P., 1987, pxv; Archer M., 1982, P397; Archer M., 1976, Australian J Zool, VNo. 39, P1; BONAPARTE JF, 1990, NATL GEOGR RES, V6, P63; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P295; CIFELLI RL, 1993, P NATL ACAD SCI USA, V90, P9413, DOI 10.1073/pnas.90.20.9413; CIFELLI RL, 1993, MAMMAL PHYLOGENY, P205; CIFELLI RL, IN PRESS J PALEONTOL; CIFELLI RL, IN PRESS J MAMM EVOL; Clemens W.A., 1986, CONTRIBUTIONS GEOLOG, V3, P55, DOI DOI 10.2113/GSR0CKY.24.SPECIAL_; Clemens W.A., 1966, U CALIFORNIA PUBLICA, V62, P1; De Muizon Christian, 1993, Annales de Paleontologie, V79, P233; DEMUIZON C, 1994, NATURE, V370, P208, DOI 10.1038/370208a0; DEMUIZON C, IN PRESS GEODIVERSIT; DEMUIZON C, 1992, REV TECN YAC PETROL, V12, P393; Fox R.C., 1987, P161; FOX RC, 1979, J PALEONTOL, V53, P733; Fox Richard C., 1995, P247; HOFFSTETTER R, 1972, CR ACAD SCI D NAT, V274, P2635; MARSHALL L G, 1978, University of California Publications in Geological Sciences, V117, P1; Marshall L.G., 1980, P345; Marshall Larry G., 1995, Memoires du Museum National d'Histoire Naturelle, V165, P21; MARSHALL LG, 1992, LETHAIA, V25, P361, DOI 10.1111/j.1502-3931.1992.tb01639.x; MARSHALL LG, 1988, NATL GEOGR RES, V4, P23; MARSHALL LG, 1977, SYST ZOOL, V26, P410, DOI 10.2307/2412796; MARSHALL LG, 1990, CURRENT MAMMALOGY, P343; MATTHEW WD, 1916, B AM MUS NAT HIST, V35, P447; Simpson G. G., 1980, CURIOUS HIST S AM MA; Szalay FS, 1996, J VERTEBR PALEONTOL, V16, P474, DOI 10.1080/02724634.1996.10011335; SZALAY FS, 1994, EVOLUTIONARY HIST PR	30	53	55	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					486	489		10.1038/39029	http://dx.doi.org/10.1038/39029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333235				2022-12-28	WOS:A1997XY90900053
J	Weindruch, R; Sohal, RS				Weindruch, R; Sohal, RS			Caloric intake and aging	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OXIDATIVE DNA-DAMAGE; DIETARY RESTRICTION; FOOD RESTRICTION; ENERGY RESTRICTION; PROTEIN OXIDATION; RHESUS-MONKEYS; LIFE-SPAN; MITOCHONDRIAL SUPEROXIDE; ANTIOXIDANT DEFENSES; GENE-TRANSCRIPTION		UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, VET AFFAIRS GERIATR RES EDUC & CLIN CTR, MADISON, WI 53706 USA; SO METHODIST UNIV, DEPT BIOL SCI, DALLAS, TX 75275 USA	University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; University of Wisconsin System; University of Wisconsin Madison; Southern Methodist University					NIA NIH HHS [R01 AG013563, R01 AG013563-13] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agarwal S, 1996, EXP GERONTOL, V31, P365, DOI 10.1016/0531-5565(95)02039-X; ALBANES D, 1990, CRIT REV ONCOL HEMAT, V10, P283, DOI 10.1016/1040-8428(90)90036-R; Andersson SO, 1996, INT J CANCER, V68, P716; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; BRAY GA, 1996, PRESENT KNOWLEDGE NU, P19; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; CARTEE GD, 1994, AM J PHYSIOL, V266, pE946, DOI 10.1152/ajpendo.1994.266.6.E946; Cefalu WT, 1997, J GERONTOL A-BIOL, V52, pB10, DOI 10.1093/gerona/52A.1.B10; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Comfort A., 1979, BIOL SENESCENCE; DEMPSEY JL, 1993, MUTAT RES, V291, P141, DOI 10.1016/0165-1161(93)90153-Q; Dubey A, 1996, ARCH BIOCHEM BIOPHYS, V333, P189, DOI 10.1006/abbi.1996.0380; DUFFY PH, 1990, CHRONOBIOL INT, V7, P113, DOI 10.3109/07420529009056963; DULLOO AG, 1993, INT J OBESITY, V17, P115; FERNANDES G, 1976, P NATL ACAD SCI USA, V73, P1279, DOI 10.1073/pnas.73.4.1279; Fishbein L., 1991, BIOL EFFECTS DIETARY; Forster MJ, 1996, P NATL ACAD SCI USA, V93, P4765, DOI 10.1073/pnas.93.10.4765; Gibbs WW, 1996, SCI AM, V275, P88, DOI 10.1038/scientificamerican0896-88; GRASLKRAUPP B, 1994, P NATL ACAD SCI USA, V91, P9995, DOI 10.1073/pnas.91.21.9995; Gronberg H, 1996, J UROLOGY, V155, P969, DOI 10.1016/S0022-5347(01)66360-2; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HANSEN BC, 1995, OBES RES, V3, pS199, DOI 10.1002/j.1550-8528.1995.tb00464.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARRISON DE, 1984, P NATL ACAD SCI-BIOL, V81, P1835, DOI 10.1073/pnas.81.6.1835; Holloszy JO, 1997, J APPL PHYSIOL, V82, P399, DOI 10.1152/jappl.1997.82.2.399; HussAshmore R, 1996, AM J HUM BIOL, V8, P159, DOI 10.1002/(SICI)1520-6300(1996)8:2<159::AID-AJHB3>3.0.CO;2-Y; INGRAM DK, 1990, J GERONTOL, V45, pB148, DOI 10.1093/geronj/45.5.B148; IWASAKI K, 1988, J GERONTOL, V43, pB5, DOI 10.1093/geronj/43.1.B5; KAGAWA Y, 1978, PREV MED, V7, P205, DOI 10.1016/0091-7435(78)90246-3; KATANBAF MN, 1989, POULTRY SCI, V68, P344, DOI 10.3382/ps.0680344; KEMNITZ JW, 1993, J GERONTOL, V48, pB17, DOI 10.1093/geronj/48.1.B17; KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540; KOIZUMI A, 1992, J NUTR, V122, P1446, DOI 10.1093/jn/122.7.1446; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; Lane MA, 1996, P NATL ACAD SCI USA, V93, P4159, DOI 10.1073/pnas.93.9.4159; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LOFT S, 1995, CANCER EPIDEM BIOMAR, V4, P515; LOFT S, 1994, FASEB J, V8, P534, DOI 10.1096/fasebj.8.8.8181672; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MCCARTER R, 1985, AM J PHYSIOL, V248, pE488; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112; Muskhelishvili L, 1996, AM J PATHOL, V149, P1585; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Pearl R., 1928, RATE LIVING BEING AC; Prosser C. L., 1973, Comparative animal physiology,, P362; Ramsey JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE901, DOI 10.1152/ajpendo.1997.272.5.E901; RAO G, 1990, J NUTR, V120, P602, DOI 10.1093/jn/120.6.602; RomeroAlvira D, 1996, MED HYPOTHESES, V47, P137, DOI 10.1016/S0306-9877(96)90453-3; Rubner M, 1908, PROBLEM LEBENSDAUER; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SOHAL RS, 1993, BIOCHEM BIOPH RES CO, V196, P7, DOI 10.1006/bbrc.1993.2208; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1995, FREE RADICAL BIO MED, V19, P499, DOI 10.1016/0891-5849(95)00037-X; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Sohal RS, 1995, LIFE SCI R, V56, P109; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tillman JB, 1996, J BIOL CHEM, V271, P3500, DOI 10.1074/jbc.271.7.3500; TUCKER VA, 1965, J CELL COMPAR PHYSL, V65, P393, DOI 10.1002/jcp.1030650313; VELTHUISTEWIERIK EJM, 1995, INT J OBESITY, V19, P318; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Weindruch R., 1988, RETARDATION AGING DI; WIERIK EJMVT, 1994, EUR J CLIN NUTR, V48, P138; WIERIK EJV, 1995, METABOLISM, V44, P1548; YU BP, 1994, MODULATION AGING PRO	69	576	585	2	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					986	994		10.1056/NEJM199710023371407	http://dx.doi.org/10.1056/NEJM199710023371407			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309105	Green Accepted			2022-12-28	WOS:A1997XY42300007
J	Agerton, T; Valway, S; Gore, B; Pozsik, C; Plikaytis, B; Woodley, C; Onorato, I				Agerton, T; Valway, S; Gore, B; Pozsik, C; Plikaytis, B; Woodley, C; Onorato, I			Transmission of a highly drug-resistant strain (strain W1) of Mycobacterium tuberculosis - Community outbreak and nosocomial transmission via a contaminated bronchoscope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION	Context.-Nosocomial transmission of multidrug-resistant tuberculosis (MDR TB) has been reported primarily in New York State and has generally been presumed to occur via respiratory aerosols. Objective.-To assess nosocomial transmission of MDR TB. In 1995, 8 patients with MDR TB were identified in South Carolina; all were resistant to 7 drugs and had matching DNA fingerprints (strain W1). Community links were identified for 5 patients (Patients 1-5). However, no links were identified for the other 3 patients (Patients 6-8) except being hospitalized at the same hospital as 1 community patient. Design.-Outbreak investigation. Setting.-Community and hospital. Patients.-Eight patients whose MDR TB isolates had DNA fingerprint patterns matching strain W1. Main Outcome Measures.-Clinical characteristics of patients with strain W1 Mycobacterium tuberculosis isolates. Results.-Patient 5 (community patient) and Patient 8, diagnosed April 1995 and November 1995, respectively, had clinical courses consistent with MDR TB, with smear-positive and culture-positive specimens and cavitary lesions on chest radiograph; both died of MDR TB less than 1 month after diagnosis. Patients 6 and 7 (diagnosed May 1995) each had 1 positive culture for MDR TB; specimens were collected during bronchoscopy. Patient 6 had a skin test conversion after bronchoscopy. Neither Patient 6 nor Patient 7 had a clinical course consistent with MDR TB, neither was treated for MDR TB, and both are alive and well. No evidence of laboratory contamination of specimens, transmission on inpatient wards, or contact among patients was found. All 4 received bronchoscopies in May 1995; Patients 6, 7, and 8 had bronchoscopies 1, 12, and 17 days, respectively, after Patient 5. Observations revealed that bronchoscope cleaning was inadequate, and the bronchoscope was never immersed in disinfectant. Conclusions.-Inadequate cleaning and disinfection of the bronchoscope after the procedure performed on Patient 5 led to subsequent false-positive cultures in Patients 6 and 7 and transmission of infection to Patient 6 and active MDR TB to Patient 8.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV PROGRAM,EPIDEM PROGRAM OFF,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV HIV STD TB LAB RES,NATL CTR INFECT DIS,ATLANTA,GA 30333; S CAROLINA DEPT HLTH & ENVIRONM CONTROL,COLUMBIA,SC 29201	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Agerton, T (corresponding author), CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,MAILSTOP E-10,ATLANTA,GA 30333, USA.							*AM THOR SOC, 1994, AM J RESP CRIT CARE, V149, P1359; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; BENNETT SN, 1994, AM J RESP CRIT CARE, V150, P245, DOI 10.1164/ajrccm.150.1.8025757; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P675; *CDCP, 1994, COR CURR TUB WHAT CL; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; FITCH LE, 1991, J HOSP INFECT, V17, P322, DOI 10.1016/0195-6701(91)90287-I; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GUBLER JGH, 1992, CHEST, V101, P1245, DOI 10.1378/chest.101.5.1245; HUSEN L, 1971, CHEST, V60, P540, DOI 10.1378/chest.60.6.540; IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152; JEREB JA, 1995, ARCH INTERN MED, V155, P854, DOI 10.1001/archinte.155.8.854; KENT DC, 1967, ARCH ENVIRON HEALTH, V14, P580, DOI 10.1080/00039896.1967.10664795; MARTIN MA, 1994, AM J INFECT CONTROL, V22, P19, DOI 10.1016/0196-6553(94)90087-6; NELSON KE, 1983, AM REV RESPIR DIS, V127, P97, DOI 10.1164/arrd.1983.127.1.97; NICHOLSON G, 1995, J HOSP INFECT, V29, P257, DOI 10.1016/0195-6701(95)90272-4; PRIGOGINE T, 1988, J HOSP INFECT, V11, P93, DOI 10.1016/0195-6701(88)90047-3; SCHMIDEK HH, 1967, CAN MED ASSOC J, V97, P178; TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767, DOI 10.1128/JCM.31.4.767-770.1993; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WHEELER PW, 1989, J INFECT DIS, V159, P954, DOI 10.1093/infdis/159.5.954; World Health Organization, 1977, INT CLASS DIS	25	126	131	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1073	1077		10.1001/jama.278.13.1073	http://dx.doi.org/10.1001/jama.278.13.1073			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315765				2022-12-28	WOS:A1997XX30300030
J	Patrick, DL; Pearlman, RA; Starks, HE; Cain, KC; Cole, WG; Uhlmann, RF				Patrick, DL; Pearlman, RA; Starks, HE; Cain, KC; Cole, WG; Uhlmann, RF			Validation of preferences for life-sustaining treatment: Implications for advance care planning	ANNALS OF INTERNAL MEDICINE			English	Article						advance directives; life support care; health status; treatment outcomes	STATES WORSE; DIRECTIVES; ATTITUDES; STABILITY; CHOICES; QUALITY; VALUES; DEATH	Background: Treatment preferences established before life-threatening illness occurs may differ from actual decisions because of changes in preferences or poor understanding of the link between prospective preferences and outcomes. Objective: To evaluate the validity of prospective treatment preferences by examining their concordance with ratings of health states. Design: Survey of seven cohorts of persons with diverse health status. Home-and hospital-based interviews were conducted at baseline and at 6, 18, and 30 months. Setting: The greater Seattle area. Participants: Younger and older well adults; persons with chronic conditions, terminal cancer, or AIDS; stroke survivors; and nursing home residents. Measurements: Concordance between six treatment preferences and five health state ratings (on a seven-point scale) was assessed by using logistic regression to measure the increase in odds of treatment refusal for each one-point change in health state ratings. Preferences were considered concordant if treatments were refused in health states rated as worse than death and were accepted in health states rated as better than death. Reasons for discordance were elicited at the final interview. Results: The probability of refusal of prospective treatment was strongly related to health state ratings. Odds ratios ranged from 1.7 to 1.9 (P < 0.001) for every treatment. When patients were shown their discordant preferences, they had a coherent explanation or changed their health state rating or treatment preference to make the two concordant. Conclusions: Prospective life-sustaining treatment preferences show high convergent validity. For most persons, treatment preferences are grounded in a consistent belief system. Concordance and discordance between treatment preferences and health state ratings offer clinicians the opportunity to explore patients' Values and reasoning.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Patrick, DL (corresponding author), UNIV WASHINGTON, DEPT HLTH SERV, BOX 357660, SEATTLE, WA 98195 USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492	AHRQ HHS [HS06343] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DOUKAS DJ, 1993, J CLIN ETHIC, V4, P41; EMANUEL LL, 1994, ARCH INTERN MED, V154, P209, DOI 10.1001/archinte.1994.00420020131014; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341; Patrick D. L., 1993, HLTH STATUS HLTH POL; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; Pearlman R. A., 1994, Journal of General Internal Medicine, V9, P97; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; PEARLMAN RA, 1995, PUBLICATION NAT TECH; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; Schonwetter RS, 1996, J AM GERIATR SOC, V44, P954, DOI 10.1111/j.1532-5415.1996.tb01867.x; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; *STAT CORP, 1993, STAT REF MAN; Sutherland H J, 1982, Med Decis Making, V2, P299, DOI 10.1177/0272989X8200200306; Tonelli MR, 1996, CHEST, V110, P816, DOI 10.1378/chest.110.3.816; TORRANCE GW, 1982, VALUES LONG TERM CAR; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	25	88	91	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					509	+		10.7326/0003-4819-127-7-199710010-00002	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY733	9313018				2022-12-28	WOS:A1997XY73300002
J	Zimmerman, RK; Medsger, AR; Ricci, EM; Raymund, M; Mieczkowski, TA; Grufferman, S				Zimmerman, RK; Medsger, AR; Ricci, EM; Raymund, M; Mieczkowski, TA; Grufferman, S			Impact of free vaccine and insurance status on physician referral of children to public vaccine clinics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	30th National Immunization Conference	APR 10-11, 1996	WASHINGTON, DC				IMMUNIZATION PRACTICES; PEDIATRICIANS; CARE	Context.-Concerns about financial barriers to vaccination led to the development of the Vaccines for Children (VFC) program, which provides free vaccines to states for children who are uninsured, Medicaid eligible, or Native American or Native Alaskan. Objective.-To understand the effect of economic factors on physician likelihood of referring children to public vaccine clinics for immunizations and to evaluate the VFC program. Design.-A standardized survey was conducted in 1995 by trained personnel using computer-assisted telephone interviewing. Setting and Participants.-A stratified random sample of family physicians, pediatricians, and general practitioners younger than 65 years who were in office-based practices across the United States. Main Outcome Measures.-Likelihood of referral of a child to a health department for vaccination by child's insurance status and by the physician's receipt of free vaccines. Results.-Of the 1769 physicians with whom an interviewer spoke, 1236 participated, Most respondents (66%) were likely to refer an uninsured child to the health department for vaccination, whereas only 8% were likely to refer a child who had insurance that covers vaccination, The majority (58%) of physicians reported differential referral based on insurance status. Among physicians who received free vaccine supplies from the VFC program or elsewhere, 44% were likely to refer an uninsured child whereas 90% of those not receiving free vaccine were likely to refer the same child (P<.001). In regression analysis, the receipt of free vaccine supplies accounted for 24% of the variance in the likelihood to refer an uninsured child for vaccination. Conclusions.-Physicians receiving free vaccine supplies report being less likely to refer children to public clinics for vaccinations.	UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT HLTH SERV ADM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zimmerman, RK (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT FAMILY MED & CLIN EPIDEMIOL,M-200 SCAIFE HALL,PITTSBURGH,PA 15261, USA.			Zimmerman, Richard/0000-0001-5941-6092; Santibanez, Tammy A./0000-0002-5784-7427	AHRQ HHS [HS08068] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY L, 1989, DESIGNING CONDUCTING; ARNOLD PJ, 1992, AM J DIS CHILD, V146, P728, DOI 10.1001/archpedi.1992.02160180088023; BORDLEY WC, 1994, PEDIATRICS, V94, P376; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P657; Cochran W.G., 2007, SAMPLING TECHNIQUES; FAIRBROTHER G, IN PRESS ARCH PEDIAT; Hamlin JS, 1996, AM J PUBLIC HEALTH, V86, P1812, DOI 10.2105/AJPH.86.12.1812; HOLTMANN AG, 1996, SUPPLYING VACCINE EC, P153; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; Murphy TV, 1997, PEDIATR INFECT DIS J, V16, P47, DOI 10.1097/00006454-199701000-00011; MURPHY TV, 1995, PEDIATR INFECT DIS J, V15, P561; *NAT VACC ADV COMM, 1991, JAMA-J AM MED ASSOC, V266, P1547; Public Health Service U.S. Department of Health and Human Services, 1991, HLTH PEOPL 2000 NAT; RUCHROSS HS, 1994, PEDIATRICS, V94, P508; *SAS I INC, 1996, SAS SYST WIND COMP P; SCHULTE JM, 1991, PEDIATRICS, V87, P204; Taylor JA, 1997, PEDIATRICS, V99, P209; *US GEN ACC OFF, 1995, VACC CHILDR REEX PRO; Wood DL, 1996, ARCH PEDIAT ADOL MED, V150, P577, DOI 10.1001/archpedi.1996.02170310011001; WRIGHT JA, 1992, AM J DIS CHILD, V146, P1033, DOI 10.1001/archpedi.1992.02160210035016; Zimmerman R K, 1993, Fam Pract Res J, V13, P213; Zimmerman R K, 1995, J Am Board Fam Pract, V8, P270; Zimmerman RK, 1997, AM J PREV MED, V13, P89, DOI 10.1016/S0749-3797(18)30204-6; Zimmerman RK, 1997, ARCH PEDIAT ADOL MED, V151, P657, DOI 10.1001/archpedi.1997.02170440019004	24	40	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					996	1000		10.1001/jama.278.12.996	http://dx.doi.org/10.1001/jama.278.12.996			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307347				2022-12-28	WOS:A1997XX01200030
J	Coste, J; Letrait, M; Carel, JC; Tresca, JP; Chatelain, P; Rochiccioli, P; Louis, J; Chaussain, JL; Job, JC				Coste, J; Letrait, M; Carel, JC; Tresca, JP; Chatelain, P; Rochiccioli, P; Louis, J; Chaussain, JL; Job, JC			Long term results of growth hormone treatment in France in children of short stature: population, register based study	BRITISH MEDICAL JOURNAL			English	Article							FINAL HEIGHT; PUBERTAL DEVELOPMENT; GH DEFICIENCY; THERAPY	Objectives: To describe the growth of children treated with growth hormone and to evaluate the prognostic factors for height at the end of treatment Design: Register based cohort study. Setting: French national register of all children treated with growth hormone. Subjects: 3233 short stature children (3165 of whom were deficient in growth hormone) who were treated with growth hormone (excluding children with Turner's syndrome) and whose treatment started between 1973 and 1989, last data being recorded in December 1993. Main outcome measures: Annual changes in height, and height at the end of treatment. Results: Mean height SD score at the end of treatment, after a mean of 4.3 years, was -2, corresponding to gain in mean height SD score of 1 and to a height SD score of 1.1 below tar-get height Ln all, 923 children prematurely stopped taking growth hormone treatment, mainly because of insufficient response (insufficient growth) or tiredness. Variables that predicted height at the end of treatment were age, target height, aetiology of short stature, use of puberty inhibitors, and type of growth hormone. Conclusions: The outcome of children of short stature with growth hormone deficiency who were treated with growth hormone has been less favourable than initially assumed. Growth hormone treatment has not restored normal growth to these children, The highly demanding nature and high costs of this treatment require an optimised prescription, and this remains to be determined.	HOP COCHIN,INST RECH THERAPEUT,F-75674 PARIS,FRANCE; ASSOC FRANCE HYPOPHYSE,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Coste, J (corresponding author), UNIV PARIS 05,HOP COCHIN,FAC COCHIN,DEPT BIOSTAT & INFORMAT MED,ACHARD 7,F-75674 PARIS 14,FRANCE.		Carel, Jean-Claude/AAZ-7691-2020	Carel, Jean-Claude/0000-0002-0424-6767				ALLEN DB, 1990, J PEDIATR-US, V117, P16, DOI 10.1016/S0022-3476(05)82438-2; BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; BERGMAN U, 1992, J CLIN EPIDEMIOL, V45, P313, DOI 10.1016/0895-4356(92)90092-2; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BLETHEN SL, 1993, J CLIN ENDOCR METAB, V76, P574, DOI 10.1210/jc.76.3.574; BRAMSWIG J, 1995, HORM RES, V43, P126, DOI 10.1159/000184256; BURNS EC, 1981, CLIN ENDOCRINOL, V14, P587, DOI 10.1111/j.1365-2265.1981.tb02969.x; BURNS EC, 1981, EUR J PEDIATR, V137, P155; CACCIARI E, 1994, J CLIN ENDOCR METAB, V79, P1663, DOI 10.1210/jc.79.6.1663; Carel JC, 1996, J CLIN ENDOCR METAB, V81, P3318, DOI 10.1210/jc.81.9.3318; CHIPMAN JJ, 1995, HORM RES, V43, P129, DOI 10.1159/000184257; COLE T, 1993, KIGS REPORT, V10, P37; FRISCH H, 1995, HORM RES, V43, P132, DOI 10.1159/000184258; GRECO L, 1995, BRIT MED J, V310, P696, DOI 10.1136/bmj.310.6981.696; Greulich WW, 1970, RADIOGRAPHIC ATLAS S; HIBI I, 1989, J CLIN ENDOCR METAB, V69, P221, DOI 10.1210/jcem-69-2-221; HIBI I, 1989, ACTA ENDOCRINOL-COP, V120, P409, DOI 10.1530/acta.0.1200409; Hindmarsh PC, 1996, LANCET, V348, P13, DOI 10.1016/S0140-6736(96)01038-0; JOB JC, 1988, ARCH FR PEDIATR, V45, P169; MAES M, 1994, KABI INT GROWTH STUD, V11, P15; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; PRICE DA, 1994, PROGR GROWTH HORMONE; Ranke MB, 1996, HORM RES, V45, P64, DOI 10.1159/000184851; Ranke MB, 1994, PROGR GROWTH HORMONE; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; *SAS I, 1990, SAS US GUID; Sempe M., 1979, AUXOLOGIE METHODES S; Sempe P., 1971, CROISSANCE MATURATIO; SEVERI F, 1995, HORM RES, V43, P138, DOI 10.1159/000184260; VANDENBROECK J, 1995, J PEDIATR-US, V127, P729, DOI 10.1016/S0022-3476(95)70161-3; VANDENBROECK J, 1988, EUR J PEDIATR, V147, P245, DOI 10.1007/BF00442688	32	68	68	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					708	713		10.1136/bmj.315.7110.708	http://dx.doi.org/10.1136/bmj.315.7110.708			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314755	Green Published			2022-12-28	WOS:A1997XX67400021
J	Oren, M				Oren, M			Lonely no more: p53 finds its kin in a tumor suppressor haven	CELL			English	Review							MUTATIONS				Oren, M (corresponding author), WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL.							CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; Oren M, 1996, BBA-REV CANCER, V1288, pR13, DOI 10.1016/S0304-419X(96)00030-3; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J	13	77	84	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					829	832		10.1016/S0092-8674(00)80347-5	http://dx.doi.org/10.1016/S0092-8674(00)80347-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298894	Bronze			2022-12-28	WOS:A1997XV56300003
J	Sidow, A; Bulotsky, MS; Kerrebrock, AW; Bronson, RT; Daly, MJ; Reeve, MP; Hawkins, TL; Birren, BW; Jaenisch, R; Lander, ES				Sidow, A; Bulotsky, MS; Kerrebrock, AW; Bronson, RT; Daly, MJ; Reeve, MP; Hawkins, TL; Birren, BW; Jaenisch, R; Lander, ES			Serrate2 is disrupted in the mouse limb-development mutant syndactylism	NATURE			English	Article							NOTCH LOCUS; DROSOPHILA	The mouse syndactylism (sin) mutation impairs some of the earliest aspects of limb development and leads to subsequent abnormalities in digit formation(1-3). In sin homozygotes, the apical ectodermal ridge (AER) is hyperplastic by embryonic day 10.5, leading to abnormal dorsoventral thickening of the limb bud, subsequent merging of the skeletal condensations that give rise to cartilage and bone in the digits, and eventual fusion of digits. The AER hyperplasia and its effect on early digital patterning distinguish sm from many other syndactylies that result from later failure of cell death in the interdigital areas(4,5). Here we use positional cloning to show that the gene mutated in sm mice encodes the putative Notch ligand Serrate2. The results provide direct evidence that a Notch signalling pathway is involved in the earliest stages of Limb-bud patterning and support the idea that an ancient genetic mechanism underlies both AER formation in vertebrates and wing-margin formation in files(6,7). In addition to cloning the sm gene, we have mapped three modifiers of sm, for which we suggest possible candidate genes.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tufts University; Tufts University			Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752				Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gruneberg H., 1956, Journal of Genetics, V54, P113, DOI 10.1007/BF02981706; GRUNEBERG H, 1960, GENET RES, V1, P196; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JOHNSON DR, 1969, J EMBRYOL EXP MORPH, V21, P285; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LYON MF, 1996, GENETIC VARIANTS STR; MILAIRE J., 1967, ARCH BIOL, V78, P223; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; *MOUS GEN DAT, 1997, MOUS GEN INF; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; Sambrook J, 1989, MOL CLONING; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601; Wilkinson DG, 1992, SITU HYBRIDIZATION P; XU T, 1992, DEVELOPMENT, V115, P913	23	96	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					722	725		10.1038/39587	http://dx.doi.org/10.1038/39587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338782				2022-12-28	WOS:A1997YA95900053
J	Delbanco, TL; Daley, J; Hartman, E				Delbanco, TL; Daley, J; Hartman, E			A 96-year-old woman with insomnia, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Mendelson W, 1997, JAMA-J AM MED ASSOC, V277, P990, DOI 10.1001/jama.277.12.990	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1185	1185						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326480				2022-12-28	WOS:A1997XY42200038
J	Zuger, A; Sharp, VL				Zuger, A; Sharp, VL			'HIV specialists': The time has come	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PRIMARY-CARE PHYSICIANS; AIDS; EXPERIENCE; INFECTION		ST LUKES ROOSEVELT HOSP,HIV AIDS CTR,NEW YORK,NY 10019; BETH ISRAEL HOSP,HIV COMPREHENS CARE CLIN,NEW YORK,NY; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10467	Mount Sinai St. Luke's; Mount Sinai West; Yeshiva University; Albert Einstein College of Medicine								*AM COLL PHYS INF, 1994, ANN INTERN MED, V120, P310; *AM SOC INT MED, 1995, REINV MAN CAR; BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KAHN JG, 1995, J ACQ IMMUN DEF SYND, V8, pS53; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LAURENCE J, 1995, AIDS READER, V5, P110; LEWIS CE, 1986, J GEN INTERN MED, V1, P287, DOI 10.1007/BF02596205; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; PAAUW DS, 1995, JAMA-J AM MED ASSOC, V274, P1380, DOI 10.1001/jama.274.17.1380; SANDE MA, 1994, J INFECT DIS, V169, P1197, DOI 10.1093/infdis/169.6.1197; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; Soloway B, 1997, AIDS Clin Care, V9, P37; VERGHESE A, 1993, CLIN INFECT DIS, V16, P459, DOI 10.1093/clind/16.4.459; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILSON IB, 1995, J ACQ IMMUN DEF SYND, V8, pS31	18	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1131	1132		10.1001/jama.278.14.1131	http://dx.doi.org/10.1001/jama.278.14.1131			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326457				2022-12-28	WOS:A1997XY42200002
J	Poole, CJM				Poole, CJM			Hazards of powdered surgical gloves	LANCET			English	Editorial Material							LATEX				Poole, CJM (corresponding author), DUDLEY PRIOR HLTH NHS TRUST,DEPT OCCUPAT HLTH,DUDLEY DY2 7BX,ENGLAND.							BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; *DEP HLTH, 1996, LAT SENS HLTH CAR SE; HAGLUND U, 1997, EUR J SURG S579, V163; Heese A, 1996, HAUTARZT, V47, P817, DOI 10.1007/s001050050514; LAMPE AS, 1988, LANCET, V2, P1140; Newsom SWB, 1997, OCCUP MED-OXFORD, V47, P155, DOI 10.1093/occmed/47.3.155; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					973	974		10.1016/S0140-6736(05)64064-0	http://dx.doi.org/10.1016/S0140-6736(05)64064-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329509				2022-12-28	WOS:A1997XZ71000005
J	Koob, GF; LeMoal, M				Koob, GF; LeMoal, M			Drug abuse: Hedonic homeostatic dysregulation	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; STRESS-INDUCED SENSITIZATION; NUCLEUS-ACCUMBENS; ETHANOL WITHDRAWAL; ALCOHOL DEPENDENCE; EXTRACELLULAR DOPAMINE; MOLECULAR MECHANISMS; COCAINE WITHDRAWAL; RECEPTOR AGONISTS; OPIATE-WITHDRAWAL	Understanding the neurobiological mechanisms of addiction requires an integration of basic neuroscience with social psychology, experimental psychology, and psychiatry. Addition is presented as a cycle of spiralling dysregulation of brain reward systems that progressively increases, resulting in compulsive drug use and a loss of control over drug-taking. Sensitization and counteradaptation are hypothesized to contribute to this hedonic homeostatic dysregulation, and the neurobiological mechanisms involved, such as the mesolimbic dopamine system, opioid peptidergic systems, and brain and hormonal stress systems, are beginning to be characterized. This framework provides a realistic approach to identifying the neurobiological factors that produce vulnerability to addiction and to relapse in individuals with a history of addiction.	UNIV BORDEAUX 2, INSERM, U259, F-33077 BORDEAUX, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Koob, GF (corresponding author), Scripps Res Inst, DEPT NEUROPHARMACOL CVN7, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		LE MOAL, Michel/B-5125-2008		NIAAA NIH HHS [AA06420, AA08459] Funding Source: Medline; NIDA NIH HHS [DA04043] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA006420, R01AA008459, R37AA008459, P50AA006420] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004043] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahlstrom Sydney E., 1972, RELIG HIST AM PEOPLE; ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Baumeister RF, 1994, LOSING CONTROL WHY P, DOI 10.5860/choice.32-6508; Bergman J., 1990, Behav Pharmacol, V1, P355; Bindra D., 1976, THEORY INTELLIGENT B; Cabib S, 1996, PSYCHOPHARMACOLOGY, V128, P331, DOI 10.1007/s002130050142; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CAINE SB, 1995, BRAIN RES, V692, P47; Carrera M. R. A., 1995, Society for Neuroscience Abstracts, V21, P725; CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407; CHEN JP, 1991, NEUROSCI LETT, V129, P136, DOI 10.1016/0304-3940(91)90739-G; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; COOLS AR, IN PRESS PHARM BIOCH; CRABBE JC, 1992, TRENDS PHARMACOL SCI, V13, P212, DOI 10.1016/0165-6147(92)90066-F; deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050; Deroche V, 1997, J PHARMACOL EXP THER, V281, P1401; DEROCHE V, 1992, BRAIN RES, V598, P343, DOI 10.1016/0006-8993(92)90205-N; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN; ENGEL JA, 1992, NOVEL PHARM INTERVEN, P68; EPPINGJORDAN M, 1995, NEUR ABSTR, V21, P719; ETTENBERG A, 1982, PHYSIOL BEHAV, V28, P873, DOI 10.1016/0031-9384(82)90207-4; Gold LH, 1996, BEHAV PHARMACOL, V7, P589; HEIMER L, 1991, ADV EXP MED BIOL, V295, P1; HEINRICHS SC, 1995, BEHAV PHARMACOL, V6, P74; HENRY DJ, 1992, ANN NY ACAD SCI, V654, P88, DOI 10.1111/j.1749-6632.1992.tb25958.x; Heyser C. J., 1995, Society for Neuroscience Abstracts, V21, P1698; HEYSER CJ, IN PRESS NEUROPSYCHO; Himmelsbach CK, 1943, FED PROC, V2, P201; HYYTIA P, 1995, EUR J PHARMACOL, V283, P151, DOI 10.1016/0014-2999(95)00314-B; Institute of Medicine, 1996, PATHW ADD; JAFFE J H, 1990, P522; Johnston JB, 1923, J COMP NEUROL, V35, P337, DOI 10.1002/cne.900350502; JUNG CG, 1969, PSYCHOL ENERGY MEANI, V8; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; Koob George F., 1995, P759; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KOOB GF, 1993, SEMIN NEUROSCI, V5, P351; KOOB GF, 1987, BRAIN REWARD SYSTEMS, P35; KOOP GF, IN PRESS J PSYCHOPHA; Kreek M.J., 1987, PSYCHOPHARMACOLOGY 3, P1597; LAULIN JP, IN PRESS EUR J PHARM; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; MALIN DH, 1990, PEPTIDES, V11, P277, DOI 10.1016/0196-9781(90)90082-G; MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17; MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.153.18.2093; MURPHY JM, 1987, PHARMACOL BIOCHEM BE, V26, P389, DOI 10.1016/0091-3057(87)90134-1; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Piazza PV, 1996, P NATL ACAD SCI USA, V93, P8716, DOI 10.1073/pnas.93.16.8716; PIAZZA PV, IN PRESS BRAIN RES R; PICH EM, 1995, J NEUROSCI, V15, P5439; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S; Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Russell M. A. H., 1976, DRUGS DRUG DEPENDENC, P182; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Schulteis G, 1997, PSYCHOPHARMACOLOGY, V129, P56, DOI 10.1007/s002130050162; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; Schulteis G, 1996, NEUROCHEM RES, V21, P1437, DOI 10.1007/BF02532385; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; SELLERS EM, 1992, TRENDS PHARMACOL SCI, V13, P69, DOI 10.1016/0165-6147(92)90026-3; Shaham Y, 1996, J NEUROSCI, V16, P1957; Shippenberg TS, 1996, J PHARMACOL EXP THER, V276, P545; SHIPPENBERG TS, 1992, ANN NY ACAD SCI, V654, P347, DOI 10.1111/j.1749-6632.1992.tb25980.x; Smith Devyn, COMMUNICATION; Solomon R.L, 1977, PSYCHOPATHOLOGY EXPT, P124; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; Spanagel R, 1996, EUR J PHARMACOL, V305, P39, DOI 10.1016/0014-2999(96)00174-4; Sterling P., 1988, HDB LIFE STRESS COGN, P629, DOI DOI 10.1016/0005-7967(90)90076-U; Stewart J., 1987, METHODS ASSESSING RE, P211; Tabakoff B., 1992, SUBSTANCE ABUSE COMP, P152; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; VOLPICELLI JR, 1986, LIFE SCI, V38, P841, DOI 10.1016/0024-3205(86)90601-6; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B; Weiss F, 1996, J NEUROSCI, V16, P3474; WHITE FJ, 1991, BIOL BASES DRUG TOLE, P153; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8; World Health Organization, 1990, INT STAT CLASS DIS R; Zhou Y, 1996, EUR J PHARMACOL, V315, P31, DOI 10.1016/S0014-2999(96)00672-3; Zhou Y, 1996, J PHARMACOL EXP THER, V279, P351	99	1797	1837	5	231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					52	58		10.1126/science.278.5335.52	http://dx.doi.org/10.1126/science.278.5335.52			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311926				2022-12-28	WOS:A1997XZ12400031
J	Narayan, SM; Cain, ME; Smith, JM				Narayan, SM; Cain, ME; Smith, JM			Atrial fibrillation	LANCET			English	Article							SICK-SINUS SYNDROME; INTACT HUMAN HEART; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; THROMBOEMBOLIC COMPLICATIONS; SPATIAL-ORGANIZATION; RANDOMIZED TRIAL; CARDIOVERSION; ANTICOAGULATION; MECHANISMS; PREVENTION				Narayan, SM (corresponding author), WASHINGTON UNIV, SCH MED,DEPT INTERNAL MED,DIV CARDIOVASC, ELECTROPHYSIOL SERV, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.							ALLESSIE M, 1995, AM HEART MONOGR S, P155; Amarenco P, 1996, NEW ENGL J MED, V334, P1216; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; [Anonymous], 1997, ARCH INTERN MED, V157, P1237; BLACK IW, 1993, J AM COLL CARDIOL, V21, P451, DOI 10.1016/0735-1097(93)90688-W; BLACK IW, 1994, CIRCULATION, V89, P2509, DOI 10.1161/01.CIR.89.6.2509; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; Botteron GW, 1996, CIRCULATION, V93, P513, DOI 10.1161/01.CIR.93.3.513; BOTTERON GW, 1995, IEEE T BIO-MED ENG, V42, P579, DOI 10.1109/10.387197; Brugada R, 1997, NEW ENGL J MED, V336, P905, DOI 10.1056/NEJM199703273361302; BURKE MC, 1997, PACE S, V20, P424; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Coumel P, 1996, AM J CARDIOL, V77, pA3, DOI 10.1016/S0002-9149(97)89113-8; COUMEL P, 1978, ARCH MAL COEUR VAISS, V71, P645; Cox JL, 1996, ANN SURG, V224, P267, DOI 10.1097/00000658-199609000-00003; COX JL, 1991, J THORAC CARDIOV SUR, V101, P402; Daoud EG, 1996, CIRCULATION, V94, P1036, DOI 10.1161/01.CIR.94.5.1036; Daoud EG, 1996, AM J CARDIOL, V78, P1433, DOI 10.1016/S0002-9149(97)89297-1; DESILVA RA, 1980, AM HEART J, V100, P881, DOI 10.1016/0002-8703(80)90071-X; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Ehlert FA, 1995, J ELECTROCARDIOL, V28, P33, DOI 10.1016/S0022-0736(95)80012-3; Ellenbogen KA, 1996, J AM COLL CARDIOL, V28, P130, DOI 10.1016/0735-1097(96)00121-0; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; Farina E., 1996, Neurology, V46, pA139; FATKIN D, 1994, J AM COLL CARDIOL, V23, P307, DOI 10.1016/0735-1097(94)90412-X; Fatkin D, 1997, CIRCULATION, V96, P889; FEINBERG WM, 1994, ARCH INTERN MED, V154, P1372; FLAKER GC, 1995, AM J CARDIOL, V76, P355, DOI 10.1016/S0002-9149(99)80100-3; FUCHS T, 1992, ATRIAL FIBRILLATION, P233; Goette A, 1996, CIRCULATION, V94, P2968, DOI 10.1161/01.CIR.94.11.2968; GOSSELINK ATM, 1994, BRIT HEART J, V72, P161; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; GROGAN M, 1992, AM J CARDIOL, V69, P1570, DOI 10.1016/0002-9149(92)90705-4; GUIRAUDON GM, 1985, CIRCULATION, V72, P220; Harjai KJ, 1997, J AM COLL CARDIOL, V30, P481, DOI 10.1016/S0735-1097(97)00173-3; HART RG, 1987, ARCH INTERN MED, V147, P636; HNATKOVA K, 1997, PACE, V20, P1465; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Jais P, 1997, CIRCULATION, V95, P572, DOI 10.1161/01.CIR.95.3.572; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; Kanuru N. K., 1997, Journal of the American College of Cardiology, V29, p292A; Kautzner J, 1996, AM J CARDIOL, V78, P575, DOI 10.1016/S0002-9149(96)00370-0; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; Klein AL, 1997, ANN INTERN MED, V126, P200, DOI 10.7326/0003-4819-126-3-199702010-00004; KONINGS KTS, 1994, CIRCULATION, V89, P1665, DOI 10.1161/01.CIR.89.4.1665; Kopecky S. L., 1997, Journal of the American College of Cardiology, V29, p105A; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; Lau CP, 1997, PACE, V20, P220, DOI 10.1111/j.1540-8159.1997.tb04847.x; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Levy S, 1997, CIRCULATION, V96, P253; Levy S, 1997, EUR HEART J, V18, P546; LIP GYH, 1994, BRIT HEART J, V71, P92; Lip GYH, 1996, CIRCULATION, V94, P425, DOI 10.1161/01.CIR.94.3.425; Lip GYH, 1996, BRIT MED J, V312, P45, DOI 10.1136/bmj.312.7022.45; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1995, ANN INTERN MED, V123, P817, DOI 10.7326/0003-4819-123-11-199512010-00001; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MCBRIDE R, 1994, LANCET, V343, P687; MCLARAN CJ, 1985, BRIT HEART J, V53, P323; MICHELUCCI A, 1984, INT J CARDIOL, V5, P75, DOI 10.1016/0167-5273(84)90060-3; MIDDLEKAUFF HR, 1993, AM J CARDIOL, V72, pF75, DOI 10.1016/0002-9149(93)90967-H; MILLER VT, 1993, NEUROLOGY, V43, P32, DOI 10.1212/WNL.43.1_Part_1.32; MOE GK, 1962, ARCH INT PHARMACOD T, V140, P183; Morady F, 1997, J AM COLL CARDIOL, V29, P113, DOI 10.1016/S0735-1097(96)00445-7; Omran H, 1997, J AM COLL CARDIOL, V29, P131, DOI 10.1016/S0735-1097(96)00439-1; PETERS KG, 1988, AM J MED, V85, P242; PETERSEN P, 1989, LANCET, V1, P175; RENSMA PL, 1988, CIRC RES, V62, P395, DOI 10.1161/01.RES.62.2.395; ROSENQVIST M, 1990, J AM COLL CARDIOL, V16, P1467, DOI 10.1016/0735-1097(90)90394-5; Rubin DN, 1996, AM J CARDIOL, V78, P774, DOI 10.1016/S0002-9149(96)00419-5; Saksena S, 1996, J AM COLL CARDIOL, V28, P687, DOI 10.1016/0735-1097(96)00232-X; SANFILIPPO AJ, 1990, CIRCULATION, V82, P792, DOI 10.1161/01.CIR.82.3.792; Schmit C, 1996, J AM COLL CARDIOL, V28, P994, DOI 10.1016/S0735-1097(96)00274-4; Schreck DM, 1997, ANN EMERG MED, V29, P135, DOI 10.1016/S0196-0644(97)70319-6; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045, DOI 10.1161/01.CIR.88.3.1045; SILVERMAN ME, 1994, AM J CARDIOL, V73, P384, DOI 10.1016/0002-9149(94)90013-2; Sohara H, 1997, J AM COLL CARDIOL, V29, P106, DOI 10.1016/S0735-1097(96)00427-5; STEINBERG JS, 1993, CIRCULATION, V88, P2618, DOI 10.1161/01.CIR.88.6.2618; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; *STROK PREV ATR FI, 1996, LANCET, V328, P633; STUEHLINGER HG, 1997, J AM COLL CARDIOL S, V29, pA177; SWARTZ JF, 1994, CIRCULATION, V90, P335; vanLatum JC, 1996, NEUROLOGY, V46, P159; WEINBERG BA, 1993, AM HEART J, V125, P109, DOI 10.1016/0002-8703(93)90063-F; WELLENS HJJ, 1994, ATRIAL FIBRILLATION, P333; Wijffels M, 1994, ATRIAL FIBRILLATION, P195; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Zipes DP, 1997, CIRCULATION, V95, P562, DOI 10.1161/01.CIR.95.3.562	91	64	68	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	1997	350	9082					943	950		10.1016/S0140-6736(97)06359-9	http://dx.doi.org/10.1016/S0140-6736(97)06359-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314883				2022-12-28	WOS:A1997XY67200041
J	Gordon, GS; Sitnikov, D; Webb, CD; Teleman, A; Straight, A; Losick, R; Murray, AW; Wright, A				Gordon, GS; Sitnikov, D; Webb, CD; Teleman, A; Straight, A; Losick, R; Murray, AW; Wright, A			Chromosome and low copy plasmid segregation in E-coli: Visual evidence for distinct mechanisms	CELL			English	Article							POLAR-CAP FORMATION; ESCHERICHIA-COLI; TN7 TRANSPOSITION; CELL-DIVISION; P1 PLASMID; PROTEIN; BINDING; REPLICATION; EXPRESSION; CLONING	We have investigated DNA segregation in E. coli by inserting multiple lac operator sequences into the chromosome near the origin of replication (oriC), in the hisC gene, a terminus marker, and into plasmids P1 and F. Expression of a GFP-LacI fusion protein allowed visualization of lac operator localization. oriC was shown to be specifically localized at or near the cell poles, and when duplicated, one copy moved to the site of new pole formation near the site of cell division. In contrast, P1 and F localized to the cell center and on duplication appeared to move rapidly to the quarter positions in the cell. Our analysis suggests that different active processes are involved in movement and localization of the chromosome and of the two plasmids during segregation.	TUFTS UNIV,DEPT MOL BIOL & MICROBIOL,BOSTON,MA 02111; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Tufts University; Harvard University; University of California System; University of California San Francisco			Teleman, Aurelio A/E-6864-2013; Teleman, Aurelio/V-8470-2019	Teleman, Aurelio A/0000-0002-4237-9368; Teleman, Aurelio/0000-0002-4237-9368; Straight, Aaron/0000-0001-5885-7881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038035, R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38035, GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, J MOL BIOL, V226, P661, DOI 10.1016/0022-2836(92)90623-R; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; AUSTIN S, 1986, J BACTERIOL, V168, P1010, DOI 10.1128/jb.168.2.1010-1013.1986; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DeBoy RT, 1996, J BACTERIOL, V178, P6184, DOI 10.1128/jb.178.21.6184-6191.1996; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HELMSTETTER CE, 1990, RES MICROBIOL, V141, P30, DOI 10.1016/0923-2508(90)90095-8; HELMSTETTER CE, 1987, J MOL BIOL, V197, P195, DOI 10.1016/0022-2836(87)90118-5; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HIRAGA S, 1993, CURR OPIN GENE DEV, V5, P789; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; LOBNEROLESEN A, 1992, J BACTERIOL, V174, P7883; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORI H, 1989, J BIOL CHEM, V264, P15535; MORI H, 1986, J MOL BIOL, V192, P1, DOI 10.1016/0022-2836(86)90459-6; NANNINGA N, 1990, RES MICROBIOL, V141, P103, DOI 10.1016/0923-2508(90)90102-V; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; OGDEN GB, 1986, BACTERIAL CHROMATIN, P45; Pogliano J, 1997, P NATL ACAD SCI USA, V94, P559, DOI 10.1073/pnas.94.2.559; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; ROTHFIELD LI, 1994, CELL, V77, P963, DOI 10.1016/0092-8674(94)90435-9; SCHAECHTER M, 1993, JOHN INN S, P61; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Wheeler RT, 1997, CELL, V88, P577, DOI 10.1016/S0092-8674(00)81898-X; WIENTJES FB, 1991, RES MICROBIOL, V142, P333, DOI 10.1016/0923-2508(91)90049-G; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; WILSON K, 1992, SHORT PROTOCOLS MOL; WOLDRINGH CL, 1990, RES MICROBIOL, V141, P39, DOI 10.1016/0923-2508(90)90096-9; WOLDRINGH CL, 1987, J GEN MICROBIOL, V133, P575; Wolkow CA, 1996, GENE DEV, V10, P2145, DOI 10.1101/gad.10.17.2145; Wu LJ, 1997, EMBO J, V16, P2161, DOI 10.1093/emboj/16.8.2161; YANG YX, 1993, INFECT IMMUN, V61, P3907, DOI 10.1128/IAI.61.9.3907-3913.1993	45	311	313	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1113	1121		10.1016/S0092-8674(00)80377-3	http://dx.doi.org/10.1016/S0092-8674(00)80377-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323139	Bronze			2022-12-28	WOS:A1997XX76800017
J	Cheeseman, EW; Bidwell, AE				Cheeseman, EW; Bidwell, AE			Angioid streaks in Pseudoxanthoma elasticum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Cheeseman, EW (corresponding author), NAVAL HOSP,GREAT LAKES,IL 60088, USA.								0	0	0	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					828	828		10.1056/NEJM199709183371206	http://dx.doi.org/10.1056/NEJM199709183371206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9295242				2022-12-28	WOS:A1997XW28300006
J	Robinson, KS; Anderson, DR; Gross, M; Petrie, D; Leighton, R; Stanish, W; Alexander, D; Mitchell, M; Flemming, B; Gent, M				Robinson, KS; Anderson, DR; Gross, M; Petrie, D; Leighton, R; Stanish, W; Alexander, D; Mitchell, M; Flemming, B; Gent, M			Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: The post-arthroplasty screening study - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							B-MODE ULTRASONOGRAPHY; TOTAL HIP-REPLACEMENT; KNEE REPLACEMENT; VEIN THROMBOSIS; SURGERY; ENOXAPARIN	Background: The clinical significance of asymptomatic deep venous thrombosis that develops after joint arthroplasty and the value of screening tests to detect thrombi are uncertain. Objectives: To determine ?) the rate of symptomatic deep venous thrombosis or pulmonary embolism occurring after hospitalization for joint arthroplasty and 2) the value of screening compression ultrasonography. Design: Double-blind, randomized, controlled trial. Setting: Tertiary care hospital. Patients: 1024 patients undergoing elective total hip or knee arthroplasty who received warfarin prophylaxis. Intervention: Patients were randomly assigned to undergo either bilateral compression ultrasonography or a sham procedure before hospital discharge. Patients with a diagnosis of asymptomatic deep venous thrombosis were treated after discharge with standard anticoagulant therapy; other patients had warfarin therapy discontinued at discharge. All patients were followed for 90 days. Results: In the screening group, asymptomatic proximal deep venous thrombosis was detected in 13 of 518 patients (2.5%). Another 4 patients subsequently developed symptomatic proximal deep Venous thrombosis, and 1 patient treated for asymptomatic deep Venous thrombosis developed major bleeding, for a total outcome event rate of 1.0% (5 of 518 patients). In the placebo group, 3 patients developed symptomatic proximal deep venous thrombosis and 2 had nonfatal pulmonary embolism, for a total event rate of 1.0% (5 of 506 patients) (difference, 0 percentage points [95% CI, -1.2 to 1.2 percentage points]). Conclusions: In patients undergoing total hip or knee arthroplasty, the use of warfarin prophylaxis during hospitalization results in a very low rate of symptomatic deep venous thrombosis or pulmonary embolism after hospital discharge. The use of screening compression ultrasonography at hospital discharge does not seem to be justified in this setting.	QUEEN ELIZABETH II HLTH SCI CTR, HALIFAX, NS B3H 2Y9, CANADA; DALHOUSIE UNIV, HALIFAX, NS B3H 3J5, CANADA; MCMASTER UNIV, HAMILTON, ON L8S 4L8, CANADA; HAMILTON CIV HOSP, RES CTR, HAMILTON, ON L8V 1C3, CANADA	Queen Elizabeth II Health Sciences Centre; Dalhousie University; McMaster University; McMaster University				Anderson, David/0000-0003-0845-1722				ANDERSON DR, 1993, THROMB HAEMOSTASIS, V69, P650; Bergqvist D, 1996, NEW ENGL J MED, V335, P696, DOI 10.1056/NEJM199609053351002; BORRIS LC, 1989, THROMB HAEMOSTASIS, V61, P363; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; GRADYBENSON JC, 1994, J BONE JOINT SURG AM, V76A, P1649, DOI 10.2106/00004623-199411000-00008; HARRIS WH, 1990, NEW ENGL J MED, V323, P725, DOI 10.1056/NEJM199009133231106; KHAW FM, 1993, J BONE JOINT SURG BR, V75, P940, DOI 10.1302/0301-620X.75B6.8245087; LENSING AW, 1995, HEMOSTASIS THROMBOSI; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LIEBERMAN JR, 1994, J BONE JOINT SURG AM, V76A, P1239, DOI 10.2106/00004623-199408000-00015; PAIEMENT GD, 1993, J BONE JOINT SURG AM, V75A, P893, DOI 10.2106/00004623-199306000-00010; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Ricotta S, 1996, THROMB HAEMOSTASIS, V76, P887; WARWICK D, 1995, J BONE JOINT SURG BR, V77B, P6, DOI 10.1302/0301-620X.77B1.7822397; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	18	138	140	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					439	445		10.7326/0003-4819-127-6-199709150-00004	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313000				2022-12-28	WOS:A1997XV77900004
J	Dynlacht, BD				Dynlacht, BD			Regulation of transcription by proteins that control the cell cycle	NATURE			English	Article							RNA-POLYMERASE-II; CDK-ACTIVATING KINASE; TERMINAL DOMAIN KINASE; RETINOBLASTOMA PROTEIN; FACTOR TFIIH; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; GENE-PRODUCT; G1 CYCLINS				Dynlacht, BD (corresponding author), HARVARD UNIV, DEPT MOL & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.							AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; DYSON N, 1994, J CELL SCI, P81; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; Rickert P, 1996, ONCOGENE, V12, P2631; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	70	191	209	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	1997	389	6647					149	152		10.1038/38225	http://dx.doi.org/10.1038/38225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296491				2022-12-28	WOS:A1997XV75700039
J	Kimura, Y; Vassylyev, DG; Miyazawa, A; Kidera, A; Matsushima, M; Mitsuoka, K; Murata, K; Hirai, T; Fujiyoshi, Y				Kimura, Y; Vassylyev, DG; Miyazawa, A; Kidera, A; Matsushima, M; Mitsuoka, K; Murata, K; Hirai, T; Fujiyoshi, Y			Surface of bacteriorhodopsin revealed by high-resolution electron crystallography	NATURE			English	Article							PROTON TRANSLOCATION; PURPLE MEMBRANE; HALOBACTERIUM-HALOBIUM; DIFFRACTION PATTERNS; SCHIFF-BASE; LIGHT; PROTEIN	Bacteriorhodopsin is a transmembrane protein that uses light energy, absorbed by its chromophore retinal, to pump protons from the cytoplasm of bacteria such as Halobacterium salinarium into the extracellular space(1,2.) It is made up of seven alpha-helices, and in the bacterium forms natural, two-dimensional crystals called purple membranes. We have analysed these crystals by electron cryo-microscopy to obtain images of bacteriorhodopsin at 3.0 Angstrom resolution. The structure covers nearly all 248 amino acids, including loops outside the membrane, and reveals the distribution of charged residues on both sides of the membrane surface. In addition, analysis of the electron-potential map produced by this method allows the determination of the charge status of these residues. On the extracellular side, four glutamate residues surround the entrance to the proton channel, whereas on the cytoplasmic side, four aspartic acids occur in a plane at the boundary of the hydrophobic-hydrophilic interface. The negative charges produced by these aspartate residues is encircled by areas of positive charge that may facilitate accumulation and lateral movement of protons on this surface.	RAT DRUG DESIGN LAB, MATSUKAWA, FUKUSHIMA 96012, JAPAN; MATSUSHITA ELECT IND CO LTD, INT INST ADV RES, SORAKU, KYOTO 61902, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYOU KU, KYOTO 60601, JAPAN	Kyoto University	Kimura, Y (corresponding author), BIOMOL ENGN RES INST, 6-2-3 FUREUDAI, SUITA, OSAKA 565, JAPAN.		Hirai, Teruhisa/G-2105-2015; Fujiyoshi, Yoshinori/E-5989-2012; Vassylyev, Dmitry/A-9005-2008	Hirai, Teruhisa/0000-0002-2114-8149; Fujiyoshi, Yoshinori/0000-0002-8070-1493; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN J, 1984, ULTRAMICROSCOPY, V14, P319, DOI 10.1016/0304-3991(84)90217-1; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; CESKA TA, 1990, J MOL BIOL, V213, P539, DOI 10.1016/S0022-2836(05)80214-1; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KIMURA Y, 1985, J MEMBRANE BIOL, V85, P225, DOI 10.1007/BF01871517; KUSHWAHA SC, 1976, BIOCHIM BIOPHYS ACTA, V426, P703, DOI 10.1016/0005-2736(76)90135-8; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; Riesle J, 1996, BIOCHEMISTRY-US, V35, P6635, DOI 10.1021/bi9600456; SAKATA K, 1992, ULTRAMICROSCOPY, V45, P253, DOI 10.1016/0304-3991(92)90513-J; SEIFF F, 1985, P NATL ACAD SCI USA, V82, P3227, DOI 10.1073/pnas.82.10.3227; SUBRAMANIAM S, 1992, J BIOL CHEM, V267, P25730; WILSON AJC, 1995, INT TABLE CRYSTALLOG, VC	23	403	411	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	1997	389	6647					206	211		10.1038/38323	http://dx.doi.org/10.1038/38323			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296502				2022-12-28	WOS:A1997XV75700055
J	Corvera, CU; Kirkwood, KS				Corvera, CU; Kirkwood, KS			Recent advances - General surgery	BRITISH MEDICAL JOURNAL			English	Review							LAPAROSCOPIC CHOLECYSTECTOMY; DOUBLE-BLIND; ONDANSETRON; MANAGEMENT; PROPOFOL; ULCER		UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								Alon E, 1996, Anasthesiol Intensivmed Notfallmed Schmerzther, V31, P200, DOI 10.1055/s-2007-995902; CARROLL BJ, 1994, SURG ENDOSC-ULTRAS, V8, P310, DOI 10.1007/BF00590960; COTTON P, 1991, GASTROINTEST ENDOSC, V37, pL383; DEBOER W, 1995, LANCET, V345, P817, DOI 10.1016/S0140-6736(95)92962-2; DEPAULA AL, 1994, SURG ENDOSC-ULTRAS, V8, P1399; Fulton B, 1996, PHARMACOECONOMICS, V9, P168, DOI 10.2165/00019053-199609020-00008; Gan TJ, 1996, ANESTHESIOLOGY, V85, P1036, DOI 10.1097/00000542-199611000-00011; HECHT AD, 1995, J CLIN ANESTH, V7, P581, DOI 10.1016/0952-8180(95)00136-0; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; LAINE L, 1996, AM J MED S, V100, P52; Lane GE, 1996, AM SURGEON, V62, P907; Pasqualucci A, 1996, ANESTHESIOLOGY, V85, P11, DOI 10.1097/00000542-199607000-00003; PETERS JH, 1995, J AM COLL SURGEONS, V180, P385; SEBASTIAN M, 1995, BRIT J SURG, V82, P860; SPECHLER SJ, 1992, DIGESTION, V51, P24, DOI 10.1159/000200911; Steinbrook RA, 1996, ANESTH ANALG, V83, P1081, DOI 10.1097/00000539-199611000-00032; TYTGAT GNJ, 1994, ALIMENT PHARM THERAP, V8, P359; WAY LW, 1994, SURG ENDOSC-ULTRAS, V3, P235; Wiebalck A, 1995, ANAESTHESIST, V44, P831, DOI 10.1007/s001010050219	19	12	12	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					586	589						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV717	9302958				2022-12-28	WOS:A1997XV71700028
J	Crane, BR; Arvai, AS; Gachhui, R; Wu, CQ; Ghosh, DK; Getzoff, ED; Stuehr, DJ; Tainer, JA				Crane, BR; Arvai, AS; Gachhui, R; Wu, CQ; Ghosh, DK; Getzoff, ED; Stuehr, DJ; Tainer, JA			The structure of nitric oxide synthase oxygenase domain and inhibitor complexes	SCIENCE			English	Article							CYTOCHROME-C PEROXIDASE; L-ARGININE; NO SYNTHASE; PROTEIN; SITE; COORDINATION; REPLACEMENT; REFINEMENT; CATALYSIS; ERRORS	The nitric oxide synthase oxygenase domain (NOSox) oxidizes arginine to synthesize the cellular signal and defensive cytotoxin nitric oxide (NO). Crystal structures determined for cytokine-inducible NOSox reveal an unusual fold and heme environment for stabilization of activated oxygen intermediates key for catalysis. A winged beta sheet engenders a curved alpha-beta domain resembling a baseball catcher's mitt with heme clasped in the palm. The location of exposed hydrophobic residues and the results of mutational analysis place the dimer interface adjacent to the heme-binding pocket. Juxtaposed hydrophobic O-2- and polar L-arginine-binding sites occupied by imidazole and aminoguanidine, respectively, provide a template for designing dual-function inhibitors and imply substrate-assisted catalysis.	CLEVELAND CLIN, DEPT IMMUNOL, CLEVELAND, OH 44106 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute; Scripps Research Institute			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL58883] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRITTAIN T, 1992, EUR J BIOCHEM, V209, P793, DOI 10.1111/j.1432-1033.1992.tb17350.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRANE BR, UNPUB; FUREY W, 1990, AM CRYST ASS M AB PA, V33, P18; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; GHOSH D, UNPUB; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIBBS MR, 1990, J MOL BIOL, V213, P167; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mansuy Daniel, 1995, P537; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Mueller Ernest J., 1995, P83; MURSHUDOV G, 1994, ACTA CRYSTALLOGR D, V50, P760; MURSHUDOV G, 1996, P DAR STUD WEEK, P157; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poulos Thomas L., 1995, P125; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; STUEHR D, 1997, ANN REV PHARM TOXICO, V18, P707; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891	52	318	326	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					425	431		10.1126/science.278.5337.425	http://dx.doi.org/10.1126/science.278.5337.425			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334294				2022-12-28	WOS:A1997YB35500034
J	Mizutani, Y; Kitagawa, T				Mizutani, Y; Kitagawa, T			Direct observation of cooling of heme upon photodissociation of carbonmonoxy myoglobin	SCIENCE			English	Article							RESOLVED RESONANCE-RAMAN; SPERM WHALE MYOGLOBIN; RELAXATION; DYNAMICS; SPECTROSCOPY; STILBENE; ENERGY; LASER; HEMOGLOBIN; PROTEINS	The formation of vibrationally excited heme upon photodissociation of carbonmonoxy myoglobin and its subsequent vibrational energy relaxation was monitored by picosecond anti-Stokes resonance Raman spectroscopy. The anti-Stokes intensity of the nu(4) band showed immediate generation of vibrationally excited hemes and biphasic decay of the excited populations. The best fit to double exponentials gave time constants of 1.9 +/- 0.6 and 16 +/- 9 picoseconds for vibrational population decay and 3.0 +/- 1.0 and 25 +/- 14 picoseconds for temperature relaxation of the photolyzed heme when a Boltzmann distribution was assumed. The decay of the nu(4) anti-Stokes intensity was accompanied by narrowing and frequency upshift of the Stokes counterpart. This direct monitoring of the cooling dynamics of the heme cofactor within the globin matrix allows the characterization of the vibrational energy flow through the protein moiety and to the water bath.	OKAZAKI NATL RES INST,INST MOL SCI,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB)			Mizutani, Yasuhisa/B-3809-2009					ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BAKKER HJ, 1990, NATURE, V347, P745, DOI 10.1038/347745a0; ELSAESSER T, 1991, ANNU REV PHYS CHEM, V42, P83; FRANZEN S, 1995, BIOCHEMISTRY-US, V34, P1224, DOI 10.1021/bi00004a016; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GREENE BI, 1978, P NATL ACAD SCI USA, V75, P5255, DOI 10.1073/pnas.75.11.5255; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; KEYES MH, 1971, J AM CHEM SOC, V93, P2035; Kruglik SG, 1997, CHEM PHYS LETT, V266, P283, DOI 10.1016/S0009-2614(97)00008-0; LI M, 1993, J CHEM PHYS, V98, P5499, DOI 10.1063/1.464899; LI P, 1994, BIOPHYS J, V66, P430, DOI 10.1016/S0006-3495(94)80793-3; LIAN TQ, 1994, J PHYS CHEM-US, V98, P11648, DOI 10.1021/j100096a005; Lim MH, 1996, J PHYS CHEM-US, V100, P12043, DOI 10.1021/jp9536458; LINGLE R, 1991, J PHYS CHEM-US, V95, P9320, DOI 10.1021/j100176a053; MARTIN JL, 1983, P NATL ACAD SCI-BIOL, V80, P173, DOI 10.1073/pnas.80.1.173; MATOUSEK P, 1995, CHEM PHYS LETT, V237, P373, DOI 10.1016/0009-2614(95)00324-W; Nakabayashi T, 1997, J PHYS CHEM A, V101, P3494, DOI 10.1021/jp963303h; PETRICH JW, 1987, BIOCHEMISTRY-US, V26, P7914, DOI 10.1021/bi00398a056; PHILLIPS DL, 1993, CHEM PHYS, V175, P1, DOI 10.1016/0301-0104(93)80224-W; RAFTERY D, 1994, J CHEM PHYS, V101, P8572, DOI 10.1063/1.468052; SATO S, 1994, APPL PHYS B-LASERS O, V59, P415, DOI 10.1007/BF01081064; SCHOMACKER KT, 1984, J CHEM PHYS, V80, P4701, DOI 10.1063/1.446535; Schultz SL, 1997, J PHYS CHEM A, V101, P1000, DOI 10.1021/jp962454h; SENSION RJ, 1993, J CHEM PHYS, V98, P6291, DOI 10.1063/1.464824; Simpson MC, 1997, J AM CHEM SOC, V119, P5110, DOI 10.1021/ja961198j	26	226	228	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					443	446		10.1126/science.278.5337.443	http://dx.doi.org/10.1126/science.278.5337.443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334299				2022-12-28	WOS:A1997YB35500039
J	Lowe, CJ; Wray, GA				Lowe, CJ; Wray, GA			Radical alterations in the roles of homeobox genes during echinoderm evolution	NATURE			English	Article							MORPHOLOGY; EXPRESSION; PHYLOGENY; MOLECULES; HOMOLOGY	Echinoderms possess one of the most highly derived body architectures of all metazoan phyla, with radial symmetry, a calcitic endoskeleton, and a water vascular system(1,2). How these dramatic morphological changes evolved has been the subject of extensive speculation and debate(3-5), but remains unresolved. Because echinoderms are closely related to chordates and postdate the protostome/deuterostome divergence(2,3,6,7), they must have evolved from bilaterally symmetrical ancestors(1-6). Here we report the expression domains in echinoderms of three important developmental regulatory genes (distal-less, engrailed and orthodenticle), all of which encode transcription factors that contain a homeodomain(8). Our findings show that the reorganization of body architecture involved extensive changes in the deployment and roles of homeobox genes. These changes include modifications in the symmetry of expression domains and the evolution of several new developmental roles, as well as the loss of roles conserved between arthropods and chordates. Some of these modifications seem to have evolved very early in the history of echinoderms, whereas others probably evolved during the subsequent diversification of adult and larval morphology, These results demonstrate the evolutionary lability of regulatory genes that are widely viewed as conservative.	SUNY STONY BROOK,DEPT ECOL & EVOLUT,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Lowe, Christopher/0000-0002-7789-8643				Averof M, 1996, SEMIN CELL DEV BIOL, V7, P539, DOI 10.1006/scdb.1996.0068; Bolker JA, 1996, BIOESSAYS, V18, P489, DOI 10.1002/bies.950180611; Brusca R.C., 1990, INVERTEBRATES; Dan, 1968, INVERTEBRATE EMBRYOL; DAVID B, IN PRESS P 9 INT ECH; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DICKINSON WJ, 1995, TRENDS GENET, V11, P119, DOI 10.1016/S0168-9525(00)89015-0; DOLECKI GJ, 1988, GENE, V64, P21, DOI 10.1016/0378-1119(88)90477-5; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; GAN L, 1995, DEV BIOL, V167, P517, DOI 10.1006/dbio.1995.1046; HOLLAND ND, 1988, ECHINODERM PHYLOGENY, P13; Holland P.W.H., 1990, Seminars in Developmental Biology, V1, P135; Hyman L. H., 1955, INVERTEBRATES; Jefferies RPS, 1996, ACTA ZOOL-STOCKHOLM, V77, P101, DOI 10.1111/j.1463-6395.1996.tb01256.x; Lacalli TC, 1996, PHILOS T R SOC B, V351, P1737, DOI 10.1098/rstb.1996.0155; MALINDA KM, 1994, DEV BIOL, V164, P562, DOI 10.1006/dbio.1994.1224; NIELSEN C, 1995, ANIMAL EVOLUTIION IN; PANGANIBAN G, 1997, P NATL ACAD SCI USA, V94, P2162; PATEL NH, 1994, SCIENCE, V266, P581, DOI 10.1126/science.7939712; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PATEL NH, METHOD CELL BIOL, V44, P446; Raff R.A., 1996, SHAPE LIFE; Sharman AC, 1996, NETH J ZOOL, V46, P47, DOI 10.1163/156854295X00050; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Smith A. B., 1988, ECHINODERM PHYLOGENY, P85; STRATHMANN MF, 1987, REPROD DEV MARINE IN; TURBEVILLE JM, 1994, MOL BIOL EVOL, V11, P648; WEDEEN CJ, 1991, DEVELOPMENT, V113, P805	29	220	226	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					718	721		10.1038/39580	http://dx.doi.org/10.1038/39580			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338781				2022-12-28	WOS:A1997YA95900052
J	Barendregt, JJ; Bonneux, L; van der Maas, PJ				Barendregt, JJ; Bonneux, L; van der Maas, PJ			The health care costs of smoking	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; INTERVENTIONS; POPULATION; GUIDELINES; DISEASE; FUTURE	Background Although smoking cessation is desirable from a public health perspective, its consequences with respect to health care costs are still debated. Smokers have more disease than nonsmokers, but nonsmokers live longer and can incur more health costs at advanced ages. We analyzed health care costs for smokers and nonsmokers and estimated the economic consequences of smoking cessation. Methods We used three life tables to examine the effect of smoking on health care costs - one for a mixed population of smokers and nonsmokers, one for a population of smokers, and one for a population of nonsmokers. We also used a dynamic method to estimate the effects of smoking cessation on health care costs over time. Results Health care costs for smokers at a given age are as much as 40 percent higher than those for nonsmokers, but in a population in which no one smoked the costs would be 7 percent higher among men and 4 percent higher among women than the costs in the current mixed population of smokers and nonsmokers. If all smokers quit, health care costs would be lower at first, but after 15 years they would become higher than at present. In the long term, complete smoking cessation would produce a net increase in health care costs, but it could still be seen as economically favorable under reasonable assumptions of discount rate and evaluation period. Conclusions if people stopped smoking, there would be a savings in health care costs, but only in the short term. Eventually, smoking cessation would lead to increased health care costs. (C) 1997, Massachusetts Medical Society.			Barendregt, JJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.		Barendregt, Jan J/F-6895-2010					BARENDREGT JJ, IN PRESS MATH POPUL; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; *CENTR BUR STAT, 1989, OV NAAR DOODS LEEFT; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Drummond M, 1990, METHODS EC EVALUATIO; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; *EINDH CANC REG, 1991, CANC INC SURV 1975 1; Gold MR, 1996, COST EFFECTIVENESS H; GUNNINGSCHEPERS LJ, 1989, LANCET, V1, P479; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; Koopmanschap M, 1994, EUR J PUB HLTH, V4, P258, DOI [10.1093/eurpub/4.4.258, DOI 10.1093/EURPUB/4.4.258]; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; LEU RE, 1983, SOC SCI MED, V17, P1907, DOI 10.1016/0277-9536(83)90168-5; LIPPIATT BC, 1990, PREV MED, V19, P515, DOI 10.1016/0091-7435(90)90050-T; MACKENZIE TD, 1994, NEW ENGL J MED, V330, P975, DOI 10.1056/NEJM199404073301406; MANNING WG, 1989, JAMA-J AM MED ASSOC, V261, P1604, DOI 10.1001/jama.261.11.1604; MASON J, 1995, HEALTH ECON, V4, P85, DOI 10.1002/hec.4730040202; Murray CJ, 1996, GLOBAL BURDEN DIS; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P663; NIESSEN LW, 1993, STROKE, V24, P931, DOI 10.1161/01.STR.24.7.931; Schoen R, 1988, MODELING MULTIGROUP; SHULTZ JM, 1991, PUBLIC HEALTH REP, V106, P326; *STICHT VOLKSG ROK, 1993, JAARV 1992; vandeMheen PJ, 1996, PUBLIC HEALTH REP, V111, P420; VANWEEL C, 1987, J ROY COLL GEN PRACT, V37, P404; VISCUSI WK, 1994, 4891 NAT BUR EC RES; West RR, 1996, J EPIDEMIOL COMMUN H, V50, P239, DOI 10.1136/jech.50.3.239	28	238	241	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1052	1057		10.1056/NEJM199710093371506	http://dx.doi.org/10.1056/NEJM199710093371506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XZ844	9321534	Green Published			2022-12-28	WOS:A1997XZ84400006
J	Dahiyat, BI; Mayo, SL				Dahiyat, BI; Mayo, SL			De novo protein design: Fully automated sequence selection	SCIENCE			English	Article							AMINO-ACIDS; MACROMOLECULAR STRUCTURES; DISTANCE GEOMETRY; NMR-SPECTROSCOPY; COILED COILS; PROPENSITIES; PEPTIDE; PACKING; POLYPEPTIDE; TRANSITION	The first fully automated design and experimental validation of a novel sequence for an entire protein is described. A computational design algorithm based on physical chemical potential functions and stereochemical constraints was used to screen a combinatorial library of 1.9 x 10(27) possible amino acid sequences for compatibility with the design target, a beta beta alpha protein motif based on the polypeptide backbone structure of a zinc finger domain. A BLAST search shows that the designed sequence, full sequence design 1 (FSD-1), has very low identity to any known protein sequence. The solution structure of FSD-1 was solved by nuclear magnetic resonance spectroscopy and indicates that FSD-1 forms a compact well-ordered structure, which is in excellent agreement with the design target structure, This result demonstrates that computational methods can perform the immense combinatorial search required for protein design, and it suggests that an unbiased and quantitative algorithm can be used in various structural contexts.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL,PASADENA,CA 91125; CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; California Institute of Technology					NIGMS NIH HHS [GM08346] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Betz SF, 1996, BIOCHEMISTRY-US, V35, P6955, DOI 10.1021/bi960095a; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; COHEN FE, 1982, J MOL BIOL, V156, P821, DOI 10.1016/0022-2836(82)90144-9; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; Dahiyat BI, 1996, PROTEIN SCI, V5, P895, DOI 10.1002/pro.5560050511; Dahiyat BI, 1997, P NATL ACAD SCI USA, V94, P10172, DOI 10.1073/pnas.94.19.10172; Dahiyat BI, 1997, PROTEIN SCI, V6, P1333, DOI 10.1002/pro.5560060622; DAHIYAT BI, UNPUB; DeMaeyer M, 1997, FOLD DES, V2, P53; DESJARLAIS JR, 1995, PROTEIN SCI, V4, P2006, DOI 10.1002/pro.5560041006; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; GOLDSTEIN RF, 1994, BIOPHYS J, V66, P1335, DOI 10.1016/S0006-3495(94)80923-3; HARBURY PB, 1995, P NATL ACAD SCI USA, V92, P8408, DOI 10.1073/pnas.92.18.8408; HELLINGA HW, 1991, J MOL BIOL, V222, P787, DOI 10.1016/0022-2836(91)90511-4; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JACKSON DY, 1994, SCIENCE, V266, P243, DOI 10.1126/science.7939659; JANIN J, 1980, J MOL BIOL, V143, P95, DOI 10.1016/0022-2836(80)90126-6; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KLEMBA M, 1995, NAT STRUCT BIOL, V2, P368, DOI 10.1038/nsb0595-368; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; Marvin JS, 1997, P NATL ACAD SCI USA, V94, P4366, DOI 10.1073/pnas.94.9.4366; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, 1991, COMPUTATIONAL ASPECT; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; Struthers MD, 1996, J AM CHEM SOC, V118, P3073, DOI 10.1021/ja954014u; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; Su A, 1997, PROTEIN SCI, V6, P1701, DOI 10.1002/pro.5560060810; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P9808, DOI 10.1021/bi00494a008; Wuthrich K., 1986, NMR PROTEINS NUCL AC	51	888	983	0	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					82	87		10.1126/science.278.5335.82	http://dx.doi.org/10.1126/science.278.5335.82			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311930				2022-12-28	WOS:A1997XZ12400041
J	Kuroda, MI; Meller, VH				Kuroda, MI; Meller, VH			Transient Xist-ence	CELL			English	Review							X-CHROMOSOME INACTIVATION; MOUSE DEVELOPMENT; EXPRESSION				Kuroda, MI (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9	19	11	11	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					9	11		10.1016/S0092-8674(01)80003-9	http://dx.doi.org/10.1016/S0092-8674(01)80003-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335329	Bronze			2022-12-28	WOS:A1997XZ80900003
J	Phillips, ML; Young, AW; Senior, C; Brammer, M; Andrew, C; Calder, AJ; Bullmore, ET; Perrett, DI; Rowland, D; Williams, SCR; Gray, JA; David, AS				Phillips, ML; Young, AW; Senior, C; Brammer, M; Andrew, C; Calder, AJ; Bullmore, ET; Perrett, DI; Rowland, D; Williams, SCR; Gray, JA; David, AS			A specific neural substrate for perceiving facial expressions of disgust	NATURE			English	Article							HUMAN AMYGDALA; MACAQUE MONKEY; ORGANIZATION; CORTEX; RECOGNITION; PERCEPTION; EMOTIONS; NEURONS; STIMULI; DAMAGE	Recognition of facial expressions is critical to our appreciation of the social and physical environment, with separate emotions having distinct facial expressions(1). Perception of fearful facial expressions has been extensively studied, appearing to depend upon the amygdala(2-6). Disgust-literally 'bad taste'-is another important emotion, with a distinct evolutionary history(7), and is conveyed by a characteristic facial expression(8-10). We have used functional magnetic resonance imaging (MRI) to examine the neural substrate for perceiving disgust expressions. Normal volunteers were presented with faces showing mild or strong disgust or fear. Cerebral activation in response to these stimuli was contrasted with that for neutral faces. Results for fear generally confirmed previous positron emission tomography findings of amygdala involvement. Both strong and mild expressions of disgust activated anterior insular cortex but not the amygdala; strong disgust also activated structures linked to a limbic cortico-striatal-thalamic circuit. The anterior insula is known to be involved in responses to offensive tastes. The neural response to facial expressions of disgust in others is thus closely related to appraisal of distasteful stimuli.	MRC, APPL PSYCHOL UNIT, CAMBRIDGE CB2 2EF, ENGLAND; INST PSYCHIAT, NEUROIMAGING UNIT, LONDON SE5 8AF, ENGLAND; INST PSYCHIAT, BRAIN IMAGE ANAL UNIT, LONDON SE5 8AF, ENGLAND; INST PSYCHIAT, DEPT PSYCHOL, LONDON SE5 8AF, ENGLAND; UNIV ST ANDREWS, SCH PSYCHOL, ST ANDREWS KY16 9JU, FIFE, SCOTLAND	University of Cambridge; University of London; King's College London; University of London; King's College London; University of London; King's College London; University of St Andrews	Phillips, ML (corresponding author), UNIV LONDON KINGS COLL, SCH MED & DENT, DEPT PSYCHOL MED, 103 DENMARK HILL, LONDON SE5 8AZ, ENGLAND.		David, Anthony S/C-1315-2011; anand, amit/A-7222-2009; Young, Andy/G-2189-2011; Bullmore, Ed/C-1706-2012; Williams, Steve C/D-6979-2011; Brammer, Michael J/B-7128-2012; David, Anthony/O-1750-2019	David, Anthony S/0000-0003-0967-774X; Young, Andy/0000-0002-1202-6297; Bullmore, Ed/0000-0002-8955-8283; Williams, Steve C/0000-0003-4299-1941; Brammer, Michael J/0000-0001-9800-2052; David, Anthony/0000-0003-0967-774X; opoku, anita/0000-0001-7243-8157; Perrett, David/0000-0002-6025-0939	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; BARBAS H, 1993, NEUROSCIENCE, V56, P841, DOI 10.1016/0306-4522(93)90132-Y; BRAMMER MJ, IN PRESS MAG RES IMA; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Bullmore E, 1996, MAGN RESON MED, V35, P261, DOI 10.1002/mrm.1910350219; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; CALDER AJ, IN PRESS P R SOC B; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; Darwin C., 1965, EXPRESS EMOT MAN; Edgington E. S., 1980, RANDOMIZATION TESTS; EKMAN P, 1992, COGNITION EMOTION, V6, P169, DOI 10.1080/02699939208411068; Ekman P., 1976, PICTURES FACIAL AFFE; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GRAY JM, IN PRESS BRAIN; KINOMURA S, 1994, BRAIN RES, V659, P263, DOI 10.1016/0006-8993(94)90890-7; Kosslyn SM, 1996, NEUROREPORT, V7, P1569, DOI 10.1097/00001756-199607080-00007; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; PERRETT DI, 1994, NATURE, V368, P239, DOI 10.1038/368239a0; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1970, DOI 10.1152/jn.1996.75.5.1970; ROLLS ET, 1994, HDB CLIN OLFACTION G; ROZIN P, 1987, PSYCHOL REV, V94, P23, DOI 10.1037/0033-295X.94.1.23; ROZIN P, 1994, J PERS SOC PSYCHOL, V66, P870, DOI 10.1037//0022-3514.66.5.870; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Talairach J., 1988, COPLANAR STEREOTAXIC; VRANA SR, 1993, PSYCHOPHYSIOLOGY, V30, P279, DOI 10.1111/j.1469-8986.1993.tb03354.x; YAXLEY S, 1988, PHYSIOL BEHAV, V42, P223, DOI 10.1016/0031-9384(88)90074-1	30	1166	1185	6	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					495	498		10.1038/39051	http://dx.doi.org/10.1038/39051			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XY909	9333238				2022-12-28	WOS:A1997XY90900056
J	Rubinstein, M; Phillips, TJ; Bunzow, JR; Falzone, TL; Dziewczapolski, G; Zhang, G; Fang, Y; Larson, JL; McDougall, JA; Chester, JA; Saez, C; Pugsley, TA; Gershanik, O; Low, MJ; Grandy, DK				Rubinstein, M; Phillips, TJ; Bunzow, JR; Falzone, TL; Dziewczapolski, G; Zhang, G; Fang, Y; Larson, JL; McDougall, JA; Chester, JA; Saez, C; Pugsley, TA; Gershanik, O; Low, MJ; Grandy, DK			Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine	CELL			English	Article							METHYL-D-ASPARTATE; EXTRACELLULAR DOPAMINE; TYROSINE-HYDROXYLASE; NUCLEUS-ACCUMBENS; FUNCTIONAL-CHARACTERIZATION; GLUTAMATE-RECEPTOR; SUBSTANTIA-NIGRA; NOVELTY SEEKING; PRIMATE BRAIN; BASAL GANGLIA	The human dopamine D4 receptor (D4R) has received considerable attention because of its high affinity for the atypical antipsychotic clozapine and the unusually polymorphic nature of its gene. To clarify the in vivo role of the D4R, we produced and analyzed mutant mice (D4R(-/-)) lacking this protein. Although less active in open field tests, D4R(-/-) mice outperformed wildtype mice on the rotarod and displayed locomotor supersensitivity to ethanol, cocaine, and methamphetamine. Biochemical analyses revealed that dopamine synthesis and its conversion to DOPAC were elevated in the dorsal striatum from D4R(-/-) mice. Based on these findings, we propose that the D4R modulates normal, coordinated and drug-stimulated motor behaviors as well as the activity of nigrostriatal dopamine neurons.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BEHAV NEUROSCI,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; UNIV BUENOS AIRES,INST INVEST FARMACOL,RA-1053 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,INST INVEST INGN GENET & BIOL MOL,CONICET,RA-1053 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,DEPT QUIM BIOL,FCEYN,RA-1053 BUENOS AIRES,DF,ARGENTINA; DEPT VET AFFAIRS MED CTR,RES SERV,PORTLAND,OR 97201; HOSP UNIV VIRGEN DEL ROCIO,SEVILLE 41013,SPAIN; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,ANN ARBOR,MI 48105	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Virgen del Rocio University Hospital; Pfizer			Falzone, Tomás/W-2528-2019; Sáez, Carmen/B-9468-2015; IBIS, TUMORIGENESIS/P-3506-2015	Sáez, Carmen/0000-0002-8600-0508; Dziewczapolski, Gustavo/0000-0003-1393-485X; Low, Malcolm/0000-0002-9900-3708; Falzone, Tomas/0000-0002-7984-1149	NIAAA NIH HHS [P60 AA010760] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; Ariano MA, 1997, BRAIN RES, V752, P26, DOI 10.1016/S0006-8993(96)01422-9; ARNT J, 1995, EUR J PHARMACOL, V283, P55, DOI 10.1016/0014-2999(95)00292-S; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; Bergson C, 1995, J NEUROSCI, V15, P7821; BOUVIER C, 1995, EUR J PHARM-MOLEC PH, V290, P11, DOI 10.1016/0922-4106(95)90011-X; CAMP DM, 1994, BRAIN RES, V668, P180, DOI 10.1016/0006-8993(94)90523-1; CARLSSON A, 1975, J NEURAL TRANSM, V40, P99; CARTER CJ, 1982, NEUROPHARMACOLOGY, V21, P379, DOI 10.1016/0028-3908(82)90019-3; CHRISTOFFERSEN CL, 1995, NEUROSCIENCE, V67, P373, DOI 10.1016/0306-4522(95)00047-M; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DAR MS, 1984, J NEURAL TRANSM, V60, P283, DOI 10.1007/BF01249100; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; FADDA F, 1991, ALCOHOL ALCOHOLISM S, V1, P439; FISHBURN CS, 1995, FEBS LETT, V361, P215, DOI 10.1016/0014-5793(95)00168-9; FREED CR, 1985, SCIENCE, V229, P62, DOI 10.1126/science.4012312; Geijer T, 1997, ALCOHOL CLIN EXP RES, V21, P35; GEORGE SR, 1993, BIOCHEM BIOPH RES CO, V196, P107, DOI 10.1006/bbrc.1993.2222; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; IMPERATO A, 1986, J PHARMACOL EXP THER, V239, P219; ISHII A, 1991, BIOCHEM BIOPH RES CO, V176, P1051, DOI 10.1016/0006-291X(91)90389-O; Kotler M, 1997, MOL PSYCHIATR, V2, P251, DOI 10.1038/sj.mp.4000248; KRISCH I, 1994, J PHARMACOL EXP THER, V271, P343; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LEYSEN JE, 1993, PSYCHOPHARMACOLOGY, V112, pS40, DOI 10.1007/BF02245006; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; MAISONNEUVE IM, 1990, BRAIN RES, V535, P221, DOI 10.1016/0006-8993(90)91604-F; MEADORWOODRUFF JH, 1994, NEUROPSYCHOPHARMACOL, V10, P239, DOI 10.1038/npp.1994.27; Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0; Muramatsu T, 1996, J MED GENET, V33, P113, DOI 10.1136/jmg.33.2.113; OVERTON P, 1992, J NEURAL TRANSM-PARK, V4, P1, DOI 10.1007/BF02257617; Phillips TJ, 1996, INT REV NEUROBIOL, V39, P243, DOI 10.1016/S0074-7742(08)60669-8; PHILLIPS TJ, 1991, PSYCHOPHARMACOLOGY, V103, P557, DOI 10.1007/BF02244259; PHILLIPS TJ, 1994, ALCOHOL CLIN EXP RES, V18, P931, DOI 10.1111/j.1530-0277.1994.tb00062.x; PHILLIPS TJ, 1995, ALCOHOL CLIN EXP RES, V19, P269, DOI 10.1111/j.1530-0277.1995.tb01502.x; Pugsley TA, 1995, J PHARMACOL EXP THER, V275, P1355; RASSNICK S, 1992, PSYCHOPHARMACOLOGY, V109, P92, DOI 10.1007/BF02245485; REYNOLDS GP, 1994, J NEUROCHEM, V63, P1576; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; VANTOL HHM, 1992, NATURE, V358, P149; WADDINGTON JL, 1993, REGULATION UNCONDITI, P51; WEISS F, 1992, J NEUROSCI, V12, P4372; Werner P, 1996, MOL PHARMACOL, V49, P656; WESTERINK BHC, 1992, N-S ARCH PHARMACOL, V345, P523, DOI 10.1007/BF00168943; White FJ, 1996, ANNU REV NEUROSCI, V19, P405, DOI 10.1146/annurev.ne.19.030196.002201; Wichmann T, 1996, CURR OPIN NEUROBIOL, V6, P751, DOI 10.1016/S0959-4388(96)80024-9; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215; ZORN SH, 1994, EUR J PHARM-MOLEC PH, V269, pR1, DOI 10.1016/0922-4106(94)90047-7	59	391	401	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					991	1001		10.1016/S0092-8674(00)80365-7	http://dx.doi.org/10.1016/S0092-8674(00)80365-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323127	Bronze			2022-12-28	WOS:A1997XX76800005
J	Mumford, DM				Mumford, DM			Thank God I have cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					956	956						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302252				2022-12-28	WOS:A1997XV64000040
J	DeLong, GR; Leslie, PW; Wang, SH; Jiang, XM; Zhang, ML; Rakeman, MA; Jiang, JY; Ma, T; Cao, XY				DeLong, GR; Leslie, PW; Wang, SH; Jiang, XM; Zhang, ML; Rakeman, MA; Jiang, JY; Ma, T; Cao, XY			Effect on infant mortality of iodination of irrigation water in a severely iodine-deficient area of China	LANCET			English	Article								Background Hotien county in Xinjiang province, China, is an area of severe iodine deficiency and has a high infant-mortality rate. We investigated whether iodine replacement through iodination of the irrigation water would decrease infant mortality. Methods We added potassium iodate to irrigation water over a 2 to 4 week period beginning in 1992 in certain areas of three townships (Tusala, Long Ru, and Bakechi). Logistic regression analysis was used to compare the odds ratios for infant and neonatal mortality in treated and untreated areas. Findings The median urinary iodine concentration significantly increased in women of child-bearing age from <10 mu g/L to 55 mu g/L Infant-mortality rates decreased in the treated areas of Long Ru (mean [SD]) 58.2 [4.4] per 1000 births to 28.7 [7.1] per 1000 births), Tusala (47.4 [12.4] per 1000 births to 19.1 [1.5] per 1000 births), and Bakechi (106.2 [9.5] per 1000 births to 57.3 [7.3] per 1000 births). Similar results were also seen for neonatal mortality. On regression analysis iodine treatment and time were significant independent predictors of infant mortality. Interpretation iodine supplementation of irrigation water in areas of severe iodine deficiency decreases neonatal and infant mortality. iodine replacement has probably been an important factor in the national decrease in infant mortality in China.	UNIV N CAROLINA, CHAPEL HILL, NC USA; XINJIANG ENDEM DIS RES INST, URUMQI, PEOPLES R CHINA; XINJIANG HLTH & ANTIEPIDEM STN, URUMQI, PEOPLES R CHINA; TIANJIN MED COLL, TIANJIN, PEOPLES R CHINA	University of North Carolina; University of North Carolina Chapel Hill; Tianjin Medical University	DeLong, GR (corresponding author), DUKE UNIV, MED CTR, DIV PEDIAT NEUROL, BOX 3936, DURHAM, NC 27710 USA.							Ansell Jack E., 1996, P821; CAO XY, 1994, NEW ENGL J MED, V331, P1739, DOI 10.1056/NEJM199412293312603; CAO XY, 1994, LANCET, V344, P107, DOI 10.1016/S0140-6736(94)91286-6; Hsiao WCL, 1996, NEW ENGL J MED, V335, P430, DOI 10.1056/NEJM199608083350611; JIANG XM, 1997, DIS THYROID, P361; Ma T., 1994, SOS BILLION, P259; THILLY CH, 1994, DAMAGED BRAIN OF IODINE DEFICIENCY, P241	7	92	101	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	1997	350	9080					771	773		10.1016/S0140-6736(96)12365-5	http://dx.doi.org/10.1016/S0140-6736(96)12365-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297997				2022-12-28	WOS:A1997XW28200012
J	Pathare, SR; Paton, C				Pathare, SR; Paton, C			ABC of mental health - Psychotropic drug treatment	BRITISH MEDICAL JOURNAL			English	Review								This article takes a broad view of the factors affecting the choice and effectiveness of common drugs in psychiatric use. Specific treatment issues are dealt with in earlier articles in this series.	OXLEAS NHS TRUST,BEXLEY,KENT,ENGLAND		Pathare, SR (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.			Pathare, Soumitra/0000-0001-9311-9024				BAZIRE S, 1995, PSYCHOTROPIC DRUG DI; DAVIES T, 1997, PSYCHIAT B, V21, P200; National Medical Advisory Committee, 1994, MAN ANX INS; THOMPSON C, 1994, BRIT J PSYCHIAT, V164, P448, DOI 10.1192/bjp.164.4.448; 1996, PRESCRIBERS J, V36, P181; 1996, DRUG THER B, V34, P65; 1994, DRUG THER B, V32, P73	7	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					661	664		10.1136/bmj.315.7109.661	http://dx.doi.org/10.1136/bmj.315.7109.661			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XW694	9310571	Green Published			2022-12-28	WOS:A1997XW69400025
J	Persson, CGA				Persson, CGA			Centennial notions of asthma as an eosinophilic, desquamative, exudative, and steroid-sensitive disease	LANCET			English	Article							MUCOSAL				Persson, CGA (corresponding author), UNIV LUND HOSP,DEPT CLIN PHARMACOL,S-22185 LUND,SWEDEN.							BERKART JJB, 1889, ASTHMA ITS PATHOLOGY; BORDLEY JE, 1949, B J HOPKINS HOSP, V85, P96; Cohen MB, 1930, J IMMUNOL, V18, P419; COHNHEIM J, 1882, VORLESUNGEN ALLGEMEI, V1, P232; CRYSTAL RG, 1977, SCI FDN LUNG; CURSCHMANN H, 1883, DTSCH ARCH KLIN MED, V32, P1; Ehrlich P, 1879, ARCH ANAT PHYSIOL, V3, P166; ELWOOD RK, 1983, AM REV RESPIR DIS, V128, P523, DOI 10.1164/arrd.1983.128.3.523; EMANUEL MB, 1995, CLIN EXP ALLERGY, V25, P15, DOI 10.1111/j.1365-2222.1995.tb00998.x; FRAENKEL A, 1898, Z KLIN MED, V35, P559; GREIFF L, 1993, THORAX, V48, P648, DOI 10.1136/thx.48.6.648; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HUTT G, 1956, Z AEROSOL FORSCH THE, V5, P131; JEZIERSKI PV, 1906, DTSCH ARCH KLIN MED, V85, P342; LAITINEN LA, 1993, AM REV RESPIR DIS, V139, P806; LENHARTZ H, 1899, HDB PRAKTISCHEN MED, P392; Leyden E., 1872, ARCH PATHOL ANAT PH, V54, P324; Marchand F, 1916, BEITR PATHOL ANAT AL, V61, P251; Persson CGA, 1996, PULM PHARMACOL THER, V9, P129, DOI 10.1006/pulp.1996.0015; Persson CGA, 1996, THORAX, V51, P441, DOI 10.1136/thx.51.4.441; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P117, DOI 10.1016/S0165-6147(97)01042-0; PERSSON CGA, 1997, SCI FDN, P2611; PERSSON CGA, 1997, BETA2 AGONISTS ASTHM, P1; PIENIAZEK, 1905, WIEN KLIN WOCHENSCHR, V18, P1201; ROSENSTERN J, 1909, JB KINDERHEILKUNDS, V69, P631; Salter HH, 1868, ASTHMA ITS PATHOLOGY; SCHADEWALDT H, 1979, GESCH ALLEGIE, V1; SCHLECHT H, 1912, DTSCH ARCH KLIN MED, V108, P405; SCHLEIMER RP, 1977, INHALED GLUCOCORTICO; SCHMIDT A, 1892, Z KLIN MED, V20, P476; Solis-Cohen S., 1900, J AM MED ASS, V34, P1164, DOI [10.1001/jama.1900.24610190014001c, DOI 10.1001/JAMA.1900.24610190014001C]; STOERK K, 1875, ASTHMA BRONCHIALE; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; Woolcock AJ, 1996, AM J RESP CRIT CARE, V153, pS1, DOI 10.1164/ajrccm/153.6_Pt_2.S1	34	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					1021	1024		10.1016/S0140-6736(96)02335-5	http://dx.doi.org/10.1016/S0140-6736(96)02335-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329527				2022-12-28	WOS:A1997XZ71000046
J	OssarehNazari, B; Bachelerie, F; Dargemont, C				OssarehNazari, B; Bachelerie, F; Dargemont, C			Evidence for a role of CRM1 in signal-mediated nuclear protein export	SCIENCE			English	Article							ORDER CHROMOSOME STRUCTURE; LOCALIZATION SIGNALS; IMPORT FACTOR; LEPTOMYCIN-B; REV PROTEIN; IDENTIFICATION; YEAST; TRANSPORT; INTERACTS; PATHWAY	Chromosome maintenance region 1 (CRM1), a protein that shares sequence similarities with the karyopherin beta family of proteins involved in nuclear import pathway, was shown to form a complex with the leucine-rich nuclear export signal (NES), This interaction was inhibited by leptomycin B, a drug that prevents the function of the CRM1 protein in yeast, To analyze the role of the CRM1-NES interaction in nuclear export, a transport assay based on semipermeabilized cells was developed. In this system, which reconstituted NES-, cytosol-, and energy-dependent nuclear export, leptomycin B specifically blocked export of NES-containing proteins, Thus, the CRM1 protein could act as a NES receptor involved in nuclear protein export.	INST CURIE,CNRS,UMR 144,F-75248 PARIS 05,FRANCE; INST PASTEUR,UNITE IMMUNOL VIRALE,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			BACHELERIE, FRANCOISE/F-8823-2013	BACHELERIE, FRANCOISE/0000-0002-0399-3277				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MELCHIOR F, 1993, J CELL BIOL, V123, P215; MICHAEL WM, 1995, CELL, V83, P415; MICHAEL WM, 1997, EMBO J, V12, P3587; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NISHI K, 1994, J BIOL CHEM, V269, P6320; OSSAREHNAZARI B, UNPUB; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; ROUT M, 1997, LCELL, V89, P715; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	37	616	627	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					141	144		10.1126/science.278.5335.141	http://dx.doi.org/10.1126/science.278.5335.141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311922				2022-12-28	WOS:A1997XZ12400058
J	Albillos, A; Dernick, G; Horstmann, H; Almers, W; deToledo, GA; Lindau, M				Albillos, A; Dernick, G; Horstmann, H; Almers, W; deToledo, GA; Lindau, M			The exocytotic event in chromaffin cells revealed by patch amperometry	NATURE			English	Article							ADRENAL-MEDULLARY CELLS; FUSION PORE; TRANSMITTER RELEASE; TIME-COURSE; SECRETORY GRANULES; SINGLE VESICLES; CATECHOLAMINES; FORMS	In mast cells and granulocytes, exocytosis starts with the formation of a fusion pore(1-3). It has been suggested that neurotransmitters may be released through such a narrow pore without full fusion(4,5). However, owing to the small size of the secretory vesicles containing neurotransmitter, the properties of the fusion pore formed during Ca2+-dependent exocytosis and its role in transmitter release are still unknown, Here we investigate exocytosis of individual chromaffin granules by using cell-attached capacitance measurements(3,6) combined,vith electrochemical detection of catecholamines(7,8), achieved by inserting a carbon-fibre electrode into the patch pipette. This allows the simultaneous determination of the opening of individual fusion pores and of the kinetics of catecholamine release from the same vesicle, We found that the fusion-pore diameter stays at <3 nm for a variable period, which can last for several seconds, before it expands, Transmitter is released much faster through this pore than in mast cells, generating a 'foot' signal(8) which precedes the amperometric spike. Occasionally, the narrow pore forms only transiently and does not expand, allowing complete transmitter release without full fusion of the vesicle with the plasma membrane.	MPI MED RES,DEPT MOL & CELL RES,D-69128 HEIDELBERG,GERMANY; UNIV SEVILLA,DEPT PHYSIOL & BIOPHYS,E-41009 SEVILLE,SPAIN	University of Sevilla			Alvarez de Toledo, Guillermo/I-2888-2015; Lindau, Manfred/ABD-3449-2021; Albillos, Almudena/AAA-9098-2019	Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Lindau, Manfred/0000-0002-5722-9557; ALBILLOS, ALMUDENA/0000-0003-3315-9715				ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; BACH G, 1967, QUANTITATIVE METHODS, P23; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; Chen BM, 1997, J NEUROSCI, V17, P904; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow RH, 1996, NEURON, V16, P369, DOI 10.1016/S0896-6273(00)80054-9; Chow Robert H., 1995, P245; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; GASNIER B, 1987, FEBS LETT, V222, P215, DOI 10.1016/0014-5793(87)80222-3; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; Moser T, 1995, PFLUG ARCH EUR J PHY, V431, P196, DOI 10.1007/BF00410191; NEHER E, 1993, NATURE, V363, P497, DOI 10.1038/363497a0; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; SCHERMAN D, 1988, NEUROSCIENCE, V27, P1029, DOI 10.1016/0306-4522(88)90207-2; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; Walker A, 1996, PFLUG ARCH EUR J PHY, V432, P885, DOI 10.1007/s004240050212; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	30	461	469	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					509	512		10.1038/39081	http://dx.doi.org/10.1038/39081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333242				2022-12-28	WOS:A1997XY90900060
J	Nightingale, SL				Nightingale, SL			New requirement for pediatric data on drug products proposed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, JAMA-J AM MED ASSOC, V273, P279	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-28	WOS:A1997XX30300008
J	Scheidler, J; Hricak, H; Yu, KK; Subak, L; Segal, MR				Scheidler, J; Hricak, H; Yu, KK; Subak, L; Segal, MR			Radiological evaluation of lymph node metastases in patients with cervical cancer - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GYNECOLOGIC ONCOLOGY GROUP; SQUAMOUS-CELL CARCINOMA; EXTENDED FIELD IRRADIATION; COMPUTED-TOMOGRAPHY; STAGE-IB; UTERINE CERVIX; RADICAL HYSTERECTOMY; INVASIVE-CARCINOMA; DIAGNOSTIC-TEST; PROGNOSTIC-SIGNIFICANCE	Objective.-To apply meta-analysis to compare the utility of lymphangiography (LAG), computed tomography (CT), and magnetic resonance (MR) imaging for the diagnosis of lymph node metastasis in patients with cervical cancer. Data Sources.-MEDLINE literature search and manual reviews of article bibliographies. Study Selection.-Studies selected included at least 20 patients with imaging-histologic correlation, described diagnostic criteria for lymph node metastasis, and presented data to allow calculation of contingency tables. Data Extraction.-Independently by 2 investigators, stratified for stage of disease (early vs late) and for lymph node location (pelvic vs para-aortic). Data Synthesis.-Seventeen studies met the inclusion criteria for LAG, 17 for CT, and 10 for MR imaging. Summary receiver operator characteristic analysis showed no significant differences in the overall performance of LAG, CT, and MR imaging. There was, however, a trend toward better performance for MR imaging than for LAG or CT, both globally and when stratified for stage of disease or for lymph node location. Bayesian analysis of clinical utility showed only moderate increases in positive posttest probability of lymph node metastasis for all methods. Negative test results had a greater impact and, depending on the clinical setting, decreased the probability of lymph node metastasis from 15% to 44% (pretest) to 3% to 18% (posttest). Conclusions.-The LAG, CT, and MR imaging perform similarly in the detection of lymph node metastasis from cervical cancer. As CT and MR imaging are less invasive than LAG and also assess local tumor extent, they should be considered the preferred adjuncts to clinical evaluation of invasive cervical cancer.	UNIV CALIF SAN FRANCISCO,DEPT RADIOL,ABDOMINAL IMAGING SECT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT & EPIDEMIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ASHRAF M, 1982, GYNECOL ONCOL, V14, P96, DOI 10.1016/0090-8258(82)90055-5; BALLON SC, 1981, OBSTET GYNECOL, V57, P90; BANDY LC, 1985, OBSTET GYNECOL, V65, P73; BERMAN ML, 1984, GYNECOL ONCOL, V19, P8, DOI 10.1016/0090-8258(84)90151-3; BERMAN ML, 1977, OBSTET GYNECOL, V50, P658; BLACK WC, 1986, AM J ROENTGENOL, V147, P1313, DOI 10.2214/ajr.147.6.1313; BONANNO JP, 1980, J AM OSTEOPATH ASSOC, V79, P567; BORONOW RC, 1977, AM J OBSTET GYNECOL, V127, P135, DOI 10.1016/S0002-9378(16)33238-0; BRENNER DE, 1982, CANCER, V50, P2323, DOI 10.1002/1097-0142(19821201)50:11<2323::AID-CNCR2820501117>3.0.CO;2-2; BROWN RC, 1979, OBSTET GYNECOL, V54, P571; BUCHSBAUM HJ, 1979, AM J OBSTET GYNECOL, V133, P814, DOI 10.1016/0002-9378(79)90118-2; BURGHARDT E, 1978, OBSTET GYNECOL, V52, P138; CAMILIEN L, 1988, GYNECOL ONCOL, V30, P209, DOI 10.1016/0090-8258(88)90026-1; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; CHUNG CK, 1981, GYNECOL ONCOL, V12, P348, DOI 10.1016/0090-8258(81)90135-9; DARGENT D, 1985, GYNECOL ONCOL, V22, P15, DOI 10.1016/0090-8258(85)90002-2; DELGADO G, 1990, GYNECOL ONCOL, V38, P352, DOI 10.1016/0090-8258(90)90072-S; DEMUYLDER X, 1984, AM J OBSTET GYNECOL, V148, P610, DOI 10.1016/0002-9378(84)90759-2; DOWNEY GO, 1989, AM J OBSTET GYNECOL, V160, P1055, DOI 10.1016/0002-9378(89)90160-9; FEIGEN M, 1987, SURG GYNECOL OBSTET, V165, P107; FULLER AF, 1989, GYNECOL ONCOL, V33, P34, DOI 10.1016/0090-8258(89)90598-2; GAUTHIER P, 1985, OBSTET GYNECOL, V66, P569; GRECO A, 1989, CLIN RADIOL, V40, P401, DOI 10.1016/S0009-9260(89)80136-9; GRUMBINE FC, 1981, GYNECOL ONCOL, V12, P286, DOI 10.1016/0090-8258(81)90127-X; HALDANE JBS, 1955, ANN HUM GENET, V20, P309; HAWNAUR JM, 1994, CLIN RADIOL, V49, P443, DOI 10.1016/S0009-9260(05)81738-6; HELLER PB, 1990, GYNECOL ONCOL, V38, P425, DOI 10.1016/0090-8258(90)90085-Y; Heuck A, 1997, ROFO-FORTSCHR RONTG, V166, P210, DOI 10.1055/s-2007-1015411; Ho Chih-Ming, 1992, Journal of the Formosan Medical Association, V91, P982; HOPKINS MP, 1991, AM J OBSTET GYNECOL, V164, P1520, DOI 10.1016/0002-9378(91)91431-U; HRICAK H, 1988, RADIOLOGY, V166, P623, DOI 10.1148/radiology.166.3.3340756; HSU CT, 1972, AM J OBSTET GYNECOL, V114, P954, DOI 10.1016/0002-9378(72)90105-6; HUGHES RR, 1980, GYNECOL ONCOL, V9, P153, DOI 10.1016/0090-8258(80)90022-0; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JANUS CL, 1989, CLIN IMAG, V13, P114, DOI 10.1016/0899-7071(89)90089-2; KARDAUN JWPF, 1990, METHOD INFORM MED, V29, P12; KIM SH, 1993, J COMPUT ASSIST TOMO, V17, P633, DOI 10.1097/00004728-199307000-00022; KIM SH, 1990, RADIOLOGY, V175, P45, DOI 10.1148/radiology.175.1.2315503; KIM SH, 1994, RADIOLOGY, V190, P807, DOI 10.1148/radiology.190.3.8115631; Kindermann G, 1970, Geburtshilfe Frauenheilkd, V30, P444; KING LA, 1986, AM J OBSTET GYNECOL, V155, P960, DOI 10.1016/0002-9378(86)90325-X; Kjorstad K E, 1980, Diagn Gynecol Obstet, V2, P71; KOLBENSTVEDT A, 1975, ACTA RADIOL DIAGN, V16, P81, DOI 10.1177/028418517501600109; La Fianza A, 1990, Radiol Med, V80, P486; LAGASSE LD, 1980, GYNECOL ONCOL, V9, P90, DOI 10.1016/0090-8258(80)90013-X; LAGASSE LD, 1979, AM J OBSTET GYNECOL, V134, P219, DOI 10.1016/0002-9378(79)90889-5; LANGLEY II, 1980, GYNECOL ONCOL, V9, P37, DOI 10.1016/0090-8258(80)90007-4; LECART C, 1971, LYMPHOLOGY, V3, P100; LEE YN, 1989, GYNECOL ONCOL, V32, P135, DOI 10.1016/S0090-8258(89)80024-1; LEMAN M H JR, 1975, Gynecologic Oncology, V3, P354, DOI 10.1016/0090-8258(75)90043-8; MARTIMBEAU PW, 1982, OBSTET GYNECOL, V60, P215; MATSUKUMA K, 1989, GYNECOL ONCOL, V33, P168, DOI 10.1016/0090-8258(89)90544-1; MENDENHALL WM, 1991, INT J RADIAT ONCOL, V21, P899, DOI 10.1016/0360-3016(91)90727-L; MIDGETTE AS, 1993, MED DECIS MAKING, V13, P253, DOI 10.1177/0272989X9301300313; MONTANA GS, 1995, INT J RADIAT ONCOL, V32, P1481, DOI 10.1016/0360-3016(95)00177-Z; MORROW CP, 1993, SYNOPSIS GYNECOLOGIC, P111; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; NELSON JH, 1977, AM J OBSTET GYNECOL, V128, P336, DOI 10.1016/0002-9378(77)90633-0; *NIH, 1996, NIH CONSENSUS STATE, V14, P1; NOGUCHI H, 1987, GYNECOL ONCOL, V27, P150, DOI 10.1016/0090-8258(87)90287-3; PIVER MS, 1973, CANCER, V32, P367, DOI 10.1002/1097-0142(197308)32:2<367::AID-CNCR2820320212>3.0.CO;2-Q; PIVER MS, 1971, AMER J ROENTGENOL RA, V111, P278, DOI 10.2214/ajr.111.2.278; PIVER MS, 1975, OBSTET GYNECOL, V46, P506; POTISH RA, 1985, CANCER, V56, P956, DOI 10.1002/1097-0142(19850815)56:4<956::AID-CNCR2820560442>3.0.CO;2-U; Russell AH, 1996, GYNECOL ONCOL, V63, P159, DOI 10.1006/gyno.1996.0300; SHINGLETON HM, 1993, GYNECOL ONCOL, V51, P299, DOI 10.1006/gyno.1993.1293; SMALES E, 1986, CLIN RADIOL, V37, P19, DOI 10.1016/S0009-9260(86)80156-8; STELLATO G, 1992, European Journal of Gynaecological Oncology, V13, P161; SUBAK LL, 1995, OBSTET GYNECOL, V86, P43, DOI 10.1016/0029-7844(95)00109-5; SUDARSANAM A, 1978, CANCER, V41, P1049, DOI 10.1002/1097-0142(197803)41:3<1049::AID-CNCR2820410337>3.0.CO;2-U; SWART E, 1989, European Journal of Gynaecological Oncology, V10, P85; VANENGELSHOVEN JMA, 1984, GYNECOL OBSTET INVES, V18, P289, DOI 10.1159/000299095; VANNAGELL JR, 1977, GYNECOL ONCOL, V5, P142, DOI 10.1016/0090-8258(77)90018-X; VANNAGELL JR, 1971, AM J OBSTET GYNECOL, V110, P973, DOI 10.1016/0002-9378(71)90551-5; VAS W, 1985, CT-J COMPUT TOMOGR, V9, P359, DOI 10.1016/0149-936X(85)90033-5; VASSALLO P, 1994, RADIOLOGY, V193, P501, DOI 10.1148/radiology.193.2.7972768; VERCAMER R, 1987, CANCER, V60, P1745, DOI 10.1002/1097-0142(19871015)60:8<1745::AID-CNCR2820600812>3.0.CO;2-8; VILLASANTA U, 1983, OBSTET GYNECOL, V62, P218; VINNICOMBE SJ, 1995, RADIOLOGY, V194, P349, DOI 10.1148/radiology.194.2.7824709; VINNICOMBE SJ, 1995, RADIOLOGY, V196, P800; WALSH JW, 1981, AM J ROENTGENOL, V137, P997, DOI 10.2214/ajr.137.5.997; WELANDER CE, 1981, GYNECOL ONCOL, V12, P336, DOI 10.1016/0090-8258(81)90134-7; WHARTON JT, 1977, OBSTET GYNECOL, V49, P333; WHITE CD, 1984, AM J OBSTET GYNECOL, V149, P342, DOI 10.1016/0002-9378(84)90235-7	85	234	245	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1096	1101		10.1001/jama.278.13.1096	http://dx.doi.org/10.1001/jama.278.13.1096			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315770				2022-12-28	WOS:A1997XX30300035
J	Warner, KE; Slade, J; Sweanor, DT				Warner, KE; Slade, J; Sweanor, DT			The emerging market for long-term nicotine maintenance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTES; TOBACCO; GUM; ADDICTION; SMOKING	In increasing numbers, Americans will seek to satisfy nicotine addictions through the use of novel nicotine-delivery products devoid of several of the poisons that make cigarettes so deadly. In the vanguard are tobacco industry devices that heat tobacco derivatives rather than burn tobacco, and pharmaceutical industry nicotine-replacement products, with nicotine gum and the patch now available over the counter. Ostensibly, these 2 industries have diametrically opposed objectives, the tobacco industry striving to sustain nicotine addictions, the pharmaceutical industry to end them. However, a series of technological, economic, political, regulatory, and social developments augurs a strange-bedfellows competition in which these industries will vie for shares of a new multibillion dollar long-term nicotine-maintenance market. Regulatory options range from encouraging competition to banning all nicotine-delivery devices. A more realistic approach discourages use of the most dangerous products, while making less hazardous products readily available to adults.	UNIV MED & DENT NEW JERSEY, DEPT MED, NEW BRUNSWICK, NJ USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, ST PETERS MED CTR, NEW BRUNSWICK, NJ 08903 USA; NON SMOKERS RIGHTS ASSOC, OTTAWA, ON, CANADA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Warner, KE (corresponding author), UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT & POLICY, 109 S OBSERV, ANN ARBOR, MI 48109 USA.			Warner, Kenneth/0000-0002-8214-1776				*ASH, 1996, ASH SMOK HLTH RE MAY, P2; Benowitz NL, 1997, J AM COLL CARDIOL, V29, P1422, DOI 10.1016/S0735-1097(97)00079-X; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; BENOWITZ NL, 1996, NIH PUBLICATION, P93; BRODER K, 1990, J NATL CANCER I, V82, P8, DOI 10.1093/jnci/82.1.8; Brownson RC, 1997, ANNU REV PUBL HEALTH, V18, P163, DOI 10.1146/annurev.publhealth.18.1.163; CAMPBELL WI, 1994, REGULATION TOBACCO P, P542; Cunningham R, 1995, TOB CONTROL, V4, P80, DOI DOI 10.1136/TC.4.1.80; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DAVIS RM, 1993, TOB CONTROL, V2, P11; Eliasson B, 1996, CIRCULATION, V94, P878, DOI 10.1161/01.CIR.94.5.878; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; GIOVINO GA, 1996, NIH PUBLICATION, P39; Glantz S.A., 1996, CIGARETTE PAPERS; GORI GB, 1978, JAMA-J AM MED ASSOC, V240, P1255; HARRIS JE, 1994, 4803 NBER; HEISHMAN SJ, 1993, DRUG ALCOHOL DEPEN, V34, P11, DOI 10.1016/0376-8716(93)90041-N; Heishman SJ, 1994, EXP CLIN PSYCHOPHARM, V2, P345, DOI 10.1037/1064-1297.2.4.345; HENNINGFIELD JE, 1996, NATL I HLTH PUBLICAT, P113; HILTS PJ, 1994, NY TIMES        1127, P1; Hilts PJ, 1996, SMOKE SCREEN TRUTH T; HILTS PJ, 1994, NY TIMES        1127, P13; HOLBROOK J, 1983, HARRISONS PRINCIPLES, P1303; HUGHES JR, 1995, TOB CONTROL, V4, pS33; HWANG SL, 1996, WALL STREET J   0521; JAMIESON S, 1997, CHARLOTTE OBSER 0317, pE1; JARVIK ME, 1993, NICOTINE ADDICTION P, P245; JIMENEZRUIZ C, 1997, NICOTINE REPLACEMENT; KLUGER R, 1996, ASHES ASHES AM HUNDR; KOZLOWSKI LT, 1996, NAT I HLTH PUBLICATI, P161; Leischow SJ, 1996, AM J HEALTH BEHAV, V20, P364; LEISCHOW SJ, 1996, J ADDICT DIS, V15, P146; LONGO WE, 1995, CANCER RES, V55, P2232; Mahood G., 1995, TOB CONTROL, V4, P10, DOI [10.1136/tc.4.1.10, DOI 10.1136/TC.4.1.10]; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Murray RP, 1996, CHEST, V109, P438, DOI 10.1378/chest.109.2.438; Oster G, 1996, MED CARE, V34, P389, DOI 10.1097/00005650-199605000-00002; PAULY JL, 1995, TOB CONTROL, V4, P261, DOI DOI 10.1136/TC.4.3.261; Puska P., 1995, TOB CONTROL, V4, P231, DOI [DOI 10.1136/TC.4.3.231, 10.1136/tc.4.3.231]; RJ Reynolds Tobacco Co, 1988, CHEM BIOL STUD NEW C; Rodu B., 1995, SMOKERS ONLY SMOKELE; RUSSELL MAH, 1991, BRIT J ADDICT, V86, P653; RUSSELL MAH, 1976, BRIT MED J, V1, P1430, DOI 10.1136/bmj.1.6023.1430; SCHWARTZ J, 1997, WASH POST       0426, pA1; SLADE J, 1989, J PSYCHOACTIVE DRUGS, V21, P281, DOI 10.1080/02791072.1989.10472169; SLADE J, 1993, NICOTINE ADDICTION P, P3; SLADE J, 1992, TOBACCO CONTROL S, V1, pS10; Smith CJ, 1996, MUTAT RES-ENVIR MUTA, V361, P1, DOI 10.1016/S0165-1161(96)90222-8; Steimle S, 1996, J NATL CANCER I, V88, P1341, DOI 10.1093/jnci/88.19.1341; *TOB HLTH PROGR, IN PRESS GUID CONTR; TOMAR SL, 1996, TOB CONTROL, V5, P77; U.S. Department of Health and Human Services, 1990, US DEP HLTH HUM SERV; *US DEP HHS, 1996, FED REGISTER, V61, P44396; *US DEP HHS, 1996, NAT I HLTH PUBL; US Department of Health and Human Services, 1988, US DEP HLTH HUM SERV, VCDC 88-8406; US Department of Health and Human Services National Center for Health Statistics, 1989, US DEP HLTH HUM SERV, V169; WEST R, 1991, BRIT J ADDICT, V86, P485; WILKE M, 1996, ADVERTISING AGE 0819, P10; WILLNER JS, 1983, FAMILY MED, P1662	59	72	73	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1087	1092		10.1001/jama.278.13.1087	http://dx.doi.org/10.1001/jama.278.13.1087			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX303	9315768				2022-12-28	WOS:A1997XX30300033
J	Martyn, CN; Greenwald, SE				Martyn, CN; Greenwald, SE			Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension	LANCET			English	Article							ADULT-BLOOD PRESSURE; GROWTH-RETARDATION; UMBILICAL ARTERY; BIRTH-WEIGHT; CHILDREN; DISTENSIBILITY; ACCUMULATION; PIG	There is much evidence that people who had low birthweight tend to have higher blood pressure in later life. However, the mechanisms that mediate this relation are unknown. We argue that, in fetuses whose growth is impaired, synthesis of elastin in the walls of the aorta and large arteries may be deficient, and that this deficiency would lead to permanent changes in the mechanical properties of these vessels. Over a lifetime, such changes could predispose an individual to higher blood pressure, increased left-ventricular mass, and cardiovascular disease.	ROYAL LONDON HOSP,INST PATHOL,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital	Martyn, CN (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Greenwald, Stephen E/C-6928-2012	Greenwald, Stephen/0000-0002-8471-7070				ALGHAZALI W, 1989, BRIT J OBSTET GYNAEC, V96, P697, DOI 10.1111/j.1471-0528.1989.tb03285.x; BENDECK MP, 1992, CIRC RES, V69, P1165; BERRY CL, 1978, BRIT HEART J, V40, P709; BERRY CL, 1973, J ANAT, V114, P83; BERRY CL, 1972, J PATHOL, V108, P265, DOI 10.1002/path.1711080402; CLARKE WR, 1978, CIRCULATION, V58, P626, DOI 10.1161/01.CIR.58.4.626; DAVIS EC, 1995, J HISTOCHEM CYTOCHEM, V43, P1115, DOI 10.1177/43.11.7560894; FOLKOW B, 1987, AM HEART J, V114, P938, DOI 10.1016/0002-8703(87)90591-6; FOURON JC, 1993, AM J PERINAT, V10, P197; GIRERD X, 1991, AM HEART J, V122, P1210, DOI 10.1016/0002-8703(91)90941-A; GREENWALD SE, 1982, CARDIOVASC RES, V16, P716, DOI 10.1093/cvr/16.12.716; Labarthe DR, 1991, ANNU REV PUBL HEALTH, V12, P19; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; Law CM, 1996, J HYPERTENS, V14, P935; LEFEVRE M, 1980, BIOCHIM BIOPHYS ACTA, V630, P519, DOI 10.1016/0304-4165(80)90006-9; Lehmann ED, 1996, LANCET, V348, P744, DOI 10.1016/S0140-6736(05)65619-X; LEUNG DYM, 1977, CIRC RES, V41, P316, DOI 10.1161/01.RES.41.3.316; LEUNG DYM, 1977, EXP CELL RES, V109, P285, DOI 10.1016/0014-4827(77)90008-8; MARTYN CN, 1995, BRIT HEART J, V73, P116; MEYER WW, 1974, ARCH DIS CHILD, V49, P671, DOI 10.1136/adc.49.9.671; Nichols WW, 1990, MCDONALDS BLOOD FLOW, P398; PERSSON E, 1992, ACTA PHYSIOL SCAND, V145, P195, DOI 10.1111/j.1748-1716.1992.tb09356.x; POWELL JT, 1992, ATHEROSCLEROSIS, V97, P201, DOI 10.1016/0021-9150(92)90132-Z; RELF IRN, 1986, ARTERIOSCLEROSIS, V6, P105, DOI 10.1161/01.ATV.6.1.105; RIZZO G, 1991, AM J OBSTET GYNECOL, V165, P876, DOI 10.1016/0002-9378(91)90431-P; Rucker R B, 1977, Int Rev Exp Pathol, V17, P1; SAFAR ME, 1990, J HYPERTENS, V8, pS113; SCHAPIRO SD, 1991, J CLIN INVEST, V87, P1828; VOORS AW, 1979, AM J EPIDEMIOL, V109, P320, DOI 10.1093/oxfordjournals.aje.a112685	29	268	272	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					953	955		10.1016/S0140-6736(96)10508-0	http://dx.doi.org/10.1016/S0140-6736(96)10508-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314885				2022-12-28	WOS:A1997XY67200043
J	Souhami, RL; Craft, AW; VanderEijken, JW; Nooij, M; Spooner, D; Bramwell, VHC; Wierzbicki, R; Malcolm, AJ; Kirkpatrick, A; Uscinska, BM; VanGlabbeke, M; Machin, D				Souhami, RL; Craft, AW; VanderEijken, JW; Nooij, M; Spooner, D; Bramwell, VHC; Wierzbicki, R; Malcolm, AJ; Kirkpatrick, A; Uscinska, BM; VanGlabbeke, M; Machin, D			Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup	LANCET			English	Article							ADJUVANT CHEMOTHERAPY; OSTEOGENIC-SARCOMA; NEOADJUVANT CHEMOTHERAPY; DOSE INTENSITY; YOUNG-ADULTS; METHOTREXATE; DOXORUBICIN; CHILDREN; TUMOR	Background A previous trial by the European Osteosarcoma Intergroup (EOI) suggested that a short intensive chemotherapy regimen with doxorubicin and cisplatin might produce survival of operable, non-metastatic osteosarcoma similar to that obtained with complex and longer-duration drug regimens based on the widely used T10 multi-drug protocol. We undertook a randomised multicentre trial to compare these two approaches. Methods 407 patients with operable, non-metastatic osteosarcoma were randomly assigned the two-drug regimen (six cycles [18 weeks] of doxorubicin 25 mg/m(2) on days 1-3 and cisplatin 100 mg/m(2) on day 1) or a multi-drug regimen (preoperatively vincristine, high-dose methotrexate, and doxorubicin; postoperatively bleomycin, cyclophosphamide, dactinomycin, vincristine, methotrexate, doxorubicin, and cisplatin; this protocol took 44 weeks). Surgery was scheduled for week 9 for the two-drug group and week 7 for the multi-drug group. Analyses of survival and progression-free survival were by intention to treat. Findings Of 407 randomised patients, 391 were eligible and have been followed up for at least 4 years (median 5.6 years). Toxic effects were qualitatively similar with the two regimens. However, 188 (94%) of 199 patients completed the six cycles of two-drug treatment, whereas only 97 (51%) of 192 completed 18 or more of the 20 cycles of the multi-drug regimen. The proportion showing a good histopathological response (>90% tumour necrosis) to preoperative chemotherapy was about 29% with both regimens and was strongly predictive of survival. Overall survival was 65% at 3 years and 55% at 5 years in both groups (hazard ratio 0.94 [95% CI 0.69-1.27]). Progression-free survival at 5 years was 44% in both groups (hazard ratio 1.01[0.77-1.33]). Interpretation We found no difference in survival between the two-drug and multi-drug regimens in operable, non-metastatic osteosarcoma. The two-drug regimen is shorter in duration and better tolerated, and is therefore the preferred treatment. However, 5-year survival is still unsatisfactory and new approaches to treatment, such as dose intensification, are needed to improve results.	ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; ONZE LIEVE VROUW HOSP, AMSTERDAM, NETHERLANDS; ACAD HOSP LEIDEN, LEIDEN, NETHERLANDS; ROYAL ORTHOPAED HOSP, BIRMINGHAM B31 2AP, W MIDLANDS, ENGLAND; LONDON REG CANC CTR, LONDON, ON N6A 4L6, CANADA; CANC TREATMENT & RES FDN, HALIFAX, NS, CANADA; EORTC DATA CTR, BRUSSELS, BELGIUM; MRC, CANC TRIALS OFF, CAMBRIDGE, ENGLAND	Newcastle University - UK; Onze Lieve Vrouwe Gasthuis Hospital; Leiden University; Leiden University Medical Center (LUMC); Royal Orthopaedic Hospital; Western University (University of Western Ontario); European Organisation for Research & Treatment of Cancer	Souhami, RL (corresponding author), UCL, SCH MED, GOWER ST, LONDON WC1E 6BT, ENGLAND.							BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; Delepine N, 1996, CANCER-AM CANCER SOC, V78, P2127, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2127::AID-CNCR13>3.3.CO;2-Z; EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21; *EUR OST INT, 1993, 80931 EORTC EUR OST; GRAF N, 1994, J CLIN ONCOL, V12, P1443, DOI 10.1200/JCO.1994.12.7.1443; GREM JL, 1988, JNCI-J NATL CANCER I, V80, P626, DOI 10.1093/jnci/80.9.626; LANGE B, 1982, CANCER TREAT REP, V66, P1699; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5; MISER JS, 1987, J CLIN ONCOL, V5, P1191, DOI 10.1200/JCO.1987.5.8.1191; ORNADEL D, 1994, J CLIN ONCOL, V12, P1842, DOI 10.1200/JCO.1994.12.9.1842; Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76; ROSEN G, 1982, CANCER TREAT REP, V66, P1687; ROSEN G, 1982, CANCER-AM CANCER SOC, V49, P1221, DOI 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E; SMITH MA, 1991, JNCI-J NATL CANCER I, V83, P1460, DOI 10.1093/jnci/83.20.1460; WINKLER K, 1984, J CLIN ONCOL, V2, P617, DOI 10.1200/JCO.1984.2.6.617; WINKLER K, 1988, J CLIN ONCOL, V6, P329, DOI 10.1200/JCO.1988.6.2.329	17	290	303	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					911	917		10.1016/S0140-6736(97)02307-6	http://dx.doi.org/10.1016/S0140-6736(97)02307-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314869				2022-12-28	WOS:A1997XY67200009
J	Steinhoff, MC; AbdElKhalek, MK; Khallaf, N; Hamza, HS; ElAyadi, A; Orabi, A; Fouad, H; Kamei, M				Steinhoff, MC; AbdElKhalek, MK; Khallaf, N; Hamza, HS; ElAyadi, A; Orabi, A; Fouad, H; Kamei, M			Effectiveness of clinical guidelines for the presumptive treatment of streptococcal pharyngitis in Egyptian children	LANCET			English	Article							RHEUMATIC HEART-DISEASE; DEVELOPING-COUNTRIES; DIAGNOSIS; FEVER; PREVENTION; MANAGEMENT	Background Primary prevention of acute rheumatic fever requires antibiotic treatment of acute streptococcal pharyngitis. In developing countries, clinicians must rely on clinical guidelines for presumptive treatment of streptococcal pharyngitis since bacterial culture and rapid diagnostic tests are not feasible. We evaluated the WHO Acute Respiratory Infection guideline in a large urban paediatric clinic in Egypt. Methods Children between 2 and 13 years of age who had a sore throat and pharyngeal erythema were enrolled in the study. Clinical, historical, and demographic information was recorded and a throat culture for group A P-haemolytic streptococci was done. Sensitivity (% of true-positive throat cultures) and specificity (% of true-negative throat cultures] were calculated for each clinical feature. The effect of various guidelines on correct presumptive treatment for throat-culture status was calculated. Findings Of 451 children with pharyngitis, 107 (24%) had group A beta-haemolytic streptococci on throat culture. A purulent exudate was seen in 22% (99/450) of these children and this sign was 31% sensitive and 81% specific for a positive culture. The WHO Acute Respiratory Infections [ARI) guidelines, which suggest treatment for pharyngeal exudate plus enlarged and tender cervical node, were 12% sensitive and 94% specific; 13/107 children with a positive throat culture would correctly receive antibiotics and 323/344 with a negative throat culture would, correctly, not receive antibiotics. Based on our data we propose a modified guideline whereby exudate or large cervical nodes would indicate antibiotic treatment, and this guideline would be 84% sensitive and 40% specific; 90/107 children with a positive throat culture would correctly receive antibiotics and 138/344 with a negative throat culture would, correctly, not receive antibiotics. Interpretation The WHO ARI clinical guideline has a high specificity but low sensitivity that limits the unnecessary use of antibiotics, but does not treat 88% of children with a positive streptococcal throat culture who are al risk of acute rheumatic fever. A modified guideline may be more useful in this population. Prospective studies of treatment guidelines from many regions are needed to assess their use since the frequency of pharyngitis varies.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; CAIRO UNIV,ABU REESH HOSP,SCH MED,CAIRO,EGYPT; MINIST HLTH CAIRO,CAIRO,EGYPT	Johns Hopkins University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt	Steinhoff, MC (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,624 N BROADWAY,SUITE 125,BALTIMORE,MD 21205, USA.							AGARWAL BL, 1981, LANCET, V2, P910; *AM AC PED COMM IN, 1994, RED BOOK, P430; ARGUEDAS A, 1992, J PEDIATR-US, V121, P569, DOI 10.1016/S0022-3476(05)81146-1; BREESE BB, 1954, J PEDIATR-US, V44, P670, DOI 10.1016/S0022-3476(54)80008-4; CHERAYIL BJ, 1987, TROP PEDIAT, V33, P157; DIPPEL DWJ, 1992, J FAM PRACTICE, V34, P149; EISENBERG MJ, 1993, EUR HEART J, V4, P122; el-Kholy A, 1973, J Med Microbiol, V6, P101; ELKHOLY A, 1980, J INFECT DIS, V141, P759, DOI 10.1093/infdis/141.6.759; GORDIS L, 1973, NEW ENGL J MED, V289, P331, DOI 10.1056/NEJM197308162890701; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; MAJEED HA, 1993, ANN TROP PAEDIATR, V13, P65, DOI 10.1080/02724936.1993.11747626; MARKOWITZ M, 1991, PEDIATR INFECT DIS J, V10, pS11, DOI 10.1097/00006454-199110001-00003; MARKOWITZ M, 1985, J PEDIATR-US, V106, P545, DOI 10.1016/S0022-3476(85)80069-X; MCLAREN MJ, 1994, ANN INTERN MED, V120, P243, DOI 10.7326/0003-4819-120-3-199402010-00012; *RHEUM FEV COMM AM, 1977, THROAT CULT RAT TREA; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P80; SOROUR AH, 1969, J EGYPT MED ASS S8, V52, P1; TILLERMAN M, 1961, AM J DIS CHILD, V101, P476; WANNAMAKER LW, 1972, AM J DIS CHILD, V124, P352, DOI 10.1001/archpedi.1972.02110150050009; WANNAMAKER LW, 1984, MANAGEMENT PHARYNGIT, P25; *WHO, 1995, B WORLD HEALTH ORGAN, V73, P735; *WHO, 1991, WHOARI905, P41; *WHO, 1994, JOINT WHO ISFC M PRI, P4; 1995, B WORLD HEALTH ORGAN, V73, P583	25	64	67	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					918	921		10.1016/S0140-6736(97)03317-5	http://dx.doi.org/10.1016/S0140-6736(97)03317-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314870				2022-12-28	WOS:A1997XY67200010
J	Pan, ZZ; Tershner, SA; Fields, HL				Pan, ZZ; Tershner, SA; Fields, HL			Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor	NATURE			English	Article							MORPHINE ANALGESIA; MEDULLARY MU; DEPENDENCE; TOLERANCE; REWARD; PHARMACOLOGY; DYNORPHIN; PEPTIDES; PATHWAYS; MODULATE	The analgesic effect of clinically used exogenous opioids, such as morphine, is mediated primarily through mu-opioid receptors(1-3), but the function of the kappa-receptor in opioid analgesia is unclear. Although kappa-receptor agonists can produce analgesia(4,5), behavioural studies indicate that kappa agonists applied intravenously or locally into the spinal cord antagonize morphine analgesia (see refs 4, 6 for reviews). As morphine, a primary mu agonist(1), also binds to kappa-receptors(7) and the analgesic effectiveness of morphine decreases with repeated use (tolerance), it is important to understand the mechanism for the functional interaction between kappa- and mu-opioid receptors in the central nervous system. Here we present in vitro electrophysiological and in vivo behavioural evidence that activation of the kappa-receptor specifically antagonizes mu-receptor-mediated analgesia. We show that in slice preparations of a rat brainstem nucleus, which is critical for the action of opioids in controlling pain, functional kappa- and mu-receptors are each localized on physiologically different types of neuron. Activation of the kappa-receptor hyperpolarizes neurons that are activated indirectly by the mu-receptor. In rats, kappa-receptor activation in this brainstem nucleus significantly attenuates local mu-receptor-mediated analgesia. Our findings suggest a new cellular mechanism for the potentially ubiquitous opposing interaction between mu- and kappa-opioid receptors and may help in the design of treatments for pain.			Pan, ZZ (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK CTR INTEGRAT NEURSCI,SAN FRANCISCO,CA 94143, USA.		Fields, Howard/ABG-9073-2020					AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BHARGAVA HN, 1994, PHARMACOL REV, V46, P293; Bolanos CA, 1996, EUR J PHARMACOL, V317, P1, DOI 10.1016/S0014-2999(96)00698-X; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; FIELDS HL, 1983, NATURE, V306, P684, DOI 10.1038/306684a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; FUNADA M, 1993, NEUROPHARMACOLOGY, V32, P1315; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRUDT TJ, 1993, P NATL ACAD SCI USA, V90, P11429, DOI 10.1073/pnas.90.23.11429; HOOKE LP, 1995, J PHARMACOL EXP THER, V273, P292; KIEFEL JM, 1993, BRAIN RES, V624, P151, DOI 10.1016/0006-8993(93)90073-V; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; MARTIN WR, 1983, PHARMACOL REV, V35, P283; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MILLAN MJ, 1990, TRENDS PHARMACOL SCI, V11, P70, DOI 10.1016/0165-6147(90)90321-X; PAN ZZ, 1990, J PHYSIOL-LONDON, V427, P519, DOI 10.1113/jphysiol.1990.sp018185; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; ROTHMAN RB, 1992, SYNAPSE, V12, P129, DOI 10.1002/syn.890120206; Roychowdhury SM, 1996, NEUROSCIENCE, V74, P863, DOI 10.1016/0306-4522(96)00180-7; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	29	134	139	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					382	385		10.1038/38730	http://dx.doi.org/10.1038/38730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311779				2022-12-28	WOS:A1997XX67500052
J	Lands, RH				Lands, RH			The house call	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					976	976		10.1001/jama.278.12.976	http://dx.doi.org/10.1001/jama.278.12.976			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307336				2022-12-28	WOS:A1997XX01200014
J	Yonkers, KA; Halbreich, U; Freeman, E; Brown, C; Endicott, J; Frank, E; Parry, B; Pearlstein, T; Severino, S; Stout, A; Stone, A; Harrison, W				Yonkers, KA; Halbreich, U; Freeman, E; Brown, C; Endicott, J; Frank, E; Parry, B; Pearlstein, T; Severino, S; Stout, A; Stone, A; Harrison, W			Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SOCIAL ADJUSTMENT; CLINICAL-TRIAL; SELF-REPORT; WOMEN; ALPRAZOLAM; FLUOXETINE; DEPRESSION; COMMUNITY	Context.-Premenstrual dysphoric disorder is an important cause of symptoms and functional impairment in menstruating women. Objective.-To evaluate the efficacy of sertraline hydrochloride for treatment of premenstrual dysphoria by measuring changes in symptom expression and functional impairment. Design.-Two screening cycles followed by 1 single-blind placebo cycle and 3 cycles of randomized, double-blind, placebo treatment. Setting.-Twelve university-affiliate outpatient psychiatry and gynecology clinics. Patients.-Of the 447 women who requested participation, 243 met criteria for premenstrual dysphoric disorder and were randomized; 200 women completed the study, Intervention.-A flexible (50-150 mg) daily dose of sertraline hydrochloride. Main Outcome Measures.-The Daily Record of Severity of Problems, Hamilton Rating Scale for Depression, Clinical Global impression Scale, and Social Adjustment Scale. Results.-Mean (+/-SD) total daily symptom scores decreased significantly (P<.001) in the sertraline-treated (64+/-22 to 44+/-19) compared with the placebo-treated (62+/-22 to 54+/-24) groups. Significant improvement (P<.05) was found for all clinically derived symptom clusters (depressive, physical, and anger/irritability symptoms). Hamilton Rating Scare for Depression scores decreased by 44% and 29% in the sertraline and placebo groups, respectively (P<.002). End-point global ratings showed much or very much improvement in 62% of the active treatment group and 34% of the placebo treatment group (P<.001). Reported functional impairment was substantial at baseline, Improvement in psychosocial functioning with treatment was similar to what is found in studies of major depression. Conclusions.-Sertraline was significantly better than placebo for treatment of premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment, Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria.	UNIV TEXAS, SW MED CTR, DEPT OBSTET & GYNECOL, DALLAS, TX 75235 USA; SUNY BUFFALO, BUFFALO, NY 14260 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; UNIV TENNESSEE, DEPT CLIN PHARM, MEMPHIS, TN USA; UNIV TENNESSEE, DEPT PSYCHIAT, MEMPHIS, TN USA; NEW YORK STATE PSYCHIAT INST & HOSP, DEPT RES ASSESSMENT & TRAINING, NEW YORK, NY USA; WESTERN PSYCHIAT INST & CLIN, DEPT PSYCHIAT, PITTSBURGH, PA USA; UNIV CALIF SAN DIEGO, DEPT PSYCHIAT, LA JOLLA, CA 92093 USA; BROWN UNIV, DEPT PSYCHIAT, PROVIDENCE, RI 02912 USA; UNIV NEW MEXICO, HLTH SCI CTR, ALBUQUERQUE, NM USA; DUKE UNIV, DEPT PSYCHIAT, DURHAM, NC 27706 USA; UNIV MASSACHUSETTS, MED CTR, DEPT PSYCHIAT, WORCESTER, MA 01655 USA; PFIZER INC, NEW YORK, NY USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Pennsylvania; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; New York State Psychiatry Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; University of California System; University of California San Diego; Brown University; University of New Mexico; University of New Mexico's Health Sciences Center; Duke University; University of Massachusetts System; University of Massachusetts Worcester; Pfizer	Yonkers, KA (corresponding author), UNIV TEXAS, SW MED CTR,DEPT PSYCHIAT,ST PAUL PROFESS BLDG 1, SUITE 520, 5959 HARRY HINES, DALLAS, TX 75235 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BANCROFT J, 1993, PSYCHOL MED, P1; BERGER CP, 1994, OBSTET GYNECOL, V84, P379; BIEGON A, 1983, LIFE SCI, V32, P2015, DOI 10.1016/0024-3205(83)90053-X; BRZEZINSKI AA, 1990, OBSTET GYNECOL, V76, P296; BURNET RB, 1991, AUST NZ J OBSTET GYN, V31, P366, DOI 10.1111/j.1479-828X.1991.tb02824.x; CHRISTENSEN AP, 1995, J AFFECT DISORDERS, V33, P47, DOI 10.1016/0165-0327(94)00072-H; DOOGAN DP, 1992, BRIT J PSYCHIAT, V160, P217, DOI 10.1192/bjp.160.2.217; ENDICOTT J, 1986, J AFFECT DISORDERS, V10, P127, DOI 10.1016/0165-0327(86)90035-2; Endicott J, 1990, DAILY RATING SEVERIT; ERIKSSON E, 1995, NEUROPSYCHOPHARMACOL, V12, P167, DOI 10.1038/sj.npp.1380251; FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; FREEMAN EW, 1995, JAMA-J AM MED ASSOC, V274, P51, DOI 10.1001/jama.274.1.51; GRAHAM CA, 1992, J PSYCHOSOM RES, V36, P257, DOI 10.1016/0022-3999(92)90090-O; Guy W, 1976, ECDEU ASSESSMENT MAN, DOI DOI 10.1037/E591322011-001; HALBREICH U, 1993, INT J PSYCHIAT MED, V23, P1; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HARRISON WM, 1989, PSYCHOSOMATICS, V30, P405, DOI 10.1016/S0033-3182(89)72246-5; HARRISON WM, 1990, ARCH GEN PSYCHIAT, V47, P270; HURT SW, 1992, AM J PSYCHIAT, V149, P525; KENDALL KE, 1987, OBSTET GYNECOL, V70, P145; KHOO SK, 1990, MED J AUSTRALIA, V153, P189, DOI 10.5694/j.1326-5377.1990.tb136857.x; LONDON RS, 1991, J AM COLL NUTR, V10, P494; MENKES DB, 1992, BRIT MED J, V305, P346, DOI 10.1136/bmj.305.6849.346; MERIKANGAS KR, 1993, EUR ARCH PSY CLIN N, V243, P23, DOI 10.1007/BF02191520; PEARLSTEIN TB, 1990, J AFFECT DISORDERS, V20, P129, DOI 10.1016/0165-0327(90)90126-S; PEARLSTEIN TB, 1995, ANN M AM PSYCH ASS M; RAPKIN AJ, 1992, CLIN OBSTET GYNECOL, V35, P629, DOI 10.1097/00003081-199209000-00022; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; *SAS I INC, 1996, STAT AN SOFTW; SCHMIDT PJ, 1993, ARCH GEN PSYCHIAT, V50, P467; SMITH S, 1987, OBSTET GYNECOL, V70, P37; STEINER M, 1995, NEW ENGL J MED, V332, P1529, DOI 10.1056/NEJM199506083322301; STONE AB, 1991, J CLIN PSYCHIAT, V52, P290; STOUT AL, 1986, J NERV MENT DIS, V174, P517, DOI 10.1097/00005053-198609000-00002; Su TP, 1997, NEUROPSYCHOPHARMACOL, V16, P346, DOI 10.1016/S0893-133X(96)00245-X; SUMNER BEH, 1995, J STEROID BIOCHEM, V54, P15, DOI 10.1016/0960-0760(95)00075-B; SUNDBLAD C, 1992, ACTA PSYCHIAT SCAND, V85, P39, DOI 10.1111/j.1600-0447.1992.tb01440.x; SUNDBLAD C, 1993, NEUROPSYCHOPHARMACOL, V9, P133, DOI 10.1038/npp.1993.52; Thase ME, 1996, ARCH GEN PSYCHIAT, V53, P777; VELLACOTT ID, 1987, CURR MED RES OPIN, V10, P450, DOI 10.1185/03007998709112403; WEISSMAN MM, 1978, J NERV MENT DIS, V166, P317, DOI 10.1097/00005053-197805000-00002; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; WOOD SH, 1992, OBSTET GYNECOL, V80, P339; WOODS NF, 1982, AM J PUBLIC HEALTH, V72, P1257, DOI 10.2105/AJPH.72.11.1257; Yonkers KA, 1996, J CLIN PSYCHOPHARM, V16, P3, DOI 10.1097/00004714-199602000-00002; YONKERS KA, 1997, CURR REV MOOD ANXIET, V1, P215	48	208	212	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					983	988		10.1001/jama.278.12.983	http://dx.doi.org/10.1001/jama.278.12.983			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX012	9307345				2022-12-28	WOS:A1997XX01200028
J	Flake, AW; Zanjani, ED				Flake, AW; Zanjani, ED			In utero hematopoietic stem cell transplantation - A status report	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW TRANSPLANTATION; INUTERO TRANSPLANTATION; SHEEP; ENGRAFTMENT; THERAPY; PERSISTENCE; EXPRESSION; CHIMERISM; GESTATION	In utero hematopoietic stem cell transplantation is currently in its early stage of development, but it holds considerable promise as a therapeutic approach for the treatment of a large number of congenital hematologic diseases. Experimental evidence supports the concept of the early gestational fetus as a favorable recipient for cellular therapy. Unique aspects of normal hematologic and immunologic ontogeny allow engraftment and long-term persistence of transplanted hematopoietic stem cells without the requirement for myeloablation or immunosuppression. To date, 21 in utero transplants have been reported. Success has been limited to 4 fetuses, all with immunodeficiency disorders. Despite this limited evidence of clinical efficacy, interest in stem cell transplantation has been gaining momentum, and clinical application is likely to increase. Parallel advances in prenatal diagnosis, fetal intervention, and hematopoietic stem cell technology have removed many of the practical, technical, and ethical obstacles to clinical application. This progress has been accompanied by an increase in the number of centers with both the stated interest and perceived expertise to develop clinical programs. However, there is currently limited consensus among investigators on many important issues, such as the mode or timing of in utero transplantation, the ideal source or dose of donor cells, estimation of maternal and fetal risks, appropriate candidate diseases for treatment, and important ethical considerations in counseling and therapy.	UNIV PENN,CHILDRENS HOSP,CTR FETAL DIAG & THERAPY,PHILADELPHIA,PA 19104; UNIV NEVADA,VET AFFAIRS MED CTR,DEPT MED,RENO,NV 89557	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Nevada System of Higher Education (NSHE); University of Nevada Reno; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Flake, AW (corresponding author), UNIV PENN,CHILDRENS HOSP,DEPT SURG,ABRAMSON PEDIAT RES CTR,ROOM 1102 D,34TH ST & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049042, R01HL048378, R37HL049042] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49042-04, HL52954, HL48378] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreani M, 1996, BLOOD, V87, P3494, DOI 10.1182/blood.V87.8.3494.bloodjournal8783494; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Blakemore K., 1996, American Journal of Obstetrics and Gynecology, V174, P312; BOWMAN J, 1994, MATERNAL FETAL MED P, P730; BUCKLEY RH, 1993, SEMIN HEMATOL, V30, P92; CEFALO RC, 1994, AM J OBSTET GYNECOL, V170, P12; CHERVENAK FA, 1990, AM J OBSTET GYNECOL, V163, P1425, DOI 10.1016/0002-9378(90)90600-C; CIVIN CI, 1993, BLOOD, V82, pA180; COWAN MJ, 1994, AM J PEDIAT HEMATOL, V16, P35; CROMBLEHOLME TM, 1990, J PEDIATR SURG, V25, P885, DOI 10.1016/0022-3468(90)90197-H; DIUKMAN R, 1992, J REPROD MED, V37, P515; Flake AW, 1997, OBSTET GYN CLIN N AM, V24, P159, DOI 10.1016/S0889-8545(05)70295-3; FLAKE AW, 1986, SCIENCE, V233, P776, DOI 10.1126/science.2874611; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; FLEISCHMAN RA, 1979, P NATL ACAD SCI USA, V76, P5736, DOI 10.1073/pnas.76.11.5736; FLETCHER JC, 1992, FETAL DIAGN THER, V7, P158, DOI 10.1159/000263664; HARRISON MR, 1989, LANCET, V2, P1425; HAYNES BF, 1988, J EXP MED, V168, P1061, DOI 10.1084/jem.168.3.1061; HOLLENBAUGH D, 1994, J CLIN INVEST, V94, P616, DOI 10.1172/JCI117377; Kawashima I, 1996, BLOOD, V87, P4136, DOI 10.1182/blood.V87.10.4136.bloodjournal87104136; LANSDORP PM, 1993, J EXP MED, V178, P787, DOI 10.1084/jem.178.3.787; LINCH D, 1986, LANCET, V1, P1382; LOBACH DF, 1985, J IMMUNOL, V135, P1752; Manis J, 1996, NEW ENGL J MED, V335, P1523, DOI 10.1056/NEJM199611143352009; McCullogh LB., 1994, ETHICS OBSTET GYNECO; MCKINNON S, 1995, BLOOD, V86, P1261; MOISE KJ, 1993, WESTERN J MED, V159, P318; MOSES SW, 1990, J PEDIATR GASTR NUTR, V11, P155, DOI 10.1097/00005176-199008000-00004; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PICUS J, 1985, TRANSPLANTATION, V39, P297, DOI 10.1097/00007890-198503000-00018; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; RICE HE, 1993, FETAL DIAGN THER, V8, P74, DOI 10.1159/000263751; SILVERSTEIN AM, 1964, J EXP MED, V119, P955, DOI 10.1084/jem.119.6.955; SLAVIN S, 1992, BONE MARROW TRANSPL, V1, P189; SROUR EF, 1992, BLOOD, V79, P1404; SROUR EF, 1993, BLOOD, V82, P3333; STEWART FM, 1993, BLOOD, V81, P2566; THILAGANTHAN B, 1993, LANCET, V342, P243, DOI 10.1016/0140-6736(93)92336-R; Touraine J L, 1991, Allergol Immunopathol (Madr), V19, P49; TOURAINE JL, 1989, LANCET, V1, P1382; TOURAINE JL, 1992, BONE MARROW TRANSPL, V1, P121; vanDijk BA, 1996, AM J MED GENET, V61, P264, DOI 10.1002/(SICI)1096-8628(19960122)61:3<264::AID-AJMG11>3.0.CO;2-R; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; Wengler GS, 1996, LANCET, V348, P1484, DOI 10.1016/S0140-6736(96)09392-0; Westgren M, 1996, TRANSPLANTATION, V61, P1176, DOI 10.1097/00007890-199604270-00010; ZANJANI ED, 1993, BLOOD, V82, pA655; ZANJANI ED, 1994, J CLIN INVEST, V93, P1051, DOI 10.1172/JCI117054; ZANJANI ED, 1992, J CLIN INVEST, V89, P1178, DOI 10.1172/JCI115701; ZANJANI ED, 1982, NATURE, V295, P244, DOI 10.1038/295244a0	49	83	86	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					932	937		10.1001/jama.278.11.932	http://dx.doi.org/10.1001/jama.278.11.932			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302247				2022-12-28	WOS:A1997XV64000033
J	Kobak, KA; Taylor, LV; Dottl, SL; Greist, JH; Jefferson, JW; Burroughs, D; Mantle, JM; Katzelnick, DJ; Norton, R; Henk, HJ; Serlin, RC				Kobak, KA; Taylor, LV; Dottl, SL; Greist, JH; Jefferson, JW; Burroughs, D; Mantle, JM; Katzelnick, DJ; Norton, R; Henk, HJ; Serlin, RC			A computer-administered telephone interview to identify mental disorders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRUCTURED CLINICAL INTERVIEW; PRIMARY-CARE; DSM-III; PSYCHIATRIC-DISORDERS; DEPRESSION; HEALTH; RELIABILITY; COMMUNITY; VERSIONS; SCHEDULE	Context.-Common mental disorders are often not identified in primary care settings. Objective.-To evaluate the validity and clinical utility of a telephone-assisted computer-administered version of Primary Care Evaluation of Mental Disorders (PRIME-MD), a brief questionnaire and interview instrument designed to identify psychiatric disorders in primary care patients, Design.-Comparison of diagnoses obtained by computer over the telephone using interactive voice response (IVR) technology vs those obtained by a trained clinician over the telephone using the Structured Clinical Interview for DSM-IV [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition] Diagnosis (SCID), A subsample also received the clinician-administered version of PRIME-MD. Patients.-Outpatients (N=200) from 4 primary care clinics, an eating disorders clinic, an alcohol treatment facility, psychiatric outpatients, and community controls. Setting.-Interviews conducted by telephone, except for face-to-face administration of PRIME-MD, which was conducted at either the primary care clinic or a research clinic, Measurements and Main Results.-Prevalence rates for any psychiatric disorder were similar between diagnoses made by the computer and those made by a mental health professional using the SCID (60.0% vs 58.5%). Prevalence rates for individual diagnoses were generally similar across versions. However, primary care patients reported twice as much alcohol abuse on the computer (15.0%) as on either the SCID (7.5%) or the clinician-administered PRIME-MD (7.5%). Using the SCID as the criterion, both the computer-and clinician-administered versions of PRIME-MD demonstrated high and roughly equivalent levels of sensitivity and specificity. Overall agreement (kappa) for any diagnosis was 0.67 for the computer-administered PRIME-MD and 0.70 for the clinician-administered PRIME-MD. Conclusions.-The computer-administered PRIME-MD appears to be a valid instrument for assessing psychopathology in primary care patients. Interactive voice response technology allows for increased availability, and provides primary care physicians with information that will increase the quality of patient care without additional physician time and at minimal expense.	UNIV WISCONSIN,DEPT EDUC PSYCHOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	Kobak, KA (corresponding author), DEAN FDN HLTH RES & EDUC,2711 ALLEN BLVD,MIDDLETON,WI 53562, USA.							ANESHENSEL CS, 1982, PUBLIC OPIN QUART, V46, P110, DOI 10.1086/268703; ANESHENSEL CS, 1982, AM J PUBLIC HEALTH, V72, P1017, DOI 10.2105/AJPH.72.9.1017; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; Campbell T L, 1987, J Fam Pract, V25, P184; *DEPR GUID PAN, 1993, AHCPR PUBL; EISENBERG L, 1995, JAMA-J AM MED ASSOC, V274, P331; ERDMAN H, 1983, BEHAV RES METH INSTR, V15, P66, DOI 10.3758/BF03203440; ERDMAN HP, 1992, J PSYCHIAT RES, V26, P85, DOI 10.1016/0022-3956(92)90019-K; ERDMAN HP, 1985, J CONSULT CLIN PSYCH, V53, P760, DOI 10.1037/0022-006X.53.6.760; First M.B., 2016, STRUCTURED CLIN INTE; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; GREIST JH, 1974, LIFE THREATENING BEH, V4, P212; GREIST JH, 1980, TECHNOLOGY MENTAL HL, P161; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1982, HDB AFFECTIVE DISORD, P3; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KAMEROW DB, 1987, J FAM PRACTICE, V25, P181; Katzelnick DJ, 1997, PSYCHIATR SERV, V48, P59; KATZELNICK DJ, 1995, AM J PSYCHIAT, V152, P1368; KESSLER LG, 1985, ARCH GEN PSYCHIAT, V42, P583; Kobak KA, 1996, PSYCHOPHARMACOLOGY, V127, P291, DOI 10.1007/BF02806006; KOBAK KA, 1994, J PERS ASSESS, V63, P173, DOI 10.1207/s15327752jpa6301_14; Kobak KA, 1990, PSYCHOL ASSESS, V2, P56, DOI DOI 10.1037/1040-3590.2.1.56; Kobak KA, 1993, PSYCHOL ASSESSMENT, V5, P487, DOI DOI 10.1037/1040-3590.5.4.487; LOCKE SE, 1992, JAMA-J AM MED ASSOC, V268, P1301, DOI 10.1001/jama.268.10.1301; LUCAS RW, 1977, BRIT J PSYCHIAT, V131, P160, DOI 10.1192/bjp.131.2.160; MAURER K, 1996, CLIN PSYCHIAT NEWS, V24, P23; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; ORLEANS CT, 1985, AM J PSYCHIAT, V142, P52; PETRIE K, 1994, COMPUT HUM BEHAV, V10, P415, DOI 10.1016/0747-5632(94)90037-X; POTTS MK, 1990, J PSYCHIATR RES, V24, P335, DOI 10.1016/0022-3956(90)90005-B; RASMUSSEN SA, 1984, J CLIN PSYCHIAT, V45, P450; Rosenfeld R., 1992, PSYCHOL ASSESSMENT, V4, P329, DOI [DOI 10.1037/1040-3590.4.3.329, https://doi.org/10.1037/1040-3590.4.3.329]; Rost K, 1994, Arch Fam Med, V3, P333, DOI 10.1001/archfami.3.4.333; RUBINSON E, 1988, J NERV MENT DIS, V176, P480, DOI 10.1097/00005053-198808000-00005; SCHULBERG HC, 1988, GEN HOSP PSYCHIAT, V10, P79, DOI 10.1016/0163-8343(88)90092-8; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SIMON G, 1995, AM J PSYCHIAT, V152, P352; SIMON GE, 1993, J PSYCHIAT RES, V27, P247, DOI 10.1016/0022-3956(93)90035-Z; SKODOL AE, 1984, HOSP COMMUNITY PSYCH, V35, P251; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; SPITZER RL, 1982, ARCH GEN PSYCHIAT, V39, P1299; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; WELLS KB, 1988, J PSYCHIAT RES, V22, P207, DOI 10.1016/0022-3956(88)90006-4; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630	46	178	178	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					905	910		10.1001/jama.278.11.905	http://dx.doi.org/10.1001/jama.278.11.905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV640	9302242				2022-12-28	WOS:A1997XV64000028
J	Lord, J; Littlejohns, P				Lord, J; Littlejohns, P			Evaluating healthcare policies: the case of clinical audit	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-AUDIT; SYSTEM				Lord, J (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,HLTH CARE EVALUAT UNIT,LONDON SW17 0RE,ENGLAND.		Lord, Joanne/H-1417-2011	Lord, Joanne/0000-0003-1086-1624				BARTON A, 1995, J EPIDEMIOL COMMUN H, V49, P445, DOI 10.1136/jech.49.5.445; BLACK N, 1993, SOC SCI MED, V36, P849, DOI 10.1016/0277-9536(93)90077-H; *COMM PUBL ACC, 1996, NATL HLTH SERV EX CL; *COMM PUBL ACC, 1994, AUD CLIN CAR SCOTL; DIXON N, 1996, GOOD PRACTICE CLIN A; Eccles MP, 1996, QUAL HEALTH CARE, V5, P193, DOI 10.1136/qshc.5.4.193; Firth-Cozens J, 1992, Qual Health Care, V1, P161, DOI 10.1136/qshc.1.3.161; GREGORY AJ, 1992, J OPER RES SOC, V43, P19, DOI 10.1057/jors.1992.3; GRUER R, 1986, LANCET, V1, P23; HAM C, 1995, BRIT MED J, V310, P71, DOI 10.1136/bmj.310.6972.71; HUMPHREY C, 1993, MED AUDIT PRIMARY CA; ILLSLEY R, 1980, PROFESSIONAL PUBLIC; LAWRENCE M, 1994, BRIT MED J, V309, P513, DOI 10.1136/bmj.309.6953.513; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; Lord J, 1996, INT J QUAL HEALTH C, V8, P527, DOI 10.1093/intqhc/8.6.527; Lord J, 1995, Int J Health Care Qual Assur, V8, P15, DOI 10.1108/09526869510089246; MAYNARD A, 1991, HLTH SERVICES J 0718, P26; MECHANIC D, 1993, SOC SCI MED, V36, P95, DOI 10.1016/0277-9536(93)90200-N; MOONEY G, 1992, J EPIDEMIOL COMMUN H, V46, P180, DOI 10.1136/jech.46.3.180; *N ENGL STUD STAND, 1992, BRIT MED J, V304, P484; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; ROBINSON MB, 1994, J EPIDEMIOL COMMUN H, V48, P435, DOI 10.1136/jech.48.5.435; Rosenhead J., 1989, RATIONAL ANAL PROBLE; Sellu D, 1996, BRIT MED J, V312, P128; SHERWOOD T, 1992, LANCET, V340, P37; Thomson R, 1996, QUAL HEALTH CARE, V5, P97, DOI 10.1136/qshc.5.2.97; WALSHE K, 1995, EVALUATING CLILN AUD; WEBB SJ, 1991, BRIT MED J, V302, P390, DOI 10.1136/bmj.302.6773.390; [No title captured]; [No title captured]	30	23	25	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					668	671		10.1136/bmj.315.7109.668	http://dx.doi.org/10.1136/bmj.315.7109.668			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XW694	9310573	Green Published			2022-12-28	WOS:A1997XW69400027
J	Rackoff, P; Feldman, T				Rackoff, P; Feldman, T			Total lymphoid irradiation - not for rheumatoid arthritis	LANCET			English	Editorial Material							TERM FOLLOW-UP				Rackoff, P (corresponding author), BETH ISRAEL MED CTR,DIV RHEUMATOL,NEW YORK,NY 10003, USA.			Rackoff, Paula/0000-0002-4669-2116				HUBERT G, 1985, ARTHRITIS RHEUM, V28, P1205; SODEN M, 1989, ARTHRITIS RHEUM, V32, P523, DOI 10.1002/anr.1780320503; TANAY A, 1987, ARTHRITIS RHEUM-US, V30, P1, DOI 10.1002/art.1780300101; TRENTHAM DE, 1987, ARTHRITIS RHEUM, V30, P980, DOI 10.1002/art.1780300904; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; Westhovens R, 1997, ARTHRITIS RHEUM, V40, P426, DOI 10.1002/art.1780400306	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					752	753		10.1016/S0140-6736(97)22037-4	http://dx.doi.org/10.1016/S0140-6736(97)22037-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297989				2022-12-28	WOS:A1997XW28200004
J	Lucock, MP; Morley, S; White, C; Peake, MD				Lucock, MP; Morley, S; White, C; Peake, MD			Responses of consecutive patients to reassurance after gastroscopy: results of self administered questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							HYPOCHONDRIASIS; DEPRESSION; SYMPTOMS; ANXIETY	Objective: To study the time course and prediction of responses to reassurance after gastroscopy showing no serious illness, Design: Selection of consecutive patients were assessed before gastroscopy, immediately after reassurance, and at follow up at 24 hours, 1 week, 1 month, and 1 year, Responses of subgroups of patients identified as high, medium, and low health anxiety by the health anxiety questionnaire were analysed. Setting: Endoscopy clinic in a general hospital. Intervention: Oral reassurance that there was nothing seriously wrong.'' Subjects: One consultant physician and 60 patients aged 18-74 referred for gastroscopy. Main outcome measures: Physician's and patients' ratings of the extent of the reassurance and patients' ratings of their anxiety about their health and of their illness belief. Results: There was good agreement between the patients and the physician about whether reassurance had been given, Health anxiety and illness belief decreased markedly after reassurance, Patients with high health anxiety showed a significant resurgence in their worry and illness belief at 24 hours and 1 week, and these levels were maintained at 1 month and 1 year later, Patients with medium levels of health anxiety showed a reduction in worry and illness belief after reassurance, and this was generally maintained during follow up, Patients with low health anxiety maintained low levels of health worry and illness belief throughout the study, Partial correlation analyses showed that the levels of worry and illness belief after reassurance were predicted by the health anxiety questionnaire, This measure also had predictive value beyond that of a measure of general anxiety. Conclusions: Medical reassurance results in a reduction of worry about health and of illness belief, but this may be very short term. Measurable individual differences in health anxiety can be used to predict the response to reassurance.	UNIV LEEDS,SCH MED,DIV PSYCHIAT & BEHAV,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; PONTEFRACT DIST GEN HOSP,DEPT CLIN PSYCHOL,PONTEFRACT WF8 1PL,W YORKSHIRE,ENGLAND; PONTEFRACT DIST GEN HOSP,CHEST UNIT,PONTEFRACT WF8 1PL,W YORKSHIRE,ENGLAND	University of Leeds				Lucock, Mike/0000-0003-0968-5475				BARSKY AJ, 1983, AM J PSYCHIAT, V140, P273; BASS C, 1990, SOMATISATION PHYSICA; BEITMAN BD, 1989, AM J CARDIOL, V63, P1399, DOI 10.1016/0002-9149(89)91056-4; CHANNER KS, 1987, Q J MED, V63, P315; Fitzpatrick R, 1996, BRIT MED J, V313, P311, DOI 10.1136/bmj.313.7053.311; FITZPATRICK R, 1981, J NEUROL NEUROSUR PS, V44, P1061, DOI 10.1136/jnnp.44.12.1061; KELLNER R, 1985, ARCH GEN PSYCHIAT, V42, P821; KELLNER R, 1983, ACTA PSYCHIAT SCAND, V67, P69, DOI 10.1111/j.1600-0447.1983.tb06725.x; KELLNER R, 1989, PSYCHOSOMATICS, V30, P57, DOI 10.1016/S0033-3182(89)72318-5; Lucock MP, 1996, BRIT J HEALTH PSYCH, V1, P137, DOI 10.1111/j.2044-8287.1996.tb00498.x; SALKOVSKIS PM, 1986, BEHAV RES THER, V24, P597, DOI 10.1016/0005-7967(86)90041-0; SPECKENS AEM, 1995, BRIT MED J, V311, P1328, DOI 10.1136/bmj.311.7016.1328; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	14	106	106	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					572	575						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	9302953				2022-12-28	WOS:A1997XV71700023
J	Lamberts, SWJ; vandenBeld, AW; vanderLely, AJ				Lamberts, SWJ; vandenBeld, AW; vanderLely, AJ			The endocrinology of aging	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; CLINICAL RESEARCH-CENTER; RALOXIFENE LY139481 HCL; BONE-MINERAL DENSITY; AGE-RELATED DECLINE; HEALTHY OLDER MEN; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; BREAST-CANCER; TESTOSTERONE REPLACEMENT	Most aging individuals die from atherosclerosis: cancer, or dementia; but in the oldest old, loss of muscle strength resulting in frailty is the limiting factor for an individual's chances of living an independent life until death. Three hormonal systems show decreasing circulating hormone concentrations during normal aging: (i) estrogen (in menopause) and testosterone (in andropause), (ii) dehydroepiandrosterone and its sulphate (in adrenopause), and (iii) the growth hormone/insulin-like growth factor I axis (in somato-pause). Physical changes during aging have been considered physiologic, but there is evidence that some of these changes are related to this decline in hormonal activity. Hormone replacement strategies have been developed, but many of their aspects remain controversial, and increasing blood hormone levels In aging individuals to those found during mid-adult life has not been uniformly proven to be safe and of benefit.	ERASMUS UNIV ROTTERDAM, DEPT MED, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam								Andersson K, 1996, LANCET, V348, P1521, DOI 10.1016/S0140-6736(05)65943-0; [Anonymous], 1992, Lancet, V339, P1; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Bagatell CJ, 1996, NEW ENGL J MED, V334, P707, DOI 10.1056/NEJM199603143341107; BarrettConnor E, 1995, ANN NY ACAD SCI, V774, P259, DOI 10.1111/j.1749-6632.1995.tb17386.x-i1; BAULIEU EE, 1995, CR ACAD SCI III-VIE, V318, P7; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P3, DOI 10.1210/jc.82.1.3; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BLACKMAN MR, 1987, ENDOCRIN METAB CLIN, V16, P981, DOI 10.1016/S0889-8529(18)30454-7; Blakesley VA, 1997, J ENDOCRINOL, V152, P339, DOI 10.1677/joe.0.1520339; BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; Brodsky IG, 1996, J CLIN ENDOCR METAB, V81, P3469, DOI 10.1210/jc.81.10.3469; BRODY JA, 1985, NATURE, V315, P463, DOI 10.1038/315463a0; BUCHNER DM, 1992, CLIN GERIATR MED, V7, P1; Burns A, 1996, LANCET, V348, P420, DOI 10.1016/S0140-6736(05)64533-3; CAMPION EW, 1994, NEW ENGL J MED, V330, P1819, DOI 10.1056/NEJM199406233302509; Chapman IM, 1996, J CLIN ENDOCR METAB, V81, P2874, DOI 10.1210/jc.81.8.2874; Chapman IM, 1996, J CLIN ENDOCR METAB, V81, P4249, DOI 10.1210/jc.81.12.4249; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CORPAS E, 1992, J CLIN ENDOCR METAB, V75, P530, DOI 10.1210/jc.75.2.530; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; DAVIDSON MB, 1979, METABOLISM, V28, P688, DOI 10.1016/0026-0495(79)90024-6; Draper MW, 1996, J BONE MINER RES, V11, P835; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FINK RI, 1984, J GERONTOL, V39, P273, DOI 10.1093/geronj/39.3.273; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GRADY D, 1991, AM J EPIDEMIOL, V134, P1396, DOI 10.1093/oxfordjournals.aje.a116043; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; GREY AB, 1995, AM J MED, V99, P636, DOI 10.1016/S0002-9343(99)80251-4; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Guyton A.C., 1991, TXB MED PHYSL, P899; HARMAN SM, 1980, J CLIN ENDOCR METAB, V51, P35, DOI 10.1210/jcem-51-1-35; HARMAN SM, 1982, J CLIN ENDOCR METAB, V54, P547, DOI 10.1210/jcem-54-3-547; Harris M I, 1990, Clin Geriatr Med, V6, P703; HAZZARD WR, 1995, JAMA-J AM MED ASSOC, V274, P1964, DOI 10.1001/jama.274.24.1964; HERBERT J, 1995, LANCET, V345, P1193, DOI 10.1016/S0140-6736(95)91987-2; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; HIJMANS W, 1984, MECH AGEING DEV, V26, P83, DOI 10.1016/0047-6374(84)90167-2; Hornsby PJ, 1995, ANN NY ACAD SCI, V774, P29, DOI 10.1111/j.1749-6632.1995.tb17370.x; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; HSICH CV, 1990, J MANIP PHYSIOL THER, V13, P72; JIANG ZM, 1989, ANN SURG, V210, P513, DOI 10.1097/00000658-198910000-00012; KALLMAN DA, 1990, J GERONTOL, V45, pM82, DOI 10.1093/geronj/45.3.M82; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORBONITS M, 1995, TRENDS ENDOCRIN MET, V6, P43, DOI 10.1016/1043-2760(94)00204-H; KORENMAN SG, 1982, ENDOCRINE ASPECTS AG; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; Labrie F, 1995, ANN NY ACAD SCI, V774, P16, DOI 10.1111/j.1749-6632.1995.tb17369.x; LEATHER AT, 1990, BRIT J OBSTET GYNAEC, V97, P1071, DOI 10.1111/j.1471-0528.1990.tb02491.x; Lindsay R, 1996, J CLIN ENDOCR METAB, V81, P3829, DOI 10.1210/jc.81.11.3829; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MARIOTTI S, 1992, LANCET, V339, P1506, DOI 10.1016/0140-6736(92)91265-A; MARIOTTI S, 1995, ENDOCR REV, V16, P686, DOI 10.1210/er.16.6.686; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MINAKER K L, 1990, Diabetes Care, V13, P34; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MOSS A, 1985, CURRENT ESTIMATES NA; MOSS AJ, 1986, VITAL HLTH STAT, V10; NASS R, 1995, J CLIN ENDOCR METAB, V80, P552, DOI 10.1210/jc.80.2.552; Nestler JE, 1995, ANN NY ACAD SCI, V774, pIX; Papadakis MA, 1996, ANN INTERN MED, V124, P708, DOI 10.7326/0003-4819-124-8-199604150-00002; PAPADAKIS MA, 1995, J AM GERIATR SOC, V43, P1350, DOI 10.1111/j.1532-5415.1995.tb06613.x; PEARLMAN CK, 1972, J UROLOGY, V107, P298, DOI 10.1016/S0022-5347(17)61008-5; PETERS AL, 1997, INT TXB DIABETES MEL, P1151; POEHLMAN ET, 1990, J CLIN ENDOCR METAB, V71, P1468, DOI 10.1210/jcem-71-6-1468; Pong SS, 1996, MOL ENDOCRINOL, V10, P57, DOI 10.1210/me.10.1.57; Prudham D, 1981, Age Ageing, V10, P141; RAKOWSKI W, 1992, J GERONTOL, V47, pM122, DOI 10.1093/geronj/47.4.M122; Ravaglia G, 1996, J CLIN ENDOCR METAB, V81, P1173, DOI 10.1210/jc.81.3.1173; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; RUBENSTEIN HA, 1973, J CLIN ENDOCR METAB, V37, P247, DOI 10.1210/jcem-37-2-247; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; RUDMAN D, 1985, J AM GERIATR SOC, V33, P800, DOI 10.1111/j.1532-5415.1985.tb04195.x; RUDMAN D, 1992, ENDOCRINOL METAB, P50; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; Saenger P, 1996, J CLIN ENDOCR METAB, V81, P2773, DOI 10.1210/jc.81.8.2773; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Santen RJ, 1996, J CLIN ENDOCR METAB, V81, P2027, DOI 10.1210/jc.81.6.2027; Skolnick AA, 1996, JAMA-J AM MED ASSOC, V276, P1365, DOI 10.1001/jama.276.17.1365; TAAFFE DR, 1994, J CLIN ENDOCR METAB, V79, P1361, DOI 10.1210/jc.79.5.1361; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; TENOVER JS, 1994, ENDOCRIN METAB CLIN, V23, P877, DOI 10.1016/S0889-8529(18)30073-2; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1987, J AM GERIATR SOC, V35, P644, DOI 10.1111/j.1532-5415.1987.tb04341.x; Toogood AA, 1996, J CLIN ENDOCR METAB, V81, P460, DOI 10.1210/jc.81.2.460; VERMEULEN A, 1991, J CLIN ENDOCR METAB, V73, P221, DOI 10.1210/jcem-73-2-221; VONKRIES R, 1991, BRIT MED J, V303, P1083, DOI 10.1136/bmj.303.6810.1083; Wang C, 1996, J CLIN ENDOCR METAB, V81, P3654, DOI 10.1210/jc.81.10.3654; Wang C, 1996, J CLIN ENDOCR METAB, V81, P3578, DOI 10.1210/jc.81.10.3578; Waters D, 1996, ANN INTERN MED, V125, P865, DOI 10.7326/0003-4819-125-11-199612010-00001; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; YARASHESKI KE, 1995, AM J PHYSIOL-ENDOC M, V268, pE268, DOI 10.1152/ajpendo.1995.268.2.E268; Yen SSC, 1995, ANN NY ACAD SCI, V774, P128, DOI 10.1111/j.1749-6632.1995.tb17377.x; 1991, HLTH PEOPLE 2000 NAT	99	692	721	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	1997	278	5337					419	424		10.1126/science.278.5337.419	http://dx.doi.org/10.1126/science.278.5337.419			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334293	Green Published			2022-12-28	WOS:A1997YB35500033
J	Targan, SR; Hanauer, SB; vanDeventer, SJH; Mayer, L; Present, DH; Braakman, T; DeWoody, KL; Schaible, TF; Rutgeerts, PJ				Targan, SR; Hanauer, SB; vanDeventer, SJH; Mayer, L; Present, DH; Braakman, T; DeWoody, KL; Schaible, TF; Rutgeerts, PJ			A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; CD4(+) T-CELLS; TNF IN-VITRO; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; DOUBLE-BLIND; SCID MICE; CYCLOSPORINE; THERAPY; TRIAL	Background Studies in animals and an open-label trial have suggested a role for antibodies to tumor necrosis factor alpha, specifically chimeric monoclonal antibody cA2, in the treatment of Crohn's disease. Methods We conducted a 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 patients with moderate-to-severe Crohn's disease that was resistant to treatment. All had scores on the Crohn's Disease Activity Index between 220 and 400 (scores can range from 0 to about 600, with higher scores indicating more severe illness). Patients were randomly assigned to receive a single two-hour intravenous infusion of either placebo or cA2 in a dose of 5 mg per kilogram of body weight, 10 mg per kilogram, or 20 mg per kilogram. Clinical response, the primary end point, was defined as a reduction of 70 or more points in the score on the Crohn's Disease Activity Index at four weeks that was not accompanied by a change in any concomitant medications. Results At four weeks, 81 percent of the patients given 5 mg of cA2 per kilogram (22 of 27 patients), 50 percent of those given 10 mg of cA2 per kilogram (14 of 28), and 64 percent of those given 20 mg of cA2 per kilogram (18 of 28) had had a clinical response, as compared with 17 percent of patients in the placebo group (4 of 24) (P<0.001 for the comparison of the cA2 group as a whole with placebo). Thirty-three percent of the patients given cA2 went into remission (defined as a score below 150 on the Crohn's Disease Activity Index), as compared with 4 percent of the patients given placebo (P=0.005). At 12 weeks, 41 percent of the cA2-treated patients (34 of 83) had had a clinical response, as compared with 12 percent of the patients in the placebo group (3 of 25) (P=0.008). The rates of adverse effects were similar in the groups. Conclusions A single infusion of cA2 was an effective short-term treatment in many patients with moderate-to-severe, treatment-resistant Crohn's disease. (C) 1997, Massachusetts Medical Society.	UNIV CHICAGO, CHICAGO, IL 60637 USA; ACAD MED CENT, AMSTERDAM, NETHERLANDS; MT SINAI MED CTR, NEW YORK, NY 10029 USA; CENTOCOR INC, MALVERN, PA 19355 USA; ACAD ZIEKENHUIS GASTHUISBERG, LOUVAIN, BELGIUM	University of Chicago; University of Amsterdam; Academic Medical Center Amsterdam; Icahn School of Medicine at Mount Sinai; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; KU Leuven; University Hospital Leuven	Targan, SR (corresponding author), CEDARS SINAI MED CTR, DIV GASTROENTEROL, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA.							AGRESTI A, 1990, CATEGORICAL DATA ANA, P230; BEST WR, 1979, GASTROENTEROLOGY, V77, P843; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; Conover WJ, 1980, PRACTICAL NONPARAMET, P318; COPE AP, 1994, J CLIN INVEST, V94, P749, DOI 10.1172/JCI117394; Davidson NJ, 1996, J EXP MED, V184, P241, DOI 10.1084/jem.184.1.241; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; EMMRICH J, 1991, LANCET, V338, P570, DOI 10.1016/0140-6736(91)91133-F; FEAGAN BG, 1994, NEW ENGL J MED, V330, P1846, DOI 10.1056/NEJM199406303302602; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Hanauer SB, 1996, NEW ENGL J MED, V335, P143; Hanauer SB, 1996, NEW ENGL J MED, V334, P841, DOI 10.1056/NEJM199603283341307; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; JEWELL DP, 1994, EUR J GASTROEN HEPAT, V6, P499, DOI 10.1097/00042737-199406000-00009; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; LEVINE DS, 1993, INFLAMM BOWEL DIS, P296; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MAINI RN, 1995, CLIN EXP IMMUNOL, V102, P443; MAINI RN, 1995, CLIN EXP IMMUNOL, V101, P207; McCabe RP, 1996, GASTROENTEROLOGY, V110, pA962; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MULLIN GE, 1992, GASTROENTEROLOGY, V102, P1620, DOI 10.1016/0016-5085(92)91722-G; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; Neurath MF, 1996, J EXP MED, V183, P2605, DOI 10.1084/jem.183.6.2605; OBRIEN JJ, 1991, GASTROENTEROLOGY, V101, P39, DOI 10.1016/0016-5085(91)90457-V; PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341; PLEVYY SE, 1993, INFLAMM BOWEL DIS, P582; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; SACHAR DB, 1995, J CLIN GASTROENTEROL, V20, P117, DOI 10.1097/00004836-199503000-00009; SANDBORN WJ, 1995, INFLAMM BOWEL DIS, V1, P48; SCALLON BJ, 1995, CYTOKINE, V7, P251, DOI 10.1006/cyto.1995.0029; SIEGEL SA, 1995, CYTOKINE, V7, P15, DOI 10.1006/cyto.1995.1003; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; STANGE EF, 1995, GASTROENTEROLOGY, V109, P774, DOI 10.1016/0016-5085(95)90384-4; STRONKHORST A, 1992, SCAND J GASTROENTERO, V27, P61, DOI 10.3109/00365529209096029; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5	38	2626	2736	1	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1029	1035		10.1056/NEJM199710093371502	http://dx.doi.org/10.1056/NEJM199710093371502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321530	Green Published, Bronze			2022-12-28	WOS:A1997XZ84400002
J	Lewis, CE				Lewis, CE			Management of patients with HIV/AIDS - Who should care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNODEFICIENCY; PHYSICIANS		UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								*CDCP, 1997, HIV AIDS SURV REP, V8, P7; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P826; DiMatteo M R, 1994, JAMA, V271, P83, DOI 10.1001/jama.271.1.79; DiMatteo MR, 1994, JAMA-J AM MED ASSOC, V271, P83; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; HUMMELL HJ, 1970, SOC SCI MED, V3, P597, DOI 10.1016/0037-7856(70)90028-4; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Kraft SK, 1997, ARCH FAM MED, V6, P29, DOI 10.1001/archfami.6.1.29; Lewis CE, 1996, WESTERN J MED, V164, P415; *US DEP HHS, 1997, FED REG         0619, V62, P33417	11	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1133	1134		10.1001/jama.278.14.1133	http://dx.doi.org/10.1001/jama.278.14.1133			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326458				2022-12-28	WOS:A1997XY42200003
J	Wise, RP; Kiminyo, KP; Salive, ME				Wise, RP; Kiminyo, KP; Salive, ME			Hair boss after routine immunizations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG-REACTIONS; ALOPECIA-AREATA	Context.-Alopecia is a recognized adverse effect of numerous medications, but vaccines are not normally considered a cause far unexpected loss of hair, Objective.-To describe case reports of hair loss after routine vaccines and to assess the hypothesis that vaccinations might induce hair loss, Design.-Case series with telephone follow-up, Methods.-Review of spontaneous reports to the Food and Drug Administration, the Centers for Disease Control and Prevention, and the Vaccine Adverse Event Reporting System. Main Outcome Measure.-Loss of hair following immunization, Results.-A total of 60 evaluable reports submitted since 1984 and coded for ''alopecia'' after immunizations included 16 with positive rechallenge (hair loss after vaccination on more than 1 occasion), 4 of which were definite and 12 possible or probable, Of the 60 cases, 46 had received hepatitis B vaccines, Both of the currently available recombinant products, as well as the former plasma-derived product, were represented, Females predominated in all age groups. The majority of patients recovered, but clinical features, such as intervals from vaccination until onset and the extent and reversibility of hair loss, varied widely. Nine patients reported previous medication allergy. Conclusion,There may be an association, probably very rare, between vaccinations and hair loss. More than 1 pathophysiologic mechanism may be responsible, Since apparently nonrandom distributions by vaccine, age, and sex could reflect biased case ascertainment, further research will be needed in defined populations with consistent case detection.	HOWARD UNIV,COLL MED,WASHINGTON,DC	Howard University	Wise, RP (corresponding author), US FDA,EPIDEMIOL BRANCH,DIV BIOSTAT & EPIDEMIOL,CTR BIOL EVALUAT & RES,HFM-225,ROCKVILLE,MD 20852, USA.							ABEL EA, 1993, SCI AM MED, V2, P1; BEGAUD B, 1985, THERAPIE, V40, P115; BOLOGNIA J, 1994, HARRISONS PRINCIPLES, P290; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P11; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; CHEN RT, 1994, PHARMACOEPIDEM DR S, P581; Council for International Organizations of Medical Sciences, 1995, GUID PREP COR CLIN S; Jones J K, 1982, Fam Community Health, V5, P58; JONES JK, 1994, PHARMACOEPIDEM DR S, P365; KARCH FE, 1977, CLIN PHARMACOL THER, V21, P247; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; LLAU ME, 1995, THERAPIE, V50, P145; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; PETKOV I, 1973, KAT KOZHNI VEN B, V12, P39; PILLANS PI, 1995, INT J DERMATOL, V34, P149, DOI 10.1111/j.1365-4362.1995.tb01556.x; RUSSELL S, 1994, SAN FRANCISCO C 0421, pA21; RUSSELL S, 1994, SAN FRANCISCO C 0421, pA17; SAFAVI KH, 1995, MAYO CLIN PROC, V70, P628, DOI 10.4065/70.7.628; SKINNER RB, 1995, JAMA-J AM MED ASSOC, V273, P1419, DOI 10.1001/jama.273.18.1419; TOSTI A, 1994, DRUG SAFETY, V10, P310, DOI 10.2165/00002018-199410040-00005; WINTROUB BU, 1994, HARRISONS PRINCIPLES, P279; WOOD AJ, 1994, HARRISONS PRINCIPLES, P405	23	66	68	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1176	1178		10.1001/jama.278.14.1176	http://dx.doi.org/10.1001/jama.278.14.1176			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326478				2022-12-28	WOS:A1997XY42200036
J	Barber, P				Barber, P			The colleges, Calman, and the new deal	LANCET			English	Editorial Material											Barber, P (corresponding author), WYTHENSHAWE HOSP,HEART & LUNG DIV,MANCHESTER M23 9LT,LANCS,ENGLAND.								0	20	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					974	974		10.1016/S0140-6736(05)64065-2	http://dx.doi.org/10.1016/S0140-6736(05)64065-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329510				2022-12-28	WOS:A1997XZ71000006
J	Nightingale, SL				Nightingale, SL			Request for public comment on informed consent waiver rule in combat situations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-28	WOS:A1997XX30300007
J	Freitas, AA; Rocha, B				Freitas, AA; Rocha, B			Lymphocyte survival: A Red Queen hypothesis	SCIENCE			English	Editorial Material							CELLULAR COMPETITION; T-CELLS; SELECTION; MICE		INST NECKER,INSERM,U345,F-75015 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Freitas, AA (corresponding author), INST PASTEUR,LAB DYNAM LYPHOCYTAIRES,CNRS,URA 1961,F-75015 PARIS,FRANCE.		freitas, antonio/A-2482-2013	freitas, antonio/0000-0001-6392-7178				Agenes F, 1997, EUR J IMMUNOL, V27, P1801, DOI 10.1002/eji.1830270731; Carroll L., 1872, LOOKING GLASS; Freitas AA, 1996, EUR J IMMUNOL, V26, P2640, DOI 10.1002/eji.1830261115; FREITAS AA, 1995, EUR J IMMUNOL, V25, P1729, DOI 10.1002/eji.1830250636; JERNE NK, 1967, COLD SPRING HARB SYM, V32, P591; KIRBERG J, 1997, IN PRESS J EXP MED; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; McLean AR, 1997, P NATL ACAD SCI USA, V94, P5792, DOI 10.1073/pnas.94.11.5792; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TANCHOT C, 1997, IN PRESS J EXP MED; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M	16	25	25	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1950	1950		10.1126/science.277.5334.1950	http://dx.doi.org/10.1126/science.277.5334.1950			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9333949				2022-12-28	WOS:A1997XX84900029
J	Albers, LH; Johnson, DE; Hostetter, MK; Iverson, S; Miller, LC				Albers, LH; Johnson, DE; Hostetter, MK; Iverson, S; Miller, LC			Health of children adopted from the former Soviet Union and Eastern Europe - Comparison with preadoptive medical records	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERELY MALNOURISHED CHILDREN; BEHAVIORAL-DEVELOPMENT; MALNUTRITION; STIMULATION	Context.-Children born in the countries of the former Soviet Union and Eastern Europe are now a main source of international adoptions in the United States, but often little information is available about these children prior to adoption. Objective.-To analyze the preadoptive medical reports of children adopted from Eastern Europe and the former Soviet Union and to compare these reports with their evaluations after arrival in the United States. Design.-Case series. Subjects and Setting.-A total of 56 children adopted from Eastern Europe and the former Soviet Union were evaluated in 2 international adoption clinics. Preadoptive medical records were available for 47 of these children. Results.-There were 43 (91%) of 47 medical reports available from the children's birth countries that included multiple unfamiliar neurologic diagnoses. Evaluations in the International Adoption Clinics frequently revealed growth delays (z score less than or equal to-1 for weight in 44% of children, height in 68%, and head circumference in 43%). Children had 1 month of linear growth lag for every 5 months in an orphanage (r=-0.48, P<.001). Developmental delays were also common (gross motor delays in 70% of children, fine motor in 82%, language in 59%, and social-emotional in 53%). While serious medical problems were found or corroborated in 11 (20%) of the 56 children evaluated in our clinics, neurologic diagnoses cited in preadoptive medical reports were not confirmed. Conclusions.-Preadoptive medical records from these international adoptees included multiple diagnoses suggesting severe neurologic impairment. Although these diagnoses were not confirmed when the children were evaluated in the United States, substantial growth and developmental delays were identified.	TUFTS UNIV, NEW ENGLAND MED CTR, FLOATING HOSP CHILDREN, INT ADOPT CLIN, BOSTON, MA 02111 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	Floating Hospital For Children; Tufts Medical Center; Tufts University; University of Minnesota System; University of Minnesota Twin Cities								ALVAREZ MD, 1991, REV SAUDE PUBL, V25, P282; COLOMBO M, 1992, DEV MED CHILD NEUROL, V34, P611; *COMM INF DIS, 1991, 199 REDB REP COMM IN; DAVIS RB, 1994, INT J ADDICT, V29, P303, DOI 10.3109/10826089409047383; GALLER JR, 1983, J AM ACAD CHILD PSY, V22, P8, DOI 10.1097/00004583-198301000-00003; GRANTHAMMCGREGOR S, 1983, PEDIATRICS, V72, P239; GRANTHAMMCGREGOR S, 1987, PEDIATRICS, V79, P247; HOSTETTER MK, 1991, NEW ENGL J MED, V325, P479, DOI 10.1056/NEJM199108153250706; JOHNSON DE, 1992, JAMA-J AM MED ASSOC, V268, P3446, DOI 10.1001/jama.268.24.3446; LEVITSKY DA, 1972, SCIENCE, V176, P68, DOI 10.1126/science.176.4030.68; LIEN NM, 1977, AM J CLIN NUTR, V30, P1734, DOI 10.1093/ajcn/30.10.1734; Linge Claire, 1996, P1; Lyons K. L., 1997, SMITHS RECOGNIZABLE, P555; MILLER LC, 1995, ARCH PEDIAT ADOL MED, V149, P40, DOI 10.1001/archpedi.1995.02170130042009; NELLHAUS G, 1968, PEDIATRICS, V41, P106; *US STAT DEP, 1997, ADOPTIVE FAMILIE JAN, P10; WINICK M, 1975, SCIENCE, V190, P1173, DOI 10.1126/science.1198103; 1995, CHICAGO TRIBUNE 1123, V1, P12	18	145	147	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					922	924		10.1001/jama.278.11.922	http://dx.doi.org/10.1001/jama.278.11.922			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV640	9302245				2022-12-28	WOS:A1997XV64000031
J	Fletcher, A; Cullum, N; Sheldon, TA				Fletcher, A; Cullum, N; Sheldon, TA			A systematic review of compression treatment for venous leg ulcers	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIAL; UNNAS BOOT; ULCERATION; MANAGEMENT	Objective: To estimate the clinical and cost effectiveness of compression systems for treating venous leg ulcers. Methods: Systematic review of research. Search of 19 electronic databases including Medline, CINAHL, and Embase. Relevant journals and conference proceedings were hand searched and experts were consulted. Main outcome measures: Rate of healing and proportion of ulcers healed within a time period. Study selection: Randomised controlled trials, published or unpublished, with no restriction on date or language, that evaluated compression as a treatment for venous leg ulcers. Results: 24 randomised controlled trials were included in the review The research evidence was quite weak: many trials had inadequate sample size and generally poor methodology, Compression seems to increase healing rates, Various high compression regimens are more effective than low compression, Few trials have compared the effectiveness of different high compression systems. Conclusions: Compression systems improve the healing of venous leg ulcers and should be used routinely in uncomplicated venous ulcers. Insufficient reliable evidence exists to indicate which system is the most effective, More good quality randomised controlled trials in association with economic evaluations are needed, to ascertain the most cost effective system for treating venous leg ulcers.	UNIV YORK,DEPT HLTH STUDIES,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK; University of York - UK			Cullum, Nicky A/F-2438-2011; Cullum, Nicky/AAT-5888-2020; Sheldon, Trevor/AAK-7088-2021	Cullum, Nicky A/0000-0003-2631-123X; Cullum, Nicky/0000-0003-2631-123X; Sheldon, Trevor/0000-0002-7479-5913				Bosanquet N, 1993, Health Trends, V25, P146; BOSANQUET N, 1992, PHLEBOLOGY S, V1, P44; CALLAM MJ, 1987, BRIT MED J, V294, P929, DOI 10.1136/bmj.294.6577.929; CALLAM MJ, 1992, PHLEBOLOGY, V7, P136, DOI 10.1177/026835559200700402; Callum M., 1992, PHLEBOLOGY S, V1, P6; CHARLES H, 1991, J DISTRICT NURSING, V4, P6; COLERIDGESMITH P, 1990, SURGERY, V108, P871; CORDTS PR, 1992, J VASC SURG, V15, P480, DOI 10.1016/0741-5214(92)90186-C; CULLUM N, 1997, EFFECTIVE HLTH CARE, V3, P1; DUBY T, 1993, WOUNDS, V5, P276; ERIKSSON G, 1984, CURR THER RES CLIN E, V35, P678; Fletcher A, 1995, J Wound Care, V4, P471; HENDRICKS WM, 1985, J AM ACAD DERMATOL, V12, P90, DOI 10.1016/S0190-9622(85)70015-1; Horakova M., 1994, PHLEBOLOGIE, V47, P53; KIKTA MJ, 1988, J VASC SURG, V7, P478, DOI 10.1067/mva.1988.avs0070478; KNIGHT CA, 1996, S ADV WOUND CAR MED, P117; MCCOLLUM CN, 1997, P C EUR WOUND MAN AS, P8; McCulloch J M, 1994, Adv Wound Care, V7, P22; Morison M. J., 1992, COLOUR GUIDE NURSING; Nelson EA, 1995, PHLEBOLOGY, V1, P915; *NHS CTR REV DISS, 1996, UND SYST REV RES EFF; NORTHEAST ADR, 1990, ROYAL SOC MED VEN FO; Orwin R.G., 1994, HDB RES SYNTHESIS; RUBIN JR, 1990, ARCH SURG-CHICAGO, V125, P489; Sikes E, 1985, J Enterostomal Ther, V12, P116; TRAVERS JP, 1992, PHLEBOLOGY, V7, P59, DOI 10.1177/026835559200700203; Wilkinson E, 1997, J Wound Care, V6, P339	27	197	201	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					576	580						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV717	9302954				2022-12-28	WOS:A1997XV71700024
J	Li, JH; Xu, M; Zhou, H; Ma, JY; Potter, H				Li, JH; Xu, M; Zhou, H; Ma, JY; Potter, H			Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation	CELL			English	Article							APOLIPOPROTEIN-E; DISEASE GENE; MISSENSE MUTATIONS; DOWNS-SYNDROME; BETA-PROTEIN; IN-VITRO; LAMIN-B; APOPTOSIS; EXPRESSION; SCLERODERMA	Mutations in two related genes, presenilin 1 and 2, account for most early-onset familial Alzheimer's disease. Although structural features indicate that the presenilins are membrane proteins, their function(s) is unknown. We have localized the presenilins to the nuclear membrane, its associated interphase kinetochores, and the centrosomes-all subcellular structures involved in cell cycle regulation and mitosis. The colocalization of the presenilins with kinetochores on the nucleoplasmic surface of the inner nuclear membrane, together with other results, suggests that they may play a role in chromosome organization and segregation, perhaps as kinetochore binding proteins/receptors. We discuss a pathogenic pathway for familial Alzheimer's disease in which defective presenilin function causes chromosome missegregation during mitosis, resulting in apoptosis and/or trisomy 21 mosaicism.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIA NIH HHS [AG08084, AG09665] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009665, R01AG008084] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; Ausubel FM, 1988, MOL REPROD DEV; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1996, SCIENCE, V271, P159, DOI 10.1126/science.271.5246.159; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Elder GA, 1996, J NEUROSCI RES, V45, P308; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LeBlanc A, 1995, J NEUROSCI, V15, P7837; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Ma JY, 1996, NEUROBIOL AGING, V17, P773; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Martins RH, 1995, NEUROREPORT, V7, P217, DOI 10.1097/00001756-199512290-00052; MCKEON FD, 1983, P NATL ACAD SCI-BIOL, V80, P4374, DOI 10.1073/pnas.80.14.4374; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Mitchell AR, 1996, MUTAT RES-FUND MOL M, V372, P153, DOI 10.1016/S0027-5107(96)00135-2; MOROI Y, 1981, J CELL BIOL, V90, P254, DOI 10.1083/jcb.90.1.254; Moussaoui S, 1996, FEBS LETT, V383, P219, DOI 10.1016/0014-5793(96)00250-5; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; POTTER H, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P643; POTTER H, 1991, AM J HUM GENET, V48, P1192; Potter H, 1996, LANCET, V348, P66, DOI 10.1016/S0140-6736(05)64399-1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHWEBER M, 1985, ANN NY ACAD SCI, V450, P223, DOI 10.1111/j.1749-6632.1985.tb21495.x; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STONE JF, 1995, MUTAT RES-DNAGING G, V338, P107, DOI 10.1016/0921-8734(95)00016-Y; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; Takashima A, 1996, BIOCHEM BIOPH RES CO, V227, P423, DOI 10.1006/bbrc.1996.1523; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; Varmus H., 1993, GENES BIOL CANC; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; WINEY M, 1993, J CELL BIOL, V122, P743, DOI 10.1083/jcb.122.4.743; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; YE Q, 1994, J BIOL CHEM, V269, P11306; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	71	184	190	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					917	927		10.1016/S0092-8674(00)80356-6	http://dx.doi.org/10.1016/S0092-8674(00)80356-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298903	Bronze			2022-12-28	WOS:A1997XV56300012
J	Bonni, A; Sun, Y; NadalVicens, M; Bhatt, A; Frank, DA; Rozovsky, I; Stahl, N; Yancopoulos, GD; Greenberg, ME				Bonni, A; Sun, Y; NadalVicens, M; Bhatt, A; Frank, DA; Rozovsky, I; Stahl, N; Yancopoulos, GD; Greenberg, ME			Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; FIBRILLARY ACIDIC PROTEIN; CEREBRAL-CORTEX; CNTF RECEPTOR; TRANSCRIPTION; CELLS; GENE; GFAP; DIFFERENTIATION; NEUROGENESIS	A mechanism by which members of the ciliary neurotrophic factor (CNTF)-leukemia inhibitory factor cytokine family regulate gliogenesis in the developing mammalian central nervous system was characterized, Activation of the CNTF receptor promoted differentiation of cerebral cortical precursor cells into astrocytes and inhibited differentiation of cortical precursors along a neuronal lineage, Although CNTF stimulated both the Janus kinase-signal transducer and activator of transcription (JAK-STAT) and Ras-mitogen-activated protein kinase signaling pathways in cortical precursor cells, the JAK-STAT signaling pathway selectively enhanced differentiation of these precursors along a glial lineage, These findings suggest that cytokine activation of the JAK-STAT signaling pathway may be a mechanism by which cell fate is controlled during mammalian development.	CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,NEUROGERONTOL DIV,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT SCI BIOL,LOS ANGELES,CA 90089; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Southern California; University of Southern California; Regeneron					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA43855] Funding Source: Medline; NICHD NIH HHS [NIHP30-HD 18655] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BESNARD F, 1991, J BIOL CHEM, V266, P18877; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BONNI A, UNPUB; CONDORELLI DF, 1994, J NEUROSCI RES, V39, P694, DOI 10.1002/jnr.490390610; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kahn MA, 1997, J NEUROCHEM, V68, P1413; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Richards LJ, 1996, EUR J NEUROSCI, V8, P291, DOI 10.1111/j.1460-9568.1996.tb01213.x; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Sun Y, 1996, MOL CELL NEUROSCI, V7, P152, DOI 10.1006/mcne.1996.0012; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WARE CB, 1995, DEVELOPMENT, V121, P1283; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Williams BP, 1997, NEURON, V18, P553, DOI 10.1016/S0896-6273(00)80297-4; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; ZIA Z, 1995, J NEUROSCI, V16, P5425	35	809	835	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					477	483		10.1126/science.278.5337.477	http://dx.doi.org/10.1126/science.278.5337.477			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334309				2022-12-28	WOS:A1997YB35500049
J	Brzozowski, AM; Pike, ACW; Dauter, Z; Hubbard, RE; Bonn, T; Engstrom, O; Ohman, L; Greene, GL; Gustafsson, JA; Carlquist, M				Brzozowski, AM; Pike, ACW; Dauter, Z; Hubbard, RE; Bonn, T; Engstrom, O; Ohman, L; Greene, GL; Gustafsson, JA; Carlquist, M			Molecular basis of agonism and antagonism in the oestrogen receptor	NATURE			English	Article							LIGAND-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; IDENTIFICATION; MECHANISMS; ACTIVATION; COMPLEX; SITES	Oestrogens are involved in the growth, development and homeostasis of a number of tissues(1). The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER)(2). Hormone binding to the ligand-binding domain (LED) of the ER initiates a series of molecular events culminating in the activation or repression of target genes, Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery(3,4). Here we report the crystal structures of the LED of ER in complex with the endogenous oestrogen, 17 beta-oestradiol, and the selective antagonist raloxifene(5), at resolutions of 3.1 and 2.6 Angstrom, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties, Agonist and antagonist bind at the same site within the core of the LED but demonstrate different binding modes, In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LED, providing structural evidence of the mechanism of antagonism.	UNIV YORK, DEPT CHEM, PROT STRUCT GRP, YORK YO1 5DD, N YORKSHIRE, ENGLAND; KARO BIO AB, NOVUM, S-14157 HUDDINGE, SWEDEN; UNIV CHICAGO, BEN MAY INST CANC RES, CHICAGO, IL 60637 USA; KAROLINSKA INST, S-14186 HUDDINGE, SWEDEN	University of York - UK; Karolinska Institutet; University of Chicago; Karolinska Institutet								Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CIOCCA DR, 1995, ENDOCR REV, V16, P35, DOI 10.1210/er.16.1.35; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Draper MW, 1996, J BONE MINER RES, V11, P835; Ekena K, 1997, J BIOL CHEM, V272, P5069, DOI 10.1074/jbc.272.8.5069; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Grese TA, 1997, J MED CHEM, V40, P146, DOI 10.1021/jm9606352; Hegy GB, 1996, STEROIDS, V61, P367, DOI 10.1016/0039-128X(96)00042-6; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Laskowski R.A., 1993, J APPL CRYSTALLOGR A, V42, P140; LHorset F, 1996, MOL CELL BIOL, V16, P6029; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAKDEL F, 1993, MOL ENDOCRINOL, V7, P1408, DOI 10.1210/me.7.11.1408; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	29	2741	2837	4	227	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					753	758		10.1038/39645	http://dx.doi.org/10.1038/39645			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338790				2022-12-28	WOS:A1997YA95900061
J	Tallman, MS; Andersen, JW; Schiffer, CA; Appelbaum, FR; Feusner, JH; Ogden, A; Shepherd, L; Willman, C; Bloomfield, CD; Rowe, JM; Wiernik, PH				Tallman, MS; Andersen, JW; Schiffer, CA; Appelbaum, FR; Feusner, JH; Ogden, A; Shepherd, L; Willman, C; Bloomfield, CD; Rowe, JM; Wiernik, PH			All-trans-retinoic acid in acute promyelocytic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	36th Meeting of the American-Society-of-Hematology	DEC 01-05, 1995	SEATTLE, WA	Amer soc Hematol			ACUTE MYELOID-LEUKEMIA; DIFFERENTIATION THERAPY; REMISSION INDUCTION; RESIDUAL DISEASE; RAR-ALPHA; TRANSLOCATION; CHEMOTHERAPY; EXPERIENCE; DIAGNOSIS; REDUCTION	Background All-trans-retinoic acid induces complete remission in acute promyelocytic leukemia. However, it is not clear whether induction therapy with all-trans-retinoic acid is superior to chemotherapy alone or whether maintenance treatment with all-trans-retinoic acid improves outcome. Methods Three hundred forty-six patients with previously untreated acute promyelocytic leukemia were randomly assigned to receive all-trans-retinoic acid or daunorubicin plus cytarabine as induction treatment. Patients who had a complete remission received consolidation therapy consisting of one cycle of treatment identical to the induction chemotherapy, then high-dose cytarabine plus daunorubicin. Patients still in complete remission after two cycles of consolidation therapy were then randomly assigned to maintenance treatment with all-trans-retinoic acid or to observation. Results Of the 174 patients treated with chemotherapy, 120 (69 percent) had a complete remission, as did 124 of the 172 (72 percent) given all-trans-retinoic acid (P=0.56). When both induction and maintenance treatments were taken into account, the estimated rates of disease-free survival at one, two, and three years were 77, 61, and 55 percent, respectively, for patients assigned to chemotherapy then all-trans-retinoic acid; 86, 75, and 75 percent for all-trans-retinoic acid then all-trans-retinoic acid; 75, 60, and 60 percent for all-trans-retinoic acid then observation; and 29, 18, and 18 percent for chemotherapy then observation. By intention-to-treat analysis, the rates of overall survival at one, two, and three years after entry into the study were 75, 57, and 50 percent, respectively, among patients assigned to chemotherapy, and 82, 72, and 67 percent among those assigned to all-trans-retinoic acid (P=0.003). Conclusions All-trans-retinoic acid as induction or maintenance treatment improves disease-free and overall survival as compared with chemotherapy alone and should be included in the treatment of acute promyelocytic leukemia. (C) 1997, Massachusetts Medical Society.	DANA FARBER CANC INST,BOSTON,MA 02115; UNIV MARYLAND,SCH MED,GREENEBAUM CANC CTR,BALTIMORE,MD 21201; UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195; CHILDRENS HOSP OAKLAND,OAKLAND,CA 94609; TEXAN CHILDRENS CANC CTR,HOUSTON,TX; NATL CANC INST,CANADA CLIN TRIALS GRP,KINGSTON,ON,CANADA; UNIV NEW MEXICO,ALBUQUERQUE,NM 87131; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,BUFFALO,NY 14263; UNIV ROCHESTER,ROCHESTER,NY; MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,BRONX,NY 10467	Harvard University; Dana-Farber Cancer Institute; University System of Maryland; University of Maryland Baltimore; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Texas Children's Cancer Center; Queens University - Canada; Canadian Cancer Trials Group; University of New Mexico; Roswell Park Cancer Institute; University of Rochester; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Tallman, MS (corresponding author), NORTHWESTERN UNIV,SCH MED,DIV HEMATOL ONCOL,ROBERT H LURIE CANC CTR,233 E ERIE ST,SUITE 700,CHICAGO,IL 60611, USA.							Avvisati G, 1996, BLOOD, V88, P1390, DOI 10.1182/blood.V88.4.1390.bloodjournal8841390; BENNETT JM, 1991, LEUKEMIA RES, V15, P223, DOI 10.1016/0145-2126(91)90124-C; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen GQ, 1996, LEUKEMIA, V10, P825; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; CHOMIENNE C, 1990, BLOOD, V76, P1710; CORDONNIER C, 1985, CANCER-AM CANCER SOC, V55, P18, DOI 10.1002/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B; CUNNINGHAM I, 1989, BLOOD, V73, P1116; DETHE H, 1990, NATURE, V347, P358; EARDLEY AM, 1994, LEUKEMIA, V8, P934; ELLIOTT S, 1992, BLOOD, V79, P1916; Estey E, 1997, J CLIN ONCOL, V15, P483, DOI 10.1200/JCO.1997.15.2.483; FENAUX P, 1993, BLOOD, V82, P3241; FENAUX P, 1992, BLOOD, V80, P2176; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; FRANKEL SR, 1994, ANN INTERN MED, V120, P278, DOI 10.7326/0003-4819-120-4-199402150-00004; Gallagher RE, 1997, BLOOD, V90, P1656; HEAD D, 1995, BLOOD, V86, P1717, DOI 10.1182/blood.V86.5.1717.bloodjournal8651717; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANAMARU A, 1995, BLOOD, V85, P1202, DOI 10.1182/blood.V85.5.1202.bloodjournal8551202; KANTARJIAN HM, 1986, AM J MED, V80, P789, DOI 10.1016/0002-9343(86)90617-0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORNINGER L, 1994, BRIT J HAEMATOL, V88, P427, DOI 10.1111/j.1365-2141.1994.tb05048.x; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; OHNO R, 1993, LEUKEMIA, V7, P1722; TAKESHITA A, 1995, CANCER-AM CANCER SOC, V76, P602, DOI 10.1002/1097-0142(19950815)76:4<602::AID-CNCR2820760410>3.0.CO;2-L; TALLMAN MS, 1992, BLOOD, V79, P543; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WIERNIK PH, 1996, NEOPLASTIC DIS BLOOD, P353; WILEY JS, 1995, LEUKEMIA, V9, P774	37	760	787	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1021	1028		10.1056/NEJM199710093371501	http://dx.doi.org/10.1056/NEJM199710093371501			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321529	Bronze			2022-12-28	WOS:A1997XZ84400001
J	Luttrell, S				Luttrell, S			Making decisions about medical treatment for mentally incapable adults in the UK	LANCET			English	Article							PROXIES				Luttrell, S (corresponding author), UCL, SCH MED, CTR GERIATR MED, ST PANCRAS HOSP, 4 ST PANCRAS WAY, LONDON NW1 0PE, ENGLAND.							HARE J, 1992, ARCH INTERN MED, V152, P1049, DOI 10.1001/archinte.152.5.1049; *HOUS LORDS, 1994, REP SEL COMM MED ETH, P55; *LAW COMM, 1993, 129 LAW COMM HM STAT, P65; *LAW COMM, 1993, 128 LAW COMM HM STAT; *LAW COMM CONS, 1991, 119 LAW COMM CONS, P11; Law Commission, 1995, MENT INC; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE, P128; Scottish Law Commission, 1995, REP INC AD; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SONNENBLICK M, 1993, J AM GERIATR SOC, V41, P599, DOI 10.1111/j.1532-5415.1993.tb06729.x; SULMASY DP, 1994, AM J MED, V96, P432, DOI 10.1016/0002-9343(94)90170-8; TOMLINSON T, 1990, GERONTOLOGIST, V30, P54, DOI 10.1093/geront/30.1.54; UHLMANN R, 1988, J GERONTOL, V48, pM115; WARD A, 1987, SLT NEWS, P69; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615	16	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					950	953		10.1016/S0140-6736(97)00001-9	http://dx.doi.org/10.1016/S0140-6736(97)00001-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY672	9314884				2022-12-28	WOS:A1997XY67200042
J	Grunstein, M				Grunstein, M			Histone acetylation in chromatin structure and transcription	NATURE			English	Article							NEWLY SYNTHESIZED HISTONES; SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; GENETIC-EVIDENCE; N-TERMINI; YEAST; DEACETYLASE; H4; DROSOPHILA; H3	The amino termini of bistones extend from the nucleosomal core and are modified by acetyltransferases and deacetylases during the cell cycle. These acetylation patterns may direct histone assembly and help regulate the unfolding and activity of genes.	UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Grunstein, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.							Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Allfrey V. G, 1977, CHROMATIN CHROMOSOME, P167; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; DeRubertis F, 1996, NATURE, V384, P589; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; Freeman L, 1996, P NATL ACAD SCI USA, V93, P12780, DOI 10.1073/pnas.93.23.12780; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 1996, MOL CELL BIOL, V16, P3112; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KUO M, 1966, NATURE, V383, P269; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; LOCKE J, 1988, GENETICS, V120, P181; MA X, UNPUB P NATL ACAD SC; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; STILLMAN DJ, 1994, GENETICS, V136, P781; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vannier D, 1996, GENETICS, V144, P1343; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WAN JS, 1995, P NATL ACAD SCI USA, V92, P5664, DOI 10.1073/pnas.92.12.5664; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	75	2291	2409	8	250	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					349	352		10.1038/38664	http://dx.doi.org/10.1038/38664			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311776				2022-12-28	WOS:A1997XX67500042
J	He, SG; Masland, RH				He, SG; Masland, RH			Retinal direction selectivity after targeted laser ablation of starburst amacrine cells	NATURE			English	Article							GANGLION-CELLS; RABBIT RETINA; CAENORHABDITIS-ELEGANS; MAMMALIAN RETINA; RECEPTIVE-FIELDS; CAT RETINA; ACETYLCHOLINE; IDENTIFICATION; RESPONSES; MECHANISM	Directionally selective retinal ganglion cells respond strongly when a stimulus moves in their preferred direction, but respond little or not at all when it moves in the opposite direction(1,2). This selectivity represents a classic paradigm of computation by neural microcircuits, but its cellular mechanism remains obscure. The directionally selective ganglion cells receive many synapses from a type of amacrine cell termed 'starburst' because of its regularly spaced, evenly radiating dendrites(3,4). Starburst amacrine cells have a synaptic asymmetry that has been proposed as the source of the directional response in the ganglion cells(5,6). Here we report experiments that make this unlikely, and offer an alternative concept of the function of starburst cells. We labelled starburst cells in living retinas, then killed them by targeted laser ablation while recording from individual directionally selective ganglion cells. Ablating starburst cells revealed no asymmetric contribution to the ganglion cell response. Instead of being direction discriminators, the starburst cells appear to potentiate generically the responses of ganglion cells to moving stimuli. The origin of direction selectivity probably lies with another type of amacrine cell.	MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute								AMES AI, 1996, J NEUROCHEM, V37, P867; AMTHOR FR, 1993, VISUAL MOTION ITS RO; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P135, DOI 10.1113/jphysiol.1982.sp014104; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; Borg-Graham L.J., 1992, SINGLE NEURON COMPUT, P347; BRECHA N, 1988, P NATL ACAD SCI USA, V85, P6187, DOI 10.1073/pnas.85.16.6187; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P277, DOI 10.1113/jphysiol.1978.sp012233; COHEN ED, 1995, P NATL ACAD SCI USA, V92, P1127, DOI 10.1073/pnas.92.4.1127; FAMIGLIETTI EV, 1991, J COMP NEUROL, V309, P40, DOI 10.1002/cne.903090105; GRZYWACZ NM, 1993, J NEUROPHYSIOL, V69, P2188, DOI 10.1152/jn.1993.69.6.2188; HUBA R, 1992, BRAIN RES, V577, P10, DOI 10.1016/0006-8993(92)90531-D; JACOBS GA, 1986, J NEUROSCI, V6, P2298; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; MARCHIAFAVA PL, 1979, VISION RES, V19, P1203, DOI 10.1016/0042-6989(79)90185-8; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MASLAND RH, 1979, J CELL BIOL, V83, P159, DOI 10.1083/jcb.83.1.159; MASLAND RH, 1986, TRENDS NEUROSCI, V9, P218, DOI 10.1016/0166-2236(86)90062-7; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P79, DOI 10.1098/rspb.1984.0084; OMALLEY DM, 1992, J NEUROSCI, V12, P1394; SCHMIDT M, 1987, J NEUROPHYSIOL, V58, P997, DOI 10.1152/jn.1987.58.5.997; Strettoi E, 1996, P NATL ACAD SCI USA, V93, P14906, DOI 10.1073/pnas.93.25.14906; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TAUCHI M, 1984, PROC R SOC SER B-BIO, V223, P101, DOI 10.1098/rspb.1984.0085; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; VANEY DI, 1991, PROG RETIN RES, V9, P1; VARDI N, 1989, J COMP NEUROL, V288, P601, DOI 10.1002/cne.902880407; YANG G, 1994, J NEUROSCI, V14, P5267	29	118	123	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					378	382		10.1038/38723	http://dx.doi.org/10.1038/38723			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311778				2022-12-28	WOS:A1997XX67500051
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 65-year-old man with an inguinal hernia, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		WANTZ GE, 1997, JAMA-J AM MED ASSOC, V277, P663	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1021	1021		10.1001/jama.278.12.1021	http://dx.doi.org/10.1001/jama.278.12.1021			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307352				2022-12-28	WOS:A1997XX01200035
J	Parker, L				Parker, L			Causes of testicular cancer	LANCET			English	Editorial Material							TRAUMA				Parker, L (corresponding author), UNIV NEWCASTLE UPON TYNE,SIR JAMES SPENCE INST CHILD HLTH,DEPT EPIDEMIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.			PARKER, LOUISE/0000-0002-5188-8113				Buetow SA, 1995, EPIDEMIOL REV, V17, P433, DOI 10.1093/oxfordjournals.epirev.a036202; Greaves MF, 1996, LEUKEMIA, V10, P372; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JENSEN TK, 1995, CLIN CHEM, V41, P1896; STONE JM, 1991, CANCER, V68, P211, DOI 10.1002/1097-0142(19910701)68:1<211::AID-CNCR2820680139>3.0.CO;2-Q; SWERDLOW AJ, 1988, BRIT J UROL, V61, P518, DOI 10.1111/j.1464-410X.1988.tb05094.x; Swerdlow AJ, 1997, BRIT MED J, V314, P1507, DOI 10.1136/bmj.314.7093.1507; WEISS L, 1990, J FORENSIC SCI, V35, P614	8	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					827	828		10.1016/S0140-6736(05)62028-4	http://dx.doi.org/10.1016/S0140-6736(05)62028-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310598				2022-12-28	WOS:A1997XX40100006
J	Stade, K; Ford, CS; Guthrie, C; Weis, K				Stade, K; Ford, CS; Guthrie, C; Weis, K			Exportin 1 (Crm1p) is an essential nuclear export factor	CELL			English	Article							ORDER CHROMOSOME STRUCTURE; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; FISSION YEAST; PORE COMPLEX; HNRNP A1; NUCLEOCYTOPLASMIC TRANSPORT; SCHIZOSACCHAROMYCES-POMBE; POLY(A)(+) RNA	Nuclear protein export is mediated by nuclear export signals (NESs), but the mechanisms governing this transport process are not well understood. Using a novel protein export assay in S. cerevisiae, we identify CRM1 as an essential mediator of nuclear protein export in yeast. Crm1p shows homology to importin beta-like transport factors and is able to specifically interact with both the NES motif and the Ran GTPase. A mutation in the shuttling protein Crm1p affects not only protein export, but also mRNA export, indicating that these pathways are tightly coupled in S. cerevisiae. The presented data are consistent with the conclusion that Crm1p is a carrier for the NES-mediated protein export pathway. We propose CRM1 be renamed exportin 1 (XPO1).	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Weis, Karsten/F-5719-2011	Weis, Karsten/0000-0001-7224-925X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Cole CN, 1997, SEMIN CELL DEV BIOL, V8, P71, DOI 10.1006/scdb.1996.0124; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; MELCHIOR F, 1994, J CELL BIOL, V124, P217; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; TURI TG, 1994, J BIOL CHEM, V269, P24229; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	61	932	942	0	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1041	1050		10.1016/S0092-8674(00)80370-0	http://dx.doi.org/10.1016/S0092-8674(00)80370-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323132	Bronze			2022-12-28	WOS:A1997XX76800010
J	Guslandi, M; Tittobello, A				Guslandi, M; Tittobello, A			Transdermal nicotine for ulcerative colitis	ANNALS OF INTERNAL MEDICINE			English	Letter							THERAPY				Guslandi, M (corresponding author), UNIV MILAN, I-20122 MILAN, ITALY.							Guslandi M, 1996, J GASTROENTEROL, V31, P627, DOI 10.1007/BF02355071; Sandborn WJ, 1997, ANN INTERN MED, V126, P364, DOI 10.7326/0003-4819-126-5-199703010-00004; Thomas GAO, 1996, EUR J GASTROEN HEPAT, V8, P769; THOMAS GAO, 1995, NEW ENGL J MED, V332, P988, DOI 10.1056/NEJM199504133321503	4	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					492	492		10.7326/0003-4819-127-6-199709150-00020	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00020			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313013				2022-12-28	WOS:A1997XV77900018
J	OByrne, PM; Israel, E; Drazen, JM				OByrne, PM; Israel, E; Drazen, JM			Antileukotrienes in the treatment of asthma	ANNALS OF INTERNAL MEDICINE			English	Review							EXERCISE-INDUCED BRONCHOCONSTRICTION; LEUKOTRIENE RECEPTOR ANTAGONIST; SLOW-REACTING SUBSTANCE; GUINEA-PIG LUNG; 5-LIPOXYGENASE ACTIVATING PROTEIN; INDUCED AIRWAY RESPONSES; ASPIRIN-INDUCED ASTHMA; BRONCHIAL RESPONSIVENESS; URINARY LEUKOTRIENE-E4; PULMONARY-FUNCTION	Purpose: To review the activity in clinical models, the efficacy, and the safety of antileukotrienes as a new class of antiasthma treatment. Data Sources: English-language trials identified from the archival literature, including the MEDLINE database, through 1996; bibliographic references; and textbooks. Study Selection: Reports from placebo-controlled, double-blind, randomized trials were selected. Data Extraction: Study designs and results were extracted from the clinical trial reports. Statistical evaluation of combined results was not attempted. Data Synthesis: The various classes of antileukotrienes have shown activity in clinical models of asthma, including exercise-induced, cold air hyperventilation-induced, allergen-induced, and aspirin-induced bronchoconstriction. In addition, the antileukotrienes partially reverse spontaneous bronchoconstriction in asthmatic persons, an effect additive to that of inhaled beta(2)-agonists. Clinical trials of the antileukotrienes have shown clinical benefit, as measured by reductions in asthma symptom scores, improvements in air flow obstruction, and reductions in the rescue use of inhaled beta(2)-agonists. Some, but not all, of the antileukotrienes have been shown to cause liver microsomal activation with increases in hepatic aminotransferase levels. Conclusions: Antileukotrienes are an important new therapy for asthma. Inhibition of leukotriene synthesis or action has a beneficial effect in the treatment of both induced and spontaneous asthma. These results show that leukotrienes are important mediators of the asthmatic response. In addition, encouraging results have been obtained from clinical trials of antileukotrienes; however, these results do not yet provide guidelines for the optimal clinical use of antileukotrienes in asthma treatment. Such recommendations await the results of further studies.	HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	OByrne, PM (corresponding author), MCMASTER UNIV,DEPT MED,DIV RESPIROL,ASTHMA RES GRP,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.		Drazen, Jeffrey M/E-5841-2012	O'Byrne, Paul/0000-0003-0979-281X				Adelroth E, 1997, J ALLERGY CLIN IMMUN, V99, P210, DOI 10.1016/S0091-6749(97)70098-8; ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ANDERSON SD, 1985, CHEST, V87, P191; ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEL EH, 1990, J ALLERGY CLIN IMMUN, V85, P1067, DOI 10.1016/0091-6749(90)90052-6; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; Chapman K.R., 1994, AM J RESP CRIT CARE, V149, pA215; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; CLOUD ML, 1989, AM REV RESPIR DIS, V140, P1336, DOI 10.1164/ajrccm/140.5.1336; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; CROOKE ST, 1990, ADV PROSTAG THROMB L, V20, P127; CROOKE ST, 1989, TRENDS PHARMACOL SCI, V10, P103, DOI 10.1016/0165-6147(89)90206-X; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN B, 1993, THORAX, V48, P1205, DOI 10.1136/thx.48.12.1205; DAVIDSON FF, 1989, BIOCHEM PHARMACOL, V38, P3645, DOI 10.1016/0006-2952(89)90567-4; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENNIS EA, 1990, ADV PROSTAG THROMB L, V20, P217; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; DIAMANT Z, 1996, AM J RESP CRIT CARE, V153, pA290; DILLARD RD, 1991, J MED CHEM, V34, P2768, DOI 10.1021/jm00113a014; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DRAZEN JM, 1974, J CLIN INVEST, V53, P1679, DOI 10.1172/JCI107719; ELLIS EF, 1984, J ALLERGY CLIN IMMUN, V73, P690, DOI 10.1016/0091-6749(84)90307-5; Feldberg W, 1938, J PHYSIOL-LONDON, V94, P187, DOI 10.1113/jphysiol.1938.sp003674; Ferguson JE, 1991, CURR OPIN CELL BIOL, V3, P206, DOI 10.1016/0955-0674(91)90140-T; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203, DOI 10.1164/ajrccm.152.4.7551371; FLEISCH JH, 1985, J PHARMACOL EXP THER, V233, P148; FORDHUTCHINSON AW, 1991, TRENDS PHARMACOL SCI, V12, P68, DOI 10.1016/0165-6147(91)90500-R; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; FUGISANG G, 1993, EUR RESPIR J, V6, P527; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; HAY DWP, 1987, J PHARMACOL EXP THER, V243, P474; HIGGINS DA, 1987, J ALLERGY CLIN IMMUN, V79, P141; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; HUI KP, 1991, LANCET, V337, P1062, DOI 10.1016/0140-6736(91)91709-4; IMPENS N, 1993, AM REV RESPIR DIS, V147, P1442, DOI 10.1164/ajrccm/147.6_Pt_1.1442; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; ISRAEL E, 1996, JAMA-J AM MED ASSOC, V275, P9831; JONES TR, 1986, CAN J PHYSIOL PHARM, V64, P1068, DOI 10.1139/y86-183; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; KAISER E, 1990, CLIN BIOCHEM, V23, P340; Kellaway CH, 1940, Q J EXP PHYSIOL CMS, V30, P121; KIRBY JG, 1987, AM REV RESPIR DIS, V136, p3P79; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; LEWIS RA, 1980, BIOCHEM BIOPH RES CO, V96, P271, DOI 10.1016/0006-291X(80)91210-3; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MANN JS, 1986, THORAX, V41, P746, DOI 10.1136/thx.41.10.746; MANNING P J, 1992, American Review of Respiratory Disease, V145, pA287; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MONG S, 1988, MOL PHARMACOL, V34, P590; MONG S, 1986, MOL PHARMACOL, V29, P235; MONG S, 1987, MOL PHARMACOL, V32, P223; MONG S, 1985, J PHARMACOL EXP THER, V234, P316; MONG S, 1987, MOL PHARMACOL, V31, P325; Nasser S. M. Shuaib, 1994, Thorax, V49, P749, DOI 10.1136/thx.49.8.749; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; ODONNELL M, 1991, J PHARMACOL EXP THER, V259, P751; PARKER CW, 1980, BIOCHEM BIOPH RES CO, V97, P1038, DOI 10.1016/0006-291X(80)91480-1; PARKER CW, 1979, PROSTAGLANDINS, V18, P673, DOI 10.1016/0090-6980(79)90088-1; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; REID GK, 1990, J BIOL CHEM, V265, P19818; Reiss TF, 1996, J ALLERGY CLIN IMMUN, V98, P528, DOI 10.1016/S0091-6749(96)70086-6; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBUSCHI M, 1992, AM REV RESPIR DIS, V145, P1285, DOI 10.1164/ajrccm/145.6.1285; ROUZER CA, 1988, J BIOL CHEM, V263, P10135; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SAMPSON AP, 1995, ARCH DIS CHILD, V73, P221, DOI 10.1136/adc.73.3.221; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SCHONFELD W, 1988, IMMUNOLOGY, V65, P529; SHEFFER AL, 1995, GLOBAL STRATEGY ASTH, P70; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SNYDER DW, 1987, J PHARMACOL EXP THER, V243, P548; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; THORPE JE, 1986, PROSTAG LEUKOTR ESS, V24, P269, DOI 10.1016/0262-1746(86)90133-2; TORPHY TJ, 1989, J PHARMACOL EXP THER, V249, P430; WAITE M, 1990, ADV EXP MED BIOL, V279, P430; WEICHMAN BM, 1984, J PHARMACOL EXP THER, V228, P128; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WETMORE LA, 1991, AM J PHYSIOL, V261, pL164, DOI 10.1152/ajplung.1991.261.2.L164; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71	109	94	100	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					472	480		10.7326/0003-4819-127-6-199709150-00009	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313005				2022-12-28	WOS:A1997XV77900009
J	Tuchman, M; Lichtenstein, GR; Rajagopal, BS; McCann, MT; Furth, EE; Bavaria, J; Kaplan, PB; Gibson, JB; Berry, GT				Tuchman, M; Lichtenstein, GR; Rajagopal, BS; McCann, MT; Furth, EE; Bavaria, J; Kaplan, PB; Gibson, JB; Berry, GT			Hepatic glutamine synthetase deficiency in fatal hyperammonemia after lung transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; IDIOPATHIC HYPERAMMONEMIA; AMMONIA METABOLISM; LIVER; HETEROGENEITY; CHEMOTHERAPY	Background: The cause of severe acquired hyperammonemia, an uncommon but often fatal complication of organ transplantation and chemotherapy for cancer, is obscure. Objective: To test the hypothesis that liver glutamine synthetase deficiency may explain hyperammonemia in patients who have had organ transplantation or are receiving chemotherapy. Design: Case report. Patients: Two patients who had fatal hyperammonemia after orthotopic lung transplantation. Measurements: Liver tissue was analyzed to determine the activities of two urea cycle enzymes and glutamine synthetase. Western blot assays for hepatic glutamine synthetase were performed to determine whether glutamine synthetase deficiency resulted from reduced enzyme levels, Results: Activities of carbamoyl phosphate synthetase I and ornithine carbamoyltransferase in the liver were normal. The activity of hepatic glutamine synthetase was markedly reduced (in patient 1, 12% of the mean value in controls; in patient 2, 28% of the mean value in controls), and a concomitant reduction in the amount of glutamine synthetase protein was observed. Conclusion: Hyperammonemia after transplantation was associated with hepatic glutamine synthetase deficiency in two patients, but the causal relation between these two conditions must be further studied.	HOSP UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA; HOSP UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; HOSP UNIV PENN, DEPT SURG, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP, DEPT METAB & GENET, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Tuchman, M (corresponding author), UNIV MINNESOTA HOSP & CLIN, DEPT PEDIAT, BOX 400, MAYO BLDG, 516 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.			Berry, Gerard/0000-0001-5299-3313	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047870] Funding Source: NIH RePORTER; NICHD NIH HHS [1PO1 HD32652] Funding Source: Medline; NIDDK NIH HHS [R01-DK47870] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GFL, 1974, J BIOL CHEM, V249, P634; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; BULERA SJ, 1995, TOXICOL APPL PHARM, V134, P313, DOI 10.1006/taap.1995.1197; Davies SM, 1996, BONE MARROW TRANSPL, V17, P1119; FINE P, 1989, AM J MED, V86, P629, DOI 10.1016/0002-9343(89)90406-3; GEBHARDT R, 1991, EUR J CELL BIOL, V56, P464; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; HAUSSINGER D, 1985, J HEPATOL, V1, P3, DOI 10.1016/S0168-8278(85)80063-5; HAWKINS RA, 1994, ADV EXP MED BIOL, V368, P11; LIAW CC, 1993, ANTI-CANCER DRUG, V4, P311, DOI 10.1097/00001813-199306000-00003; Lichtenstein GR, 1997, GASTROENTEROLOGY, V112, P236, DOI 10.1016/S0016-5085(97)70240-3; MATSUZAKI H, 1990, ACTA HAEMATOL-BASEL, V84, P130; MEISTER A, 1985, METHOD ENZYMOL, V113, P185; MITCHELL RB, 1988, AM J MED, V85, P662; MURIANA FJG, 1993, J BIOCHEM, V113, P738, DOI 10.1093/oxfordjournals.jbchem.a124113; SHARP RA, 1987, LANCET, V1, P805; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSE N, 1991, AM J HEMATOL, V38, P140, DOI 10.1002/ajh.2830380213; TUCHMAN M, 1989, PEDIATR RES, V26, P77, DOI 10.1203/00006450-198907000-00021; WATSON AJ, 1985, LANCET, V2, P1271	20	47	49	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					446	449		10.7326/0003-4819-127-6-199709150-00005	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313001				2022-12-28	WOS:A1997XV77900005
J	VandeWerf, F; Adgey, A; Agnelli, G; Aylward, P; Binbrek, A; Col, J; Diaz, R; Heikkila, J; Horgan, J; Myburgh, D; Oto, A; Paolasso, E; Pehrsson, K; Piegas, L; RuanoMarco, M; Gomes, RS; Tebbe, U; ToftegaardNielsen, T; Toutouzas, P; Vahanian, A; Verheugt, F; vonderLippe, G; White, H; Wilcox, R; Wojcik, J; Verstraete, M; Jones, D; Metzger, J; Fieschi, C; Hacke, W; Lardoux, H; vonKummer, R				VandeWerf, F; Adgey, A; Agnelli, G; Aylward, P; Binbrek, A; Col, J; Diaz, R; Heikkila, J; Horgan, J; Myburgh, D; Oto, A; Paolasso, E; Pehrsson, K; Piegas, L; RuanoMarco, M; Gomes, RS; Tebbe, U; ToftegaardNielsen, T; Toutouzas, P; Vahanian, A; Verheugt, F; vonderLippe, G; White, H; Wilcox, R; Wojcik, J; Verstraete, M; Jones, D; Metzger, J; Fieschi, C; Hacke, W; Lardoux, H; vonKummer, R			A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR; IMPROVED THROMBOLYSIS; CLINICAL-TRIALS; EFFICACY	Background Accelerated infusion of alteplase (tissue plasminogen activator) over a period of 90 minutes induces more rapid lysis of coronary-artery thrombi than a 3-hour infusion. With two bolus doses of alteplase, further shortening the duration of administration, complete reperfusion was achieved in more than 85 percent of the patients in initial angiographic studies. We tested the hypothesis that double-bolus alteplase is at least as effective as accelerated infusion. Methods In 398 hospitals, 7169 patients with acute myocardial infarction were randomly assigned to weight-adjusted, accelerated infusion of 100 mg of alteplase or to a bolus of 50 mg of alteplase over a period of 1 to 3 minutes followed 30 minutes later by a second bolus of 50 mg (or 40 mg for patients who weighed less than 60 kg). The primary end point was death from any cause at 30 days. The trial was stopped prematurely because of concern about the safety of the double-bolus injection. Results Thirty-day mortality was higher in the double-bolus group than in the accelerated-infusion group: 7.98 percent as compared with 7.53 percent, The absolute difference was 0.44 percent, with a one-sided 95 percent upper boundary of 1.49 percent, which exceeded the prespecified upper limit of 0.40 percent to indicate equivalence in 30-day mortality between the two regimens. The respective rates of any stroke and of hemorrhagic stroke were 1.92 and 1.12 percent after double-bolus alteplase, as compared with 1.53 and 0.81 percent after an accelerated infusion of alteplase (P = 0.24 and P = 0.23, respectively). Conclusions Double-bolus alteplase was not shown to be equivalent, according to the prespecified criteria, to accelerated infusion with regard to 30-day mortality, There was also a slightly higher rate of intracranial hemorrhage with the double-bolus method. Therefore, accelerated infusion of alteplase over a period of 90 minutes remains the preferred regimen. (C) 1997, Massachusetts Medical Society.			VandeWerf, F (corresponding author), UNIV HOSP GASTHUISBERG, DEPT CARDIOL, HERESTR 49, B-3000 LOUVAIN, BELGIUM.		von Kummer, Rüdiger/AAA-4478-2019; Hacke, Werner/ABE-8661-2020; Manolis, Antonis/F-5003-2014	von Kummer, Rüdiger/0000-0003-0119-4604; Manolis, Antonis/0000-0002-0336-4745				AGNELLI G, 1985, BLOOD, V66, P399; ANDREOTTI F, 1993, LANCET, V342, P937, DOI 10.1016/0140-6736(93)91991-T; [Anonymous], 1990, LANCET, V336, P65; BLEICH SD, 1995, CIRCULATION S1, V92, P415; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; GEMMILL JD, 1991, BRIT HEART J, V66, P134; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; HUNT D, 1992, LANCET, V339, P753; *INJECT INV, 1995, LANCET, V346, P980; *INT JOINT EFF COM, 1995, LANCET, V346, P329; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PURVIS JA, 1994, J AM COLL CARDIOL, V23, P6, DOI 10.1016/0735-1097(94)90495-2; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1993, AM J CARDIOL, V72, pG40, DOI 10.1016/0002-9149(93)90106-M; VANDEWERF F, 1990, LANCET, V336, P71; White HD, 1996, CIRCULATION, V94, P1826, DOI 10.1161/01.CIR.94.8.1826; WHITEHEAD J, 1992, DESIGN ANAL SEQUENTI, P188	20	128	130	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1124	1130						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9340504				2022-12-28	WOS:A1997YA91200004
J	McKinnon, WC; Baty, BJ; Bennett, RL; Magee, M; NeufeldKaiser, WA; Peters, KF; Sawyer, JC; Schneider, KA				McKinnon, WC; Baty, BJ; Bennett, RL; Magee, M; NeufeldKaiser, WA; Peters, KF; Sawyer, JC; Schneider, KA			Predisposition genetic testing for late-onset disorders in adults - A position paper of the National Society of Genetic Counselors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUNTINGTONS-DISEASE; COLORECTAL-CANCER; INFORMED CONSENT; OVARIAN-CANCER; FAMILY HISTORY; BRCA1; PROTOCOL; BREAST; SUSCEPTIBILITY; MODEL		UNIV VERMONT, COLL MED, DEPT PEDIAT, BURLINGTON, VT USA; UNIV UTAH, MED CTR, DEPT PEDIAT, SALT LAKE CITY, UT USA; UNIV WASHINGTON, DIV MED GENET, SEATTLE, WA 98195 USA; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, CTR HUMAN & MOL GENET, NEWARK, NJ 07103 USA; ODESSA CHILDRENS CLIN, COMPREHENS SICKLE CELL PROGRAM, SEATTLE, WA USA; NIH, NATL CTR HUMAN GENOME RES, MED GENET BRANCH, BETHESDA, MD 20892 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BEHAV SCI, HOUSTON, TX USA; DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA	University of Vermont; Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA063681] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000199, P30HG000199] Funding Source: NIH RePORTER; NCI NIH HHS [CA63681] Funding Source: Medline; NCRR NIH HHS [RR00064] Funding Source: Medline; NHGRI NIH HHS [HG00199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		*AM SOC CLIN ONC, 1996, J CLIN ONCOL, V14, P1737; [Anonymous], 1995, JAMA, V274, P1627; Baty B J, 1997, J Genet Couns, V6, P223, DOI 10.1023/A:1025620404473; Bennett R L, 1993, J Genet Couns, V2, P123, DOI 10.1007/BF00962073; Bennett RL, 1995, J GENET COUNS, V4, P267, DOI DOI 10.1007/BF01408073; Bernstein T, 1994, RADON RENTAL HOUSING; Biesecker B B, 1995, J Natl Cancer Inst Monogr, P115; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V270, P832; BIRD TD, 1995, ANN NEUROL, V38, P141, DOI 10.1002/ana.410380204; Botkin JR, 1996, J NATL CANCER I, V88, P872, DOI 10.1093/jnci/88.13.872; BOWCOCK AM, 1994, AM J HUM GENET, V55, pR1; BROHOLM J, 1994, J MED GENET, V31, P555; BURGESS MM, 1994, ALZ DIS ASSOC DIS, V8, P71, DOI 10.1097/00002093-199408020-00004; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; CODORI AM, 1994, AM J MED GENET, V54, P174, DOI 10.1002/ajmg.1320540304; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; COLLINS FS, 1996, NATL ACTION PLAN BRE; COPLEY TT, 1995, AM J MED GENET, V58, P59, DOI 10.1002/ajmg.1320580113; CRAUFURD D, 1992, J MED GENET, V29, P915, DOI 10.1136/jmg.29.12.915; Croyle RT, 1997, HEALTH PSYCHOL, V16, P63, DOI 10.1037/0278-6133.16.1.63; de Wert G, 1992, Birth Defects Orig Artic Ser, V28, P133; Dinkel MK, 1997, J CLIN ONCOL, V15, P2157; EVANS DGR, 1994, BRIT J CANCER, V70, P934, DOI 10.1038/bjc.1994.423; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; GELLER G, 1995, NAT GENET, V11, P364, DOI 10.1038/ng1295-364; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; HOLTZMAN NA, 1997, TASK FORCE GENETIC T; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; KESSLER S, 1994, AM J MED GENET, V54, P161, DOI 10.1002/ajmg.1320540302; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Lerman C, 1996, Oncology (Williston Park), V10, P191; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LOVE RR, 1985, J CHRON DIS, V38, P289, DOI 10.1016/0021-9681(85)90074-8; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McKinnon W C, 1997, J Genet Couns, V6, P131, DOI 10.1023/A:1025603900839; Mehlman MJ, 1996, AM J HUM GENET, V58, P393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; *NAT AT FDN, 1997, GUID GEN TEST DOM HE; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; PERICAKVANCE MA, 1995, TRENDS GENET, V11, P504, DOI 10.1016/S0168-9525(00)89161-1; Peters JA, 1994, J ONCOL MANAGE   SEP, P20; Petersen GM, 1996, INT J CANCER, V69, P53, DOI 10.1002/(SICI)1097-0215(19960220)69:1<53::AID-IJC13>3.0.CO;2-L; PRETZER M, 1997, MED EC          0609, P129; Quaid K A, 1992, J Genet Couns, V1, P277, DOI 10.1007/BF00962825; QUAID KA, 1995, AM J MED GENET, V57, P46, DOI 10.1002/ajmg.1320570111; ROSENBERG RN, 1995, CLIN NEUROSCI, V3, P1; SHARPE NF, 1994, AM J MED GENET, V50, P239, DOI 10.1002/ajmg.1320500306; Smith LB, 1996, J MED GENET, V33, P544, DOI 10.1136/jmg.33.7.544; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Vasen HFA, 1996, LANCET, V348, P433, DOI 10.1016/S0140-6736(96)01340-2; WAGNER A, 1995, LANCET, V346, P380, DOI 10.1016/S0140-6736(95)92262-8; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; 1992, FED REG         0228, P740; 1992, FED REG 0228, V57, P7139	60	76	76	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1217	1220		10.1001/jama.278.15.1217	http://dx.doi.org/10.1001/jama.278.15.1217			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333247				2022-12-28	WOS:A1997XZ70900002
J	Clarke, VRJ; Ballyk, BA; Hoo, KH; Mandelzys, A; Pellizzari, A; Bath, CP; Thomas, J; Sharpe, EF; Davies, CH; Ornstein, PL; Schoepp, DD; Kamboj, RK; Collingridge, GL; Lodge, D; Bleakman, D				Clarke, VRJ; Ballyk, BA; Hoo, KH; Mandelzys, A; Pellizzari, A; Bath, CP; Thomas, J; Sharpe, EF; Davies, CH; Ornstein, PL; Schoepp, DD; Kamboj, RK; Collingridge, GL; Lodge, D; Bleakman, D			A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission	NATURE			English	Article							INDUCED EPILEPTIFORM ACTIVITY; AMINO-ACID RECEPTORS; KAINIC ACID; GLUTAMATE RECEPTORS; RAT HIPPOCAMPUS; NERVOUS-SYSTEM; AMPA RECEPTORS; NEURONS; DESENSITIZATION; PHARMACOLOGY	The principal excitatory neurotransmitter in the vertebrate central nervous system, L-glutamate, acts on three classes of ionotripic glutamate receptors, named after the agonists AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxalole-4-propionic acid),NMDA (N-methyl-D-aspartate) and kainate(1). The development of selective pharmacological agents has led to a detailed understanding of the physiological and pathological roles of AMPA and NMDA receptors(2-8). in contrast, the lack of selective kainate receptor ligands has greatly hindered progress in understanding the roles of kainate receptors(9,10). Here we describe the effects of a potent and selective agonist, ATPA ((RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid) and a selective antagonist, LY294486 ((3SR, 4aRS, 6SR, 8aRS)-6-((((1H-tetrazol-5-yl) methyl)oxy)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid), of the GluR5 subtype of kainate receptor(11). We have used these agents to show that kainate receptors, comprised of or containing GluR5 subunits, regulate synaptic inhibition in the hippocampus, an action that could contribute to the epileptogenic effects of kainate(12-17).	ELI LILLY & CO, LILLY RES CTR LTD, WINDLESHAM GU20 6PH, SURREY, ENGLAND; UNIV BRISTOL, DEPT ANAT, BRISTOL BS8 1TD, AVON, ENGLAND; ALLELIX BIOPHARMACEUT, MISSISSAUGA, ON L4V 1V7, CANADA; UNIV EDINBURGH, DEPT PHARMACOL, EDINBURGH EH8 9JZ, MIDLOTHIAN, SCOTLAND; ELI LILLY & CO, LILLY CORP CTR, INDIANAPOLIS, IN 46285 USA	Eli Lilly; University of Bristol; University of Edinburgh; Eli Lilly			Collingridge, Graham L/C-4605-2015; Ornstein, Paul/E-4212-2016; collingridge, graham/AAI-8362-2020	Collingridge, Graham L/0000-0002-9572-5359; Ornstein, Paul/0000-0002-4335-1877; Clarke, Vernon/0000-0002-6154-6555	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENARI Y, 1988, J PHYSIOL-LONDON, V404, P365, DOI 10.1113/jphysiol.1988.sp017294; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Bleakman D, 1996, MOL PHARMACOL, V49, P581; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAVIES CH, 1993, NEUROPHARMACOLOGY, V32, P1071, DOI 10.1016/0028-3908(93)90073-C; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; FELDMEYER D, 1994, CURR BIOL, V4, P82, DOI 10.1016/S0960-9822(00)00021-X; FISHER RS, 1984, J NEUROSCI, V4, P1312; Fletcher EJ, 1996, PHARMACOL THERAPEUT, V70, P65, DOI 10.1016/0163-7258(96)00014-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; KEHL SJ, 1984, NEUROSCIENCE, V11, P111, DOI 10.1016/0306-4522(84)90217-3; KORCZAK B, 1995, RECEPTOR CHANNEL, V3, P41; KROGSGAARDLARSE.P, 1994, EXCITATORY AMINO ACI, P34; LAURIDSEN J, 1985, J MED CHEM, V28, P668, DOI 10.1021/jm50001a022; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Partin KM, 1996, MOL PHARMACOL, V49, P142; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SLOVITER RS, 1981, NEUROPHARMACOLOGY, V20, P1003, DOI 10.1016/0028-3908(81)90088-5; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; WILDING TJ, 1995, MOL PHARMACOL, V47, P582	30	362	372	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					599	603		10.1038/39315	http://dx.doi.org/10.1038/39315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335499				2022-12-28	WOS:A1997YA00800059
J	Lowe, MD; Harcombe, AA; Grace, AA; Petch, MC				Lowe, MD; Harcombe, AA; Grace, AA; Petch, MC			A breathless woman with hepatosplenomegaly for 12 years	LANCET			English	Article							CONSTRICTIVE PERICARDITIS		PAPWORTH HOSP,CARDIAC UNIT,CAMBRIDGE CB3 8RE,ENGLAND	Papworth Hospital								ARORA A, 1991, J CLIN GASTROENTEROL, V13, P178, DOI 10.1097/00004836-199104000-00012; BLAKE S, 1993, AM HEART J, V106, P432; IDRISS FS, 1974, ARCH SURG-CHICAGO, V109, P223; MASUI T, 1992, RADIOLOGY, V182, P369, DOI 10.1148/radiology.182.2.1732952; WOOD P, 1961, AM J CARDIOL, V7, P48, DOI 10.1016/0002-9149(61)90422-2	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					1000	1000		10.1016/S0140-6736(97)06302-2	http://dx.doi.org/10.1016/S0140-6736(97)06302-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329516				2022-12-28	WOS:A1997XZ71000012
J	Sheardown, SA; Duthie, SM; Johnston, CM; Newall, AET; Formstone, EJ; Arkell, RM; Nesterova, TB; Alghisi, GC; Rastan, S; Brockdorff, N				Sheardown, SA; Duthie, SM; Johnston, CM; Newall, AET; Formstone, EJ; Arkell, RM; Nesterova, TB; Alghisi, GC; Rastan, S; Brockdorff, N			Stabilization of Xist RNA mediates initiation of X chromosome inactivation	CELL			English	Article							MOUSE EMBRYOS; CONTROLLING ELEMENTS; LINKED GENES; FEMALE MOUSE; EXPRESSION; STABILITY; CELLS; DIFFERENTIATION; METHYLATION; EUKARYOTES	The onset of X inactivation is preceded by a marked increase in the level of Xist RNA. Here we demonstrate that increased stability of Xist RNA is the primary determinant of developmental up-regulation. Unstable transcript is produced by both alleles in XX ES cells and in XX embryos prior to the onset of random X inactivation. Following differentiation, transcription of unstable RNA from the active X chromosome allele continues for a period following stabilization and accumulation of transcript on the inactive X allele. We discuss the implications of these findings in terms of models for the initiation of random and imprinted X inactivation.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CTR CLIN SCI,X INACTIVAT GRP,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CTR CLIN SCI,EMBRYOL GRP,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London			Arkell, Ruth/AAR-8471-2021; arkell, ruth m/D-1525-2009	Arkell, Ruth/0000-0002-6213-7323; arkell, ruth m/0000-0002-6213-7323; Brockdorff, Neil/0000-0003-4838-2653; Nesterova, Tatyana/0000-0001-7740-4386				BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BEDDINGTON R, 1987, P43; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; CATTANACH BM, 1969, GENET RES, V14, P223, DOI 10.1017/S0016672300002068; CHEW LJ, 1994, MOL ENDOCRINOL, V8, P603, DOI 10.1210/me.8.5.603; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; DREWS U, 1974, CELL, V1, P3, DOI 10.1016/0092-8674(74)90148-2; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; Hendrich BD, 1997, NUCLEIC ACIDS RES, V25, P2661, DOI 10.1093/nar/25.13.2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Hogan B, 1994, MANIPULATING MOUSE E; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MARTIN GR, 1978, NATURE, V271, P329, DOI 10.1038/271329a0; MCBURNEY MW, 1980, CELL, V21, P357, DOI 10.1016/0092-8674(80)90472-9; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RACK KA, 1994, HUM MOL GENET, V3, P1053, DOI 10.1093/hmg/3.7.1053; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1982, J EMBRYOL EXP MORPH, V71, P11; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; RUSSELL LB, 1965, GENETICS, V52, P470; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHEARDOWN SA, 1997, IN PRESS GENE; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; Simmler MC, 1996, HUM MOL GENET, V5, P1713, DOI 10.1093/hmg/5.11.1713; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; TAKAGI N, 1982, CHROMOSOMA, V85, P275, DOI 10.1007/BF00294971; WEBB S, 1992, GENET RES, V59, P205, DOI 10.1017/S0016672300030494; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	52	217	223	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					99	107		10.1016/S0092-8674(01)80012-X	http://dx.doi.org/10.1016/S0092-8674(01)80012-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335338	Bronze			2022-12-28	WOS:A1997XZ80900012
J	vonBulow, GU; Bram, RJ				vonBulow, GU; Bram, RJ			NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily	SCIENCE			English	Article							DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; KAPPA-B; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; APOPTOSIS; BINDING; LIGAND; FAMILY; GENE	Activation of the nuclear factor of activated T cells transcription factor (NF-AT) is a key event underlying lymphocyte action. The CAML (calcium-modulator and cyclophilin ligand) protein is a coinducer of NF-AT activation when overexpressed in Jurkat T cells. A member of the tumor necrosis factor receptor superfamily was isolated by Virtue of its affinity for CAML. Cross-linking of this lymphocyte-specific protein, designated TACl (transmembrane activator and CAML-interactor), on the surface of transfected Jurkat cells with TACl-specific antibodies led to activation of the transcription factors NF-AT, AP-1, acid NF kappa B. TACl-induced activation of NF-AT was specifically blocked by a dominant-negative CAML mutant, thus implicating CAML as a signaling intermediate.	ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; HOLLOWAY MP, UNPUB; JAIN J, 1993, NATURE, V35, P352; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; VONBULOW GU, UNPUB; WILSONRAWLS J, 1994, VIROLOGY, V201, P66, DOI 10.1006/viro.1994.1266	32	296	341	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					138	141		10.1126/science.278.5335.138	http://dx.doi.org/10.1126/science.278.5335.138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311921				2022-12-28	WOS:A1997XZ12400057
J	Bingham, J				Bingham, J			A reluctant doctor shopper	ANNALS OF INTERNAL MEDICINE			English	Article																			0	4	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					569	570		10.7326/0003-4819-127-7-199710010-00010	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313025				2022-12-28	WOS:A1997XY73300010
J	Sallusto, F; Mackay, CR; Lanzavecchia, A				Sallusto, F; Mackay, CR; Lanzavecchia, A			Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells	SCIENCE			English	Article							EOSINOPHIL CHEMOATTRACTANT; FUNCTIONAL-PROPERTIES; MOLECULAR-CLONING; PHENOTYPE; ASTHMA; INTERLEUKIN-4; INFLAMMATION; ACTIVATION; MECHANISM; ANTIGEN	There is growing evidence that T helper cell subsets (T(H)1 and T(H)2) can be differentially recruited to promote different types of inflammatory reactions. Murine T(H)1 but not T(H)2 cells are recruited through P-and E-selectin into inflamed tissues, where they induce delayed-type hypersensitivity reactions. The human eotaxin-receptor CCR3, originally described on eosinophils and basophils, was also found to be expressed by T(H)2 cells. An antibody to CCR3 was used to isolate T cells from peripheral blood that give rise to T(H)2-polarized cell lines and to identify T(H)2 cells derived from naive T cells in vitro. Eotaxin stimulated increases in intracellular calcium and chemotaxis of CCR3(+) T cells. The attraction of T(H)2 cells by eotaxin could represent a key mechanism in allergic reactions, because it promotes the allergen-driven production of interleukin-4 and interleukin-5 necessary to activate basophils and eosinophils.	LEUKOSITE INC,CAMBRIDGE,MA 02142		Sallusto, F (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340				Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; FORRSMANN U, 1997, J EXP MED, V185, P2171; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GERBER BO, UNPUB; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lichtman AH, 1997, CURR BIOL, V7, P242; MACKAY CR, UNPUB; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SAD S, 1994, J IMMUNOL, V153, P3514; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SALLUSTO F, UNPUB; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SOMASSE T, 1996, J EXP MED, V184, P473; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; UGUCCIONI MG, IN PRESS J CLIN INVE; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577	36	890	920	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					2005	2007		10.1126/science.277.5334.2005	http://dx.doi.org/10.1126/science.277.5334.2005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302298				2022-12-28	WOS:A1997XX84900048
J	Brown, P				Brown, P			The risk of bovine spongiform encephalopathy ('mad cow disease') to human health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREUTZFELDT-JAKOB-DISEASE; VARIANT; TRANSMISSION	Some human cases of the transmissible neurodegenerative disorder Creutzfeldt-Jakob disease recently seen in Great Britain are thought to have resulted from eating beef infected with the agent of bovine spongiform encephalopathy. Reasons for and against this presumption are explained, and the question of a similar situation occurring in countries other than Britain-in particular, the United States-is discussed in terms of the existence of scrapie (in sheep) or unrecognized bovine spongiform encephalopathy (in cattle), the practice of recycling nonedible sheep and cattle tissue for animal nutrition, and precautionary measures already taken or under consideration by government agencies.			Brown, P (corresponding author), NINCDS, CENT NERVOUS SYST STUDIES LAB, NIH, BLDG 36, ROOM 5B21, BETHESDA, MD 20892 USA.							BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; Brown Paul, 1996, P139; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; Collee JG, 1997, LANCET, V349, P636, DOI 10.1016/S0140-6736(96)01310-4; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; FOSTER JD, 1994, ANN NY ACAD SCI, V724, P300, DOI 10.1111/j.1749-6632.1994.tb38920.x; Gibbs C.J., 1979, SLOW TRANSMISSIBLE D, V1, P87; GIBBS CJ, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91336-9; GIBBS CJ, 1996, BOVINE SPONGIFORM EN, P84; HOINVILLE IJ, 1996, REV SCI TECH OIE, V15, P827; Holman RC, 1996, EMERG INFECT DIS, V2, P333, DOI 10.3201/eid0204.960409; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MARSH RF, 1991, CURR T VET, V55, P41; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; Will R, 1996, BRIT MED J, V313, P833; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	18	27	32	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1008	1011		10.1001/jama.278.12.1008	http://dx.doi.org/10.1001/jama.278.12.1008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307349				2022-12-28	WOS:A1997XX01200032
J	Menendez, C; Kahigwa, E; Hirt, R; Vounatsou, P; Aponte, JJ; Font, F; Acosta, CJ; Schellenberg, DM; Galindo, CM; Kimario, J; Urassa, H; Brabin, B; Smith, TA; Kitua, AY; Tanner, M; Alonso, PL				Menendez, C; Kahigwa, E; Hirt, R; Vounatsou, P; Aponte, JJ; Font, F; Acosta, CJ; Schellenberg, DM; Galindo, CM; Kimario, J; Urassa, H; Brabin, B; Smith, TA; Kitua, AY; Tanner, M; Alonso, PL			Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants	LANCET			English	Article							TRADITIONAL BIRTH ATTENDANTS; PAPUA-NEW-GUINEA; GAMBIAN CHILDREN; PLASMODIUM-FALCIPARUM; PREVALENCE; PREGNANCY; MORTALITY; TRANSMISSION; CHLOROQUINE; INFECTION	Background Malaria and anaemia, especially that due to iron deficiency, are two leading causes of morbidity worldwide. Little is known about the relative contribution of Plasmodium falciparum infection and iron deficiency to the aetiology of anaemia in malaria-endemic areas. We undertook a randomised comparison of different strategies for control of anaemia and malaria in infants, including an assessment of the effect of iron supplementation on malaria susceptibility. Methods 832 infants born at one hospital in a malaria-hyperendemic area of Tanzania between January and October, 1995, were randomly assigned to group DI, receiving daily oral iron (2 mg/kg daily) plus weekly Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone); group IP, receiving iron plus weekly placebo; group DP, receiving daily placebo plus weekly Deltaprim; or group PP, receiving daily placebo plus weekly placebo. Daily supplementation was given from 8 to 24 weeks of age, and the weekly chemoprophylaxis from 8 to 48 weeks. The frequency of severe anaemia (packed-cell volume <25%) and malaria episodes was assessed through a combination of passive case detection and cross-sectional surveys. Findings The groups that received iron supplementation had a lower frequency of severe anaemia than those that did not receive iron (0.62 vs 0.87 cases per person-year; protective efficacy 28.8% [95% CI 6.3-45.8). Iron supplementation had no effect on the frequency of malaria (0.87 vs 1.00 cases per person-year; protective efficacy 12.8% [-12.8 to 32.5]). The groups that received malaria prophylaxis had lower frequencies of both severe anaemia (0.45 vs 1.04 episodes per person-year; protective efficacy 57.3% [43.0-67.9]) and malaria (0.53 vs 1.34 episodes per person-year; protective efficacy 60.5% [48.2-69.9]) than the groups that did not receive prophylaxis. After the end of the intervention period, children who had received malaria chemoprophylaxis had higher rates of severe anaemia and malaria than non-chemoprophylaxis groups (relative risks 2.2 [1.3-3.7] and 1.8 [1.3-2.6]). Interpretation Malaria chemoprophylaxis during the first year of life was effective in prevention of malaria and anaemia but apparently impaired the development of natural immunity. Iron supplementation was effective in preventing severe anaemia without increasing susceptibility to malaria. Our findings support iron supplementation of infants to prevent iron-deficiency anaemia, even in malaria-endemic areas.	ST FRANCIS DESIGNATED DIST HOSP, IFAKARA, TANZANIA; NATL INST MED RES, IFAKARA CTR, IFAKARA, TANZANIA; SWISS TROP INST, DEPT EPIDEMIOL & PUBL HLTH, CH-4002 BASEL, SWITZERLAND; UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, MERSEYSIDE, ENGLAND	Ifakara Health Institute; University of Basel; Swiss Tropical & Public Health Institute; Liverpool School of Tropical Medicine; University of Liverpool	Menendez, C (corresponding author), HOSP CLIN BARCELONA, UNIDAD EPIDEMIOL & BIOESTADIST, VILLARROEL 170, E-08036 BARCELONA, SPAIN.		Alonso, Pedro L/AAZ-3645-2020; Brabin, Bernard/AAJ-7389-2020; Menéndez, Clara/Q-3446-2016; Smith, Thomas/B-5569-2015	Alonso, Pedro L/0000-0003-3292-3443; Menéndez, Clara/0000-0002-2641-6907; Smith, Thomas/0000-0002-3650-9381; Brabin, Bernard/0000-0001-6860-2508; Vounatsou, Penelope/0000-0002-4904-5352; Schellenberg, David/0000-0001-8222-0186				ABDALLA SH, 1990, ANN TROP PAEDIATR, V10, P265, DOI 10.1080/02724936.1990.11747441; ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; [Anonymous], 1978, PEDIATRICS, V62, P246; BAIRD JK, 1991, AM J TROP MED HYG, V45, P65, DOI 10.4269/ajtmh.1991.45.65; BATES CJ, 1987, T ROY SOC TROP MED H, V81, P286, DOI 10.1016/0035-9203(87)90244-6; BRADLEYMOORE AM, 1985, ANN TROP MED PARASIT, V79, P549, DOI 10.1080/00034983.1985.11811962; BYLES AB, 1970, BRIT MED J, V3, P625, DOI 10.1136/bmj.3.5723.625; CLARK HC, 1949, MALARIOLOGY, P875; DeMaeyer EM., 1989, PREVENTING CONTROLLI; Greenwood BM, 1995, T ROY SOC TROP MED H, V89, P629, DOI 10.1016/0035-9203(95)90419-0; GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3; HARVEY PWJ, 1989, AM J TROP MED HYG, V40, P12, DOI 10.4269/ajtmh.1989.40.12; Hershko Chaim, 1996, P231; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MENENDEZ C, 1994, T ROY SOC TROP MED H, V88, P590, DOI 10.1016/0035-9203(94)90176-7; Molineaux L, 1997, LANCET, V349, P1636, DOI 10.1016/S0140-6736(97)22023-4; Molineaux L, 1980, THE GARKI PROJECT; MOLYNEUX ME, 1989, AM J TROP MED HYG, V40, P470, DOI 10.4269/ajtmh.1989.40.470; Mshinda H, 1996, TROP MED INT HEALTH, V1, P797; MURRAY MJ, 1978, BRIT MED J, V2, P1113, DOI 10.1136/bmj.2.6145.1113; NESTEL P, 1995, P IR INT CHILD SURV; OPPENHEIMER SJ, 1989, ACTA PAEDIATR SCAND, P53; OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9; OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P818, DOI 10.1016/0035-9203(86)90393-7; SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17, DOI 10.1080/02724936.1989.11748589; SMITH T, 1993, ACTA TROP, V54, P55, DOI 10.1016/0001-706X(93)90068-M; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Stoltzfus RJ, 1997, LANCET, V349, P1764, DOI 10.1016/S0140-6736(96)12355-2; THIBAULT H, 1993, EUR J PEDIATR, V152, P120, DOI 10.1007/BF02072487; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; WEWEATHERALL DJ, 1987, BR MED B, V38, P147; *WHO, 1996, TDRGEN961 WHO	36	277	282	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	1997	350	9081					844	850		10.1016/S0140-6736(97)04229-3	http://dx.doi.org/10.1016/S0140-6736(97)04229-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310602				2022-12-28	WOS:A1997XX40100010
J	Lesburg, CA; Zhai, GZ; Cane, DE; Christianson, DW				Lesburg, CA; Zhai, GZ; Cane, DE; Christianson, DW			Crystal structure of pentalenene synthase: Mechanistic insights on terpenoid cyclization reactions in biology	SCIENCE			English	Article							SESQUITERPENE CYCLASES; FARNESYL PYROPHOSPHATE; ENZYMATIC CYCLIZATION; BIOSYNTHESIS; STEREOCHEMISTRY; PURIFICATION; DIPHOSPHATE; STRATEGY; PROTEINS; PATHWAY	The crystal structure of pentalenene synthase at 2.6 angstrom resolution reveals critical active site features responsible for the cyclization of farnesyl diphosphate into the tricyclic hydrocarbon pentalenene. Metal-triggered substrate ionization initiates catalysis, and the alpha-barrel active site serves as a template to channel and stabilize the conformations of reactive carbocation intermediates through a complex cyclization cascade. The core active site structure of the enzyme may be preserved among the greater family of terpenoid synthases, possibly implying divergence from a common ancestral synthase to satisfy biological requirements for increasingly diverse natural products.	UNIV PENN, DEPT CHEM, ROY & DIANA VAGELOS LABS, PHILADELPHIA, PA 19104 USA; BROWN UNIV, DEPT CHEM, PROVIDENCE, RI 02912 USA	University of Pennsylvania; Brown University								ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; Back KW, 1996, P NATL ACAD SCI USA, V93, P6841, DOI 10.1073/pnas.93.13.6841; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1991, PHILOS T ROY SOC B, V332, P123, DOI 10.1098/rstb.1991.0040; CANE DE, 1984, BIOORG CHEM, V12, P312, DOI 10.1016/0045-2068(84)90013-0; CANE DE, 1994, CAN J CHEM, V72, P118, DOI 10.1139/v94-019; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CANE DE, 1985, ACCOUNTS CHEM RES, V18, P220, DOI 10.1021/ar00115a005; Cane DE, 1996, J AM CHEM SOC, V118, P1563, DOI 10.1021/ja953751n; CANE DE, 1990, J AM CHEM SOC, V112, P4513, DOI 10.1021/ja00167a059; CHAYET L, 1984, BIOORG CHEM, V12, P329, DOI 10.1016/0045-2068(84)90014-2; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; Corey EJ, 1996, J AM CHEM SOC, V118, P11982, DOI 10.1021/ja9632926; COREY EJ, 1995, J AM CHEM SOC, V117, P11819, DOI 10.1021/ja00152a030; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; Dolara P, 1996, NATURE, V379, P29, DOI 10.1038/379029a0; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESBURG CA, 1995, PROTEIN SCI, V4, P2436, DOI 10.1002/pro.5560041124; LESBURG CA, UNPUB; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHIE CA, 1991, J ROY SOC MED, V84, P602; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nyborg J., 1977, ROTATION METHOD CRYS, P139; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLINY, 1969, NATURALIS HIST; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; RUZICKA L., 1963, PURE AND APPL CHEM, V6, P493, DOI 10.1351/pac196306040493; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018	44	335	353	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1820	1824		10.1126/science.277.5333.1820	http://dx.doi.org/10.1126/science.277.5333.1820			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295272				2022-12-28	WOS:A1997XX29800046
J	Masson, GS; Busettini, C; Miles, FA				Masson, GS; Busettini, C; Miles, FA			Vergence eye movements in response to binocular disparity without depth perception	NATURE			English	Article							VIEWING DISTANCE; VISUAL-CORTEX; MONKEY; DEPENDENCE; MECHANISMS; STEREOPSIS; MOTION	Primates use vergence eye movements to align their two eyes on the same object and can correct misalignments by sensing the difference in the positions of the two retinal images of the object (binocular disparity). When large random-dot patterns are viewed dichoptically and small binocular misalignments are suddenly imposed (disparity steps), corrective vergence eye movements are elicited at ultrashort latencies(1,2). Here we show that the same steps applied to dense anticorrelated patterns, in which each black dot in one eye is matched to a white dot in the other eye, initiate vergence responses that are very similar, except that they are in the opposite direction. This sensitivity to the disparity of anticorrelated patterns is shared by many disparity-selective neurons in cortical area V1 (ref. 3), despite the fact that human subjects fail to perceive depth in such stimuli(4,5). These data indicate that the vergence eye movements initiated at ultrashort latencies result solely from locally matched binocular features, and derive their visual input from an early stage of cortical processing before the level at which depth percepts are elaborated.	NEI,SENSORIMOTOR RES LAB,NIH,BETHESDA,MD 20892; CNRS,CTR RECH NEUROSCI COGNIT,F-13402 MARSEILLE,FRANCE	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Centre National de la Recherche Scientifique (CNRS)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				BISHOP PO, 1986, VISION RES, V26, P1587, DOI 10.1016/0042-6989(86)90177-X; Busettini C, 1996, J NEUROPHYSIOL, V75, P1392, DOI 10.1152/jn.1996.75.4.1392; BUSETTINI C, 1994, EXP BRAIN RES, V100, P484, DOI 10.1007/BF02738407; Busettini C., 1994, Society for Neuroscience Abstracts, V20, P1403; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; Collewijn H, 1990, Rev Oculomot Res, V4, P213; Cumming BG, 1997, NATURE, V389, P280, DOI 10.1038/38487; CUMMING BG, 1986, J NEUROPHYSIOL, V55, P896, DOI 10.1152/jn.1986.55.5.896; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; JUDGE SJ, 1991, VISION VISUAL DYSFUN, V8, P157; JULESZ B, 1960, AT&T TECH J, V39, P1125, DOI 10.1002/j.1538-7305.1960.tb03954.x; MITCHELL DE, 1970, VISION RES, V10, P145, DOI 10.1016/0042-6989(70)90112-4; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; Parker A. J., 1996, Investigative Ophthalmology and Visual Science, V37, pS424; POGGIO GF, 1995, CEREB CORTEX, V5, P193, DOI 10.1093/cercor/5.3.193; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; QIAN N, 1994, NEURAL COMPUT, V6, P390, DOI 10.1162/neco.1994.6.3.390; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P339, DOI 10.1113/jphysiol.1961.sp006812; REGAN D, 1986, INVEST OPHTH VIS SCI, V27, P584; Trotter Y, 1996, J NEUROPHYSIOL, V76, P2872, DOI 10.1152/jn.1996.76.5.2872; WESTHEIMER G, 1969, VISION RES, V9, P749, DOI 10.1016/0042-6989(69)90012-1	21	175	178	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					283	286		10.1038/38496	http://dx.doi.org/10.1038/38496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305842				2022-12-28	WOS:A1997XW77200047
J	Somasundaram, K; Zhang, HB; Zeng, YX; Houvras, Y; Peng, Y; Zhang, HX; Wu, GS; Licht, JD; Weber, BL; ElDeiry, WS				Somasundaram, K; Zhang, HB; Zeng, YX; Houvras, Y; Peng, Y; Zhang, HX; Wu, GS; Licht, JD; Weber, BL; ElDeiry, WS			Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21(WAF1/CiP1)	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; CANCER-CELLS; HUMAN BREAST; GENE BRCA1; EXPRESSION; MOUSE	Much of the predisposition to hereditary breast and ovarian cancer has been attributed to inherited defects in the BRCA1 tumour-suppressor gene(1-3). The nuclear protein BRCA1 has the properties of a transcription factor(4-7), and can interact with the recombination and repair protein pAD51 (ref. 8), Young women with germline alterations in BRCA1 develop breast cancer at rates 100-fold higher than the general population(3), and BRCA1-null mice die before day 8 of development(9,10). However, the mechanisms of BRCA1-mediated growth regulation and tumour suppression remain unknown, Here we show that BRCA1 transactivates expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in a p53-independent manner, and that BRCA1 inhibits cell-cycle progression into the S-phase following its transfection into human cancer cells, BRCA1 does not inhibit S-phase progression in p21(-/-) cells, unlike p21(+/+) cells, and tumour-associated, transactivation-deficient mutants of BRCA1 are defective in both transactivation of p21 and cell-cycle inhibition, These data suggest that one mechanism by which BRCA1 contributes to cell-cycle arrest and growth suppression is through the induction of p21.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,LAB MOL ONCOL & CELL CYCLE REGULAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR CANC,PHILADELPHIA,PA 19104; CUNY MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			El-Deiry, Wafik/AAJ-6080-2020; Licht, Jonathan/L-4239-2019	El-Deiry, Wafik/0000-0002-9577-8266; Licht, Jonathan/0000-0002-3942-1369; Houvras, Yariv/0000-0003-0751-3215				Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WALDMAN T, 1995, CANCER RES, V55, P5187; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG W, 1995, CANCER RES, V55, P668	25	461	484	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					187	190		10.1038/38291	http://dx.doi.org/10.1038/38291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296497				2022-12-28	WOS:A1997XV75700050
J	Greenhalgh, T				Greenhalgh, T			How to read a paper - Papers that tell you what things cost (economic analyses)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; MEDICAL LITERATURE; CLINICAL-PRACTICE; USERS GUIDES; ARTICLE; UTILITY				Greenhalgh, T (corresponding author), UCL, SCH MED, ROYAL FREE HOSP, SCH MED, WHITTINGTON HOSP, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				Cairns J, 1996, BRIT MED J, V313, P6, DOI 10.1136/bmj.313.7048.6; DRUMMOND M, 1994, F5106625155K R D DIR; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; FALLOWFIELD LJ, 1995, ACTA ONCOL, V34, P689, DOI 10.3109/02841869509094050; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GREENHALGH T, 1997, IN PRESS BMJ; HAM C, 1995, BR J HLTH CARE MANAG, V1, P27; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; Hickey AM, 1996, BRIT MED J, V313, P29, DOI 10.1136/bmj.313.7048.29; HOPKINS A, 1992, MEASURES QUALITY LIF; JEFFERSON T, 1996, ELEMENTARY EC EVALUA; Krabbe PFM, 1996, MED DECIS MAKING, V16, P120, DOI 10.1177/0272989X9601600204; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; Patrick D. L., 1993, HLTH STATUS HLTH POL; Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443; Richardson J, 1996, INT J TECHNOL ASSESS, V12, P151, DOI 10.1017/S026646230000948X; Weinberger M, 1996, J CLIN EPIDEMIOL, V49, P135, DOI 10.1016/0895-4356(95)00556-0	18	33	33	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	1997	315	7108					596	599		10.1136/bmj.315.7108.596	http://dx.doi.org/10.1136/bmj.315.7108.596			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV717	9302961	Green Published			2022-12-28	WOS:A1997XV71700032
J	Canagarajah, BJ; Khokhlatchev, A; Cobb, MH; Goldsmith, EJ				Canagarajah, BJ; Khokhlatchev, A; Cobb, MH; Goldsmith, EJ			Activation mechanism of the MAP kinase ERK2 by dual phosphorylation	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; GROWTH-FACTOR; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; DOMAIN; IDENTIFICATION; SPECIFICITY; INSULIN	The structure of the active form of the MAP kinase ERK2 has been solved, phosphorylated on a threonine and a tyrosine residue within the phosphorylation lip. The lip is refolded, bringing the phosphothreonine and phosphotyrosine into alignment with surface arginine-rich binding sites. Conformational changes occur in the lip and neighboring structures, including the P+1 site, the MAP kinase insertion, the C-terminal extension, and helix C. Domain rotation and remodeling of the proline-directed P+1 specificity pocket account for the activation. The conformation of the P+1 pocket is similar to a second proline-directed kinase, CDK2-CyclinA, thus permitting the origin of this specificity to be defined. Conformational changes outside the lip provide loci at which the state of phosphorylation can be felt by other cellular components.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046993] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46993] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENG P, 1992, SCIENCE, V257, P1404; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Goldsmith EJ, 1996, FASEB J, V10, P702, DOI 10.1096/fasebj.10.7.8635687; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1993, O VERSION 5 9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	75	605	620	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					859	869		10.1016/S0092-8674(00)80351-7	http://dx.doi.org/10.1016/S0092-8674(00)80351-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298898	Bronze			2022-12-28	WOS:A1997XV56300007
J	Verma, R; Annan, RS; Huddleston, MJ; Carr, SA; Reynard, G; Deshaies, RJ				Verma, R; Annan, RS; Huddleston, MJ; Carr, SA; Reynard, G; Deshaies, RJ			Phosphorylation of Sic1p by G(1) Cdk required for its degradation and entry into S phase	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; SELECTIVE DETECTION; MASS-SPECTROMETRY; G1 CYCLINS; START; PHOSPHOPEPTIDES; TRANSITION; PATHWAY; FAMILY	G(1) cyclin-dependent kinase (Cdk)-triggered degradation of the S-phase Cdk inhibitor Sic1p has been implicated in the transition from G(1) to S phase in the cell cycle of budding yeast. A multidimensional electrospray mass spectrometry technique was used to map G(1) Cdk phosphorylation sites in Sic1p both in vitro and in vivo. A Sic1p mutant lacking three Cdk phosphorylation sites did not serve as a substrate for Cdc34p-dependent ubiquitination in vitro, was stable in vivo, and blocked DNA replication. Moreover, purified phosphoSic1p was ubiquitinated in cyclin-depleted G(1) extract, indicating that a primary function of G(1) cyclins is to tag Sic1p for destruction. These data suggest a molecular model of how phosphorylation and proteolysis cooperate to bring about the G(1)/S transition in budding yeast.	SMITHKLINE BEECHAM PHARMACEUT,MASS SPECTROMETRY RES LAB,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	Verma, R (corresponding author), CALTECH,DIV BIOL,BOX 156-29,PASADENA,CA 91125, USA.		Deshaies, Raymond/B-8354-2014; Carr, Steven A./AAH-8366-2019	Deshaies, Raymond/0000-0002-3671-9354; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052466] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52466-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FELDMAN RMR, IN PRESS CELL; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; HENCHOZ S, IN PRESS GENES DEV; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Mathias N, 1996, MOL CELL BIOL, V16, P6634; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; REYNARD GJ, UNPUB; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SKOWYRA D, IN PRESS CELL; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, METHOD ENZYMOL, V283, P366; Verma R. P., UNPUB; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	28	390	399	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					455	460		10.1126/science.278.5337.455	http://dx.doi.org/10.1126/science.278.5337.455			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334303				2022-12-28	WOS:A1997YB35500043
J	McCord, TB; Carlson, RW; Smythe, WD; Hansen, GB; Clark, RN; Hibbitts, CA; Fanale, FP; Granahan, JC; Segura, M; Matson, DL; Johnson, TV; Martin, PD				McCord, TB; Carlson, RW; Smythe, WD; Hansen, GB; Clark, RN; Hibbitts, CA; Fanale, FP; Granahan, JC; Segura, M; Matson, DL; Johnson, TV; Martin, PD			Organics and other molecules in the surfaces of Callisto and Ganymede	SCIENCE			English	Article							GALILEAN SATELLITES; REFLECTANCE SPECTRUM; INTERNAL STRUCTURE; OPTICAL-CONSTANTS; CARBON-DIOXIDE; ICE ANALOGS; MU-M; FROST	Five absorption features are reported at wavelengths of 3.4, 3.88, 4.05, 4.25, and 4.57 micrometers in the surface materials of the Galilean satellites Callisto and Ganymede from analysis of reflectance spectra returned by the Galileo mission near-infrared mapping spectrometer. Candidate materials include CO2, organic materials (such as tholins containing C=N and C-H), SO2, and compounds containing an SH-functional group; CO2, SO2, and perhaps cyanogen [(CN)(2)] may be present within the surface material itself as collections of a few molecules each. The spectra indicate that the primary surface constituents are water ice and hydrated minerals.	CALTECH,JET PROP LAB,PASADENA,CA 91109; US GEOL SURVEY,DENVER,CO 80225; SCI & TECHNOL INT INC,HONOLULU,HI	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of the Interior; United States Geological Survey	McCord, TB (corresponding author), UNIV HAWAII,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822, USA.		Hibbitts, Charles/B-7787-2016	Hibbitts, Charles/0000-0001-9089-4391				Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; Anderson JD, 1997, NATURE, V387, P264, DOI 10.1038/387264a0; ANDERSON JD, 1997, NATURE, V276, P1236; Bishop JL, 1997, METEORIT PLANET SCI, V32, pA14; BLAKE D, 1991, SCIENCE, V254, P548, DOI 10.1126/science.11538372; CALVIN WM, 1991, ICARUS, V89, P305, DOI 10.1016/0019-1035(91)90180-2; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; Clark R. N., 1986, SATELLITES, P437; CLARK RN, UNPUB USGS DIGITAL S; Colthup N.B., 1990, INTRO INFRARED RAMAN; CRUIKSHANK DP, 1991, ICARUS, V94, P345, DOI 10.1016/0019-1035(91)90233-J; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; FALK M, 1987, J CHEM PHYS, V86, P560, DOI 10.1063/1.452307; FANALE FP, 1979, NATURE, V280, P761, DOI 10.1038/280761a0; Farmer V. C., 1974, INFRARED SPECTRA MIN; FARRELL EF, 1967, AM MINERAL, V52, P380; FINK U, 1973, ASTROPHYS J, V179, pL155, DOI 10.1086/181139; FINK UWE, 1975, ICARUS, V24, P411, DOI 10.1016/0019-1035(75)90058-5; Goody R.M., 1989, ATMOSPHERIC RAD, P67; HOBBS PV, 1974, ICE PHYSICS; IRVINE WM, 1968, ICARUS, V8, P324, DOI 10.1016/0019-1035(68)90083-3; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; MCCORD TB, 1997, T AM GEOPHYS UNION, V78, pS202; MCCORD TB, 1996, B AM ASTRON SOC, V28, P1138; MCCORD TB, 1996, T AM GEOPHYS UNION, V77, pF445; MCDONALD GD, 1991, ICARUS, V94, P354, DOI 10.1016/0019-1035(91)90234-K; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; Notesco G, 1997, ICARUS, V126, P336, DOI 10.1006/icar.1996.5654; OCKMAN N, 1958, ADV PHYS, V7, P199, DOI 10.1080/00018735800101227; PIERSON RH, 1956, ANAL CHEM, V28, P1218, DOI 10.1021/ac60116a002; PILCHER CB, 1972, SCIENCE, V178, P1087, DOI 10.1126/science.178.4065.1087; POLLACK JB, 1978, ICARUS, V36, P271, DOI 10.1016/0019-1035(78)90110-0; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; ROUSH TL, 1990, ICARUS, V86, P355, DOI 10.1016/0019-1035(90)90225-X; SALISBURY JW, 1991, INFRARED SPECTRA MIN; SANDFORD SA, 1988, ICARUS, V76, P201, DOI 10.1016/0019-1035(88)90069-3; SANDFORD SA, 1990, ASTROPHYS J, V355, P357, DOI 10.1086/168770; Sill G. T., 1982, SATELLITES JUPITER, P174; SMYTHE WD, 1979, NATURE, V280, P766, DOI 10.1038/280766a0; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; Swayze G., 1993, B AM ASTRON SOC, V25, P1033; WARREN SG, 1986, APPL OPTICS, V25, P2650, DOI 10.1364/AO.25.002650; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WATSON K, 1963, ICARUS, V1, P361; Whittet DCB, 1996, ASTRON ASTROPHYS, V315, pL357; Wilkening L. L, 1982, IAU C 61 COMET DISCO, P85; WOOD DL, 1967, J CHEM PHYS, V47, P2220, DOI 10.1063/1.1703295; [No title captured]; 1996, SCIENCE, V274, P377	54	138	140	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					271	275		10.1126/science.278.5336.271	http://dx.doi.org/10.1126/science.278.5336.271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323203				2022-12-28	WOS:A1997YA56400040
J	Kretzschmar, M; Doody, J; Massague, J				Kretzschmar, M; Doody, J; Massague, J			Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1	NATURE			English	Article							MAD-RELATED PROTEIN; GROWTH-FACTOR-BETA; SIGNALING PATHWAYS; TRANSDUCTION; SPECIFICITY; RECEPTORS; DPC4	The growth factor TGF-beta, bone morphogenetic proteins (BMPs) and related factors regulate cell proliferation, differentiation and apoptosis, controlling the development and maintenance of most tissues(1,2). Their signals are transmitted through the phosphorylation of the tumour-suppressor SMAD proteins by receptor protein serine/threonine kinases (RS/TKs)(3-10), leading to the nuclear accumulation(5,9,11,12) and transcriptional activity of SMAD proteins(6,12,13). Here we report that Smad1, which mediates BMP signals, is also a target of mitogenic growth-factor signalling through epidermal growth factor and hepatocyte growth factor receptor protein tyrosine kinases (RTKs). Phosphorylation occurs at specific serines within the region linking the inhibitory and effector domains of Smad1, and is catalysed by the Erk family of mitogen-activated protein kinases. In contrast to the BMP-stimulated phosphorylation of Smad1, which affects carboxy-terminal serines and induces nuclear accumulation of Smad1(6), Erk-mediated phosphorylation specifically inhibits the nuclear accumulation of Smad1. Thus, Smad1 receives opposing regulatory inputs through RTKs and RS/TKs, and it is this balance that determines the level of Smad1 activity in the nucleus, and so possibly the role of Smad1 in the control of cell fate.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BERNIER SM, 1992, J CELL PHYSIOL, V152, P317, DOI 10.1002/jcp.1041520213; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ganan Y, 1996, DEVELOPMENT, V122, P2349; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	34	748	775	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					618	622		10.1038/39348	http://dx.doi.org/10.1038/39348			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335504				2022-12-28	WOS:A1997YA00800064
J	Labarrere, CA; Nelson, DR; Faulk, WP				Labarrere, CA; Nelson, DR; Faulk, WP			Endothelial activation and development of coronary artery disease in transplanted human hearts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN CARDIAC ALLOGRAFTS; TISSUE-PLASMINOGEN-ACTIVATOR; ADHESION MOLECULE EXPRESSION; ANTIENDOTHELIAL ANTIBODIES; VASCULAR IMMUNOPATHOLOGY; PROCOAGULANT ACTIVITY; CHRONIC REJECTION; MOUSE HEARTS; RECIPIENTS; CELLS	Context.-The development of coronary artery disease in heart transplants is often associated with graft failure, Early detection of allografts prone to develop this disease is essential to institute new therapeutic approaches that could prolong allograft function. Objective.-To determine if early activation of arterial/arteriolar endothelium predicts the development of coronary artery disease, graft failure, or both in transplanted human hearts. Design.-Prospective cohort study. Setting.-Heart Transplant Center. Participants.-A total of 121 consecutive adult cardiac allograft recipients who received transplants between 1988 and 1995 and were followed up through 1996. Main Outcome Measures.-Development of coronary artery disease and graft failure, Methods.-Immunocytochemistry was performed on serial endomyocardial biopsy specimens to evaluate endothelial activation markers (intercellular adhesion molecule-1 and histocompatibility antigen HLA-DR) in arteries and arterioles. The presence and progression of coronary artery disease was evaluated by annual coronary angiograms with side-by-side comparisons, Results.-None of the 121 donor hearts showed arterial/arteriolar endothelial activation before transplantation. Arterial/arteriolar endothelial activation was present in 78 and absent in 43 of 121 allografts during the first 3 months after transplantation. The time of appearance and the proportion of biopsy specimens showing endothelial activation during these first 3 months were significantly associated with the risk of developing coronary artery disease, the progression of the disease, and the time required to develop the disease (P<.001). Significantly more patients with arterial/arteriolar endothelial activation died or received a second transplant (P<.001). Conclusions.-Activation of arterial/arteriolar endothelium in transplanted human hearts predicts development of coronary artery disease and increased risk of graft failure.	METHODIST RES INST, CLARIAN HLTH, CTR HLTH SERV RES, INDIANAPOLIS, IN 46202 USA; RILEY HOSP, INDIANAPOLIS, IN USA	Indiana University System; James Whitcomb Riley Hospital Children	Labarrere, CA (corresponding author), METHODIST RES INST, CLARIAN HLTH, CTR REPROD & TRANSPLANTAT IMMUNOL, 1701 N SENATE BLVD, INDIANAPOLIS, IN 46202 USA.			Nelson, David/0000-0002-3240-0725				ADAMS DH, 1993, IMMUNOL REV, V134, P5, DOI 10.1111/j.1600-065X.1993.tb00637.x; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Billingham M E, 1990, J Heart Transplant, V9, P587; BRISCOE DM, 1995, TRANSPLANTATION, V59, P204, DOI 10.1097/00007890-199501270-00009; CRISP SJ, 1994, J HEART LUNG TRANSPL, V13, P81; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; FAULK WP, 1989, SEMIN THROMB HEMOST, V15, P88, DOI 10.1055/s-2007-1002691; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, P219; FAULK WP, 1995, TRANSPLANT P, V27, P1944; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, pS125; FAULK WP, 1994, SEMIN HEMATOL, V31, P26; FAULK WP, 1992, ARCH PATHOL LAB MED, V116, P1337; FAULK WP, 1994, MAJOR PROBL PATHOL, V30, P49; Gag SZ, 1996, J AM COLL CARDIOL, V28, P673, DOI 10.1016/0735-1097(96)00201-X; GAO SZ, 1994, J HEART LUNG TRANSPL, V13, P1119; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349; KARNOVSKY MJ, 1994, CLIN TRANSPLANT, V8, P308; LABARRERE CA, 1993, TRANSPLANTATION, V55, P1056, DOI 10.1097/00007890-199305000-00021; LABARRERE CA, 1994, CIRCULATION, V89, P1599, DOI 10.1161/01.CIR.89.4.1599; LABARRERE CA, 1995, NEW ENGL J MED, V333, P1111, DOI 10.1056/NEJM199510263331704; LABARRERE CA, 1995, TRANSPLANT P, V27, P1941; LABARRERE CA, 1995, TRANSPLANT P, V27, P1939; LABARRERE CA, 1994, AM J OBSTET GYNECOL, V171, P165, DOI 10.1016/0002-9378(94)90464-2; MEHRA MR, 1995, J AM COLL CARDIOL, V26, P1537, DOI 10.1016/0735-1097(95)00357-6; MILLER LW, 1995, TRANSPLANT REV, V9, P77; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POSTON RN, 1992, AM J PATHOL, V140, P665; ROSE EA, 1992, J HEART LUNG TRANSPL, V11, pS120; RUSSELL ME, 1994, J CLIN INVEST, V94, P722, DOI 10.1172/JCI117391; RUSSELL PS, 1994, J IMMUNOL, V152, P5135; RUSSELL PS, 1994, AM J PATHOL, V144, P260; SALOMON RN, 1991, AM J PATHOL, V138, P791; SCHOEN JF, 1994, ROBBINS PATHOLOGIC B, P467; SCHROEDER JS, 1991, NEW ENGL J MED, V324, P1805, DOI 10.1056/NEJM199106203242509; STOVIN PGI, 1993, J HEART LUNG TRANSPL, V12, P110; TANIO JW, 1994, CIRCULATION, V89, P1760, DOI 10.1161/01.CIR.89.4.1760; TAYLOR PM, 1992, TRANSPLANTATION, V54, P451, DOI 10.1097/00007890-199209000-00013; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; VERSTRAETE M, 1992, THROMBOSIS CARDIOVAS, P175; WOJTA J, 1993, THROMB HAEMOSTASIS, V70, P469	45	90	93	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1169	1175		10.1001/jama.278.14.1169	http://dx.doi.org/10.1001/jama.278.14.1169			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326477				2022-12-28	WOS:A1997XY42200035
J	Buratowski, S				Buratowski, S			Multiple TATA-binding factors come back into style	CELL			English	Review							TRANSCRIPTIONAL ACTIVATION; PROMOTER; EXPRESSION; GENE; ELEMENTS; PROTEIN; INVITRO; YEAST; TBP				Buratowski, S (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA.							CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOMA FL, 1988, GENE DEV, V2, P40, DOI 10.1101/gad.2.1.40; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X	19	22	22	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	1997	91	1					13	15		10.1016/S0092-8674(01)80004-0	http://dx.doi.org/10.1016/S0092-8674(01)80004-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335330	Bronze			2022-12-28	WOS:A1997XZ80900004
J	Heck, MMS				Heck, MMS			Condensins, cohesins, and chromosome architecture: How to make and break a mitotic chromosome	CELL			English	Review							METAPHASE; PROTEINS				Heck, MMS (corresponding author), UNIV EDINBURGH,INST CELL & MOL BIOL,KINGS BLDG,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.							Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEIB JD, 1996, SCIENCE, V274, P1732; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SUTANI T, 1997, NATURE, V288, P798; TRASK BJ, 1993, COLD SPRING HARB SYM, V58, P767, DOI 10.1101/SQB.1993.058.01.084	20	52	52	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					5	8		10.1016/S0092-8674(01)80002-7	http://dx.doi.org/10.1016/S0092-8674(01)80002-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335328	Green Published, Bronze			2022-12-28	WOS:A1997XZ80900002
J	Poon, CS; Merrill, CK				Poon, CS; Merrill, CK			Decrease of cardiac chaos in congestive heart failure	NATURE			English	Article							LOW-DIMENSIONAL CHAOS; NONLINEAR DYNAMICS; RATE-VARIABILITY; TIME-SERIES; FIBRILLATION; TURBULENCE; CARDIOLOGY	The electrical properties of the mammalian heart undergo many complex transitions In normal and diseased states(1-7). It has been proposed that the normal heartbeat may display complex nonlinear dynamics, including deterministic chaos(8,9), and that such cardiac chaos may be a useful physiological marker for the diagnosis(10-12) and management(13,14) of certain heart trouble, However, it is not clear whether the heartbeat series of healthy and diseased hearts are chaotic or stochastic(15-17), or whether cardiac chaos represents normal or abnormal behaviour's. Here we have used a highly sensitive technique, which is robust to random noise, to detect chaos(19). We analysed the electrocardiograms from a group of healthy subjects and those with severe congestive heart failure (CHF), a clinical condition associated with a high risk of sudden death. The short-term variations of beat-to-beat interval exhibited strongly and consistently chaotic behaviour in all healthy subjects, but were frequently interrupted by periods of seemingly non-chaotic fluctuations in patients with CHE Chaotic dynamics in the CHF data, even when discernible, exhibited a high degree of random variability over time, suggesting a weaker form of chaos. These findings suggest that cardiac chaos is prevalent in healthy heart, and a decrease in such chaos may be indicative of CHF.			Poon, CS (corresponding author), MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA.							Barahona M, 1996, NATURE, V381, P215, DOI 10.1038/381215a0; CASOLO G, 1989, AM J CARDIOL, V64, P1162, DOI 10.1016/0002-9149(89)90871-0; CHIALVO DR, 1987, NATURE, V330, P749, DOI 10.1038/330749a0; CHIALVO DR, 1990, NATURE, V343, P653, DOI 10.1038/343653a0; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; DENTON TA, 1990, AM HEART J, V120, P1419, DOI 10.1016/0002-8703(90)90258-Y; GARFINKEL A, 1995, TRENDS CARDIOVAS MED, V5, P76, DOI 10.1016/1050-1738(94)00083-2; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; Glass L, 1996, PHYS TODAY, V49, P40, DOI 10.1063/1.881510; GLASS L, 1990, J CARDIOVASC ELECTR, V1, P481; Goldberger AL, 1996, LANCET, V347, P1312, DOI 10.1016/S0140-6736(96)90948-4; GOLDBERGER AL, 1988, EXPERIENTIA, V44, P983, DOI 10.1007/BF01939894; GOLDBERGER AL, 1991, NEWS PHYSIOL SCI, V6, P87, DOI 10.1152/physiologyonline.1991.6.2.87; GREBOGI C, 1984, PHYSICA D, V13, P261, DOI 10.1016/0167-2789(84)90282-3; Ivanov PC, 1996, NATURE, V383, P323, DOI 10.1038/383323a0; JALIFE J, 1990, ANN NY ACAD SCI, P591; KANTERS JK, 1994, J CARDIOVASC ELECTR, V5, P591, DOI 10.1111/j.1540-8167.1994.tb01300.x; KAPLAN DT, 1990, CIRC RES, V67, P886, DOI 10.1161/01.RES.67.4.886; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; POMEAU Y, 1980, COMMUN MATH PHYS, V74, P189, DOI 10.1007/BF01197757; SKINNER JE, 1990, BIO-TECHNOL, V8, P1018, DOI 10.1038/nbt1190-1018; SKINNER JE, 1993, AM HEART J, V125, P731, DOI 10.1016/0002-8703(93)90165-6; SMITH JM, 1984, P NATL ACAD SCI-BIOL, V81, P233, DOI 10.1073/pnas.81.1.233; Sugihara G, 1996, P NATL ACAD SCI USA, V93, P2608, DOI 10.1073/pnas.93.6.2608; Turcott RG, 1996, ANN BIOMED ENG, V24, P269, DOI 10.1007/BF02667355; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648	26	251	266	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					492	495		10.1038/39043	http://dx.doi.org/10.1038/39043			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333237				2022-12-28	WOS:A1997XY90900055
J	Suwa, G; Asfaw, B; Beyene, Y; White, TD; Katoh, S; Nagaoka, S; Nakaya, H; Uzawa, K; Renne, P; WoldeGabriel, G				Suwa, G; Asfaw, B; Beyene, Y; White, TD; Katoh, S; Nagaoka, S; Nakaya, H; Uzawa, K; Renne, P; WoldeGabriel, G			The first skull of Australopithecus boisei	NATURE			English	Article							LAKE TURKANA; EARLY HOMINID; KENYA; HOMO; EVOLUTION; ETHIOPIA; REGION; EAST; WEST	Australopithecus boisei was first described from a cranium recovered in 1959 from Olduvai Gorge, Tanzania(1,2). This and subsequent finds, mostly from Kenya's Turkana basin(3-5), resulted in its characterization as a specialized Australopithecus species with a hyper-robust masticatory apparatus(2,4,6). A distinct A. boisei facial morphology has been emphasized to differentiate robust Australopithecus lineages from East and South Africa(6). A preference for closed and/or wet habitats has been hypothesizes. Here we report some new A. boisei specimens, including the taxon's first cranium and associated mandible, from Konso, Ethiopia These fossils extend the known geographical range of A. boisei. They provide clear evidence for the coexistence of A. boisei and Homo erectus within a predominantly dry grassland environment. The A. boisei specimens from Konso demonstrate considerable morphological variation within the species. The unexpected combination of cranial and facial features of this skull cautions against the excessive taxonomic splitting of early hominids based on morphological detail documented in small and/or geographically restricted samples.	RIFT VALLEY RES SERV,ADDIS ABABA,ETHIOPIA; MINIST INFORMAT & CULTURE,DEPT ARCHAEOL & ANTHROPOL,CRCCH,ADDIS ABABA,ETHIOPIA; UNIV CALIF BERKELEY,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720; HYOGO MUSEUM HIMAN & NAT ACTIV,DIV EARTH SCI,SANDA,HYOGO 66913,JAPAN; NAGASAKI UNIV,DEPT GEOG,NAGASAKI 852,JAPAN; KAGAWA UNIV,DEPT EARTH SCI,TAKAMATSU,KAGAWA 852,JAPAN; BERKELEY GEOCHRONOL CTR,BERKELEY,CA 94709; LOS ALAMOS NATL LAB,EES1 D462,LOS ALAMOS,NM 87545	University of California System; University of California Berkeley; Nagasaki University; Kagawa University; Berkeley Geochronolgy Center; United States Department of Energy (DOE); Los Alamos National Laboratory	Suwa, G (corresponding author), UNIV TOKYO,DEPT SCI BIOL,BUNKYO KU,TOKYO 113,JAPAN.			Renne, Paul/0000-0003-1769-5235				Albrecht Gene H., 1993, P123; [Anonymous], 1987, SCI GEOL B; ASFAW B, 1992, NATURE, V360, P732, DOI 10.1038/360732a0; BROWN B, 1993, AM J PHYS ANTHROPOL, V91, P137, DOI 10.1002/ajpa.1330910202; Brunet M, 1996, CR ACAD SCI II A, V322, P907; CARNEY J, 1971, NATURE, V230, P509, DOI 10.1038/230509a0; DUBRUL EL, 1977, AM J PHYS ANTHROPOL, V47, P305, DOI 10.1002/ajpa.1330470211; GOWLETT JAJ, 1981, NATURE, V294, P125, DOI 10.1038/294125a0; HARRIS JM, 1983, KOOBI FORA RES PROJE, V2; HARRIS JM, 1991, KOOBI FORA RES PROJE, V3; Holloway R L, 1983, Hum Neurobiol, V2, P105; Kimbel W.H., 1988, P259; Kimbel WH, 1997, AM J PHYS ANTHROPOL, V103, P235, DOI 10.1002/(SICI)1096-8644(199706)103:2<235::AID-AJPA8>3.3.CO;2-V; LEAKEY LSB, 1959, NATURE, V184, P491, DOI 10.1038/184491a0; LEAKEY LSB, 1964, NATURE, V202, P5, DOI 10.1038/202005a0; LEAKEY MG, 1978, KOOBI FORA RES PROJE, V1; LEAKEY REF, 1988, AM J PHYS ANTHROPOL, V76, P1, DOI 10.1002/ajpa.1330760102; MCCOLLUM MA, 1993, J HUM EVOL, V24, P87, DOI 10.1006/jhev.1993.1009; Rak Y., 1983, AUSTRALOPITHECINE FA, DOI [10.1016/B978-0-12-576280-9.50006-7, DOI 10.1016/B978-0-12-576280-9.50006-7]; RIGHTMIRE GP, 1993, AM J PHYS ANTHROPOL, V90, P1, DOI 10.1002/ajpa.1330900102; SCHRENK F, 1993, NATURE, V365, P833, DOI 10.1038/365833a0; Shipman P., 1988, P343; Suwa G, 1996, AM J PHYS ANTHROPOL, V101, P247, DOI 10.1002/(SICI)1096-8644(199610)101:2<247::AID-AJPA9>3.0.CO;2-Z; Tobias P.V, 1967, OLDUVAI GORGE, V2; UCHIDA A, 1996, PEABODY MUSEUM B, V4; WALKER A, 1986, NATURE, V322, P517, DOI 10.1038/322517a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOOD B, 1994, AM J PHYS ANTHROPOL, V95, P117, DOI 10.1002/ajpa.1330950202; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B. A., 1991, HOMINID CRANIAL REMA, V4	30	80	82	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					489	492		10.1038/39037	http://dx.doi.org/10.1038/39037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XY909	9333236				2022-12-28	WOS:A1997XY90900054
J	Nightingale, SL				Nightingale, SL			Implanted brain stimulator approved to control tremors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-28	WOS:A1997XX30300009
J	Mostad, SB; Overbaugh, J; DeVange, DM; Welch, MJ; Chohan, B; Mandaliya, K; Nyange, P; Martin, HL; NdinyaAchola, J; Bwayo, JJ; Kreiss, JK				Mostad, SB; Overbaugh, J; DeVange, DM; Welch, MJ; Chohan, B; Mandaliya, K; Nyange, P; Martin, HL; NdinyaAchola, J; Bwayo, JJ; Kreiss, JK			Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina	LANCET			English	Article							LONG TERMINAL REPEAT; IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUALLY-TRANSMITTED DISEASES; CERVICOVAGINAL SECRETIONS; BACTERIAL VAGINOSIS; WOMEN; TRANSMISSION; DNA; ASSOCIATION; LYMPHOCYTES	Background Factors that influence shedding of HIV-1 infected cells in cervical and vaginal secretions may be important determinants of sexual and vertical transmission of the virus. We investigated whether hormonal contraceptive use, vitamin A deficiency, and other variables were risk factors for cervical and vaginal shedding of HIV-infected cells. Methods Between December, 1994, and April, 1996, women who attended a municipal sexually transmitted diseases (STDs) clinic in Mombasa, Kenya, and had previously tested positive for HIV-1, were invited to take part in our cross-sectional study. Cervical and vaginal secretions from 318 women were evaluated for the presence of HIV-1 infected cells by PCR amplification of gag DNA sequences. Findings HIV-1 infected cells were detected in 51% of endocervical and 14% of vaginal-swab specimens. Both cervical and vaginal shedding of HIV-1 infected cells were highly associated with CD4 lymphocyte depletion (p=0.0000) and p=0.003, respectively). After adjustment for CD4 count, cervical proviral shedding was significantly associated with use of depot medroxyprogesterone acetate (odds ratio 2.9, 95% CI 1.5-5.7), and with use of low-dose and high-dose oral contraceptive pills (3.8, 1.4-9.9 and 12.3, 1.5-101, respectively), Vitamin A deficiency was highly predictive of vaginal HIV-1 DNA shedding. After adjustment for CD4 count, severe vitamin A deficiency, moderate deficiency, and low normal vitamin A status were associated with 12.9, 8.0, and 4.9-fold increased odds of vaginal shedding, respectively. Gonococcal cervicitis (3.1, 1.1-9.8) and vaginal candidiasis (2.6, 1.2-5.4) were also correlated with significant increases in HIV-1 DNA detection, but Chlamydia trachomatis and Trichomonas vaginalis were not. Interpretation Our study documents several novel correlates of HIV-1 shedding in cervical and vaginal secretions, most notably hormonal contraceptive use and vitamin A deficiency. These factors may be important determinants of sexual or vertical transmission of HIV-1 and are of public health importance because they are easily modified by simple interventions.	UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; COAST PROV GEN HOSP,MOMBASA,KENYA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Nairobi	Mostad, SB (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,IARTP,BOX 359909,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039996, R01AI038518, R37AI038518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38518, AI 39996] Funding Source: Medline; NIDDK NIH HHS [DK35816] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amatayakul Kosin, 1994, P363; [Anonymous], 1992, BMJ, V304, P809; BRENNER PF, 1977, AM J OBSTET GYNECOL, V129, P133, DOI 10.1016/0002-9378(77)90733-5; CAROL W, 1992, EXP CLIN ENDOCRINOL, V99, P12, DOI 10.1055/s-0029-1211124; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; CORMACK D, 1987, HAMS HISTOLOGY, P638; EFRON JJ, 1996, JAMA-J AM MED ASSOC, V275, P36; ESCHENBACH DA, 1989, J CLIN MICROBIOL, V27, P251, DOI 10.1128/JCM.27.2.251-256.1989; FURTH PA, 1990, AIDS RES HUM RETROV, V6, P553, DOI 10.1089/aid.1990.6.553; GHOSH D, 1992, J VIROL, V66, P586, DOI 10.1128/JVI.66.1.586-590.1992; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; GROSSMAN CJ, 1984, ENDOCR REV, V5, P435, DOI 10.1210/edrv-5-3-435; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; John GC, 1997, J INFECT DIS, V175, P57, DOI 10.1093/infdis/175.1.57; KOLESNITCHENKO V, 1992, AIDS RES HUM RETROV, V8, P1977, DOI 10.1089/aid.1992.8.1977; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; LANDAY A, 1993, AIDS, V7, P1565, DOI 10.1097/00002030-199312000-00004; MISHELL DR, 1972, AM J OBSTET GYNECOL, V114, P923, DOI 10.1016/0002-9378(72)90098-1; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; ORTIZ A, 1977, J CLIN ENDOCR METAB, V44, P32, DOI 10.1210/jcem-44-1-32; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P200; Schuurs A. H. W. M., 1994, P379; SEMBA RD, 1994, CLIN INFECT DIS, V19, P489, DOI 10.1093/clinids/19.3.489; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; SOMMER A, 1996, VITAMIN A DEFICIENCY; Speroff L, 1996, CLIN GUIDE CONTRACEP, P25; TOWERS G, 1995, AIDS, V9, P129, DOI 10.1097/00002030-199509020-00003; VANDEPERRE P, 1988, GENITOURIN MED, V64, P30; WOFSY CB, 1986, LANCET, V1, P527; YAMAGUCHI K, 1994, AIDS, V8, P1675, DOI 10.1097/00002030-199412000-00006	36	249	254	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					922	927		10.1016/S0140-6736(97)04240-2	http://dx.doi.org/10.1016/S0140-6736(97)04240-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314871				2022-12-28	WOS:A1997XY67200011
J	Koljak, R; Boutaud, O; Shieh, BH; Samel, N; Brash, AR				Koljak, R; Boutaud, O; Shieh, BH; Samel, N; Brash, AR			Identification of a naturally occurring peroxidase-lipoxygenase fusion protein	SCIENCE			English	Article							CORAL PLEXAURA-HOMOMALLA; ALLENE OXIDE SYNTHASE; MOLECULAR-CLONING; ACID; BIOSYNTHESIS; PURIFICATION; EICOSANOIDS; PROSTANOIDS; CATALASE; PATHWAY	A distant relative of catalase that is specialized for metabolism of a fatty acid hydroperoxide was identified. This heme peroxidase occurs in coral as part of a fusion protein, the other component of which is a lipoxygenase that forms the hydroperoxide substrate, The end product is an unstable epoxide (an allene oxide) that is a potential precursor of prostaglandin-like molecules. These results extend the known chemistry of catalase-like proteins and reveal a distinct type of enzymatic construct involved in the metabolism of polyunsaturated fatty acids.	VANDERBILT UNIV, MED CTR, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; INST CHEM, DEPT BIOORGAN CHEM, EE-0026 TALLINN, ESTONIA	Vanderbilt University			Samel, Nigulas/A-1420-2019		FIC NIH HHS [TW00404] Funding Source: Medline; NIGMS NIH HHS [GM49502] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049502] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BJ, 1985, J AM CHEM SOC, V107, P2976, DOI 10.1021/ja00296a026; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; BRASH AR, 1989, J AM CHEM SOC, V111, P1891, DOI 10.1021/ja00187a060; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, 1991, J BIOL CHEM, V266, P22926; BUNDY GL, 1985, ADV PROSTAG THROMB L, V14, P229; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; Crombie L, 1991, J CHEM SOC P1, V1, P581; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; Gerwick WH, 1996, LIPIDS, V31, P1215, DOI 10.1007/BF02587906; GRIFFIN BW, 1991, PEROXIDASES CHEM BIO, V2, P85; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; Hamberg M, 1996, ACTA CHEM SCAND, V50, P219, DOI 10.3891/acta.chem.scand.50-0219; HAMBERG M, 1989, J AM OIL CHEM SOC, V66, P1445, DOI 10.1007/BF02661968; KIKUCHI H, 1982, TETRAHEDRON LETT, V23, P5171, DOI 10.1016/S0040-4039(00)85788-3; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; Peterson Julian A., 1995, P151; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; VALNSHTEIN BK, 1981, NATURE, V293, P411; Wang Y, 1995, Adv Pharmacol, V34, P71; WEINHEIMER AJ, 1969, TETRAHEDRON LETT, P5185; WEINHEIMER AJ, 1974, PROSTAGLANDINS PLEXA, P17	29	100	102	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					1994	1996		10.1126/science.277.5334.1994	http://dx.doi.org/10.1126/science.277.5334.1994			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302294				2022-12-28	WOS:A1997XX84900044
J	Jarrett, RJ				Jarrett, RJ			Should we screen for gestational diabetes?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLUCOSE-TOLERANCE; PREGNANCY; MELLITUS; NIDDM; WOMEN											ALES KL, 1989, LANCET, V1, P1187; *AM COLL OBST GYN, 1994, MAN DIAB MELL PREGN; Barker DJP, 1992, FETAL INFANT ORIGINS; Coustan DR, 1996, JAMA-J AM MED ASSOC, V275, P1199, DOI 10.1001/jama.275.15.1199; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; Gabbe SG, 1989, CARBOHYD METABOL, VIV, P309; Gavin JR, 1997, DIABETES CARE, V20, P1183; Goldenberg RL, 1996, JAMA-J AM MED ASSOC, V275, P1127, DOI 10.1001/jama.275.14.1127; HANSON U, 1990, DIABETOLOGIA, V33, P100, DOI 10.1007/BF00401047; JARRETT RJ, 1993, BMJ-BRIT MED J, V306, P37, DOI 10.1136/bmj.306.6869.37; MOLSTEDPEDERSEN L, 1989, CARBOHYD METABOL, V4, P277; NELSONPIERCY C, 1994, DIABETIC MED, V11, P493, DOI 10.1111/j.1464-5491.1994.tb00313.x; OSULLIVAN JB, 1964, DIABETES, V13, P278; ROBERTS RN, 1993, DIABETIC MED, V10, P438, DOI 10.1111/j.1464-5491.1993.tb00095.x; SAMANTA A, 1989, DIABETES RES CLIN PR, V7, P127, DOI 10.1016/0168-8227(89)90103-4; TOWNER D, 1995, DIABETES CARE, V18, P1446, DOI 10.2337/diacare.18.11.1446; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18	18	33	33	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	1997	315	7110					736	737		10.1136/bmj.315.7110.736	http://dx.doi.org/10.1136/bmj.315.7110.736			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314761	Green Published			2022-12-28	WOS:A1997XX67400027
J	Robbins, JB; Towne, DW; Gotschlich, EC; Schneerson, R				Robbins, JB; Towne, DW; Gotschlich, EC; Schneerson, R			''Love's labours lost'': failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa	LANCET			English	Editorial Material							GROUP-A; NEISSERIA-MENINGITIDIS; POLYSACCHARIDE VACCINE; CAPSULAR POLYSACCHARIDE; EPIDEMIC; DISEASE; ANTIBODY; CHILDREN; EFFICACY; AGE		ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University	Robbins, JB (corresponding author), NICHHD,DEV & MOL IMMUN LAB,NIH,BETHESDA,MD 20892, USA.							BAUDON D, 1988, OCEAE B LIAISON DOCU, P51; BINKIN N, 1982, LANCET, V2, P315; BOSMANS E, 1980, ANN SOC BELG MED TR, V60, P297; Claesson BA, 1996, PEDIATR INFECT DIS J, V15, P170, DOI 10.1097/00006454-199602000-00016; COCHI SL, 1987, INT J EPIDEMIOL, V16, P91, DOI 10.1093/ije/16.1.91; de Oliveira Bastos C, 1975, Bol Oficina Sanit Panam, V79, P54; DENAMUR E, 1987, LANCET, V2, P1211; ERWA HH, 1973, B WORLD HEALTH ORGAN, V49, P301; ETTORI D, 1977, MED TROP, V225, P30; GOLD R, 1975, J CLIN INVEST, V56, P1536, DOI 10.1172/JCI108235; GOLD R, 1979, J INFECT DIS, V140, P690, DOI 10.1093/infdis/140.5.690; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GREENWOOD BM, 1986, T ROY SOC TROP MED H, V80, P1006, DOI 10.1016/0035-9203(86)90303-2; GREENWOOD BM, 1978, BRIT MED J, V1, P1317, DOI 10.1136/bmj.1.6123.1317; GREENWOOD BM, 1980, LANCET, V1, P729; GREENWOOD BM, 1984, LANCET, V2, P1339; GREENWOOD BM, 1984, REV INFECT DIS, V6, pS374; GUIRGUIS N, 1985, J EXP MED, V162, P1837, DOI 10.1084/jem.162.6.1837; Haelterman E, 1996, TROP MED INT HEALTH, V1, P385, DOI 10.1046/j.1365-3156.1996.d01-49.x; HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8; JAMBA G, 1979, B WORLD HEALTH ORGAN, V57, P943; LENGELER C, 1995, ACTA TROP, V59, P211, DOI 10.1016/0001-706X(95)00081-O; LENNON D, 1992, PEDIATR INFECT DIS J, V11, P617; MAKELA PH, 1975, LANCET, V2, P883; MOHAMMED I, 1981, LANCET, V2, P80; MOORE PS, 1990, B WORLD HEALTH ORGAN, V68, P587; NOVELLI VM, 1987, LANCET, V2, P863; PELTOLA H, 1978, SCAND J INFECT DIS, V10, P41, DOI 10.3109/inf.1978.10.issue-1.09; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; PELTOLA H, 1982, LANCET, V2, P595; PINNER RW, 1992, J INFECT DIS, V166, P359, DOI 10.1093/infdis/166.2.359; REINGOLD AL, 1985, LANCET, V2, P114; ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387; SANBORN WR, 1972, PROGR IMMUNOBIOLOGIC, V5, P497; SPIEGEL A, 1993, B WORLD HEALTH ORGAN, V71, P311; VANAIPHEN L, IN PRESS J PEDIAT; WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667; WAHDAN MH, 1977, B WORLD HEALTH ORGAN, V55, P645; *WHO, 1992, WKLY EPIDEMIOL REC, V67, P333; *WHO, 1977, WHO TECH REP SER, V610, P50; ZANGWILL KM, 1994, J INFECT DIS, V169, P847, DOI 10.1093/infdis/169.4.847	41	55	55	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					880	882		10.1016/S0140-6736(97)03227-3	http://dx.doi.org/10.1016/S0140-6736(97)03227-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310615				2022-12-28	WOS:A1997XX40100048
J	Vandenbroucke, JP				Vandenbroucke, JP			Homoeopathy trials: Going nowhere - Commentary	LANCET			English	Editorial Material											Vandenbroucke, JP (corresponding author), LEIDEN UNIV,DEPT CLIN EPIDEMIOL,NL-2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; Carr E. H., 1964, WHAT IS HIST; Fleck Ludwik, 1979, GENESIS DEV SCI FACT; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A	5	74	71	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					824	824		10.1016/S0140-6736(97)22038-6	http://dx.doi.org/10.1016/S0140-6736(97)22038-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310594				2022-12-28	WOS:A1997XX40100002
J	Kovall, R; Matthews, BW				Kovall, R; Matthews, BW			Toroidal structure of lambda-exonuclease	SCIENCE			English	Article							BREAK REPAIR MODEL; CRYSTAL-STRUCTURE; PHAGE-LAMBDA; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; GENETIC RECOMBINATION; ECORV ENDONUCLEASE; PVUII ENDONUCLEASE; BETA PROTEIN; RED PATHWAY	Structure determination at 2.4 angstrom resolution shows that lambda-exonuclease consists of three subunits that form a toroid. The central channel is funnel shaped, tapering from an inner diameter of about 30 angstroms at the wider end to 15 angstroms at the narrow end. This is adequate to accommodate the DNA substrate and thus provides a structural basis for the ability of the enzyme to sequentially hydrolyze thousands of nucleotides in a highly processive manner, The results also suggest the locations of the active sites and the constraints that limit cleavage to a single strand.	UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	University of Oregon	Kovall, R (corresponding author), UNIV OREGON, HOWARD HUGHES MED INST, INST MOL BIOL, EUGENE, OR 97403 USA.		Kovall, Rhett/A-3106-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020066, R37GM020066] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20066] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CARTER DM, 1971, J BIOL CHEM, V246, P2502; CASSUTO E, 1971, P NATL ACAD SCI USA, V68, P1639, DOI 10.1073/pnas.68.7.1639; CASSUTO E, 1971, NATURE-NEW BIOL, V229, P13, DOI 10.1038/newbio229013a0; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; COLMAN PM, 1972, J MOL BIOL, V70, P701, DOI 10.1016/0022-2836(72)90569-4; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KLEE CB, 1968, J BIOL CHEM, V243, P923; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; Linn S.M., 1993, NUCLEASES; LITTLE JW, 1967, J BIOL CHEM, V242, P672; LITTLE JW, 1967, J BIOL CHEM, V242, P679; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OTWINOWSKI Z, 1991, DARESBURY STUDY WEEK, P80; RADDING CM, 1966, J MOL BIOL, V18, P235, DOI 10.1016/S0022-2836(66)80243-7; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; STAHL FW, 1985, J MOL BIOL, V181, P199, DOI 10.1016/0022-2836(85)90085-3; STAHL FW, 1985, J GENET, V64, P31; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKAHASHI N, 1990, P NATL ACAD SCI USA, V87, P2790, DOI 10.1073/pnas.87.7.2790; THALER DS, 1987, J MOL BIOL, V195, P75, DOI 10.1016/0022-2836(87)90328-7; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANOOSTRUM J, 1985, ARCH BIOCHEM BIOPHYS, V243, P332, DOI 10.1016/0003-9861(85)90510-7; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	46	174	219	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1824	1827		10.1126/science.277.5333.1824	http://dx.doi.org/10.1126/science.277.5333.1824			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295273				2022-12-28	WOS:A1997XX29800047
J	Scales, SJ; Pepperkok, R; Kreis, TE				Scales, SJ; Pepperkok, R; Kreis, TE			Visualization of ER-to-Golgi transport in living cells reveals a sequential mode of action for COPII and COPI	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; ENDOPLASMIC-RETICULUM; BETA-COP; INTERMEDIATE COMPARTMENT; COATED VESICLES; BREFELDIN-A; SECRETORY PATHWAY; MEMBRANE GLYCOPROTEIN; MONOCLONAL-ANTIBODY; VIRAL GLYCOPROTEIN	Exocytic transport from the endoplasmic reticulum (ER) to the Golgi complex has been visualized in living cells using a chimera of the temperature-sensitive glycoprotein of vesicular stomatitis virus and green fluorescent protein (ts-G-GFP(ct)). Upon shifting to permissive temperature, ts-G-GFP(ct) concentrates into COPII-positive structures close to the ER, which then build up to form an intermediate compartment or transport complex, containing ERGIC-53 and the KDEL receptor, where COPII is replaced by COPI. These structures appear heterogenous and move in a microtubule-dependent manner toward the Golgi complex. Our results suggest a sequential mode of COPII and COPI action and indicate that the transport complexes are ER-to-Golgi transport intermediates from which COPI may be involved in recycling material to the ER.	UNIV GENEVA,DEPT CELL BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283; Pepperkok, Rainer/0000-0002-9762-3583				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P553; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAWANO JI, 1994, J HISTOCHEM CYTOCHEM, V42, P363, DOI 10.1177/42.3.8308253; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOCKER JK, 1994, J CELL BIOL, V124, P55; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; WHITNEY JA, 1995, CELL, V83, P703	71	417	427	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1137	1148		10.1016/S0092-8674(00)80379-7	http://dx.doi.org/10.1016/S0092-8674(00)80379-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323141	Bronze			2022-12-28	WOS:A1997XX76800019
J	Schwacha, A; Kleckner, N				Schwacha, A; Kleckner, N			Interhomolog bias during meiotic recombination: Meiotic functions promote a highly differentiated interhomolog-only pathway	CELL			English	Article							DOUBLE-STRAND BREAK; SYNAPTONEMAL COMPLEX-FORMATION; SISTER-CHROMATID EXCHANGE; SACCHAROMYCES-CEREVISIAE; RAD51 PROTEIN; CHROMOSOME SYNAPSIS; RECA HOMOLOGS; YEAST MEIOSIS; HOT-SPOT; DNA	Meiotic recombination occurs preferentially between homologous nonsister chromatids rather than between sisters, opposite to the bias of mitotic recombinational repair. We have examined formation of joint molecule recombination intermediates (JMs) between homologs and between sisters in yeast strains lacking the meiotic chromosomal protein Red1, the meiotic recA homolog Dmc1, and/or mitotic recA homolog(s), Rad51, Rad55, and Rad57. Mutant phenotypes imply that most meiotic recombination occurs via an interhomolog-only pathway along which interhomolog bias is established early, prior to or during double strand break (DSB) formation, and then enforced, just at the time when DSBs initiate JM formation. A parallel, less differentiated pathway yields intersister and, probably, a few interhomolog events. Coordinate action of mitotic recA homologs as one functional unit, two functions of RED1, and an interhomolog interaction function of DMC1 are also revealed.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [R01GM44794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LK, 1997, P NATL ACAD SCI USA, V94, P6868, DOI 10.1073/pnas.94.13.6868; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1986, GENETICS, V113, P551; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; GAME JC, 1989, GENETICS, V123, P695; Gilbertson LA, 1996, GENETICS, V144, P27; HABER JE, 1984, GENETICS, V106, P185; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; HEYER WD, 1994, EXPERIENTIA, V50, P223, DOI 10.1007/BF01924005; Ivanov EL, 1996, GENETICS, V142, P693; JACKSON JA, 1985, GENETICS, V109, P303; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; KADYK LC, 1992, GENETICS, V132, P387; KENNEY S, 1996, GENES CELLS, V1, P475; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MaoDraayer Y, 1996, GENETICS, V144, P71; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Petes TD, 1995, ADV GENET, V33, P41, DOI 10.1016/S0065-2660(08)60330-2; PORTER SE, 1993, GENETICS, V134, P5; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; ROCKMILL B, 1990, GENETICS, V126, P563; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SCHWACHA A, 1996, THESIS HARVARD U CAM; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; SUN H, 1991, MOL CELL BIOL, V11, P6328, DOI 10.1128/MCB.11.12.6328; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; Xu LH, 1997, GENE DEV, V11, P106, DOI 10.1101/gad.11.1.106; ZENVIRTH D, 1997, IN PRESS GENES CELLS	48	356	362	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1123	1135		10.1016/S0092-8674(00)80378-5	http://dx.doi.org/10.1016/S0092-8674(00)80378-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323140	Bronze			2022-12-28	WOS:A1997XX76800018
J	Takeyama, K; Kitanaka, S; Sato, T; Kobori, M; Yanagisawa, J; Kato, S				Takeyama, K; Kitanaka, S; Sato, T; Kobori, M; Yanagisawa, J; Kato, S			25-hydroxyvitamin D-3 1 alpha-hydroxylase and vitamin D synthesis	SCIENCE			English	Article							D ENDOCRINE SYSTEM; GENE-EXPRESSION; D METABOLISM; CALCIFEROL METABOLISM; PARATHYROID-HORMONE; MESSENGER-RNA; RAT; KIDNEY; 24-HYDROXYLASE; 1,25-DIHYDROXYVITAMIN-D3	Renal 25-hydroxyvitamin D-3 1 alpha-hydroxylase [1 alpha(OH)ase] catalyzes metabolic activation of 25-hydroxyvitamin D-3 into 1 alpha,25-dihydroxyvitamin D-3 [1 alpha,25(OH)(2)D-3], an active form of vitamin D, and is inhibited by 1 alpha,25(OH)(2)D-3. 1 alpha(OH)ase, which was cloned from the kidney of mice lacking the vitamin D receptor (VDR-/- mice), is a member of the P450 family of enzymes (P450(VD1 alpha)). Expression of 1 alpha(OH)ase was suppressed by 1 alpha,25(OH)(2)D-3 in VDR+/+ and VDR+/- mice but not in VDR-/- mice. These results indicate that the negative feedback regulation of active vitamin D synthesis is mediated by 1 alpha(OH)ase through liganded VDR.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; JAPAN SCI & TECHNOL, CREST, KAWAGUCHI, SAITAMA 332, JAPAN; YAMANOUCHI PHARMACEUT CO LTD, INST DRUG DISCOVERY RES, MOL MED LABS, TSUKUBA, IBARAKI 305, JAPAN	University of Tokyo; Japan Science & Technology Agency (JST); Astellas Pharmaceuticals								ADAMS JS, 1985, J CLIN ENDOCR METAB, V60, P960, DOI 10.1210/jcem-60-5-960; AXEN E, 1995, FEBS LETT, V375, P277, DOI 10.1016/0014-5793(95)01226-5; BALSAN S, 1991, NESTLE NUTR WORKS SE, V21, P155; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BECKMAN MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P535, DOI 10.1006/abbi.1995.1328; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BURGOSTRINIDAD M, 1992, J BIOL CHEM, V267, P3498; COLSTON KW, 1973, BIOCHEM J, V134, P817, DOI 10.1042/bj1340817; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DeLuca H F, 1986, Adv Exp Med Biol, V196, P361; DILWORTH FJ, 1995, J BIOL CHEM, V270, P16766, DOI 10.1074/jbc.270.28.16766; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; FRASER D, 1973, NEW ENGL J MED, V289, P817, DOI 10.1056/NEJM197310182891601; FRASER DR, 1973, NATURE-NEW BIOL, V241, P163, DOI 10.1038/newbio241163a0; FREDERICK MA, 1995, CURRENT PROTOCOLS MO; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; GRAY TK, 1979, SCIENCE, V204, P1311, DOI 10.1126/science.451538; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HENRY HL, 1974, J BIOL CHEM, V249, P7584; HENRY HL, 1992, J CELL BIOCHEM, V49, P4, DOI 10.1002/jcb.240490103; HENRY HL, 1974, J BIOL CHEM, V249, P7529; HOWARD GA, 1981, J BIOL CHEM, V256, P7738; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531; ITOH S, 1995, BBA-GENE STRUCT EXPR, V1264, P26, DOI 10.1016/0167-4781(95)00147-9; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KAWASHIMA H, 1981, NATURE, V291, P327, DOI 10.1038/291327a0; KAWASHIMA H, 1981, P NATL ACAD SCI-BIOL, V78, P1199, DOI 10.1073/pnas.78.2.1199; KOBORI M, 1993, NUCLEIC ACIDS RES, V21, P2782, DOI 10.1093/nar/21.11.2782; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944; MANO H, 1994, J BIOL CHEM, V269, P1591; MATKOVITS T, 1995, ENDOCRINOLOGY, V136, P3971, DOI 10.1210/en.136.9.3971; MAWER EB, 1994, J CLIN ENDOCR METAB, V79, P554, DOI 10.1210/jc.79.2.554; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PICADOLEONARD J, 1988, MOL ENDOCRINOL, V2, P1145, DOI 10.1210/mend-2-11-1145; Sakaki T, 1996, J BIOL CHEM, V271, P26209, DOI 10.1074/jbc.271.42.26209; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; TANAKA Y, 1974, SCIENCE, V183, P1198, DOI 10.1126/science.183.4130.1198; TONG HS, 1994, J BONE MINER RES, V9, P577; TURNER RT, 1980, P NATL ACAD SCI-BIOL, V77, P5720, DOI 10.1073/pnas.77.10.5720; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; Wakino S, 1996, GERONTOLOGY, V42, P67; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; WARNER M, 1982, J BIOL CHEM, V257, P2995; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	55	408	428	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1827	1830		10.1126/science.277.5333.1827	http://dx.doi.org/10.1126/science.277.5333.1827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295274				2022-12-28	WOS:A1997XX29800048
J	Ulrich, HD; Mundroff, E; Santarsiero, BD; Driggers, EM; Stevens, RC; Schultz, PG				Ulrich, HD; Mundroff, E; Santarsiero, BD; Driggers, EM; Stevens, RC; Schultz, PG			The interplay between binding energy and catalysis in the evolution of a catalytic antibody	NATURE			English	Article							OXY-COPE REARRANGEMENT; IMMUNE-RESPONSE; GERM-LINE; DIVERSITY; MECHANISM; GENES; VL; VH	Antibody catalysis(1) provides an opportunity to examine the evolution of binding energy and its relation to catalytic function in a system that has many parallels with natural enzymes. Here we report such a study involving an antibody AZ-28 that catalyses an oxy-Cope rearrangement, a pericyclic reaction that belongs to a well studied and widely used class of reactions in organic chemistry(2). Immunization with transition state analogue 1 results in a germline-encoded antibody that catalyses the rearrangement of hexadiene 2 to aldehyde 3 with a rate approaching that of a related pericyclic reaction catalysed by the enzyme chorismate mutase(3). Affinity maturation gives antibody AZ-28, which has six amino acid substitutions, one of which results in a decrease in catalytic rate. To understand the relationship between binding and catalytic rate in this system we characterized a series of active-site mutants and determined the three-dimensional crystal structure of the complex of AZ-28 with the transition state analogue. This analysis indicates that the activation energy depends on a complex balance of several, stereoelectronic effects which are controlled by an extensive network of binding interactions in the active site, Thus in this instance the combinatorial diversity of the immune system provided both an efficient catalyst far a reaction where no enzyme is known, as well as an opportunity to explore the mechanisms and evolution of biological catalysis.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV MAT SCI, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley			Santarsiero, Bernard D/N-9249-2018; Stevens, Raymond/K-7272-2015	Santarsiero, Bernard D/0000-0002-9032-9699; Stevens, Raymond/0000-0002-4522-8725; Ulrich, Helle D./0000-0003-0431-2223				AKOLKAR PN, 1987, J IMMUNOL, V138, P4472; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BRAISTED AC, 1994, J AM CHEM SOC, V116, P2211, DOI 10.1021/ja00084a098; BRUNGER AT, 1996, X PLOR VERSION 3 851; DEWAR MJS, 1977, J AM CHEM SOC, V99, P4417, DOI 10.1021/ja00455a034; DOERING WVE, 1962, TETRAHEDRON, V18, P67; DRIGGERS EM, UNPUB J AM CHEM SOC; GAJEWSKI JJ, 1991, J AM CHEM SOC, V113, P967, DOI 10.1021/ja00003a033; GAJEWSKI JJ, 1980, ACCOUNTS CHEM RES, V13, P142, DOI 10.1021/ar50149a003; Haldane JBS, 1930, ENZYMES; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; NAHMIAS C, 1988, J IMMUNOL, V140, P1304; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PECH M, 1981, NATURE, V291, P668, DOI 10.1038/291668a0; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; STEIGERWALD ML, 1979, J AM CHEM SOC, V101, P1994, DOI 10.1021/ja00502a011; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; ULRICH H, 1996, THESIS U CALIFORNIA; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Ulrich HD, 1996, ACTA CHEM SCAND, V50, P328, DOI 10.3891/acta.chem.scand.50-0328; ULRICH HD, UNPUB J MOL BIOL; Woodward R. B., 1970, CONSERVATION ORBITAL	33	76	77	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					271	275		10.1038/38470	http://dx.doi.org/10.1038/38470			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305839				2022-12-28	WOS:A1997XW77200043
J	Leirs, H; Stenseth, NC; Nichols, JD; Hines, JE; Verhagen, R; Verheyen, W				Leirs, H; Stenseth, NC; Nichols, JD; Hines, JE; Verhagen, R; Verheyen, W			Stochastic seasonality and nonlinear density-dependent factors regulate population size in an African rodent	NATURE			English	Article							CAPTURE-RECAPTURE; TANZANIA; SURVIVAL; CYCLES; MODELS; RATS	Ecology has long been troubled by the controversy over how populations are regulated(1,2). Some ecologists focus on the role of environmental effects, whereas others argue that density-dependent feedback mechanisms are central(3-6). The relative importance of both processes is still hotly debated, but clear examples of both processes acting in the same population are rare(7,8). Key-factor analysis (regression of population changes on possible causal factors) and time-series analysis are often used to investigate the presence of density dependence, but such approaches may be biased and provide no information on actual demographic rates(9,10). Here we report on both density-dependent and density-independent effects in a murid rodent pest species, the multimammute rat Mastomys natalensis (Smith, 1834), using statistical capture-recapture models, Both effects occur simultaneously, but we also demonstrate that they do not affect all demographic rates in the same way. We have incorporated the obtained estimates of demographic rates in a population dynamics model and show that the observed dynamics are affected by stabilizing nonlinear density-dependent components coupled with strong deterministic and stochastic seasonal components.	UNIV OSLO,DEPT BIOL,DIV ZOOL,N-0316 OSLO,NORWAY; NATL BIOL SERV,PATUXENT WILDLIFE RES CTR,LAUREL,MD 20708; UNIV ANTWERP,RIJKSUNIV CTR ANTWERP,DEPT BIOL,B-2020 ANTWERP,BELGIUM	University of Oslo; University of Antwerp	Leirs, H (corresponding author), DANISH PEST INFESTAT LAB,SKOVBRYNET 14,DK-2800 LYNGBY,DENMARK.		Leirs, Herwig/B-8197-2008; Stenseth, Nils Chr./G-5212-2016	Leirs, Herwig/0000-0002-7612-5024; Stenseth, Nils Chr./0000-0002-1591-5399				ANDREWARTHA HG, 1954, DISTRIBUTION ABUNDAN; BROWNIE C, 1993, BIOMETRICS, V49, P1173, DOI 10.2307/2532259; COHEN JE, 1995, NATURE, V378, P610, DOI 10.1038/378610a0; Ebenman B., 1988, SIZE STRUCTURED POPU; GRANJON L, 1994, POL ECOL STUD, V30, P343; GRENFELL BT, 1992, NATURE, V355, P823, DOI 10.1038/355823a0; HINES JE, 1994, MSSURVTV USERS MANUA; HORNFELDT B, 1994, ECOLOGY, V75, P791, DOI 10.2307/1941735; HUBERT B, 1982, REV ECOL, V35, P73; ITO Y, 1972, OECOLOGIA, V10, P347, DOI 10.1007/BF00345737; KENDALL WL, 1992, WILDLIFE 2001 : POPULATIONS, P31; Krebs C.J., 2014, ECOLOGICAL METHODOLO; Kuno E., 1971, Researches Popul Ecol Kyoto Univ, V13, P28, DOI 10.1007/BF02522011; Lebreton J.-D., 1991, BIRD POPULATION STUD, P105; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; LEIRS H, 1994, J TROP ECOL, V10, P55, DOI 10.1017/S0266467400007719; Leirs H, 1996, J APPL ECOL, V33, P937, DOI 10.2307/2404675; LEIRS H, 1993, OIKOS, V68, P53, DOI 10.2307/3545308; NICHOLS JD, 1984, ACTA THERIOL, V29, P357, DOI 10.4098/AT.arch.84-35; Nicholson AJ, 1933, J ANIM ECOL, V2, P132, DOI 10.2307/954; OSTFELD RS, 1995, ECOLOGY, V76, P521, DOI 10.2307/1941210; OSTFELD RS, 1993, NATURE, V366, P259, DOI 10.1038/366259a0; Pollock K. H., 1982, J WILDLIFE MANAGE, V46, P757, DOI DOI 10.2307/3808568; POLLOCK KH, 1981, BIOMETRICS, V37, P521, DOI 10.2307/2530565; Putman RJ, 1996, MAMMAL REV, V26, P81, DOI 10.1111/j.1365-2907.1996.tb00148.x; Saitoh T, 1997, J ANIM ECOL, V66, P14, DOI 10.2307/5960; SUGIHARA G, 1995, NATURE, V378, P559, DOI 10.1038/378559a0; White A, 1996, P ROY SOC B-BIOL SCI, V263, P1731, DOI 10.1098/rspb.1996.0253; WOLDA H, 1993, OECOLOGIA, V95, P581, DOI 10.1007/BF00317444; [No title captured]	30	244	249	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					176	180		10.1038/38271	http://dx.doi.org/10.1038/38271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296494				2022-12-28	WOS:A1997XV75700047
J	Case, RB; Pierce, DW; HomBooher, N; Hart, CL; Vale, RD				Case, RB; Pierce, DW; HomBooher, N; Hart, CL; Vale, RD			The directional preference of kinesin motors is specified by an element outside of the motor catalytic domain	CELL			English	Article							DIRECTED MICROTUBULE MOTOR; STIMULATED ATP HYDROLYSIS; CRYSTAL-STRUCTURE; DIMERIC KINESIN; NCD PROTEIN; HEAVY-CHAIN; MOVEMENT; DROSOPHILA; MOLECULES; SEGREGATION	Members of the kinesin superfamily share a similar motor catalytic domain yet move either toward the plus end (e.g., conventional kinesin) or the minus end (e.g., Ncd) of microtubules. The structural features that determine the polarity of movement have remained enigmatic. Here, we show that kinesin's catalytic domain (316 residues) in a dimeric construct (560 residues) can be replaced with the catalytic domain of Ncd and that the resultant motor moves in the kinesin direction. We also demonstrate that this chimera does not move processively over many tubulin subunits, which is similar to Ncd but differs from the highly processive motion of conventional kinesin. These findings reveal that the catalytic domain contributes to motor processivity but does not control the polarity of movement. We propose that a region adjacent to the catalytic domain serves as a mechanical transducer that determines directionality.										Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1995, PROTEIN PROFILE, V2, P1112; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GIBBONS IR, 1979, J BIOL CHEM, V254, P187; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; HYMAN AA, 1991, J CELL SCI S, V14, P125; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; Morii H, 1997, BIOCHEMISTRY-US, V36, P1933, DOI 10.1021/bi962392l; MORRIS RL, 1997, IN PRESS J CELL BIOL; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; Pierce DW, 1997, NATURE, V388, P338, DOI 10.1038/41009; PIERCE DW, 1997, IN PRESS METH ENZYMO; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TAYLOR EW, 1993, NATURE, V361, P115, DOI 10.1038/361115a0; Tripet B, 1997, J BIOL CHEM, V272, P8946; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	46	283	286	2	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					959	966		10.1016/S0092-8674(00)80360-8	http://dx.doi.org/10.1016/S0092-8674(00)80360-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298907	Bronze			2022-12-28	WOS:A1997XV56300016
J	Glasier, A				Glasier, A			Drug therapy - Emergency postcoital contraception	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POST-COITAL CONTRACEPTION; ETHINYLESTRADIOL-NORGESTREL COMBINATION; EARLY LUTEAL-PHASE; MIFEPRISTONE RU-486; YUZPE REGIMEN; MENSTRUAL-CYCLE; ENDOMETRIUM; ESTROGENS; DANAZOL; WOMEN		EDINBURGH HEALTHCARE TRUST FAMILY PLANNING & WELL, EDINBURGH, MIDLOTHIAN, SCOTLAND		Glasier, A (corresponding author), UNIV EDINBURGH, DEPT OBSTET & GYNAECOL, 18 DEAN TERR, EDINBURGH EH4 1NL, MIDLOTHIAN, SCOTLAND.		Dilek, Umut/AAP-6047-2021; dilek, umut Kutlu/E-4527-2016	Dilek, Umut/0000-0003-4297-3081; 				ALVAREZ F, 1988, FERTIL STERIL, V49, P768; Barnett AA, 1996, LANCET, V348, P53, DOI 10.1016/S0140-6736(05)64372-3; BRACKEN MB, 1990, OBSTET GYNECOL, V76, P552; CHANG MC, 1966, ENDOCRINOLOGY, V78, P860, DOI 10.1210/endo-78-4-860; COUZINET B, 1990, FERTIL STERIL, V54, P1039; DIXON GW, 1980, JAMA-J AM MED ASSOC, V244, P1336, DOI 10.1001/jama.244.12.1336; FASOLI M, 1989, CONTRACEPTION, V39, P459, DOI 10.1016/0010-7824(89)90123-6; FASOLI M, 1989, CONTRACEPTION, V39, P699; *FOOD DRUG ADM, 1997, FED REGISTER, V62, P8610; GEMZELLDANIELSSON K, 1993, HUM REPROD, V8, P870, DOI 10.1093/oxfordjournals.humrep.a138157; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; Glasier A, 1996, FAM PLANN PERSPECT, V28, P49, DOI 10.2307/2136123; GLASIER A, 1993, BRIT J OBSTET GYNAEC, V100, P611, DOI 10.1111/j.1471-0528.1993.tb14223.x; GLASIER A, 1995, PROVISION EMERGENCY, P16; Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; GROU F, 1994, AM J OBSTET GYNECOL, V171, P1529, DOI 10.1016/0002-9378(94)90396-4; Hagenfeldt K, 1972, Acta Endocrinol Suppl (Copenh), V169, P3; HARPER CC, 1995, AM J OBSTET GYNECOL, V173, P1438, DOI 10.1016/0002-9378(95)90630-4; HASPELS AA, 1976, CONTRACEPTION, V14, P375, DOI 10.1016/S0010-7824(76)80052-2; HO PC, 1993, HUM REPROD, V8, P389, DOI 10.1093/oxfordjournals.humrep.a138057; *INT PLANN PAR FED, 1994, IPPF MED B, V28, P1; JESPERSEN J, 1990, AM J OBSTET GYNECOL, V163, P396, DOI 10.1016/0002-9378(90)90590-4; KUBBA AA, 1986, FERTIL STERIL, V45, P512; LEDGER WL, 1992, HUM REPROD, V7, P945, DOI 10.1093/oxfordjournals.humrep.a137776; LEHMANN F, 1975, ACTA ENDOCRINOL-COP, V79, P329, DOI 10.1530/acta.0.0790329; LING WY, 1983, FERTIL STERIL, V39, P292; MORRIS JM, 1966, AM J OBSTET GYNECOL, V96, P804, DOI 10.1016/0002-9378(66)90676-4; MORRIS JM, 1973, AM J OBSTET GYNECOL, V115, P101, DOI 10.1016/0002-9378(73)90095-1; POULTER NR, 1995, LANCET, V346, P1575; RAMSAY S, 1995, LANCET, V345, P1169, DOI 10.1016/S0140-6736(95)90996-6; ROWLANDS S, 1986, CONTRACEPTION, V33, P539, DOI 10.1016/0010-7824(86)90042-9; SHIRLEY B, 1995, CONTRACEPTION, V52, P277, DOI 10.1016/0010-7824(95)00211-R; SIMPSON J L, 1990, Advances in Contraception, V6, P141, DOI 10.1007/BF01849490; Steiner M, 1994, INT FAMILY PLANNING, V20, P55; SWAHN ML, 1988, HUM REPROD, V3, P915, DOI 10.1093/oxfordjournals.humrep.a136809; Swahn ML, 1996, ACTA OBSTET GYN SCAN, V75, P738, DOI 10.3109/00016349609065738; SWAHN ML, 1990, HUM REPROD, V5, P402, DOI 10.1093/oxfordjournals.humrep.a137111; Thorogood M., 1993, PHARMACOEPIDEMIOL DR, V2, P3; Trussell J, 1996, FAM PLANN PERSPECT, V28, P58, DOI 10.2307/2136125; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P262, DOI 10.2307/2135855; TRUSSELL J, 1995, FERTILITY CONTROL RE, V4, P8; VANLOOK PFA, 1995, MODERN METHODS INDUC, P1; VANSANTEN MR, 1985, FERTIL STERIL, V43, P206; Webb A., 1993, Advances in Contraception, V9, P75, DOI 10.1007/BF02115904; WEBB AMC, 1992, BMJ-BRIT MED J, V305, P927, DOI 10.1136/bmj.305.6859.927; WEENINK GH, 1981, LANCET, V1, P1105; *WHO, 1996, WHOFRHFPP969, P31; WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301; Williams C, 1996, BRIT MED J, V312, P463, DOI 10.1136/bmj.312.7029.463a; YUZPE AA, 1977, FERTIL STERIL, V28, P932; ZULIANI G, 1990, EUR J OBSTET GYN R B, V37, P253, DOI 10.1016/0028-2243(90)90032-V	51	193	197	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1058	1064		10.1056/NEJM199710093371507	http://dx.doi.org/10.1056/NEJM199710093371507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321535				2022-12-28	WOS:A1997XZ84400007
J	Barnes, PF; Yang, ZH; PrestonMartin, S; Pogoda, JM; Jones, BE; Otaya, M; Eisenach, KD; Knowles, L; Harvey, S; Cave, MD				Barnes, PF; Yang, ZH; PrestonMartin, S; Pogoda, JM; Jones, BE; Otaya, M; Eisenach, KD; Knowles, L; Harvey, S; Cave, MD			Tuberculosis transmission in central Los Angeles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; HOMELESS MEN; SHELTER; EPIDEMIOLOGY; OUTBREAK; PTBN12	Context.-Recent studies suggest that many tuberculosis cases in urban areas result from recent transmission. Delineation of the epidemiologic links between patients is important to optimize strategies to reduce tuberculosis transmission. Objective.-To identify epidemiologic links among recently infected urban patients with tuberculosis. Design.-Prospective evaluation of patients with tuberculosis. Setting.-Central Los Angeles, Calif. Patients.-A total of 162 patients who had culture-proven tuberculosis, Interventions.-Patients were prospectively interviewed to identify their contacts and whereabouts. The IS6110-based and pTBN12-based restriction fragment length polymorphism analyses were performed on Mycobacterium tuberculosis isolates. Patients whose isolates had identical or closely related restriction fragment length polymorphism patterns were considered a cluster. Unconditional logistic regression was used to identify independent predictors of clustering. Main Outcome Measures.-Relationship of clinical and epidemiologic variables to clustering, Results.-A total of 96 (59%) of 162 patients were in 8 clusters, Only 2 of the 96 clustered patients named others in the cluster as contacts, The degree of homelessness was an independent predictor of clustering, Compared with nonclustered patients, patients in 6 clusters were significantly more likely to have spent time at 3 shelters and other locations when at least 1 patient in the cluster was contagious, and these locations were independent predictors of clustering. Among nonhomeless persons, clustered patients were significantly more likely than nonclustered patients to have used daytime services at 3 shelters, Conclusions.-(1) Traditional contact investigation does not reliably identify patients infected with the same M tuberculosis strain, and (2) locations at which the homeless congregate are important sites of tuberculosis transmission for homeless and nonhomeless persons. Measures that reduce tuberculosis transmission should be based on locations rather than on personal contacts.	UNIV SO CALIF, SCH MED, DEPT MED, DIV INFECT DIS, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90089 USA; LOS ANGELES CTY PUBL HLTH LAB, LOS ANGELES, CA USA; CTY LOS ANGELES DEPT HLTH SERV TB CONTROL PROGRAM, LOS ANGELES, CA USA; STATOLOGY, TRUCKEE, CA USA; UNIV ARKANSAS MED SCI, DEPT PATHOL, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI, DEPT ANAT, LITTLE ROCK, AR 72205 USA; JOHN L MCCLELLAN MEM VET ADM MED CTR, MED RES SERV, LITTLE ROCK, AR USA	University of Southern California; University of Southern California; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035222, R01AI035265] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35222, AI35265] Funding Source: Medline; PHS HHS [CCU901877] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1992, MMWR Recomm Rep, V41, P13; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P869; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; ROST K, 1993, MED CARE, V31, P189, DOI 10.1097/00005650-199303000-00001; SAS Institute INC, 1988, SAS STAT US GUID REL; SEGALMAURER S, 1994, CLIN INFECT DIS, V19, P299, DOI 10.1093/clinids/19.2.299; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987, DOI 10.1128/JCM.31.8.1987-1995.1993; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; YANG ZH, 1995, J CLIN MICROBIOL, V33, P1064, DOI 10.1128/JCM.33.5.1064-1069.1995	24	171	177	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1159	1163		10.1001/jama.278.14.1159	http://dx.doi.org/10.1001/jama.278.14.1159			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326475				2022-12-28	WOS:A1997XY42200033
J	Hall, WJ				Hall, WJ			Update in geriatrics	ANNALS OF INTERNAL MEDICINE			English	Article							BENIGN PROSTATIC HYPERPLASIA; FRACTURES; RISK				Hall, WJ (corresponding author), UNIV ROCHESTER, SCH MED & DENT, DEPT MED, 601 ELMWOOD AVE, BOX MED, ROCHESTER, NY 14642 USA.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; COOPER DS, 1987, JAMA-J AM MED ASSOC, V258, P246, DOI 10.1001/jama.258.2.246; Danese MD, 1996, JAMA-J AM MED ASSOC, V276, P285, DOI 10.1001/jama.276.4.285; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; NEVITT MC, 1992, FALLS, BALANCE AND GAIT DISORDERS IN THE ELDERLY, P69; NEVITT MC, 1994, OSTEOPOROSIS INT, V4, P325, DOI 10.1007/BF01622192; PIANI AL, 1993, VITAL HLTH STAT, V185; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; Sager MA, 1996, J AM GERIATR SOC, V44, P251, DOI 10.1111/j.1532-5415.1996.tb00910.x; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; Walsh PC, 1996, NEW ENGL J MED, V335, P586, DOI 10.1056/NEJM199608223350809; WELLER TH, 1992, J INFECT DIS, V166, pS1	13	12	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					557	564		10.7326/0003-4819-127-7-199710010-00007	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313023				2022-12-28	WOS:A1997XY73300007
J	Sidney, S; Petitti, DB; Quesenberry, CP				Sidney, S; Petitti, DB; Quesenberry, CP			Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; menopause; estrogen replacement therapy; progestational hormones	HORMONE REPLACEMENT THERAPY; CARDIOVASCULAR-DISEASE; HEART-DISEASE; FOLLOW-UP; MORTALITY; RISK; DEATH	Objective: To estimate the relative risk for incident acute myocardial infarction in relation to the current use of estrogen and estrogen-progestogen. Design: Retrospective case-control study. Setting: Medical centers of a large prepaid health care program, the Kaiser Permanente Medical Care Program (KPMCP), Northern California region. Participants: All women hospitalized at a KPMCP center for incident acute myocardial infarction during a 3-year period from 1991 to 1994. Controls were matched to case-patients for year of birth and KPMCP facility and were selected at random from among all female members of the KPMCP. Intervention: An in-person interview that included questions about current and lifetime use of estrogen and estrogen-progestogen; known cardiovascular risk factors; and other medical, sociodemographic, and behavioral factors that might affect risk for myocardial infarction. Main Outcome Measure: Odds ratios for myocardial infarction associated with use of estrogen and estrogen-progestogen. Results: The odds ratio for myocardial infarction in current users of estrogen or estrogen-progestogen compared with women who had never used these agents was 0.96 (95% CI, 0.66 to 1.40) after adjustment for confounders. The odds ratio for myocardial infarction in past users of estrogen or estrogen-progestogen was 1.07 (CI, 0.72 to 1.58). Duration of hormone use was unrelated to the odds ratio for myocardial infarction. Conclusions: This study did not show a statistically significant decrease in the odds ratio for myocardial infarction associated with current use of estrogen or estrogen-progestogen. it neither confirms nor refutes the hypothesis that hormone use prevents myocardial infarction in postmenopausal women.			Sidney, S (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, 3505 BROADWAY, OAKLAND, CA 94611 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047043] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-47043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; AVILA MH, 1990, EPIDEMIOLOGY, V1, P128; BAIN C, 1981, CIRCULATION, V64, P42, DOI 10.1161/01.CIR.64.1.42; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; BYRD BF, 1977, ANN SURG, V185, P574, DOI 10.1097/00000658-197705000-00010; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; MACMAHON B, 1978, CORONARY HEART DISEA, P197; MANN RD, 1994, J CLIN EPIDEMIOL, V47, P307, DOI 10.1016/0895-4356(94)90014-0; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; PFEFFER RI, 1978, AM J EPIDEMIOL, V107, P479, DOI 10.1093/oxfordjournals.aje.a112567; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; ROSENBERG L, 1976, NEW ENGL J MED, V294, P1256, DOI 10.1056/NEJM197606032942302; ROSS RK, 1981, LANCET, V1, P858; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; TALBOTT E, 1977, AM J CARDIOL, V39, P858, DOI 10.1016/S0002-9149(77)80040-4; 1995, OTABPH144 OFF TECHN	27	101	101	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					501	+		10.7326/0003-4819-127-7-199710010-00001	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313017				2022-12-28	WOS:A1997XY73300001
J	Vohra, A; Saiz, E; Ratzan, KR				Vohra, A; Saiz, E; Ratzan, KR			A young woman with a sore throat, septicaemia and respiratory failure	LANCET			English	Article							LEMIERRES SYNDROME				Vohra, A (corresponding author), MT SINAI MED CTR, DEPT MED, MIAMI BEACH, FL 33140 USA.							CARLSON ER, 1994, J ORAL MAXIL SURG, V52, P74, DOI 10.1016/0278-2391(94)90019-1; KARANAS YL, 1995, ANN PLAS SURG, V35, P525, DOI 10.1097/00000637-199511000-00015; Lemierre A, 1936, LANCET, V1, P701; Leugers C M, 1995, J Am Board Fam Pract, V8, P384; SINAVE CP, 1989, MEDICINE, V68, P85, DOI 10.1097/00005792-198903000-00002	5	21	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	1997	350	9082					928	928		10.1016/S0140-6736(97)05261-6	http://dx.doi.org/10.1016/S0140-6736(97)05261-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314872				2022-12-28	WOS:A1997XY67200012
J	Krishna, S				Krishna, S			Science, medicine, and the future - Malaria	BMJ-BRITISH MEDICAL JOURNAL			English	Review											Krishna, S (corresponding author), ST GEORGE HOSP, SCH MED, DEPT CELL & MOL SCI, DIV INFECT DIS, CRANMER TERRACE, LONDON SW17 0RE, ENGLAND.			Krishna, Sanjeev/0000-0003-0066-0634	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P13, DOI 10.1016/0035-9203(93)90170-U; Anderson J., 1996, MALARIA RES AUDIT IN; NEWTON CW, IN PRESS PHARM THER; Nosten F, 1996, CURR OPIN INFECT DIS, V9, P429, DOI 10.1097/00001432-199612000-00015; PASVOL G, 1995, MALARIA; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1	7	11	13	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	1997	315	7110					730	732		10.1136/bmj.315.7110.730	http://dx.doi.org/10.1136/bmj.315.7110.730			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314759	Green Published			2022-12-28	WOS:A1997XX67400025
J	Fornerod, M; Ohno, M; Yoshida, M; Mattaj, IW				Fornerod, M; Ohno, M; Yoshida, M; Mattaj, IW			CRM1 is an export receptor for leucine-rich nuclear export signals	CELL			English	Article							BINDING PROTEIN COMPLEX; ORDER CHROMOSOME STRUCTURE; REV ACTIVATION DOMAIN; U-SNRNA EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; HNRNP A1; REGULATORY PROTEINS; LEPTOMYCIN-B; TRANSFER-RNA; HIV REV	CRM1 is distantly related to receptors that mediate nuclear protein import and was previously shown to interact with the nuclear pore complex. Overexpression of CRM1 in Xenopus oocytes stimulates Rev and U snRNA export from the nucleus. Conversely, leptomycin B, a cytotoxin that is shown to bind to CRM1 protein, specifically inhibits the nuclear export of Rev and U snRNAs. In vitro, CRM1 forms a leptomycin B-sensitive complex involving cooperative binding of both RanGTP and the nuclear export signal (NES) from either the Rev or PKI proteins. We conclude that CRM1 is an export receptor for leucine-rich nuclear export signals and discuss a model for the role of RanGTP in CRM1 function and in nuclear export in general.	EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV TOKYO, DEPT BIOTECHNOL, TOKYO 113, JAPAN	European Molecular Biology Laboratory (EMBL); University of Tokyo			Fornerod, Maarten/A-7503-2010; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Fornerod, Maarten/0000-0002-6166-3030; Mattaj, Iain/0000-0002-5537-8284				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CESTARI IN, 1993, BIOTECHNIQUES, V14, P404; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1996, ONCOGENE, V13, P1801; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fridell RA, 1997, J CELL SCI, V110, P1325; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Izaurralde E, 1995, COLD SPRING HARB SYM, V60, P669, DOI 10.1101/SQB.1995.060.01.072; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	63	1677	1707	0	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1051	1060		10.1016/S0092-8674(00)80371-2	http://dx.doi.org/10.1016/S0092-8674(00)80371-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323133	Bronze			2022-12-28	WOS:A1997XX76800011
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Primary target	SCIENCE			English	Article																		Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; Gardner RL, 1997, INT J DEV BIOL, V41, P235	3	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1848	1848		10.1126/science.277.5333.1848	http://dx.doi.org/10.1126/science.277.5333.1848			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324771				2022-12-28	WOS:A1997XX29800053
J	Rosenheck, R; Cramer, J; Xu, WC; Thomas, J; Henderson, W; Frisman, L; Fye, C; Charney, D				Rosenheck, R; Cramer, J; Xu, WC; Thomas, J; Henderson, W; Frisman, L; Fye, C; Charney, D			A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COST-EFFECTIVENESS; SCALE; CARE; AGRANULOCYTOSIS; OUTPATIENTS; QUALITY; BURDEN; ISSUES; VIEW; LIFE	Background Clozapine, a relatively expensive antipsychotic drug, is widely used to treat patients with refractory schizophrenia. It has a low incidence of extrapyramidal side effects but may cause agranulocytosis. There have been no long-term assessments of its effect on symptoms, social functioning, and the use and cost of health care. Methods We conducted a randomized, one-year, double-blind comparative study of clozapine (in 205 patients) and haloperidol (in 218 patients) at 15 Veterans Affairs medical centers. All participants had refractory schizophrenia and had been hospitalized for the disease for 30 to 364 days in the previous year. All patients received case-management and social-rehabilitation services, as clinically indicated. Results In the clozapine group, 117 patients (57 percent) continued their assigned treatment for the entire year, as compared with 61 (28 percent) of the patients in the haloperidol group (P < 0.001). As judged according to the Positive and Negative Syndrome Scale of Schizophrenia, patients in the clozapine group had 5.4 percent lower symptom levels than those in the haloperidol group at all follow-up evaluations (mean score, 79.1 vs. 83.6; P = 0.02). The differences on a quality-of-life scale were not significant in the intention-to-treat analysis, but they were significant among patients who did not cross over to the other treatment (P = 0.003). Over a one-year period, patients assigned to clozapine had fewer mean days of hospitalization for psychiatric reasons than patients assigned to haloperidol (143.8 vs. 168.1 days, P = 0.03) and used more outpatient services (133.6 vs. 97.9 units of service, P = 0.03). The total per capita costs to society were high - $58,151 in the clozapine group and $60,885 in the haloperidol group (P = 0.41). The per capita costs of antipsychotic drugs were $3,199 in the clozapine group and $367 in the haloperidol group (P < 0.001). Patients assigned to clozapine had less tardive dyskinesia and fewer extrapyramidal side effects. Agranulocytosis developed in three patients in the clozapine group; all recovered fully. Conclusions For patients with refractory schizophrenia and high levels of hospital use, clozapine was somewhat more effective than haloperidol and had fewer side effects and similar overall costs. (C) 1997, Massachusetts Medical Society.	YALE UNIV,SCH MED,DEPT PSYCHIAT,NEW HAVEN,CT; EDWARD HINES VET ADM MED CTR,CTR COOPERAT STUDIES HLTH SERV,HINES,IL 60141; VET AFFAIRS COOPERAT STUDIES PROGRAM CLIN RES PHA,ALBUQUERQUE,NM	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Rosenheck, R (corresponding author), VA CONNECTICUT HEALTHCARE SYST,NE PROGRAM EVALUAT CTR 182,950 CAMPBELL AVE,W HAVEN,CT 06516, USA.		Brzezinski, Bogumil/E-1322-2011	Frisman, Linda/0000-0002-6724-2210				ALVIR JMJ, 1993, NEW ENGL J MED, V329, P162, DOI 10.1056/NEJM199307153290303; [Anonymous], 1987, DIAGNOSTIC STAT MANU; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; BREIER A, 1993, HOSP COMMUNITY PSYCH, V44, P1145; BREIER A, 1994, AM J PSYCHIAT, V151, P20; BROMET EJ, 1996, TXB PSYCHIAT EPIDEMI, P283; Buchanan RW, 1995, SCHIZOPHRENIA BULL, V21, P579, DOI 10.1093/schbul/21.4.579; CARPENTER WT, 1995, AM J PSYCHIAT, V152, P827; CICCHETTI DV, IN PRESS PSYCHIAT RE; *DEP JUST OFF JUST, 1991, BUR JUST STAT PUBL; Essock SM, 1996, PSYCHOPHARMACOL BULL, V32, P683; First M.B., 1990, USERS GUIDE STRUCTUR; Frisman L, 1996, ADM POLICY MENT HLTH, V23, P533, DOI 10.1007/BF02108689; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; GRIFFITH RW, 1975, LANCET, V2, P657; Guy W., 1976, ASSESSMENT MANUAL PS, P218, DOI DOI 10.1186/1471-244X-7-7; Guy W., 1976, ECDEU ASSESSMENT MAN, VRev; HEINRICHS DW, 1984, SCHIZOPHRENIA BULL, V10, P388, DOI 10.1093/schbul/10.3.388; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; LIEBERMAN JA, 1994, AM J PSYCHIAT, V151, P1744; MARDER SR, 1996, J CLIN PSYCHIAT MONO, V14, P11; MELTZER HY, 1995, AM J PSYCHIAT, V152, P821; MELTZER HY, 1993, AM J PSYCHIAT, V150, P1630; MELTZER HY, 1990, HOSP COMMUNITY PSYCH, V41, P892; MELTZER HY, 1994, J CLIN PSYCHIAT SB, V55, P61; *OFF INSP GEN, 1992, COMP COSTS OUTC MATC; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PICKAR D, 1992, ARCH GEN PSYCHIAT, V49, P345; REID WH, 1994, HOSP COMMUNITY PSYCH, V45, P261; REVICKI DA, 1990, HOSP COMMUNITY PSYCH, V41, P850; ROSENHECK R, 1995, SCHIZOPHRENIA BULL, V21, P129, DOI 10.1093/schbul/21.1.129; ROSENHECK R, 1994, ADM POLICY MENT HLTH, V21, P493, DOI 10.1007/BF00707261; ROSENHECK R, 1995, PSYCHIAT QUART, V66, P9, DOI 10.1007/BF02238713; RUPP A, 1993, PSYCHIAT CLIN N AM, V16, P413; SCHOBEL BD, 1981, SOC SECUR BULL, V44, P21; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; TESSLER R, 1994, MILBANK Q, V72, P149, DOI 10.2307/3350342	39	412	427	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					809	815		10.1056/NEJM199709183371202	http://dx.doi.org/10.1056/NEJM199709183371202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XW283	9295240	Bronze			2022-12-28	WOS:A1997XW28300002
J	Bland, JM; Kerry, SM				Bland, JM; Kerry, SM			Statistics notes - Trials randomised in clusters	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER		ST GEORGE HOSP,SCH MED,DIV GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND	St Georges University London	Bland, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Altman DG, 1997, BRIT MED J, V314, P1874, DOI 10.1136/bmj.314.7098.1874; ALTMAN DG, 1995, BRIT MED J, V312, P1472; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; TABAR L, 1981, RADIOLOGY, V138, P219, DOI 10.1148/radiology.138.1.7005939; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TABAR L, 1995, CANCER, V75, P2507, DOI 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182	8	368	366	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					600	600						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV717	9302962				2022-12-28	WOS:A1997XV71700034
J	LaMendola, NP; Bever, TG				LaMendola, NP; Bever, TG			Peripheral and cerebral asymmetries in the rat	SCIENCE			English	Article							TOPOGRAPHICAL DISORIENTATION; POSTERIOR PARIETAL; UNILATERAL REMOVAL; SPATIAL DEFICITS; CORTEX LESIONS; VIBRISSAE; SYSTEM; MEMORY; DISCRIMINATION; LATERALIZATION	Rats learn a novel foraging pattern better with their right-side whiskers than with their left-side whiskers, They also learn better with the left cerebral hemisphere than with the right hemisphere. Rotating an already learned maze relative to the external environment most strongly reduces right-whisker performance; starting an already learned maze at a different location most strongly reduces left-whisker performance. These results suggest that the right-periphery-left-hemisphere system accesses a map-like representation of the foraging problem, whereas the left-periphery-right-hemisphere system accesses a rote path. Thus, as in humans, functional asymmetries in rats can be elicited by both peripheral and cortical manipulation, and each hemisphere makes qualitatively distinct contributions to a complex natural behavior.	UNIV ARIZONA, PROGRAM COGNIT SCI, TUCSON, AZ 85721 USA; UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85721 USA	University of Arizona; University of Arizona								ADELSTEIN A, 1991, BEHAV NEUROSCI, V105, P459, DOI 10.1037/0735-7044.105.3.459; AHL AS, 1986, VET RES COMMUN, V10, P245, DOI 10.1007/BF02213989; AMMASSARITEULE M, 1985, BEHAV BRAIN RES, V17, P9, DOI 10.1016/0166-4328(85)90003-8; BANICH M, 1997, NEUROPSYCHOLOGY NEUR, pCH6; BEVER TG, 1970, MECH LANGUAGE DEV, P186; Bianki V. L., 1988, RIGHT LEFT HEMISPHER; Bradshaw JL., 1993, EVOLUTION LATERAL AS; Brown Halle D., 1995, P77; Burcham K. J., 1996, Society for Neuroscience Abstracts, V22, P682; CASTELLANO MA, 1989, BEHAV NEUROSCI, V103, P46, DOI 10.1037/0735-7044.103.1.46; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; COLLINS RL, 1968, J HERED, V59, P9, DOI 10.1093/oxfordjournals.jhered.a107656; CORWIN JV, 1994, BEHAV BRAIN RES, V61, P79, DOI 10.1016/0166-4328(94)90010-8; COWELL PE, IN PRESS LATERALITY; CROWNE DP, 1992, BEHAV NEUROSCI, V106, P808, DOI 10.1037/0735-7044.106.5.808; De Renzi E., 1982, DISORDERS SPACE EXPL; DIMATTIA BV, 1988, BEHAV NEUROSCI, V102, P397, DOI 10.1037/0735-7044.102.3.397; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; FRANCO L, 1977, NEUROPSYCHOLOGIA, V15, P107, DOI 10.1016/0028-3932(77)90120-8; Gallistel CR, 1996, J EXP BIOL, V199, P211; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154, DOI 10.1152/jn.1956.19.2.154; GUICROBLES E, 1989, BEHAV BRAIN RES, V31, P285, DOI 10.1016/0166-4328(89)90011-9; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; HEFFNER HE, 1986, J NEUROPHYSIOL, V56, P683, DOI 10.1152/jn.1986.56.3.683; HUSTON JP, 1986, EXP NEUROL, V93, P380, DOI 10.1016/0014-4886(86)90198-6; HUTSON KA, 1986, J NEUROPHYSIOL, V56, P1196, DOI 10.1152/jn.1986.56.4.1196; JACOBS RA, 1991, COGNITIVE SCI, V15, P219, DOI 10.1207/s15516709cog1502_2; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KESNER RP, 1989, BEHAV NEUROSCI, V103, P956, DOI 10.1037/0735-7044.103.5.956; KIMURA D, 1973, SCI AM, V228, P70, DOI 10.1038/scientificamerican0373-70; KING VR, 1992, BEHAV BRAIN RES, V50, P53; Kinsbourne M., 1975, ATTENTION PERFORM, VV, P81; KOLB B, 1984, BEHAV NEUROSCI, V98, P44, DOI 10.1037/0735-7044.98.1.44; Kolb B., 1990, CEREBRAL CORTEX RAT, P437; KOROLEVA VI, 1993, NEUROSCI LETT, V149, P153, DOI 10.1016/0304-3940(93)90759-E; KOSSLYN SM, 1987, PSYCHOL REV, V94, P148, DOI 10.1037/0033-295X.94.2.148; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEVY J, 1969, NATURE, V224, P614, DOI 10.1038/224614a0; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MCNAUGHTON BL, 1991, J COGNITIVE NEUROSCI, V3, P192, DOI 10.1162/jocn.1991.3.2.190; MEHTA Z, 1991, CORTEX, V27, P153, DOI 10.1016/S0010-9452(13)80121-9; MILANI H, 1989, BEHAV NEUROSCI, V103, P1067, DOI 10.1037/0735-7044.103.5.1067; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; NOTTEBOHM F, 1976, J COMP PHYSIOL, V108, P171, DOI 10.1007/BF02169047; O'Keefe J, 1991, Hippocampus, V1, P230, DOI 10.1002/hipo.450010303; O'Keefe J., 1978, HIPPOCAMPUS SPATIAL; OLTON DS, 1977, SCI AM, V236, P82, DOI 10.1038/scientificamerican0677-82; RATCLIFF G, 1973, J NEUROL NEUROSUR PS, V36, P448, DOI 10.1136/jnnp.36.3.448; SCHIFFMA.HR, 1970, ANIM BEHAV, V18, P290, DOI 10.1016/S0003-3472(70)80040-9; SHERMAN GF, 1985, CEREBRAL LATERALIZAT, P89; THOR DH, 1973, PSYCHOL REP, V33, P815, DOI 10.2466/pr0.1973.33.3.815; VINCENT SB, 1912, BEHAV MONOGR, V9, P1; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; ZIMMERBERG B, 1974, SCIENCE, V185, P623, DOI 10.1126/science.185.4151.623	54	60	60	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	1997	278	5337					483	486		10.1126/science.278.5337.483	http://dx.doi.org/10.1126/science.278.5337.483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YB355	9334310				2022-12-28	WOS:A1997YB35500050
J	Wiklund, RA; Rosenbaum, SH				Wiklund, RA; Rosenbaum, SH			Anesthesiology .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTENSIVE-CARE UNIT; CORONARY-ARTERY DISEASE; CRITICALLY-ILL PATIENTS; NEUROMUSCULAR BLOCKING-AGENT; CIS-ATRACURIUM 51W89; NITROUS-OXIDE; MYOCARDIAL-INFARCTION; CLINICAL-PHARMACOLOGY; CARDIAC EVENTS; MALIGNANT HYPERTHERMIA				Wiklund, RA (corresponding author), YALE UNIV, SCH MED, DEPT ANESTHESIOL, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.							*ACC AHA, 1996, CIRCULATION, V93, P1280; ADAMS JE, 1994, NEW ENGL J MED, V330, P670, DOI 10.1056/NEJM199403103301003; *AM SOC AN, 1995, GUID SED AN NON; [Anonymous], 1985, PEDIATRICS, V76, P317; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; [Anonymous], 1988, Natl Inst Health Consens Dev Conf Consens Statement, V7, P1; ARCHER C, 1993, CAN J ANAESTH, V40, P1022, DOI 10.1007/BF03009471; BASTA SJ, 1983, BRIT J ANAESTH, V55, pS105; BELANI K G, 1987, Anesthesiology (Hagerstown), V67, pA156, DOI 10.1097/00000542-198709001-00156; BENNETT SN, 1995, NEW ENGL J MED, V333, P147, DOI 10.1056/NEJM199507203330303; BLOOMFIELD EL, 1993, RADIOLOGY, V186, P93, DOI 10.1148/radiology.186.1.8416594; BLOUIN RT, 1993, ANESTHESIOLOGY, V79, P1177, DOI 10.1097/00000542-199312000-00007; BORGEAT A, 1994, CAN J ANAESTH, V41, P1117, DOI 10.1007/BF03015664; BOWDLE TA, 1994, ANESTH ANALG, V78, P783; BOWDLE TA, 1987, ANESTHESIOLOGY, V67, P593, DOI 10.1097/00000542-198710000-00030; Boyd AH, 1996, BRIT J ANAESTH, V76, P382, DOI 10.1093/bja/76.3.382; BROWN BR, 1987, BRIT J ANAESTH, V59, P14, DOI 10.1093/bja/59.1.14; BRULL SJ, 1995, ANESTHESIOLOGY, V83, P702, DOI 10.1097/00000542-199510000-00009; Brull SJ, 1996, ANESTHESIOLOGY, V84, P1014; BRULL SJ, 1993, ANESTHESIOL CLIN N A, V11, P325; BUFFINGTON CW, 1988, ANESTHESIOLOGY, V69, P721, DOI 10.1097/00000542-198811000-00014; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Chamorro C, 1996, CRIT CARE MED, V24, P932, DOI 10.1097/00003246-199606000-00010; CHARLSON ME, 1988, SURG GYNECOL OBSTET, V167, P407; CODA BA, 1996, CLIN ANESTH, P329; CRAWFORD M, 1993, BRIT J ANAESTH, V70, P419, DOI 10.1093/bja/70.4.419; DELPHIN E, 1987, ANESTH ANALG, V66, P1190; Dietz NM, 1996, ANESTH ANALG, V82, P390, DOI 10.1097/00000539-199602000-00032; Divatia JV, 1996, ANESTHESIOLOGY, V85, P1055, DOI 10.1097/00000542-199611000-00014; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; EASTWOOD NB, 1995, BRIT J ANAESTH, V75, P431, DOI 10.1093/bja/75.4.431; EGER EI, 1969, ANESTHESIOLOGY, V30, P129; EGER EI, 1992, ANESTH ANALG, V75, pS3; EGER EI, 1994, ANESTHESIOLOGY, V80, P906, DOI 10.1097/00000542-199404000-00024; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; Fischer SP, 1996, ANESTHESIOLOGY, V85, P196, DOI 10.1097/00000542-199607000-00025; FISER WP, 1983, SURGERY, V94, P736; FLEISHER LA, 1995, ANESTHESIOLOGY, V83, P906, DOI 10.1097/00000542-199511000-00003; FLEISHER LA, 1991, AM HEART J, V122, P980, DOI 10.1016/0002-8703(91)90461-P; FOLDES FF, 1952, NEW ENGL J MED, V247, P596, DOI 10.1056/NEJM195210162471603; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FREUND FG, 1973, ANESTHESIOLOGY, V38, P358; FRINK EJ, 1992, ANESTH ANALG, V74, P231, DOI 10.1213/00000539-199202000-00010; GENCARELLI PJ, 1982, ANESTHESIOLOGY, V56, P192, DOI 10.1097/00000542-198203000-00007; GONSOWSKI CT, 1994, ANESTHESIOLOGY, V80, P556, DOI 10.1097/00000542-199403000-00012; GONSOWSKI CT, 1994, ANESTHESIOLOGY, V80, P566, DOI 10.1097/00000542-199403000-00013; GOUDSOUZIAN NG, 1995, ANESTH ANALG, V80, P207, DOI 10.1097/00000539-199501000-00039; HADZIC A, 1995, ANESTHESIOLOGY, V83, P863, DOI 10.1097/00000542-199510000-00028; HARRISON GG, 1975, BRIT J ANAESTH, V47, P62, DOI 10.1093/bja/47.1.62; Hartung J, 1996, ANESTH ANALG, V83, P114, DOI 10.1097/00000539-199607000-00020; HELMAN JD, 1992, ANESTHESIOLOGY, V77, P47, DOI 10.1097/00000542-199207000-00008; Hess JR, 1996, SEMIN HEMATOL, V33, P369; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; HIRSCH IB, 1991, ANESTHESIOLOGY, V74, P346, DOI 10.1097/00000542-199102000-00023; HUGHES R, 1981, BRIT J ANAESTH, V53, P31, DOI 10.1093/bja/53.1.31; JAFFE RS, 1991, CLIN NEUROANESTHESIA, P351; KENNA JG, 1995, ANESTH ANALG, V81, pS51, DOI 10.1097/00000539-199512001-00008; KOBLIN DD, 1994, ANESTH ANALG, V79, P1043; Kofke WA, 1996, ANESTH ANALG, V83, P141, DOI 10.1097/00000539-199607000-00025; LANDESBERG G, 1993, LANCET, V341, P715, DOI 10.1016/0140-6736(93)90486-Z; LARACH MG, 1994, ANESTHESIOLOGY, V80, P771, DOI 10.1097/00000542-199404000-00008; LARIJANI GE, 1989, ANESTH ANALG, V68, P734; LITTLEJOHN IH, 1995, ANAESTHESIA, V50, P499, DOI 10.1111/j.1365-2044.1995.tb06038.x; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MANGANO DT, 1995, ANESTHESIOLOGY, V83, P897, DOI 10.1097/00000542-199511000-00001; MEYER KC, 1994, ANESTH ANALG, V78, P772; MILLER ED, 1978, ANESTHESIOLOGY, V48, P146, DOI 10.1097/00000542-197802000-00012; MILLER RD, 1984, ANESTHESIOLOGY, V61, P444, DOI 10.1097/00000542-198410000-00014; MORIO M, 1992, ANESTHESIOLOGY, V77, P1155, DOI 10.1097/00000542-199212000-00017; MUIR AW, 1989, BRIT J ANAESTH, V63, P400, DOI 10.1093/bja/63.4.400; Muzi M, 1996, ANESTHESIOLOGY, V84, P1035, DOI 10.1097/00000542-199605000-00004; NARR BJ, 1991, MAYO CLIN PROC, V66, P155, DOI 10.1016/S0025-6196(12)60487-X; NELSON AH, 1993, CRIT CARE MED, V21, P860, DOI 10.1097/00003246-199306000-00013; NGAI SH, 1970, NEW ENGL J MED, V282, P541, DOI 10.1056/NEJM197003052821006; NGAI SH, 1970, NEW ENGL J MED, V282, P479, DOI 10.1056/NEJM197002262820905; PISCIOTTO PT, 1993, BLOOD TRANSFUSION TH; PRIELIPP RC, 1995, ANESTH ANALG, V81, P3, DOI 10.1097/00000539-199507000-00002; PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P122, DOI 10.1093/bja/43.2.122; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; REIZ S, 1983, ANESTHESIOLOGY, V59, P91, DOI 10.1097/00000542-198308000-00004; ROSENBERG H, 1992, ANESTHESIOLOGY, V77, P1054, DOI 10.1097/00000542-199211000-00040; SAVAGE DS, 1980, BRIT J ANAESTH, V52, pS3, DOI 10.1093/bja/52.suppl_1.3S; SAVARESE JJ, 1988, ANESTHESIOLOGY, V68, P723, DOI 10.1097/00000542-198805000-00010; Scheiber G, 1996, PAEDIATR ANAESTH, V6, P209, DOI 10.1111/j.1460-9592.1996.tb00430.x; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SLOGOFF S, 1991, ANESTH ANALG, V72, P22; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Spiess BD, 1996, J CARDIOTHOR VASC AN, V10, P83, DOI 10.1016/S1053-0770(96)80182-0; STELZNER J, 1993, ANAESTHESIST, V42, P44; STEVENS WC, 1971, ANESTHESIOLOGY, V35, P8, DOI 10.1097/00000542-197107000-00005; STILLER RL, 1985, BRIT J ANAESTH, V57, P1085, DOI 10.1093/bja/57.11.1085; STONE FL, 1968, B NY STATE ACAD ANES, V20, P42; STONE JG, 1988, ANESTHESIOLOGY, V68, P495, DOI 10.1097/00000542-198804000-00004; Subcommittee on the National Halothane Study of the Committee on Anesthesia National Academy of Sciences-National Research Council, 1966, JAMA-J AM MED ASSOC, V197, P775; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; VANDENBROEK L, 1994, J CLIN ANESTH, V6, P288, DOI 10.1016/0952-8180(94)90075-2; VEBER B, 1994, ANESTHESIOLOGY, V80, P712, DOI 10.1097/00000542-199403000-00050; WIKLUND RA, 1996, CLIN ANAESTHESIA, P485; YOUNIS L, 1994, AM J CARDIOL, V74, P311, DOI 10.1016/0002-9149(94)90395-6	102	27	28	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1132	1141		10.1056/NEJM199710163371606	http://dx.doi.org/10.1056/NEJM199710163371606			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329935				2022-12-28	WOS:A1997YA91200006
J	Wong, FL; Boice, JD; Abramson, DH; Tarone, RE; Kleinerman, RA; Stovall, M; Goldman, MB; Seddon, JM; Tarbell, N; Fraumeni, JF; Li, FP				Wong, FL; Boice, JD; Abramson, DH; Tarone, RE; Kleinerman, RA; Stovall, M; Goldman, MB; Seddon, JM; Tarbell, N; Fraumeni, JF; Li, FP			Cancer incidence after retinoblastoma - Radiation dose and sarcoma risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOFT-TISSUE SARCOMAS; BILATERAL RETINOBLASTOMA; HEREDITARY RETINOBLASTOMA; TRILATERAL RETINOBLASTOMA; SURVIVORS; TUMORS; RADIOTHERAPY; NEOPLASMS; CARCINOMAS; MORTALITY	Context.-There is a substantial risk of a second cancer for persons with hereditary retinoblastoma, which is enhanced by radiotherapy. Objective.-To examine long-term risk of new primary cancers in survivors of childhood retinoblastoma and quantify the role of radiotherapy in sarcoma development. Design.-Cohort incidence study of patients with retinoblastoma followed for a median of 20 years, and nested case-control study of a radiation dose-response relationship for bone and soft tissue sarcomas. Setting/Participants.-A total of 1604 patients with retinoblastoma who survived at least 1 year after diagnosis, identified from hospital records in Massachusetts and New York during 1914 to 1984. Results.-Incidence of subsequent cancers was statistically significantly elevated only in the 961 patients with hereditary retinoblastoma, in whom 190 cancers were diagnosed, vs 6.3 expected in the general population (relative risk [RR], 30 [95% confidence interval, 26-47]), Cumulative incidence (+/-SE) of a second cancer at 50 years after diagnosis was 51.0% (+/-6.2%) for hereditary retinoblastoma, and 5.0% (+/-3.0%) for nonhereditary retinoblastoma. All 114 sarcomas of diverse histologic types occurred in patients with hereditary retinoblastoma. For soft tissue sarcomas, the RRs showed a stepwise increase at all dose categories, and were statistically significant at 10 to 29.9 Gy and 30 to 59.9 Gy. A radiation risk for all sarcomas combined was evident at doses above 5 Gy, rising to 10.7-fold at doses of 60 Gy or greater (P<.05). Conclusions.-Genetic predisposition has a substantial impact on risk of subsequent cancers in retinoblastoma patients, which is further increased by radiation treatment. A radiation dose-response relationship is demonstrated for all sarcomas and, for the first time in humans, for soft tissue sarcomas. Retinoblastoma patients should be examined for new cancers and followed into later life to determine whether their extraordinary cancer risk extends to common cancers of adulthood.	NCI, DIV CANC EPIDEMIOL & GENET, NIH, ROCKVILLE, MD 20892 USA; UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX USA; NEW YORK HOSP, CORNELL MED CTR, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital				Kleinerman, Ruth/0000-0001-7415-2478	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085604] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-85604, N02-CP-33013] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; [Anonymous], 1986, Natl Cancer Inst Monogr, V70, P1; BADER JL, 1982, CANCER GENET CYTOGEN, V5, P203, DOI 10.1016/0165-4608(82)90026-7; BOICE JD, 1985, NATL CANCER I MONOGR, V68, P1; DAVIS FG, 1989, CANCER RES, V49, P6130; DERKINDEREN DJ, 1987, OPHTHALMIC PAED GEN, V8, P23, DOI 10.3109/13816818709028511; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FOLBERG R, 1983, ARCH OPHTHALMOL-CHIC, V101, P1562; FRANCOIS J, 1980, OPHTHALMOLOGICA, V181, P93, DOI 10.1159/000309033; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hawkins MM, 1996, J NATL CANCER I, V88, P270, DOI 10.1093/jnci/88.5.270; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN EA, 1992, CANCER-AM CANCER SOC, V70, P423, DOI 10.1002/1097-0142(19920715)70:2<423::AID-CNCR2820700209>3.0.CO;2-B; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; Kony SJ, 1997, LANCET, V350, P91, DOI 10.1016/S0140-6736(97)01116-1; LASKIN WB, 1988, CANCER-AM CANCER SOC, V62, P2330, DOI 10.1002/1097-0142(19881201)62:11<2330::AID-CNCR2820621113>3.0.CO;2-2; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; Moll AC, 1996, INT J CANCER, V67, P515, DOI 10.1002/(SICI)1097-0215(19960807)67:4<515::AID-IJC9>3.0.CO;2-V; MONSON RR, 1969, COMPUT BIOMED RES, V105, P529; PESIN SR, 1989, AM J OPHTHALMOL, V107, P121, DOI 10.1016/0002-9394(89)90209-2; PRESTON DL, 1991, EPICURE USERS GUIDE; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; ROBINSON E, 1988, JNCI-J NATL CANCER I, V80, P233, DOI 10.1093/jnci/80.4.233; RUKA W, 1991, EUR J SURG ONCOL, V17, P585; SCHIFTER S, 1983, CANCER, V51, P1746, DOI 10.1002/1097-0142(19830501)51:9<1746::AID-CNCR2820510930>3.0.CO;2-G; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; TRABOULSI EI, 1988, ARCH OPHTHALMOL-CHIC, V106, P1059; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; *UN SCI COMM EFF A, 1994, 1994 UN SCI COMM EFF, VE; *WHO, 1976, ICD O INT CLASSIFICA; WINTHER J, 1988, CANCER, V62, P1458, DOI 10.1002/1097-0142(19881001)62:7<1458::AID-CNCR2820620735>3.0.CO;2-2; XU HJ, 1991, CANCER RES, V51, P2735; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P70	38	462	473	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1262	1267		10.1001/jama.278.15.1262	http://dx.doi.org/10.1001/jama.278.15.1262			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333268				2022-12-28	WOS:A1997XZ70900032
J	Hansen, SK; Takada, S; Jacobson, RH; Lis, JT; Tjian, R				Hansen, SK; Takada, S; Jacobson, RH; Lis, JT; Tjian, R			Transcription properties of a cell type-specific TATA-binding protein, TRF	CELL			English	Article							RNA-POLYMERASE-II; ALCOHOL-DEHYDROGENASE GENE; DIRECT BASAL TRANSCRIPTION; RICH ACTIVATION MOTIF; CRYSTAL-STRUCTURE; DNA-BINDING; FUNCTIONAL-ANALYSIS; DROSOPHILA; COMPLEX; PROMOTER	Eukaryotic cells are thought to contain a single TATA-binding protein (TBP) that directs transcription by cellular RNA polymerases. Here we report a cell type-specific TBP-related factor (TRF) that can form a stable TRF/IIA/IIB TATA DNA complex and substitute for TBP in directing RNA polymerase II transcription in vitro. Transfection studies reveal that TRF can differentially mediate activation by some enhancer proteins but not others. Like TBP, TRF forms a stable complex containing multiple novel subunits, nTAFs. Antibody staining of embryos and polytene chromosomes reveals cell type-specific expression and gene-selective properties consistent with the shaker/male sterile phenotype of trf mutants. These findings suggest TRF is a homolog of TBP that functions to direct tissue-and gene-specific transcription.	CORNELL UNIV,BIOCHEM SECT,ITHACA,NY 14853	Cornell University	Hansen, SK (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.				NCI NIH HHS [CA25417] Funding Source: Medline; NIGMS NIH HHS [GM25232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA025417, R01CA025417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025232, R01GM025232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BRAY SJ, 1988, EMBO J, V7, P177, DOI 10.1002/j.1460-2075.1988.tb02798.x; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PAPAZIAN DM, 1988, ANNU REV PHYSIOL, V50, P379; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PASCAL E, 1992, THESIS U CALIFORNIA; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; Shopland LS, 1996, CHROMOSOMA, V105, P158, DOI 10.1007/BF02509497; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Wang X, 1997, P NATL ACAD SCI USA, V94, P433, DOI 10.1073/pnas.94.2.433; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	50	149	153	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					71	83		10.1016/S0092-8674(01)80010-6	http://dx.doi.org/10.1016/S0092-8674(01)80010-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335336	hybrid			2022-12-28	WOS:A1997XZ80900010
J	Inouye, C; Dhillon, N; Thorner, J				Inouye, C; Dhillon, N; Thorner, J			Ste5 RING-H2 domain: Role in Ste4-promoted oligomerization for yeast pheromone signaling	SCIENCE			English	Article							GLUTATHIONE-S-TRANSFERASE; PROTEIN-PROTEIN INTERACTIONS; MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; RESPONSE PATHWAY; SCHISTOSOMA-JAPONICUM; 2-HYBRID SYSTEM; FINGER DOMAIN; DIMERIZATION; BRCA1	Ste5 is a scaffold for the mitogen-activated protein kinase (MAPK) cascade components in a yeast pheromone response pathway. Ste5 also associates with Ste4, the beta subunit of a heterotrimeric guanine nucleotide-binding protein, potentially linking receptor activation to stimulation of the MAPK cascade, A RING-H2 motif at the Ste5 amino terminus is apparently essential for function because Ste5(C177S) and Ste5(C177A C180A) mutants did not rescue the mating defect of a ste5 Delta cell. In vitro Ste5(C177A C180A) bound each component of the MAPK cascade, but not Ste4, Unlike wild-type Ste5, the mutant did not appear to oligomerize; however, when fused to a heterologous dimerization domain (glutathione S-transferase), the chimeric protein restored mating in an ste5 Delta cell and an ste4 Delta ste5 Delta double mutant. Thus, the RING-H2 domain mediates Ste4-Ste5 interaction, which is a prerequisite for Ste5-Ste5 self-association and signaling.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BENTON BM, 1990, MOL CELL BIOL, V10, P353, DOI 10.1128/MCB.10.1.353; Bienstock RJ, 1996, CANCER RES, V56, P2539; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CHOI KY, 1994, CELL, V78, P499; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Evangelista C, 1996, TRENDS CELL BIOL, V6, P196, DOI 10.1016/0962-8924(96)40002-2; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; INOUYE C, IN PRESS GENETICS; INOUYE C, UNPUB; Johannsson O, 1996, AM J HUM GENET, V58, P441; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; MCTIGUE MA, 1995, PROTEINS, V22, P55, DOI 10.1002/prot.340220108; OEHLEN B, 1994, CURR OPIN CELL BIOL, V6, P836, DOI 10.1016/0955-0674(94)90053-1; PRINTEN JA, 1994, GENETICS, V138, P609; Riley LG, 1996, PROTEIN ENG, V9, P223, DOI 10.1093/protein/9.2.223; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sherman F., 1986, METHODS YEAST GENETI; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864	37	139	144	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					103	106		10.1126/science.278.5335.103	http://dx.doi.org/10.1126/science.278.5335.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311911				2022-12-28	WOS:A1997XZ12400047
J	Nesse, RM; Berridge, KC				Nesse, RM; Berridge, KC			Psychoactive drug use in evolutionary perspective	SCIENCE			English	Article							SENSITIZATION; ADDICTION; RECEPTORS	Pure psychoactive drugs and direct routes of administration are evolutionarily novel features of our environment. They are inherently pathogenic because they bypass adaptive information processing systems and act directly on ancient brain mechanisms that control emotion and behavior. Drugs that induce positive emotions give a false signal of a fitness benefit. This signal hijacks incentive mechanisms of ''liking'' and ''wanting,'' and can result in continued use of drugs that no longer bring pleasure. Drugs that block negative emotions can impair useful defenses, although there are several reasons why their use is often safe nonetheless. A deeper understanding of the evolutionary origins and functions of the emotions and their neural mechanisms is needed as a basis Tor decisions about the use of psychoactive drugs.	UNIV MICHIGAN, INST SOCIAL RES, ANN ARBOR, MI 48106 USA; UNIV MICHIGAN, DEPT PSYCHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nesse, RM (corresponding author), UNIV MICHIGAN, DEPT PSYCHIAT, 5057 ISR, POB 1248, ANN ARBOR, MI 48106 USA.		Berridge, Kent C/C-1525-2009	Berridge, Kent C/0000-0002-6031-2626; Nesse, Randolph/0000-0003-1768-0949				Barlow DH, 1991, PSYCHOL INQ, V2, P97; BARRINGTON EJW, 1982, BRIT MED BULL, V38, P227, DOI 10.1093/oxfordjournals.bmb.a071765; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BERNTSON GG, 1993, ANN NY ACAD SCI, V702, P75, DOI 10.1111/j.1749-6632.1993.tb17243.x; Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI 10.1016/0149-7634(95)00033-B; BERRIDGE KC, IN PRESS UNDERSTANDI; Bloom Floyd E., 1995, P1063; Buss DM, 1996, PSYCHOL SCI, V7, P373, DOI 10.1111/j.1467-9280.1996.tb00392.x; Butler A. B., 1996, COMP VERTEBRATE NEUR, DOI DOI 10.1002/0471733849.CH19; DUPONT HL, 1973, JAMA-J AM MED ASSOC, V226, P1525, DOI 10.1001/jama.226.13.1525; EATON SB, 1985, NEW ENGL J MED, V312, P283, DOI 10.1056/NEJM198501313120505; Frank R. H., 1988, PASSIONS REASON STRA; FRYXELL KJ, 1995, J MOL EVOL, V41, P85, DOI 10.1007/BF00174044; GAZZANIGA MS, 1987, INTEGRATED MIND; GELPERIN A, 1986, TRENDS NEUROSCI, V9, P323, DOI 10.1016/0166-2236(86)90098-6; Gilbert P., 1992, DEPRESSION EVOLUTION; GRAY JA, 1987, FEAR STRESS; HOEBEL BG, 1988, STEVENS HDB EXPT PSY, V1, P547; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KEFTNER D, 1996, COGNITION EMOTION, V10, P155; KETELAAR T, IN PRESS PERSONALITY; KETELAAR T, UNPUB; Kluger MJ., 1979, FEVER ITS BIOL EVOLU; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; LeDoux J. E., 1996, EMOTIONAL BRAIN; Li X, 1996, J MOL EVOL, V43, P179, DOI 10.1007/BF02338825; MARKS IM, 1994, ETHOL SOCIOBIOL, V15, P247, DOI 10.1016/0162-3095(94)90002-7; MCGUIRE MT, 1997, DARWINIAN PSYCHIAT; MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723; Nesse R M, 1990, Hum Nat, V1, P261, DOI 10.1007/BF02733986; NESSE RM, 1994, ETHOL SOCIOBIOL, V15, P339, DOI 10.1016/0162-3095(94)90007-8; Nesse RM, 1995, WHY WE GET SICK NEW; NESSE RM, 1991, PSYCHOLOQUY, V2; PEROUTKA SJ, 1994, NEUROCHEM INT, V25, P533, DOI 10.1016/0197-0186(94)90151-1; Pomerleau CS, 1997, ADDICTION, V92, P397; Pribbenow B, 1996, NEUROBIOL LEARN MEM, V66, P109, DOI 10.1006/nlme.1996.0052; PRICE J, 1994, BRIT J PSYCHIAT, V164, P309, DOI 10.1192/bjp.164.3.309; RIJDA NH, 1994, NATURE EMOTION, P59; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Shizgal P, 1997, CURR OPIN NEUROBIOL, V7, P198, DOI 10.1016/S0959-4388(97)80008-6; SMITH M, 1986, ADV HUM GENET, V15, P249; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; TOOBY J, 1990, ETHOL SOCIOBIOL, V11, P375, DOI 10.1016/0162-3095(90)90017-Z; Walker RJ, 1996, PARASITOLOGY, V113, pS3, DOI 10.1017/S0031182000077878; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; Wilson E.O., 1975, P1; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535; ZAJONC RB, 1985, SCIENCE, V228, P15, DOI 10.1126/science.3883492; [No title captured]	50	226	228	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					63	66		10.1126/science.278.5335.63	http://dx.doi.org/10.1126/science.278.5335.63			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311928				2022-12-28	WOS:A1997XZ12400033
J	Chan, L; Koepsell, TD; Deyo, RA; Esselman, PC; Haselkorn, JK; Lowery, JK; Stolov, WC				Chan, L; Koepsell, TD; Deyo, RA; Esselman, PC; Haselkorn, JK; Lowery, JK; Stolov, WC			The effect of Medicare's payment system for rehabilitation hospitals on length of stay, charges, and total payments	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Medicare's system for the payment of rehabilitation hospitals is based on limits derived from a hospital's average allowable charges per patient discharged during a base year. Thereafter, payments are capped, but hospitals receive incentive payments if charges per patient are reduced in succeeding years. We hypothesized that per-patient charges would increase during the base year and then decrease in subsequent years. Hospitals would thus have higher reimbursement limits and receive incentive payments for reducing their charges. Methods We analyzed Medicare claims data for 190,921 discharges from 69 rehabilitation hospitals from 1987 through 1994. We compared total charges, length of stay, and interim payments before, during, and alter each hospital's base year. Results After we controlled for inflation and temporal and seasonal trends, mean charges per patient discharged increased from $25,131 for patients discharged before the base year to $32,167 for patients discharged in the base year (a 28 percent increase, P<0.001) and the mean length of stay increased from 22.1 to 26.7 days (a 21 percent increase, P<0.001). After the base year, mean charges decreased to $29,307 (a 9 percent decrease) and the mean length of stay decreased to 24.0 days (a 10 percent decrease) (P<0.001 for both comparisons). Analysis of data on patients according to diagnosis-for example, spinal cord injury, brain injury, stroke, amputation or deformity, hip fracture, and arthritis or other joint disorders-showed similar findings for each, with increases in charges and length of stay in the base year, followed by small reductions thereafter For-profit hospitals had greater increases than nonprofit hospitals in their per-patient charges (mean increase, $7,434 vs. $2,929; P<0.001) and length of slay (mean increase, 4.6 vs. 2.3 days, P<0.001) during the base year. Conclusions Although Medicare's reimbursement system far rehabilitation hospitals put an upper limit on total payments, its design was associated with substantial extra costs, including significantly increased payments to hospitals and doctors and increased numbers of hospital days for the average patient. (C) 1997, Massachusetts Medical Society.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chan, L (corresponding author), HLTH CARE FINANCING ADM,DIV CLIN STAND & QUAL,REG 10,MS-RX 40,2201 6TH AVE,SEATTLE,WA 98121, USA.							ALTMAN DG, 1991, PRACTICAL STAT MED R, P194; ARNOLD S, 1992, C9205 PROSP PAYM ASS, P16; *BUR LAB STAT, 1996, CPI DET REP DAT MARC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CROMWELL J, 1990, TEFRA PSYCH HOSP UNI; Davis L M, 1993, Adv Health Econ Health Serv Res, V14, P87; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FEDER J, 1987, NEW ENGL J MED, V317, P867, DOI 10.1056/NEJM198710013171405; Guterman S, 1988, Health Care Financ Rev, V9, P67; HARADA N, 1993, INQUIRY-J HEALTH CAR, V30, P54; HARROW B, 1990, IMPACT ANAL TEFRA SY; *HLTH CAR FIN ADM, 1994, MED PROV REIMB MAN 1, P30; *HLTH CAR FIN ADM, 1995, REG OFF MAN MED, pI25; HOSEK S, 1986, R3424HCFA RAND, P1; HSIA DC, 1990, NEW ENGL J MED, V322, P1540; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Langenbrunner J C, 1989, Health Care Financ Rev, V10, P91; *PROSP PAYM ASS CO, 1996, REP REC C MARCH 1 19; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; Searle S.R., 1992, VARIANCE COMPONENTS, P168; 1993, FED REGISTER, V58, P63820	21	71	71	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					978	985		10.1056/NEJM199710023371406	http://dx.doi.org/10.1056/NEJM199710023371406			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309104				2022-12-28	WOS:A1997XY42300006
J	Poland, GA				Poland, GA			Lessons from the influenza vaccine recall of 1996-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ELDERLY PEOPLE; COST-EFFECTIVENESS; IMMUNIZATION; EFFICACY				Poland, GA (corresponding author), MAYO CLIN & MAYO FDN, MAYO VACCINE RES GRP, 601 B GUGGENHEIM BLDG, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P1100; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P601; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; GOVAERT TME, 1994, VACCINE, V12, P1185, DOI 10.1016/0264-410X(94)90241-0; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1987, J CLIN MICROBIOL, V25, P1763, DOI 10.1128/JCM.25.9.1763-1765.1987; Gross PA, 1996, CLIN DIAGN LAB IMMUN, V3, P361, DOI 10.1128/CDLI.3.3.361-362.1996; GROSS PA, 1988, J AM GERIATR SOC, V36, P209, DOI 10.1111/j.1532-5415.1988.tb01802.x; Hilleman MR, 1996, JAMA-J AM MED ASSOC, V275, P241, DOI 10.1001/jama.275.3.241; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; KILBOURNE ED, 1994, VACCINES, P565; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; *NAT VACC ADV COMM, 1994, AD IMM; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; U.S. Department of Health and Human Services Office of Disease Pre- vention and Health Promotion, 1990, HLTH PEOPL 2000	17	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1022	1023		10.1001/jama.278.12.1022	http://dx.doi.org/10.1001/jama.278.12.1022			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307353				2022-12-28	WOS:A1997XX01200036
J	Jones, CM; Taylor, GO; Whittle, JG; Evans, D; Trotter, DP				Jones, CM; Taylor, GO; Whittle, JG; Evans, D; Trotter, DP			Water fluoridation, tooth decay in 5 year olds, and social deprivation measured by the Jarman score: analysis of data from British dental surveys	BRITISH MEDICAL JOURNAL			English	Article							CARIES EXPERIENCE; AREAS; CHILDREN; IDENTIFICATION; DENTITION	Objective: To examine the effect of water fluoridation, both artificial and natural, on dental decay, after socioeconomic deprivation was controlled for. Design: Ecological study based on results from the NHS dental surveys in 5 year olds in 1991-2 and 1993-4 and Jarman underprivileged area scores from the 1991 census. Setting: Electoral wards in three areas: Hartlepool (naturally fluoridated), Newcastle and North Tyneside (fluoridated), and Salford and Trafford (non-fluoridated). Subjects: 5 year old children (n = 10 004). Intervention: Water fluoridation (artificial and occurring naturally). Main outcome measure: Ward tooth decay score (score on the ''decayed, missing, and filled tooth index'' for each electoral ward). Results: Multiple linear regression showed a significant interaction between Jarman score for ward, mean number of teeth affected by decay, and both types of water fluoridation. This confirms that the more deprived an area, the greater benefit derived from fluoridation whether natural or artificial (R-2 = 0.84, P < 0.001), At a Jarman score of zero (national mean score) there was a predicted 44% reduction in decay in fluoridated areas, increasing to a 54% reduction in wards with a Jarman score of 40 (very deprived). The area with natural fluoridation (at a level of 1.2 parts per million-higher than levels in artificially fluoridated areas) had a 66% reduction in decay, with a 74% reduction in wards with a Jarman score of 40. Conclusion: Tooth decay is confirmed as a disease associated with social deprivation, and the more socially deprived areas benefit more from fluoridation. Widespread water fluoridation is urgently needed to reduce the ''dental health divide'' by improving the dental health of the poorer people in Britain.	WESHAM PK HOSP,N W DENT PUBL HLTH,PRESTON PR4 3AL,LANCS,ENGLAND; NEWCASTLE & N TYNESIDE HLTH AUTHOR,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND									BEAL JF, 1990, PREVENTION DENT DIS; BLAND M, 1993, INTRO MED STAT, P148; *BRIT FLUOR SOC, 1996, ONE MILL WAT FLUOR D; CARMICHAEL CL, 1989, BRIT DENT J, V167, P57, DOI 10.1038/sj.bdj.4806919; Ellwood R P, 1995, Community Dent Health, V12, P18; Ellwood RP, 1996, COMMUNITY DENT ORAL, V24, P1, DOI 10.1111/j.1600-0528.1996.tb00802.x; EVANS RW, 1984, COMMUNITY DENT ORAL, V12, P5, DOI 10.1111/j.1600-0528.1984.tb01401.x; HAUSEN H, 1982, COMMUNITY DENT ORAL, V10, P33, DOI 10.1111/j.1600-0528.1982.tb00357.x; HAUSEN H, 1981, COMMUNITY DENT ORAL, V9, P289, DOI 10.1111/j.1600-0528.1981.tb00348.x; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; Jarman B., 1984, BRIT MED J, V289, P587; NAYLOR MN, 1990, PREVENTION DENT DIS; NEWBRUN E, 1989, J PUBLIC HEALTH DENT, V49, P279, DOI 10.1111/j.1752-7325.1989.tb02086.x; Pitts N B, 1995, Community Dent Health, V12, P52; PITTS NB, 1997, COMMUNITY DENT HL S1, V14, pS6; PITTS NB, 1994, COMMUNITY DENT HLTH, V11, P45; Provart S J, 1995, Community Dent Health, V12, P200; Provart S J, 1995, Community Dent Health, V12, P138; Slade GD, 1996, COMMUNITY DENT ORAL, V24, P89, DOI 10.1111/j.1600-0528.1996.tb00822.x; TAYLOR GO, 1995, BRIT DENT J, V178, P47, DOI 10.1038/sj.bdj.4808644; WINTER GB, 1990, ARCH ORAL BIOL, V35, pS1, DOI 10.1016/0003-9969(90)90124-S	21	56	62	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					514	517		10.1136/bmj.315.7107.514	http://dx.doi.org/10.1136/bmj.315.7107.514			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329305	Green Published			2022-12-28	WOS:A1997XU50600017
J	Thompson, GN; Hsu, BYL; Pitt, JJ; Treacy, E; Stanley, CA				Thompson, GN; Hsu, BYL; Pitt, JJ; Treacy, E; Stanley, CA			Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FATTY-ACID OXIDATION; RAT MITOCHONDRIAL; KETOGENESIS; CARNITINE; LIVER; GENE		ROYAL CHILDRENS HOSP, MURDOCH INST, PARKVILLE, VIC 3052, AUSTRALIA; CHILDRENS HOSP PHILADELPHIA, DIV ENDOCRINOL & DIABET, PHILADELPHIA, PA 19104 USA; ROYAL CHILDRENS HOSP, DEPT BIOCHEM, PARKVILLE, VIC 3052, AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Royal Children's Hospital Melbourne				STANLEY, CHARLES/0000-0003-4881-9392; Treacy, Eileen/0000-0002-6226-1615	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043841] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00240] Funding Source: Medline; NIDDK NIH HHS [R01-DK43841] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; AYTE J, 1993, BIOCHEM J, V295, P807, DOI 10.1042/bj2950807; CASALS N, 1992, BIOCHEM J, V283, P261, DOI 10.1042/bj2830261; CEDERBLA.G, 1972, CLIN CHIM ACTA, V37, P235, DOI 10.1016/0009-8981(72)90438-X; CURI R, 1989, INT J BIOCHEM, V21, P1133, DOI 10.1016/0020-711X(89)90055-4; DURAN M, 1988, CLIN CHEM, V34, P548; FOURRE C, 1987, ACTA PHARM BIOL CLIN, V4, P420; GILGOMEZ G, 1993, EUR J BIOCHEM, V213, P773, DOI 10.1111/j.1432-1033.1993.tb17819.x; GRANTHAM BD, 1988, BIOCHEM J, V249, P409, DOI 10.1042/bj2490409; GUZMAN M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P227, DOI 10.1016/0005-2760(93)90224-W; KATTARCOOLEY PA, 1990, ARCH BIOCHEM BIOPHYS, V283, P523, DOI 10.1016/0003-9861(90)90677-Q; MANNING NJ, 1990, J INHERIT METAB DIS, V13, P58, DOI 10.1007/BF01799333; MILLINGTON DS, 1991, INT J MASS SPECTROM, V111, P211, DOI 10.1016/0168-1176(91)85056-R; QUANT PA, 1989, BIOCHEM J, V262, P159, DOI 10.1042/bj2620159; ROE CR, 1995, METABOLIC MOL BASIS, V1, P1501; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; ROYO T, 1993, J LIPID RES, V34, P867; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V307, P40, DOI 10.1006/abbi.1993.1557; STANLEY CA, 1983, PEDIATR RES, V17, P224, DOI 10.1203/00006450-198303000-00012; STANLEY CA, 1992, NEW ENGL J MED, V327, P19, DOI 10.1056/NEJM199207023270104; TANAKA K, 1980, CLIN CHEM, V26, P1847; THOMPSON GN, 1990, EUR J PEDIATR, V149, P346, DOI 10.1007/BF02171564; WILLIAMS.DH, 1968, BIOCHEM J, V108, P353, DOI 10.1042/bj1080353; WILLIAMSON DH, 1985, FED PROC, V44, P2342; WYSOCKI SJ, 1976, CLIN CHIM ACTA, V73, P373, DOI 10.1016/0009-8981(76)90186-8	25	54	59	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1203	1207		10.1056/NEJM199710233371704	http://dx.doi.org/10.1056/NEJM199710233371704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337379	Bronze			2022-12-28	WOS:A1997YB71800004
J	Ouyang, Q; Kaplan, PD; Liu, SM; Libchaber, A				Ouyang, Q; Kaplan, PD; Liu, SM; Libchaber, A			DNA solution of the maximal clique problem	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; GENE	The maximal clique problem has been solved by means of molecular biology techniques. A pool of DNA molecules corresponding to the total ensemble of six-vertex cliques was built, followed by a series of selection processes. The algorithm is highly parallel and has satisfactory fidelity. This work represents further evidence for the ability of DNA computing to solve NP-complete search problems.	ROCKEFELLER UNIV,CTR STUDIES PHYS & BIOL,NEW YORK,NY 10021	Rockefeller University	Ouyang, Q (corresponding author), NEC RES INST,4 INDEPENDENCE WAY,PRINCETON,NJ 08540, USA.		Kaplan, Peter/A-2972-2009	Kaplan, Peter/0000-0002-2292-6862				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; CASTI J, 1997, NEW SCI, V2082, P30; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DESALLE R, 1993, EXPERIENTIA, V49, P906, DOI 10.1007/BF01952607; Eckert K A, 1991, PCR Methods Appl, V1, P17; Garey M.R., 1979, COMPUTERS INTRACTABI; Guarnieri F, 1996, SCIENCE, V273, P220, DOI 10.1126/science.273.5272.220; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAYARAMAN K, 1991, P NATL ACAD SCI USA, V88, P4084, DOI 10.1073/pnas.88.10.4084; Kaplan PD, 1997, J THEOR BIOL, V188, P333, DOI 10.1006/jtbi.1997.0475; LIPTON RJ, 1995, SCIENCE, V268, P542, DOI 10.1126/science.7725098; Paun G., 1996, Journal of Automata, Languages and Combinatorics, V1, P27; SAMBROOK J, 1987, MOL CLONING; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4	15	376	478	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					446	449		10.1126/science.278.5337.446	http://dx.doi.org/10.1126/science.278.5337.446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334300				2022-12-28	WOS:A1997YB35500040
J	Visintin, R; Prinz, S; Amon, A				Visintin, R; Prinz, S; Amon, A			CDC20 and CDH1: A family of substrate-specific activators of APC-dependent proteolysis	SCIENCE			English	Article							B-TYPE CYCLINS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; G1 CYCLINS; MITOSIS; DROSOPHILA; YEAST; DESTRUCTION; FIZZY; DEGRADATION	Proteolysis mediated by the anaphase-promoting complex (APC) triggers chromosome segregation and exit from mitosis, yet its regulation is poorly understood. The conserved Cdc20 and Cdh1 proteins were identified as limiting, substrate-specific activators of APC-dependent proteolysis. CDC20 was required for the degradation of the APC substrate Pds1 but not for that of other APC substrates, such as Clb2 and Ase1. Conversely, cdh1 Delta mutants were impaired in the degradation of Ase1 and Clb2 but not in that of Pds1. Overexpression of either CDC20 or CDH1 was sufficient to induce APC-dependent proteolysis of the appropriate target in stages of the cell cycle in which substrates are normally stable.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute			Visintin, Rosella/J-9690-2012	Amon, Angelika/0000-0001-9837-0314; Visintin, Rosella/0000-0001-6758-9946				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SKOWYRA D, IN PRESS CELL; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; VISINTIN R, UNPUB; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	24	700	709	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					460	463		10.1126/science.278.5337.460	http://dx.doi.org/10.1126/science.278.5337.460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334304				2022-12-28	WOS:A1997YB35500044
J	Gostin, LO; Ward, JW; Baker, AC				Gostin, LO; Ward, JW; Baker, AC			National HIV case reporting for the United States - A defining moment in the history of the epidemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH INFORMATION PRIVACY; PARTNER NOTIFICATION; AIDS SURVEILLANCE; CUBIC MILLIMETER; INFECTION; TRANSMISSION; ZIDOVUDINE; SYSTEM; COMBINATION		CTR DIS CONTROL & PREVENT, ATLANTA, GA 30333 USA; NATL ASSOC PEOPLE AIDS, WASHINGTON, DC 20005 USA	Centers for Disease Control & Prevention - USA	Gostin, LO (corresponding author), GEORGETOWN UNIV, CTR LAW, WASHINGTON, DC 20001 USA.							*AD HIV AIDS, 1993, CDC5042A AD HIV AIDS; *AIDS ACT FDN, 1993, SHOULD HIV TEST RES; ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; [Anonymous], 1989, PRIVATE ACTS SOCIAL; *ASS STAT TERR HLT, 1988, GUID PUBL HLTH PRACT; *AT COUNC STAT TER, 1997, CONF REP HIV INF; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BAYER R, 1992, AM J PUBLIC HEALTH, V82, P1158, DOI 10.2105/AJPH.82.8.1158; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Buehler JW, 1996, PUBLIC HEALTH REP, V111, P133; BURR C, 1996, ATLANTIC MONTHLY JUN, P57; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDC ADV COMM PREV, 1994, EXT REV CDCS HIV PRE; *CDCP, 1996, HIV AIDS SURV, V8, P29; *CDCP, 1997, HIV AIDS SURV REP, V9; *CDCP, 1992, STRAT PLAN PREV HUM; *CDCP, 1994, HIV COUNS TEST REF S; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; FEHRS LJ, 1988, LANCET, V2, P379; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Forbes Anna, 1996, AIDS Policy Law, VBonus Report, P1; FOX DM, 1986, HASTINGS CENT REP, V16, pS11, DOI 10.2307/3562097; FRANCIS DP, 1983, J NATL CANCER I, V71, P1; FRANCIS DP, 1993, J ACQ IMMUN DEF SYND, V6, P285; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; GOSTIN LO, 1995, CORNELL LAW REV, V80, P451; GOSTIN LO, 1992, HEALTH AFFAIR, V11, P248, DOI 10.1377/hlthaff.11.3.248; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Hecht F. M., 1997, JGIM, V12, P108; HIRANO D, 1994, AM J PUBLIC HEALTH, V84, P2008, DOI 10.2105/AJPH.84.12.2008; *HIV AIDS MED, 1996, MEDICAID PHARM B, V10, P1; *HIV TEST ACT COAL, 1997, STAT NAT HIV TEST AC; HOFFMAN RE, 1995, J ACQ IMMUN DEF SYND, V8, P406; *I MED, 1986, CONFR AIDS DIR PUBL; Kahn JG, 1996, AM J PUBLIC HEALTH, V86, P1709, DOI 10.2105/AJPH.86.12.1709; KAMB ML, 1997, 4 C RETR OPP INF WAS; KEGELES SM, 1990, AIDS, V4, P585, DOI 10.1097/00002030-199006000-00016; LANDRY S, 1996, ST PETERSBURG T 0920, P51; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MCDONALD AM, 1994, AM J PUBLIC HEALTH, V84, P1923, DOI 10.2105/AJPH.84.12.1923; McQuillan GM, 1997, J ACQ IMMUN DEF SYND, V14, P355, DOI 10.1097/00042560-199704010-00008; MEYER PA, 1994, SOUTHERN MED J, V87, P344, DOI 10.1097/00007611-199403000-00009; Morris S, 1996, J PUBLIC HEALTH MED, V18, P415, DOI 10.1093/oxfordjournals.pubmed.a024539; *NIH PAN DEF PRINC, 1997, REP NIH PAN DEF PRIN; PEARSON RK, 1997, NONLINEAR PROCESS CO, P20; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PHILLIPS KA, 1994, J ACQ IMMUN DEF SYND, V7, P403; *PROV PUBL HLTH SE, 1985, MMWR-MORBID MORTAL W, V34, P1; Richardson Lynda, 1997, N Y Times Web, pB4; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; SMITH E, 1994, AM J PUBLIC HEALTH, V84, P1929, DOI 10.2105/AJPH.84.12.1929; Staszewski S, 1997, AIDS, V11, P477, DOI 10.1097/00002030-199704000-00011; Steinbrook LD, 1997, NEW ENGL J MED, V337, P779, DOI 10.1056/NEJM199709113371109; SWEENEY P, 1995, AIDS, V9, P645, DOI 10.1097/00002030-199506000-00018; WARD JW, 1994, AM J PUBLIC HEALTH, V84, P1888, DOI 10.2105/AJPH.84.12.1888; Wortley PM, 1996, J ACQ IMMUN DEF SYND, V11, P205, DOI 10.1097/00042560-199602010-00016; 1997, MMWR-MORBID MORTAL W, V46, P861; 1989, MMWR-MORBID MORTAL W, V38, P496; 1997, MMWR-MORBID MORTAL W, V46, P165; 1990, MMWR-MORBID MORTAL W, V39, P853; 1990, MMWR-MORBID MORTAL W, V39, P859	64	61	61	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1162	1167		10.1056/NEJM199710163371611	http://dx.doi.org/10.1056/NEJM199710163371611			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA912	9329940				2022-12-28	WOS:A1997YA91200011
J	Eng, CM; Schechter, C; Robinowitz, J; Fulop, G; Burgert, T; Levy, B; Zinberg, R; Desnick, RJ				Eng, CM; Schechter, C; Robinowitz, J; Fulop, G; Burgert, T; Levy, B; Zinberg, R; Desnick, RJ			Prenatal genetic carrier testing using triple disease screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TAY-SACHS-DISEASE; CYSTIC-FIBROSIS; GAUCHER DISEASE; ASHKENAZI JEWS; HUMAN GENOME; POPULATION; MUTATIONS; COMMON	Context.-Rapid progress in gene discovery has dramatically increased diagnostic capabilities for carrier screening and prenatal testing for genetic diseases. However, simultaneous prenatal carrier screening for prevalent genetic disease has not been evaluated, and patient acceptance and attitudes toward this testing strategy remain undefined. Objective.-To evaluate an educational, counseling, and carrier testing program for 3 genetic disorders: Tay-Sachs disease (TSD), type 1 Gaucher disease (GD), and cystic fibrosis (CF) that differ in detectability, severity, and availability of therapy. Design.-Potential participants received education and genetic counseling, gave informed consent, chose screening tests, and completed pre-education and posteducation questionnaires that assessed knowledge, attitudes toward genetic testing, and disease testing preferences. Setting.-Medical genetics referral center. Patients.-Volunteer sample of 2824 Ashkenazi Jewish individuals enrolled as couples who were referred for TSD testing. Intervention.-Genetic counseling, education, and ii chosen, genetic testing for any or all 3 disorders. Main Outcome Measure.-Acceptance of screening for each of the 3 disorders. Secondary outcomes include attitudes toward genetic testing and reproductive considerations. Results.-Of the 2824 individuals tested for TSD, 97% and 95% also chose testing for CF and GD, respectively. The frequency of detected carriers was 1.21 for TSD, 1:25 for CF, and 1:18 for GD. Twenty-one carrier couples were identified, counseled, and all postconception couples opted for prenatal diagnosis. Pre-education and posteducation questionnaires revealed that patients initially knew little about the diseases, but acquired disease information and increased knowledge of genetic concepts. Education and genetic counseling increased understanding and retention of genetic concepts and disease-related information, and minimized test-related anxiety. Although individuals sought screening for all 3 diseases, reproductive attitudes and decisions varied directly with disease severity and treatability. Conclusions.-These findings emphasize the importance of genetic counseling for prenatal carrier testing and may improve understanding, acceptance, and informed decision making for prenatal carrier screening for multiple genetic diseases.	CUNY MT SINAI SCH MED, DEPT PEDIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT COMMUNITY MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Eng, CM (corresponding author), CUNY MT SINAI SCH MED, DEPT HUMAN GENET, BOX 1497, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NCRR NIH HHS [2M01 RR00071] Funding Source: Medline; NHGRI NIH HHS [1R01 HG006440] Funding Source: Medline; NICHD NIH HHS [5P30 HD28822] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BEUTLER E, 1992, BLOOD, V79, P1662; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; Beutler E., 1995, METABOLIC MOL BASES, P2641; Brock DJH, 1996, LANCET, V347, P148, DOI 10.1016/S0140-6736(96)90340-2; CUTTING GR, 1992, AM J HUM GENET, V50, P1185; DEMARCHI JM, 1994, HUM MUTAT, V4, P281, DOI 10.1002/humu.1380040409; ENG CM, 1995, AM J HUM GENET, V57, P302; GRODY WW, IN PRESS AM J HUM GE; GUYER MS, 1995, P NATL ACAD SCI USA, V92, P10841, DOI 10.1073/pnas.92.24.10841; HIETALA M, 1995, AM J HUM GENET, V56, P1493; KABACK M, 1993, JAMA-J AM MED ASSOC, V270, P2307, DOI 10.1001/jama.270.19.2307; Lindeman R., 1980, INTRO BIVARIATE MULT; MASSARIK F, 1981, GENETIC DIS CONTROL, P102; McCabe ERB, 1996, JAMA-J AM MED ASSOC, V275, P548, DOI 10.1001/jama.1996.03530310054033; Morris J K, 1995, J Med Screen, V2, P22; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; ROWLEY PT, 1984, AM J HUM GENET, V36, P677; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCRIVER CR, 1995, METABOLIC MOL BASES, P2839; SIBILLE A, 1993, AM J HUM GENET, V52, P1094; TOUCHETTE N, 1995, NAT MED, V1, P501, DOI 10.1038/nm0695-501; TRIGGSRAINE BL, 1992, AM J HUM GENET, V51, P793; TRIGGSRAINE BL, 1990, NEW ENGL J MED, V323, P6, DOI 10.1056/NEJM199007053230102; VOGEL F, 1996, HUM GENET, P559; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; Wilkinson L., 1990, SYSTAT SYSTEM STAT; IN PRESS GENETIC TES	29	61	61	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1268	1272		10.1001/jama.278.15.1268	http://dx.doi.org/10.1001/jama.278.15.1268			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333269				2022-12-28	WOS:A1997XZ70900033
J	Dores, GM; Miller, ME				Dores, GM; Miller, ME			Pathologic fracture	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Dores, GM (corresponding author), BROWN UNIV,MEM HOSP RHODE ISL,PAWTUCKET,RI 02860, USA.			Dores, Graca/0000-0002-3985-2935					0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1043	1043		10.1056/NEJM199710093371504	http://dx.doi.org/10.1056/NEJM199710093371504			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321532				2022-12-28	WOS:A1997XZ84400004
J	Lang, AE; Lozano, AM; Montgomery, E; Duff, J; Tasker, R; Hutchinson, W				Lang, AE; Lozano, AM; Montgomery, E; Duff, J; Tasker, R; Hutchinson, W			Posteroventral medial pallidotomy in advanced Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORE ASSESSMENT PROGRAM; VENTRAL PALLIDOTOMY; GPI PALLIDOTOMY; TRANSPLANTATION; SYMPTOMS	Background Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up. Methods Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (''off'' period) and while taking their optimal medical regimens (''on'' period). All patients were examined preoperatively, and 39 were examined at six months; 27 of the patients were also examined at one year, and 11 at two years. Results The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent). The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two yeats. The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months. Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery. The complications of surgery were generally well tolerated, and there were no significant changes in the use of medication. Conclusions In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability. Much of the benefit is sustained at two years, although some improvements, such as those on the ipsilateral side and in axial symptoms, wane within the first year. The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy. (C) 1997, Massachusetts Medical Society.	TORONTO HOSP,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA; UNIV ARIZONA,COLL MED,DEPT NEUROL,TUCSON,AZ	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Arizona	Lang, AE (corresponding author), TORONTO HOSP,MOVEMENT DISORDERS CTR,DIV NEUROL,399 BATHURST ST,MP 11-306,TORONTO,ON M5T 2S8,CANADA.		Lang, Anthony/ABF-8114-2021; Lozano, Andres M/A-5058-2012	Lozano, Andres M./0000-0001-8257-3694; Lang, Anthony/0000-0003-1229-3667				Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Davis KD, 1997, NAT MED, V3, P671, DOI 10.1038/nm0697-671; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Fazzini E, 1997, NEUROLOGY, V48, P1273, DOI 10.1212/WNL.48.5.1273; Galvez-Jimenez Nestor, 1996, Neurology, V46, pA402; GALVEZJIMENEZ N, 1996, MOVEMENT DISORD, V11, P242; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; IACONO RP, 1995, J CLIN NEUROSCI, V2, P140, DOI 10.1016/0967-5868(95)90007-1; IACONO RP, 1995, NEUROSURGERY, V36, P1118, DOI 10.1227/00006123-199506000-00008; Johansson F, 1997, J NEUROL NEUROSUR PS, V62, P125, DOI 10.1136/jnnp.62.2.125; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; LAITINEN LV, 1995, NEUROSURG CLIN N AM, V6, P105; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Lang A. E. T., 1989, QUANTIFICATION NEURO, P285; LANG AE, 1995, MOVEMENT DISORD, V10, P527, DOI 10.1002/mds.870100426; LANG AE, IN PRESS ADV UNDERST; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Lozano A, 1996, J NEUROSURG, V84, P194, DOI 10.3171/jns.1996.84.2.0194; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; SAINTCYR JA, 1996, MOV DISORD S1, V0011, P00161; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SUTTON JP, 1995, NEUROSURGERY, V36, P1112; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x	25	384	389	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1036	1042		10.1056/NEJM199710093371503	http://dx.doi.org/10.1056/NEJM199710093371503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321531				2022-12-28	WOS:A1997XZ84400003
J	Chan, FKL; Sung, JJY; Chung, SCS; To, KF; Yung, MY; Leung, VKS; Lee, YT; Chan, CSY; Li, EKM; Woo, J				Chan, FKL; Sung, JJY; Chung, SCS; To, KF; Yung, MY; Leung, VKS; Lee, YT; Chan, CSY; Li, EKM; Woo, J			Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SERIOUS GASTROINTESTINAL COMPLICATIONS; RHEUMATOID-ARTHRITIS; CAMPYLOBACTER-PYLORI; DOUBLE-BLIND; INFECTION; RISK; ULCERATION; GASTRITIS; INJURY	Background Helicobacter pylori infection is common in patients with peptic ulcers caused by the use of nonsteroidal anti-inflammatory drugs (NSAIDs). But the pathogenic role of H pylori in this disease is controversial. We studied the efficacy of eradication of H pylori in the prevention of NSAID-induced peptic ulcers. Methods We recruited patients with musculoskeletal pain who required NSAID treatment, None of the patients had previous exposure to NSAID therapy. Patients who had H pylori infection but no pre-existing ulcers on endoscopy were randomly allocated naproxen alone (750 mg daily) for 8 weeks or a 1-week course of triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, each given orally four times daily) before administration of naproxen (750 mg daily). Endoscopy was repeated after 8 weeks of naproxen treatment or when naproxen treatment was stopped early because of bleeding or intractable dyspepsia. All endoscopic examinations were done by one endoscopist who was unaware of treatment assignment. The primary endpoint was the cumulative rate of gastric and duodenal ulcers, Findings 202 patients underwent endoscopic screening for enrolment in the trial, and 100 eligible patients were randomly assigned treatment. 92 patients completed the trial (47 in the naproxen group, 45 in the triple-therapy group), At 8 weeks, H pylori had been eradicated from no patients in the naproxen group and 40 (89%) in the triple-therapy group (p<0.001). 12 (26%) naproxen-group patients developed ulcers: five had ulcer pain and one developed ulcer bleeding. Only three (7%) patients on triple therapy had ulcers, and two of these patients had failure of H pylori eradication (p=0.01). Thus, 12 (26%) patients with persistent H pylori infection but only one (3%) with successful H pylori eradication developed ulcers with naproxen (p=0.002). Interpretation Eradication of H pylori before NSAID therapy reduces the occurrence of NSAID-induced peptic ulcers.	PRINCE WALES HOSP, DEPT SURG, SHATIN, NT, HONG KONG; PRINCE WALES HOSP, DEPT ANAT & CELLULAR PATHOL, SHATIN, NT, HONG KONG; CHINESE UNIV HONG KONG, DEPT COMMUNITY & FAMILY MED, HONG KONG, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong	Chan, FKL (corresponding author), PRINCE WALES HOSP, DEPT MED, SHATIN, NT, HONG KONG.		Sung, Joseph J. Y./R-3203-2018; Chan, Francis K. L./F-4851-2010; Woo, Jean/K-2625-2014	Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Francis K. L./0000-0001-7388-2436; Woo, Jean/0000-0001-7593-3081				Bloom B S, 1988, Am J Med, V84, P20, DOI 10.1016/0002-9343(88)90250-1; Ekstrom P, 1996, SCAND J GASTROENTERO, V31, P753, DOI 10.3109/00365529609010347; FRIES JF, 1991, AM J MED, V91, P213, DOI 10.1016/0002-9343(91)90118-H; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GOGGIN PM, 1993, GUT, V34, P1677, DOI 10.1136/gut.34.12.1677; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; Hawkey CJ, 1996, SCAND J GASTROENTERO, V31, P124, DOI 10.3109/00365529609094763; HERESBACH D, 1992, GUT, V33, P1608, DOI 10.1136/gut.33.12.1608; Kim Jong G., 1994, American Journal of Gastroenterology, V89, P203; LAINE L, 1995, ALIMENT PHARM THERAP, V9, P127; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LANGMAN MJS, 1995, EXCERPTA MED, V72, P1; LANZA FL, 1991, AM J GASTROENTEROL, V86, P735; LEVINE JS, 1995, ANN INTERN MED, V123, P309, DOI 10.7326/0003-4819-123-4-199508150-00010; Li EKM, 1996, SCAND J RHEUMATOL, V25, P42, DOI 10.3109/03009749609082667; LOEB DS, 1992, GASTROENTEROLOGY, V102, P1899, DOI 10.1016/0016-5085(92)90311-L; MARTIN DF, 1989, AM J GASTROENTEROL, V84, P1268; Porro GB, 1996, GUT, V39, P22, DOI 10.1136/gut.39.1.22; PUBLIG W, 1994, WIEN KLIN WOCHENSCHR, V106, P276; SEPPALA K, 1995, GUT, V36, P834, DOI 10.1136/gut.36.6.834; SHALLCROSS TM, 1990, ALIMENT PHARM THERAP, V4, P515; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; SOMERVILLE K, 1986, LANCET, V1, P462; TAHA AS, 1995, GUT, V36, P334, DOI 10.1136/gut.36.3.334; Taha AS, 1996, NEW ENGL J MED, V334, P1435, DOI 10.1056/NEJM199605303342204; TAHA AS, 1992, J CLIN PATHOL, V45, P135, DOI 10.1136/jcp.45.2.135; THILLAINAYAGAM AV, 1994, DIGEST DIS SCI, V39, P1085, DOI 10.1007/BF02087562; UPADHYAY R, 1988, BRIT J RHEUMATOL, V27, P113	28	338	345	2	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 4	1997	350	9083					975	979		10.1016/S0140-6736(97)04523-6	http://dx.doi.org/10.1016/S0140-6736(97)04523-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329511				2022-12-28	WOS:A1997XZ71000007
J	Cowles, CR; Odorizzi, G; Payne, GS; Emr, SD				Cowles, CR; Odorizzi, G; Payne, GS; Emr, SD			The AP-3 adaptor complex is essential for cargo-selective transport to the yeast vacuole	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; GOLGI-COMPLEX; DIPEPTIDYL AMINOPEPTIDASE; PROTEIN COMPLEX; ALPHA-FACTOR; CLATHRIN; GENE; MEMBRANE; ENDOCYTOSIS; MUTANTS	Three distinct adaptor protein (AP) complexes involved in protein trafficking have been identified. AP-1 and AP-2 mediate protein sorting at the trans-Golgi network and plasma membrane, respectively, whereas the function of AP-3 has not been defined. A screen for factors specifically involved in transport of alkaline phosphatase (ALP) from the Golgi to the vacuole/lysosome has identified Apl6p and Apl5p of the yeast AP-3 complex. Deletion of each of the four AP-3 subunits results in selective mislocalization of ALP and the vacuolar t-SNARE, Vam3p (but not CPS and CPY), while deletion of AP-1 and AP-2 subunits has no effect on vacuolar protein delivery. This study, therefore, provides evidence that the AP-3 complex functions in cargo-selective protein transport from the Golgi to the vacuole/lysosome.	UNIV CALIF SAN DIEGO,SCH MED,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Odorizzi, Greg/0000-0002-1143-1098	NCI NIH HHS [CA58689, CA 58689] Funding Source: Medline; NIGMS NIH HHS [GM32703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; COWLES CR, 1994, J CELL SCI, V107, P3449; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Feng DF, 1996, METHOD ENZYMOL, V266, P368; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; RAD MR, 1995, J CELL SCI, V108, P1605; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROBINSON JS, 1991, MOL CELL BIOL, V12, P5813; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; SPRAGUE GF, 1981, J MOL BIOL, V153, P323, DOI 10.1016/0022-2836(81)90281-3; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEPP JD, 1995, MOL BIOL CELL, V6, P41, DOI 10.1091/mbc.6.1.41; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; Wada Y, 1997, J CELL SCI, V110, P1299; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	48	335	345	2	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					109	118		10.1016/S0092-8674(01)80013-1	http://dx.doi.org/10.1016/S0092-8674(01)80013-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335339	Bronze			2022-12-28	WOS:A1997XZ80900013
J	Guacci, V; Koshland, D; Strunnikov, A				Guacci, V; Koshland, D; Strunnikov, A			A direct link between sister chromatid cohesion and chromosome condensation revealed through the analysis of MCD1 in S-cerevisiae	CELL			English	Article							UBIQUITOUS PROTEIN FAMILY; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CELL-CYCLE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; GENE; DNA; MITOSIS; PROTEOLYSIS	The S. cerevisiae MCD1 (mitotic chromosome determinant) gene was identified in genetic screens for genes important for chromosome structure. MCD1 is essential for viability and homologs are found from yeast to humans. Analysis of the mcd1 mutant and cell cycle-dependent expression pattern of Mcd1p suggest that this protein functions in chromosome morphogenesis from S phase through mitosis. The mcd1 mutant is defective in sister chromatid cohesion and chromosome condensation. The physical association between Mcd1p and Smc1p, one of the SMC family of chromosomal proteins, further suggests that Mcd1p functions directly on chromosomes. These data implicate Mcd1p as a nexus between cohesion and condensation. We present a model for mitotic chromosome structure that incorporates this previously unsuspected link.	NICHHD,UNIT CHROMOSOME STRUCT & FUNCT,NIH,MOL EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Guacci, V (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES MED INST,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.			Strunnikov, Alexander/0000-0002-9058-2256	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041718] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999, Z01 HD001903-11] Funding Source: Medline; NIGMS NIH HHS [GM41718] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPH KW, 1977, CELL, V12, P805, DOI 10.1016/0092-8674(77)90279-3; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; GUACCI V, 1993, COLD SPRING HARB SYM, V58, P677, DOI 10.1101/SQB.1993.058.01.075; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAWRENCE JB, 1988, CELL, V52, P51; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LICA LM, 1986, J CELL BIOL, V103, P1145, DOI 10.1083/jcb.103.4.1145; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Rao P N, 1984, Symp Fundam Cancer Res, V37, P45; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Rose MD., 1990, METHODS YEAST GENETI; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; YU S, 1995, CELL STRUCT FUNCT, V20, P263, DOI 10.1247/csf.20.263	53	675	684	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					47	57		10.1016/S0092-8674(01)80008-8	http://dx.doi.org/10.1016/S0092-8674(01)80008-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335334	Bronze, Green Accepted			2022-12-28	WOS:A1997XZ80900008
J	Glinka, A; Wu, W; Onichtchouk, D; Blumenstock, C; Niehrs, C				Glinka, A; Wu, W; Onichtchouk, D; Blumenstock, C; Niehrs, C			Head induction by simultaneous repression of Bmp and Wnt signalling in Xenopus	NATURE			English	Article							HOMEOBOX GENE; SPEMANNS ORGANIZER; SIGNALING PATHWAYS; EMBRYOS; MESODERM; EXPRESSION; HOMOLOG; XWNT-8	The Spemann organizer of the amphibian embryo can be subdivided into two discrete activities, namely trunk organizer and head organizer(1). Several factors secreted from the organizer that are involved in trunk organization are thought to act by repressing Bmp signalling(2-4). With the exception of the secreted factor cerberus(5), little is known about head-organizer inducers, Here we show that co-expression of a dominant-negative Bmp receptor with inhibitors of the Wnt-signalling pathway in Xenopus leads to the induction of complete secondary axes, including a head, This induction does not require expression of the siamois marker of Nieuwkoop centre signalling, suggesting that cells are directly shifting to head-organizer fate, Furthermore, we fmd that cerberus is a potent inhibitor of Wnt signalling, Our results indicate that head-organizer activity results from the simultaneous repression of Bmp and Wnt signalling and they suggest a mechanism for region-specific induction by the organizer.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV MOL EMBRYOL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Onichtchouk, Daria/E-1741-2012	Onichtchouk, Daria/0000-0001-6497-1445				BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Gammill LS, 1997, DEVELOPMENT, V124, P471; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GERHART J, 1991, BOD MAR LAB, P57; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Itoh K, 1995, DEVELOPMENT, V121, P3979; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; PANNESE M, 1995, DEVELOPMENT, V121, P707; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4	30	300	307	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					517	519		10.1038/39092	http://dx.doi.org/10.1038/39092			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333244				2022-12-28	WOS:A1997XY90900062
J	Hilden, J				Hilden, J			Discrepant analysis - or behaviour?	LANCET			English	Editorial Material							SENSITIVITY; SPECIFICITY; BIAS				Hilden, J (corresponding author), UNIV COPENHAGEN,DEPT BIOSTAT,BLEGDAMSVEJ 3,DK-2200 COPENHAGEN N,DENMARK.							DIAMOND GA, 1986, J CHRON DIS, V39, P343, DOI 10.1016/0021-9681(86)90119-0; DIETZ K, 1985, J MATH BIOL, V22, P117; Hadgu A, 1997, STAT MED, V16, P1391, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1391::AID-SIM636>3.0.CO;2-1; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; HILDEN J, 1986, J CHRON DIS, V39, P853, DOI 10.1016/0021-9681(86)90087-1; KEIDING N, 1991, J R STAT SOC A STAT, V154, P371, DOI 10.2307/2983150; McGee DL, 1996, LANCET, V348, P1307, DOI 10.1016/S0140-6736(05)65781-9	7	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					902	902		10.1016/S0140-6736(05)63264-3	http://dx.doi.org/10.1016/S0140-6736(05)63264-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314866				2022-12-28	WOS:A1997XY67200006
J	tenWolde, PR; Frenkel, D				tenWolde, PR; Frenkel, D			Enhancement of protein crystal nucleation by critical density fluctuations	SCIENCE			English	Article							PHASE-BEHAVIOR; CRYSTALLIZATION; POLYMER; SYSTEM; TRANSITIONS; ENERGY; GROWTH; LATEX	Numerical simulations of homogeneous crystal nucleation with a model for globular proteins with short-range attractive interactions showed that the presence of a metastable fluid-fluid critical point drastically changes the pathway for the formation of a crystal nucleus. Close to this critical point, the free-energy barrier for crystal nucleation is strongly reduced and hence, the crystal nucleation rate increases by many orders of magnitude. Because the location of the metastable critical point can be controlled by changing the composition of the solvent, the present work suggests a systematic approach to promote protein crystallization.	FOM,INST ATOM & MOL PHYS,NL-1098 SJ AMSTERDAM,NETHERLANDS	AMOLF			Wolde, Pieter Rein Ten/U-4433-2019; Frenkel, Daan/G-2580-2014	Wolde, Pieter Rein Ten/0000-0001-9933-4016; Frenkel, Daan/0000-0002-6362-2021				Asherie N, 1996, PHYS REV LETT, V77, P4832, DOI 10.1103/PhysRevLett.77.4832; Bennett C.H., 1975, DIFFUSION SOLIDS, P73, DOI [10.1016/B978-0-12-522660-8.50007-6, DOI 10.1016/B978-0-12-522660-8.50007-6]; BERLAND CR, 1992, P NATL ACAD SCI USA, V89, P1214, DOI 10.1073/pnas.89.4.1214; Broide ML, 1996, PHYS REV E, V53, P6325, DOI 10.1103/PhysRevE.53.6325; Durbin SD, 1996, ANNU REV PHYS CHEM, V47, P171, DOI 10.1146/annurev.physchem.47.1.171; GAST AP, 1983, J COLLOID INTERF SCI, V96, P251, DOI 10.1016/0021-9797(83)90027-9; GAST AP, 1986, J COLLOID INTERF SCI, V109, P161, DOI 10.1016/0021-9797(86)90291-2; GEORGE A, 1994, ACTA CRYSTALLOGR D, V50, P361, DOI 10.1107/S0907444994001216; HAAS C, 1995, J CRYST GROWTH, V154, P126, DOI 10.1016/0022-0248(95)00135-2; HAGEN MHJ, 1994, J CHEM PHYS, V101, P4093, DOI 10.1063/1.467526; HANSEN JP, 1969, PHYS REV, V184, P151, DOI 10.1103/PhysRev.184.151; HILL TL, 1986, INTRO STAT THERMODYN, pCH15; ILETT SM, 1995, PHYS REV E, V51, P1344, DOI 10.1103/PhysRevE.51.1344; KELTON KF, 1991, SOLID STATE PHYS, V45, P75; KOSE A, 1976, J COLLOID INTERF SCI, V55, P487, DOI 10.1016/0021-9797(76)90059-X; LEKKERKERKER HNW, 1992, EUROPHYS LETT, V20, P559, DOI 10.1209/0295-5075/20/6/015; MALKIN AJ, 1993, J CRYST GROWTH, V133, P29, DOI 10.1016/0022-0248(93)90100-B; MALKIN AJ, 1992, J CRYST GROWTH, V128, P1232; MCPHERSON A, 1976, J BIOL CHEM, V251, P6300; McPherson A, 1982, PREPARATION ANAL PRO; Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547; Poon WCK, 1997, PHYS REV E, V55, P3762, DOI 10.1103/PhysRevE.55.3762; Poon WCK, 1995, FARADAY DISCUSS, V101, P65, DOI 10.1039/fd9950100065; RICHARDS EG, 1980, INTRO PHYSICAL PROPE; Rosenbaum D, 1996, PHYS REV LETT, V76, P150, DOI 10.1103/PhysRevLett.76.150; Rosenbaum DF, 1996, J CRYST GROWTH, V169, P752, DOI 10.1016/S0022-0248(96)00455-1; Rosenberger F, 1996, J CRYST GROWTH, V166, P40, DOI 10.1016/0022-0248(95)00921-3; SMITS C, 1990, PHASE TRANSIT, V21, P157, DOI 10.1080/01411599008206888; TENWOLDE PR, 1995, PHYS REV LETT, V75, P2714, DOI 10.1103/PhysRevLett.75.2714; tenWolde PR, 1996, J CHEM PHYS, V104, P9932, DOI 10.1063/1.471721; TORRIE GM, 1974, CHEM PHYS LETT, V28, P578, DOI 10.1016/0009-2614(74)80109-0	31	1074	1081	7	253	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1975	1978		10.1126/science.277.5334.1975	http://dx.doi.org/10.1126/science.277.5334.1975			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302288	Green Submitted			2022-12-28	WOS:A1997XX84900038
J	Falk, RH; Comenzo, RL; Skinner, M				Falk, RH; Comenzo, RL; Skinner, M			Medical progress - The systemic amyloidoses	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL MEDITERRANEAN FEVER; IMMUNOGLOBULIN LIGHT-CHAINS; BONE-MARROW TRANSPLANTATION; CARDIAC AMYLOIDOSIS; AL AMYLOIDOSIS; LIVER-TRANSPLANTATION; TRANSTHYRETIN PREALBUMIN; PRE-ALBUMIN; HEREDITARY AMYLOIDOSIS; HEART-TRANSPLANTATION		BOSTON UNIV, MED CTR,SCH MED,DEPT MED, AMYLOID TREATMENT & RES PROGRAM, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR,SCH MED,DEPT PATHOL & LAB MED, TRANSFUS MED PROGRAM, BOSTON, MA 02118 USA	Boston University; Boston University					NIAMS NIH HHS [AR 20613, AR 40414] Funding Source: Medline; FDA HHS [FD-R-001346] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040414, P60AR020613] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FDA HHS; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTLAND K, 1986, ELECTROPHORESIS, V7, P529, DOI 10.1002/elps.1150071110; [Anonymous], 1993, Bull World Health Organ, V71, P105; Aprile C, 1995, EUR J NUCL MED, V22, P1393, DOI 10.1007/BF01791147; BELLOTTI V, 1990, BRIT J HAEMATOL, V74, P65, DOI 10.1111/j.1365-2141.1990.tb02539.x; BENDITT EP, 1971, FEBS LETT, V19, P169, DOI 10.1016/0014-5793(71)80506-9; Bennhold H., 1922, MUNCHEN MED WOCHEN, V69, P1537; BENSON MD, 1993, NAT GENET, V3, P252, DOI 10.1038/ng0393-252; Bergethon PR, 1996, NEUROLOGY, V47, P944, DOI 10.1212/WNL.47.4.944; Billadeau D, 1996, BLOOD, V88, P289; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BONAR L, 1969, P SOC EXP BIOL MED, V131, P1373; CARLSON HC, 1986, SEMIN ROENTGENOL, V21, P128, DOI 10.1016/0037-198X(86)90029-5; CASEY RP, 1996, FIGHTING LIFE; COHEN AS, 1959, NATURE, V183, P1202, DOI 10.1038/1831202a0; Comenzo RL, 1996, BLOOD, V88, P2801, DOI 10.1182/blood.V88.7.2801.bloodjournal8872801; Comezno R. L., 1996, Blood, V88, p686A; COSTA PP, 1978, P NATL ACAD SCI USA, V75, P4499, DOI 10.1073/pnas.75.9.4499; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; CUETOGARCIA L, 1985, J AM COLL CARDIOL, V6, P737, DOI 10.1016/S0735-1097(85)80475-7; DANBY P, 1990, Q J MED, V76, P915; DICKSON PW, 1986, NEUROSCI LETT, V66, P311, DOI 10.1016/0304-3940(86)90037-6; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; Divry P, 1927, CR SOC BIOL, V97, P1808; Dubrey S, 1996, ANN INTERN MED, V125, P481, DOI 10.7326/0003-4819-125-6-199609150-00009; DUBREY S, 1995, BRIT HEART J, V74, P541; Dubrey S, 1995, AMYLOID, V2, P284, DOI 10.3109/13506129508999012; Dubrey SW, 1996, AM J CARDIOL, V77, P313, DOI 10.1016/S0002-9149(97)89403-9; Duston M A, 1987, Am J Med, V82, P412, DOI 10.1016/0002-9343(87)90439-6; ERICZON BG, 1996, NEUROMUS DIS S1, V6, pS65; FALK RH, 1984, AM J CARDIOL, V54, P1150, DOI 10.1016/S0002-9149(84)80170-8; FALK RH, 1987, AM J CARDIOL, V59, P418, DOI 10.1016/0002-9149(87)90948-9; FAULKES DJ, 1994, AMYLOID, V1, P255, DOI 10.3109/13506129409146117; GERTZ MA, 1991, BLOOD, V77, P257; GERTZ MA, 1985, AM J CARDIOL, V55, P1645, DOI 10.1016/0002-9149(85)90995-6; GERTZ MA, 1991, MEDICINE, V70, P246, DOI 10.1097/00005792-199107000-00002; GERTZ MA, 1983, ANN INTERN MED, V98, P475, DOI 10.7326/0003-4819-98-4-475; GIANNI L, 1995, BLOOD, V86, P855; GLENNER GG, 1971, SCIENCE, V172, P1150, DOI 10.1126/science.172.3988.1150; HALL R, 1994, BRIT MED J, V309, P1135, DOI 10.1136/bmj.309.6962.1135; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; HOLMGREN G, 1988, CLIN GENET, V33, P176; HOLMGREN G, 1991, CLIN GENET, V40, P242; HOSENPUD JD, 1991, CIRCULATION, V84, P338; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; HUSBY G, 1985, CLIN EXP RHEUMATOL, V3, P173; Jacobson D R, 1991, Adv Hum Genet, V20, P69; JACOBSON DR, 1990, AM J HUM GENET, V47, P127; Jacobson DR, 1996, HUM GENET, V98, P236, DOI 10.1007/s004390050199; Jacobson DR, 1997, NEW ENGL J MED, V336, P466, DOI 10.1056/NEJM199702133360703; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KLEIN AL, 1989, J AM COLL CARDIOL, V13, P1017, DOI 10.1016/0735-1097(89)90254-4; KLUVEBECKERMAN B, 1988, J CLIN INVEST, V82, P1670, DOI 10.1172/JCI113779; Kyle RA, 1997, NEW ENGL J MED, V336, P1202, DOI 10.1056/NEJM199704243361702; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; Kyle RA, 1996, AM J MED, V101, P395, DOI 10.1016/S0002-9343(96)00229-X; KYLE RA, 1992, BLOOD, V79, P1817; LEWIS WD, 1994, CLIN TRANSPLANT, V8, P107; LIBBEY CA, 1983, ARCH INTERN MED, V143, P1549, DOI 10.1001/archinte.143.8.1549; LIEPNIEKS JJ, 1991, AMYLOID AND AMYLOIDOSIS 1990, P153; Marinone MG, 1996, HAEMATOLOGICA, V81, P110; MAURY CPJ, 1990, FEBS LETT, V276, P75, DOI 10.1016/0014-5793(90)80510-P; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Moreau P, 1996, BLOOD, V87, P3063, DOI 10.1182/blood.V87.7.3063.bloodjournal8773063; NICHOLS WC, 1988, BIOCHEM BIOPH RES CO, V156, P762, DOI 10.1016/S0006-291X(88)80909-4; NICHOLS WC, 1991, J LAB CLIN MED, V117, P175; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; RUBINOW A, 1981, CIRCULATION, V63, P1285, DOI 10.1161/01.CIR.63.6.1285; RUBINOW A, 1978, AM J MED, V64, P937, DOI 10.1016/0002-9343(78)90447-3; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; SARAIVA MJM, 1990, SCAND J IMMUNOL, V32, P341, DOI 10.1111/j.1365-3083.1990.tb02928.x; SHIRAHAMA T, 1967, J CELL BIOL, V33, P679, DOI 10.1083/jcb.33.3.679; Shirihama T., 1984, ADV IMMUNOHISTOCHEMI, P277; SKARE J, 1990, HUM GENET, V86, P89; Skinner M, 1996, AM J MED, V100, P290, DOI 10.1016/S0002-9343(97)89487-9; SKINNER M, 1994, ANN INTERN MED, V120, P133, DOI 10.7326/0003-4819-120-2-199401150-00006; SKINNER M, 1980, INT C SERIES, V497, P361; SKINNER M, 1996, CURRENT THERAPY ALLE, P235; SMITH RRL, 1979, AM J MED, V66, P96, DOI 10.1016/0002-9343(79)90488-1; SOLOMON A, 1982, J CLIN INVEST, V70, P453, DOI 10.1172/JCI110635; STEEN L, 1994, AMYLOID, V1, P138, DOI 10.3109/13506129409148636; STEVENS FJ, 1995, BIOCHEMISTRY-US, V34, P10697, DOI 10.1021/bi00034a001; TADA S, 1993, GUT, V34, P1412, DOI 10.1136/gut.34.10.1412; TAWARA S, 1983, BIOCHEM BIOPH RES CO, V116, P880, DOI 10.1016/S0006-291X(83)80224-1; Utz JP, 1996, ANN INTERN MED, V124, P407, DOI 10.7326/0003-4819-124-4-199602150-00004; Valle, 1995, METABOLIC BASIS INHE, P4159; VANBUREN M, 1995, ANN INTERN MED, V122, P508, DOI 10.7326/0003-4819-122-7-199504010-00005; VIRCHOW R, 1954, VIRCHOWS ARCH PATHOL, V6, P135, DOI DOI 10.1007/BF01930815; WALLACE MR, 1986, J CLIN INVEST, V78, P6, DOI 10.1172/JCI112573; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; YOOD RA, 1983, JAMA-J AM MED ASSOC, V249, P1322, DOI 10.1001/jama.249.10.1322; ZEMER D, 1986, NEW ENGL J MED, V314, P1001, DOI 10.1056/NEJM198604173141601	94	860	932	0	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					898	909		10.1056/NEJM199709253371306	http://dx.doi.org/10.1056/NEJM199709253371306			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX302	9302305				2022-12-28	WOS:A1997XX30200006
J	Butland, BK; Strachan, DP; Lewis, S; Bynner, J; Butler, N; Britton, J				Butland, BK; Strachan, DP; Lewis, S; Bynner, J; Butler, N; Britton, J			Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ECZEMA; ATOPY; PREVALENCE; ASTHMA; CHILDREN; ALLERGY; DISEASE; SMOKING	Objective: To investigate whether changes in certain perinatal and social factors explain the increased prevalence of hay fever and eczema among British adolescents between 1974 and 1986. Design: Two prospective birth cohort studies. Setting: England, Wales, and Scotland. Subjects: 11 195 children born 3-9 March 1958 and 9387 born 5-11 April 1970. Main outcome measures: Parental reports of eczematous rashes and of hay fever or allergic rhinitis in the previous 12 months at age 16. Results: The prevalence of the conditions over the 12 month period increased between 1974 and 1986 from 3.1% to 6.4% (prevalence ratio 2.04 (95% confidence interval 1.79 to 2.32)) for eczema and from 12.0% to 23.3% (prevalence ratio 1.93 (1.82 to 2.06)) for hay fever. Both conditions were more commonly reported among children of higher birth order and those who were breast fed for longer than 1 month. Eczema was more commonly reported among girls and hay fever among boys. The prevalence of hay fever decreased sharply between social classes I and V, increased with maternal age up to the early 30s, and was lower in children whose mothers smoked during pregnancy. Neither condition varied significantly with birth weight When adjusted for these factors, the relative odds of hay fever (1986 v 1974) increased from 2.23 (2.05 to 2.43) to 2.40 (2.19 to 2.63). Similarly, the relative odds of eczema rose from 2.02 (1.73 to 2.36) to 2.14 (1.81 to 2.52). Conclusions: Taken together, changes between cohorts in sex, birth weight, birth order, maternal age, breast feeding, maternal smoking during pregnancy, and father's social dass at birth did not seem to explain any of the observed rise in the prevalence of hay fever and eczema. However, correlates of these factors which have changed over time may still underlie recent increases' in allergic disease.	UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,INT CTR CHILD STUDIES,LONDON EC1V 0HB,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; City University London; University of London; University College London	Butland, BK (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Britton, John R/G-9705-2011	Butland, Barbara/0000-0001-9952-3108				ASTARITA C, 1988, CLIN ALLERGY, V18, P341, DOI 10.1111/j.1365-2222.1988.tb02881.x; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; Butler NR, 1986, BIRTH 5 STUDY HLTH B; DAVIE R, 1972, BIRTH 7 FULL STAT AP; FINN R, 1992, LANCET, V340, P1453; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; Golding J, 1986, BIRTH 5 STUDY HLTH B; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; *LUNG ASTHM INF AG, 1993, 935 ST GEORG HOSP ME; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; *REG GEN ENGL WAL, 1951, CLASS OCC; *REG GEN ENGL WAL, 1966, CLASS OCC; RONCHETTI R, 1992, ARCH DIS CHILD, V67, P496, DOI 10.1136/adc.67.4.496; SAARINEN UM, 1979, LANCET, V2, P163; *SAS I, 1989, SAS STAT US GUID VER; SIBBALD B, 1990, BRIT J GEN PRACT, V40, P338; SOYSETH V, 1995, CHEST, V107, P389, DOI 10.1378/chest.107.2.389; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P791, DOI 10.1111/j.1365-2222.1995.tb00019.x; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132	25	179	183	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					717	721		10.1136/bmj.315.7110.717	http://dx.doi.org/10.1136/bmj.315.7110.717			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314757	Green Published			2022-12-28	WOS:A1997XX67400023
J	Toczyski, DP; Galgoczy, DJ; Hartwell, LH				Toczyski, DP; Galgoczy, DJ; Hartwell, LH			CDC5 and CKII control adaptation to the yeast DNA damage checkpoint	CELL			English	Article							CASEIN KINASE-II; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; BUDDING YEAST; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; RAD9 CHECKPOINT; BINDING PROTEIN	A single double-stranded DNA (dsDNA) break will cause yeast cells to arrest in G2/M at the DNA damage checkpoint. If the dsDNA break cannot be repaired, cells will eventually override (that is, adapt to) this checkpoint, even though the damage that elicited the arrest is still present. Here, we report the identification of two adaptation-defective mutants that remain permanently arrested as large-budded cells when faced with an irreparable dsDNA break in a nonessential chromosome. This adaptation-defective phenotype was entirely relieved by deletion of RAD9, a gene required for the G2/M DNA damage checkpoint arrest. We show that one mutation resides in CDC5, which encodes a polo-like kinase, whereas a second, less penetrant, adaptation-defective mutant is affected at the CKB2 locus, which encodes a nonessential specificity subunit of casein kinase II.			Toczyski, DP (corresponding author), FRED HUTCHINSON CANC RES CTR, 1100 FAIRVIEW AVE N, C3-167, SEATTLE, WA 98109 USA.				NCI NIH HHS [CAO9437] Funding Source: Medline; NIGMS NIH HHS [GM-17709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017709, R01GM017709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BIDWAI AP, 1995, J BIOL CHEM, V270, P10395, DOI 10.1074/jbc.270.18.10395; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HARTWELL LH, 1973, GENETICS, V74, P267; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; REED JC, 1994, J BIOL CHEM, V269, P18192; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	41	357	359	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1097	1106		10.1016/S0092-8674(00)80375-X	http://dx.doi.org/10.1016/S0092-8674(00)80375-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323137	Bronze			2022-12-28	WOS:A1997XX76800015
J	Kim, D; Jun, KS; Lee, SB; Kang, NG; Min, DS; Kim, YH; Ryu, SH; Suh, PG; Shin, HS				Kim, D; Jun, KS; Lee, SB; Kang, NG; Min, DS; Kim, YH; Ryu, SH; Suh, PG; Shin, HS			Phospholipase C isozymes selectively couple to specific neurotransmitter receptors	NATURE			English	Article							PHOSPHOINOSITIDE HYDROLYSIS; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; MESSENGER-RNAS; RAT-BRAIN; EPILEPSY; SEIZURES; MICE; LOCALIZATION; INTERNEURONS	A variety of extracellular signals are transduced across the cell membrane by the enzyme phosphoinositide-specific phospholipase C-beta (PLC-beta) coupled with guanine-nucleotide-binding G proteins'. There are four isoenzymes of PLC-beta, beta 1-beta 4, but their functions in vivo are not known. Here we investigate the role of PLC-beta 1 and PLC-beta 4 in the brain by generating-null mutations in mice: we found that PLC beta 1(-/-) mice developed epilepsy and PLC beta 4(-/-) mice showed ataxia. We determined the molecular basis of these phenotypes and show that PLC-beta 1 is involved in signal transduction in the cerebral cortex and hippocampus by coupling pre-dominantly to the muscarinic acetylcholine receptor, whereas PLC-beta 4 works through the metabotropic glutamate receptor in the cerebellum, illustrating how PLC-beta isoenzymes are used to generate different functions in the brain.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA; INJE UNIV,INST NEUROSCI,PUSAN 614735,SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Inje University			Kim, Daesoo/C-1625-2011; Suh, Pann-Ghill/F-3610-2010	Kim, Daesoo/0000-0001-9915-1463; Ryu, Sung Ho/0000-0003-0913-3048; Lee, Seong-Beom/0000-0002-2767-6188; KANG, NAE-GYU/0000-0002-3318-3873				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; BUZSAKI G, 1989, NEUROSCIENCE, V28, P527, DOI 10.1016/0306-4522(89)90002-X; CREWS FT, 1994, LIFE SCI, V55, P1993, DOI 10.1016/0024-3205(94)00379-3; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; FISHER SK, 1992, J NEUROCHEM, V58, P18, DOI 10.1111/j.1471-4159.1992.tb09273.x; FRANKEL WN, 1995, MAMM GENOME, V6, P839, DOI 10.1007/BF00292432; Hesdorffer DC, 1996, NEUROLOGY, V46, P727, DOI 10.1212/WNL.46.3.727; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; Kelly JF, 1996, P NATL ACAD SCI USA, V93, P6753, DOI 10.1073/pnas.93.13.6753; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; PITLER TA, 1992, J PHYSIOL-LONDON, V450, P127, DOI 10.1113/jphysiol.1992.sp019119; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHOEPP DD, 1991, EUR J PHARM-MOLEC PH, V207, P351, DOI 10.1016/0922-4106(91)90010-F; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; STAFSTROM CE, 1992, DEV BRAIN RES, V65, P227, DOI 10.1016/0165-3806(92)90184-X; TANAKA O, 1994, NEUROSCI LETT, V182, P17, DOI 10.1016/0304-3940(94)90194-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0	26	241	252	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					290	293		10.1038/38508	http://dx.doi.org/10.1038/38508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305844				2022-12-28	WOS:A1997XW77200049
J	Lusk, RC				Lusk, RC			The healing touch	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					486	486		10.7326/0003-4819-127-6-199709150-00012	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313008				2022-12-28	WOS:A1997XV77900012
J	Horton, R				Horton, R			Medical editors trial amnesty	LANCET			English	Editorial Material																		DICKERSIN K, 1993, ON LINE J CURR  0428; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390	4	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					756	756		10.1016/S0140-6736(05)62564-0	http://dx.doi.org/10.1016/S0140-6736(05)62564-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297993	Bronze			2022-12-28	WOS:A1997XW28200008
J	Jost, CA; Marin, MC; Kaelin, WG				Jost, CA; Marin, MC; Kaelin, WG			p73 is a human p53-related protein that can induce apoptosis	NATURE			English	Article							P53 GENE-MUTATIONS; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; DNA-BINDING; NEUROBLASTOMA; IDENTIFICATION; DOMAIN	The protein p53 is the most frequently mutated tumour suppressor to be identified so far in human cancers(1,2). The ability of p53 to inhibit cell growth is due, at least in part, to its ability to bind to specific DNA sequences and activate the transcription of target genes such as that encoding the cell-cycle inhibitor p21(Waf1/Cip1) (ref. 3), A gene has recently been identified that is predicted to encode a protein with significant amino-acid sequence similarity to p53 (ref, 4), In particular, each of the p53 amino-acid residues implicated in direct sequence-specific DNA binding is conserved in this protein(5). This gene, called p73, maps to the short arm of chromosome 1, and is found in a region that is frequently deleted in neuroblastomas(6). Here we show that p73 can, at least when overproduced, activate the transcription of p53-responsive genes and inhibit cell growth in a p53-like manner by inducing apoptosis (programmed cell death).	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN XB, 1993, GENE DEV, V7, P2652; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DILLER L, 1995, CANCER RES, V55, P2910; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLEMINGTON EK, 1994, MOL CELL BIOL, V14, P3041, DOI 10.1128/MCB.14.5.3041; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; KAGHAD M, IN PRESS CELL; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; VOGAN K, 1993, CANCER RES, V53, P5269	25	870	906	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					191	194		10.1038/38298	http://dx.doi.org/10.1038/38298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296498				2022-12-28	WOS:A1997XV75700051
J	Nolan, GP				Nolan, GP			Harnessing viral devices as pharmaceuticals: Fighting HIV-1's fire with fire	CELL			English	Review									STANFORD UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,STANFORD,CA 94305	Stanford University	Nolan, GP (corresponding author), STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305, USA.		Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043				Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Broder CC, 1997, J LEUKOCYTE BIOL, V62, P20, DOI 10.1002/jlb.62.1.20; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Conzelmann KK, 1996, J GEN VIROL, V77, P381, DOI 10.1099/0022-1317-77-3-381; Mebatsion T, 1997, CELL, V90, P841, DOI 10.1016/S0092-8674(00)80349-9; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; YOUNG JAT, 1990, SCIENCE, V250, P1421, DOI 10.1126/science.2175047	10	18	20	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					821	824		10.1016/S0092-8674(00)80345-1	http://dx.doi.org/10.1016/S0092-8674(00)80345-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298892	Bronze			2022-12-28	WOS:A1997XV56300001
J	Finch, CE; Tanzi, RE				Finch, CE; Tanzi, RE			Genetics of aging	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; SACCHAROMYCES-CEREVISIAE; HUMAN LONGEVITY; LIFE-SPAN; OXIDATIVE STRESS; TRANSGENIC MICE; CELL-DEATH; AGE; SENESCENCE	The role of genetics in determining life-span is complex and paradoxical, Although the heritability of life-span is relatively minor, some genetic variants significantly modify senescence of mammals and invertebrates, with both positive and negative impacts on age-related disorders and life-spans, In certain examples, the gene variants alter metabolic pathways, which could thereby mediate interactions with nutritional and other environmental factors that influence life-span, Given the relatively minor effect and variable penetrance of genetic risk factors that appear to affect survival and health at advanced ages, life-style and other environmental influences may profoundly modify outcomes of aging.	UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA; MASSACHUSETTS GEN HOSP, CTR NEUROSCI, GENET & AGING UNIT, CHARLESTOWN, MA 02129 USA	University of Southern California; Harvard University; Massachusetts General Hospital	Finch, CE (corresponding author), UNIV SO CALIF, ETHEL PERCY ANDRUS GERONTOL CTR, NEUROGERONTOL DIV, 3715 MCCLINTOCK AVE, LOS ANGELES, CA 90089 USA.		Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454				[Anonymous], COMMUNICATION; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Benson D, 1996, MUTAT RES-FUND MOL M, V356, P209, DOI 10.1016/0027-5107(96)00057-7; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; CAREY J, COMMUNICATION; Carey JR, 1997, BETWEEN ZEUS AND THE SALMON, P127; CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeBenedictis G, 1997, HUM GENET, V99, P312; DiMichele L, 1997, MAR BIOL, V128, P1, DOI 10.1007/s002270050062; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Fahrbach SE, 1996, DEV NEUROSCI-BASEL, V18, P102, DOI 10.1159/000111474; FERGUSON A, 1991, BIOL J LINN SOC, V43, P221, DOI 10.1111/j.1095-8312.1991.tb00595.x; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; Finch CE, 1990, LONGEVITY SENESCENCE; FINCH CE, IN PRESS BEHAV GENET; FRIEDMAN DB, 1988, GENETICS, V118, P75; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gatz M, 1997, J GERONTOL A-BIOL, V52, pM117, DOI 10.1093/gerona/52A.2.M117; GATZ M, 1997, ALZHEIMER RES, V2, P229; GELMAN R, 1988, GENETICS, V118, P693; Giray T, 1996, P NATL ACAD SCI USA, V93, P11718, DOI 10.1073/pnas.93.21.11718; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; HELLER DA, 1994, AM J HUM GENET, V55, P1255; Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/s004390050042; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; JAZWINSKI SM, 1990, MOL MICROBIOL, V4, P337, DOI 10.1111/j.1365-2958.1990.tb00601.x; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; Kaiser M, 1997, HEREDITY, V78, P1, DOI 10.1038/hdy.1997.1; Kale SP, 1996, DEV GENET, V18, P154, DOI 10.1002/(SICI)1520-6408(1996)18:2<154::AID-DVG8>3.0.CO;2-8; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kruman I, 1997, J NEUROSCI, V17, P5089; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1995, GENETICS, V139, P1567; LJUNGQUIST E, 1995, AGING SURVIVAL STUDI, pCH5; Ma YX, 1997, MECH AGEING DEV, V94, P191; Mangel M, 1996, EVOL ECOL, V10, P249, DOI 10.1007/BF01237683; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; McCullough KD, 1997, CANCER RES, V57, P1807; MILLER RE, COMMUNICATION; Morgan TE, 1997, FREE RADICAL BIO MED, V23, P524, DOI 10.1016/S0891-5849(97)00120-2; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Osiewacz HD, 1996, MOL GEN GENET, V252, P115, DOI 10.1007/BF02173211; Promislow DEL, 1996, GENETICS, V143, P839; PROUST J, 1982, TISSUE ANTIGENS, V19, P168, DOI 10.1111/j.1399-0039.1982.tb01436.x; Roff Derek A., 1992; Rogina B, 1997, MECH DEVELOP, V63, P89, DOI 10.1016/S0925-4773(97)00033-6; Rogina B, 1997, P NATL ACAD SCI USA, V94, P6303, DOI 10.1073/pnas.94.12.6303; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; Rose MR, 1997, BETWEEN ZEUS AND THE SALMON, P96; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SCHACHTER F, 1993, HUM GENET, V91, P519; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; Schulte PM, 1997, GENETICS, V145, P759; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shinkai T, 1997, J NEUROSCI RES, V47, P393; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SOBEL E, 1995, NEUROLOGY, V45, P903, DOI 10.1212/WNL.45.5.903; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Spaulding CC, 1997, MECH AGEING DEV, V93, P25, DOI 10.1016/S0047-6374(96)01808-8; Stearns S.C., 1992, pi; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; TAKATA H, 1987, LANCET, V2, P824; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Tater M., COMMUNICATION; Terry R. D., 1994, ALZHEIMER DIS; THOMPSON JS, 1984, J AM GERIATR SOC, V32, P274, DOI 10.1111/j.1532-5415.1984.tb02021.x; Tower J, 1996, BIOESSAYS, V18, P799, DOI 10.1002/bies.950181006; Tuljapurkar S, 1997, BETWEEN ZEUS AND THE SALMON, P65; Vaupel JW, 1997, BETWEEN ZEUS AND THE SALMON, P17; WANG E, 1995, CANCER RES, V55, P2284; WHEELER JC, 1995, P NATL ACAD SCI USA, V92, P10408, DOI 10.1073/pnas.92.22.10408; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; YU CE, 1997, AM J MED GENET, V68, P494; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	89	330	343	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	1997	278	5337					407	411		10.1126/science.278.5337.407	http://dx.doi.org/10.1126/science.278.5337.407			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334291				2022-12-28	WOS:A1997YB35500031
J	Gu, JGG; MacDermott, AB				Gu, JGG; MacDermott, AB			Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses	NATURE			English	Article							SYNAPTIC TRANSMISSION; GATED CURRENTS; CHANNELS; CALCIUM; DORSAL; RAT; NICOTINE	Painful stimuli to the skin initiate action potentials in the peripheral terminals of dorsal root ganglion (DRG) neurons. These action potentials propagate to DRG central terminals in the dorsal horn of the spinal cord, evoking release of excitatory transmitters such as glutamate onto postsynaptic dorsal horn neurons. P2X receptors, a family of ligand-gated ion channels(1,2) activated by the endogenous ligand ATP, are highly expressed by DRG neurons(3-5). Immunoreactivity to P2X receptors has been identified in the dorsal horn superficial laminae associated with nociceptive DRG central terminals(5), suggesting the presence of presynaptic P2X receptors. Here we have used a DRG-dorsal horn co-culture system to show that P2X receptors are localized at presynaptic sites on DRG neurons; that activation of these receptors results in increased frequency of spontaneous glutamate release; and that activation of P2X receptors at or near presynaptic DRG nerve terminals elicits action potentials that cause evoked glutamate release. Thus activation of P2X receptors at DRG central terminals can modify sensory signal throughput, and might even initiate sensory signals at central synapses without direct peripheral input. This putative central modulation and generation of sensory signals maybe associated with physiological and pathological pain sensation, making presynaptic P2X receptors a possible target for pain therapy.	COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	Gu, JGG (corresponding author), COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA.							Bardoni R, 1997, J NEUROSCI, V17, P5297; BEAN BP, 1990, J NEUROSCI, V10, P11; BEHHAM CD, 1987, NATURE, V328, P275; Burnstock G, 1996, CIBA F SYMP, V198, P1; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cook SP, 1997, NATURE, V387, P505, DOI 10.1038/387505a0; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LI J, 1995, J NEUROSCI, V15, P3357; Liu HT, 1997, NATURE, V386, P721, DOI 10.1038/386721a0; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCLAREN GJ, 1994, BRIT J PHARMACOL, V111, P913, DOI 10.1111/j.1476-5381.1994.tb14825.x; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; North RA, 1996, CIBA F SYMP, V198, P91; REICHLING DB, 1991, J PHYSIOL-LONDON, V441, P199, DOI 10.1113/jphysiol.1991.sp018746; ROGERS M, 1995, BIOPHYS J, V68, P501, DOI 10.1016/S0006-3495(95)80211-0; ROY ML, 1992, J NEUROSCI, V12, P2104; SEGAL MM, 1990, J NEUROPHYSIOL, V64, P1390, DOI 10.1152/jn.1990.64.5.1390; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; WHITE TD, 1985, BRAIN RES, V334, P372, DOI 10.1016/0006-8993(85)90235-5	22	413	435	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					749	753		10.1038/39639	http://dx.doi.org/10.1038/39639			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338789				2022-12-28	WOS:A1997YA95900060
J	Howell, BW; Hawkes, R; Soriano, P; Cooper, JA				Howell, BW; Hawkes, R; Soriano, P; Cooper, JA			Neuronal position in the developing brain is regulated by mouse disabled-1	NATURE			English	Article							ABL TYROSINE KINASE; TARGETED DISRUPTION; CORTICAL-NEURONS; CEREBRAL-CORTEX; REELER MICE; CELL; MUTATION; PROTEIN; PROTOONCOGENE; MIGRATION	During mammalian brain development, immature neurons migrate radially from the neuroectoderm to defined locations, giving rise to characteristic cell layers(1,2). Here we show that targeted disruption of the mouse disabled1 (mdab1) gene(3) disturbs neuronal layering in the cerebral cortex, hippocampus and cerebellum. The gene encodes a cytoplasmic protein, mDab1 p80, which is expressed and tyrosine-phosphorylated in the developing nervous system(3). It is likely to be an adaptor protein, docking to others through its phosphotyrosine residues and protein-interacting domain(4). The mdab1 mutant phenotype is very similar to that of the reeler mouse(5-7). The product of the reeler gene, Reelin, is a secreted protein that has been proposed to act as an extracellular signpost for migrating neurons(8-10). Because mDab1 is expressed in wild-type cortical neurons, and Reelin expression is normal in mdab1 mutants, mDab1 may be part of a Reelin-regulated or parallel pathway that controls the final positioning of neurons.	UNIV CALGARY, DEPT ANAT, CALGARY, AB T2N 4N1, CANADA; UNIV CALGARY, NEUROSCI RES GRP, CALGARY, AB T2N 4N1, CANADA	University of Calgary; University of Calgary	Howell, BW (corresponding author), FRED HUTCHINSON CANC RES CTR, 1100 FAIRVIEW AVE N, SEATTLE, WA 98109 USA.		Hawkes, Richard/F-7971-2011; Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Howell, Brian/0000-0002-0204-0773				Caviness V S Jr, 1982, Brain Res, V256, P293; CAVINESS VS, 1973, J COMP NEUROL, V147, P235, DOI 10.1002/cne.901470206; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFFINET AM, 1979, ANAT EMBRYOL, V157, P205, DOI 10.1007/BF00305160; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1984, DEV BRAIN RES, V16, P263, DOI 10.1016/0165-3806(84)90031-2; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HOFFARTH RM, 1995, J NEUROSCI, V15, P4838; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; LANNOO MJ, 1991, J COMP NEUROL, V310, P215, DOI 10.1002/cne.903100207; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; McConnell S K, 1992, Curr Opin Neurobiol, V2, P23, DOI 10.1016/0959-4388(92)90156-F; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; Miyata T, 1996, J COMP NEUROL, V372, P215; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; ONESHIMA H, IN PRESS NEUROSCI RE; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SMEYNE RJ, 1995, MOL CELL NEUROSCI, V6, P230, DOI 10.1006/mcne.1995.1019; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANFIELD BB, 1979, J COMP NEUROL, V185, P393, DOI 10.1002/cne.901850302; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	30	594	607	1	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					733	737		10.1038/39607	http://dx.doi.org/10.1038/39607			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338785				2022-12-28	WOS:A1997YA95900056
J	Rittinger, K; Walker, PA; Eccleston, JF; Smerdon, SJ; Gamblin, SJ				Rittinger, K; Walker, PA; Eccleston, JF; Smerdon, SJ; Gamblin, SJ			Structure at 1.65 angstrom of RhoA and its GTPase-activating protein in complex with a transition-state analogue	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING PROTEINS; HYDROLYSIS; MECHANISM; RAC	Small G proteins of the Rho family, which includes Rho, pac and Cdc42Hs, regulate phosphorylation pathways that control a range of biological functions including cytoskeleton formation and cell proliferation(1-7). They operate as molecular switches, cycling between the biologically active GTP-bound form and the inactive GDP-bound state, Their rate of hydrolysis of GTP to GDP by virtue of their intrinsic GTPase activity is slow, but can be accelerated by up to 10(5)-fold through interaction with rhoGAP, a GTPase-activating protein that stimulates Rho-family proteins(8,9). As such, rhoGAP plays a crucial role in regulating Rho-mediated signalling pathways. Here we report the crystal structure of RhoA and rhoGAP complexed with the transition-state analogue GDP.AlF4- at 1.65 Angstrom resolution. There is a rotation of 20 degrees between the Rho and rhoGAP proteins in this complex when compared with the ground-state complex Cdc42Hs.GMPPNP/rhoGAP, in which Cdc42Hs is bound to the non-hydrolysable GTP analogue GMPPNP(10). Consequently, in the transition state complex but not in the ground state, the rhoGAP domain contributes a residue, Arg85(GAP), directly into the active site of the G protein, We propose that this residue acts to stabilize the transition state of the GTPase reaction. RhoGAP also appears to function by stabilizing several regions of RhoA that are important in signalling the hydrolysis of GTP.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research			Rittinger, Katrin/D-2586-2014	Rittinger, Katrin/0000-0002-7698-4435; Smerdon, Stephen/0000-0001-5688-8465				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MCCORMICK F, 1989, NATURE, V340, P678, DOI 10.1038/340678a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WITTINGHOFER A, 1993, HDB EXPT PHARM, V108, P195; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579	30	346	355	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					758	762		10.1038/39651	http://dx.doi.org/10.1038/39651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338791				2022-12-28	WOS:A1997YA95900062
J	Sheldon, M; Rice, DS; DArcangelo, G; Yoneshima, H; Nakajima, K; Mikoshiba, K; Howell, BW; Cooper, JA; Goldowitz, D; Curran, T				Sheldon, M; Rice, DS; DArcangelo, G; Yoneshima, H; Nakajima, K; Mikoshiba, K; Howell, BW; Cooper, JA; Goldowitz, D; Curran, T			Scrambler and yotari disrupt the disabled gene and produce a reeler-like phenotype in mice	NATURE			English	Article							ABL TYROSINE KINASE; LEPTIN RECEPTOR; DROSOPHILA; MOUSE; PROTEIN; ENCODES; NEURONS; DOMAIN; ORGANIZATION; EXPRESSION	Formation of the mammalian brain requires choreographed migration of neurons to generate highly ordered laminar structures such as those in the cortices of the forebrain and the cerebellum, These processes are severely disrupted by mutations in reelin(1) which cause widespread misplacement of neurons and associated ataxia in reeler mice(2,3). Reelin is a large extracellular protein secreted by pioneer neurons that coordinates cell positioning during neurodevelopment(1,4-8). Two new autosomal recessive mouse mutations, scrambler(9) and yotari(10) have been described that exhibit a phenotype identical to reeler(9-11). Here we report that scrambler and yotari arise from mutations in mdab1 (ref, 12), a mouse gene related to the Drosophila gene disabled (dab)(13). Both scrambler and yotari mice express mutated forms of mdab1 messenger RNA and little or no mDab1 protein. mDab1 is a phosphoprotein that appears to function as an intracellular adaptor in protein kinase pathways, Expression analysis indicates that mdab1 is expressed in neuronal populations exposed to Reelin. The similar phenotypes of reeler, scrambler, yotari and mdab1 null mice(14) indicate that Reelin and mDab1 function as signalling molecules that regulate cell positioning in the developing brain.	ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA; UNIV TOKYO, INST MED SCI, DEPT MOL NEUROBIOL, MINATO KU, TOKYO 108, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOL NEUROBIOL LAB, TSUKUBA, IBARAKI 305, JAPAN; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV TENNESSEE, COLL MED, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tokyo; RIKEN; Fred Hutchinson Cancer Center; University of Tennessee System; University of Tennessee Health Science Center			Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Nakajima, Kazunori/L-3396-2013; Mikoshiba, Katsuhiko/N-7943-2015	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Nakajima, Kazunori/0000-0003-1864-9425; Goldowitz, Daniel/0000-0003-4756-4017; D'Arcangelo, Gabriella/0000-0003-1575-1010; Howell, Brian/0000-0002-0204-0773				Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1995, NATURE, V374, P675, DOI 10.1038/374675a0; GOLDOWITZ D, IN PRESS J NEUROSCI; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Miyata T, 1997, J NEUROSCI, V17, P3599; Miyata T, 1996, J COMP NEUROL, V372, P215; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YONESHINA H, IN PRESS NEUROSCI RE; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	31	528	540	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					730	733		10.1038/39601	http://dx.doi.org/10.1038/39601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338784				2022-12-28	WOS:A1997YA95900055
J	Leiden, JM				Leiden, JM			The genetics of dilated cardiomyopathy - Emerging clues to the puzzle	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MUSCLE				Leiden, JM (corresponding author), UNIV CHICAGO,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054592] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54592-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304	3	47	50	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1080	1081		10.1056/NEJM199710093371511	http://dx.doi.org/10.1056/NEJM199710093371511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321539				2022-12-28	WOS:A1997XZ84400011
J	OConnor, PG; Carroll, KM; Shi, JM; Schottenfeld, RS; Kosten, TR; Rounsaville, BJ				OConnor, PG; Carroll, KM; Shi, JM; Schottenfeld, RS; Kosten, TR; Rounsaville, BJ			Three methods of opioid detoxification in a primary care setting - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; OPIATE WITHDRAWAL; DRUG-USERS; CLONIDINE; BUPRENORPHINE; ADDICTION	Background: Opioid detoxification in a primary care setting followed by ongoing substance abuse treatment may be appropriate for selected opioid-dependent patients. Objective: To compare three pharmacologic protocols for opioid detoxification in a primary care setting. Design: Randomized, double-blind clinical trial with random assignment to treatment protocols. Setting: A free-standing primary care clinic affiliated with drug treatment programs. Patients: 162 heroin-dependent patients. Interventions: Three detoxification protocols: clonidine, combined clonidine and naltrexone, and buprenorphine. Measurements: Successful detoxification (that is, when study participants received a full opioid-blocking dose [50 mg] of naltrexone), treatment retention (8 days), and withdrawal symptoms. Results: Overall, 65% of participants (36 of 55) who received clonidine, 81% (44 of 54) who received combined clonidine and naltrexone, and 81% (43 of 53) who received buprenorphine were successfully detoxified. Retention did not differ significantly across the groups: 65% of participants (36 of 55) who received clonidine, 54% (29 of 54) who received combined clonidine and naltrexone, and 60% (32 of 53) who received buprenorphine. Participants who received buprenorphine had a significantly lower mean withdrawal symptom score than those who received clonidine or combined clonidine and naltrexone. Conclusions: Participants in the combined clonidine and naltrexone group and those in the buprenorphine group were more likely to complete detoxification, although retention at 8 days did not differ among the groups. Participants who were assigned to the buprenorphine group experienced less severe withdrawal symptoms than those assigned to the other two groups.	Yale Univ, Sch Med,Yale New Haven Hosp,Primary Care Ctr, 333 Cedar St,POB 208025, New Haven, CT 06520 USA; Yale Univ, Sch Med,Connecticut Ment Hlth Ctr, New Haven, CT 06519 USA; Yale Univ, Sch Med,Vet Affairs Connecticut Hlth Care Syst, New Haven, CT 06516 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	OConnor, PG (corresponding author), Yale Univ, Sch Med,Yale New Haven Hosp,Primary Care Ctr, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.		Carroll, Kathleen/A-7526-2009; Kosten, Thomas/AAI-5998-2021	Carroll, Kathleen/0000-0003-3263-3374	NATIONAL INSTITUTE ON DRUG ABUSE [R18DA006963, K05DA000457] Funding Source: NIH RePORTER; NIDA NIH HHS [K05 DA000457, R18DAO6963] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1995, FEDERAL REGULATION M; Ball J.C., 2012, EFFECTIVENESS METHAD; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; DOLE VP, 1995, JAMA-J AM MED ASSOC, V274, P1307; GERRA G, 1995, J SUBST ABUSE TREAT, V12, P35, DOI 10.1016/0740-5472(94)00077-8; GRAY RF, 1989, BRIT J ADDICT, V84, P1373; KOSTEN TR, 1985, AM J DRUG ALCOHOL AB, V11, P1, DOI 10.3109/00952998509016845; Kosten TR, 1996, AM J ADDICTION, V5, P58; KOSTEN TR, 1989, AM J PSYCHIAT, V146, P1349; LEGARDA JJ, 1994, DRUG ALCOHOL DEPEN, V35, P91, DOI 10.1016/0376-8716(94)90115-5; LOIMER N, 1990, BRIT J PSYCHIAT, V157, P748, DOI 10.1192/bjp.157.5.748; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; NIGAM AK, 1993, J SUBST ABUSE TREAT, V10, P391, DOI 10.1016/0740-5472(93)90024-V; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; OCONNOR PG, 1995, J GEN INTERN MED, V10, P255, DOI 10.1007/BF02599882; OCONNOR PG, 1994, NEW ENGL J MED, V331, P450, DOI 10.1056/NEJM199408183310707; OCONNOR PG, 1992, AM J MED, V93, P382, DOI 10.1016/0002-9343(92)90166-9; RIORDAN CE, 1980, LANCET, V1, P1079; VINING E, 1988, BRIT J ADDICT, V83, P567; 1989, FED REG, V54, P8954	20	133	136	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					526	530		10.7326/0003-4819-127-7-199710010-00004	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY733	9313020				2022-12-28	WOS:A1997XY73300004
J	Selker, HP; Griffith, JL; Beshansky, JR; Schmid, CH; Califf, RM; DAgostino, RB; Laks, MM; Lee, KL; Maynard, C; Selvester, RH; Wagner, GS; Weaver, WD				Selker, HP; Griffith, JL; Beshansky, JR; Schmid, CH; Califf, RM; DAgostino, RB; Laks, MM; Lee, KL; Maynard, C; Selvester, RH; Wagner, GS; Weaver, WD			Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: A thrombolytic predictive instrument	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-CARE-UNIT; TISSUE PLASMINOGEN-ACTIVATOR; ACUTE CARDIAC ISCHEMIA; QRS SCORING SYSTEM; RANDOMIZED TRIAL; CLINICAL-TRIAL; THERAPY; MULTICENTER; MORTALITY; STREPTOKINASE	Background: Thrombolytic therapy can be life-saving in patients with acute myocardial infarction. However, if given too late or insufficiently selectively, it may provide little benefit but still cause serious complications and incur substantial costs. Objective: To develop a thrombolytic predictive instrument for real-time use in emergency medical service settings that could 1) identify patients likely to benefit from thrombolysis and 2) facilitate the earliest possible use of this therapy. Design: Creation and validation of logistic regression-based predictive instruments based on secondary analysis of clinical data. Patients: 4911 patients who had acute myocardial infarction and ST-segment elevation on electrocardiogram; 3483 received thrombolytic therapy. Measurements: Data were obtained from 13 major clinical trials and registries and directly from medical records, including electrocardiograms obtained at presentation. Input variables include presenting clinical and electrocardiographic features; predictive models generate probabilities for acute (30-day) mortality if and if not treated with thrombolysis, 1-year mortality rates if and if not treated with thrombolysis, cardiac arrest if and if not treated with thrombolysis, thrombolysis-related intracranial hemorrhage, and thrombolysis-related major bleeding episode requiring transfusion. Together, these models constitute the thrombolytic predictive instrument. Results: The predictive models generated the following mean predictions for patients in the Thrombolytic Predictive Instrument Database: 30-day mortality rate, 7.1%; 1-year mortality rate, 10.9%; rate of cardiac arrest, 3.7%; rate of thrombolysis-related intracranial hemorrhage, 0.6%; and rate of other thrombolysis-related major bleeding episodes, 5.0%. They discriminated well between persons having and those not having the predicted outcome; areas under the receiver-operating characteristic (ROC) curve were between 0.77 and 0.84 for the five outcomes. Calibration between each instrument's predicted and observed rates was excellent. Validation of the predictive instruments for 30-day and 1-year mortality, done on a separate test dataset, yielded areas under the ROC curve of 0.76 for each. Conclusions: After the basic features of a clinical presentation are entered into a computerized electrocardiograph, the predictions of the thrombolytic predictive instrument can be printed on the electrocardiogram report. This decision aid may facilitate earlier and more appropriate use of thrombolytic therapy in patients with acute myocardial infarction.	BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; DUKE UNIV, MED CTR, DURHAM, NC 27705 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA; UNIV SO CALIF, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, LOS ANGELES, CA 90024 USA	Boston University; Duke University; University of Washington; University of Washington Seattle; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Selker, HP (corresponding author), TUFTS UNIV, CTR CARDIOVASC HLTH SERV RES, DIV CLIN CARE RES, SCH MED, NEW ENGLAND MED CTR, BOSTON, MA 02111 USA.		Maynard, Charles/N-3906-2015; Schmid, Christopher H./J-2398-2014	Maynard, Charles/0000-0002-1644-7814; Schmid, Christopher H./0000-0002-0855-5313	AHRQ HHS [R01 HS06208] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; ANDERSON WD, 1988, AM J CARDIOL, V61, P729, DOI 10.1016/0002-9149(88)91056-9; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CAIRNS CB, 1992, J ELECTROCARDIOL, V24, P46; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CENTOR RM, 1991, MED DECIS MAKING, V11, P102, DOI 10.1177/0272989X9101100205; CHAMBERS JM, 1992, STAT MODELS S, P249; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Gunnar R M, 1990, Circulation, V82, P664; HASTIE TJ, 1990, GEN ADDITIVE MODELS, P95; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; LAROSA JH, 1992, P NAT HEART LUNG BLO; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MAYNARD C, 1995, MED DECIS MAKING, V15, P38, DOI 10.1177/0272989X9501500107; Midgette AS, 1996, AM J CARDIOL, V78, P389, DOI 10.1016/S0002-9149(96)00325-6; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PRYOR DB, 1985, MED CARE, V23, P623, DOI 10.1097/00005650-198505000-00020; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; *SAS I INC, 1989, SAS STAT US GUID VER, P1077; SCHMID CH, 1997, IN PRESS J CLIN EPID; SELKER HP, 1988, J ELECTROCARDIOL, V21, pS11, DOI 10.1016/0022-0736(88)90047-7; SELKER HP, 1994, MED CARE, V32, P1040, DOI 10.1097/00005650-199410000-00005; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; Selker HP, 1997, ANN EMERG MED, V29, P1, DOI 10.1016/S0196-0644(97)70297-X; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; SELKER HP, 1995, J INVEST MED, V43, P468; SELKER HP, 1989, AM J MED, V87, P491; SELKER HP, 1994, CIRCULATION, V90, P1657, DOI 10.1161/01.CIR.90.4.1657; SELKER HP, 1992, THROMBOLYTIC PREDICT, P9; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; Wall T C, 1989, N C Med J, V50, P363; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211	45	69	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					538	556		10.7326/0003-4819-127-7-199710010-00006	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00006			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313022				2022-12-28	WOS:A1997XY73300006
J	Ruiz, M; Karpen, JW				Ruiz, M; Karpen, JW			Single cyclic nucleotide-gated channels locked in different ligand-bound states	NATURE			English	Article							GMP-ACTIVATED CHANNEL; ROD OUTER SEGMENT; RETINAL RODS; ION CHANNELS; TIGER SALAMANDER; CONDUCTANCE; MEMBRANE; PATCHES; PROTONS; SITES	Cyclic nucleotide-gated (CNG) channels are directly activated by the binding of several ligands(1-6). For these channels as well as for other allosteric proteins, the functional effects of each ligand-binding event have been difficult to assess because ligands continuously bind and unbind at each site. Furthermore, in retinal rod photoreceptors the low cytoplasmic concentration of cyclic GMP(7) means that channels exist primarily in partially liganded states, so it is important to determine how such channels behave. Previous studies of single channels have suggested that they occasionally open to subconducting states at low cGMP(2,3,8-10), but the significance of these states and how they arise is poorly understood. Here we combine the high resolution of single-channel recording with the use of a photoaffinity analogue of cGMP(11,12) that tethers cGMP moieties covalently to their binding sites to show single retinal CNG channels can be effectively locked in four distinct ligand-bound states. Our results indicate that channels open more than they would spontaneously when two ligands are bound (similar to 1% of the maximum current), significantly more with three ligands bound (similar to 33%), and open maximally with four ligands bound. In each ligand-bound state, channels opened to two or three different conductance states, These findings place strong constraints on the activation mechanism of CNG channels.	UNIV COLORADO,SCH MED,DEPT PHYSIOL,DEPT PHYSIOL & BIOPHYS,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BROWN RL, 1993, P NATL ACAD SCI USA, V90, P5369, DOI 10.1073/pnas.90.11.5369; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HANKE W, 1988, P NATL ACAD SCI USA, V85, P94, DOI 10.1073/pnas.85.1.94; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; ILDEFONSE M, 1991, J MEMBRANE BIOL, V123, P133, DOI 10.1007/BF01998084; Karpen JW, 1996, J GEN PHYSIOL, V107, P169, DOI 10.1085/jgp.107.2.169; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P731, DOI 10.1113/jphysiol.1988.sp016943; NIZZARI M, 1993, P ROY SOC B-BIOL SCI, V254, P69, DOI 10.1098/rspb.1993.0128; Picco C, 1996, J GEN PHYSIOL, V108, P265, DOI 10.1085/jgp.108.4.265; PICONES A, 1995, J PHYSIOL-LONDON, V485, P699, DOI 10.1113/jphysiol.1995.sp020763; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; TANAKA JC, 1993, BIOPHYS J, V65, P2517, DOI 10.1016/S0006-3495(93)81294-3; TAYLOR WR, 1995, J PHYSIOL-LONDON, V483, P567, DOI 10.1113/jphysiol.1995.sp020607; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; TORRE V, 1992, P ROY SOC B-BIOL SCI, V250, P209, DOI 10.1098/rspb.1992.0151; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZIMMERMAN AL, 1992, J PHYSIOL-LONDON, V449, P759, DOI 10.1113/jphysiol.1992.sp019112; ZIMMERMAN AL, 1995, CURR OPIN NEUROBIOL, V5, P296, DOI 10.1016/0959-4388(95)80041-7; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	27	120	120	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					389	392		10.1038/38744	http://dx.doi.org/10.1038/38744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311781				2022-12-28	WOS:A1997XX67500054
J	Gilbert, DN; Dworkin, RJ; Raber, SR; Leggett, JE				Gilbert, DN; Dworkin, RJ; Raber, SR; Leggett, JE			Outpatient parenteral antimicrobial-drug therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CENTRAL VENOUS CATHETERS; INTRAVENOUS ANTIBIOTIC-THERAPY; LUMEN SUBCLAVIAN CATHETERS; VENA-CAVA SYNDROME; STAPHYLOCOCCUS-EPIDERMIDIS; HOSPITALIZED-PATIENTS; POLYVINYL-CHLORIDE; RANDOMIZED TRIAL; INFECTION-RATE; INFUSION-PUMP		OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201	Oregon Health & Science University	Gilbert, DN (corresponding author), PROVIDENCE PORTLAND MED CTR,DEPT MED EDUC,EARLE A CHILES RES INST,5050 NE HOYT,SUITE 540,PORTLAND,OR 97213, USA.							ADAMS KS, 1993, AM J INFECT CONTROL, V21, P263, DOI 10.1016/0196-6553(93)90419-5; ANTONISKIS A, 1978, WESTERN J MED, V128, P203; ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; ASHKENAZI S, 1986, J LAB CLIN MED, V107, P136; BAUCH TD, 1992, JPEN-PARENTER ENTER, V16, P175, DOI 10.1177/0148607192016002175; BIRDWELL BG, 1994, ARCH INTERN MED, V154, P808; BLACK MD, 1993, CHEST, V103, P1887, DOI 10.1378/chest.103.6.1887; *CDCP, 1995, FED REGISTER, V60, P49978; CLARKCHRISTOFF N, 1992, JPEN-PARENTER ENTER, V16, P403, DOI 10.1177/0148607192016005403; CONLY JM, 1989, J INFECT DIS, V159, P310, DOI 10.1093/infdis/159.2.310; COOPER GL, 1985, NEW ENGL J MED, V312, P1142, DOI 10.1056/NEJM198505023121802; CTANIA PN, 1996, KING GUIDE PARENTERA; DANZIG LE, 1995, JAMA-J AM MED ASSOC, V273, P1862, DOI 10.1001/jama.273.23.1862; DECICCO M, 1989, LANCET, V2, P1258, DOI 10.1016/S0140-6736(89)91861-8; DIMAYUGA E, 1995, INFECT DIS CLIN PRAC, V4, P468, DOI 10.1097/00019048-199511000-00031; EISENBERG JM, 1986, JAMA-J AM MED ASSOC, V255, P1584, DOI 10.1001/jama.255.12.1584; ENSMINGER WD, 1993, J INFUS CHEMOTHER, V3, P200; FARBER BF, 1990, J INFECT DIS, V161, P37, DOI 10.1093/infdis/161.1.37; FARKAS JC, 1992, AM J MED, V93, P277, DOI 10.1016/0002-9343(92)90233-2; GARRISON RN, 1994, SURG CLIN N AM, V74, P557, DOI 10.1016/S0039-6109(16)46329-2; GRAHAM DR, 1991, AM J MED S3B, V91; GRAY ED, 1984, LANCET, V1, P365; GRAYSON ML, 1995, MED J AUSTRALIA, V162, P249, DOI 10.5694/j.1326-5377.1995.tb139878.x; GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258; GROEGER JS, 1993, ANN INTERN MED, V119, P1168, DOI 10.7326/0003-4819-119-12-199312150-00003; HAIRE WD, 1994, THROMB HAEMOSTASIS, V72, P543; HINDES R, 1995, INFECT DIS CLIN PRAC, V4, P211, DOI 10.1097/00019048-199505000-00016; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; HOGR AH, 1983, FEMS MICROBIOL LETT, V18, P211; JENSEN BL, 1993, INTRAVENOUS THERAPY, P303; JOHNSON GM, 1986, INFECT IMMUN, V54, P13, DOI 10.1128/IAI.54.1.13-20.1986; KRAVITZ GR, 1993, HOSP PRACT, V28, P21, DOI 10.1080/21548331.1993.11442931; LaRue G D, 1995, J Intraven Nurs, V18, P24; LAWSON M, 1982, AM J IV THER CLIN NU, V9, P29; LEINHARDT DJ, 1992, JPEN-PARENTER ENTER, V16, P168, DOI 10.1177/0148607192016002168; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; LINDBECK G, 1993, HOSP PRACT, V28, P44, DOI 10.1080/21548331.1993.11442947; LINZ DN, 1994, JPEN-PARENTER ENTER, V18, P198; Maki Dennis G., 1994, P155; MAKI DG, 1994, CRIT CARE MED, V22, P1729; MAKI DG, 1995, ANN INTERN MED, V123, P884, DOI 10.7326/0003-4819-123-11-199512010-00013; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; MAKI DG, 1991, IMPROVING CATHETER S; Mayhall C G, 1992, Curr Clin Top Infect Dis, V12, P83; MCCARTHY MC, 1987, JPEN-PARENTER ENTER, V11, P259, DOI 10.1177/0148607187011003259; MENNIM P, 1992, BRIT MED J, V305, P171, DOI 10.1136/bmj.305.6846.171; MERMEL LA, 1995, ANN INTERN MED, V123, P841, DOI 10.7326/0003-4819-123-11-199512010-00005; MILLER Z, 1993, HOSP PRACT, V28, P48, DOI 10.1080/21548331.1993.11442948; Ng PK, 1997, MAYO CLIN PROC, V72, P225, DOI 10.4065/72.3.225; OSULLIVAN TL, 1993, J INFECT DIS, V168, P773, DOI 10.1093/infdis/168.3.773; PARKER JW, 1995, J BONE JOINT SURG AM, V77A, P572, DOI 10.2106/00004623-199504000-00010; PERDUE M, 1993, INTRAVENOUS THERAPY, P419; PORETZ DM, 1993, HOSP PRACT, V28, P40, DOI 10.1080/21548331.1993.11442946; POWERS DL, 1982, J GRAPH THEOR, V6, P43, DOI 10.1002/jgt.3190060106; PRESS OW, 1984, MEDICINE, V63, P189, DOI 10.1097/00005792-198407000-00001; RAAD I, 1993, ARCH INTERN MED, V153, P1791, DOI 10.1001/archinte.153.15.1791; Raad I, 1993, J INFECT DIS, V168, P400; RANTIS PC, 1994, J VASC SURG, V20, P108, DOI 10.1016/0741-5214(94)90182-1; RAVIGLIONE MC, 1989, AM J MED, V86, P780, DOI 10.1016/0002-9343(89)90473-7; RUSSELL PB, 1987, J CLIN MICROBIOL, V25, P1083, DOI 10.1128/JCM.25.6.1083-1087.1987; RYDER MA, 1993, NURS CLIN N AM, V28, P937; SALADOW JM, 1995, INFUSION, V1, P17; Salzman M B, 1995, Adv Pediatr Infect Dis, V10, P337; SCHEIS TG, 1996, AM J HEALTH-SYST PH, V53, P868; SHETH NK, 1983, J CLIN MICROBIOL, V18, P1061, DOI 10.1128/JCM.18.5.1061-1063.1983; SIMMONS TC, 1991, JPEN-PARENTER ENTER, V15, P676, DOI 10.1177/0148607191015006676; Sing Ronald F., 1995, Journal of the American Osteopathic Association, V95, P204; STANLEY HD, 1994, J ACQ IMMUN DEF SYND, V7, P272; STILES ML, 1995, AM J HEALTH-SYST PH, V52, P70, DOI 10.1093/ajhp/52.1.70; STIVER HG, 1982, CAN MED ASSOC J, V127, P207; SUTCLIFFE AG, 1995, J ROY SOC MED, V88, pP173; SWANIKER F, 1995, AM SURGEON, V61, P877; TICE AD, 1995, EUR J CLIN MICROBIOL, V14, P655, DOI 10.1007/BF01690748; TICE AD, 1993, INFECT DIS CLIN PRAC, V2, P186, DOI 10.1097/00019048-199305000-00005; TICE AD, 1993, HOSP PRACT, V28, P6, DOI 10.1080/21548331.1993.11442928; TRISSEL L A, 1990, Cancer Bulletin (Houston), V42, P393; TRISSEL LA, 1994, HDB INJECTABLE DRUGS; VAUDAUX P, 1984, J INFECT DIS, V150, P546, DOI 10.1093/infdis/150.4.546; WAGGONER SE, 1993, GYNECOL ONCOL, V48, P394, DOI 10.1006/gyno.1993.1068; WEINSTEIN SM, 1993, PRINCIPLES PRACTICE, P143; WEVER MLG, 1995, THROMB HAEMOSTASIS, V73, P180; WILLIAMS DN, 1989, ARCH INTERN MED, V149, P1157, DOI 10.1001/archinte.149.5.1157; WILLIAMS DN, 1994, AM J MED, V97, P50, DOI 10.1016/0002-9343(94)90288-7; WOODYARD TC, 1993, CANCER, V71, P2621, DOI 10.1002/1097-0142(19930415)71:8<2621::AID-CNCR2820710829>3.0.CO;2-V; YEUNG C, 1988, INFECT CONT HOSP EP, V9, P154; 1993, HOSP PRACT S1, V28, P1; 1996, MMWR-MORBID MORTAL W, V45, P101; 1993, HOSP PRACT S2, V28, P1; 1994, AM J MED S2A, V97, P1	89	75	76	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					829	838		10.1056/NEJM199709183371207	http://dx.doi.org/10.1056/NEJM199709183371207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9297114				2022-12-28	WOS:A1997XW28300007
J	Weisbord, SD; Soule, JB; Kimmel, PL				Weisbord, SD; Soule, JB; Kimmel, PL			Poison on line - Acute renal failure caused by oil of wormwood purchased through the Internet	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RHABDOMYOLYSIS		GEORGE WASHINGTON UNIV,MED CTR,DEPT MED,DIV RENAL DIS & HYPERTENS,WASHINGTON,DC 20037; GEORGE WASHINGTON UNIV,MED CTR,DEPT PATHOL,WASHINGTON,DC 20037	George Washington University; George Washington University								ADAMS EC, 1980, ANN CLIN LAB SCI, V10, P493; Amory R, 1868, BOSTON MED SURG J, V78, P83; AMORY R, 1868, AMORON MED SURG J, V1, P68; ARNOLD WN, 1989, SCI AM, V260, P112, DOI 10.1038/scientificamerican0689-112; DIAMOND JR, 1994, AM J KIDNEY DIS, V24, P219, DOI 10.1016/S0272-6386(12)80186-7; HAMILTON RW, 1989, CLIN CHEM, V35, P1713; HARRIS F, 1960, OSCAR WILDE; JADOUL M, 1993, LANCET, V341, P392; Magnan V, 1874, LANCET, V104, P410; MATERSON BJ, 1988, HOSP PRACT, V23, P29; MCCARRON DA, 1979, AM J MED, V67, P905, DOI 10.1016/0002-9343(79)90753-8; POELS PJE, 1993, CLIN NEUROL NEUROSUR, V95, P175, DOI 10.1016/0303-8467(93)90122-W; RUBIN RB, 1989, AM J MED, V86, P551, DOI 10.1016/0002-9343(89)90383-5; SINGHAL PC, 1990, J TOXICOL-CLIN TOXIC, V28, P321, DOI 10.3109/15563659008994433; STEINMETZ G, 1996, WALL STREET J   1224, pA1; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207	16	111	115	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					825	827		10.1056/NEJM199709183371205	http://dx.doi.org/10.1056/NEJM199709183371205			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9297113	Bronze			2022-12-28	WOS:A1997XW28300005
J	Petticrew, M; Kennedy, SC				Petticrew, M; Kennedy, SC			Detecting the effects of thromboprophylaxis: the case of the rogue reviews	BRITISH MEDICAL JOURNAL			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; TOTAL HIP-REPLACEMENT; VENOUS THROMBOEMBOLISM; STANDARD HEPARIN; PERIOPERATIVE THROMBOSIS; PULMONARY-EMBOLISM; RANDOMIZED TRIALS; CLINICAL-TRIALS; PREVENTION				Petticrew, M (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Petticrew, Mark/AAY-6274-2021					ANDAZ S, 1994, PHLEBOLOGY, V9, P2, DOI 10.1177/026835559400900102; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; BORRIS LC, 1995, DRUG SAFETY, V12, P26, DOI 10.2165/00002018-199512010-00002; BORRIS LC, 1994, INT J CLIN PHARM TH, V32, P262; Campling EA, 1995, REPORT NATL CONFIDEN; CHERINGTON M, 1987, NEUROLOGY, V37, P824, DOI 10.1212/WNL.37.5.824; CLAGETT GP, 1992, CHEST S, V102, P391; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Craig P C, 1972, Trans Pa Acad Ophthalmol Otolaryngol, V25, P42; DAURES JP, 1989, REV EPIDEMIOL SANTE, V37, P363; Dirckx J H, 1979, J Dermatol Surg Oncol, V5, P191; DOYLE AC, 1928, SHERLOCK HOLMES; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; GALLUS AS, 1992, THROMB HAEMOSTASIS, V68, P238; GENT M, 1986, CHEST, V89, P396; GOLDHABER SZ, 1992, JAMA-J AM MED ASSOC, V268, P1727, DOI 10.1001/jama.268.13.1727; GREEN D, 1994, PHARMACOL REV, V46, P89; GREYER HG, 1991, SEMIN THROMB HEMOST, V17, P336; HAAS S, 1993, BLOOD COAGUL FIBRIN, V4, pS5; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; JONES DR, 1991, ANN ROY COLL SURG, V73, P219; JORGENSEN LN, 1993, BRIT J SURG, V80, P689, DOI 10.1002/bjs.1800800607; KEARON C, 1995, ARCH INTERN MED, V155, P366, DOI 10.1001/archinte.155.4.366; Koch A, 1997, BRIT J SURG, V84, P750, DOI 10.1002/bjs.1800840605; LASSEN MR, 1991, SEMIN THROMB HEMOST, V17, P284; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LOWRY JC, 1995, BRIT J ORAL MAX SURG, V33, P101, DOI 10.1016/0266-4356(95)90209-0; MALTBY JR, 1988, CAN J ANAESTH, V35, P58, DOI 10.1007/BF03010546; MOHR DN, 1993, ARCH INTERN MED, V153, P2221, DOI 10.1001/archinte.153.19.2221; Murray DW, 1996, J BONE JOINT SURG BR, V78B, P863, DOI 10.1302/0301-620X78B6.6714; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OBRIEN BJ, 1994, CAN MED ASSOC J, V150, P1083; SIMONNEAU G, 1992, ANN FR ANESTH, V11, P354, DOI 10.1016/S0750-7658(05)80376-4; SKRABANEK P, 1990, LANCET, V335, P1446, DOI 10.1016/0140-6736(90)91460-R; *THROMB RISK FACT, 1992, BRIT MED J, V305, P567; WELLS PS, 1994, ARCH INTERN MED, V154, P67, DOI 10.1001/archinte.154.1.67	38	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					665	668		10.1136/bmj.315.7109.665	http://dx.doi.org/10.1136/bmj.315.7109.665			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310572	Green Published			2022-12-28	WOS:A1997XW69400026
J	Singer, AJ; Hollander, JE; Quinn, JV				Singer, AJ; Hollander, JE; Quinn, JV			Evaluation and management of traumatic lacerations	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PEDIATRIC FACIAL LACERATIONS; HIGH-PRESSURE IRRIGATION; BUFFERED LIDOCAINE; SURGICAL WOUNDS; TISSUE ADHESIVE; CLOSURE; REPAIR; ANTIBIOTICS; ANESTHESIA; TETRACAINE		UNIV PENN, DEPT EMERGENCY MED, PHILADELPHIA, PA 19104 USA; UNIV MICHIGAN, SECT EMERGENCY MED, ANN ARBOR, MI 48109 USA	University of Pennsylvania; University of Michigan System; University of Michigan	Singer, AJ (corresponding author), SUNY STONY BROOK, UNIV MED CTR, DEPT EMERGENCY MED, STONY BROOK, NY 11794 USA.		Singer, Adam/ABG-4506-2021	Hollander, Judd/0000-0002-1318-2785; Quinn, James/0000-0002-3694-2118				AUSTIN PE, 1995, ANN EMERG MED, V25, P317, DOI 10.1016/S0196-0644(95)70286-5; BARTFIELD JM, 1990, ANN EMERG MED, V19, P1387, DOI 10.1016/S0196-0644(05)82603-4; Bartfield JM, 1996, ACAD EMERG MED, V3, P1001, DOI 10.1111/j.1553-2712.1996.tb03341.x; BENKO LB, 1996, INVESTORS BUSIN 1220; BERK WA, 1988, ANN EMERG MED, V17, P496, DOI 10.1016/S0196-0644(88)80246-4; BODIWALA GG, 1982, LANCET, V2, P91; Brogan GX, 1997, AM J EMERG MED, V15, P25, DOI 10.1016/S0735-6757(97)90042-5; BROGAN GX, 1995, ANN EMERG MED, V26, P121, DOI 10.1016/S0196-0644(95)70139-7; Caliendo J E, 1976, JACEP, V5, P278, DOI 10.1016/S0361-1124(76)80013-5; Cardany C R, 1976, JACEP, V5, P965, DOI 10.1016/S0361-1124(76)80123-2; CRUSE PJE, 1973, ARCH SURG-CHICAGO, V107, P206, DOI 10.1001/archsurg.1973.01350200078018; CUMMINGS P, 1995, AM J EMERG MED, V13, P396, DOI 10.1016/0735-6757(95)90122-1; CUMMINGS P, 1994, ANN EMERG MED, V23, P535, DOI 10.1016/S0196-0644(94)70073-7; DIRE DJ, 1990, ANN EMERG MED, V19, P704, DOI 10.1016/S0196-0644(05)82484-9; DIRE DJ, 1995, ACAD EMERG MED, V2, P4, DOI 10.1111/j.1553-2712.1995.tb03070.x; DIRE DJ, 1993, ANN EMERG MED, V22, P1419, DOI 10.1016/S0196-0644(05)81989-4; EDLICH RF, 1988, ANN EMERG MED, V17, P1284, DOI 10.1016/S0196-0644(88)80354-8; ERNST AA, 1995, AM J EMERG MED, V13, P151, DOI 10.1016/0735-6757(95)90082-9; FADDIS D, 1977, J TRAUMA, V17, P895, DOI 10.1097/00005373-197712000-00001; George T K, 1985, J R Coll Surg Edinb, V30, P54; GRIMES PE, 1993, CLIN PLAST SURG, V20, P27; HAURY B, 1978, AM J SURG, V135, P238, DOI 10.1016/0002-9610(78)90108-3; HINMAN CD, 1963, NATURE, V200, P377, DOI 10.1038/200378a0; HOLLANDER JE, 1995, ANN EMERG MED, V25, P675, DOI 10.1016/S0196-0644(95)70183-4; HOLLANDER JE, 1995, ANN EMERG MED, V26, P532; JOHNSON A, 1981, ANN EMERG MED, V10, P631, DOI 10.1016/S0196-0644(81)80086-8; Kelly Anne-Maree, 1994, Journal of Emergency Medicine, V12, P593, DOI 10.1016/0736-4679(94)90408-1; Madden J, 1971, CURR TOP SURG RES, V3, P85; Maw JL, 1997, J OTOLARYNGOL, V26, P26; Mehta PH, 1996, ANN EMERG MED, V27, P43, DOI 10.1016/S0196-0644(96)70295-0; MILEWSKI PJ, 1980, BRIT J SURG, V67, P393, DOI 10.1002/bjs.1800670604; OBERG MS, 1987, AM J DIS CHILD, V141, P27, DOI 10.1001/archpedi.1987.04460010027015; OSMOND MH, 1995, J PEDIATR-US, V126, P892, DOI 10.1016/S0022-3476(95)70203-2; PANEK P H, 1972, American Surgeon, V38, P343; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; Quinn J, 1997, SURGERY, V122, P69, DOI 10.1016/S0039-6060(97)90266-X; Quinn J, 1997, JAMA-J AM MED ASSOC, V277, P1527; Quinn James V., 1995, Journal of Emergency Medicine, V13, P581, DOI 10.1016/0736-4679(95)00057-H; QUINN JV, 1993, ANN EMERG MED, V22, P1130, DOI 10.1016/S0196-0644(05)80977-1; RATNER D, 1994, SEMIN DERMATOL, V13, P20; RITCHIE AJ, 1989, INJURY, V20, P217, DOI 10.1016/0020-1383(89)90116-2; RODEHEAVER G, 1974, AM J SURG, V128, P8, DOI 10.1016/0002-9610(74)90226-8; RODEHEAVER GT, 1975, SURG GYNECOL OBSTET, V141, P357; ROTHNIE NG, 1963, BMJ-BRIT MED J, P1027, DOI 10.1136/bmj.2.5364.1027; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; SCHAUERH.RA, 1971, AM J SURG, V122, P74, DOI 10.1016/0002-9610(71)90352-7; SEROPIAN R, 1971, AM J SURG, V121, P251, DOI 10.1016/0002-9610(71)90199-1; SHARP WV, 1982, SURGERY, V91, P61; SINGER AJ, 1994, ANN EMERG MED, V24, P36, DOI 10.1016/S0196-0644(94)70159-8; SINGER AJ, 1996, EMERGENCY MED PEARLS; SINGER AJ, 1997, ACAD EMERG MED, V4, P475; STEELE MT, 1989, ANN EMERG MED, V18, P847, DOI 10.1016/S0196-0644(89)80210-0; Stevenson T R, 1976, JACEP, V5, P17, DOI 10.1016/S0361-1124(76)80160-8; STUSSMAN BJ, 1996, DHHS PUBL; WHEELER CB, 1976, SURG GYNECOL OBSTET, V143, P775; WINTER GD, 1962, NATURE, V193, P293, DOI 10.1038/193293a0; WORRALL GJ, 1987, CAN FAM PHYSICIAN, V33, P1185; WRAY RC, 1983, PLAST RECONSTR SURG, V72, P380, DOI 10.1097/00006534-198309000-00021	58	133	143	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1142	1148		10.1056/NEJM199710163371607	http://dx.doi.org/10.1056/NEJM199710163371607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329936				2022-12-28	WOS:A1997YA91200007
J	PericakVance, MA; Bass, MP; Yamaoka, LH; Gaskell, PC; Scott, WK; Terwedow, HA; Menold, MM; Conneally, PM; Small, GW; Vance, JM; Saunders, AM; Roses, AD; Haines, JL				PericakVance, MA; Bass, MP; Yamaoka, LH; Gaskell, PC; Scott, WK; Terwedow, HA; Menold, MM; Conneally, PM; Small, GW; Vance, JM; Saunders, AM; Roses, AD; Haines, JL			Complete genomic screen in late-onset familial Alzheimer disease - Evidence for a new locus on chromosome 12	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFFECTED RELATIVE PAIRS; LINKAGE STRATEGIES; ALLELE; GENE; TRAITS; POLYMORPHISM; ASSOCIATION; DIAGNOSIS	Context.-Four genetic loci have been identified as contributing to Alzheimer disease (AD), including the amyloid precursor protein gene, the presenilin 1 gene, the presenilin 2 gene, and the apolipoprotein E gene, but do not account for all the genetic risk for AD. Objective.-To identify additional genetic risk factors for late-onset AD. Design.-A complete genomic screen was performed (N=280 markers). Critical values for chromosomal regional follow-up were a P value of .05 or less for affected relative pair analysis or sibpair analysis, a parametric lod score of 1.0 or greater, or both. Regional follow-up included analysis of additional markers and a second data set. Setting.-Clinic populations in the continental United States. Patients.-From a series of multiplex families affected with late-onset (greater than or equal to 60 years) AD ascertained during the last 14 years (National Insititute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorders Association diagnostic criteria) and for which DNA has been obtained, a subset of 16 families (135 total family members, 52 of whom were patients with AD) was used for the genomic screen. A second subset of 38 families (216 total family members, 89 of whom were patients with AD) was used for the follow-up analysis. Main Outcome Measures.-Linkage analysis results generated using both genetic model-dependent (led score) and model-independent methods. Results.-Fifteen chromosomal regions warranted initial follow-up. Follow-up analyses revealed 4 regions of continued interest on chromosomes 4, 6, 12, and 20, with the strongest results observed for chromosome 12. Peak 2-point affecteds-only rod scores (n=54) were 1.3, 1.6, 2.7, and 2.2 and affected relative pairs P values (n=54) were .04, .03, .14, and .04 for D125373, D12S1057, D1251042, and D12S390, respectively. Sibpair analysis (n=54) resulted in maximum lod scores (MLSs) of 1.5, 2.6, 3.2, and 2.3 for these markers, with a peak multipoint MLS of 3.5. A priori stratification by APOEgenotype identified 27 families that had at least 1 member with AD whose genotype did not contain an APOE*4 allele. Analysis of these 27 families resulted in MLSs of 1.0, 2.4, 3.7, and 3.3 and a peak multipoint MLS of 3.9. Conclusions.-A complete genomic screen in families affected with late-onset AD identified 4 regions of interest after follow-up. Chromosome 12 gave the strongest and most consistent results with a peak multipoint MLS of 3.5, suggesting that this region contains a new susceptibility gene for AD. Additional analyses are necessary to identify the chromosome 12 susceptibility gene for AD and to follow up the regions of interest on chromosomes 4, 6, and 20.	MASSACHUSETTS GEN HOSP,MOL NEUROGENET UNIT,CHARLESTOWN,MA; INDIANA UNIV,MED CTR,DEPT MED & MOL GENET,INDIANAPOLIS,IN; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT,LOS ANGELES,CA	Harvard University; Massachusetts General Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Los Angeles	PericakVance, MA (corresponding author), DUKE UNIV,MED CTR,MED GENET SECT,DEPT MED,BOX 3445,DURHAM,NC 27710, USA.		Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009	Haines, Jonathan/0000-0002-4351-4728; Vance, Jeffery/0000-0003-3815-8199; Scott, William/0000-0001-9336-6404	NATIONAL INSTITUTE ON AGING [U24AG021886] Funding Source: NIH RePORTER; NIA NIH HHS [U24 AG021886] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; *CAS W RES U, 1994, SAGE STAT AN GEN EP; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAUSSET J, 1986, PRESSE MED, V15, P1801; Davis S, 1996, AM J HUM GENET, V58, P867; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HERRINGTON R, 1995, NATURE, V375, P754; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOCKE PA, 1995, GENET EPIDEMIOL, V12, P83, DOI 10.1002/gepi.1370120108; MAX W, 1993, NEUROLOGY, V43, pS6; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1994, CURRENT PROTOCOLS HU; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1990, AM J HUM GENET, V46, P222; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roses A. D., 1995, American Journal of Human Genetics, V57, pA202; ROSES AD, 1997, EMERY RIMOINS PRINCI, P1807; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCOTT WK, IN PRESS NEUROGENETI; Smalley SL, 1996, AM J HUM GENET, V58, P844; STRITTMATTER WJ, 1990, P NATL ACAD SCI USA, V90, P1971; Vance JM, 1996, AM J HUM GENET, V58, P757; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74	31	302	308	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1237	1241		10.1001/jama.278.15.1237	http://dx.doi.org/10.1001/jama.278.15.1237			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333264				2022-12-28	WOS:A1997XZ70900028
J	Uysal, KT; Wiesbrock, SM; Marino, MW; Hotamisligil, GS				Uysal, KT; Wiesbrock, SM; Marino, MW; Hotamisligil, GS			Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; TYROSINE KINASE-ACTIVITY; ADIPOSE-TISSUE; EXPRESSION; RECEPTOR; PHOSPHORYLATION	Obesity is highly associated with insulin resistance and is the biggest risk factor for non-insulin-dependent diabetes mellitus(1-3). The molecular basis of this common syndrome, however, is poorly understood. It has been suggested that tumour necrosis factor (TNF)-alpha is a candidate mediator of insulin resistance in obesity as it is overexpressed in the adipose tissues of rodents and humans(4-10) and it blocks the action of insulin in cultured cells and whole animals(10-14). To investigate the role of TNF-alpha in obesity and insulin resistance, we have generated obese mice with a targeted null mutation in the gene encoding TNF-alpha and those encoding the two receptors for TNF-alpha. The absence of TNF-alpha resulted in significantly improved insulin sensitivity in both diet-induced obesity and that resulting for the ob/ob model of obesity. The TNF alpha-deficient obese mice had lower levels of circulating free fatty acids, and were protected from the obesity-related reduction in the insulin receptor signalling in muscle and fat tissues, These results indicate that TNF-alpha is an important mediator of insulin resistance in obesity through its effects on several important sites of insulin action.	HARVARD UNIV,SCH PUBL HLTH,DIV BIOL SCI,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; MEM SLOAN KETTERING CANC CTR,LUDWIG INST CANC RES,NEW YORK,NY 10021	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center			Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793				BODEN G, 1997, DIABETES, V45, P3; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; COLEMAN DL, 1982, MOUSE BIOMEDICAL RES, P125; CORNELIUS P, 1989, BIOCHEM BIOPH RES CO, V165, P429, DOI 10.1016/0006-291X(89)91088-7; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Fiedorek Fred T. Jr., 1996, P604; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hotamisligil GS, 1997, DIABETES, V46, P451, DOI 10.2337/diabetes.46.3.451; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; OLFESKY JM, 1990, DIABETES MELLITUS, P121; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; WHITE MF, 1994, J BIOL CHEM, V269, P1	26	1744	1826	1	106	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					610	614		10.1038/39335	http://dx.doi.org/10.1038/39335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335502				2022-12-28	WOS:A1997YA00800062
J	Komaroff, AL; Delbanco				Komaroff, AL; Delbanco			A 56-year-old woman with chronic fatigue syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE DYSFUNCTION SYNDROME; PRIMARY-CARE PRACTICE; BORNA-DISEASE VIRUS; CONTROLLED TRIAL; ENTEROVIRAL RNA; DOUBLE-BLIND; FOLLOW-UP; PREVALENCE; FIBROMYALGIA; DEPRESSION		HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GEN MED & PRIMARY CARE,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School					PHS HHS [U01 AL 32246] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASHBERNAL R, 1995, ACTA OTO-LARYNGOL, V115, P9, DOI 10.3109/00016489509133339; BAKHEIT AMO, 1992, BRIT MED J, V304, P1010, DOI 10.1136/bmj.304.6833.1010; BATES DW, 1995, ARCH INTERN MED, V155, P97, DOI 10.1001/archinte.155.1.97; BATES DW, 1993, ARCH INTERN MED, V153, P2759, DOI 10.1001/archinte.153.24.2759; Bode L, 1996, MOL PSYCHIATR, V1, P200; BOUHOLAIGAH I, 1995, JAMA-J AM MED ASSOC, V274, P961, DOI 10.1001/jama.274.12.961; BUCHWALD D, 1995, ANN INTERN MED, V123, P81, DOI 10.7326/0003-4819-123-2-199507150-00001; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; BUCHWALD D, 1987, ARTHRITIS RHEUM, V30, P1132, DOI 10.1002/art.1780301007; BUCHWALD D, 1994, CLIN INFECT DIS, V18, P568; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CLEARE AJ, 1995, J AFFECT DISORDERS, V35, P283; CUNNINGHAM L, 1990, J GEN VIROL, V71, P1399, DOI 10.1099/0022-1317-71-6-1399; Deale A, 1997, AM J PSYCHIAT, V154, P408; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; DELUCA J, 1995, J NEUROL NEUROSUR PS, V58, P38, DOI 10.1136/jnnp.58.1.38; DEMITRACK MA, 1992, BIOL PSYCHIAT, V32, P1065, DOI 10.1016/0006-3223(92)90187-5; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; Dobbins J.G., 1997, J CHRONIC FATIGUE SY, V3, P15, DOI DOI 10.1300/J092v03n02_03; Freeman R, 1997, AM J MED, V102, P357, DOI 10.1016/S0002-9343(97)00087-9; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; FURMAN JMR, 1991, REV INFECT DIS, V13, pS109; GERBER P D, 1989, Journal of General Internal Medicine, V4, P7, DOI 10.1007/BF02596483; GOLDENBERG DL, 1986, ARTHRITIS RHEUM, V29, P1371, DOI 10.1002/art.1780291110; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; ICHISE M, 1992, NUCL MED COMMUN, V13, P767, DOI 10.1097/00006231-199213100-00011; KATON WJ, 1991, J GEN INTERN MED, V6, P277, DOI 10.1007/BF02597420; KESSLER LG, 1985, ARCH GEN PSYCHIAT, V42, P583; KHAN AS, 1993, ANN INTERN MED, V118, P241, DOI 10.7326/0003-4819-118-4-199302150-00001; Komaroff AL, 1996, AM J MED, V100, P56, DOI 10.1016/S0002-9343(96)90012-1; Konstantinov K, 1996, J CLIN INVEST, V98, P1888, DOI 10.1172/JCI118990; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KRUESI MJP, 1989, J CLIN PSYCHIAT, V50, P53; KRUPP LB, 1993, J PSYCHOSOM RES, V37, P325, DOI 10.1016/0022-3999(93)90134-2; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LLOYD AR, 1993, AM J MED, V94, P197, DOI 10.1016/0002-9343(93)90183-P; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; Marcel B, 1996, BIOL PSYCHIAT, V40, P535, DOI 10.1016/0006-3223(95)00422-X; Marmion BP, 1996, LANCET, V347, P977, DOI 10.1016/S0140-6736(96)91469-5; MCDONALD E, 1993, J NEUROL NEUROSUR PS, V56, P812, DOI 10.1136/jnnp.56.7.812; MCGARRY F, 1994, ANN INTERN MED, V120, P972, DOI 10.7326/0003-4819-120-11-199406010-00020; MORRISON LJA, 1991, CLIN EXP IMMUNOL, V83, P441; MORRISS R, 1993, BRIT MED J, V306, P1161, DOI 10.1136/bmj.306.6886.1161; Mowbray JF., 1991, POST VIRAL FATIGUE S, P305; Nakaya T, 1996, FEBS LETT, V378, P145, DOI 10.1016/0014-5793(95)01439-X; NATELSON BH, 1993, J NEUROL SCI, V120, P213, DOI 10.1016/0022-510X(93)90276-5; PATNAIK M, 1995, J INFECT DIS, V172, P1364, DOI 10.1093/infdis/172.5.1364; Peakman M, 1997, CLIN IMMUNOL IMMUNOP, V82, P83, DOI 10.1006/clin.1996.4284; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; POWELL R, 1990, J PSYCHOSOM RES, V34, P665, DOI 10.1016/0022-3999(90)90111-G; SANDMAN CA, 1993, BIOL PSYCHIAT, V33, P618, DOI 10.1016/0006-3223(93)90100-R; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SCHMALING KB, 1994, PSYCHOSOM MED, V56, P383, DOI 10.1097/00006842-199409000-00001; Schor J., 1992, OVERWORKED AM UNEXPE; SCHWARTZ RB, 1994, AM J ROENTGENOL, V162, P943, DOI 10.2214/ajr.162.4.8141022; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SUHADOLNIK RJ, 1994, CLIN INFECT DIS, V18, pS96, DOI 10.1093/clinids/18.Supplement_1.S96; SWANINK CMA, 1994, CLIN INFECT DIS, V19, P860, DOI 10.1093/clinids/19.5.860; Vercoulen JHMM, 1996, LANCET, V347, P858, DOI 10.1016/S0140-6736(96)91345-8; WARE NC, 1992, MED ANTHROPOL Q, V6, P347, DOI 10.1525/maq.1992.6.4.02a00030; YALCIN S, 1994, MICROBIOL IMMUNOL, V38, P587, DOI 10.1111/j.1348-0421.1994.tb01827.x; Zorzenon M., 1996, J CHRONIC FATIGUE SY, V2, P3	66	12	12	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1179	1185						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY422	9326479				2022-12-28	WOS:A1997XY42200037
J	BrunVezinet, F; Boucher, C; Loveday, C; Descamps, D; Fauveau, V; Izopet, J; Jeffries, D; Kaye, S; Krzyanowski, C; Nunn, A; Schuurman, R; Seigneurin, JM; Tamalet, C; Tedder, R; Weber, J; Weverling, GJ; Aber, V; Aboulker, JP; Babiker, AG; Bragman, K; Breckenridge, AM; Carbon, C; Charreau, I; Chene, G; Collis, P; Cooper, D; Darbyshire, JH; Dormont, J; Fiddian, P; Flepp, M; Gazzard, B; Goebel, FD; Hooker, M; Lange, J; Luthy, R; Peto, TEA; Reiss, P; Seligmann, M; Stone, AB; Thomis, J; Vella, S; Walckenaer, G; Warrell, D; Weller, IVD; Wilber, R; Yeni, P; Yeo, J; Withnall, R; Babiker, A; Bloch, J; Poucher, C; Darbyshire, J; Goudsmit, J; Huraux, JM; vanderNoordaa, J; Weiss, R; Weverling, G				BrunVezinet, F; Boucher, C; Loveday, C; Descamps, D; Fauveau, V; Izopet, J; Jeffries, D; Kaye, S; Krzyanowski, C; Nunn, A; Schuurman, R; Seigneurin, JM; Tamalet, C; Tedder, R; Weber, J; Weverling, GJ; Aber, V; Aboulker, JP; Babiker, AG; Bragman, K; Breckenridge, AM; Carbon, C; Charreau, I; Chene, G; Collis, P; Cooper, D; Darbyshire, JH; Dormont, J; Fiddian, P; Flepp, M; Gazzard, B; Goebel, FD; Hooker, M; Lange, J; Luthy, R; Peto, TEA; Reiss, P; Seligmann, M; Stone, AB; Thomis, J; Vella, S; Walckenaer, G; Warrell, D; Weller, IVD; Wilber, R; Yeni, P; Yeo, J; Withnall, R; Babiker, A; Bloch, J; Poucher, C; Darbyshire, J; Goudsmit, J; Huraux, JM; vanderNoordaa, J; Weiss, R; Weverling, G			HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; VIRUS TYPE-1 RNA; COMBINATION THERAPY; CUBIC MILLIMETER; ZIDOVUDINE MONOTHERAPY; INFECTED PATIENTS; CD4 CELLS; PLASMA; ASSAY; QUANTIFICATION	Background The Delta trial showed that combination therapy (zidovudine plus didanosine and zidovudine plus zalcitabine) substantially lengthened life and reduced disease progression compared with zidovudine monotherapy. We did a nested virological study in three countries (France, the Netherlands, and the UK) to investigate changes in markers for viral load and antiretroviral-drug resistance during therapy. Methods 240 zidovudine-naive HIV-l-infected patients were randomly assigned zidovudine only (n=87), zidovudine plus didanosine (n=80), or zidovudine plus zalcitabine (n=73). Viral load in peripheral-blood mononuclear cells and plasma was measured by quantitative culture. Plasma HIV-1 RNA was measured by reverse-transcriptase PCR amplification, and serum p24 antigen by ELISA. Resistance to antiretroviral drugs was measured phenotypically by culture and genotypically by detection and quantification of drug-related point mutations in the pol gene. Analyses were done by intention to treat. Findings The reduction in viral load was greatest 4-12 weeks after the start of therapy and was most pronounced in the combination-therapy study groups (median reductions of RNA at 4 weeks 1.58, 1.28, and 0.49 log(10) copies/mL for zidovudine plus didanosine, zidovudine plus zalcitabine, and zidovudine only, respectively). RNA levels at 8 weeks were predictive of disease progression and death after allowance for baseline values. At 48 weeks, the proportion of participants with phenotypic zidovudine resistance was similar in all three groups: didanosine and zalcitabine resistance were rare; zidovudine genomic resistance correlated with phenotypic resistance (r=0.54, p<0.0001) and developed earlier in the combined-therapy groups. However, participants in the zidovudine monotherapy group had higher circulating loads of resistant virus than those in the combined-therapy groups. Interpretation Combined antiretroviral therapy was more efficient at lowering virus load than monotherapy. Although zidovudine resistance was common in monotherapy and combined-therapy groups, circulating concentrations of resistant virus were substantially lower in the combination groups, which is likely to be a result of the continued antiviral activity of didanosine or zalcitabine.	HOP BICHAT CLAUDE BERNARD, F-75877 PARIS 18, FRANCE; UNIV UTRECHT HOSP, UTRECHT, NETHERLANDS; ROYAL FREE HOSP, SCH MED, LONDON, ENGLAND; HOP ROTHSCHILD, F-75571 PARIS, FRANCE; HOP PURPAN, TOULOUSE, FRANCE; ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT, LONDON, ENGLAND; UCL, SCH MED, LONDON W1N 8AA, ENGLAND; INSERM, SC10, VILLEJUIF, FRANCE; MRC, HIV CLIN TRIALS CTR, LONDON, ENGLAND; HOP RICHALLON, GRENOBLE, FRANCE; HOP ENFANTS LA TIMONE, MARSEILLE, FRANCE; ST MARYS HOSP, LONDON, ENGLAND; UNIV AMSTERDAM, NL-1012 WX AMSTERDAM, NETHERLANDS	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Utrecht University; Utrecht University Medical Center; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; University of London; Queen Mary University London; University of London; University College London; UCL Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Medical Research Council Clinical Trials Unit; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Imperial College London; University of Amsterdam			chene, genevieve/H-8665-2014; VELLA, STEFANO/ABI-3368-2020; IZOPET, Jacques/L-5756-2014; Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/D-4912-2015	chene, genevieve/0000-0002-8368-6460; Tedder, Richard/0000-0002-9672-5721; Nunn, Andrew/0000-0002-9158-4595; VELLA, STEFANO/0000-0003-2347-5984				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BRUNVEZINET F, 1992, J VIROL METHODS, V37, P177, DOI 10.1016/0166-0934(92)90045-F; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KAYE S, 1992, J MED VIROL, V37, P241, DOI 10.1002/jmv.1890370402; Larder BA, 1996, J VIROL, V70, P5922, DOI 10.1128/JVI.70.9.5922-5929.1996; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; REY D, 1996, 5 INT WORKSH HIV DRU; ROUZIOUX C, 1992, AIDS, V6, P373, DOI 10.1097/00002030-199204000-00003; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; Schooley RT, 1996, J INFECT DIS, V173, P1354, DOI 10.1093/infdis/173.6.1354; Schuurman R, 1996, J CLIN MICROBIOL, V34, P3016, DOI 10.1128/JCM.34.12.3016-3022.1996; Stuyver L., 1997, International Antiviral News, V5, P38; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006	23	92	92	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					983	990		10.1016/S0140-6736(97)03380-1	http://dx.doi.org/10.1016/S0140-6736(97)03380-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329513	Green Submitted			2022-12-28	WOS:A1997XZ71000009
J	Wang, YZ; Small, DL; Stanimirovic, DB; Morley, P; Durkin, JP				Wang, YZ; Small, DL; Stanimirovic, DB; Morley, P; Durkin, JP			AMPA receptor-mediated regulation of a G(i)-protein in cortical neurons	NATURE			English	Article							NUCLEOTIDE-BINDING-PROTEINS; METABOTROPIC GLUTAMATE-RECEPTOR; BETA-GAMMA-SUBUNITS; PERTUSSIS TOXIN; ACID; LOCALIZATION; MECHANISMS; AGONIST; KINASES	Excitatory synaptic transmission in the central nervous system is mediated primarily by the release of glutamate from presynaptic terminals onto postsynaptic channels gated by N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors(1,2). The myriad intracellular responses arising from the activation of the NMDA and AMPA receptors have previously been attributed to the flow of Ca2+ and/or Na+ through these ion channels(1-6). Here we report that the binding of the agonist AMPA. to its receptor can generate intracellular signals that are independent of Ca2+ and Na+ in rat cortical neurons, In the absence of intracellular Ca2+ and Na+, AMPA, but not NMDA, brought about changes in a guanine-nucleotide-binding protein (G alpha(il)) that inhibited pertussis toxin-mediated ADP-ribosylation of the protein in an in vitro assay, This effect was observed in intact neurons treated with AMPA as well as in isolated membranes exposed to AMPA, and was also found in MIN6 cells, which express functional AMPA receptors but have no metabotropic glutamate receptors, AMPA also inhibited forskolin-stimulated activity of adenylate cyclase in neurons, demonstrating that G(i) proteins were activated. Moreover, both G beta gamma blockage and co-precipitation experiments demonstrated that the modulation of the G(i) protein arose from the association of G alpha(il) with the glutamate receptor-1 (GluR1) subunit, These results suggest that, as well as acting as an ion channel, the APA receptor can exhibit metabotropic activity.			Wang, YZ (corresponding author), NATL RES COUNCIL CANADA,INST BIOL SCI,CELLULAR NEUROBIOL GRP,100 SUSSEX DR,OTTAWA,ON K1A 0R6,CANADA.							Brauner-Osborne H, 1996, J MED CHEM, V39, P3188, DOI 10.1021/jm9602569; CARNEY DH, 1992, THROMBIN STRUCTURE F, P351; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Durkin JP, 1996, J NEUROCHEM, V66, P951; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GHOSH A, 1995, SCIENCE, V268, P238; GIOVANELLI A, 1991, P NATL ACAD SCI USA, V88, P10069, DOI 10.1073/pnas.88.22.10069; GONOI T, 1994, J BIOL CHEM, V269, P16989; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KASAHARA J, 1994, FEBS LETT, V355, P41, DOI 10.1016/0014-5793(94)01170-2; KATADA T, 1986, J BIOL CHEM, V261, P8182; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLIGAN G, 1988, BIOCHEM J, V255, P1; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; Sorenson EM, 1996, J PHARMACOL EXP THER, V277, P1733; Wang YZ, 1996, EXP CELL RES, V225, P382, DOI 10.1006/excr.1996.0189; WANG YZ, 1995, J BIOL CHEM, V270, P22783, DOI 10.1074/jbc.270.39.22783; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977	23	122	125	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					502	504		10.1038/39062	http://dx.doi.org/10.1038/39062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333240				2022-12-28	WOS:A1997XY90900058
J	Cummings, P; Grossman, DC; Rivara, FP; Koepsell, TD				Cummings, P; Grossman, DC; Rivara, FP; Koepsell, TD			State gun safe storage laws and child mortality due to firearms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Since 1989, several states have passed laws that make gun owners criminally liable if someone is injured because a child gains unsupervised access to a gun. These laws are controversial, and their effect on firearm-related injuries is unknown. Objective.-To determine if state laws that require safe storage of firearms are associated with a reduction in child mortality due to firearms. Design.-An ecological study of firearm mortality from 1979 through 1994. Setting.-All 50 states and the District of Columbia. Participants.-All children younger than 15 years. Main Outcome Measures.-Unintentional deaths, suicides, and homicides due to firearms. Results.-Laws that make gun owners responsible for storing firearms in a manner that makes them inaccessible to children were in effect for at least 1 year in 12 states from 1990 through 1994. Among children younger than 15 years, unintentional shooting deaths were reduced by 23% (95% confidence interval, 6%-37%) during the years covered by these laws. This estimate was based on within-state comparisons adjusted for national trends in unintentional firearm-related mortality. Gun-related homicide and suicide showed modest declines, but these were not statistically significant. Conclusions.-State safe storage laws intended to make firearms less accessible to children appear to prevent unintentional shooting deaths among children younger than 15 years.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98104; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cummings, P (corresponding author), UNIV WASHINGTON,HARBORVIEW INJURY PREVENT & RES CTR,BOX 359960,325 9TH AVE,SEATTLE,WA 98104, USA.				PHS HHS [R49/CCR002570] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P207; Day NE., 1987, STATISTICAL METHODS, VII, P131; FISHER LD, 1993, BIOSTATISTICS METHOD, P389; FURJUOH SN, 1996, INJ PREV, V2, P278; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; GAYNOR PE, 1994, INTRO TIME SERIES MO, P410; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; KLECK G, 1991, POINT BLANK GUNS VIO, P51; MAGUIRE K, 1994, SOURCEBOOK CRIMINAL, P203; MAUTE ML, 1995, RUTGERS LJ, V26, P431; MCCULLAGH P, 1989, GEN LINEAR MODELS, P39; MORGENSTERN H, 1995, ANNU REV PUBL HEALTH, V16, P61, DOI 10.1146/annurev.pu.16.050195.000425; SINGH GK, 1996, MONTHLY VITAL STAT R, P55; WHITE AM, 1993, HOUS L REV, V30, P1389; World Health Organization, 1977, INT CLASS DIS	16	123	124	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1084	1086		10.1001/jama.278.13.1084	http://dx.doi.org/10.1001/jama.278.13.1084			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX303	9315767				2022-12-28	WOS:A1997XX30300032
J	DiFiglia, M; Sapp, E; Chase, KO; Davies, SW; Bates, GP; Vonsattel, JP; Aronin, N				DiFiglia, M; Sapp, E; Chase, KO; Davies, SW; Bates, GP; Vonsattel, JP; Aronin, N			Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain	SCIENCE			English	Article							GLUTAMINE REPEATS; NEURODEGENERATIVE DISEASES; TRINUCLEOTIDE REPEAT; MUTANT HUNTINGTIN; CEREBRAL-CORTEX; EXPRESSION; EXPANSION; PATHOLOGY; VESICLES; LENGTH	The cause of neurodegeneration in Huntington's disease (HD) is unknown. Patients with HD have an expanded NH2-terminal polyglutamine region in huntingtin. An NH2-terminal fragment of mutant huntingtin was localized to neuronal intranuclear inclusions (NIIs) and dystrophic neurites (DNs) in the HD cortex and striatum, which are affected in HD, and polyglutamine length influenced the extent of huntingtin accumulation in these structures. Ubiquitin was also found in NIIs and DNs, which suggests that abnormal huntingtin is targeted for proteolysis but is resistant to removal. The aggregation of mutant huntingtin may be part of the pathogenic mechanism in HD.	UNIV LONDON UNIV COLL, DEPT ANAT & DEV BIOL, LONDON WC1E 6BT, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, LONDON SE1 7EH, ENGLAND; UNIV MASSACHUSETTS, MED CTR, DEPT MED & CELL BIOL, WORCESTER, MA 01655 USA	University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Massachusetts System; University of Massachusetts Worcester	DiFiglia, M (corresponding author), MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA.		Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031579, P01NS016367, P50NS016367] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16367, NS 31579] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], ADV NEUROL; ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; ARONIN N, 1991, NEUROSCIENCE, V44, P409, DOI 10.1016/0306-4522(91)90065-V; Bhide PG, 1996, J NEUROSCI, V16, P5523; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; BYERS RK, 1973, NEUROLOGY, V23, P561, DOI 10.1212/WNL.23.6.561; CAMMARATA S, 1993, NEUROSCI LETT, V156, P96, DOI 10.1016/0304-3940(93)90448-T; CUDKOWICZ M, 1990, ANN NEUROL, V27, P200, DOI 10.1002/ana.410270217; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DELAMONTE SM, 1988, J NEUROPATH EXP NEUR, V47, P516, DOI 10.1097/00005072-198809000-00003; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE, P1; FUNATA N, 1990, CLIN NEUROPATHOL, V9, P89; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; HALTIA M, 1984, ANN NEUROL, V15, P316, DOI 10.1002/ana.410150403; HEDREEN JC, 1991, NEUROSCI LETT, V133, P257, DOI 10.1016/0304-3940(91)90583-F; JACKSON M, 1995, NEUROPATH APPL NEURO, V21, P18, DOI 10.1111/j.1365-2990.1995.tb01024.x; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; Sapp E, 1997, ANN NEUROL, V42, P604, DOI 10.1002/ana.410420411; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003	37	2185	2249	2	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					1990	1993		10.1126/science.277.5334.1990	http://dx.doi.org/10.1126/science.277.5334.1990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302293				2022-12-28	WOS:A1997XX84900043
J	Whitaker, RC; Wright, JA; Pepe, MS; Seidel, KD; Dietz, WH				Whitaker, RC; Wright, JA; Pepe, MS; Seidel, KD; Dietz, WH			Predicting obesity in young adulthood from childhood and parental obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	37th Annual Meeting of the Ambulatory-Pediatric-Association	MAY 02-06, 1997	WASHINGTON, D.C.	Ambulatory Pediat Assoc			BODY-MASS INDEX; NUTRITION EXAMINATION SURVEYS; FOLLOW-UP; NATIONAL-HEALTH; BLOOD-PRESSURE; CHILDREN; ADOLESCENTS; OVERWEIGHT; FATNESS; WEIGHT	Background Childhood obesity increases the risk of obesity in adulthood, but how parental obesity affects the chances of a child's becoming an obese adult is unknown. We investigated the risk of obesity in young adulthood associated with both obesity in childhood and obesity in one or both parents. Methods Height and weight measurements were abstracted from the records of 854 subjects born at a health maintenance organization in Washington State between 1965 and 1971. Their parents' medical records were also reviewed. Childhood obesity was defined as a body-mass index at or above the 85th percentile for age and sex, and obesity in adulthood as a mean body-mass index at or above 27.8 for men and 27.3 for women. Results In young adulthood (defined as 21 to 29 years of age), 135 subjects (16 percent) were obese. Among those who were obese during childhood, the chance of obesity in adulthood ranged from 8 percent for 1- or 2-year-olds without obese parents to 79 percent for 10-to-14-year-olds with at least one obese parent. After adjustment for parental obesity, the odds ratios for obesity in adulthood associated with childhood obesity ranged from 1.3 (95 percent confidence interval, 0.6 to 3.0) for obesity at 1 or 2 years of age to 17.5 (7.7 to 39.5) for obesity at 15 to 17 years of age. After adjustment for the child's obesity status, the odds ratios for obesity in adulthood associated with having one obese parent ranged from 2.2 (95 percent confidence interval, 1.1 to 4.3) at 15 to 17 years of age to 3.2 (1.8 to 5.7) at 1 or 2 years of age. Conclusions Obese children under three years of age without obese parents are at low risk for obesity in adulthood, but among older children, obesity is an increasingly important predictor of adult obesity, regardless of whether the parents are obese. Parental obesity more than doubles the risk of adult obesity among both obese and nonobese children under 10 years of age. (C) 1997, Massachusetts Medical Society.	UNIV CINCINNATI, COLL MED, CINCINNATI, OH USA; UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DIV PUBL HLTH SCI, BIOSTAT PROGRAM, SEATTLE, WA 98104 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	University System of Ohio; University of Cincinnati; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Tufts Medical Center	Whitaker, RC (corresponding author), CHILDRENS HOSP, MED CTR,DIV GEN & COMMUNITY PEDIAT,DEPT PEDIAT, CH-1 S, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793	NIDDK NIH HHS [P30DK46200] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; ABRAHAM S, 1960, PUBLIC HEALTH REP, V75, P263, DOI 10.2307/4590775; [Anonymous], 1985, Ann Intern Med, V103, P147; CLARKE WR, 1993, CRIT REV FOOD SCI, V33, P423, DOI 10.1080/10408399309527641; EPSTEIN LH, 1990, JAMA-J AM MED ASSOC, V264, P2519, DOI 10.1001/jama.264.19.2519; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; Folsom AR, 1996, AM J EPIDEMIOL, V144, P235, DOI 10.1093/oxfordjournals.aje.a008918; Frisancho AR, 1990, ANTHROPOMETRIC STAND; GARN SM, 1985, AM J DIS CHILD, V139, P181, DOI 10.1001/archpedi.1985.02140040083033; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; GUTIN B, 1990, JAMA-J AM MED ASSOC, V264, P1123, DOI 10.1001/jama.264.9.1123; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; KRAEMER H C, 1990, Annals of Behavioral Medicine, V12, P112, DOI 10.1207/s15324796abm1203_3; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LASKARZEWSKI P, 1980, AM J EPIDEMIOL, V111, P395, DOI 10.1093/oxfordjournals.aje.a112914; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Liu K, 1996, CIRCULATION, V93, P60, DOI 10.1161/01.CIR.93.1.60; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MOLL PP, 1991, AM J HUM GENET, V49, P1243; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Perusse L, 1997, OBES RES, V5, P49, DOI 10.1002/j.1550-8528.1997.tb00283.x; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; ROBINSON TN, 1993, CRIT REV FOOD SCI, V33, P313, DOI 10.1080/10408399309527626; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831, DOI 10.1093/ajcn/34.12.2831; ROLLANDCACHERA MF, 1987, ANN HUM BIOL, V14, P219, DOI 10.1080/03014468700008991; ROLLANDCACHERA MF, 1982, AM J CLIN NUTR, V36, P178, DOI 10.1093/ajcn/36.1.178; RONNEMAA T, 1991, ANN MED, V23, P67, DOI 10.3109/07853899109147933; SCHAPPERT SM, 1996, DHHS PUBLICATION; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005	32	2870	2939	2	236	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					869	873		10.1056/NEJM199709253371301	http://dx.doi.org/10.1056/NEJM199709253371301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XX302	9302300	Bronze			2022-12-28	WOS:A1997XX30200001
J	Wendt, KU; Poralla, K; Schulz, GE				Wendt, KU; Poralla, K; Schulz, GE			Structure and function of a squalene cyclase	SCIENCE			English	Article							ENCODING LANOSTEROL SYNTHASE; RAT OXIDOSQUALENE CYCLASE; HOPENE CYCLASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; BACILLUS-ACIDOCALDARIUS; 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE; PARTIAL-PURIFICATION; CANDIDA-ALBICANS	The crystal structure of squalene-hopene cyclase from Alicyclobacillus acidocaldarius was determined at 2.9 angstrom resolution. The mechanism and sequence of this cyclase are closely related to those of 2,3-oxidosqualene cyclases that catalyze the cyclization step in cholesterol biosynthesis. The structure reveals a membrane protein with membrane-binding characteristics similar to those of prostaglandin-H-2 synthase, the only other reported protein of this type. The active site of the enzyme is located in a large central cavity that is of suitable size to bind squalene in its required conformation and that is lined by aromatic residues. The structure supports a mechanism in which the acid starting the reaction by protonating a carbon-carbon double bond is an aspartate that is coupled to a histidine. Numerous surface alpha helices are connected by characteristic QW-motifs (Q is glutamine and W is tryptophan) that tighten the protein structure, possibly for absorbing the reaction energy without structural damage.	UNIV FREIBURG, INST ORGAN CHEM & BIOCHEM, D-79104 FREIBURG, GERMANY; INST BIOL, D-72076 TUBINGEN, GERMANY	University of Freiburg								ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; ABE I, 1994, J BIOL CHEM, V269, P802; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER CH, 1995, BIOCHEM BIOPH RES CO, V213, P154, DOI 10.1006/bbrc.1995.2110; BALLIANO G, 1992, ARCH BIOCHEM BIOPHYS, V293, P122, DOI 10.1016/0003-9861(92)90374-6; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOAR RB, 1984, J AM CHEM SOC, V106, P2476, DOI 10.1021/ja00320a064; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUNTEL CJ, 1992, J AM CHEM SOC, V114, P9711, DOI 10.1021/ja00050a090; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COREY EJ, 1993, P NATL ACAD SCI USA, V90, P11628, DOI 10.1073/pnas.90.24.11628; Corey EJ, 1996, BIOCHEM BIOPH RES CO, V219, P327, DOI 10.1006/bbrc.1996.0232; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; CORNFORT.JW, 1965, J AM CHEM SOC, V87, P3224, DOI 10.1021/ja01092a038; ESCHENMOSER A, 1955, HELV CHIM ACTA, V38, P1890, DOI 10.1002/hlca.19550380728; Feil C, 1996, EUR J BIOCHEM, V242, P51, DOI 10.1111/j.1432-1033.1996.0051r.x; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; JOHNSON WS, 1987, J AM CHEM SOC, V109, P5852, DOI 10.1021/ja00253a048; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kaneko T, 1996, DNA Res, V3, P109; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NEUMANN S, 1986, BIOL CHEM H-S, V367, P723, DOI 10.1515/bchm3.1986.367.2.723; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OCHS D, 1990, EUR J BIOCHEM, V194, P75, DOI 10.1111/j.1432-1033.1990.tb19429.x; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; OURISSON G, 1992, ACCOUNTS CHEM RES, V25, P403, DOI 10.1021/ar00021a004; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; REIPEN IG, 1995, MICROBIOL-SGM, V141, P155, DOI 10.1099/00221287-141-1-155; ROESSNER CA, 1993, GENE, V127, P149, DOI 10.1016/0378-1119(93)90631-C; SECKLER B, 1986, BIOCHIM BIOPHYS ACTA, V881, P356, DOI 10.1016/0304-4165(86)90027-9; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; SIMON SA, 1977, BIOPHYS J, V19, P83, DOI 10.1016/S0006-3495(77)85570-7; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; VANTAMELEN EE, 1982, J AM CHEM SOC, V104, P6480, DOI 10.1021/ja00387a070; Wendt KU, 1997, PROTEIN SCI, V6, P722; WOODWARD RB, 1953, J AM CHEM SOC, V75, P2023, DOI 10.1021/ja01104a535; ZHENG YF, 1995, J AM CHEM SOC, V117, P670, DOI 10.1021/ja00107a011	46	363	377	5	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1811	1815		10.1126/science.277.5333.1811	http://dx.doi.org/10.1126/science.277.5333.1811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295270				2022-12-28	WOS:A1997XX29800044
J	Jack, D				Jack, D			Hot shots inside the body	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					790	790		10.1016/S0140-6736(05)62583-4	http://dx.doi.org/10.1016/S0140-6736(05)62583-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9298011				2022-12-28	WOS:A1997XW28200035
J	ScottSamuel, A				ScottSamuel, A			Health inequalities recognised in UK	LANCET			English	Editorial Material											ScottSamuel, A (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,EQUITY HLTH RES & DEV UNIT,LIVERPOOL L69 3GB,MERSEYSIDE,ENGLAND.							BOTTING B, 1995, OFFICE POPULARION DS, V11; CHARLTON J, 1997, OFFICE NATL STAT DS, V12; DREVER F, 1997, OFFICE NATL STA DS S, V15; DREVER F, 1995, HLTH SAFETY EXECU DS, V10; GREGORY G, 1842, LANCET, V2, P1; 1997, LANCET, V349, P1185	6	6	6	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					753	753		10.1016/S0140-6736(05)62561-5	http://dx.doi.org/10.1016/S0140-6736(05)62561-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297990				2022-12-28	WOS:A1997XW28200005
J	Morris, AD; Boyle, DIR; MacAlpine, R; EmslieSmith, A; Jung, RT; Newton, RW; MacDonald, TM				Morris, AD; Boyle, DIR; MacAlpine, R; EmslieSmith, A; Jung, RT; Newton, RW; MacDonald, TM			The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; CARE	Objectives: To identify all patients with diabetes in a community using electronic record linkage of multiple data sources and to compare this method of case ascertainment with registers of diabetic patients derived from primary care. Design: Electronic capture-recapture linkage of records included data on all patients attending hospital diabetes clinics, all encashed prescriptions for diabetes related drugs and monitoring equipment, all patients discharged from hospital, patients attending a mobile unit for eye screening, and results for glycated haemoglobin and plasma glucose concentrations from the regional biochemistry database, Diabetes registers from primary care were from a random sample of eight Tayside general practices. A detailed manual study of relevant records for the 35 144 patients registered with these eight general practices allowed for validation of the case ascertainment. Setting: Tayside region of Scotland, population 391 274 on 1 January 1996. Main outcome measures: Prevalence of diabetes; population of patients identified by different data sources; sensitivity and positive predictive value of ascertainment methods. Results: Electronic record linkage identified 7596 diabetic patients, giving a prevalence of known diabetes of 1.94% (0.21% insulin dependent diabetes, 1.73% non-insulin dependent): 63% of patients had attended hospital diabetes clinics, 68% had encashed diabetes related prescriptions, 72% had attended the mobile eye screening unit, and 48% had biochemical results diagnostic of diabetes. A further 701 patients had isolated hyperglycaemia (plasma glucose > 11.1 mmol/l) but were not considered diabetic by general practitioners. Validation against the eight general practices (636 diabetic patients) showed electronic linkage to have a sensitivity of 0.96 and a positive predictive value of 0.95 for ascertainment of known diabetes. General practice lists had a sensitivity of 0.91 and a positive predictive value of 0.98. Conclusions: Electronic record linkage was more sensitive than general practice registers in identifying diabetic subjects and identified an additional 0.18% of the population with a history of hyperglycaemia who might warrant screening for undiagnosed diabetes.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, MONITORING UNIT, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CTR DIABET, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee	Morris, AD (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, DUNDEE DD1 9SY, SCOTLAND.		Morris, Andrew D/C-2837-2009; Boyle, Douglas/B-9193-2017	Boyle, Douglas/0000-0002-4779-7083; MacDonald, Thomas/0000-0001-5189-6669	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1990, Diabet Med, V7, P360; BEARDON PHG, 1988, PHARM MED, V3, P185; BRANGER PJ, 1992, BRIT MED J, V305, P1068, DOI 10.1136/bmj.305.6861.1068; *BRIT DIAB ASS, 1995, REP JOINT DEP HLTH B; BURNETT SD, 1992, BRIT MED J, V305, P627, DOI 10.1136/bmj.305.6854.627; Buxton C, 1996, DIABETIC MED, V13, pS122; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CONNOLLY V, 1995, DIABETIC MED, V12, pS31; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; HARRIS MI, 1989, CURRENT TRENDS NONIN; HOWITT AJ, 1993, BRIT MED J, V307, P1046, DOI 10.1136/bmj.307.6911.1046; Hurlbut S., 1996, CHEETAH SURVIVAL NAM, P1; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; KEEN H, 1988, COMP TYPE 1 TYPE 2 D, P31; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; MACKINNON M, 1995, DIABETIC MED S, V12, pS10; ROBLES SC, 1988, J CLIN EPIDEMIOL, V41, P495, DOI 10.1016/0895-4356(88)90052-2; *SIGN ADM SUPP GRO, 1996, SIGN PUBL, V4; Sutherland HW, 1989, CARBOHYD METABOL, P209; TONKS A, 1993, BRIT MED J, V307, P1227, DOI 10.1136/bmj.307.6914.1227; Vaughan NJA, 1996, DIABETIC MED, V13, P175, DOI 10.1002/(SICI)1096-9136(199602)13:2<175::AID-DIA18>3.0.CO;2-W; WHITFORD DL, 1995, DIABETIC MED, V12, P691, DOI 10.1111/j.1464-5491.1995.tb00571.x; *WHO, 1987, WHO TECH REP SER, V727, P1; Williams D R, 1985, Diabet Med, V2, P27; WILLIAMS DRR, 1995, DIABETIC MED, V12, P30, DOI 10.1111/j.1464-5491.1995.tb02058.x; Woodward B, 1996, BRIT MED J, V312, P653; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1	28	235	239	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	1997	315	7107					524	528		10.1136/bmj.315.7107.524	http://dx.doi.org/10.1136/bmj.315.7107.524			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329309	Green Published			2022-12-28	WOS:A1997XU50600022
J	Hurt, RD; Sachs, DPL; Glover, ED; Offord, KP; Johnston, JA; Dale, LC; Khayrallah, MA; Schroeder, DR; Glover, PN; Sullivan, CR; Croghan, IT; Sullivan, PM				Hurt, RD; Sachs, DPL; Glover, ED; Offord, KP; Johnston, JA; Dale, LC; Khayrallah, MA; Schroeder, DR; Glover, PN; Sullivan, CR; Croghan, IT; Sullivan, PM			A comparison of sustained-release bupropion and placebo for smoking cessation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NICOTINE DEPENDENCE; WEIGHT-GAIN; SMOKERS; DEPRESSION; SYMPTOMS; PATCH; DRUGS; GUM	Background and Methods Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or ''target quit date'') was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less. Results At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P=0.02) and the 300-mg group (P=0.01) but not the 100-mg group (P=0.09) - were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P=0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups. Conclusions A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year. (C) 1997, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV COMMUNITY INTERNAL MED, ROCHESTER, MN 55905 USA; PALO ALTO CTR PULM DIS PREVENT, PALO ALTO, CA USA; W VIRGINIA UNIV, ROBERT C BYRD HLTH SCI CTR, MORGANTOWN, WV 26506 USA; GLAXO WELLCOME INC, RES TRIANGLE PK, NC 27709 USA	Mayo Clinic; Mayo Clinic; West Virginia University; GlaxoSmithKline	Hurt, RD (corresponding author), MAYO CLIN & MAYO FDN, NICOTINE RES CTR, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							[Anonymous], 1991, JAMA, V266, P3133; ASCHER JA, 1995, J CLIN PSYCHIAT, V56, P395; Beck A.T, 1978, BECK DEPRESSION INVE; CLARKE PBS, 1993, BIOCHEM SOC SYMP, P83; COVEY LS, 1990, COMPR PSYCHIAT, V31, P350, DOI 10.1016/0010-440X(90)90042-Q; DAVIDSON J, 1989, J CLIN PSYCHIAT, V50, P256; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; EDWARDS NB, 1989, AM J PSYCHIAT, V146, P373; FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; Ferris R.M., 1993, J CLIN PSYCHIAT MONO, V11, P2; FERRY LH, 1994, J ADDICT DIS, V13, P249; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; First M.B., 1990, USERS GUIDE STRUCTUR; GILMAN AG, 1988, GOODMAN GILMANS PHAR; GLASS RM, 1990, JAMA-J AM MED ASSOC, V264, P1583; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; Glynn TJ, 1990, NIH PUBLICATION, P1990; HALL SM, 1994, J CONSULT CLIN PSYCH, V62, P141, DOI 10.1037/0022-006X.62.1.141; Hall SM, 1991, NIDA RES MONOGR, V705, P312; HUGHES J R, 1988, P261; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; JOHNSTON A, 1991, J CLIN PSYCHIAT, V52, P450; KLESGES RC, 1988, HEALTH PSYCHOL, V7, P387, DOI 10.1037/0278-6133.7.5.387; Leischow S J, 1992, Arch Fam Med, V1, P233, DOI 10.1001/archfami.1.2.233; NIDES M, 1994, HEALTH PSYCHOL, V13, P354, DOI 10.1037/0278-6133.13.4.354; Perkins Kenneth A., 1994, Annals of Behavioral Medicine, V16, P46; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SELLERS EM, 1987, J CLIN PSYCHOPHARM, V7, P417; SHIFFMAN S, 1982, J CONSULT CLIN PSYCH, V50, P71, DOI 10.1037/0022-006X.50.1.71; SUTHERLAND G, 1992, LANCET, V340, P324, DOI 10.1016/0140-6736(92)91403-U; SWENSON WM, 1975, MAYO CLIN PROC, V50, P204; TONNESEN P, 1988, NEW ENGL J MED, V318, P15, DOI 10.1056/NEJM198801073180104; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; WISE RA, 1983, NEUROBIOLOGY OPIATE, P405	36	933	969	0	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1195	1202		10.1056/NEJM199710233371703	http://dx.doi.org/10.1056/NEJM199710233371703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9337378				2022-12-28	WOS:A1997YB71800003
J	Riethmacher, D; SonnenbergRiethmacher, E; Brinkmann, V; Yamaai, T; Lewin, GR; Birchmeier, C				Riethmacher, D; SonnenbergRiethmacher, E; Brinkmann, V; Yamaai, T; Lewin, GR; Birchmeier, C			Severe neuropathies in mice with targeted mutations in the ErbB3 receptor	NATURE			English	Article							NERVOUS-SYSTEM; GROWTH-FACTOR; SCHWANN-CELL; NEUREGULIN; DIFFERENTIATION; HEREGULIN; GENE; NEUROTROPHIN-3; REQUIREMENT; MYELINATION	Neuregulins and their specific receptors, members of the ErbB family of tyrosine kinases, have been implicated in the control of growth and development of Schwann cells(1-3), specialized cells that wrap around nerve axons to provide electrical insulation. Here we use gene targeting to generate mice that lack ErbB3, a high-affinity neuregulin receptor(4-6). Homozygous erbB3 mutant embryos lack Schwann-cell precursors and Schwann cells that accompany peripheral axons of sensory and motor neurons. The initial development of motor neurons and sensory neurons of dorsal root ganglia occurs as it should, but at later stages most motor neurons (79%) and sensory neurons in dorsal root ganglia (82%) undergo cell death in erbB3 mutant embryos. Degeneration of the peripheral nervous system in erbB3 mutant pups is thus much more severe than the cell death in mice that lack neurotrophins or neurotrophin receptors(7,8). We also show that ErbB3 functions in a cell-autonomous way during the development of Schwann cells, but not in the survival of sensory or motor neurons. Our results indicate that sensory and motor neurons require factors for their survival that are provided by developing Schwann cells.	MAX DELBRUCK CTR MOL MED,DEPT MED GENET,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT CELL BIOL,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT NEUROSCI,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Lewin, Gary R/B-8028-2011; Riethmacher, Dieter/A-6242-2010; Brinkmann, Volker/A-6015-2009; Riethmacher, Dieter/AAP-2227-2021; Riethmacher, Dieter/AAB-8690-2022	Riethmacher, Dieter/0000-0002-4206-5529; Lewin, Gary/0000-0002-2890-6352				Barinaga M, 1996, SCIENCE, V273, P1657, DOI 10.1126/science.273.5282.1657; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Davies A. M., 1995, NEURAL CELL CULTURE, P153; DONG Z, 1995, NEURON, V15, P686; ElShamy WM, 1996, NEURON, V16, P963, DOI 10.1016/S0896-6273(00)80119-1; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; KUCERA J, 1995, NEUROSCIENCE, V69, P321, DOI 10.1016/0306-4522(95)00221-4; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMKE G, 1993, GLIA, V7, P163; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MEYER D, IN PRESS DEVELOPMENT; Ockel M, 1996, DEVELOPMENT, V122, P301; ORR UA, 1993, P NATL ACAD SCI USA, V90, P1867; PAPAIOANNOU V, 1993, GENE TARGETING PRACT, P1807; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PINKASKRAMARSKI R, 1996, J BIOL CHEM, V271, P19022; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1	30	557	568	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					725	730		10.1038/39593	http://dx.doi.org/10.1038/39593			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338783				2022-12-28	WOS:A1997YA95900054
J	Lebowitz, BD; Pearson, JL; Schneider, LS; Reynolds, CF; Alexopoulos, GS; Bruce, ML; Conwell, Y; Katz, IR; Meyers, BS; Morrison, MF; Mossey, J; Niederehe, G; Parmelee, P				Lebowitz, BD; Pearson, JL; Schneider, LS; Reynolds, CF; Alexopoulos, GS; Bruce, ML; Conwell, Y; Katz, IR; Meyers, BS; Morrison, MF; Mossey, J; Niederehe, G; Parmelee, P			Diagnosis and treatment of depression in late life - Consensus statement update	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE PATIENTS; MAJOR DEPRESSION; GENERAL-PRACTITIONERS; GERIATRIC DEPRESSION; PHYSICAL HEALTH; FOLLOW-UP; SUICIDE; SYMPTOMS; MOOD; ANTIDEPRESSANTS	Objective.-To reexamine the conclusions of the 1991 National Institutes of Health Consensus Panel on Diagnosis and Treatment of Depression in Late Life in light of current scientific evidence. Participants.-Participants included National institutes of Health staff and experts drawn from the Planning Committee and presenters of the 1991 Consensus Development Conference. Evidence.-Participants summarized relevant data from the world scientific literature on the original questions posed for the conference. Process.-Participants reviewed the original consensus statement and identified areas for update. The list of issues was circulated to all participants and amended to reflect group agreement. Selected participants prepared first drafts of the consensus update for each issue. All drafts were read by all participants and were amended and edited to reflect group consensus. Conclusions.-The review concluded that, although the initial consensus statement still holds, there is important new information in a number of areas. These areas include the onset and course of late-life depression; comorbidity and disability; sex and hormonal issues; newer medications, psychotherapies, and approaches to long-term treatment; impact of depression on health services and health care resource use; late-life depression as a risk factor for suicide; and the importance of the heterogeneous forms of depression, Depression in older people remains a significant public health problem. The burden of unrecognized or inadequately treated depression is substantial, Efficacious treatments are available. Aggressive approaches to recognition, diagnosis, and treatment are warranted to minimize suffering, improve overall functioning and quality of life, and limit inappropriate use of health care resources.	UNIV SO CALIF, LOS ANGELES, CA 90089 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; CORNELL UNIV, MED CTR, WHITE PLAINS, NY 10605 USA; UNIV ROCHESTER, ROCHESTER, NY 14627 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; ALLEGHENY UNIV HLTH SCI, PHILADELPHIA, PA 19102 USA	University of Southern California; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cornell University; University of Rochester; University of Pennsylvania; Drexel University	Lebowitz, BD (corresponding author), NIMH, 5600 FISHERS LN, ROOM 18-101, ROCKVILLE, MD 20857 USA.		Conwell, Yeates/C-9347-2011	Conwell, Yeates/0000-0001-8517-2132; Lebowitz, Barry/0000-0002-6467-646X; Alexopoulos, George/0000-0001-5677-7001				ALEXOPOULOS GS, 1993, AM J PSYCHIAT, V150, P1693; Alexopoulos GS, 1997, AM J PSYCHIAT, V154, P562; Alexopoulos GS, 1996, ARCH GEN PSYCHIAT, V53, P305; ALEXOPOULOS GS, 1992, BIOL PSYCHIAT, V31, P591, DOI 10.1016/0006-3223(92)90245-U; ALEXOPOULOS GS, IN PRESS ARCH GEN PS; ALLENBURGE R, 1994, PSYCHOL AGING, V9, P443, DOI 10.1037/0882-7974.9.3.443; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; AREAN PA, 1993, J CONSULT CLIN PSYCH, V61, P1003, DOI 10.1037/0022-006X.61.6.1003; BORSON S, 1992, PSYCHOSOMATICS, V33, P190, DOI 10.1016/S0033-3182(92)71995-1; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; BRUCE ML, 1994, SOC PSYCH PSYCH EPID, V29, P165; CALLAHAN CM, 1995, J GERONTOL A-BIOL, V50, pM196, DOI 10.1093/gerona/50A.4.M196; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P833, DOI 10.1111/j.1532-5415.1994.tb06554.x; Callahan CM, 1996, J AM GERIATR SOC, V44, P1205, DOI 10.1111/j.1532-5415.1996.tb01370.x; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P3; CLARK DC, 1993, SUICIDE LIFE-THREAT, V23, P21; COFFEY CE, 1993, ARCH GEN PSYCHIAT, V50, P7; Conwell Y, 1996, AM J PSYCHIAT, V153, P1001; CONWELL Y, IN PRESS PSYCHIAT CL; COOPERPATRICK L, 1994, MED CARE, V32, P15, DOI 10.1097/00005650-199401000-00002; Duberstein P R, 1995, Int Psychogeriatr, V7, P183, DOI 10.1017/S1041610295001967; FRIEDHOFF AJ, 1992, JAMA-J AM MED ASSOC, V268, P1018, DOI 10.1001/jama.1992.03490080092032; FRIES BE, 1993, MED CARE, V31, P898, DOI 10.1097/00005650-199310000-00004; GALLO JJ, 1994, J GERONTOL, V49, pP251, DOI 10.1093/geronj/49.6.P251; GLASSMAN AH, 1994, GERONTOLOGY, V40, P15, DOI 10.1159/000213616; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; Henriksson M M, 1995, Int Psychogeriatr, V7, P275, DOI 10.1017/S1041610295002031; Henriksson MM, 1995, J AFFECT DISORDERS, V36, P11, DOI 10.1016/0165-0327(95)00047-X; ISOMETSA ET, 1995, AM J PSYCHIAT, V152, P919; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; JUDD LL, 1994, J CLIN PSYCHIAT, V55, P18; Katz IR, 1996, AM J GERIAT PSYCHIAT, V4, P1, DOI 10.1097/00019442-199624410-00001; KOENIG HG, 1996, AM J GERIAT PSYCHI S, V4, pS14; KRISHNAN KRR, 1996, AM J GERIAT PSYCHI S, V4, pS22; LEUCHTER A, 1994, AM J GERIAT PSYCHIAT, V2, P290, DOI 10.1097/00019442-199402040-00004; LEUCHTER AF, 1994, J NEUROL NEUROSUR PS, V57, P1347, DOI 10.1136/jnnp.57.11.1347; Mossey JM, 1996, J GERONTOL A-BIOL, V51, pM172, DOI 10.1093/gerona/51A.4.M172; MOSSEY JM, 1990, J GERONTOL, V45, pM163, DOI 10.1093/geronj/45.5.M163; Nemeroff CB, 1996, AM J PSYCHIAT, V153, P311; Newman AB, 1997, J AM GERIATR SOC, V45, P1; NIEDEREHE G, 1996, AM J GERIAT PSYCHI S, V4, pS66; Olfson M, 1996, AM J PSYCHIAT, V153, P1353; Reynolds C F 3rd, 1995, Int Psychogeriatr, V7 Suppl, P27, DOI 10.1017/S104161029500233X; Reynolds CF, 1996, AM J PSYCHIAT, V153, P1288; Rihmer Z, 1995, J AFFECT DISORDERS, V35, P147, DOI 10.1016/0165-0327(95)00055-0; ROOSE SP, 1994, AM J PSYCHIAT, V151, P1735; Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P83, DOI 10.1111/j.1600-0447.1992.tb01448.x; Salzman Carl, 1995, P1471; Schmidt PJ, 1997, PSYCHOPHARMACOL BULL, V33, P219; SCHNEIDER LS, 1994, DIAGNOSIS TREATMENT; SCHNEIDER LS, 1996, AM J GERIAT PSYCHI S, V4, pS51; SIMON GE, 1995, ARCH GEN PSYCHIAT, V52, P850; STONE AB, 1994, OBSTET GYN CLIN N AM, V21, P391; TOLLEFSON GD, 1993, INT CLIN PSYCHOPHARM, V8, P253, DOI 10.1097/00004850-199300840-00008; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; WILLIAMSRUSSO P, 1996, NAT I MENT HLTH PRIM; WILLIAMSRUSSO P, 1996, AM J GERIAT PSYCHI S, V4, pS84; 1991, NIH CONSENS STATEMEN, V9	63	547	563	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1186	1190		10.1001/jama.278.14.1186	http://dx.doi.org/10.1001/jama.278.14.1186			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY422	9326481				2022-12-28	WOS:A1997XY42200039
J	Blasco, MA; Lee, HW; Hande, MP; Samper, E; Lansdorp, PM; DePinho, RA; Greider, CW				Blasco, MA; Lee, HW; Hande, MP; Samper, E; Lansdorp, PM; DePinho, RA; Greider, CW			Telomere shortening and tumor formation by mouse cells lacking telomerase RNA	CELL			English	Article							MINOR SATELLITE DNA; EMBRYO FIBROBLASTS; IMMORTAL CELLS; REPEAT ARRAYS; STEM-CELLS; SENESCENCE; LENGTH; CANCER; IDENTIFICATION; CHROMOSOMES	To examine the role of telomerase in normal and neoplastic growth, the telomerase RNA component (mTR) was deleted from the mouse germline. mTR(-/-) mice lacked detectable telomerase activity yet were viable for the six generations analyzed. Telomerase-deficient cells could be immortalized in culture, transformed by viral oncogenes, and generated tumors in nude mice following transformation. Telomeres were shown to shorten at a rate of 4.8 +/- 2.4 kb per mTR(-/-) generation. Cells from the fourth mTR(-/-) generation onward possessed chromosome ends lacking detectable telomere repeats, aneuploidy, and chromosomal abnormalities, including end-to-end fusions. These results indicate that telomerase is essential for telomere length maintenance but is not required for establishment of cell lines, oncogenic transformation, or tumor formation in mice.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; UNIV AUTONOMA MADRID,DEPT IMMUNOL & ONCOL,CTR NACL BIOTECNOL,CSIC,E-28049 MADRID,SPAIN; BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1M9,CANADA	Cold Spring Harbor Laboratory; Yeshiva University; Albert Einstein College of Medicine; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); British Columbia Cancer Agency; University of British Columbia			Blasco, Maria A./M-1694-2014; Hande, M. Prakash/B-1645-2008	Blasco, Maria A./0000-0002-4211-233X; Hande, M. Prakash/0000-0002-4511-6256; Lansdorp, Peter/0000-0001-7435-1071; DePinho, Ronald/0000-0002-5625-577X; Greider, Carol/0000-0002-5494-8126	NCI NIH HHS [5P30-CA45508] Funding Source: Medline; NIA NIH HHS [R01AG09383] Funding Source: Medline; NICHD NIH HHS [R01HD348880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009383] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; AUSUBEL RM, 1993, CURRENT PROTOCOLS MO; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; BEDNAREK A, 1995, CANCER RES, V55, P4566; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, ONCOGENE, V11, P893; Conzen SD, 1995, ONCOGENE, V11, P2295; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DROST JB, 1995, ENVIRON MOL MUTAGEN, V25, P48, DOI 10.1002/em.2850250609; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARAGNA S, 1995, CHROMOSOMA, V103, P685, DOI 10.1007/BF00344229; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; Harley C.B., 1990, METHOD MOL BIOL, P25; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1991, GENOMICS, V11, P235, DOI 10.1016/0888-7543(91)90128-2; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KRAEMER PM, 1996, J NATL CANCER I, V76, P703; Kyo S, 1997, CANCER RES, V57, P610; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NANDA I, 1995, CHROMOSOME RES, V3, P399, DOI 10.1007/BF00713889; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SINGER MS, 1994, SCIENCE, V266, P387; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	53	1695	1775	3	151	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					25	34		10.1016/S0092-8674(01)80006-4	http://dx.doi.org/10.1016/S0092-8674(01)80006-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335332	hybrid			2022-12-28	WOS:A1997XZ80900006
J	Denzin, LK; SantAngelo, DB; Hammond, C; Surman, MJ; Cresswell, P				Denzin, LK; SantAngelo, DB; Hammond, C; Surman, MJ; Cresswell, P			Negative regulation by HLA-DO of MHC class II-restricted antigen processing	SCIENCE			English	Article							INVARIANT CHAIN PEPTIDES; BARE LYMPHOCYTE SYNDROME; T-CELL; INTRACELLULAR-TRANSPORT; DR MOLECULES; DM; GENES; EXPRESSION; COMPARTMENTS; COMPLEX	HLA-DM is a major histocompatibility complex (MHC) class II-like molecule that facilitates antigen processing by catalyzing the exchange of invariant chain-derived peptides (CLIP) from class II molecules for antigenic peptides. HLA-DO is a second class II-like molecule that physically associates with HLA-DM in B cells. HLA-DO was shown to block HLA-DM function. Purified HLA-DM-DO complexes could not promote peptide exchange in vitro. Expression of HLA-DO in a class II+ and DM+, DO- human T cell line caused the accumulation of class II-CLIP complexes, indicating that HLA-DO blocked DM function in two and suggesting that HLA-DO is an important modulator of class II-restricted antigen processing.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University					NIAID NIH HHS [AI14579, AI23081] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014579, R01AI014579, R01AI023081, R37AI023081] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; AVVA RR, 1994, IMMUNITY, V1, P63; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; CHANG CH, 1995, INT IMMUNOL, V7, P1515, DOI 10.1093/intimm/7.9.1515; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; DENZIN LK, UNPUB; Douek DC, 1997, INT IMMUNOL, V9, P355, DOI 10.1093/intimm/9.3.355; ECKELS DD, 1984, IMMUNOGENETICS, V19, P409, DOI 10.1007/BF00364644; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND CI, UNPUB; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; Katz JF, 1996, J EXP MED, V184, P1747, DOI 10.1084/jem.184.5.1747; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; LAMPSON LA, 1980, J IMMUNOL, V125, P293; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PONZONI M, 1993, INT J CANCER, V55, P817, DOI 10.1002/ijc.2910550521; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; REITH W, 1995, IMMUNOL TODAY, V16, P539, DOI 10.1016/0167-5699(95)80048-4; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Robbins NF, 1996, HUM IMMUNOL, V45, P13, DOI 10.1016/0198-8859(95)00152-2; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SANTANGELO DB, UNPUB; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WAKE CT, 1985, CELL, V42, P623, DOI 10.1016/0092-8674(85)90119-9; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	47	194	195	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					106	109		10.1126/science.278.5335.106	http://dx.doi.org/10.1126/science.278.5335.106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311912				2022-12-28	WOS:A1997XZ12400048
J	Michele, TM; Cronin, WA; Graham, NMH; Dwyer, DM; Pope, DS; Harrington, S; Chaisson, RE; Bishai, WR				Michele, TM; Cronin, WA; Graham, NMH; Dwyer, DM; Pope, DS; Harrington, S; Chaisson, RE; Bishai, WR			Transmission of Mycobacterium tuberculosis by a fiberoptic bronchoscope - Identification by DNA fingerprinting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-CITY; NOSOCOMIAL TRANSMISSION; APIC GUIDELINE; INFECTION; ENDOSCOPY; OUTBREAK; DISINFECTANTS; CONTAMINATION; SPREAD; UNIT	Context.-An ongoing restriction fragment length polymorphism (RFLP) study of Mycobacterium tuberculosis isolates from tuberculosis (TB) cases revealed an identical 10-banded 1S6110 RFLP pattern unique to 2 patients diagnosed as having TB 6 months apart. Their only identifiable link was care at the same hospital. Objective.-To determine if nosocomial transmission had occurred. Design.-Traditional and molecular epidemiologic investigation. Measurements.-We reviewed medical charts and bronchoscopic 00records, examined hospital locations visited by both patients, evaluated hospital ventilation systems, and observed cleaning and disinfection of bronchoscopes. Results.-A patient with cough, hoarseness, and fever underwent bronchoscopy and was diagnosed as having TB. A second patient with a mediastinal mass underwent bronchoscopy 2 days later and was diagnosed as having small cell carcinoma. Following 6 months of chemotherapy and radiation therapy, the second patient developed fever and an infiltrate of the right upper robe of the lung. Bronchoscopic washings revealed acid-fast bacilli and were culture positive for M tuberculosis. Both patients had undergone bronchoscopy with the same instrument in the same operating room with no intervening bronchoscopies. Bronchoscope cleaning and disinfection procedures were inconsistent with national guidelines. Conclusions.-A contaminated bronchoscope was the most likely source of M tuberculosis transmission between these 2 patients. The RFLP analysis of M tuberculosis isolates was responsible for detecting this nosocomial source of transmission and led to the implementation of public health measures to prevent further spread of infection and disease. This study emphasizes the need for continued vigilance in endoscope cleaning techniques.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; BALTIMORE CITY DEPT HLTH,BALTIMORE,MD; MARYLAND DEPT HLTH & MENTAL HYG,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036973, R01AI036973] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07534] Funding Source: Medline; NIAID NIH HHS [AI36973] Funding Source: Medline; NIDA NIH HHS [DA07061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BEST M, 1990, J CLIN MICROBIOL, V28, P2234, DOI 10.1128/JCM.28.10.2234-2239.1990; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P718; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; MALASKY C, 1990, AM REV RESPIR DIS, V142, P505, DOI 10.1164/ajrccm/142.3.505; MARTIN MA, 1994, AM J INFECT CONTROL, V22, P19, DOI 10.1016/0196-6553(94)90087-6; MBITHI JN, 1993, J CLIN MICROBIOL, V31, P2988, DOI 10.1128/JCM.31.11.2988-2995.1993; NELSON KE, 1983, AM REV RESPIR DIS, V127, P97, DOI 10.1164/arrd.1983.127.1.97; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PRAKASH UBS, 1993, CHEST, V104, P552, DOI 10.1378/chest.104.2.552; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; RUTALA WA, 1995, INFECT CONT HOSP EP, V16, P231; Rutala WA, 1996, AM J INFECT CONTROL, V24, P313, DOI 10.1016/S0196-6553(96)90066-8; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SPACH DH, 1993, ANN INTERN MED, V118, P117, DOI 10.7326/0003-4819-118-2-199301150-00008; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WHEELER PW, 1989, J INFECT DIS, V159, P954, DOI 10.1093/infdis/159.5.954	27	84	89	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1093	1095		10.1001/jama.278.13.1093	http://dx.doi.org/10.1001/jama.278.13.1093			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315769				2022-12-28	WOS:A1997XX30300034
J	Kaplan, EL				Kaplan, EL			Clinical guidelines for group A streptococcal throat infections	LANCET			English	Editorial Material							PHARYNGITIS; DIAGNOSIS				Kaplan, EL (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PEDIAT,WHO COLLABORATING CTR REFERENCE & RES STREPTOCOCC,MINNEAPOLIS,MN 55455, USA.							BASS JW, 1994, ARCH PEDIAT ADOL MED, V148, P67, DOI 10.1001/archpedi.1994.02170010069016; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; KAPLAN EL, 1993, CIRCULATION, V88, P1964, DOI 10.1161/01.CIR.88.4.1964; WANNAMAKER LW, 1972, AM J DIS CHILD, V124, P352, DOI 10.1001/archpedi.1972.02110150050009; WANNAMAKER LW, 1984, PHARYNGITIS MANAGEME, P33	5	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					899	900		10.1016/S0140-6736(05)63261-8	http://dx.doi.org/10.1016/S0140-6736(05)63261-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314863				2022-12-28	WOS:A1997XY67200003
J	Giuffrida, A; Torgerson, DJ				Giuffrida, A; Torgerson, DJ			Should we pay the patient? Review of financial incentives to enhance patient compliance	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; CONTINGENT REINFORCEMENT; BEHAVIORAL TREATMENT; IMPROVING ADHERENCE; COCAINE ABSTINENCE; EDUCATION-PROGRAM; TUBERCULOSIS; STRATEGIES; SMOKING; WOMEN	Objective: To determine whether financial incentives increase patients' compli Data sources: Systematic literature review of computer databases-Medline Embase, PsyckLit, EconLit, and the Cochrane Database of Clinical Trials in addition, the reference list of each retrieved article was reviewed and relevant citations retrieved. Study selection: Only randomised trials with quantitative data concerning the effect of financial incentives (cash, vouchers, lottery tickets, or gifts) on compliance with medication, medical advice, or medical appointments were included in the review. Eleven papers were identified as meeting the selection criteria. Data extraction: Data on study populations, interventions, and outcomes were extracted and analysed using odds ratios and the number of patients needed to be treated to improve compliance by one patient Results: 10 of the 11 studies showed improvements in patient compliance with the use of financial incentives. Conclusions: Financial incentives can improve patient compliance.			Giuffrida, A (corresponding author), UNIV YORK, CTR HLTH ECON, CARE RES & DEV CTR, YORK YO1 5DD, N YORKSHIRE, ENGLAND.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				ABRAMSON R, 1980, J CLIN PSYCHIAT, V41, P234; Becker M H, 1980, J Community Health, V6, P113, DOI 10.1007/BF01318980; BEGG D, 1984, J ROY COLL GEN PRACT, V34, P272; BERADON PHG, 1993, BRIT MED J, V307, P846; BIGELOW G, 1976, BEHAV RES THER, V14, P378, DOI 10.1016/0005-7967(76)90028-0; BIRKHEAD GS, 1995, JAMA-J AM MED ASSOC, V274, P312, DOI 10.1001/jama.274.4.312; BRANTLEY PJ, 1990, HEALTH PSYCHOL, V9, P103, DOI 10.1037/0278-6133.9.1.103; CAREY KB, 1990, J BEHAV THER EXP PSY, V21, P205, DOI 10.1016/0005-7916(90)90008-9; CHACKO MR, 1987, SEX TRANSM DIS, V14, P75, DOI 10.1097/00007435-198704000-00003; Chaisson RE, 1996, J ACQ IMMUN DEF SYND, V11, P455, DOI 10.1097/00042560-199604150-00005; CUNEO WD, 1989, CLIN CHEST MED, V10, P375; DERN S, 1994, PUBLIC HLTH REP, V109, P548; DIDLAKE RH, 1988, TRANSPLANT P, V20, P63; DONALD GT, 1971, APPL STAT SA, V20, pS36; ELK R, 1995, ADDICT BEHAV, V20, P533, DOI 10.1016/0306-4603(94)00076-B; Farmer P, 1991, Semin Respir Infect, V6, P254; FINNEY JW, 1990, J PEDIATR PSYCHOL, V15, P571, DOI 10.1093/jpepsy/15.4.571; GRABOWSKI J, 1979, AM J DRUG ALCOHOL AB, V6, P355, DOI 10.3109/00952997909001724; Grabowski J, 1979, NIDA Res Monogr, V27, P402; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; HIGGINS ST, 1993, AM J PSYCHIAT, V150, P763; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; HILBRANDS LB, 1995, TRANSPLANTATION, V60, P914, DOI 10.1097/00007890-199511150-00006; JEFFERY RW, 1993, J CONSULT CLIN PSYCH, V61, P1038, DOI 10.1037/0022-006X.61.6.1038; KENT JH, 1993, MED CLIN N AM, V77, P1391, DOI 10.1016/S0025-7125(16)30200-0; LAKEN MP, 1995, OBSTET GYNECOL, V85, P326; MACHARIA WM, 1992, JAMA-J AM MED ASSOC, V267, P1813, DOI 10.1001/jama.267.13.1813; MARCUS AC, 1992, MED CARE, V30, P216, DOI 10.1097/00005650-199203000-00004; MAVIS BE, 1994, PSYCHOL REC, V44, P239, DOI 10.1007/BF03395130; MAYER JA, 1993, AM J PREV MED, V9, P244, DOI 10.1016/S0749-3797(18)30722-0; MAYER JA, 1994, AM J PREV MED, V10, P353, DOI 10.1016/S0749-3797(18)30564-6; MCCAUL ME, 1984, J APPL BEHAV ANAL, V17, P35, DOI 10.1901/jaba.1984.17-35; MELNIKOW J, 1994, J GEN INTERN MED, V9, P96, DOI 10.1007/BF02600211; MORISKY DE, 1990, HEALTH EDUC QUART, V17, P253, DOI 10.1177/109019819001700303; Newhouse JP, 1993, FREE ALL LESSONS RAN; OPPENHEIM GL, 1979, J FAM PRACTICE, V8, P789; PARRISH JM, 1986, J PEDIATR PSYCHOL, V11, P81, DOI 10.1093/jpepsy/11.1.81; Pilote L, 1996, ARCH INTERN MED, V156, P161, DOI 10.1001/archinte.156.2.161; RAND CS, 1989, ADDICT BEHAV, V14, P121, DOI 10.1016/0306-4603(89)90041-5; RASHID A, 1982, BRIT MED J, V284, P24, DOI 10.1136/bmj.284.6308.24; REISS ML, 1976, J APPL BEHAV ANAL, V9, P387, DOI 10.1901/jaba.1976.9-387; REISS ML, 1982, J APPL BEHAV ANAL, V15, P352; RICE JM, 1984, J APPL BEHAV ANAL, V17, P303, DOI 10.1901/jaba.1984.17-303; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; SHEPARD DS, 1979, NAT C HIGH BLOOD PRE; SMITH CM, 1994, J FAM PRACTICE, V38, P25; SMITH PB, 1990, J ADOLESCENT HEALTH, V11, P445, DOI 10.1016/0197-0070(90)90093-H; StevensSimon C, 1997, JAMA-J AM MED ASSOC, V277, P977, DOI 10.1001/jama.277.12.977; STEVENSSIMON C, 1994, J ADOLESCENT HEALTH, V15, P396, DOI 10.1016/1054-139X(94)90263-1; STITZER ML, 1986, J APPL BEHAV ANAL, V19, P197, DOI 10.1901/jaba.1986.19-197; STITZER ML, 1984, J APPL BEHAV ANAL, V17, P477, DOI 10.1901/jaba.1984.17-477; STITZER ML, 1985, ADDICT BEHAV, V10, P345, DOI 10.1016/0306-4603(85)90030-9; SZAL GR, 1994, J SUBST ABUSE TREAT, V11, P217; Titmuss R., 1970, GIFT RELATIONSHIP HU; TORGERSON DJ, 1994, BMJ-BRIT MED J, V308, P117, DOI 10.1136/bmj.308.6921.117; TYSON JE, 1988, EARLY HUM DEV, V16, P13, DOI 10.1016/0378-3782(88)90083-7; VOGELER DM, 1978, AM REV RESPIR DIS, V117, P227; WATERS WHR, 1976, BRIT MED J, V1, P1062, DOI 10.1136/bmj.1.6017.1062; YORKLEY JM, 1984, J APPL BEHAV ANAL, V17, P313; Zuckerman RA, 1996, SEX TRANSM DIS, V23, P299, DOI 10.1097/00007435-199607000-00010; 1993, MMWR-MORBID MORTAL W, V42, P75; 1993, ANN PHARMACOTHER, V27, pS5	63	229	280	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					703	707		10.1136/bmj.315.7110.703	http://dx.doi.org/10.1136/bmj.315.7110.703			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX674	9314754	Green Published			2022-12-28	WOS:A1997XX67400019
J	Gonzales, R; Steiner, JF; Sande, MA				Gonzales, R; Steiner, JF; Sande, MA			Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; COMMON-COLD; ERYTHROMYCIN; CHILDREN; COMMUNITY; CARRIAGE; BACTERIA; DISEASE; HEALTH; TRIAL	Contex.-Antibiotic use is associated with increased rates of antibiotic-resistant organisms. A previous study has shown that colds, upper respiratory tract infections, and bronchitis account for nearly one third of all antibiotic prescribing by ambulatory care physicians. How frequently antibiotics are prescribed for these conditions and for and by whom is not known. Objectives.-To measure antibiotic prescription rates and to identify predictors of antibiotic use for adults diagnosed as having colds, upper respiratory tract infections, and bronchitis in the United States. Design.-Sample survey of practicing physicians participating in the National Ambulatory Medical Care Survey, 1992. Setting.-Office-based physician practices. Subjects.-Physicians (n=1529) completing patient record forms for adult office visits (n=28787). Main Outcome Measures.-Antibiotic prescriptions for colds, upper respiratory tract infections, and bronchitis. Results.-Office visits for colds, upper respiratory tract infections, and bronchitis resulted in approximately 12 million antibiotic prescriptions, accounting for 21% of all antibiotic prescriptions to adults in 1992. A total of 51% of patients diagnosed as having colds, 52% of patients diagnosed as having upper respiratory tract infections, and 66% of patients diagnosed as having bronchitis were treated with antibiotics. Female sex (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.05-2.62) and rural practice location (OR, 2.25; 95% CI, 1.33-3.80) were associated with greater antibiotic prescription rates, whereas black race (OR, 0.44; 95% CI, 0.21-0.93) was associated with lower antibiotic prescription rates. Patient age, Hispanic ethnicity, geographic region, physician specialty, and payment sources were not associated with antibiotic prescription rates in the bivariate analysis. Multivariate logistic regression analysis identified only rural practice location (adjusted OR, 2.58; 95% CI, 1.39-4.76) to be independently associated with more frequent antibiotic prescriptions for colds, upper respiratory tract infections, and bronchitis. Conclusion.-Although antibiotics have little or no benefit for colds, upper respiratory tract infections, or bronchitis, these conditions account for a sizable proportion of total antibiotic prescriptions for adults by office-based physicians in the United States.; Overuse of antibiotics is widespread across geographical areas, medical specialties, and payment sources. Therefore, effective strategies for changing prescribing behavior for these conditions will need to be broad based.	UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA; UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84112 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Gonzales, R (corresponding author), UNIV COLORADO, HLTH SCI CTR, DIV GEN INTERNAL MED, BOX B-180, 4200 E 9TH AVE, DENVER, CO 80262 USA.				BHP HRSA HHS [5 T32 PE10006-04] Funding Source: Medline	BHP HRSA HHS		Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; BOLDY DAR, 1990, RESP MED, V84, P377, DOI 10.1016/S0954-6111(08)80072-8; BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DEFRIESE GH, 1989, HEALTH SERV RES, V23, P931; DUNLAY J, 1987, J FAM PRACTICE, V25, P137; *FOOD DRUG ADM, 1986, NAT DRUG COD DIR 198; FRANKS P, 1984, J FAM PRACTICE, V19, P185; HEIKKINEN T, 1995, J PEDIATR-US, V126, P313, DOI 10.1016/S0022-3476(95)70569-4; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; HOWIE JGR, 1970, LANCET, V2, P1099; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; King DE, 1996, J FAM PRACTICE, V42, P601; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Lederberg J, 1996, JAMA-J AM MED ASSOC, V276, P417, DOI 10.1001/jama.276.5.417; Mainous AG, 1996, ARCH FAM MED, V5, P79, DOI 10.1001/archfami.5.2.79; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; Meza R A, 1994, Aust Fam Physician, V23, P1550; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; POTTHOFF RF, 1992, J AM STAT ASSOC, V87, P383, DOI 10.2307/2290269; PRAYER OL, 1996, AM MED NEWS, V39, P42; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHAPPERT SM, 1994, ADV DAT VIT HLTH STA, V253; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; *US DEP HHS, 1988, INT CLASS DIS 9 REV; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; VERJEIJ TJM, 1994, BR J GEN PRACT, V44, P400; WEINER J, 1995, ANN INTERN MED, V122, P380; WILLIAMSON HA, 1984, J FAM PRACTICE, V19, P481; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, MMWR-MORBID MORTAL W, V43, P31	35	549	563	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					901	904		10.1001/jama.278.11.901	http://dx.doi.org/10.1001/jama.278.11.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302241				2022-12-28	WOS:A1997XV64000027
J	Edwards, SJL; Lilford, RJ; Braunholtz, D; Jackson, J				Edwards, SJL; Lilford, RJ; Braunholtz, D; Jackson, J			Why ''underpowered'' trials are not necessarily unethical	LANCET			English	Editorial Material							CLINICAL-TRIALS; RANDOMIZED TRIALS; P-VALUES; METAANALYSIS; ETHICS; SIZE; QUALITY; SAMPLE		UNIV LEEDS,DEPT PHILOSOPHY,LEEDS,W YORKSHIRE,ENGLAND	University of Leeds	Edwards, SJL (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BARNARD GA, 1990, STAT MED, V9, P601, DOI 10.1002/sim.4780090606; Botros S., 1990, ETHICS LAW HLTH CARE, P9; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; CLAYTON DG, 1982, BRIT J CLIN PHARMACO, V13, P469; DEBONO M, 1990, J PERINAT MED, V18, P77, DOI 10.1515/jpme.1990.18.2.77; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; FAYERS PM, 1995, BRIT J CANCER, V72, P1, DOI 10.1038/bjc.1995.268; FAYERS PM, 1993, EUR J CANCER, V29A, P907, DOI 10.1016/S0959-8049(05)80436-8; FREEDMAN LS, 1989, BRIT J CANCER, V59, P396, DOI 10.1038/bjc.1989.79; FREEMAN PR, 1993, STAT MED, V12, P1443, DOI 10.1002/sim.4780121510; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; LIBERATI A, 1995, J CLIN EPIDEMIOL, V48, P81, DOI 10.1016/0895-4356(94)00115-7; Lilford R J, 1989, Int J Technol Assess Health Care, V5, P459; Lilford RJ, 1995, BMJ-BRIT MED J, V311, P1621, DOI 10.1136/bmj.311.7020.1621; Lilford RJ, 1995, J ROY SOC MED, V88, P552; LILFORD RJ, 1990, NEW ENGL J MED, V322, P780; Lilford RJ, 1996, BRIT MED J, V313, P603; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Sim I, 1996, BRIT MED J, V313, P702; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; Thornton H, 1996, BREAST, V5, P1, DOI 10.1016/S0960-9776(96)90041-7; Thornton JG, 1996, BRIT J OBSTET GYNAEC, V103, P611, DOI 10.1111/j.1471-0528.1996.tb09826.x	26	74	74	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					804	807		10.1016/S0140-6736(97)02290-3	http://dx.doi.org/10.1016/S0140-6736(97)02290-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9298015				2022-12-28	WOS:A1997XW28200051
J	Stern, JM; Simes, RJ				Stern, JM; Simes, RJ			Publication bias: evidence of delayed publication in a cohort study of clinical research projects	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRIALS	Objectives: To determine the extent to which publication is influenced by stud Design: A cohort of studies submitted to a hospital ethics committee over 10 years were examined retrospectively by reviewing the protocols and by questionnaire. The primary mettled of analysis was Cox's proportional hazards model. Setting: University hospital, Sydney, Australia. Studies: 748 eligible studies submitted to Royal Prince Alfred Hospital Ethics Committee between 1979 and 1988. Main outcome measures: Time to publication. Results: Response to che questionnaire was received for 520 (70%) of the eligible studies, Of the 218 studies analysed with tests of significance, those with positive results (P < 0.05) were much more likely to be published that those with negative results (P greater than or equal to 0.10) (hazard ratio 2.32 (95% confidence interval 1.47 to 3.66), P = 0.0003), with a significantly shelter time to publication (median 4.8 vs 8.0 years). This finding was even stronger for the group of 130 clinical trials (hazard ratio 3.13 (1.76 to 5.58), P = 0.0001), with median times to publication of 4.7 and 8.0 years respectively. These results were not materially changed after adjusting for other significant predictors of publication. Studies with indefinite conclusions (0.05 less than or equal to P < 0.10) tended to have an even lower publication rate and longer time to publication than studies with negative results (hazard ratio 0.39 (0.13 to 1.12), P = 0.08). For the 103 studies in which outcome was rated qualitatively, there was no clear cut evidence of publication bias, although the number of studies in this group was not large. Conclusions: This study confirms the evidence of publication bias found in other studies and identifies delay in publication as an additional important factor. The study results support the need for prospective registration of trials to avoid publication bias and also support restricting the selection of trials to those started before a common date in undertaking systematic reviews.	UNIV SYDNEY, NATL HLTH & MED RES COUNCIL, CLIN TRIALS CTR, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney			Simes, Robert John/P-1497-2014					BEGG CB, 1987, CANCER, V60, P2811, DOI 10.1002/1097-0142(19871201)60:11<2811::AID-CNCR2820601136>3.0.CO;2-P; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; CHALMERS I, 1995, BRIT MED J, V311, P262, DOI 10.1136/bmj.311.6999.262b; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FRANK E, 1987, BRIT MED J, V295, P654; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; JUHL E, 1977, NEW ENGL J MED, V296, P20, DOI 10.1056/NEJM197701062960105; KOREN G, 1991, JAMA-J AM MED ASSOC, V266, P1824, DOI 10.1001/jama.266.13.1824; KOTELCHUCK D, 1974, HLTH PAC B, V61, P1; Mahoney M.J., 1977, COGNITIVE THER RES, V1, P161, DOI [10.1007/BF01173636, DOI 10.1007/BF01173636]; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; *NAT HLH MED RES C, 1985, NHMRC STAT HUM EXP S; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SIMES RJ, 1995, AM J CARDIOL, V76, pC122; SIXKWEAIN K, 1993, ONLINE J CURR CLIN T; SOMMER B, 1987, PSYCHOL WOMEN QUART, V11, P233, DOI 10.1111/j.1471-6402.1987.tb00786.x; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137	26	557	569	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	1997	315	7109					640	645		10.1136/bmj.315.7109.640	http://dx.doi.org/10.1136/bmj.315.7109.640			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310565	Green Published			2022-12-28	WOS:A1997XW69400018
J	Teasdale, TW; Engberg, A				Teasdale, TW; Engberg, A			Duration of cognitive dysfunction after concussion, and cognitive dysfunction as a risk factor: a population study of young men	BRITISH MEDICAL JOURNAL			English	Article							MINOR HEAD-INJURY; SECULAR TRENDS; INTELLIGENCE; SYMPTOMS; SEQUELAE; RECOVERY	Objectives: To establish how long cognitive dysfunction lasts after concussion, and the extent to which it may be a predisposing risk factor for concussion, by examining the prevalence of cognitive dysfunction among young men who have sustained concussion. Design: Observational study. Setting: Denmark. Subjects: 1220 young men who had been admitted to hospital for concussion between the ages of 16 and 24 (identified in a national register of admissions) and who had also been cognitively tested by the Danish conscription draft board. Main outcome measure: Score on the draft board's cognitive screening test, dichotomised as dysfunctional or non-dysfunctional (20.4% of the general population of Danish men appearing before the draft board had a dysfunctional score). Results: 700 of the 1220 men had been tested after sustaining concussion; 520 had been tested before concussion. Four (50%) of the eight men who were tested less than seven days after the injury had a dysfunctional score. Among groups of the remaining 692 men who were tested at later time points after injury, the rates were only marginally raised (range 21.4% to 26.5%) above the population level. Among men tested before injury, the rate of dysfunctional scores was higher (30.4% (158/520)). Apart from suggesting cognitive dysfunction as a risk factor for concussion, this higher proportion seems to relate to the fact that they were typically injured as young adults, whereas those men who were tested after concussion had more often been injured as adolescents. The relative risk for concussion in the presence of cognitive dysfunction is estimated to be 1.57 (95% confidence interval 1.32 to 1.86). Conclusions: Cognitive dysfunction is not only a short term consequence of concussion but also a predisposing risk factor for concussion, more so for young adults than for adolescents.	ODENSE UNIV HOSP,DEPT NEUROL,DK-5000 ODENSE C,DENMARK	University of Southern Denmark; Odense University Hospital	Teasdale, TW (corresponding author), UNIV COPENHAGEN,PSYCHOL LAB,NJALSGADE 88,DK-2300 COPENHAGEN S,DENMARK.							BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Duus B R, 1991, Ugeskr Laeger, V153, P2111; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; GRONWALL D, 1974, LANCET, V2, P605; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1989, MANAGEMENT HEAD INJU; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MORTENSEN EL, 1989, SCAND J PSYCHOL, V30, P315, DOI 10.1111/j.1467-9450.1989.tb01094.x; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; TEASDALE TW, 1994, SCAND J PSYCHOL, V35, P328, DOI 10.1111/j.1467-9450.1994.tb00957.x; TEASDALE TW, 1987, NATURE, V325, P119, DOI 10.1038/325119a0	19	30	30	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					569	572						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	9302952				2022-12-28	WOS:A1997XV71700022
J	Larsson, O; Barker, CJ; Sjoholm, A; Carlqvist, H; Michell, RH; Bertorello, A; Nilsson, T; Honkanen, RE; Mayr, GW; Zwiller, J; Berggren, PO				Larsson, O; Barker, CJ; Sjoholm, A; Carlqvist, H; Michell, RH; Bertorello, A; Nilsson, T; Honkanen, RE; Mayr, GW; Zwiller, J; Berggren, PO			Inhibition of phosphatases and increased Ca2+ channel activity by inositol hexakisphosphate	SCIENCE			English	Article							SERINE/THREONINE PROTEIN PHOSPHATASES; PANCREATIC BETA-CELLS; CALCIUM CHANNELS; OKADAIC ACID; 1,2,3-TRISPHOSPHATE; 1,2-BISPHOSPHATE; POLYPHOSPHATES; PURIFICATION; SPECIFICITY; ACTIVATION	Inositol hexakisphosphate (InsP(6)), the dominant inositol phosphate in insulin-secreting pancreatic beta cells, inhibited the serine-threonine protein phosphatases type 1, type 2A, and type 3 in a concentration-dependent manner. The activity of voltage-gated L-type calcium channels is increased in cells treated with inhibitors of serine-threonine protein phosphatases. Thus, the increased calcium channel activity obtained in the presence of InsP(6) might result from the inhibition of phosphatase activity. Glucose elicited a transient increase in InsP(6) concentration, which indicates that this inositol polyphosphate may modulate calcium influx over the plasma membrane and serve as a signal in the pancreatic beta cell stimulus-secretion coupling.	KAROLINSKA INST,DEPT MOL MED,ROLF LUFT CTR DIABET RES,S-17176 STOCKHOLM,SWEDEN; ASTRA PAIN CONTROL AB,NOVUM UNIT,S-14157 HUDDINGE,SWEDEN; UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV S ALABAMA,COLL MED,DEPT BIOCHEM,MOBILE,AL 36688; UNIV HAMBURG,HOSP EPPENDORF,INST PHYSIOL CHEM,D-20246 HAMBURG,GERMANY; INSERM,U338,F-67084 STRASBOURG,FRANCE	Karolinska Institutet; University of Birmingham; University of South Alabama; University of Hamburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Michell, Robert H/AAT-4974-2020	Michell, Robert H/0000-0001-9422-9858; Berggren, Per-Olof/0000-0001-8991-413X				AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BARKER CV, UNPUB; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CARPENTER D, 1989, BIOCHEM SOC T, V17, P3, DOI 10.1042/bst0170003; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Efanov AM, 1997, P NATL ACAD SCI USA, V94, P4435, DOI 10.1073/pnas.94.9.4435; FUKADA M, 1994, J BIOL CHEM, V269, P29206; GRAF E, 1984, J BIOL CHEM, V259, P3620; HABY C, 1994, BIOCHEM J, V298, P341, DOI 10.1042/bj2980341; HAWKINS PT, 1993, BIOCHEM J, V294, P929, DOI 10.1042/bj2940929; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; Hughes P J, 1993, Curr Opin Neurobiol, V3, P383, DOI 10.1016/0959-4388(93)90132-I; Krizanova O, 1996, GEN PHYSIOL BIOPHYS, V15, P79; LARSSON O, UNPUB; LI G, 1991, J BIOL CHEM, V267, P4349; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; POYNER DR, 1993, J BIOL CHEM, V268, P1032; SJOHOLM A, 1993, BIOSCIENCE REP, V13, P349, DOI 10.1007/BF01150479; Spiers ID, 1996, CARBOHYD RES, V282, P81, DOI 10.1016/0008-6215(95)00361-4; STUART JA, 1994, BIOCHEM J, V303, P517, DOI 10.1042/bj3030517; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3161; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WALAAS SI, 1991, PHARMACOL REV, V43, P229; ZWILLER J, UNPUB	34	115	119	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					471	474		10.1126/science.278.5337.471	http://dx.doi.org/10.1126/science.278.5337.471			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334307				2022-12-28	WOS:A1997YB35500047
J	Severin, K; Lee, DH; Kennan, AJ; Ghadiri, MR				Severin, K; Lee, DH; Kennan, AJ; Ghadiri, MR			A synthetic peptide ligase	NATURE			English	Article							HELICAL COILED-COILS; GCN4 LEUCINE-ZIPPER; ELECTROSTATIC INTERACTIONS; CATALYSIS; POLYPEPTIDES; ANTIBODIES; LIGATION; DESIGN	The preparation of synthetic molecules showing the remarkable efficiencies characteristic of natural biopolymer catalysts remains a formidable challenge for chemical biology, Although significant advances have been made in the understanding of protein structure and function, the ne novo construction of such systems remains elusive(1-5). Re-engineered natural enzymes and catalytic antibodies, possessing tailored binding pockets with appropriately positioned functional groups, have been successful in catalysing a number of chemical transformations, sometimes with impressive efficiencies(6-11). But efforts to produce wholly synthetic catalytic peptides have typically resulted in compounds with questionable structural stability, let alone reactivity(1). Here we describe a 33-residue synthetic peptide, based on the coiled-coil structural motif(12-14), which efficiently catalyses the condensation of two shorter peptide fragments with high sequence-and diastereoselectivity. Depending on the substrates used, we observe rate enhancements of tenfold to 4,100-fold over the background, with catalytic efficiencies in excess of 10(4). These results augur well for the rational design of functional peptides.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute				Severin, Kay/0000-0003-2224-7234				ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; BRUICE TC, 1964, J AM CHEM SOC, V86, P738, DOI 10.1021/ja01058a044; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Corey MJ, 1996, P NATL ACAD SCI USA, V93, P11428, DOI 10.1073/pnas.93.21.11428; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DOUGLAS K T, 1992, Current Opinion in Biotechnology, V3, P370, DOI 10.1016/0958-1669(92)90165-F; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HIRSCHMANN R, 1994, SCIENCE, V265, P234, DOI 10.1126/science.8023141; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JACOBSEN JR, 1994, P NATL ACAD SCI USA, V91, P5888, DOI 10.1073/pnas.91.13.5888; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P537; JOHNSSON K, 1993, NATURE, V365, P530, DOI 10.1038/365530a0; KAISER ET, 1988, ANGEW CHEM INT EDIT, V27, P913, DOI 10.1002/anie.198809131; KEMP DS, 1993, J ORG CHEM, V58, P2216, DOI 10.1021/jo00060a043; Kirby AJ, 1996, ACTA CHEM SCAND, V50, P203, DOI 10.3891/acta.chem.scand.50-0203; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; MacBeath G, 1996, CHEM BIOL, V3, P433, DOI 10.1016/S1074-5521(96)90091-5; MARTIN RB, 1962, J AM CHEM SOC, V84, P106, DOI 10.1021/ja00860a025; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; Muir TW, 1996, CHEM BIOL, V3, P817, DOI 10.1016/S1074-5521(96)90067-8; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SEVERIN RS, 1997, CHEM-EUR J, V3, P1017; Smithrud DB, 1997, J AM CHEM SOC, V119, P278, DOI 10.1021/ja963167u; Tam JP, 1995, P NATL ACAD SCI USA, V92, P12485, DOI 10.1073/pnas.92.26.12485; WONG CH, 1994, ENZYMES SYNTHETIC OR; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250	31	123	125	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					706	709		10.1038/39556	http://dx.doi.org/10.1038/39556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338780				2022-12-28	WOS:A1997YA95900048
J	Gronberg, H; Isaacs, SD; Smith, JR; Carpten, JD; Bova, GS; Freije, D; Xu, JF; Meyers, DA; Collins, FS; Trent, JM; Walsh, PC; Isaacs, WB				Gronberg, H; Isaacs, SD; Smith, JR; Carpten, JD; Bova, GS; Freije, D; Xu, JF; Meyers, DA; Collins, FS; Trent, JM; Walsh, PC; Isaacs, WB			Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; PATHOLOGICAL FEATURES; RISK; RELATIVES	Context.-Approximately 9% of prostate cancer cases have been estimated to result from inheritance of mutated prostate cancer susceptibility genes. Few data exist as to whether there are clinical differences between prostate cancers that are inherited and those that occur in the general population. Objective.-To investigate phenotypic characteristics of families potentially linked to the hereditary prostate cancer 1 (HPC1) locus on chromosome 1q24-25. Design.-Retrospective case study in which clinical data were extracted from medical and pathological records. Families.-A total of 74 North American families with hereditary prostate cancer. Prostate cancer cases from the National Cancer Data Base were used as a reference population for comparison. Main Outcome Measures.-The families were divided into 2 groups: either potentially linked (33 families with 133 men with prostate cancer), and thus likely to be carrying an altered HPC1 gene, or potentially unlinked (41 families with 172 men with prostate cancer), on the basis of haplotype analysis in the region of HPC1, The age at diagnosis of prostate cancer, serum prostate-specific antigen levels, digital rectal examination status, stage, grade, primary treatment of prostate cancers, and occurrence of other cancers were compared between the groups. Results.-The mean age at diagnosis of prostate cancer for men in potentially linked families was significantly lower than for men in potentially unlinked families (63.7 vs 65.9 years, respectively, P=.01; mean age at diagnosis in the reference population was 71.6 years). Higher-grade cancers (grade 3) were more common in potentially linked families, and advanced-stage disease was found in 41% of the case patients in potentially linked families compared with 31% in both the potentially unlinked families and the reference groups (P=.03 for the tatter comparison). In the other clinical parameters, we found no significant differences between the groups, A modest excess of breast cancer and colon cancer was found in potentially linked families in comparison with potentially unlinked families, but this difference was not statistically significant. Conclusions.-Families that provide evidence for segregation of an altered HPC1 gene are characterized by multiple cases of prostate cancer that, in most respects, are indistinguishable from nonhereditary cases, However, 3 characteristics were observed: younger age at diagnosis, higher-grade tumors, and more advanced-stage disease, Our study shows that a significant fraction of hereditary prostate cancers are diagnosed in advanced stages, emphasizing the clinical importance of early detection in men potentially carrying prostate cancer susceptibility genes, These findings support the current recommendations to screen men with a positive family history of prostate cancer beginning at age 40 years.	JOHNS HOPKINS UNIV HOSP,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD; UMEA UNIV,DEPT ONCOL,UMEA,SWEDEN	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Umea University			Smith, Jeff/C-3484-2012	Smith, Jeffrey/0000-0001-8424-910X; Bova, George/0000-0003-1639-3104	NCI NIH HHS [CA58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1993, BREAST CANCER RES TR, V28, P107, DOI 10.1007/BF00666423; ANDERSON DE, 1992, J NATL CANCER I, V84, P1114, DOI 10.1093/jnci/84.14.1114; BASTACKY SI, 1995, J UROLOGY, V153, P987, DOI 10.1016/S0022-5347(01)67619-5; BOVA GS, 1995, P AM UROL ASS, V153, pA505; Breslow N., 1987, STATISTICAL METHODS; CANNON L, 1983, INHERITANCE SUSCEPTI, P47; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gronberg H, 1996, CANCER, V77, P138, DOI 10.1002/(SICI)1097-0142(19960101)77:1<138::AID-CNCR23>3.0.CO;2-5; ISAACS SD, 1995, J NATL CANCER I, V87, P991, DOI 10.1093/jnci/87.13.991; Keetch DW, 1996, J UROLOGY, V155, P1841, DOI 10.1016/S0022-5347(01)66024-5; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; METTLIN CJ, 1995, CANCER, V76, P1104, DOI 10.1002/1097-0142(19950915)76:6<1104::AID-CNCR2820760627>3.0.CO;2-D; OTT J, 1985, ANAL HUMAN GENETIC L, P200; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; SPITZ MR, 1991, J UROLOGY, V146, P1305, DOI 10.1016/S0022-5347(17)38074-6; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855	21	127	127	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1251	1255		10.1001/jama.278.15.1251	http://dx.doi.org/10.1001/jama.278.15.1251			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333266				2022-12-28	WOS:A1997XZ70900030
J	Jewitt, DC; Matthews, HE; Owen, T; Meier, R				Jewitt, DC; Matthews, HE; Owen, T; Meier, R			Measurements of C-12/C-13, N-14/N-15, and S-32/S-34 ratios in comet Hale-Bopp (C/1995 O1)	SCIENCE			English	Article							RADIO OBSERVATIONS; ISOTOPE ABUNDANCE; HALLEY; P/HALLEY; HCN	The C-12/C-13, N-14/N-15, and S-32/S-34 isotope ratios in comet Hale-Bopp (C/1995 O1) were determined through observations taken with the James Clerk Maxwell Telescope, Measurements of rare isotopes in HCN and CS revealed isotope ratios of (HCN)-C-12/(HCN)-C-13 = 111 +/- 12, (HCN)-N-14/(HCN)-N-15 = 323 +/- 46, and (CS)-S-32/(CS)-S-34 = 27 +/- 3. Within the measurement uncertainties, the isotopic ratios are consistent with solar system values. The cometary volatiles thus have an origin in the solar system and show no evidence for an interstellar component.	NATL RES COUNCIL CANADA, HERZBERG INST ASTROPHYS, DOMINION ASTROPHYS OBSERV, VICTORIA, BC V8X 4M6, CANADA; JOINT ASTRON CTR, HILO, HI 96720 USA	National Research Council Canada	Jewitt, DC (corresponding author), UNIV HAWAII, INST ASTRON, 2680 WOODLAWN DR, HONOLULU, HI 96822 USA.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; BOCKELEEMORVAN D, 1984, ASTRON ASTROPHYS, V141, P411; CAO YX, 1993, ASTRON J, V105, P1027, DOI 10.1086/116490; Chin YN, 1996, ASTRON ASTROPHYS, V305, P960; DAHMEN G, 1995, ASTRON ASTROPHYS, V295, P194; DANKS AC, 1974, ASTROPHYS J, V194, P745, DOI 10.1086/153297; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; FRERKING MA, 1980, ASTROPHYS J, V240, P65, DOI 10.1086/158207; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; KLEINE M, 1995, ASTROPHYS J, V439, P1021, DOI 10.1086/175239; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; LIS DC, 1997, 6566 IAU; MATTHEWS H, 1997, 6567 IAU; SCHLOERB FP, 1987, ASTRON ASTROPHYS, V187, P469; STAWIKOWSKI A, 1964, ASTROPHYS J, V140, P1280, DOI 10.1086/148023; VANYSEK V, 1991, ASTROPHYS SPACE SC L, V167, P879; VANYSEK V, 1977, COMETS ASTEROIDS MET, P499; WILSON TL, 1994, ANNU REV ASTRON ASTR, V32, P191; WYCKOFF S, 1989, ASTROPHYS J, V339, P488, DOI 10.1086/167312	20	108	108	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					90	93		10.1126/science.278.5335.90	http://dx.doi.org/10.1126/science.278.5335.90			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311932				2022-12-28	WOS:A1997XZ12400043
J	Leshner, AI				Leshner, AI			Addiction is a brain disease, and it matters	SCIENCE			English	Article							INJECTION-DRUG USERS; MOLECULAR MECHANISMS; COCAINE; ABUSE; ADAPTATIONS; BEHAVIOR; PATHWAYS; EXPOSURE; SYSTEM	Scientific advances over the past 20 years have shown that drug addiction is a chronic, relapsing disease that results from the prolonged effects of drugs on the brain. As with many other brain diseases, addiction has embedded behavioral and social-context aspects that are important parts of the disorder itself. Therefore, the most effective treatment approaches will include biological, behavioral, and social-context components. Recognizing addiction as a chronic, relapsing brain disorder characterized by compulsive drug seeking and use can impact society's overall health and social policy strategies and help diminish the health and social costs associated with drug abuse and addiction.			Leshner, AI (corresponding author), NIDA, NIH, 5600 FISHERS LANE, ROOM 10-05, ROCKVILLE, MD 20857 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1994, SEMIN NEUROSCI; Baxter Jr, 1996, Semin Clin Neuropsychiatry, V1, P32; Booth RE, 1996, DRUG ALCOHOL DEPEN, V42, P11, DOI 10.1016/0376-8716(96)01257-4; Childress A R, 1988, NIDA Res Monogr, V84, P25; COLON HM, 1995, AIDS EDUC PREV, V7, P195; Daley D.C., 1997, SUBSTANCE ABUSE COMP, P458; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; ICIARDI JA, 1997, J DRUG ISSUES, V27, P261; Institute of Medicine, 1996, PATHW ADD; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; LESHNER AI, 1997, HOSP PRACTICE SPECIA; MCLELLAN AT, 1997, TREATING DRUG ABUSER, P7; Melega WP, 1997, BEHAV BRAIN RES, V84, P259, DOI 10.1016/S0166-4328(97)83333-5; Nestler EJ, 1996, MOL PSYCHIATR, V1, P190; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; OBRIEN CP, 1975, PHARMACOL REV, V27, P533; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; Stephens R. C., 1993, HDB RISK AIDS INJECT, P519; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719; WEXLER HK, 1993, DRUG TREATMENT CRIMI, P261; Wiebel WW, 1996, J ACQ IMMUN DEF SYND, V12, P282, DOI 10.1097/00042560-199607000-00008	30	937	1014	1	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					45	47		10.1126/science.278.5335.45	http://dx.doi.org/10.1126/science.278.5335.45			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311924				2022-12-28	WOS:A1997XZ12400029
J	Ollmann, MM; Wilson, BD; Yang, YK; Kerns, JA; Chen, YR; Gantz, I; Barsh, GS				Ollmann, MM; Wilson, BD; Yang, YK; Kerns, JA; Chen, YR; Gantz, I; Barsh, GS			Antagonism of central melanocortin receptors in vitro and in vivo by Agouti-related protein	SCIENCE			English	Article							MELANOCYTE-STIMULATING-HORMONE; MOLECULAR-CLONING; HUMAN HOMOLOG; YELLOW MICE; CELL-LINE; GENE; EXPRESSION; MUTATION; IDENTIFICATION; LOCALIZATION	Expression of Agouti protein is normally limited to the skin where it affects pigmentation, but ubiquitous expression causes obesity. An expressed sequence tag was identified that encodes Agouti-related protein, whose RNA is normally expressed in the hypothalamus and whose levels were increased eightfold in ob/ob mice. Recombinant Agoutirelated protein was a potent, selective antagonist of Mc3r and Mc4r, melanocortin receptor subtypes implicated in weight regulation, Ubiquitous expression of human AGRP complementary DNA in transgenic mice caused obesity without altering pigmentation, Thus, Agouti-related protein is a neuropeptide implicated in the normal control of body weight downstream of leptin signaling.	STANFORD UNIV,SCH MED,BECKMAN CTR B271A,DEPT PEDIAT,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; UNIV MICHIGAN,SCH MED,DEPT SURG,ANN ARBOR,MI 48109	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NEI NIH HHS [EY07106] Funding Source: Medline; NIDDK NIH HHS [P30DK-34933] Funding Source: Medline; NIGMS NIH HHS [GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KENAKIN TP, 1982, CAN J PHYSIOL PHARM, V60, P249, DOI 10.1139/y82-036; Kiefer LL, 1997, BIOCHEMISTRY-US, V36, P2084, DOI 10.1021/bi962647v; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; OLLMANN MM, UNPUB; POTENZA MN, 1992, PIGM CELL RES, V5, P372, DOI 10.1111/j.1600-0749.1992.tb00565.x; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; QUILLAN JM, 1995, P NATL ACAD SCI USA, V92, P2894, DOI 10.1073/pnas.92.7.2894; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Siegrist W, 1997, J RECEPT SIGNAL TR R, V17, P75, DOI 10.3109/10799899709036595; Silvers W. K., 1979, COAT COLORS MICE, P6; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	1479	1538	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					135	138		10.1126/science.278.5335.135	http://dx.doi.org/10.1126/science.278.5335.135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311920				2022-12-28	WOS:A1997XZ12400056
J	Ickovics, JR; Viscoli, CM; Horwitz, RI				Ickovics, JR; Viscoli, CM; Horwitz, RI			Functional recovery after myocardial infarction in men: The independent effects of social class	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Plenary Session of the Association-of-American-Physicians	MAY, 1996	WASHINGTON, D.C.	Assoc Amer Physicians		myocardial infarction; social class; outcome assessment (health care); ventricular function, left; coronary disease	CORONARY HEART-DISEASE; QUALITY-OF-LIFE; SOCIOECONOMIC-STATUS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; FORMAL EDUCATION; ARTERY DISEASE; FOLLOW-UP; HEALTH; MORTALITY	Background: Social class has been repeatedly associated with cardiovascular-related illness and death, but no studies have examined the effect of social class on recovery from myocardial infarction. Moreover, few studies have simultaneously evaluated a broad array of demographic, clinical, and psychosocial factors that may influence health outcomes after myocardial infarction. Objective: To determine whether social class remains independently associated with functional recovery after myocardial infarction, even after controlling for clinical, demographic, and psychosocial factors known to influence outcomes after infarction. Design: Analysis of prospective data from a multicenter, randomized, double-blind clinical trial. Setting: 25 hospitals or clinical settings in the United States and Canada that participated in the Beta Blocker Heart Attack Trial, including the Health Insurance Plan substudy. Patients: 2145 men 29 to 69 years of age who were hospitalized with acute myocardial infarction and were recruited into the Beta Blocker Heart Attack Trial. Measurements: The primary outcome was change in New York Heart Association functional class between baseline assessment and 12 months after infarction, dichotomized as improved or not improved (that is, no change, decline in at least one category, or death). Results: Social class maintained its independent effect on improved functional status, even after controlling for pertinent prognostic factors. Persons of high social class were significantly more likely than persons of low or middle social class to have improved functional status 1 year after infarction. Certain clinical, demographic, and psychosocial features were related to recovery, but the effect of social class could not be explained by these additional features. Conclusions: Social class has a substantial influence on recovery from myocardial infarction and may explain differences in clinical outcomes.			Ickovics, JR (corresponding author), YALE UNIV, DEPT INTERNAL MED, POB 208025, NEW HAVEN, CT 06520 USA.							ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; ANDERSON NB, 1993, HEALTH PSYCHOL, V12, P3, DOI 10.1037/0278-6133.12.1.3; BAKER DW, 1994, JAMA-J AM MED ASSOC, V272, P1528, DOI 10.1001/jama.272.19.1528; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; BURING JE, 1987, JAMA-J AM MED ASSOC, V258, P791, DOI 10.1001/jama.258.6.791; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; COHEN DJ, 1992, NEW ENGL J MED, V327, P1329, DOI 10.1056/NEJM199211053271901; DOEHRMAN SR, 1977, SOC SCI MED, V11, P199, DOI 10.1016/0037-7856(77)90094-4; EAKER ED, 1992, AM J EPIDEMIOL, V135, P854, DOI 10.1093/oxfordjournals.aje.a116381; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GLASS TA, 1995, J GERONTOL B-PSYCHOL, V50, pS65, DOI 10.1093/geronb/50B.2.S65; GORKIN L, 1993, AM J CARDIOL, V71, P1069, DOI 10.1016/0002-9149(93)90575-W; HANSEN V, 1989, BRIT MED J, V299, P85, DOI 10.1136/bmj.299.6691.85; Harpole DH, 1996, ANN THORAC SURG, V62, P756, DOI 10.1016/S0003-4975(96)00378-5; HILLERS TK, 1994, J CLIN EPIDEMIOL, V47, P1287, DOI 10.1016/0895-4356(94)90134-1; HINKLE LE, 1968, SCIENCE, V161, P238, DOI 10.1126/science.161.3838.238; HOLME I, 1976, LANCET, V2, P1396; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Ickovics JR, 1996, AM J EPIDEMIOL, V143, P144; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KONSTANTINIDES S, 1995, NEW ENGL J MED, V333, P469, DOI 10.1056/NEJM199508243330801; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; Link BG, 1996, AM J PUBLIC HEALTH, V86, P471, DOI 10.2105/AJPH.86.4.471; Lubsen J, 1996, AM J CARDIOL, V77, P1191, DOI 10.1016/S0002-9149(96)00161-0; LUOTO R, 1994, J EPIDEMIOL COMMUN H, V48, P348, DOI 10.1136/jech.48.4.348; LYNCH J, 1995, CIRCULATION, V92, P1786, DOI 10.1161/01.CIR.92.7.1786; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MATTHEWS KA, 1989, AM J EPIDEMIOL, V129, P1132, DOI 10.1093/oxfordjournals.aje.a115235; MYERS A, 1975, BRIT HEART J, V37, P1133; O'Leary V E, 1995, Womens Health, V1, P121; PEKKANEN J, 1995, BRIT MED J, V311, P589, DOI 10.1136/bmj.311.7005.589; Peltola T, 1996, ANN CHIR GYNAECOL FE, V85, P40; PINCUS T, 1994, J CLIN EPIDEMIOL, V47, P355, DOI 10.1016/0895-4356(94)90156-2; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; SGARBOSSA EB, 1993, ANN INTERN MED, V119, P359, DOI 10.7326/0003-4819-119-5-199309010-00002; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; Tei CW, 1996, J AM COLL CARDIOL, V28, P658, DOI 10.1016/0735-1097(96)00202-1; TILDSLEY GJ, 1992, J CLIN PATHOL, V45, P6, DOI 10.1136/jcp.45.1.6; Trouillet JL, 1996, J THORAC CARDIOV SUR, V112, P926, DOI 10.1016/S0022-5223(96)70092-2; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; VISCOLI CM, 1993, ANN INTERN MED, V118, P99, DOI 10.7326/0003-4819-118-2-199301150-00004; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; WOO KS, 1994, ANNU REV MED, V45, P325; 1983, NEW ENGL J MED, V309, P321	57	48	49	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					518	+		10.7326/0003-4819-127-7-199710010-00003	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XY733	9313019				2022-12-28	WOS:A1997XY73300003
J	Newman, CC; Wagner, RF				Newman, CC; Wagner, RF			Black hairy tongue	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Newman, CC (corresponding author), UNIV TEXAS,MED BRANCH,GALVESTON,TX 77555, USA.								0	3	3	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					897	897		10.1056/NEJM199709253371305	http://dx.doi.org/10.1056/NEJM199709253371305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX302	9302304				2022-12-28	WOS:A1997XX30200005
J	Gough, A; Clapperton, M; Rolando, N; Foster, AVM; PhilpottHoward, J; Edmonds, ME				Gough, A; Clapperton, M; Rolando, N; Foster, AVM; PhilpottHoward, J; Edmonds, ME			Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection	LANCET			English	Article							PERIPHERAL-BLOOD; MELLITUS; LEUKOCYTES; GLUCOSE; CELLS	Background Diabetic foot infections cause substantial morbidity and mortality. Neutrophil superoxide generation, a crucial part of neutrophil bactericidal activity, is impaired in diabetes. Granulocyte-colony stimulating factor (G-CSF) increases the release of neutrophils from the bone marrow and improves neutrophil function. We assessed G-CSF as adjuvant therapy for the treatment of severe foot infections in diabetic patients. Methods 40 diabetic patients with foot infections were enrolled in a double-blind placebo-controlled study. On admission, patients were randomly assigned G-CSF (filgrastim) therapy (n=20) or placebo (n=20) for 7 days. Both groups received similar antibiotic and insulin treatment. Neutrophils from the peripheral blood of these participants and from healthy controls were stimulated with opsonised zymosan, and superoxide production was measured by a spectrophotometric assay (reduction of ferricytochrome C). Findings G-CSF therapy was associated with earlier eradication of pathogens from the infected ulcer (median 4 [range 2-10] vs 8 [2-79] days in the placebo group; p=0.02), quicker resolution of cellulitis (7 [5-20] vs 12 [5-93] days; p=0.03), shorter hospital stay (10 [7-31] vs 17.5 [9-100] days; p=0.02), and a shorter duration of intravenous antibiotic treatment (8.5 [5-30] vs 14.5 [8-63] days; p=0.02). No G-CSF-treated patient needed surgery, whereas two placebo recipients underwent toe amputation and two had extensive debridement under anaesthesia. After 7 days' treatment, neutrophil superoxide production was significantly higher in the G-CSF group than in the placebo group (16.1 [42-24.2] vs 7.3 [2.1-11.5] nmol per 10(6) neutrophils in 30 min; p<0.0001). G-CSF therapy was generally well tolerated. Interpretation G-CSF treatment was associated with improved clinical outcome of foot infection in diabetic patients. This improvement may be related to an increase in neutrophil superoxide production.	UNIV LONDON KINGS COLL HOSP, KINGS DIABET CTR, LONDON, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, INST LIVER STUDIES, LONDON SE5 9PJ, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, DEPT MED MICROBIOL, LONDON, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, PUBL HLTH LAB, LONDON, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London								APELQVIST J, 1994, J INTERN MED, V235, P463, DOI 10.1111/j.1365-2796.1994.tb01104.x; BOLAND OM, 1993, DIABETES, V42, P336, DOI 10.2337/diabetes.42.2.336; BRIDGES RM, 1994, SURG CLIN N AM, V74, P537, DOI 10.1016/S0039-6109(16)46328-0; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; CEBON J, 1994, BRIT J HAEMATOL, V86, P265, DOI 10.1111/j.1365-2141.1994.tb04725.x; CHATTA GS, 1994, BLOOD, V84, P2923; DALE DC, 1995, J INFECT DIS, V172, P1061, DOI 10.1093/infdis/172.4.1061; DAVIDSON NJ, 1984, J CLIN PATHOL, V37, P783, DOI 10.1136/jcp.37.7.783; ENEROTH M, 1997, THESIS LUND U SWEDEN; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; GRAYSON ML, 1994, CLIN INFECT DIS, V18, P683, DOI 10.1093/clinids/18.5.683; GRAYSON ML, 1995, JAMA-J AM MED ASSOC, V273, P721, DOI 10.1001/jama.273.9.721; HOLLINGSHEAD LM, 1991, DRUGS, V42, P300, DOI 10.2165/00003495-199142020-00009; JACOBS MJHM, 1992, EUR J VASCULAR SURG, V6, P135, DOI 10.1016/S0950-821X(05)80230-0; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; Leibovici L, 1996, DIABETIC MED, V13, P457, DOI 10.1002/(SICI)1096-9136(199605)13:5<457::AID-DIA83>3.0.CO;2-T; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; MARPHOFFER W, 1993, DIABETES RES CLIN PR, V19, P183; MARPHOFFER W, 1992, DIABETES CARE, V15, P256; MOWAT AG, 1971, NEW ENGL J MED, V284, P621, DOI 10.1056/NEJM197103252841201; NELSON S, 1994, CLIN INFECT DIS, V18, pS197, DOI 10.1093/clinids/18.Supplement_2.S197; NIELSON CP, 1989, DIABETES, V38, P1031, DOI 10.2337/diabetes.38.8.1031; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; ROILIDES E, 1991, J INFECT DIS, V163, P579, DOI 10.1093/infdis/163.3.579; SANDERS LJ, 1991, INFECT DIS LOWER EXT, P193; SATO N, 1992, DIABETES CARE, V15, P1050, DOI 10.2337/diacare.15.8.1050; Sato N, 1997, DIABETES, V46, P133, DOI 10.2337/diabetes.46.1.133; SELIG C, 1995, INFECT IMMUN, V63, P104, DOI 10.1128/IAI.63.1.104-109.1995; WEST NJ, 1995, AM J HEALTH-SYST PH, V52, P1199, DOI 10.1093/ajhp/52.11.1199; WILLIAMS DRR, 1994, FOOT DIABETES, P15	31	160	169	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	1997	350	9081					855	859		10.1016/S0140-6736(97)04495-4	http://dx.doi.org/10.1016/S0140-6736(97)04495-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310604				2022-12-28	WOS:A1997XX40100012
J	Liu, JW; Hsu, NY; Huang, TC				Liu, JW; Hsu, NY; Huang, TC			Pustules and bacteraemia	LANCET			English	Article							PYODERMA-GANGRENOSUM; MULTIFOCAL OSTEOMYELITIS		CHANG GUNG MEM HOSP,DEPT INTERNAL MED,DIV INFECT DIS,KAOHSIUNG,TAIWAN; CHANG GUNG MEM HOSP,DEPT SURG,DIV THORAC & CARDIOVASC SURG,KAOHSIUNG,TAIWAN	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital								DAGAN O, 1995, PEDIATR DERMATOL, V12, P39, DOI 10.1111/j.1525-1470.1995.tb00122.x; DUGUID CM, 1993, CLIN DERMATOL, V11, P129, DOI 10.1016/0738-081X(93)90109-P; Powell FC, 1996, J AM ACAD DERMATOL, V34, P395, DOI 10.1016/S0190-9622(96)90428-4; Sundaram M, 1996, SKELETAL RADIOL, V25, P333, DOI 10.1007/s002560050091	4	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					860	860		10.1016/S0140-6736(97)04454-1	http://dx.doi.org/10.1016/S0140-6736(97)04454-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310605				2022-12-28	WOS:A1997XX40100013
J	Johnson, RL; Tabin, CJ				Johnson, RL; Tabin, CJ			Molecular models for vertebrate limb development	CELL			English	Review							APICAL ECTODERMAL RIDGE; DEVELOPING CHICK LIMB; BONE MORPHOGENETIC PROTEINS; FIBROBLAST GROWTH-FACTORS; SONIC-HEDGEHOG; POLARIZING ACTIVITY; PATTERN-FORMATION; GENE-EXPRESSION; RETINOIC ACID; FEEDBACK LOOP		HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Johnson, RL (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA.							BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHAN DC, 1995, DEVELOPMENT, V121, P3151; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Concordet JP, 1996, DEVELOPMENT, V122, P2835; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Davis AP, 1996, DEVELOPMENT, V122, P1175; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; DUBOULE D, 1994, SCIENCE, V266, P575, DOI 10.1126/science.7939709; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; Duprez DM, 1996, DEVELOPMENT, V122, P1821; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1975, J EXP ZOOL, V193, P449, DOI 10.1002/jez.1401930324; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FALLON JF, 1977, J EMBRYOL EXP MORPH, V41, P223; Favier B, 1996, DEVELOPMENT, V122, P449; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; FERNANDEZTERAN M, 1997, IN PRESS DEV BIOL; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; GARDNER CA, 1992, DEV DYNAM, V193, P370, DOI 10.1002/aja.1001930410; GEDUSPAN JS, 1992, DEV BIOL, V151, P242, DOI 10.1016/0012-1606(92)90230-E; GOETINCK PF, 1964, DEV BIOL, V10, P71, DOI 10.1016/0012-1606(64)90005-3; GOFF DJ, 1997, IN PRESS DEVELOPMENT; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Grieshammer U, 1996, DEVELOPMENT, V122, P3851; HALL BK, 1992, ANAT EMBRYOL, V186, P107; Hamburger V, 1938, J EXP ZOOL, V77, P379, DOI 10.1002/jez.1400770304; Haramis AG, 1995, DEVELOPMENT, V121, P4237; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; Harrison RG, 1921, J EXP ZOOL, V32, P1, DOI 10.1002/jez.1400320102; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Helms JA, 1996, DEVELOPMENT, V122, P1385; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HONIG LS, 1981, NATURE, V291, P72, DOI 10.1038/291072a0; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Loomis CA, 1996, NATURE, V382, P360, DOI 10.1038/382360a0; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; Lu HC, 1997, DEVELOPMENT, V124, P1643; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTI E, 1995, DEVELOPMENT, V121, P2537; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; Michaud JL, 1997, DEVELOPMENT, V124, P1453; Nelson CE, 1996, DEVELOPMENT, V122, P1449; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; Noramly S, 1996, DEV BIOL, V179, P339, DOI 10.1006/dbio.1996.0265; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Pagan SM, 1996, DEV BIOL, V180, P35, DOI 10.1006/dbio.1996.0282; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PAUTOU MP, 1977, J EMBRYOL EXP MORPH, V42, P177; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Ros MA, 1996, DEVELOPMENT, V122, P2319; ROWE DA, 1982, J EMBRYOL EXP MORPH, V68, P1; Saunders J., 1966, MAJOR PROBLEMS DEV B, P289; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; SMITH JC, 1978, NATURE, V272, P612, DOI 10.1038/272612a0; STEPHENS TD, 1981, J EMBRYOL EXP MORPH, V61, P191; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Stratford T, 1996, CURR BIOL, V6, P1124, DOI 10.1016/S0960-9822(02)70679-9; STRECKER TR, 1983, TERATOLOGY, V27, P159, DOI 10.1002/tera.1420270204; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SUMMERBELL D, 1975, J EMBRYOL EXP MORPH, V33, P621; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TODT WL, 1984, J EMBRYOL EXP MORPH, V80, P21; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; Vortkamp A, 1997, CURR BIOL, V7, pR104, DOI 10.1016/S0960-9822(06)00049-2; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0; YONEI S, 1995, DEV BIOL, V170, P542, DOI 10.1006/dbio.1995.1235	120	460	472	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					979	990		10.1016/S0092-8674(00)80364-5	http://dx.doi.org/10.1016/S0092-8674(00)80364-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323126	Bronze			2022-12-28	WOS:A1997XX76800004
J	Bence, K; Ma, W; Kozasa, T; Huang, XY				Bence, K; Ma, W; Kozasa, T; Huang, XY			Direct stimulation of Bruton's tyrosine kinase by G(q)-protein alpha-subunit	NATURE			English	Article							ACTIVATED PROTEIN-KINASE; COLI EXPRESSION SYSTEM; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; ESCHERICHIA-COLI; MAP KINASE; CYTOPLASMIC DOMAIN; PURIFICATION; RECEPTOR; CELLS	Heterotrimeric guanine-nucleotide-binding regulatory proteins (G proteins) transduce signals from a wide variety of cell-surface receptors to generate physiological responses(1). Protein-tyrosine kinases are another group of critical cellular signal transducers and their malfunction often leads to cancer(2). Although activation of G-protein-coupled receptors can elicit rapid stimulation cellular protein-tyrosine phosphorylation(3), the mechanism used by G proteins to activate protein-tyrosine kinases is unclear. Here we show that the purified alpha-subunit of the G(q) class of G proteins (G alpha q) directly stimulates the activity of a purified non-receptor kinase, Bruton's tyrosine kinase (Btk)(4), whereas purified alpha-subunits from G(i1), G(0) or G(z) proteins do not, G alpha q can also activate Btk in vivo, Furthermore, in Btk-deficient cells, stimulation of another kinase, a p38 MAP kinase, by Gq-coupled receptors is blocked. Our results demonstrate that certain protein-tyrosine kinases can be direct effecters of G proteins.	CORNELL UNIV, COLL MED, DEPT PHYSIOL, NEW YORK, NY 10021 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BOYER JL, 1994, J BIOL CHEM, V269, P2814; FLINT NA, 1994, J CELL BIOCHEM, V55, P389, DOI 10.1002/jcb.240550317; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEE CW, 1994, J BIOL CHEM, V269, P25335; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PRICE DJ, 1995, BBA-MOL CELL RES, V1265, P133, DOI 10.1016/0167-4889(94)00213-X; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; Satterthwaite A, 1996, ANNU REV IMMUNOL, V14, P131, DOI 10.1146/annurev.immunol.14.1.131; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913	28	161	163	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					296	299		10.1038/38520	http://dx.doi.org/10.1038/38520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305846				2022-12-28	WOS:A1997XW77200051
J	Winter, MC; Welsh, MJ				Winter, MC; Welsh, MJ			Stimulation of CFTR activity by its phosphorylated R domain	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; CYSTIC-FIBROSIS; CHLORIDE CHANNEL; CL CHANNELS; ATP HYDROLYSIS; PYROPHOSPHATE; INACTIVATION	Phosphorylation controls the activity of ion channels in many tissues. In epithelia, the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is activated by phosphorylation of serine residues in its regulatory (R) domain and then gated by binding and hydrolysis of ATP by the nucleotide-binding domains(1-3). Current models propose that the unphosphorylated R domain serves as an inhibitory particle that occludes the pore(1,2,4-6), much like the inhibitory 'ball' in Shaker K+ channels(7,8); presumably, phosphorylation relieves this inhibition. Here we test this by adding an R-domain peptide to a CFTR variant in which much of the R domain had been deleted (CFTR-Delta R/S660A): in contrast to predictions, we found that adding an unphosphorylated R domain to CFTR-Delta R/S660A did not inhibit activity, whereas a phosphorylated R-domain peptide stimulated activity. To investigate how phosphorylation controls activity, we studied channel gating and found that phosphorylation of the R domain increases the rate of channel opening by enhancing the sensitivity to ATP. Our results indicate that CFTR is regulated by a new mechanism in which phosphorylation of one domain stimulates the interaction of ATP with another domain, thereby increasing activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LI C, 1996, J BIOL CHEM, V45, P28463; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; MALLER JL, 1978, P NATL ACAD SCI USA, V75, P248, DOI 10.1073/pnas.75.1.248; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Welsh M, 1995, METABOLIC MOL BASIS, V7, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	116	118	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					294	296		10.1038/38514	http://dx.doi.org/10.1038/38514			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305845				2022-12-28	WOS:A1997XW77200050
J	Ende, J; Kelley, M; Sox, H				Ende, J; Kelley, M; Sox, H			The federated council of internal medicine's resource guide for residency education: An instrument for curricular change	ANNALS OF INTERNAL MEDICINE			English	Article								The Federated Council of Internal Medicine has developed a resource guide to help internal medicine residency programs produce internists who are prepared for today's practice of internal medicine and the challenges of practice in the future. The guide situates general internal medicine as the primary care profession that focuses on preventive, short-term, and long-term care of adult patients. It assumes that a single pathway is sufficient for educating general internists and subspecialty-bound trainees. It identifies the learning experiences that should be part of general internal medicine residency training, lists the clinical competencies that are important for primary care practice, and describes the role of the integrative disciplines that should inform the care of every patient. It also describes a process that program directors and local program committees can use to develop competency-based curricula.			Ende, J (corresponding author), UNIV PENN, PRESBYTERIAN MED CTR, SCH MED, DEPT MED, 39TH & MARKET ST, PHILADELPHIA, PA 19104 USA.							BLOOM SW, 1989, MED EDUC, V23, P228, DOI 10.1111/j.1365-2923.1989.tb01538.x	1	19	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					454	457		10.7326/0003-4819-127-6-199709150-00007	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313003				2022-12-28	WOS:A1997XV77900007
J	Ecker, JR				Ecker, JR			BRI-ghtening the pathway to steroid hormone signaling events in plants	CELL			English	Review							LEUCINE-RICH REPEATS; BRASSINOSTEROIDS; ARABIDOPSIS; GROWTH; POLLEN				Ecker, JR (corresponding author), UNIV PENN,DEPT BIOL,INST PLANT SCI,PHILADELPHIA,PA 19104, USA.		Ecker, Joseph R/B-9144-2008	Ecker, Joseph R/0000-0001-5799-5895				Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BRAUN DM, 1996, TRENDS BIOCHEM SCI, V21, P69; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Clouse SD, 1996, PLANT J, V10, P1, DOI 10.1046/j.1365-313X.1996.10010001.x; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; Kauschmann A, 1996, PLANT J, V9, P701, DOI 10.1046/j.1365-313X.1996.9050701.x; Kende H, 1997, PLANT CELL, V9, P1197, DOI 10.1105/tpc.9.7.1197; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Li JM, 1997, P NATL ACAD SCI USA, V94, P3554, DOI 10.1073/pnas.94.8.3554; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.arplant.39.1.23; MITCHELL JW, 1970, NATURE, V225, P1065, DOI 10.1038/2251065a0; SAKURAI A, 1993, PLANT GROWTH REGUL, V13, P147, DOI 10.1007/BF00024257; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; Yokota T, 1997, TRENDS PLANT SCI, V2, P137, DOI 10.1016/S1360-1385(97)01017-0	18	13	14	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					825	827		10.1016/S0092-8674(00)80346-3	http://dx.doi.org/10.1016/S0092-8674(00)80346-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298893	Bronze			2022-12-28	WOS:A1997XV56300002
J	Niki, H; Hiraga, S				Niki, H; Hiraga, S			Subcellular distribution of actively partitioning F plasmid during the cell division cycle in E-coli	CELL			English	Article							ESCHERICHIA-COLI; BACTERIAL PLASMIDS; BACILLUS-SUBTILIS; ESSENTIAL PROTEIN; ATPASE ACTIVITY; DAUGHTER CELLS; PARB PROTEIN; P1 PLASMID; CHROMOSOME; GENES	F plasmid is partitioned with fidelity to daughter cells during cell division cycle owing to two trans-acting genes, sopA and sops, and a cis-acting site, sopC. We visualized the subcellular distribution of mini-F-plasmid molecules by fluorescence in situ hybridization. Mini-F-plasmid molecules having the sopABC segment were localized at midcell in newborn cells. Replicated plasmid molecules migrated to cell positions 1/4 and 3/4 without coupling with cell elongation and were tethered to these positions until completion of cell division. In contrast, molecules of a mini F plasmid lacking the sopABC segment were distributed randomly in spaces not occupied by nucleoids. The sopABC system caused replicated plasmid molecules to be positioned and tethered at the cell quarter sites.			Niki, H (corresponding author), KUMAMOTO UNIV,SCH MED,INST MED EMBRYOL & GENET,DEPT MOL CELL BIOL,4-24-1 KUHONJI,KUMAMOTO 862,JAPAN.			Niki, Hironori/0000-0002-5391-6595				AUSTIN S, 1990, CELL, V60, P351, DOI 10.1016/0092-8674(90)90584-2; AUSTIN S, 1983, J MOL BIOL, V169, P373, DOI 10.1016/S0022-2836(83)80056-4; Davis MA, 1996, MOL MICROBIOL, V21, P1029, DOI 10.1046/j.1365-2958.1996.721423.x; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; ELLASSON A, 1992, MOL MICROBIOL, V6, P165; EZAKI B, 1991, J BACTERIOL, V173, P6643, DOI 10.1128/jb.173.20.6643-6646.1991; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1995, J BACTERIOL, V177, P2381, DOI 10.1128/jb.177.9.2381-2386.1995; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; Helmstetter CE, 1997, J BACTERIOL, V179, P1393, DOI 10.1128/jb.179.4.1393-1399.1997; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRAGA S, 1991, RES MICROBIOL, V142, P189, DOI 10.1016/0923-2508(91)90029-A; HOGAN JE, 1982, PLASMID, V8, P36, DOI 10.1016/0147-619X(82)90039-7; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JAFFE A, 1985, J BACTERIOL, V163, P841; KLINE BC, 1985, PLASMID, V14, P1, DOI 10.1016/0147-619X(85)90027-7; KUSUKAWA N, 1987, MOL GEN GENET, V208, P365, DOI 10.1007/BF00328125; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Miller J.H., 1972, EXPT MOL GENETICS; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORI H, 1989, J BIOL CHEM, V264, P15535; MORI H, 1986, J MOL BIOL, V192, P1, DOI 10.1016/0022-2836(86)90459-6; MOTALLEBIVESHAREH M, 1990, MOL MICROBIOL, V4, P1455, DOI 10.1111/j.1365-2958.1990.tb02056.x; MYSLIWIEC TH, 1991, J BACTERIOL, V173, P1911, DOI 10.1128/jb.173.6.1911-1919.1991; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; NIKI H, 1988, J BACTERIOL, V170, P5272, DOI 10.1128/jb.170.11.5272-5278.1988; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; OGURA T, 1983, CELL, V32, P351, DOI 10.1016/0092-8674(83)90454-3; SCOTT JR, 1984, MICROBIOL REV, V48, P1; WATANABE E, 1989, MOL GEN GENET, V218, P431, DOI 10.1007/BF00332406; WATANABE E, 1992, MOL GEN GENET, V234, P346, DOI 10.1007/BF00538693; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Yamanaka K, 1996, MOL GEN GENET, V250, P241	39	163	163	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					951	957		10.1016/S0092-8674(00)80359-1	http://dx.doi.org/10.1016/S0092-8674(00)80359-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298906	Bronze			2022-12-28	WOS:A1997XV56300015
J	Botstein, D; Chervitz, SA; Cherry, JM				Botstein, D; Chervitz, SA; Cherry, JM			Genetics - Yeast as a model organism	SCIENCE			English	Editorial Material											Botstein, D (corresponding author), STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.			Cherry, J. Michael/0000-0001-9163-5180	NHGRI NIH HHS [P41 HG001315, P41 HG001315-06, HG 01315] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG001315] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOTSTEIN D, 1988, SCIENCE, V240, P1439, DOI 10.1126/science.3287619; GISH W, UNPUB; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0	7	261	279	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 29	1997	277	5330					1259	1260		10.1126/science.277.5330.1259	http://dx.doi.org/10.1126/science.277.5330.1259			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9297238	Green Accepted			2022-12-28	WOS:A1997XT82700041
J	Cao, A; Saba, L; Galanello, R; Rosatelli, C				Cao, A; Saba, L; Galanello, R; Rosatelli, C			Molecular diagnosis and carrier screening for beta thalassemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRADIENT GEL-ELECTROPHORESIS; LOCUS-CONTROL REGION; PRENATAL-DIAGNOSIS; ALPHA-THALASSEMIA; FETAL HEMOGLOBIN; GLOBIN GENE; DNA; MUTATIONS; TRANSCRIPTION; HETEROGENEITY	Thalassemias are common autosomal recessive disorders especially in populations of Mediterranean, Middle Eastern, and Far Eastern descent. Relatively high incidence is also observed in people of Asian Indian origin but the incidence is more limited in those of African descent. beta Thalassemias are heterogeneous at the molecular level, with more than 150 different molecular defects identified to date. Despite this heterogeneity, each at-risk population has its own spectrum of common mutations, usually from 5 to 10, a finding that simplifies mutation analysis. Homozygosity for beta thalassemias usually results in transfusion-dependent thalassemia major and, rarely, in mild non-transfusion-dependent conditions. Molecular diagnosis may be used to define genotypes associated with mild forms. Advances in carrier diagnosis using hematologic analysis followed by mutation analysis have made possible the population screening of women al childbearing age and prenatal diagnosis. This approach in combination with nondirective genetic counseling has resulted in a consistent decline of the birth of affected homozygotes in several Mediterranean at-risk populations, as well as knowledge of the risks of being a carrier. Molecular diagnosis of homozygotes and identification of carriers of beta thalassemia may lead to improved clinical management of patients with the disorder and prevention of the birth of affected homozygotes.			Cao, A (corresponding author), UNIV CAGLIARI, IST CLIN & BIOL ETA EVOLUT, VIA JENNER S-N, I-09121 CAGLIARI, ITALY.			SABA, Luisella/0000-0002-3470-3279; ROSATELLI, MARIA CRISTINA/0000-0001-6821-3190				ANGASTINIOTIS M, 1988, CYPRUS THALASSEMIA C, V23, P417; [Anonymous], 1983, Bull World Health Organ, V61, P63; BAYSAL E, 1995, HEMOGLOBIN, V19, P213, DOI 10.3109/03630269509036943; BENNANI C, 1993, BRIT J HAEMATOL, V84, P335, DOI 10.1111/j.1365-2141.1993.tb03075.x; BOLLEKENS JA, 1991, HEMATOL ONCOL CLIN N, V5, P399, DOI 10.1016/S0889-8588(18)30422-2; CAI SP, 1990, J CLIN INVEST, V85, P550, DOI 10.1172/JCI114471; CAO A, 1993, BAILLIERE CLIN HAEM, V6, P263, DOI 10.1016/S0950-3536(05)80072-1; CAO A, 1987, Blood Reviews, V1, P169, DOI 10.1016/0268-960X(87)90032-4; CAO A, 1985, ANN NY ACAD SCI, V445, P380, DOI 10.1111/j.1749-6632.1985.tb17208.x; CAO A, 1997, CIBA F S, V197, P137; Cao A, 1990, EUR J INTERN MED, V1, P227; CHEHAB FF, 1987, BLOOD, V69, P1141; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; GALANELLO R, 1984, HEMOGLOBIN, V8, P25; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GONZALEZREDONDO JM, 1988, BLOOD, V72, P1007; GONZALEZREDONDO JM, 1989, BLOOD, V73, P1705; GRANT A, 1991, LANCET, V337, P1491; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; KANAVAKIS E, 1982, BRIT J HAEMATOL, V52, P465, DOI 10.1111/j.1365-2141.1982.tb03916.x; KATTAMIS C, 1990, BRIT J HAEMATOL, V74, P342, DOI 10.1111/j.1365-2141.1990.tb02593.x; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KULOZIK AE, 1991, J CLIN INVEST, V87, P2142, DOI 10.1172/JCI115246; LIEINJO LE, 1989, AM J HUM GENET, V45, P971; LIU JZ, 1989, HEMOGLOBIN, V13, P585, DOI 10.3109/03630268908993109; LOUDIANOS G, 1990, BLOOD, V75, P526; Loukopoulos D, 1996, SEMIN HEMATOL, V33, P76; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MELIS MA, 1983, BLOOD, V62, P226; MILLER BA, 1987, NEW ENGL J MED, V316, P244, DOI 10.1056/NEJM198701293160504; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; ONER R, 1990, HEMOGLOBIN, V14, P1, DOI 10.3109/03630269009002250; ORKIN SH, 1992, BLOOD, V80, P575; Poncz M, 1988, Oxf Surv Eukaryot Genes, V5, P163; PORTER JB, 1990, SEMIN HEMATOL, V27, P95; ROSATELLI C, 1984, HEMOGLOBIN, V8, P25, DOI 10.3109/03630268408996958; ROSATELLI C, 1994, HEMATOL PATHOL, V8, P25; ROSATELLI MC, 1992, AM J HUM GENET, V50, P422; ROSATELLI MC, 1992, HUM GENET, V89, P585; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; THEIN SL, 1990, AM J HUM GENET, V47, P369; THEIN SL, 1988, BRIT J HAEMATOL, V70, P225, DOI 10.1111/j.1365-2141.1988.tb02468.x; THEIN SL, 1992, BRIT J HAEMATOL, V80, P273, DOI 10.1111/j.1365-2141.1992.tb08132.x; THEIN SL, 1993, BAILLIERE CLIN HAEM, V6, P151, DOI 10.1016/S0950-3536(05)80069-1; WEATHERALL DJ, 1991, NATURE, V349, P275, DOI 10.1038/349275a0; Weatherall DJ, 1981, THALASSEMIA SYNDROME; WILKIE AOM, 1990, AM J HUM GENET, V46, P1112; WOOD WG, 1993, BAILLIERE CLIN HAEM, V6, P177, DOI 10.1016/S0950-3536(05)80070-8	52	55	59	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1273	1277		10.1001/jama.278.15.1273	http://dx.doi.org/10.1001/jama.278.15.1273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333270				2022-12-28	WOS:A1997XZ70900034
J	Falvo, MR; Clary, GJ; Taylor, RM; Chi, V; Brooks, FP; Washburn, S; Superfine, R				Falvo, MR; Clary, GJ; Taylor, RM; Chi, V; Brooks, FP; Washburn, S; Superfine, R			Bending and buckling of carbon nanotubes under large strain	NATURE			English	Article							INSTABILITIES; FLEXIBILITY; ENERGETICS	The curling of a graphitic sheet to form carbon nanotubes(1) produces a class of materials that seem to have extraordinary electrical and mechanical properties(2). In particular, the high elastic modulus of the graphite sheets means that the nanotubes might be stiffer and stronger than and other known material(3-5), with beneficial consequences for their application in composite bulk materials and as individual elements of nanometre-scale devices and sensors(6). The mechanical properties are predicted to be sensitive to details of their structure and to the presence of defects(7), which means that measurements on individual nanotubes are essential to establish these properties. Here we show that multiwalled carbon nanotubes can be bent repeatedly through large angles using the tip of an atomic force microscope, without undergoing catastrophic failure. We observe a range of responses to this high-strain deformation, which together suggest that nanotubes are remarkably flexible and resilient.	UNIV N CAROLINA,DEPT PHYS & ASTRON,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT COMP SCI,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Superfine, Richard/A-1968-2012	Superfine, Richard/0000-0002-2569-071X				AXELRAD EL, 1985, INT J NONLINEAR MECH, V20, P249, DOI 10.1016/0020-7462(85)90033-2; CHOPRA NG, 1995, NATURE, V377, P135, DOI 10.1038/377135a0; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; DESPRES JF, 1995, CARBON, V33, P87, DOI 10.1016/0008-6223(95)91118-Q; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; EBBESEN TW, 1997, CARBON NANOTUBES PRE, P225; FINCH M, 1995, SURFACE MODIFICATION, P13; FRITSCH DS, 1994, INFORMATION PROCESSI, P365; Iijima S, 1996, J CHEM PHYS, V104, P2089, DOI 10.1063/1.470966; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; JU GT, 1992, INT J SOLIDS STRUCT, V29, P1143, DOI 10.1016/0020-7683(92)90140-O; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; LIEBER C, 1997, B AM PHYS SOC, V42, P591; Lu JP, 1997, PHYS REV LETT, V79, P1297, DOI 10.1103/PhysRevLett.79.1297; PIZER SM, IN PRESS COMPUT VISI; ROBERTSON DH, 1992, PHYS REV B, V45, P12592, DOI 10.1103/PhysRevB.45.12592; RUOFF RS, 1995, CARBON, V33, P925, DOI 10.1016/0008-6223(95)00021-5; RUOFF RS, 1995, RECENT ADV CHEM PHYS, V2; SAWADA S, 1992, SOLID STATE COMMUN, V83, P917, DOI 10.1016/0038-1098(92)90911-R; TAYLOR RM, 1993, NANOMANIPULATOR VIRT, P127; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; Yakobson BI, 1996, PHYS REV LETT, V76, P2511, DOI 10.1103/PhysRevLett.76.2511; Yakobson BI, 1997, COMP MATER SCI, V8, P341, DOI 10.1016/S0927-0256(97)00047-5; ZHOU O, 1994, SCIENCE, V263, P1744, DOI 10.1126/science.263.5154.1744	25	1324	1402	6	398	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					582	584		10.1038/39282	http://dx.doi.org/10.1038/39282			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335495				2022-12-28	WOS:A1997YA00800053
J	Katzenstein, D				Katzenstein, D			Combination therapies for HIV infection and genomic drug resistance	LANCET			English	Editorial Material							CUBIC MILLIMETER; CELLS				Katzenstein, D (corresponding author), STANFORD UNIV,MED CTR,STANFORD,CA 94305, USA.			katzenstein, david/0000-0002-8593-4560				Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502	5	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					970	971		10.1016/S0140-6736(97)22040-4	http://dx.doi.org/10.1016/S0140-6736(97)22040-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329506				2022-12-28	WOS:A1997XZ71000002
J	Smith, BM				Smith, BM			Trends in health care coverage and financing and their implications for policy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									GEORGE WASHINGTON UNIV,MED CTR,WASHINGTON,DC 20006	George Washington University								AUERBACH S, 1997, WASHINGTON POST 0305, pC10; BROWN RS, 1993, MEDICARE RISK PROGRA; *BUR CENS, 1993, CURR POP REP P70, V43; *GEN ACC OFF, 1997, 9735 GAO HEHS; MANN J, 1995, HEALTH AFFAIR, V14, P263, DOI 10.1377/hlthaff.14.1.263; PEAR R, 1997, NY TIMES        0813, P17; ROSENBAUM S, 1997, NEGOTIATING NEW HLTH, V1, P58; ROSENBAUM S, 1996, PROVIDING UNIVERSAL, P7; RUSSELL S, 1994, SAN FRANCISCO C 1208, pA8; WEINER JP, 1993, J HEALTH POLIT POLIC, V18, P75, DOI 10.1215/03616878-18-1-75; Weissman J, 1996, JAMA-J AM MED ASSOC, V276, P823, DOI 10.1001/jama.276.10.823; 1997, WEEKLY CHILD HL 0626	12	30	30	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					1000	1003		10.1056/NEJM199710023371410	http://dx.doi.org/10.1056/NEJM199710023371410			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY423	9309108				2022-12-28	WOS:A1997XY42300010
J	Chuang, LSH; Ian, HI; Koh, TW; Ng, HH; Xu, GL; Li, BFL				Chuang, LSH; Ian, HI; Koh, TW; Ng, HH; Xu, GL; Li, BFL			Human DNA (cytosine-5) methyltransferase PCNA complex as a target for p21(WAF1)	SCIENCE			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR SUPPRESSION; BINDING DOMAINS; POLYMERASE-III; HISTONE H1; REPLICATION; METHYLATION	DNA-(cytosine-5) methyltransferase (MCMT) methylates newly replicated mammalian DNA, but the factors regulating this activity are unknown. Here, MCMT is shown to bind proliferating cell nuclear antigen (PCNA), an auxiliary factor for DNA replication and repair. Binding of PCNA requires amino acids 163 to 174 of MCMT, occurs in intact cells at fool of newly replicated DNA, and does not alter MCMT activity. A peptide derived from the cell cycle regulator p21(WAF1) disrupt the MCMT-PCNA interaction, which suggests that p21(WAF1) may regulate methylation by blocking access of MCMT to PCNA, MCMT and p21(WAF1) may be linked in a regulatory pathway, because the extents of their expression are inversely related in both SV40-transformed and nontransformed cells.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,CHEM CARCINOGENESIS LAB,SINGAPORE 119260,SINGAPORE; NATL UNIV SINGAPORE,BIOSCI CTR,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore			Koh, Tong-Wey/M-3774-2013; Ng, Huck Hui/A-1135-2009	Koh, Tong-Wey/0000-0001-9136-3189; 				AYI TC, 1992, CANCER RES, V52, P6423; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Carotti D, 1996, BIOCHEMISTRY-US, V35, P11660, DOI 10.1021/bi9606051; CHEN YQ, 1995, CANCER RES, V55, P4536; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Herendeen DR, 1996, CELL, V84, P5, DOI 10.1016/S0092-8674(00)80069-0; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Lim A, 1996, EMBO J, V15, P4050, DOI 10.1002/j.1460-2075.1996.tb00778.x; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Oh HK, 1996, BIOCHEMISTRY-US, V35, P12259, DOI 10.1021/bi9603635; PETERSON SR, 1995, CANCER RES, V55, P4651; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TAN NW, 1990, BIOCHEMISTRY-US, V29, P9234, DOI 10.1021/bi00491a018; TEO AKC, UNPUB; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996	43	707	733	8	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1996	2000		10.1126/science.277.5334.1996	http://dx.doi.org/10.1126/science.277.5334.1996			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302295				2022-12-28	WOS:A1997XX84900045
J	Hayden, FG; Osterhaus, ADME; Treanor, JJ; Fleming, DM; Aoki, FY; Nicholson, KG; Bohnen, AM; Hirst, HM; Keene, O; Wightman, K				Hayden, FG; Osterhaus, ADME; Treanor, JJ; Fleming, DM; Aoki, FY; Nicholson, KG; Bohnen, AM; Hirst, HM; Keene, O; Wightman, K			Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							4-GUANIDINO-2,4-DIDEOXY-2,3-DEHYDRO-N-ACETYLNEURAMINIC ACID; SIALIDASE; REPLICATION; THERAPY; GG167	Background The sialic acid analogue zanamivir (GG167) is a selective inhibitor of influenza A and B virus neuraminidases. These viral enzymes are essential for the release of virus from infected cells, and they may also reduce the inactivation of virus by respiratory secretions. When administered experimentally directly to the respiratory tract, zanamivir has potent antiviral effects. We assessed the therapeutic activity of zanamivir in adults with acute influenza. Methods We conducted separate randomized, double-blind studies in 38 centers in North America and 32 centers in Europe during the influenza season of 1994-1995. A total of 417 adults with influenza-like illness of less than or equal to 48 hours' duration were randomly assigned to one of three treatments: 6.4 mg of zanamivir by intranasal spray plus 10 mg by inhalation, 10 mg of zanamivir by inhalation plus placebo spray, or placebo by both routes. Treatments were self-administered twice daily for five days. Results Of 262 patients with confirmed influenzavirus infection (63 percent of all patients), the median length of time to the alleviation of all major symptoms was one day shorter (four days vs. five days) in the 88 patients given inhaled and intranasal zanamivir (P=0.02) and the 85 patients given inhaled zanamivir alone (P=0.05) than in the 89 patients given placebo. Among the infected patients who were febrile at enrollment and among those who began treatment within 30 hours after the onset of symptoms, the median time to the alleviation of major symptoms was four days in both zanamivir groups and seven days in the placebo group (P less than or equal to 0.01). Viral titers of nasal washings in the group given inhaled and intranasal zanamivir were significantly lower than those in the placebo group. The topically administered zanamivir was well tolerated. Conclusions In adults with influenza A or B virus infections, direct administration of a selective neuraminidase inhibitor, zanamivir, to the respiratory tract is safe and reduces symptoms if begun early. (C) 1997, Massachusetts Medical Society.	ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS; UNIV ROCHESTER,ROCHESTER,NY; NORTHFIELD HLTH CTR,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV MANITOBA,WINNIPEG,MB,CANADA; UNIV LEICESTER,LEICESTER,LEICS,ENGLAND; GLAXO WELLCOME INC,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME,GREENFORD,MIDDX,ENGLAND	Erasmus University Rotterdam; University of Rochester; University of Manitoba; University of Leicester; GlaxoSmithKline; GlaxoSmithKline	Hayden, FG (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,BOX 473,CHARLOTTESVILLE,VA 22908, USA.		Bohnen, Arthur M/F-7814-2011	Keene, Oliver/0000-0003-0016-9773	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ADV COMM IMM PRAC, 1996, MMWR-MORBID MORTAL W, V45, P1; AOKI FY, 1976, BRIT J CLIN PHARMACO, V3, P869, DOI 10.1111/j.1365-2125.1976.tb00640.x; BURNET FM, 1948, AUST J EXP BIOL MED, V26, P381, DOI 10.1038/icb.1948.39; CASS LMR, 1996, 3 INT C OPT CONTR IN, P37; COLMAN PM, 1989, INFLUENZA VIRUSES, P175; DOUGLAS RG, 1990, NEW ENGL J MED, V322, P443, DOI 10.1056/NEJM199002153220706; FLEISS JL, 1981, STATISTICAL METHODS, P260; GOULD AL, 1980, BIOMETRICS, V36, P721, DOI 10.2307/2556126; HARDY JG, 1985, J PHARM PHARMACOL, V37, P294, DOI 10.1111/j.2042-7158.1985.tb05069.x; Hayden FG, 1996, JAMA-J AM MED ASSOC, V275, P295, DOI 10.1001/jama.275.4.295; HAYDEN FG, 1986, ANTIMICROB AGENTS CH, V29, P339, DOI 10.1128/AAC.29.2.339; HAYDEN FG, 1994, ANTIVIR RES, V25, P287, DOI 10.1016/0166-3542(94)90011-6; HAYDEN FG, 1994, ANTIVIR RES, V25, P123, DOI 10.1016/0166-3542(94)90101-5; HAYDEN FG, 1984, J INFECT DIS, V150, P174, DOI 10.1093/infdis/150.2.174; Hayden FG, 1996, ANTIVIRAL DRUG RESIS, P59; HAYDEN FG, 1996, OPTIONS CONTROL INFL, V3, P718; HAYDEN FG, 1994, TXB RESP MED, V1, P977; HOLZER CT, 1993, GLYCOCONJUGATE J, V10, P40, DOI 10.1007/BF00731185; KARK JD, 1982, NEW ENGL J MED, V307, P1042, DOI 10.1056/NEJM198210213071702; Koch G G, 1984, Drug Inf J, V18, P131; KOCH GG, 1988, BIOPHARMACEUTICAL ST, V86, P403; LIU CG, 1993, VIROLOGY, V194, P403, DOI 10.1006/viro.1993.1276; RYAN DM, 1994, ANTIMICROB AGENTS CH, V38, P2270, DOI 10.1128/AAC.38.10.2270; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102; WOODS JM, 1993, ANTIMICROB AGENTS CH, V37, P1473, DOI 10.1128/AAC.37.7.1473	27	544	573	1	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					874	880		10.1056/NEJM199709253371302	http://dx.doi.org/10.1056/NEJM199709253371302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX302	9302301	Green Published			2022-12-28	WOS:A1997XX30200002
J	Coyne, KJ; Qin, XX; Waite, JH				Coyne, KJ; Qin, XX; Waite, JH			Extensible collagen in mussel byssus: A natural block copolymer	SCIENCE			English	Article							DRAGLINE SILK; PROTEINS; ELASTIN; CDNA; GENE; IDENTIFICATION; EVOLUTION; SEQUENCE; THREADS; FIBROIN	To adhere to solid surfaces, marine mussels produce byssal threads, each of which is a stiff tether at one end and a shock absorber with 160 percent extensibility at the other end. The elastic extensibility of proximal byssus is extraordinary given its construction of collagen and the limited extension (less than 10 percent) of most collagenous materials. From the complementary DNA, we deduced that the primary structure of a collagenous protein (preCol-P) predominating in the extensible proximal portion of the threads encodes an unprecedented natural block copolymer with three major domain types: a central collagen domain, flanking elastic domains, and histidine-rich terminal domains. The elastic domains have sequence motifs that strongly resemble those of elastin and the amorphous glycine-rich regions of spider silk fibroins. Byssal thread extensibility may be imparted by the elastic domains of preCol-P.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware	Coyne, KJ (corresponding author), UNIV DELAWARE,COLL MARINE STUDIES,NEWARK,DE 19716, USA.			Coyne, Kathryn/0000-0001-8846-531X				BAIRATI A, 1991, FORM FUNCTION ZOOLOG, P163; Bell EC, 1996, J EXP BIOL, V199, P1005; BELL EJ, UNPUB; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; BRYAN GW, 1979, J MAR BIOL ASSOC UK, V59, P969, DOI 10.1017/S0025315400036961; COOMBS TL, 1981, AQUAT TOXICOL, V1, P291, DOI 10.1016/0166-445X(81)90023-0; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Denny M. W., 1988, BIOL MECH WAVE SWEPT; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; Hall, 1981, POLYM MAT, DOI 10.1007/978-1-349-10187-0_4; HINMAN MB, 1992, J BIOL CHEM, V267, P19320; HUANG X, 1991, GENOMICS, V14, P18; JOHNSON KS, 1987, MOL BIOCHEM PARASIT, V22, P89, DOI 10.1016/0166-6851(87)90072-7; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; LILIUS G, 1991, EUR J BIOCHEM, V198, P499, DOI 10.1111/j.1432-1033.1991.tb16042.x; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; MELNICK SC, 1958, NATURE, V181, P1483, DOI 10.1038/1811483a0; Patwary MU, 1996, J SHELLFISH RES, V15, P265; PIKKARAINEN J, 1968, EUR J BIOCHEM, V4, P555, DOI 10.1111/j.1432-1033.1968.tb00248.x; Qin X., UNPUB; QIN XX, 1995, J EXP BIOL, V198, P633; RAJU K, 1987, J BIOL CHEM, V262, P5755; ROBSON P, 1993, J BIOL CHEM, V268, P1440; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; Rudall K. M., 1955, S SOC EXP BIOL, V9, P49; SAGE H, 1979, COMP BIOCHEM PHYS B, V64, P313, DOI 10.1016/0305-0491(79)90277-3; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; SMEATHERS JE, 1979, J MOLLUS STUD, V49, P219; SMITH MC, 1987, INORG CHEM, V26, P1965, DOI 10.1021/ic00259a030; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; THIEL BL, 1995, MRS BULL, V20, P52, DOI 10.1557/S0883769400034941; URRY DW, 1984, J PROTEIN CHEM, V3, P403, DOI 10.1007/BF01025061; VITELLAROZUCCARELLO L, 1983, TISSUE CELL, V15, P547, DOI 10.1016/0040-8166(83)90006-X; Waite J.H., 1992, Results and Problems in Cell Differentiation, V19, P27; WAITE JH, 1989, BIOCHEMISTRY-US, V28, P6104, DOI 10.1021/bi00440a056; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; [No title captured]	38	210	221	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1830	1832		10.1126/science.277.5333.1830	http://dx.doi.org/10.1126/science.277.5333.1830			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295275				2022-12-28	WOS:A1997XX29800049
J	Sun, ZS; Albrecht, U; Zhuchenko, O; Bailey, J; Eichele, G; Lee, CC				Sun, ZS; Albrecht, U; Zhuchenko, O; Bailey, J; Eichele, G; Lee, CC			RIGUI, a putative mammalian ortholog of the Drosophila period gene	CELL			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; SUPRACHIASMATIC NUCLEUS; PARS TUBERALIS; MELATONIN RECEPTORS; MESSENGER-RNA; CLOCK; PROTEIN; LIGHT; RAT; ZEITGEBERS	The molecular components of mammalian circadian clocks are elusive. We have isolated a human gene termed RIGUI that encodes a bHLH/PAS protein 44% homologous to Drosophila period. The highly conserved mouse homolog (m-rigui) is expressed in a circadian pattern in the suprachiasmatic nucleus (SCN), the master regulator of circadian clocks in mammals. Circadian expression in the SCN continues in constant darkness, and a shift in the light/dark cycle evokes a proportional shift of m-rigui expression in the SCN. m-rigui transcripts also appear in a periodic pattern in Purkinje neurons, pars tuberalis, and retina, but with a timing of oscillation different from that seen in the SCN. Sequence homology and circadian patterns of expression suggest that RIGUI is a mammalian ortholog of the Drosophila period gene, raising the possibility that a regulator of circadian clocks is conserved.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; MAX PLANCK INST EXPT ENDOCRINOL,D-30625 HANNOVER,GERMANY	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society			Albrecht, Urs/A-9831-2011; Jansen, Heiko T./A-5770-2008; Sun, Zhongsheng/AAS-4883-2020	Albrecht, Urs/0000-0002-0663-8676; Jansen, Heiko T./0000-0003-0178-396X; Sun, Zhongsheng/0000-0002-7640-5026				Albrecht U, 1997, MOL CELLULAR METHODS, P23; ARENDT J, 1987, CHRONOBIOL INT, V4, P273, DOI 10.3109/07420528709078534; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ASCHOFF J, 1969, AEROSPACE MED, V40, P844; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DEREVIERS MM, 1989, NEUROSCI LETT, V100, P89, DOI 10.1016/0304-3940(89)90665-4; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Fraschini F, 1993, LIGHT BIOL RHYTHMS M, P121; GOTO M, 1989, J PINEAL RES, V7, P195, DOI 10.1111/j.1600-079X.1989.tb00667.x; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; IJDO JW, 1992, GENOMICS, V14, P1019, DOI 10.1016/S0888-7543(05)80125-9; KALLIONIEMI OP, 1994, GENOMICS, V20, P125, DOI 10.1006/geno.1994.1138; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KRAFT M, 1995, DIS MON, V41, P501; LEE CC, 1995, HUM MOL GENET, V4, P1373, DOI 10.1093/hmg/4.8.1373; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; NAKAZAWA K, 1991, P NATL ACAD SCI USA, V88, P7576, DOI 10.1073/pnas.88.17.7576; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SIWICKI KK, 1992, J NEUROGENET, V8, P33, DOI 10.3109/01677069209167270; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; STANKOV B, 1991, NEUROENDOCRINOLOGY, V53, P214, DOI 10.1159/000125721; Sun Z. S., 1996, American Journal of Human Genetics, V59, pA160; SWAAB DF, 1996, HYPOTHALAMIC INTEGRA, P349; TAKAHASHI JS, 1987, BRAIN RES, V405, P199, DOI 10.1016/0006-8993(87)91010-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Teicher MH, 1997, ARCH GEN PSYCHIAT, V54, P124; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Vignau J, 1993, LIGHT BIOL RHYTHMS M, P261; WEAVER DR, 1990, ENDOCRINOLOGY, V127, P2607, DOI 10.1210/endo-127-5-2607; WEHR TA, 1996, HYPOTHALAMIC INTEGRA, P321; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	47	561	585	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1003	1011		10.1016/S0092-8674(00)80366-9	http://dx.doi.org/10.1016/S0092-8674(00)80366-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323128	Bronze			2022-12-28	WOS:A1997XX76800006
J	Debanne, D; Guerineau, NC; Gahwiler, BH; Thompson, SM				Debanne, D; Guerineau, NC; Gahwiler, BH; Thompson, SM			Action-potential propagation gated by an axonal I-A-like K+ conductance in hippocampus	NATURE			English	Article							SLICE CULTURES; POTASSIUM CURRENTS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; CELLS; CA3; MECHANISM; FREQUENCY; RELEASE	Integration of membrane-potential changes is traditionally reserved for neuronal somatodendritic compartments. Axons are typically considered to transmit reliably the result of this integration, the action potential(1), to nerve terminals(2,3). By recording from pairs of pyramidal cells in hippocampal slice cultures(4-6), we show here that the propagation of action potentials to nerve terminals is impaired if presynaptic action potentials are preceded by brief or tonic hyperpolarization. Action-potential propagation fails only when the presynaptic action potential is triggered within the first 15-20 ms of a depolarizing step from hyperpolarized potentials; action-potential propagation failures are blocked when presynaptic cells are impaled with electrodes containing 4-aminopyridine, indicating that a fast-inactivating, A-type K+ conductance is involved. Propagation failed between some, but not all, of the postsynaptic cells contacted by a single presynaptic cell, suggesting that the presynaptic action potentials failed at axonal branch points. We conclude that the physiological activation of an I-A-like potassium conductance can locally block propagation of presynaptic action potentials in axons of the central nervous system, Thus axons do not always behave as simple electrical cables: their capacity to transmit action potentials is determined by a time-dependent integration of recent membrane-potential changes.	UNIV ZURICH, BRAIN RES INST, CH-8029 ZURICH, SWITZERLAND	University of Zurich			Debanne, Dominique/O-4673-2016; Thompson, Scott M/K-8921-2015	Debanne, Dominique/0000-0001-8581-5695; Guerineau, Nathalie/0000-0003-2517-4210				Bossu JL, 1996, J PHYSIOL-LONDON, V495, P367, DOI 10.1113/jphysiol.1996.sp021600; Colbert CM, 1996, J NEUROSCI, V16, P6676; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; Debanne D, 1996, J PHYSIOL-LONDON, V491, P163, DOI 10.1113/jphysiol.1996.sp021204; Eccles, 2013, PHYSL SYNAPSES; FROTSCHER M, 1988, NEUROSCIENCE, V24, P541, DOI 10.1016/0306-4522(88)90348-X; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; KOCSIS JD, 1986, BRAIN RES, V383, P357, DOI 10.1016/0006-8993(86)90040-5; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; LUSCHER C, 1994, J NEUROPHYSIOL, V72, P622, DOI 10.1152/jn.1994.72.2.622; MacKenzie PJ, 1996, NEURON, V16, P783, DOI 10.1016/S0896-6273(00)80098-7; PARNAS I, 1972, J NEUROPHYSIOL, V35, P903, DOI 10.1152/jn.1972.35.6.903; PARNAS I, 1976, J NEUROPHYSIOL, V39, P909, DOI 10.1152/jn.1976.39.4.909; SEGEV I, 1990, J NEUROPHYSIOL, V63, P987, DOI 10.1152/jn.1990.63.5.987; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STEPHENS GJ, 1994, J PHYSIOL-LONDON, V477, P187, DOI 10.1113/jphysiol.1994.sp020183; Storm J. F., 1994, Society for Neuroscience Abstracts, V20, P1339; STORM JF, 1990, PROG BRAIN RES, V83, P161; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Vincent P, 1996, J PHYSIOL-LONDON, V494, P183, DOI 10.1113/jphysiol.1996.sp021484; WALL PD, 1995, TRENDS NEUROSCI, V18, P99, DOI 10.1016/0166-2236(95)93883-Y	21	221	221	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					286	289		10.1038/38502	http://dx.doi.org/10.1038/38502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305843				2022-12-28	WOS:A1997XW77200048
J	Nedelec, FJ; Surrey, T; Maggs, AC; Leibler, S				Nedelec, FJ; Surrey, T; Maggs, AC; Leibler, S			Self-organization of microtubules and motors	NATURE			English	Article							CHROMOSOME SEGREGATION; KINESIN; EXTRACTS; INVITRO; FORCE	Cellular structures are established and maintained through a dynamic interplay between assembly and regulatory processes. Self-organization of molecular components provides a variety of possible spatial structures: the regulatory machinery chooses the most appropriate to express a given cellular function(1). Here we study the extent and the characteristics of self-organization using microtubules and molecular motors(2) as a model system. These components are known to participate in the formation of many cellular structures, such as the dynamic asters found in mitotic and meiotic spindles(3,4). Purified motors and microtubules have previously been observed to form asters in vitro(5). We have reproduced this result with a simple system consisting solely of multi-headed constructs of the motor protein kinesin(6) and stabilized microtubules. We show that dynamic asters can also be obtained from a homogeneous solution of tubulin and motors. By varying the relative concentrations of the components, we obtain a variety of self-organized structures. Further, by studying this process in a constrained geometry of micro-fabricated glass chambers(7), we demonstrate that the same final structure can be reached through different assembly 'pathways'.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544; ECOLE SUPER PHYS & CHIM IND VILLE PARIS,LAB PHYSICOCHIM THEOR,F-75231 PARIS,FRANCE	Princeton University; Princeton University; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)			Nedelec, Francois J/H-3317-2011; Nedelec, Francois/AAC-1673-2019; Surrey, Thomas/AAC-4608-2021	Nedelec, Francois J/0000-0002-8141-5288; Nedelec, Francois/0000-0002-8141-5288; Surrey, Thomas/0000-0001-9082-1870				ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BAYER E, 1990, METHOD ENZYMOL, V184, P51; BERLINER E, 1994, J BIOL CHEM, V269, P8610; DOGTEROM M, 1993, PHYS REV LETT, V70, P1347, DOI 10.1103/PhysRevLett.70.1347; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Holy TE, 1997, P NATL ACAD SCI USA, V94, P6228, DOI 10.1073/pnas.94.12.6228; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; MAYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Rodionov VI, 1997, NATURE, V386, P170, DOI 10.1038/386170a0; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TABONY J, 1994, SCIENCE, V264, P245, DOI 10.1126/science.8146654; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926; [No title captured]	29	615	624	2	99	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					305	308		10.1038/38532	http://dx.doi.org/10.1038/38532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305848				2022-12-28	WOS:A1997XW77200053
J	OMeara, JJ; Dehmer, GJ				OMeara, JJ; Dehmer, GJ			Care of the patient and management of complications after percutaneous coronary artery interventions	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; PERIPHERAL VASCULAR COMPLICATIONS; ANGIOGRAPHIC FOLLOW-UP; ATHERECTOMY TRIAL CAVEAT; PLACEBO-CONTROLLED TRIAL; STABLE ANGINA-PECTORIS; ULTRASOUND-GUIDED COMPRESSION; CONVERTING ENZYME-INHIBITION; RADIOGRAPHIC CONTRAST AGENT; ACTIVATED CLOTTING TIMES	Certain aspects of patient management are common with conventional balloon angioplasty and newer coronary artery interventions. These aspects include the evaluation of chest pain or treatment of acute vessel closure shortly after the intervention, management of the vascular access site (especially if complications occur), prevention and treatment of contrast-induced renal dysfunction, and the use of anticoagulant or antiplatelet agents after the procedure. However, some aspects of management vary among techniques. Several different drug therapies are indicated after these procedures, but pharmacologic therapy for restenosis has been largely unsuccessful. Placement of an intracoronary stent decreases the frequency of restenosis and subsequent revascularization procedures, and functional testing may be of value in some patients after coronary artery interventions. It is important for the specialist in internal medicine to have a firm working knowledge of the various aspects of care that are required because their role in management is increasing.	UNIV N CAROLINA, CHAPEL HILL, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill			Dehmer, Gregory/AAQ-9380-2021					Abdelmeguid AE, 1996, AM HEART J, V131, P1097, DOI 10.1016/S0002-8703(96)90083-6; ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; AGRAWAL SK, 1992, J AM COLL CARDIOL, V20, P610, DOI 10.1016/0735-1097(92)90015-F; Aguilar C, 1992, Arch Med Res, V23, P19; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; *AM HEART ASS, 1996, HEART STROK FACTS 19, P22; Annex Brian H., 1994, Cardiology Clinics, V12, P611; [Anonymous], 1995, Lancet, V346, P1179; ARNOLD AM, 1994, AM J CARDIOL, V74, P18, DOI 10.1016/0002-9149(94)90484-7; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; BAIM DS, 1995, CIRCULATION S1, V92, P544; BAIRATI I, 1992, CIRCULATION, V85, P950, DOI 10.1161/01.CIR.85.3.950; BARNATHAN ES, 1987, CIRCULATION, V76, P125, DOI 10.1161/01.CIR.76.1.125; BARRETT BJ, 1992, KIDNEY INT, V41, P1274, DOI 10.1038/ki.1992.189; BAUTERS C, 1995, CIRCULATION, V91, P1410, DOI 10.1161/01.CIR.91.5.1410; BENGTSON JR, 1990, AM J CARDIOL, V65, P28, DOI 10.1016/0002-9149(90)90021-R; BERTRAND ME, 1990, CIRCULATION, V82, P190; BITTL JA, 1995, NEW ENGL J MED, V333, P764, DOI 10.1056/NEJM199509213331204; BOGART DB, 1995, CATHETER CARDIO DIAG, V34, P8, DOI 10.1002/ccd.1810340304; BOURASSA MG, 1991, J AM COLL CARDIOL, V18, P368, DOI 10.1016/0735-1097(91)90588-Z; BRODIE B, 1995, J AM COLL CARDIOL, V25, pA5; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; Brodie BR, 1995, J INVASIVE CARDIOL, V7, pF22; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BYRD L, 1979, MEDICINE, V58, P270, DOI 10.1097/00005792-197905000-00006; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CAMENZIND E, 1994, J AM COLL CARDIOL, V24, P655, DOI 10.1016/0735-1097(94)90011-6; CASCADE PN, 1987, AM J CARDIOL, V59, P996, DOI 10.1016/0002-9149(87)91143-X; CAVALLINI C, 1994, AM HEART J, V127, P1504, DOI 10.1016/0002-8703(94)90377-8; Chesebro JH, 1989, CIRCULATION S2, V80, pII; CIGARROA RG, 1989, AM J MED, V86, P649, DOI 10.1016/0002-9343(89)90437-3; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; COWLEY MJ, 1993, J AM COLL CARDIOL, V22, P1289, DOI 10.1016/0735-1097(93)90532-6; CURRIER JW, 1995, J AM COLL CARDIOL, V25, P516, DOI 10.1016/0735-1097(95)98445-J; DAIDA H, 1994, AM J CARDIOL, V73, P1037, DOI 10.1016/0002-9149(94)90279-8; DAVIDSON CJ, 1989, ANN INTERN MED, V110, P119, DOI 10.7326/0003-4819-110-2-119; DEFEYTER PJ, 1992, AM HEART J, V123, P1633, DOI 10.1016/0002-8703(92)90818-G; DEFEYTER PJ, 1991, CIRCULATION, V83, P927, DOI 10.1161/01.CIR.83.3.927; DEFEYTER PJ, 1992, CLIN CARDIOL, V15, P317, DOI 10.1002/clc.4960150503; DEHMER GJ, 1988, NEW ENGL J MED, V319, P733, DOI 10.1056/NEJM198809223191201; DELAMORENA G, 1993, CHEST, V103, P391, DOI 10.1378/chest.103.2.391; DEPUEY EG, 1984, J AM COLL CARDIOL, V4, P1103; DEPUEY EG, 1991, CIRCULATION, V84, pI59; DEPUEY EG, 1983, CATHETER CARDIO DIAG, V9, P153, DOI 10.1002/ccd.1810090207; DESMET W, 1995, AM HEART J, V129, P452, DOI 10.1016/0002-8703(95)90267-8; DESMET W, 1994, CIRCULATION, V89, P385, DOI 10.1161/01.CIR.89.1.385; DESWART H, 1993, AM J CARDIOL, V72, P445, DOI 10.1016/0002-9149(93)91138-8; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; DOUGHERTY KG, 1992, CATHETER CARDIO DIAG, V26, P260, DOI 10.1002/ccd.1810260404; Elizaga J., 1993, European Heart Journal, V14, P118; ELLIOTT JM, 1995, CIRCULATION, V91, P2158, DOI 10.1161/01.CIR.91.8.2158; ELLIS SG, 1988, J AM COLL CARDIOL, V11, P211, DOI 10.1016/0735-1097(88)90082-4; ELLIS SG, 1995, J AM COLL CARDIOL, V25, P1137, DOI 10.1016/0735-1097(94)00541-W; ELLIS SG, 1989, AM HEART J, V117, P777, DOI 10.1016/0002-8703(89)90612-1; ELLIS SG, 1991, CIRCULATION, V83, P1905, DOI 10.1161/01.CIR.83.6.1905; ELLIS SG, 1994, TXB INTERVENTIONAL C, P201; ERLEY CM, 1994, KIDNEY INT, V45, P1425, DOI 10.1038/ki.1994.186; ERNST SMPG, 1993, J AM COLL CARDIOL, V21, P851, DOI 10.1016/0735-1097(93)90339-3; ESTELLA P, 1993, J AM COLL CARDIOL, V21, P1550, DOI 10.1016/0735-1097(93)90367-A; FAXON DP, 1995, J AM COLL CARDIOL, V25, P362, DOI 10.1016/0735-1097(94)00368-Z; FAXON DP, 1994, CIRCULATION, V90, P908, DOI 10.1161/01.CIR.90.2.908; FAXON DP, 1992, AM HEART J, V123, P854, DOI 10.1016/0002-8703(92)90687-Q; FELD R, 1992, J VASC SURG, V16, P832; FERGUSON JJ, 1994, J AM COLL CARDIOL, V23, P1061, DOI 10.1016/0735-1097(94)90590-8; FERGUSON JJ, 1994, J INVASIVE CARDIOL, V6, pA3; FERGUSON JJ, 1995, CIRCULATION, V92, P3371, DOI 10.1161/01.CIR.92.12.3371; FISCHELL TA, 1994, CIRCULATION, V90, P2956, DOI 10.1161/01.CIR.90.6.2956; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDMAN HZ, 1994, J AM COLL CARDIOL, V24, P1214, DOI 10.1016/0735-1097(94)90101-5; GABLIANI G, 1988, AM HEART J, V116, P696, DOI 10.1016/0002-8703(88)90326-2; GALAN KM, 1985, HEART LUNG, V14, P109; GAN SC, 1992, ARCH INTERN MED, V152, P2333, DOI 10.1001/archinte.152.11.2333; GAUL G, 1989, J AM COLL CARDIOL, V13, P283, DOI 10.1016/0735-1097(89)90499-3; Gentile R, 1994, Cardiologia, V39, P651; GEORGE BS, 1993, J AM COLL CARDIOL, V22, P135, DOI 10.1016/0735-1097(93)90827-N; GERSHLICK AH, 1994, BRIT HEART J, V71, P7; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRIGG LE, 1989, J AM COLL CARDIOL, V13, P665, DOI 10.1016/0735-1097(89)90609-8; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; HANNAN EL, 1992, JAMA-J AM MED ASSOC, V268, P3092, DOI 10.1001/jama.268.21.3092; HARDOFF R, 1990, J AM COLL CARDIOL, V15, P1486, DOI 10.1016/0735-1097(90)92815-J; HARRINGTON RA, 1995, J AM COLL CARDIOL, V25, P1693, DOI 10.1016/0735-1097(95)00091-H; HAUDE M, 1993, AM HEART J, V126, P15, DOI 10.1016/S0002-8703(07)80005-6; HECHT HS, 1991, J AM COLL CARDIOL, V17, P670, DOI 10.1016/S0735-1097(10)80183-4; HECHT HS, 1990, AM J CARDIOL, V66, P1314, DOI 10.1016/0002-9149(90)91160-8; HECHT HS, 1993, AM J CARDIOL, V71, P293, DOI 10.1016/0002-9149(93)90793-C; HEINLE SK, 1993, AM J CARDIOL, V72, P1220, DOI 10.1016/0002-9149(93)90287-M; HERAS M, 1989, CIRCULATION, V79, P657, DOI 10.1161/01.CIR.79.3.657; HERNANDEZ RA, 1992, J AM COLL CARDIOL, V19, P1402, DOI 10.1016/0735-1097(92)90594-D; HILLEGASS WB, 1994, AM J CARDIOL, V73, P835, DOI 10.1016/0002-9149(94)90805-2; HILLEGASS WB, 1992, CIRCULATION, V86, P137; HILLEGASS WB, 1994, TXB INTERVENTIONAL C, P415; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; HOLMES DR, 1994, J AM COLL CARDIOL, V24, P431, DOI 10.1016/0735-1097(94)90300-X; HOLMES DR, 1994, J AM COLL CARDIOL, V23, P330, DOI 10.1016/0735-1097(94)90415-4; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; HONAN MB, 1989, CIRCULATION, V80, P1585, DOI 10.1161/01.CIR.80.6.1585; JAIN A, 1988, J AM COLL CARDIOL, V11, P970, DOI 10.1016/S0735-1097(98)90053-5; JEVNIKAR AM, 1988, NEPHRON, V48, P300, DOI 10.1159/000184947; JOELSON JM, 1987, AM J CARDIOL, V60, P792, DOI 10.1016/0002-9149(87)91025-3; JOHNSON LW, 1994, CATHETER CARDIO DIAG, V31, P165, DOI 10.1002/ccd.1810310302; JOHNSON LW, 1993, CATHETER CARDIO DIAG, V28, P219, DOI 10.1002/ccd.1810280305; JOHNSON LW, 1992, CATHETER CARDIO DIAG, V25, P186, DOI 10.1002/ccd.1810250304; KADEL C, 1989, EUR HEART J, V10, P22, DOI 10.1093/eurheartj/10.suppl_G.22; Kaul U, 1993, Indian Heart J, V45, P469; KENT K M, 1988, Journal of the American College of Cardiology, V11, p132A; KENT KC, 1994, J VASC SURG, V20, P905, DOI 10.1016/0741-5214(94)90227-5; KENT KM, 1982, NEW ENGL J MED, V306, P441, DOI 10.1056/NEJM198202253060801; KHOURY M, 1992, AM J SURG, V164, P205, DOI 10.1016/S0002-9610(05)81071-2; KIM D, 1992, CATHETER CARDIO DIAG, V25, P91, DOI 10.1002/ccd.1810250203; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; KLEIN LW, 1991, J AM COLL CARDIOL, V17, P621, DOI 10.1016/S0735-1097(10)80174-3; KORZICK DH, 1990, CLEV CLIN J MED, V57, P53, DOI 10.3949/ccjm.57.1.53; KRESOWIK TF, 1991, J VASC SURG, V13, P328, DOI 10.1016/0741-5214(91)90226-K; KRON J, 1985, AM J CARDIOL, V55, P1445, DOI 10.1016/0002-9149(85)90532-6; KUGELMASS AD, 1994, AM J CARDIOL, V74, P748, DOI 10.1016/0002-9149(94)90427-8; KUMAR S, 1981, ARCH INTERN MED, V141, P1268, DOI 10.1001/archinte.141.10.1268; KUNTZ RE, 1992, J AM COLL CARDIOL, V19, P1493, DOI 10.1016/0735-1097(92)90609-Q; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; LAARMAN G, 1990, J AM COLL CARDIOL, V16, P578, DOI 10.1016/0735-1097(90)90346-Q; LALAU JD, 1994, NEPHROL DIAL TRANSPL, V9, P126; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LASKEY MAL, 1990, AM J CARDIOL, V65, P1425, DOI 10.1016/0002-9149(90)91348-A; LASKEY MAL, 1990, AM J CARDIOL, V65, P179, DOI 10.1016/0002-9149(90)90081-B; LEAF A, 1994, CIRCULATION, V90, P2248, DOI 10.1161/01.CIR.90.5.2248; LEFEUVRE C, 1994, AM J CARDIOL, V73, P840, DOI 10.1016/0002-9149(94)90806-0; LEFEUVRE C, 1993, AM J CARDIOL, V71, P1153, DOI 10.1016/0002-9149(93)90638-S; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; LEITSCHUH ML, 1991, AM J CARDIOL, V67, P1056, DOI 10.1016/0002-9149(91)90865-I; LINCOFE AM, 1992, J AM COLL CARDIOL, V19, P926, DOI 10.1016/0735-1097(92)90272-O; LINCOFF AM, 1994, TXB INTERVENTIONAL C, P207; LITVACK F, 1994, J AM COLL CARDIOL, V23, P323, DOI 10.1016/0735-1097(94)90414-6; LUMSDEN AB, 1994, AM SURGEON, V60, P132; MANYARI DE, 1988, CIRCULATION, V77, P86, DOI 10.1161/01.CIR.77.1.86; MARESTA A, 1994, CIRCULATION, V90, P2710, DOI 10.1161/01.CIR.90.6.2710; MAZUR W, 1994, TEX HEART I J, V21, P104; MCGARRY TF, 1992, AM HEART J, V123, P1445, DOI 10.1016/0002-8703(92)90793-U; MELER B, 1984, J AM COLL CARDIOL, V4, P463; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; MILLER DD, 1994, J AM COLL CARDIOL, V24, P260, DOI 10.1016/0735-1097(94)90572-X; MILLER DD, 1987, J AM COLL CARDIOL, V10, P275; MOSCUCCI M, 1994, AM J CARDIOL, V74, P448, DOI 10.1016/0002-9149(94)90901-6; MULLER DWM, 1992, AM J CARDIOL, V69, P63, DOI 10.1016/0002-9149(92)90677-Q; Narins CR, 1996, CIRCULATION, V93, P667, DOI 10.1161/01.CIR.93.4.667; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; OGILBY JD, 1989, CATHETER CARDIO DIAG, V18, P206, DOI 10.1002/ccd.1810180403; OH JK, 1985, AM HEART J, V109, P1225, DOI 10.1016/0002-8703(85)90343-6; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; OKADA RD, 1985, AM J CARDIOL, V55, P347, DOI 10.1016/0002-9149(85)90374-1; OKEEFE JH, 1992, J AM COLL CARDIOL, V19, P1597, DOI 10.1016/0735-1097(92)90624-V; OKEEFE JH, 1993, AM J CARDIOL, V71, P897, DOI 10.1016/0002-9149(93)90903-P; OKEEFE JH, 1988, AM J CARDIOL, V61, P51, DOI 10.1016/0002-9149(88)91303-3; OMOIGUI NA, 1995, J AM COLL CARDIOL, V26, P922, DOI 10.1016/0735-1097(95)00263-4; ONAKA H, 1994, JPN CIRC J, V58, P100, DOI 10.1253/jcj.58.100; PANDE AK, 1992, AM HEART J, V124, P337, DOI 10.1016/0002-8703(92)90595-M; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; PATTEE PL, 1993, J AM COLL CARDIOL, V22, P1044, DOI 10.1016/0735-1097(93)90414-V; PAULETTO P, 1987, AM J CARDIOL, V59, P999, DOI 10.1016/0002-9149(87)91145-3; PEDERSEN TR, 1994, LANCET, V344, P1383; PEPINE CJ, 1990, CIRCULATION, V81, P1753, DOI 10.1161/01.CIR.81.6.1753; Pepine CJ, 1996, J AM COLL CARDIOL, V28, P782; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFISTERER M, 1993, J AM COLL CARDIOL, V22, P1446, DOI 10.1016/0735-1097(93)90556-G; PHILLIPS SJ, 1989, AM J CARDIOL, V64, P940, DOI 10.1016/0002-9149(89)90848-5; PICUS D, 1984, AM J ROENTGENOL, V142, P567, DOI 10.2214/ajr.142.3.567; PIRELLI S, 1993, AM J CARDIOL, V71, P1052, DOI 10.1016/0002-9149(93)90572-T; POPMA JJ, 1993, CIRCULATION, V88, P1569, DOI 10.1161/01.CIR.88.4.1569; POPMA JJ, 1988, AM J CARDIOL, V62, P1298, DOI 10.1016/0002-9149(88)90279-2; POPMA JJ, 1989, ANN INTERN MED, V110, P547, DOI 10.7326/0003-4819-110-7-547; PREISACK MB, 1993, EUR HEART J, V14, P195, DOI 10.1093/eurheartj/14.2.195; RATH B, 1990, BRIT HEART J, V65, P1425; RAVKILDE J, 1994, AM HEART J, V127, P13, DOI 10.1016/0002-8703(94)90504-5; Reisman Mark, 1994, Cardiology Clinics, V12, P595; RENKIN J, 1990, J AM COLL CARDIOL, V16, P1333, DOI 10.1016/0735-1097(90)90373-W; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; ROSING DR, 1984, AM J CARDIOL, V53, pC36, DOI 10.1016/0002-9149(84)90743-4; ROTH A, 1994, EUR HEART J, V15, P1164, DOI 10.1093/oxfordjournals.eurheartj.a060649; ROTH A, 1994, CARDIOLOGY, V84, P106, DOI 10.1159/000176528; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SANBORN TA, 1993, J AM COLL CARDIOL, V22, P1273, DOI 10.1016/0735-1097(93)90529-A; SCHAUB F, 1994, CIRCULATION, V90, P1861, DOI 10.1161/01.CIR.90.4.1861; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SCHROEDER E, 1989, EUR HEART J, V10, P18, DOI 10.1093/eurheartj/10.suppl_G.18; SCHWAB SJ, 1989, NEW ENGL J MED, V320, P149, DOI 10.1056/NEJM198901193200304; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SCOTT NA, 1993, AM J CARDIOL, V71, P1159, DOI 10.1016/0002-9149(93)90639-T; SCULPHER MJ, 1994, LANCET, V344, P927, DOI 10.1016/S0140-6736(94)92274-8; SERRUYS PW, 1993, CIRCULATION, V88, P1588, DOI 10.1161/01.CIR.88.4.1588; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SETSUDA M, 1993, CLIN THER, V15, P374; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMONTON CA, 1988, J AM COLL CARDIOL, V11, P698, DOI 10.1016/0735-1097(88)90198-2; SIMONTON CA, 1995, CIRCULATION S1, V92, P545; SIMPFENDORFER C, 1988, CLEV CLIN J MED, V55, P299, DOI 10.3949/ccjm.55.4.299; SINCLAIR IN, 1988, AM J CARDIOL, V61, pG61, DOI 10.1016/S0002-9149(88)80034-1; SKILLMAN JJ, 1988, ARCH SURG-CHICAGO, V123, P1207; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; SPADARO JJ, 1986, CATHETER CARDIO DIAG, V12, P230, DOI 10.1002/ccd.1810120406; SREERAM S, 1993, AM SURGEON, V59, P94; SRIDHAR K, 1994, CIRCULATION, V90, P621; Stone GW, 1995, J INVASIVE CARDIOL, V7, pF12; STUCKEY TD, 1989, AM J CARDIOL, V63, P517, DOI 10.1016/0002-9149(89)90891-6; SUNEJA R, 1993, AM HEART J, V125, P530, DOI 10.1016/0002-8703(93)90037-A; TALIERCIO CP, 1986, ANN INTERN MED, V104, P501, DOI 10.7326/0003-4819-104-4-501; TEIRSTEIN PS, 1989, J AM COLL CARDIOL, V13, P291, DOI 10.1016/0735-1097(89)90501-9; TENAGLIA AN, 1993, AM J CARDIOL, V72, P21, DOI 10.1016/0002-9149(93)90212-U; TOMMASO CL, 1994, CATHETER CARDIO DIAG, V31, P316, DOI 10.1002/ccd.1810310414; TOPOL EJ, 1993, CIRCULATION, V87, P1622, DOI 10.1161/01.CIR.87.5.1622; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; TOPOL EJ, 1991, AM J CARDIOL, V68, pB136, DOI 10.1016/0002-9149(91)90396-3; VANDENBOS AA, 1993, CIRCULATION, V88, P2058, DOI 10.1161/01.CIR.88.5.2058; VANDORMAEL M, 1991, AM J CARDIOL, V67, P1, DOI 10.1016/0002-9149(91)90089-4; VETROVEC G, 1990, Journal of the American College of Cardiology, V15, p59A; Violaris AG, 1996, CIRCULATION, V93, P889, DOI 10.1161/01.CIR.93.5.889; WAGNER LK, 1994, J VASC INTERV RADIOL, V5, P71, DOI 10.1016/S1051-0443(94)71456-1; WAKSMAN R, 1995, CIRCULATION, V91, P1533, DOI 10.1161/01.CIR.91.5.1533; WALFORD GD, 1991, CIRCULATION, V84, P592; WARTH DC, 1994, J AM COLL CARDIOL, V24, P641, DOI 10.1016/0735-1097(94)90009-4; WEBB JG, 1993, CATHETER CARDIO DIAG, V30, P314, DOI 10.1002/ccd.1810300412; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002; WEINTRAUB WS, 1993, CIRCULATION, V87, P831, DOI 10.1161/01.CIR.87.3.831; WHITE CW, 1987, CIRCULATION, V76, P400; WIEDERMANN JG, 1994, J AM COLL CARDIOL, V23, P1491, DOI 10.1016/0735-1097(94)90397-2; WIJNS W, 1985, AM J CARDIOL, V55, P357, DOI 10.1016/0002-9149(85)90375-3; WILLIAMS DO, 1984, AM J CARDIOL, V53, pC32, DOI 10.1016/0002-9149(84)90742-2; WILLIAMS DO, 1995, AM J CARDIOL, V75, pC27; Yellayi Subrahmanya, 1994, Cardiology Clinics, V12, P651; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	243	14	14	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					458	471		10.7326/0003-4819-127-6-199709150-00008	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00008			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313004				2022-12-28	WOS:A1997XV77900008
J	Hajenius, PJ; Engelsbel, S; Mol, BWJ; VanderVeen, F; Ankum, WM; Bossuyt, PMM; Hemrika, DJ; Lammes, FB				Hajenius, PJ; Engelsbel, S; Mol, BWJ; VanderVeen, F; Ankum, WM; Bossuyt, PMM; Hemrika, DJ; Lammes, FB			Randomised trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy	LANCET			English	Article							HUMAN CHORIONIC-GONADOTROPIN; UNRUPTURED ECTOPIC GESTATION; SINGLE-DOSE METHOTREXATE; CLEARANCE CURVES; CLINICAL-TRIAL; MANAGEMENT; INJECTION; DIAGNOSIS; SALPINGOTOMY; THERAPY	Background Laparoscopic salpingostomy is a well-established treatment for patients with tubal pregnancy who desire to-retain fertility. Another approach that preserves the fallopian tube is medical treatment. We compared systemic methotrexate and laparoscopic salpingostomy in the treatment of tubal pregnancy. Outcome measures were treatment success, tubal preservation, and homolateral tubal patency. Methods Between January, 1994, and September, 1996, haemodynamically stable patients with laparoscopically confirmed unruptured tubal pregnancy and no signs of active bleeding were randomly assigned systemic methotrexate (four 1.0 mg/kg doses of intramuscular methotrexate alternated with 0.1 mg/kg oral folinic acid) or laparoscopic salpingostomy. Treatment success was defined, as complete elimination of the tubal pregnancy (serum human chorionic gonadotropin <2 IU/L) and preservation of the tube. Homolateral tubal patency was assessed by hysterosalpingography. Analysis was by intention to treat. Findings 100 patients were included in the trial. Of 51 patients allocated systemic methotrexate, 42 (82%) were successfully treated with one course; two (4%) patients needed a second course Cor persistent trophoblast. Surgical intervention was needed in seven (14%) patients; salpingectomy was necessary in five of these patients for tubal rupture. Of the 49 patients allocated laparoscopic salpingostomy, 35 (72%) were successfully treated by laparoscopic salpingostomy alone; salpingectomy was needed in four (8%) patients, and ten (20%) needed methotrexate for persistent trophoblast, The tube was preserved in 46 (90%) methotrexate group versus 45 salpingostomy group (rate ratio 0.98 [95% CI 0.87-1.1]). Homolateral tubal patency could be assessed in 81 patients: the tube was patent in 23 (55%) of 42 patients in the methotrexate group and in 23 (59%) of 39 patients in the salpingostomy group (rate ratio 0.93 [0.64-1.4]). Interpretation In haemodynamically stable patients with unruptured tubal pregnancy, systemic methotrexate and laparoscopic salpingostomy were successful in treating the majority of cases. We found no significant difference between the treatments in the homolateral patency rate. Subsequent fertility outcome has to be awaited to show which treatment yields better fertility prospects.	UNIV AMSTERDAM,ACAD MED CTR,CTR REPROD MED,NL-1100 DE AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,NL-1100 DE AMSTERDAM,NETHERLANDS; ONZE LIEVE VROUW HOSP,DEPT OBSTET & GYNAECOL,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Onze Lieve Vrouwe Gasthuis Hospital	Hajenius, PJ (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT OBSTET & GYNAECOL,POB 22700,NL-1100 DE AMSTERDAM,NETHERLANDS.		Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021; Mol, Ben/I-4526-2012	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; 				ANKUM WM, 1995, J REPROD MED, V40, P525; ANKUM WM, 1993, HUM REPROD, V8, P1307, DOI 10.1093/oxfordjournals.humrep.a138247; ANKUM WM, 1993, HUM REPROD, V8, P1301, DOI 10.1093/oxfordjournals.humrep.a138246; BUSTER JE, 1995, CURR OPIN OBSTET GYN, V7, P168, DOI 10.1097/00001703-199506000-00003; Clausen I, 1996, ACTA OBSTET GYN SCAN, V75, P8, DOI 10.3109/00016349609033276; CORSAN GH, 1995, HUM REPROD, V10, P2719, DOI 10.1093/oxfordjournals.humrep.a135774; FERNANDEZ H, 1995, FERTIL STERIL, V63, P25, DOI 10.1016/S0015-0282(16)57291-4; FLORIDON C, 1994, ACTA OBSTET GYN SCAN, V73, P746, DOI 10.3109/00016349409072497; GOLDENBERG M, 1993, HUM REPROD, V8, P660, DOI 10.1093/oxfordjournals.humrep.a138116; GRAINGER DA, 1995, CURR OPIN OBSTET GYN, V7, P277; Hajenius P J, 1995, Early Pregnancy, V1, P258; Hajenius PJ, 1996, FERTIL STERIL, V66, P723, DOI 10.1016/S0015-0282(16)58625-7; HAJENIUS PJ, 1995, HUM REPROD, V10, P683, DOI 10.1093/oxfordjournals.humrep.a136012; LAATIKAINEN T, 1993, FERTIL STERIL, V60, P80; MOTTLA GL, 1992, FERTIL STERIL, V57, P685; OSHEA RT, 1994, FERTIL STERIL, V62, P876; RANSOM MX, 1994, OBSTET GYNECOL, V83, P1033, DOI 10.1097/00006250-199406000-00026; Schulz KF, 1996, LANCET, V348, P596, DOI 10.1016/S0140-6736(96)01201-9; STOVALL TG, 1993, AM J OBSTET GYNECOL, V168, P1759, DOI 10.1016/0002-9378(93)90687-E; VERMESH M, 1989, OBSTET GYNECOL, V73, P400; Zilber U, 1996, AM J OBSTET GYNECOL, V175, P600	21	170	177	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					774	779		10.1016/S0140-6736(97)05487-1	http://dx.doi.org/10.1016/S0140-6736(97)05487-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297998	Green Submitted			2022-12-28	WOS:A1997XW28200013
J	Hongeng, S; Krance, RA; Bowman, LC; Srivastava, DK; Cunningham, JM; Horwitz, EM; Brenner, MK; Heslop, HE				Hongeng, S; Krance, RA; Bowman, LC; Srivastava, DK; Cunningham, JM; Horwitz, EM; Brenner, MK; Heslop, HE			Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia	LANCET			English	Article							VERSUS-HOST DISEASE; CHRONIC MYELOGENOUS LEUKEMIA; T-CELL DEPLETION; HEMATOLOGIC MALIGNANCIES; MYELOID-LEUKEMIA; GRAFT; RECIPIENTS; LYMPHOCYTES; BLOOD; MYELODYSPLASIA	Background For most conditions amenable to bone-marrow transplantation, grafts from HLA-matched but unrelated donors have yielded poorer results than those obtained from matched-sibling donors, We assessed this pattern in the light of improvements in donor selection and posttransplant supportive care. Methods We reviewed transplant outcome in 103 with childhood leukaemia who bone-marrow transplantation with HLA-matched sibling marrow (n=52) or matched unrelated donor marrow (n=51) between May, 1990, and March, 1996, at St Jude Children's Research Hospital. Findings Analysis of engraftment, frequency of procedure-related complications, and disease-free survival revealed no advantage from use of matched-sibling marrow, The 2-year disease-free survival estimate for standard-risk recipients of matched-sibling marrow was 81 [8.1]% compared with 73 [12.1]% in the unrelated donor marrow group (p=0.77), In the high-risk category, patients with a matched-sibling donor had a 2-year disease-free survival of 31 [11.6]%, compared with 32 [15.1]% among recipients of matched unrelated donor marrow (p=0.87). Interpretation We believe this improved result with unrelated donor marrow is a consequence of recent innovations in histocompatibility matching, prevention of graft-versus-host disease (GvHD), and antiviral prophylaxis. We suggest that such grafts can now be used in patients at both standard and high risk without compromising treatment outcome.	ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN USA; ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Heslop, Helen/AAC-9500-2020; srivastava, dhiraj kumar/HHT-1225-2022; Brenner, Malcolm/Y-2509-2019	Hongeng, Suradej/0000-0002-7376-9393	NCI NIH HHS [CA 61384, P 30 CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA061384, U01CA061384] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANASETTI C, 1995, ANNU REV MED, V46, P169; Anderson JE, 1996, BRIT J HAEMATOL, V93, P59, DOI 10.1046/j.1365-2141.1996.4811022.x; AVERSA F, 1994, BLOOD, V84, P3948, DOI 10.1182/blood.V84.11.3948.bloodjournal84113948; BALDUZZI A, 1995, BLOOD, V86, P3247; Beatty P G, 1995, Clin Transpl, P271; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; CASPER J, 1995, BLOOD, V85, P2354, DOI 10.1182/blood.V85.9.2354.bloodjournal8592354; DAVIES SM, 1994, BONE MARROW TRANSPL, V13, P54; GAMIS AS, 1993, J CLIN ONCOL, V11, P834, DOI 10.1200/JCO.1993.11.5.834; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; HESLOP HE, 1995, LANCET, V346, P805, DOI 10.1016/S0140-6736(95)91621-0; HESLOP HE, 1994, HUM GENE THER, V5, P381, DOI 10.1089/hum.1994.5.3-381; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; HOWARD MR, 1990, TRANSPLANTATION, V49, P547, DOI 10.1097/00007890-199003000-00015; HOWS J, 1993, BONE MARROW TRANSPL, V12, P371; KOEHLER M, 1994, BONE MARROW TRANSPL, V13, P571; Kook H, 1996, BLOOD, V88, P1089; KRANCE R, 1993, BONE MARROW TRANSPL, V11, P33; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Lucas KG, 1996, BLOOD, V87, P2594, DOI 10.1182/blood.V87.6.2594.bloodjournal8762594; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; MCGLAVE P, 1993, BLOOD, V81, P543; NADEMANEE A, 1995, BLOOD, V86, P1228, DOI 10.1182/blood.V86.3.1228.bloodjournal8631228; Nash RA, 1996, BLOOD, V88, P3634, DOI 10.1182/blood.V88.9.3634.bloodjournal8893634; Oakhill A, 1996, BRIT J HAEMATOL, V94, P574, DOI 10.1046/j.1365-2141.1996.d01-1834.x; Petersdorf EW, 1996, P NATL ACAD SCI USA, V93, P15358, DOI 10.1073/pnas.93.26.15358; PETERSDORF EW, 1995, BLOOD, V86, P1606, DOI 10.1182/blood.V86.4.1606.bloodjournal8641606; PRENTICE HG, 1984, LANCET, V1, P472; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SPIESER DE, 1996, BLOOD, V87, P4455; Szydlo R, 1997, J CLIN ONCOL, V15, P1767, DOI 10.1200/JCO.1997.15.5.1767; Wagner JE, 1996, BLOOD, V88, P795	35	139	142	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					767	771		10.1016/S0140-6736(97)03098-5	http://dx.doi.org/10.1016/S0140-6736(97)03098-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297996				2022-12-28	WOS:A1997XW28200011
J	Feuchtgruber, H; Lellouch, E; deGraauw, T; Bezard, B; Encrenaz, T; Griffin, M				Feuchtgruber, H; Lellouch, E; deGraauw, T; Bezard, B; Encrenaz, T; Griffin, M			External supply of oxygen to the atmospheres of the giant planets	NATURE			English	Article							SHORT-PERIOD COMETS; MIXING RATIOS; NEPTUNE; SATURN; RINGS; URANUS; DUST; MODEL; CO; SPECTROMETER	The atmospheres of the giant planets are reducing, being mainly composed of hydrogen, helium and methane. But the rings and icy satellites that surround these planets, together with the flux of interplanetary dust, could act as important sources of oxygen, which would be delivered to the atmospheres mainly in the form of water ice or silicate dust(1-7). Here we report the detection, by infrared spectroscopy, of gaseous H2O in the upper atmospheres of Saturn, Uranus and Neptune. The implied H2O column densities are 1.5 x 10(15), 9 x 10(13) and 3 x 10(14) molecules cm(-2) respectively, CO2 in comparable amounts was also detected in the atmospheres of Saturn and Neptune, These observations can be accounted for by external fluxes of 10(5)-10(7) H2O molecules cm(-2) s(-1) and subsequent chemical processing in the atmospheres, The presence of gaseous water and infalling dust will affect the photochemistry, energy budget and ionospheric properties of these atmospheres. Moreover, our findings may help to constrain the injection rate and possible activity of distant icy objects in the Solar System.	OBSERV PARIS,DESPA,F-92195 MEUDON,FRANCE; MAX PLANCK INST EXTRATERR PHYS,D-85748 GARCHING,GERMANY; ESA,ISO,SCI OPERAT CTR,VILLAFRANCA 28080,SPAIN; SRON,NL-9700 AV GRONINGEN,NETHERLANDS; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON E1 4NS,ENGLAND	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Max Planck Society; University of London; Queen Mary University London				Bezard, Bruno/0000-0002-5433-5661				ATNEYA SK, 1990, URANUS, P110; Atreya S. K., 1984, SATURN, P239; BISHOP J, 1992, J GEOPHYS RES-PLANET, V97, P11681, DOI 10.1029/92JE00959; BISHOP J, 1990, ICARUS, V88, P448, DOI 10.1016/0019-1035(90)90094-P; BROADFOOT AL, 1986, SCIENCE, V233, P74, DOI 10.1126/science.233.4759.74; COLWELL JE, 1992, J GEOPHYS RES-PLANET, V97, P10227, DOI 10.1029/92JE00788; COLWELL JE, 1990, GEOPHYS RES LETT, V17, P1741, DOI 10.1029/GL017i010p01741; COLWELL JE, 1990, ICARUS, V86, P530, DOI 10.1016/0019-1035(90)90232-X; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CROVISIER J, 1993, ASTEROIDS COMETS MET, P313; CUZZI JN, 1990, ICARUS, V84, P467, DOI 10.1016/0019-1035(90)90049-F; deGraauw T, 1997, ASTRON ASTROPHYS, V321, pL13; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; FERNANDEZ JA, 1985, ICARUS, V64, P308; Foryta DW, 1996, ICARUS, V123, P129, DOI 10.1006/icar.1996.0146; FOUCHET T, 1996, B AM ASTRON SOC, V28, P1129; GRUN E, 1994, ASTRON ASTROPHYS, V286, P915; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; HUBBARD WB, UNPUB ICARUS; HUMES DH, 1980, J GEOPHYS RES-SPACE, V85, P5841, DOI 10.1029/JA085iA11p05841; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; Lara LM, 1996, J GEOPHYS RES-PLANET, V101, P23261, DOI 10.1029/96JE02036; LELLOUCH E, 1996, COLLISION COMET SHOE, P213; MAJEED T, 1991, PLANET SPACE SCI, V39, P1715, DOI 10.1016/0032-0633(91)90031-5; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; MORFILL GE, 1983, ICARUS, V55, P439, DOI 10.1016/0019-1035(83)90114-8; MOSES JI, 1992, ICARUS, V99, P368, DOI 10.1016/0019-1035(92)90153-X; NOLL KS, 1990, ICARUS, V89, P168; NORTHROP TG, 1993, J GEOPHYS RES, V88, P6102; PRATHER MJ, 1978, ASTROPHYS J, V223, P1072, DOI 10.1086/156340; QUINN T, 1990, ASTROPHYS J, V355, P667, DOI 10.1086/168800; RIZK B, 1990, ICARUS, V88, P429, DOI 10.1016/0019-1035(90)90093-O; ROMANI PN, 1993, ICARUS, V106, P442, DOI 10.1006/icar.1993.1184; ROSENQVIST J, 1992, ASTROPHYS J, V392, pL99, DOI 10.1086/186435; SAMUELSON RE, 1983, J GEOPHYS RES-SPACE, V88, P8709, DOI 10.1029/JA088iA11p08709; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SMITH GR, 1983, J GEOPHYS RES-SPACE, V88, P8667, DOI 10.1029/JA088iA11p08667; STROBEL DF, 1979, ICARUS, V37, P256, DOI 10.1016/0019-1035(79)90130-1; STROBEL DF, 1990, URANUS, P65; WINKELSTEIN P, 1983, ICARUS, V54, P309, DOI 10.1016/0019-1035(83)90200-2	40	163	163	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					159	162		10.1038/38236	http://dx.doi.org/10.1038/38236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296492				2022-12-28	WOS:A1997XV75700041
J	Schnell, MJ; Johnson, JE; Buonocore, L; Rose, JK				Schnell, MJ; Johnson, JE; Buonocore, L; Rose, JK			Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; G-PROTEIN; RECEPTOR; EXPRESSION; GENE; GLYCOPROTEIN; FUSION; SYSTEM; ENTRY	We describe a recombinant vesicular stomatitis virus lacking its glycoprotein gene and expressing instead the HIV-1 receptor CD4 and a coreceptor, CXCR4. This virus was unable to infect normal cells but did infect, propagate on, and kill cells that were first infected with HIV-1 and therefore had the HIV membrane fusion protein on their surface. Killing of HIV-l-infected cells controlled HIV infection in a T cell line and reduced titers of infectious HIV-1 in the culture by as much as 10(4)-fold. Such a targeted virus could have therapeutic value in reducing HIV viral load. Our results also demonstrate a general strategy of targeting one virus to the envelope protein of another virus to control infection.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Schnell, Matthias/0000-0001-9040-9405	NIAID NIH HHS [AI24345, AI49235] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI049235, R01AI024345, R01AI049235, R37AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Johnson JE, 1997, J VIROL, V71, P5060, DOI 10.1128/JVI.71.7.5060-5068.1997; KNIPE DM, 1977, J VIROL, V21, P1149, DOI 10.1128/JVI.21.3.1149-1158.1977; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LAWSON ND, 1995, P NATL ACAD SCI USA, V92, P4477, DOI 10.1073/pnas.92.10.4477; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mebatsion T, 1996, CELL, V84, P941, DOI 10.1016/S0092-8674(00)81072-7; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; REED L. J., 1938, AMER JOUR HYG, V27, P493; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; RIEDEL H, 1984, EMBO J, V3, P1477, DOI 10.1002/j.1460-2075.1984.tb01999.x; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Schuitemaker H, 1996, AIDS, V10 Suppl A, pS25, DOI 10.1097/00002030-199601001-00004; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wagner RR., 1996, FIELDS VIROLOGY, V1, P1121; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	34	184	206	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					849	857		10.1016/S0092-8674(00)80350-5	http://dx.doi.org/10.1016/S0092-8674(00)80350-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298897	hybrid			2022-12-28	WOS:A1997XV56300006
J	Wawryk, A; Mavromatis, C; Gold, M				Wawryk, A; Mavromatis, C; Gold, M			Electronic monitoring of vaccine cold chain in a metropolitan area	BRITISH MEDICAL JOURNAL			English	Article							STORAGE	Successful immunisation strategies depend on the provision of immunogenic vaccines and the correct manufacture and storage of those vaccines, Studies in developed and developing countries have shown that vaccines are stored inadequately and that the vaccine cold chain can be disrupted.(1 2) We measured the temperature of vaccines stored long term in a metropolitan area of a developed country using electronic data loggers to determine how long vaccines had been exposed to temperatures < 0 degrees C.	WOMENS & CHILDRENS HOSP,DEPT PAEDIAT,ADELAIDE,SA,AUSTRALIA; CHILD & YOUTH HLTH,ADELAIDE,SA 5000,AUSTRALIA	Womens & Childrens Hospital Australia								LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; MCLEAN AA, 1982, ANN INTERN MED, V97, P451, DOI 10.7326/0003-4819-97-3-451_1; THAKKER Y, 1992, BRIT MED J, V304, P756, DOI 10.1136/bmj.304.6829.756; *WHO, 1980, EPIDEMIOL REC, V50, P385	4	16	18	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					518	518		10.1136/bmj.315.7107.518	http://dx.doi.org/10.1136/bmj.315.7107.518			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329306	Green Published			2022-12-28	WOS:A1997XU50600018
J	Eizinger, A; Sommer, RJ				Eizinger, A; Sommer, RJ			The homeotic gene lin-39 and the evolution of nematode epidermal cell fates	SCIENCE			English	Article							C-ELEGANS	The fate of ventral epidermal cells differs among nematode species. Nonvulval cells fuse with the epidermis in Caenorhabditis elegans, whereas the homologous cells undergo apoptosis in Pristionchus pacificus. The homeotic gene lin-39 is involved in the regulation of these epidermal cell fates. in Caenorhabditis, lin-39 prevents cell fusion of potential vulval cells and specifies the vulva equivalence group. Pristionchus vulvaless mutants that displayed apoptosis of the vulval precursor cells were isolated, and point mutations in lin-39 were identified. Thus, the evolution of these epidermal cell fates is driven by different intrinsic properties of homologous cells.	MAX PLANCK INST ENTWICKLUNGSBIOL,ABT ZELLBIOL,D-72076 TUBINGEN,GERMANY	Max Planck Society								BIRD DM, 1994, J NEMATOL, V26, P138; Clandinin TR, 1997, DEV BIOL, V182, P150, DOI 10.1006/dbio.1996.8471; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; Lee K. T., UNPUB; Malakhov VV., 1994, NEMATODES; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SOMMER R, UNPUB; Sommer RJ, 1996, CURR BIOL, V6, P52, DOI 10.1016/S0960-9822(02)00421-9; Sommer RJ, 1997, BIOESSAYS, V19, P225, DOI 10.1002/bies.950190308; Sommer RJ, 1997, DEVELOPMENT, V124, P243; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1	13	74	76	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					452	455		10.1126/science.278.5337.452	http://dx.doi.org/10.1126/science.278.5337.452			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334302				2022-12-28	WOS:A1997YB35500042
J	Groux, H; OGarra, A; Bigler, M; Rouleau, M; Antonenko, S; deVries, JE; Roncarolo, MG				Groux, H; OGarra, A; Bigler, M; Rouleau, M; Antonenko, S; deVries, JE; Roncarolo, MG			A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis	NATURE			English	Article							T-HELPER-2 POPULATIONS; INTERLEUKIN-10 IL-10; MICE; PROLIFERATION; STIMULATION; EXPRESSION; CLONES; ANERGY	Induction and maintenance of peripheral tolerance are important mechanisms to maintain the balance of the immune system. In addition to the deletion of T cells and their failure to respond in certain circumstances, active suppression mediated by T cells or T-cell factors has been proposed as a mechanism for maintaining peripheral tolerance(1). However, the inability to isolate and clone regulatory T cells involved in antigen-specific inhibition of immune responses has made it difficult to understand the mechanisms underlying such active suppression. Here we show that chronic activation of both human and murine CD4(+) T cells in the presence of interleukin (IL)-10 gives rise to CD4(+) T-cell clones with low proliferative capacity, producing high levels of IL-10, low levels of IL-2 and no IL-4. These antigen-specific T-cell clones suppress the proliferation of CD4(+) T cells in response to antigen, and prevent colitis induced in SCID mice by pathogenic CD4(+)CD45RB(high) splenic T cells. Thus IL-10 drives the generation of a CD4(+) T-cell subset, designated T regulatory cells 1 (Tr1), which suppresses antigen-specific immune responses and actively downregulates a pathological immune response in vivo.	DNAX RES INST MOL & CELLULAR BIOL INC, DEPT HUMAN IMMUNOL, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Rouleau, Matthieu/D-5774-2016	Rouleau, Matthieu/0000-0002-0075-9880; O'Garra, Anne/0000-0001-9845-6134; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ABRAMOWICZ D, 1993, TRANSPLANT P, V25, P312; ALLEN RD, 1993, EUR J IMMUNOL, V23, P333, DOI 10.1002/eji.1830230205; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BECKER JC, 1994, INT IMMUNOL, V6, P1605, DOI 10.1093/intimm/6.10.1605; BLAZAR BR, 1995, BLOOD, V85, P842, DOI 10.1182/blood.V85.3.842.bloodjournal853842; Cannella B, 1996, J NEUROSCI RES, V45, P735, DOI 10.1002/(SICI)1097-4547(19960915)45:6<735::AID-JNR10>3.0.CO;2-V; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; GERMAIN RN, 1981, SCAND J IMMUNOL, V13, P1, DOI 10.1111/j.1365-3083.1981.tb00104.x; GORCZYNSKI RM, 1994, J IMMUNOL, V152, P2011; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; HAU HS, 1996, J AUTOIMMUN, V9, P331; JENKINS MK, 1990, J IMMUNOL, V144, P16; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LEE MS, 1994, J CLIN INVEST, V93, P1332, DOI 10.1172/JCI117092; MALEFYT RD, 1991, J EXP MED, V174, P915; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NISITANI S, 1995, EUR J IMMUNOL, V25, P3047, DOI 10.1002/eji.1830251110; Nossal G J, 1987, Int Rev Immunol, V2, P321, DOI 10.3109/08830188709044760; OGarra A, 1996, CHEM IMMUNOL, V63, P1; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; RENNICK D, 1995, INTERLEUKIN 10, P141; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUZUKI T, 1995, J EXP MED, V182, P477, DOI 10.1084/jem.182.2.477; Weiner HL, 1996, FASEB J, V10, pA1444; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	30	2964	3123	2	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					737	742		10.1038/39614	http://dx.doi.org/10.1038/39614			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338786				2022-12-28	WOS:A1997YA95900057
J	Kothakota, S; Azuma, T; Reinhard, C; Klippel, A; Tang, J; Chu, KT; McGarry, TJ; Kirschner, MW; Koths, K; Kwiatkowski, DJ; Williams, LT				Kothakota, S; Azuma, T; Reinhard, C; Klippel, A; Tang, J; Chu, KT; McGarry, TJ; Kirschner, MW; Koths, K; Kwiatkowski, DJ; Williams, LT			Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; ICE/CED-3 PROTEASE; ACTIN; CELLS; INHIBITION; SUBSTRATE; IDENTIFICATION; PLASMA; CED-3; MICE	The caspase-3 (CPP32, apopain, YAMA) family of cysteinyl proteases has been implicated as key mediators of apoptosis in mammalian cells, Gelsolin was identified as a substrate for caspase-3 by screening the translation products of small complementary DNA pools for sensitivity to cleavage by caspase-3. Gelsolin was cleaved in vivo in a caspase-dependent manner in cells stimulated by Fas. Caspase-cleaved gelsolin severed actin filaments in vitro in a Ca2+-independent manner, Expression of the gelsolin cleavage product in multiple cell types caused the cells to round up, detach from the plate, and undergo nuclear fragmentation. Neutrophils isolated from mice lacking gelsolin had delayed onset of both blebbing and DNA fragmentation, following apoptosis induction, compared with wild-type neutrophils. Thus, cleaved gelsolin may be one physiological effector of morphologic change during apoptosis.	CHIRON CORP,EMERYVILLE,CA 94608; BRIGHAM & WOMENS HOSP,DIV EXPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Novartis; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [P01 HL48743, R01 HL54188] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048743, R01HL054188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Asch HL, 1996, CANCER RES, V56, P4841; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; King RW, 1997, SCIENCE, V277, P973, DOI 10.1126/science.277.5328.973; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; KWIATKOWSKI DJ, UNPUB; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TAKEDA Y, 1993, INT IMMUNOL, V5, P691, DOI 10.1093/intimm/5.6.691; TANAKA M, 1995, CANCER RES, V55, P3228; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WEEDS AG, 1991, BIOCHEM SOC T, V19, P1016, DOI 10.1042/bst0191016; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	37	978	1013	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					294	298		10.1126/science.278.5336.294	http://dx.doi.org/10.1126/science.278.5336.294			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323209				2022-12-28	WOS:A1997YA56400046
J	Tsuneizumi, K; Nakayama, T; Kamoshida, Y; Kornberg, TB; Christian, JL; Tabata, T				Tsuneizumi, K; Nakayama, T; Kamoshida, Y; Kornberg, TB; Christian, JL; Tabata, T			Daughters against dpp modulates dpp organizing activity in Drosophila wing development	NATURE			English	Article							PATTERN; PROTEIN; MORPHOGEN; HEDGEHOG; XENOPUS; EXPRESSION; MESODERM; MOTHERS; FAMILY; GENES	The family of TGF-beta signalling molecules play inductive roles in various developmental contexts(1). One member of this family, Drosophila Decapentaplegic (Dpp)(2) serves as a morphogen that patterns both the embryo(3,1) and adult(4,5). We have now isolated a gene, Daughters against dpp (Dad), whose transcription is induced by Dpp, Dad shares weak homology with Drosophila Mad (Mothers against dpp)(6), a protein required for transduction of Dpp signals. In contrast to Mad or the activated Dpp receptor, whose overexpression hyperactivates the Dpp signalling pathway, overexpression of Dad blocks Dpp activity, Expression of Dad together with either Mad or the activated receptor rescues phenotypic defects induced by each protein alone. Dad can also antagonize the activity of a vertebrate homologue of Dpp, bone morphogenetic protein (BMP-4; ref. 7), as evidenced by induction of dorsal or neural fate following overexpression in Xenopus embryos. We conclude that the pattern-organizing mechanism governed by Dpp involves a negative-feedback circuit in which Dpp induces expression of its own antagonist, Dad, This feedback loop appears to be conserved in vertebrate development.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,TOKYO 113,JAPAN; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of Tokyo; Oregon Health & Science University; University of California System; University of California San Francisco			Nakayama, Takuya/J-5812-2015	Nakayama, Takuya/0000-0002-5531-6710				BLITZ IL, 1995, DEVELOPMENT, V121, P993; BRAND AH, 1993, DEVELOPMENT, V118, P401; Burke R, 1996, DEVELOPMENT, V122, P2261; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ito K, 1997, DEVELOPMENT, V124, P761; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAI CJ, 1995, DEVELOPMENT, V121, P2349; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MACIASSILVA M, 1997, CELL, V87, P1215; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moon R. T., 1989, TECHNIQUE, V1, P76; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; ZECCA M, 1995, DEVELOPMENT, V121, P2265	32	346	352	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					627	631		10.1038/39362	http://dx.doi.org/10.1038/39362			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335506				2022-12-28	WOS:A1997YA00800066
J	Garbe, E; LeLorier, J; Boivin, JF; Suissa, S				Garbe, E; LeLorier, J; Boivin, JF; Suissa, S			Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids	LANCET			English	Article							INTRAOCULAR-PRESSURE	Background Ocular hypertension and open-angle glaucoma are well-known side-effects of treatment with topical ophthalmic glucocorticoids. There is uncertainty about the risk of these disorders with oral glucocorticoid therapy. Methods Data from the Quebec universal health insurance programme for the elderly were used to identify 9793 patients with a new diagnosis of ocular hypertension or open-angle glaucoma, or on newly prescribed treatment for these disorders (cases). 38 325 controls were randomly selected from ophthalmology patients seen in the same month and year as the case (index date). Current use of oral glucocorticoids was defined as that within 14 days of the index date. All glucocorticoid doses were converted to the equivalent amount of hydrocortisone. The case-control analysis was done by conditional logistic regression and adjusted for age, sex, systemic hypertension, diabetes mellitus, ophthalmic glucocorticoids, glucocorticoid injections, and variables related to general health. Findings The mean ages of cases and controls were similar (74.9 [SD 6.3] vs 74.7 [6.4]). The adjusted odds ratio of ocular hypertension or open-angle glaucoma for current users of oral glucocorticoids compared with non-users was 1.41 (95% CI 1.22-1.63). There was a dose-related increase in the adjusted odds ratios for current users: 1.26 (1.01-1.56) for less than 40 mg per day of hydrocortisone, 1.37 (1.06-1.76) for patients on 40-79 mg per day, and 1.88 (1.40-2.53) for patients on 80 mg or more per day. The odds ratios also increased with the duration of treatment over the first 11 months of exposure. Interpretation The use of oral glucocorticoids increases the risk of ocular hypertension or open-angle glaucoma in elderly patients. In patients in this age-group who need long-term treatment with high doses of oral glucocorticoids, monitoring of intraocular pressure may be justified.	ROYAL VICTORIA HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ H3A 2T5,CANADA; UNIV MONTREAL,HOTEL DIEU,CTR RECH,MONTREAL,PQ H3C 3J7,CANADA; POTSDAM INST PHARMACOEPIDEMIOL & TECHNOL ASSESSME,POTSDAM,GERMANY	McGill University; Royal Victoria Hospital; McGill University; Laval University; Universite de Montreal								ABEL R, 1987, AVERYS DRUG TREATMEN, P387; ADHIKARY HP, 1982, BRIT J OPHTHALMOL, V66, P290, DOI 10.1136/bjo.66.5.290; ALFANO JE, 1963, AM J OPHTHALMOL, V56, P245, DOI 10.1016/0002-9394(63)91858-0; ARMALY MF, 1986, GLAUCOMA, P697; BECKER B, 1963, ARCH OPHTHALMOL-CHIC, V70, P500; BERNSTEIN HN, 1962, ARCH OPHTHALMOL-CHIC, V68, P742; CLARK WG, 1992, GOTHS MED PHARM, P773; DAVID DS, 1969, LANCET, V2, P149; DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GODEL V, 1972, ACTA OPHTHALMOL, V50, P655; HAYNES R C JR, 1990, P1431; Hodapp EA, 1982, SECONDARY GLAUCOMAS, P258; KITAZAWA Y, 1976, AM J OPHTHALMOL, V82, P492, DOI 10.1016/0002-9394(76)90500-6; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEE PF, 1958, AM J OPHTHALMOL, V46, P328, DOI 10.1016/0002-9394(58)90256-3; LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626; LONG WF, 1977, AM J OPTOM PHYS OPT, V54, P248; QUIGLEY HA, 1993, NEW ENGL J MED, V328, P1097, DOI 10.1056/NEJM199304153281507; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P87; Skuta GL, 1996, GLAUCOMAS, P1177; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; STERN JJ, 1953, AM J OPHTHALMOL, V36, P389, DOI 10.1016/0002-9394(53)91389-0; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; WEINREB RN, 1981, INVEST OPHTH VIS SCI, V21, P403; *WHO, 1977, 9 REV C 1975; WILLIAMSON J, 1969, BRIT J OPHTHALMOL, V53, P361, DOI 10.1136/bjo.53.6.361	27	111	113	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					979	982		10.1016/S0140-6736(97)03392-8	http://dx.doi.org/10.1016/S0140-6736(97)03392-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329512				2022-12-28	WOS:A1997XZ71000008
J	Liem, KF; Tremml, G; Jessell, TM				Liem, KF; Tremml, G; Jessell, TM			A role for the roof plate and its resident TGF beta-related proteins in neuronal patterning in the dorsal spinal cord	CELL			English	Article							NEURAL CREST CELLS; BONE MORPHOGENETIC PROTEIN-4; FLOOR PLATE; SONIC HEDGEHOG; VERTEBRATE DEVELOPMENT; NERVOUS-SYSTEM; MOTOR-NEURONS; EXPRESSION; ACTIVIN; DIFFERENTIATION	Distinct neuronal cell types are generated at characteristic times and positions in the dorsal horn of the spinal cord. We provide evidence that the identity and pattern of generation of dorsal neurons depend initially on BMP-mediated signals that derive from the epidermal ectoderm and induce dorsal midline cells of the roof plate. Roof plate cells provide a secondary source of TGF beta-related signals that are required for the generation of distinct classes of dorsal interneurons. These inductive interactions involve both qualitative and quantitative differences in signaling by TGF beta-related factors and temporal changes in the response of neural progenitor cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOPHYS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10021	Columbia University; Howard Hughes Medical Institute					NIGMS NIH HHS [5T32GM07367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN J, 1984, DEV RAT SPINAL CORD; Arkell R, 1997, DEVELOPMENT, V124, P1; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; Brown AG, 1981, ORG SPINAL CORD; CARPENTER EM, 1992, DEV BIOL, V150, P144, DOI 10.1016/0012-1606(92)90014-8; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Dudley AT, 1997, DEV DYNAM, V208, P349; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; Eichmann A, 1997, MECH DEVELOP, V65, P111, DOI 10.1016/S0925-4773(97)00063-4; EIDE AL, 1997, ANAT EMBRYOL, V197, P195; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gale NW, 1996, ONCOGENE, V13, P1343; GURDON JB, 1994, NATURE, V225, P40; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; LEBER SM, 1995, J NEUROSCI, V15, P1236; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MASON AJ, 1989, MOL ENDOCRINOL, V3, P1352, DOI 10.1210/mend-3-9-1352; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; MUHR J, 1997, IN PRESS NEURON; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NEWGREEN DF, 1986, INT REV CYTOL, V103, P89, DOI 10.1016/S0074-7696(08)60834-7; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; OPPENHEIM RW, 1988, J COMP NEUROL, V275, P159, DOI 10.1002/cne.902750202; PITUELLO F, 1995, P NATL ACAD SCI USA, V92, P6952, DOI 10.1073/pnas.92.15.6952; PUOPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUELLIG RA, 1992, EUR J BIOCHEM, V204, P453, DOI 10.1111/j.1432-1033.1992.tb16655.x	62	458	466	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					127	138		10.1016/S0092-8674(01)80015-5	http://dx.doi.org/10.1016/S0092-8674(01)80015-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335341	Bronze			2022-12-28	WOS:A1997XZ80900015
J	Meade, MO; Richardson, WS				Meade, MO; Richardson, WS			Selecting and appraising studies for a systematic review	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; MEDICAL LITERATURE; USERS GUIDES; SCIENTIFIC DISCIPLINE; META-ANALYSIS; QUALITY; BIAS; METAANALYSIS; PUBLICATION; ASSIGNMENT		UNIV ROCHESTER, DEPT MED, SCH MED & DENT, ROCHESTER, NY 14621 USA; UNIV TORONTO, TORONTO, ON, CANADA	University of Rochester; University of Toronto								Altman D.G., 1991, PRACTICAL STAT MED R; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; BERLIN JA, ONLINE J CURR CLIN T; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Counsell C, 1997, ANN INTERN MED, V127, P380, DOI 10.7326/0003-4819-127-5-199709010-00008; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; LAU J, 1997, IN PRESS ANN INTERN; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; OXMAN AD, 1994, SECTION 6 PREPARING, P28; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Richardson W S, 1995, ACP J Club, V123, pA12; SACKS HS, 1983, NEW ENGL J MED, V309, P1353; SCHERER RW, 1994, JAMA-J AM MED ASSOC, V272, P158, DOI 10.1001/jama.272.2.158; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; WILLIAMS DH, 1994, CONTROL CLIN TRIALS, V15, P294, DOI 10.1016/0197-2456(94)90045-0	32	172	176	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					531	537		10.7326/0003-4819-127-7-199710010-00005	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313021				2022-12-28	WOS:A1997XY73300005
J	Cher, DJ; Lenert, LA				Cher, DJ; Lenert, LA			Method of Medicare reimbursement and the rate of potentially ineffective care of critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; APACHE-II; MECHANICAL VENTILATION; HOSPITALIZED ADULTS; OUTCOME PREDICTION; CANCER-PATIENTS; MANAGED CARE; SURVIVAL; UNIT; MORTALITY	Context.-The worst outcome of critical care may not be death itself; rather, the worst may be an extended death process in which a patient's and his or her family's suffering has been prolonged by services that are ultimately impotent. We have previously used potentially ineffective care (PIC) as a proxy measure for this type of care. Objective.-To determine if PIC is delivered less often to Medicare patients enrolled in health maintenance organizations (HMOs) than those in traditional fee-for-service health plans. Patients.-All Medicare patients hospitalized in intensive care units in California during fiscal year 1994. Outcome.-Potentially ineffective care was defined as the concurrence of in-hospital death or death within 100 days of hospital discharge and resource use (total hospital costs) above the 90th percentile. Methods.-Hospital costs were adjusted for institution-specific cost-to-charge ratios and local wage indices derived from Health Care Financing Administration cost reports. A multivariate regression model adjusted Pie rates for age, sex, race, elective admission to the hospital, Charlson index diseases, the 15 most common diagnosis related groups for death by 100 days, intensive care unit size, and number of residents at the hospital. Results.-A total of 3914 (4.8%) of 81 494 patients experienced PIC and used 21.6% of total intensive care unit resources, The occurrence of PIC was less common among HMO members (adjusted odds ratio, 0.75; 95% confidence interval, 0.65-0.87). However, HMO members were not more likely to experience in-hospital death (adjusted odds ratio, 0.99; 95% confidence interval, 0.91-1.07) and only slightly more likely to experience death by 100 days after hospital discharge (adjusted odds ratio, 1.08; 95% confidence interval, 1.01-1.15). Conclusions.-Patients who experience PIC outcomes are not uncommon in the Medicare population, and patients experiencing this outcome consume a disproportionate amount of medical resources, Medicare beneficiaries in HMO practice settings had a lower risk of experiencing PIC outcomes after adjusting for age, sex, diagnosis, comorbid conditions, and characteristics of the treating hospital, This suggests that HMO practices may be better at limiting or avoiding injudicious use of critical care near the end of life.	STANFORD UNIV,SCH MED,DIV CLIN PHARMACOL,STANFORD,CA 94305; PALO ALTO VET AFFAIRS HLTH CARE SYST,DIV GEN INTERNAL MED,PALO ALTO,CA	Stanford University				Cher, Daniel/0000-0002-3747-7879	NLM NIH HHS [LM 0562-03] Funding Source: Medline	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Angus DC, 1996, JAMA-J AM MED ASSOC, V276, P1075, DOI 10.1001/jama.276.13.1075; BRANNEN AL, 1989, ARCH INTERN MED, V149, P1083, DOI 10.1001/archinte.149.5.1083; CHANG RWS, 1988, CRIT CARE MED, V16, P34, DOI 10.1097/00003246-198801000-00007; CHANG RWS, 1989, LANCET, V2, P143; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; CHEVROLET JC, 1991, EUR J CANCER, V27, P210, DOI 10.1016/0277-5379(91)90490-5; CHRISTENSEN C, 1993, METHOD INFORM MED, V32, P302; CHU DY, 1993, CRIT CARE CLIN, V9, P89, DOI 10.1016/S0749-0704(18)30209-4; CIVETTA JM, 1992, SURG GYNECOL OBSTET, V175, P195; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; DEES A, 1990, NETH J MED, V37, P183; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; ESSERMAN L, 1995, JAMA-J AM MED ASSOC, V274, P1544, DOI 10.1001/jama.274.19.1544; *FRENCH MULT GROUP, 1989, CRIT CARE MED, V17, P305; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; Gold MR, 1996, COST EFFECTIVENESS H; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEGALL JR, 1994, CRIT CARE MED, V22, pA46; LEMESHOW S, 1988, CRIT CARE MED, V16, P470, DOI 10.1097/00003246-198805000-00002; MCCLISH DK, 1989, MED DECIS MAKING, V9, P125, DOI 10.1177/0272989X8900900207; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; Rubenfeld GD, 1996, ANN INTERN MED, V125, P625, DOI 10.7326/0003-4819-125-8-199610150-00001; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; Szaflarski N L, 1990, AACN Clin Issues Crit Care Nurs, V1, P215; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541	29	67	67	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1001	1007		10.1001/jama.278.12.1001	http://dx.doi.org/10.1001/jama.278.12.1001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307348				2022-12-28	WOS:A1997XX01200031
J	Richardson, P				Richardson, P			ABC of mental health - Psychological treatments	BRITISH MEDICAL JOURNAL			English	Review											Richardson, P (corresponding author), GUYS HOSP,LEWISHAM & GUYS MENTAL HLTH NHS TRUST,PSYCHOL TREATMENTS SERV,LONDON SE1 9RT,ENGLAND.							Burns D. D., 1990, FEELING GOOD HDB; CAPE J, 1996, COUNSELLING PSYCHOL; DAVIES T, 1994, BRIT MED J, V309, P353, DOI 10.1136/bmj.309.6951.353; Enright SJ, 1997, BRIT MED J, V314, P1811, DOI 10.1136/bmj.314.7097.1811; *NHS EX, 1996, NHS PSYCH SERV ENGL; Roth A., 1996, WHAT WORKS WHOM CRIT; *ROYAL COLL PSYCH, 1995, CR37 ROYAL COLL PSYC; Smith M. L., 1980, BENEFITS PSYCHOTHERA	8	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					733	735		10.1136/bmj.315.7110.733	http://dx.doi.org/10.1136/bmj.315.7110.733			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX674	9314760	Green Published			2022-12-28	WOS:A1997XX67400026
J	Davies, SC; Oni, L				Davies, SC; Oni, L			Fortnightly review - Management of patients with sickle cell disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RISK-FACTORS; CHILDREN; ANEMIA; PAIN; MORTALITY; HEMOGLOBINOPATHIES; PROPHYLAXIS; ADOLESCENTS; PENICILLIN; IMPACT				Davies, SC (corresponding author), CENT MIDDLESEX HOSP, IMPERIAL COLL SCH MED, BRENT SICKLE CELL & THALASSAEMIA CTR, LONDON NW10, ENGLAND.							Arason VA, 1996, BMJ-BRIT MED J, V313, P387; BROZOVIC M, 1987, BRIT MED J, V294, P1206, DOI 10.1136/bmj.294.6581.1206; CALMAN K, 1996, STATE PUBLIC HLTH AN; Cavill I, 1996, BRIT MED J, V312, P430; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; CUMMINS D, 1991, BRIT MED J, V302, P989, DOI 10.1136/bmj.302.6783.989; Davies S C, 1991, Baillieres Clin Haematol, V4, P361, DOI 10.1016/S0950-3536(05)80164-7; Davies S C, 1996, Curr Opin Hematol, V3, P485; Davies SC, 1996, ARCH DIS CHILD, V75, P3, DOI 10.1136/adc.75.1.3; Davies SC, 1997, BLOOD REV, V11, P57, DOI 10.1016/S0268-960X(97)90012-6; DAVIES SC, 1995, VOX SANG, V68, P145, DOI 10.1111/j.1423-0410.1995.tb03916.x; deCraen AJM, 1996, BRIT MED J, V313, P321, DOI 10.1136/bmj.313.7053.321; *DEP HTLH, 1993, REP WORK PART STAND; FLINT J, 1993, BAILLIERE CLIN HAEM, V6, P215, DOI 10.1016/S0950-3536(05)80071-X; Fuggle P, 1996, ARCH DIS CHILD, V75, P199, DOI 10.1136/adc.75.3.199; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GILL FM, 1995, BLOOD, V86, P776, DOI 10.1182/blood.V86.2.776.bloodjournal862776; Goldblatt D, 1996, ARCH DIS CHILD, V75, P159, DOI 10.1136/adc.75.2.159; GRAY A, 1991, J CLIN PATHOL, V44, P459, DOI 10.1136/jcp.44.6.459; GRIFFIN TC, 1994, NEW ENGL J MED, V330, P733, DOI 10.1056/NEJM199403173301101; Hanks GW, 1996, BRIT MED J, V312, P823; Hood AT, 1996, BLOOD, V87, P1600, DOI 10.1182/blood.V87.4.1600.bloodjournal8741600; Kaul DK, 1996, BLOOD REV, V10, P29, DOI 10.1016/S0268-960X(96)90018-1; KLUGMAN KP, 1989, LANCET, V2, P444; Lee A, 1995, BRIT MED J, V311, P1600, DOI 10.1136/bmj.311.7020.1600; Midence K, 1996, BRIT J CLIN PSYCHOL, V35, P439, DOI 10.1111/j.2044-8260.1996.tb01198.x; NAGEL RL, 1992, BAILLIERE CLIN HAEM, V5, P331, DOI 10.1016/S0950-3536(11)80023-5; PLATT OS, 1984, NEW ENGL J MED, V311, P7, DOI 10.1056/NEJM198407053110102; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; PRYLE BJ, 1992, BRIT MED J, V304, P1478, DOI 10.1136/bmj.304.6840.1478; Sergeant GR, 1992, SICKLE CELL DIS; SERJEANT GR, 1993, LANCET, V341, P1237, DOI 10.1016/0140-6736(93)91145-C; SHAPIRO BS, 1995, PAIN, V61, P139, DOI 10.1016/0304-3959(94)00164-A; STEINBERG MH, 1995, BLOOD, V86, P3997, DOI 10.1182/blood.V86.10.3997.bloodjournal86103997; STREETLY A, 1997, SICKLE CELL DISORDER; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; SWIFT AV, 1989, PEDIATRICS, V84, P1077; VICHINSKY EP, 1991, SEMIN HEMATOL, V28, P220; Walters M C, 1996, Biol Blood Marrow Transplant, V2, P100; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; Weatherall DJ, 1997, BRIT MED J, V314, P492, DOI 10.1136/bmj.314.7079.492; YOUNG RC, 1992, J NATL MED ASSOC, V84, P267	44	62	63	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	1997	315	7109					656	660		10.1136/bmj.315.7109.656	http://dx.doi.org/10.1136/bmj.315.7109.656			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310570	Green Published			2022-12-28	WOS:A1997XW69400024
J	Egger, M; Smith, GD; Schneider, M; Minder, C				Egger, M; Smith, GD; Schneider, M; Minder, C			Bias in meta-analysis detected by a simple, graphical test	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; COMPREHENSIVE GERIATRIC ASSESSMENT; RANDOMIZED CONTROLLED TRIALS; PUBLICATION BIAS; MEDICAL-RESEARCH; HEART-FAILURE; METAANALYSIS; MORTALITY; MAGNESIUM; THERAPY	Objective: Funnel plots (plots of effect estimates against sample size) may be useful to detect bias in meta-analyses that were later contradicted by large trials. We examined whether a simple test of asymmetry of funnel plots predicts discordance of results when meta-analyses are compared to large trials, and we assessed the prevalence of bias in published meta-analyses. Design: Medline search to identify pairs consisting of a meta-analysis and a single large trial (concordance of results was assumed if effects were in the same direction and the meta-analytic estimate was within 30% of the trial); analysis of funnel plots from 37 meta-analyses identified from a hand search of four leading general medicine journals 1993-6 and 38 meta-analyses from the second 1996 issue of the Cochrane Database of Systematic Reviews. Main outcome measure: Degree of funnel plot asymmetry as measured by die intercept from regression of standard normal deviates against precision. Results: Ln the eight pairs of meta-analysis and large trial that were identified (five from cardiovascular medicine, one from diabetic medicine, one from geriatric medicine, one from perinatal medicine) there were four concordant and four discordant pairs. In all cases discordance was due to meta-analyses showing larger effects. Funnel plot asymmetry was present in three out of four discordant pairs but in none of concordant pairs. In 14 (38%)journal meta-analyses and 5 (13%) Cochrane reviews, funnel plot asymmetry indicated chat there was bias. Conclusions: A simple analysis of funnel plots provides a useful test for the likely presence of bias in meta-analyses, but as the capacity to detect bias will be limited when meta-analyses are based on a limited number of small trials the results from such analyses should be treated with considerable caution.	UNIV BERN, DEPT SOCIAL & PREVENT MED, CH-3012 BERN, SWITZERLAND	University of Bern	Egger, M (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.		Bannuru, Raveendhara/G-2601-2011; Davey Smith, George/A-7407-2013; Franzeck, Fabian C/B-5055-2011	Bannuru, Raveendhara/0000-0002-8069-5783; Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, LANCET, V2, P57; Baxter GF, 1996, LANCET, V348, P1424, DOI 10.1016/S0140-6736(96)07281-9; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BEROYZ G, 1994, LANCET, V343, P619; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; *COCHR COLL, 1996, COCHR DAT SYST REV; Collins R, 1997, LANCET, V349, P282, DOI 10.1016/S0140-6736(97)26004-6; COLLINS R, 1995, LANCET, V345, P669; COLLINS R, 1994, PREGNANCY CHILDBIRTH; DEVITA C, 1994, LANCET, V343, P1115; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; EGGER M, IN PRESS BMJ; EYSENCK HJ, 1978, AM PSYCHOL, V33, P517, DOI 10.1037/0003-066X.33.5.517.a; FLOURNOY N, 1995, LANCET, V345, P741, DOI 10.1016/S0140-6736(95)90632-0; GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; Huque MF, 1988, PROC BIOPHARM SECT A, V2, P28; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; IMPERIALE TF, 1991, JAMA-J AM MED ASSOC, V266, P261; LEVY G, 1992, CLIN PHARMACOL THER, V52, P115, DOI 10.1038/clpt.1992.119; Light R.J., 1984, SUMMING SCI REV RES; MULROW CD, 1988, JAMA-J AM MED ASSOC, V259, P3422, DOI 10.1001/jama.259.23.3422; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; REUBEN DB, 1995, NEW ENGL J MED, V332, P1345, DOI 10.1056/NEJM199505183322007; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; TEO KK, 1993, DRUGS, V46, P347, DOI 10.2165/00003495-199346030-00002; Villar J, 1997, J CLIN EPIDEMIOL, V50, P997, DOI 10.1016/S0895-4356(97)00148-0; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1988, LANCET, V1, P1088	46	33002	33414	87	1442	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	1997	315	7109					629	634		10.1136/bmj.315.7109.629	http://dx.doi.org/10.1136/bmj.315.7109.629			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310563	Green Published			2022-12-28	WOS:A1997XW69400016
J	Mays, N; Goodwin, N; Bevan, G; Wyke, S				Mays, N; Goodwin, N; Bevan, G; Wyke, S			What is total purchasing?	BRITISH MEDICAL JOURNAL			English	Article									UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND	University of Bristol; University of Edinburgh	Mays, N (corresponding author), KINGS FUND POLICY INST,LONDON W1M 0AN,ENGLAND.			Goodwin, Nicholas/0000-0003-4900-3352				*AUD COMM, 1995, BRIEF GP FUNDH; Bachmann MO, 1996, BRIT MED J, V313, P1054; DIXON J, 1994, BRIT MED J, V308, P772, DOI 10.1136/bmj.308.6931.772; GLENNERSTER H, 1996, ALTERNATIVES FUNDHOL; Martin S, 1997, RISK GP BUDGET HOLDE; MAYS N, 1997, TOTAL PURCHASING PRO; MAYS N, 1996, PURCHASER PLURALITY; *NHS EX, 1994, DEV NHS PURCH GEN PR; *NHS EX, 1997, EL9733 NHS EX; SCHIFFLER R, 1989, LANCET, V1, P950; Secretaries of State, 1989, WORK PAT	11	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					652	655		10.1136/bmj.315.7109.652	http://dx.doi.org/10.1136/bmj.315.7109.652			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310569	Green Published			2022-12-28	WOS:A1997XW69400022
J	Zeman, A				Zeman, A			Persistent vegetative state	LANCET			English	Article							RECOVERY; GLUCOSE; CONSCIOUSNESS; IMPROVEMENT; METABOLISM; MANAGEMENT; INJURY; COMA				Zeman, A (corresponding author), UNIV EDINBURGH, WESTERN GEN HOSP, NHS TRUST, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.			Zeman, Adam/0000-0003-4875-658X				*AM DIET ASS, 1995, J AM DIET ASSOC, V95, P231; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANDREWS K, 1993, BRIT MED J, V306, P1600, DOI 10.1136/bmj.306.6892.1600; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; Baron -Cohen S., 1997, MINDBLINDNESS ESSAY; BERNAT JL, 1994, ETHICAL ISSUES NEURO, pCH7; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; BOYD K, 1991, LANCET, V337, P96; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; *BRIT AM ASS, 1996, BMA GUID TREATM DEC; *BRIT AM ASS, 1995, BMA VIEWS ADV STAT; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; CELESIA, 1993, ANN NEUROL, V33, P386; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Chokroverty S., 2017, SLEEP DISORDERS MED, VVolume 1, P29; Cowey A, 1997, DEV MED CHILD NEUROL, V39, P54; Crick F., 1994, ASTONISHING HYPOTHES; DEVOLDER AG, 1994, ACTA NEUROL BELG, V94, P183; EDELMAN G, 1992, BRIGHT AIR BRILLANT; GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GILLON R, 1993, BRIT MED J, V306, P1602, DOI 10.1136/bmj.306.6892.1602; Grubb A, 1996, LANCET, V348, P35, DOI 10.1016/S0140-6736(96)02030-2; GUERIT JM, 1994, ACTA NEUROL BELG, V94, P174; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; *HL REP SEL COMM M, 1994, REP SEL COMM MED ETH; Howsepian AA, 1996, ISSUES LAW MED, V12, P3; JENNETT B, 1972, LANCET, V1, P734; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; LaBerge D., 1995, ATTENTIONAL PROCESSI; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; MARCEL AJ, 1992, CONSCIOUSNESS CONT S; MCQUILLEN MP, 1991, ISSUES LAW MED, V6, P373; MILNER AD, 1992, NEUROPSYCHOLOGY CONS; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; Pallis C. A., 1996, ABC BRAIN STEM DEATH; Parker S.T., 1995, SELF AWARENESS ANIMA; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; Plum F, 1980, DIAGNOSIS STUPOR COM, Vthird; ROSENBERG GA, 1977, ANN NEUROL, V2, P167, DOI 10.1002/ana.410020215; *ROYAL HOSP NEUR, 1996, INT WORK PART REP VE; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Stoerig P, 1997, BRAIN, V120, P535, DOI 10.1093/brain/120.3.535; STUMPF DA, 1990, NEW ENGL J MED, V322, P669; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; Tsubokawa T, 1990, Brain Inj, V4, P315; TSUBOKAWA T, 1990, Brain Injury, V4, P329, DOI 10.3109/02699059009026186; TURKSTRA LS, 1995, BRAIN INJURY, V9, P61, DOI 10.3109/02699059509004573; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; Wilson SL, 1996, BRAIN INJURY, V10, P105, DOI 10.1080/026990596124593; Zeki S., 1993, VISION BRAIN; Zeman AZJ, 1997, J NEUROL NEUROSUR PS, V62, P549, DOI 10.1136/jnnp.62.6.549; [No title captured]	63	52	54	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	1997	350	9080					795	799		10.1016/S0140-6736(97)06447-7	http://dx.doi.org/10.1016/S0140-6736(97)06447-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9298013				2022-12-28	WOS:A1997XW28200049
J	Nacul, LC; Kirkwood, BR; Arthur, P; Morris, SS; Magalhaes, M; Fink, MCDS				Nacul, LC; Kirkwood, BR; Arthur, P; Morris, SS; Magalhaes, M; Fink, MCDS			Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							A SUPPLEMENTATION; YOUNG INFANTS; MORBIDITY; CHILDREN; SINGLE	Objective: To evaluate the impact on clinical recovery and severity of the addition of large doses of vitamin A to the standard treatment for childhood pneumonia. Design: A randomised, double blind, placebo controlled trial. Setting: Study children were recruited at a public hospital in Recife, north east Brazil, an area of marginal vitamin A deficiency. Subjects: 472 children aged 6 to 59 months with clinical diagnosis of pneumonia. Interventions: 200 000 IU (infants) or 400 000 IU (1-4 year olds) of vitamin A in oil or similar capsules of placebo divided into two daily oral doses, in addition to the standard treatment. Main outcome measures: Duration of the episode and incidence of adverse outcomes. Results: The groups were similar with respect to overall duration of pneumonia and incidence of adverse outcomes, Children who received vitamin A, however, were less likely to have fever by day 3 (P = 0.008) and were 29% less likely to fail to respond to the first line antibiotic (P = 0.054). Conclusion: There was little evidence for an effect of vitamin A treatment on the immediate outcome of the pneumonia episode.	UNIV LONDON LONDON SCH HYG & TROP MED, MAT & CHILD EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND; UNIV FED PERNAMBUCO, BR-50000 RECIFE, PE, BRAZIL; UNIV SAO PAULO, TVER MED INST, VIROL LAB, BR-05403000 SAO PAULO, BRAZIL	University of London; London School of Hygiene & Tropical Medicine; Universidade Federal de Pernambuco; Universidade de Sao Paulo				Kirkwood, Betty/0000-0001-5274-6072; Nacul, Luis/0000-0003-1411-8088				AGOESTINA T, 1994, B WORLD HEALTH ORGAN, V72, P859; Armitage P., 1987, STAT METHODS MED RES; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; Beaton G. H., 1992, EFFECTIVENESS VITAMI; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; COUTSOUDIS A, 1991, INT J VITAM NUTR RES, V61, P199; Cox D. R., 1984, ANAL SURVIVAL DATA; DEFRANCISCO A, 1993, LANCET, V342, P526, DOI 10.1016/0140-6736(93)91648-6; DERUYTER MGM, 1976, CLIN CHEM, V22, P1593; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; FAWZI WW, 1996, M INT VIT A CONS GRO; GLASZIOU PP, 1993, BMJ-BRIT MED J, V306, P366, DOI 10.1136/bmj.306.6874.366; HOSMER DW, 1989, APPL LOGIC REGRESSIO; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; Kirkwood B., 1988, BR K ESSENTIALS MED; Kirkwood BR, 1995, B WORLD HEALTH ORGAN, V73, P793; KJOLHEDE CL, 1995, J PEDIATR-US, V126, P807, DOI 10.1016/S0022-3476(95)70416-7; Kyran P.Q., 1996, ARCH PEDIAT ADOLESC, V150, P25; MADHULIKA, 1994, J TROP PEDIATRICS, V40, P305, DOI 10.1093/tropej/40.5.305; MCAULIFFE J, 1991, DEFICIENCIA VITAMINA; OGARO FO, 1993, TROP GEOGR MED, V45, P283; OLSON JA, 1984, J NATL CANCER I, V73, P1439; RAHMAN MM, 1995, EUR J CLIN NUTR, V49, P439; Rosales FJ, 1996, AM J EPIDEMIOL, V143, P413, DOI 10.1093/oxfordjournals.aje.a008761; Sommer A., 1996, VITAMIN A DEFICIENCY, P19; *VIT A PNEUM WORK, 1995, B WORLD HEALTH ORGAN, V73, P309; WEST KP, 1992, B WORLD HEALTH ORGAN, V70, P733	27	36	39	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	1997	315	7107					505	510		10.1136/bmj.315.7107.505	http://dx.doi.org/10.1136/bmj.315.7107.505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329303	Green Published			2022-12-28	WOS:A1997XU50600015
J	Anderson, SA; Eisenstat, DD; Shi, L; Rubenstein, JLR				Anderson, SA; Eisenstat, DD; Shi, L; Rubenstein, JLR			Interneuron migration from basal forebrain to neocortex: Dependence on Dlx genes	SCIENCE			English	Article							LATERAL GANGLIONIC EMINENCE; NEURONS; CELLS; MOUSE; IMMUNOREACTIVITY; DISPERSION; EXPRESSION; CORTEX; BRAIN; ZONE	Although previous analyses indicate that neocortical neurons originate from the cortical proliferative zone, evidence suggests that a subpopulation of neocortical interneurons originates within the subcortical telencephalon. For example, gamma-aminobutyric acid (GABA)-expressing cells migrate in vitro from the subcortical telencephalon into the neocortex. The number of GABA-expressing cells in neocortical slices is reduced by separating the neocortex from the subcortical telencephalon. Finally, mice lacking the homeodomain proteins DLX-1 and DLX-2 show no detectable cell migration from the subcortical telencephalon to the neocortex and also have few GABA-expressing cells in the neocortex.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,CTR NEUROBIOL & PSYCHIAT,NINA IRELAND LAB DEV NEUROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Eisenstat, David/AAA-4653-2020		NIMH NIH HHS [K02 MH01046, R01 MH51561] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051561, K02MH001046] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANDERSON S, UNPUB; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bhide PG, 1996, J COMP NEUROL, V374, P506; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; BUIFONE A, 1993, J NEUROSCI, V13, P3155; DEACON TW, 1994, BRAIN RES, V668, P211, DOI 10.1016/0006-8993(94)90526-6; DeCarlos JA, 1996, J NEUROSCI, V16, P6146; DEDIEGO I, 1994, EUR J NEUROSCI, V6, P983, DOI 10.1111/j.1460-9568.1994.tb00593.x; DEFELIPE J, 1993, CEREB CORTEX, V3, P273, DOI 10.1093/cercor/3.4.273; DELRIO JA, 1995, CEREB CORTEX, V5, P13, DOI 10.1093/cercor/5.1.13; DELRIO JA, 1992, J COMP NEUROL, V326, P501, DOI 10.1002/cne.903260403; Fishell G, 1997, CURR OPIN NEUROBIOL, V7, P62, DOI 10.1016/S0959-4388(97)80121-3; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; FISHELL G, 1995, DEVELOPMENT, V121, P803; Gotz M, 1996, NEURON, V16, P551, DOI 10.1016/S0896-6273(00)80074-4; LIU FC, 1992, J COMP NEUROL, V320, P304, DOI 10.1002/cne.903200304; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Metin C, 1996, J NEUROSCI, V16, P3219; Mione MC, 1997, J NEUROSCI, V17, P2018; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; PORTEUS MH, 1994, J NEUROSCI, V14, P6370; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; TAMAMAKI N, 1996, IN PRESS J NEUROSCI, V16; VANEDEN CG, 1989, J COMP NEUROL, V289, P213, DOI 10.1002/cne.902890204; WALSH C, 1993, NATURE, V362, P632, DOI 10.1038/362632a0	27	1147	1162	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					474	476		10.1126/science.278.5337.474	http://dx.doi.org/10.1126/science.278.5337.474			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334308				2022-12-28	WOS:A1997YB35500048
J	Roingeard, P; Machet, L				Roingeard, P; Machet, L			Orf skin ulcer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Roingeard, P (corresponding author), CHU TOURS,F-37044 TOURS,FRANCE.		Machet, Laurent/A-2976-2010	Machet, Laurent/0000-0001-5985-878X					0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1131	1131		10.1056/NEJM199710163371605	http://dx.doi.org/10.1056/NEJM199710163371605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329934				2022-12-28	WOS:A1997YA91200005
J	Brown, ME; Bouchez, AH				Brown, ME; Bouchez, AH			The response of Jupiter's magnetosphere to an outburst on Io	SCIENCE			English	Article							PLASMA TORUS; JOVIAN MAGNETOSPHERE; STABILITY; VARIABILITY; MODEL	A 6-month-long monitoring campaign of the lo plasma torus and neutral cloud was conducted to determine the characteristics of their interaction. During the observations, a large outburst of material from lo-inferred to be caused by the eruption of a volcanic plume on lo-caused a transient increase in the neutral cloud and plasma torus masses. The response of the plasma torus to this outburst shows that the interaction between to and Jupiter's magnetosphere is stabilized by a feedback mechanism in which increases in the plasma torus mass cause a nonlinear increase in loss from the plasma torus, limiting plasma buildup.			Brown, ME (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.			Brown, Michael E./0000-0002-8255-0545				BAGENAL F, 1994, J GEOPHYS RES-SPACE, V99, P11043, DOI 10.1029/93JA02908; BARBOSA DD, 1983, GEOPHYS RES LETT, V10, P210, DOI 10.1029/GL010i003p00210; BERGSTRALH JT, 1977, ASTROPHYS J, V211, pL51, DOI 10.1086/182340; BROWN ME, 1995, J GEOPHYS RES-SPACE, V100, P21683, DOI 10.1029/95JA01988; Brown R.A., 1976, JUPITER, P1102; CHENG AF, 1988, J GEOPHYS RES, V93, P12751, DOI 10.1029/JA093iA11p12751; DESSLER AJ, 1992, GEOPHYS RES LETT, V19, P2099, DOI 10.1029/92GL02380; HILL TW, 1979, J GEOPHYS RES-SPACE, V84, P6554, DOI 10.1029/JA084iA11p06554; HUANG TS, 1986, J GEOPHYS RES, V91, P163, DOI 10.1029/JA091iA09p10163; JOHNSON RE, 1993, GEOPHYS RES LETT, V20, P1735, DOI 10.1029/93GL00838; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; MOOS HW, 1985, ASTROPHYS J, V294, P369, DOI 10.1086/163304; NASH DB, 1986, SATELLITES, P629; PILCHER CB, 1980, SCIENCE, V207, P181, DOI 10.1126/science.207.4427.181; PONTIUS DH, 1990, GEOPHYS RES LETT, V17, P49, DOI 10.1029/GL017i001p00049; SANDEL BR, 1988, J GEOPHYS RES, V93, P5487, DOI 10.1029/JA093iA06p05487; SCHNEIDER NM, 1995, ASTROPHYS J, V450, P450, DOI 10.1086/176155; SCHNEIDER NM, 1989, NASA SP494, P75; SISCOE GL, 1981, J GEOPHYS RES-SPACE, V86, P8471, DOI 10.1029/JA086iA10p08471; SMYTH WH, 1988, ASTROPHYS J, V328, P888, DOI 10.1086/166346; Spencer JR, 1996, ANNU REV EARTH PL SC, V24, P125, DOI 10.1146/annurev.earth.24.1.125; STROBEL DF, 1989, NASA SP494, P183; Strom R. G., 1982, SATELLITES JUPITER, P598; THOMAS N, 1993, J GEOPHYS RES-PLANET, V98, P18737, DOI 10.1029/93JE01461; VEEDER GJ, 1994, J GEOPHYS RES-PLANET, V99, P17095, DOI 10.1029/94JE00637; WILSON JK, IN PRESS J GEOPHYS R; YANG YS, 1994, J GEOPHYS RES-SPACE, V99, P8755, DOI 10.1029/94JA00142	27	44	44	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					268	271		10.1126/science.278.5336.268	http://dx.doi.org/10.1126/science.278.5336.268			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323202				2022-12-28	WOS:A1997YA56400039
J	Mantyh, PW; Rogers, SD; Honore, P; Allen, BJ; Ghilardi, JR; Li, J; Daughters, RS; Lappi, DA; Wiley, RG; Simone, DA				Mantyh, PW; Rogers, SD; Honore, P; Allen, BJ; Ghilardi, JR; Li, J; Daughters, RS; Lappi, DA; Wiley, RG; Simone, DA			Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor	SCIENCE			English	Article							SPINOTHALAMIC TRACT NEURONS; EXCITATORY AMINO-ACIDS; GENE-RELATED PEPTIDE; DORSAL HORN NEURONS; MEDIATED INTERNALIZATION; NEUROKININ-1 RECEPTORS; TRIGEMINAL NUCLEUS; AXONAL-TRANSPORT; SENSORY NEURONS; DOWN-REGULATION	Substance P is released in the spinal cord in response to painful stimuli, but its role in nociceptive signaling remains unclear, When a conjugate of substance P and the ribosome-inactivating protein saporin was infused into the spinal cord, it was internalized and cytotoxic to lamina I spinal cord neurons that express the substance P receptor. This treatment left responses to mild noxious stimuli unchanged, but markedly attenuated responses to highly noxious stimuli and mechanical and thermal hyperalgesia. Thus, lamina I spinal cord neurons that express the substance P receptor play a pivotal role in the transmission of highly noxious stimuli and the maintenance of hyperalgesia.	UNIV MINNESOTA, SCH DENT, DEPT PREVENT SCI, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; ADV TARGETING SYST, CARLSBAD, CA 92008 USA; VET ADM MED CTR, NEUROL SERV 147, NASHVILLE, TN 37212 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mantyh, PW (corresponding author), VET ADM MED CTR, MOL NEUROBIOL LAB 151, MINNEAPOLIS, MN 55417 USA.			Lappi, Douglas/0000-0003-4239-7387	NIMH NIH HHS [MH56368] Funding Source: Medline; NINDS NIH HHS [NS23970, NS31223] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R43MH056368, R44MH056368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023970, R29NS031223, R37NS023970] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbadie C, 1996, NEUROSCIENCE, V70, P201, DOI 10.1016/0306-4522(95)00343-H; BENYA RV, 1994, J BIOL CHEM, V269, P11721; BOEHMER CG, 1989, PEPTIDES, V10, P1179, DOI 10.1016/0196-9781(89)90011-9; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BRIMIJOIN S, 1980, BRAIN RES, V191, P443, DOI 10.1016/0006-8993(80)91293-7; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; COX BM, 1993, HDB EXPT PHARM OPIOI, V1, P145; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; DELFIACCO M, 1994, NEUROREPORT, V5, P2349, DOI 10.1097/00001756-199411000-00035; DICKENSON AH, 1995, BRIT J ANAESTH, V75, P193, DOI 10.1093/bja/75.2.193; DING YQ, 1995, BRAIN RES, V674, P336, DOI 10.1016/0006-8993(95)00022-I; DOUGHERTY PM, 1995, PAIN, V61, P411, DOI 10.1016/0304-3959(94)00222-Z; DOUGHERTY PM, 1993, BRAIN RES REV, V18, P227, DOI 10.1016/0165-0173(93)90003-I; DOUGHERTY PM, 1994, J NEUROPHYSIOL, V72, P1464, DOI 10.1152/jn.1994.72.4.1464; DOUGHERTY PM, 1991, PAIN, V47, P85, DOI 10.1016/0304-3959(91)90015-P; DUGGAN AW, 1991, NEUROSCI LETT, V122, P191, DOI 10.1016/0304-3940(91)90855-N; FERGUSON IA, 1990, J NEUROSCI, V10, P2176; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; Iversen LL, 1996, NATURE, V383, P759, DOI 10.1038/383759a0; IWASHITA T, 1992, BRAIN RES, V581, P59, DOI 10.1016/0006-8993(92)90344-9; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; KAR S, 1994, EUR J NEUROSCI, V6, P345, DOI 10.1111/j.1460-9568.1994.tb00277.x; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAPPI DA, 1985, BIOCHEM BIOPH RES CO, V129, P934, DOI 10.1016/0006-291X(85)91981-3; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; LITTLEWOOD NK, 1995, NEUROSCIENCE, V66, P597, DOI 10.1016/0306-4522(95)00039-L; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Marshall GE, 1996, NEUROSCIENCE, V72, P255, DOI 10.1016/0306-4522(95)00558-7; MUNGLANI R, 1995, BRIT J ANAESTH, V75, P186, DOI 10.1093/bja/75.2.186; MUNRO FE, 1993, NEUROPEPTIDES, V25, P299, DOI 10.1016/0143-4179(93)90047-E; NAGY I, 1994, NEUROREPORT, V5, P2105, DOI 10.1097/00001756-199410270-00029; NAGY I, 1993, NEUROSCIENCE, V52, P1029, DOI 10.1016/0306-4522(93)90549-U; NICOL GD, 1992, J NEUROSCI, V12, P1917; QUARTU M, 1992, J CHEM NEUROANAT, V5, P143, DOI 10.1016/0891-0618(92)90040-W; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SALTER MW, 1991, NEUROSCIENCE, V43, P601, DOI 10.1016/0306-4522(91)90319-J; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; Simone D A, 1992, Curr Opin Neurobiol, V2, P479, DOI 10.1016/0959-4388(92)90183-L; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; Traub RJ, 1996, PAIN, V67, P151, DOI 10.1016/0304-3959(96)03076-X; URBAN L, 1994, TRENDS NEUROSCI, V17, P432, DOI 10.1016/0166-2236(94)90018-3; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WUWONG JR, 1995, J PHARMACOL EXP THER, V274, P499; Yaksh TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/j.1399-6576.1997.tb04623.x; YAMAMOTO T, 1993, ANESTHESIOLOGY, V79, P1042, DOI 10.1097/00000542-199311000-00023	52	498	512	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					275	279		10.1126/science.278.5336.275	http://dx.doi.org/10.1126/science.278.5336.275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323204				2022-12-28	WOS:A1997YA56400041
J	Ingram, D; Sanders, K; Kolybaba, M; Lopez, D				Ingram, D; Sanders, K; Kolybaba, M; Lopez, D			Case-control study of phyto-oestrogens and breast cancer	LANCET			English	Article							NUTRITION EXAMINATION SURVEY; ISOFLAVONOID PHYTOESTROGENS; ALCOHOL-CONSUMPTION; NATIONAL-HEALTH; POSSIBLE ROLES; DIETARY-FAT; LIGNANS; WOMEN; EXCRETION; RISK	Background Phyto-oestrogens are a group of naturally occurring chemicals derived from plants; they have a structure similar to oestrogen, and form part of our diet. They also have potentially anticarcinogenic biological activity. We did a case-control study to assess the association between phyto-oestrogen intake (as measured by urinary excretion) and the risk of breast cancer. Methods Women with newly diagnosed early breast cancer were interviewed by means of questionnaires, and a 72 h urine collection and blood sample were taken before any treatment started. Controls were randomly selected from the electoral roll after matching for age and area of residence. 144 pairs were included for analysis. The urine samples were assayed for the isoflavonic phyto-oestrogens daidzein, genistein, and equol, and the lignans enterodiol, enterolactone, and matairesinol. Findings After adjustment for age at menarche, parity, alcohol intake, and total fat intake, high excretion of both equol and enterolactone was associated with a substantial reduction in breast-cancer risk, with significant trends through the quartiles: equol odds ratios were 1.00, 0.45 (95% CI 0.20, 1.02), 0.52 (0.23, 1.17), and 0.27 (0.10, 0.69)-trend p=0.009-and enterolactone odds ratios were 1.00, 0.91 (0.41, 1.98), 0.65 (0.29, 1.44), 0.36 (0.15, 0.86)-trend p=0.013 For most other phytoestrogens there was a reduction in risk, but it did nat reach significance. Difficulties with the genistein assay precluded analysis of that substance. Interpretation There is a substantial reduction in breast-cancer risk among women with a high intake (as measured by excretion) of phyto-oestrogens-particularly the isoflavonic phyto-oestrogen equol and the lignan enterolactone. These findings could be important in the prevention of breast cancer.	QUEEN ELIZABETH II MED CTR,UNIV DEPT SURG,PERTH,WA,AUSTRALIA	University of Western Australia			Lopez, Derrick/AAH-5046-2021	Lopez, Derrick/0000-0003-0677-0420				Adlercreutz H., 1991, Nutrition, toxicity, and cancer., P137; ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ADLERCREUTZ H, 1986, J STEROID BIOCHEM, V25, P791, DOI 10.1016/0022-4731(86)90310-9; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; ADLERCREUTZ H, 1982, LANCET, V2, P1295; ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; ADLERCREUTZ H, 1993, SCAND J CLIN LAB INV, V53, P5, DOI 10.3109/00365519309090693; ADLERCREUTZ H, 1991, CLIN CHIM ACTA, V199, P263, DOI 10.1016/0009-8981(91)90120-2; ADLERCREUTZ H, 1986, ADV MASS SPECTROM, V85, P1293; ADLERERCUTZ CHT, 1995, J NUTR, V125, pS575; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AXELSON M, 1984, J ENDOCRINOL, V102, P49, DOI 10.1677/joe.0.1020049; AXELSON M, 1982, NATURE, V298, P659, DOI 10.1038/298659a0; BURGE JC, 1992, JPEN, V17, P529; DWYER JT, 1994, J AM DIET ASSOC, V94, P739, DOI 10.1016/0002-8223(94)91939-9; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; HUSE DM, 1974, AM J CLIN NUTR, V27, P771, DOI 10.1093/ajcn/27.8.771; HUTCHINS AM, 1995, J AM DIET ASSOC, V95, P545, DOI 10.1016/S0002-8223(95)00149-2; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KELLY GE, 1995, P SOC EXP BIOL MED, V208, P40, DOI 10.3181/00379727-208-43829; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; LAMPE JW, 1994, AM J CLIN NUTR, V60, P122, DOI 10.1093/ajcn/60.1.122; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SETCHELL KDR, 1984, AM J CLIN NUTR, V40, P569, DOI 10.1093/ajcn/40.3.569; SETCHELL KDR, 1981, LANCET, V2, P4; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; THOMPSON LU, 1991, NUTR CANCER, V16, P43, DOI 10.1080/01635589109514139; VANTVEER P, 1991, INT J CANCER, V47, P649, DOI 10.1002/ijc.2910470503; VANVEER P, 1989, CANCER RES, V49, P4020; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263	34	579	608	1	54	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					990	994		10.1016/S0140-6736(97)01339-1	http://dx.doi.org/10.1016/S0140-6736(97)01339-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329514				2022-12-28	WOS:A1997XZ71000010
J	Verrees, M				Verrees, M			Secondary survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1047	1047						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315747				2022-12-28	WOS:A1997XX30300002
J	Ahmed, A; Kilby, MD				Ahmed, A; Kilby, MD			Hypoxia or hyperoxia in placental insufficiency?	LANCET			English	Editorial Material							PREGNANCIES; VILLI; FORMS				Ahmed, A (corresponding author), UNIV BIRMINGHAM,DEPT OBSTET & GYNAECOL,REPROD PHYSIOL GRP,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND.		Ahmed, Asif/A-7268-2010; FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Ahmed, Asif/ABE-9544-2020	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Ahmed, Asif/0000-0002-8755-8546; Goswami, Kaushal/0000-0002-7052-4358				Ahmed A, 1997, LAB INVEST, V76, P779; AHMED A, 1997, TROPHOBLAST RES, V10, P215; Burton GJ, 1996, PLACENTA, V17, P49, DOI 10.1016/S0143-4004(05)80643-5; Genbacev O, 1996, J CLIN INVEST, V97, P540, DOI 10.1172/JCI118447; Krebs C, 1996, AM J OBSTET GYNECOL, V175, P1534, DOI 10.1016/S0002-9378(96)70103-5; LYALL F, 1977, PLACENTA, V18, P269; Macara L, 1996, PLACENTA, V17, P37, DOI 10.1016/S0143-4004(05)80642-3; PANIGEL M, 1972, ACTA ANAT, V81, P481; PARDI G, 1992, AM J OBSTET GYNECOL, V166, P699, DOI 10.1016/0002-9378(92)91700-K	9	41	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					826	827		10.1016/S0140-6736(05)62027-2	http://dx.doi.org/10.1016/S0140-6736(05)62027-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310597				2022-12-28	WOS:A1997XX40100005
J	Fischer, U; Liu, Q; Dreyfuss, G				Fischer, U; Liu, Q; Dreyfuss, G			The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; L929 MOUSE FIBROBLASTS; SMALL NUCLEAR-RNA; NUCLEOCYTOPLASMIC TRANSPORT; CAP TRIMETHYLATION; PROTEIN-BINDING; GENE FREQUENCY; M3G CAP; PATHWAY; DOMAIN	Spinal muscular atrophy (SMA) is an often fatal neuromuscular disease that has been directly linked to the protein product of the Survival of Motor Neurons (SMN) gene. The SMN protein is tightly associated with a novel protein, SIP1, and together they form a complex with several spliceosomal snRNP proteins. Here we show that the SMN-SIP1 complex is associated with spliceosomal snRNAs U1 and U5 in the cytoplasm of Xenopus oocytes. Antibodies directed against the SMN-SIP1 complex strongly interfere with the cytoplasmic assembly of the common (Sm) snRNP proteins with spliceosomal snRNAs and with the import of the snRNP complex into the nucleus. Thus, the SMN-SIP1 complex is directly involved in the biogenesis of spliceosomal snRNPs. Defects in spliceosomal snRNP biogenesis may, therefore, be the cause of SMA.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania			Fischer, Utz/A-4090-2016; Dreyfuss, Gideon/D-1218-2013; Fischer, Utz/AAT-8422-2020	Fischer, Utz/0000-0002-1465-6591; Dreyfuss, Gideon/0000-0001-8129-8774; Fischer, Utz/0000-0002-1465-6591				BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; FISHER DE, 1985, CELL, V42, P751, DOI 10.1016/0092-8674(85)90271-5; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Liu Q, 1996, COLD SPRING HARB SYM, V61, P689; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; Moore M., 1993, RNA WORLD, P303; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; SAUTERER RA, 1990, J BIOL CHEM, V265, P1048; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2	39	536	550	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1023	1029		10.1016/S0092-8674(00)80368-2	http://dx.doi.org/10.1016/S0092-8674(00)80368-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323130	hybrid			2022-12-28	WOS:A1997XX76800008
J	Horiuchi, H; Lippe, R; McBride, HM; Rubino, M; Woodman, P; Stenmark, H; Rybin, V; Wilm, M; Ashman, K; Mann, M; Zerial, M				Horiuchi, H; Lippe, R; McBride, HM; Rubino, M; Woodman, P; Stenmark, H; Rybin, V; Wilm, M; Ashman, K; Mann, M; Zerial, M			A novel Rab5 GDP/GTP exchange factor complexed to Rabaptin-5 links nucleotide exchange to effector recruitment and function	CELL			English	Article							GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; ENDOCYTIC MEMBRANE-FUSION; VACUOLAR PROTEINS; BOVINE BRAIN; YEAST; VESICLES; PATHWAY; DOCKING; CELLS	The small GTPase Rab5 plays an essential role in endocytic traffic. Rab GDP dissociation inhibitor delivers Rab5 to the membrane, where a nucleotide exchange activity allows recruitment of an effector protein, Rabaptin-5. Here we uncovered a novel 60 kDa Rab5-binding protein, Rabex-5. Rabex-5 forms a tight physical complex with Rabaptin-5, and this complex is essential for endocytic membrane fusion. Sequencing of mammalian Rabex-5 by nanoelectrospray mass spectrometry and cloning revealed striking homology to Vps9p, a yeast protein implicated in endocytic traffic. Rabex-5 displays GDP/GTP exchange activity on Rab5 upon delivery of the GTPase to the membrane. This demonstrates that a soluble exchange factor coupled to a Rab effector translocates from cytosol to the membrane, where the complex stabilizes the GTPase in the active state.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV MANCHESTER,SCH BIOL SCI,DIV BIOCHEM,MANCHESTER M13 9PT,LANCS,ENGLAND; NORWEGIAN RADIUM HOSP,DEPT BIOCHEM,N-0310 OSLO,NORWAY	European Molecular Biology Laboratory (EMBL); University of Manchester; University of Oslo			McBride, Heidi M./ABD-5774-2021; Ashman, Keith/G-2328-2011; Stenmark, Harald/B-8868-2008; Mann, Matthias/A-3454-2013; McBride, Heidi M/C-1162-2008	McBride, Heidi M./0000-0003-4666-2280; Mann, Matthias/0000-0003-1292-4799; McBride, Heidi M/0000-0003-4666-2280; Wilm, Matthias/0000-0002-5461-6834; Lippe, Roger/0000-0001-5066-3070				Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burd CG, 1996, MOL CELL BIOL, V16, P2369; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; LI GP, 1994, J BIOL CHEM, V269, P14631; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; SHEVCHENKO A, 1996, ANAL CHEM, V68, P820; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1995, METHOD ENZYMOL, V257, P243; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	48	460	479	4	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1149	1159		10.1016/S0092-8674(00)80380-3	http://dx.doi.org/10.1016/S0092-8674(00)80380-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323142	Bronze			2022-12-28	WOS:A1997XX76800020
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Just one word: Plastics	SCIENCE			English	Article																		DORDICK JS, COMMUNICATION; Wang P, 1997, NAT BIOTECHNOL, V15, P789, DOI 10.1038/nbt0897-789; YANG Z, 1995, J AM CHEM SOC, V117, P4843, DOI 10.1021/ja00122a014	3	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1849	1849						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324772				2022-12-28	WOS:A1997XX29800054
J	Tamblyn, R; Berkson, L; Dauphinee, WD; Gayton, D; Grad, R; Huang, A; Isaac, L; McLeod, P; Snell, L				Tamblyn, R; Berkson, L; Dauphinee, WD; Gayton, D; Grad, R; Huang, A; Isaac, L; McLeod, P; Snell, L			Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PEPTIC-ULCER DISEASE; LONGITUDINAL DATA-ANALYSIS; ANTI-INFLAMMATORY DRUGS; GASTROINTESTINAL COMPLICATIONS; STANDARDIZED PATIENTS; COST-EFFECTIVENESS; ELDERLY PERSONS; PHYSICIANS; RISK	Background: Use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk for hospitalization and death from gastrointestinal bleeding and perforation. Objectives: To 1) estimate the extent to which NSAIDs are prescribed unnecessarily and NSAID-related side effects are inaccurately diagnosed and inappropriately managed and 2) identify the physician and visit characteristics associated with suboptimal use of NSAIDs. Design: Prospective cohort study. Setting: Montreal, Canada. Participants: 112 physicians representing academically affiliated general practitioners, community-based general practitioners, and residents in family medicine and internal medicine. Interventions: Blinded, office-based assessment of the management of two clinical cases (chronic hip pain due to early osteoarthritis and NSAID-related gastropathy) using elderly standardized patients. Measurements: Quality of drug management and potential predictors of suboptimal drug management. Results: Unnecessary prescriptions for NSAIDs or other drugs were written during 41.7% of visits. Gastropathy related to NSAID use was correctly diagnosed in 93.4% of visits and was acceptably managed in 77.4% of visits. The risk for an unnecessary NSAID prescription was greater when the contraindications to NSAID therapy were incompletely assessed (odds ratio, 2.3 [95% CI, 1.0 to 5.21) and when the case was managed by residents in internal medicine (odds ratio, 4.1 [CI, 1.2 to 14.7]). The risk for suboptimal management of NSAID-related side effects was increased by incorrect diagnosis (odds ratio, 16.6 [Cl, 3.6 to 76.5]) and shorter visits. Conclusions: Unnecessary NSAID prescribing and suboptimal management of NSAID-related side effects were sufficiently common to raise questions about the appropriateness of NSAID use in the general population. If these results reflect current practice, prescribing patterns may contribute to avoidable gastrointestinal morbidity in elderly persons.	MCGILL UNIV, DEPT FAMILY MED, HERZL FAMILY PRACTICE CTR, MONTREAL, PQ H3T 1E2, CANADA; MED COUNCIL CANADA, OTTAWA, ON K1G 3H7, CANADA; KAISER PERMANENTE, SAN FRANCISCO, CA USA	McGill University; Kaiser Permanente			Tamblyn, Robyn/L-6010-2016					ALFIREVIC Z, 1995, BRIT J OBSTET GYNAEC, V102, P638, DOI 10.1111/j.1471-0528.1995.tb11402.x; BAUMANN AO, 1991, SOC SCI MED, V32, P167, DOI 10.1016/0277-9536(91)90057-J; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; Bloom B S, 1988, Am J Med, V84, P20, DOI 10.1016/0002-9343(88)90250-1; BLOOM BS, 1991, ANN INTERN MED, V114, P558, DOI 10.7326/0003-4819-114-7-558; CAFFERATA GL, 1990, MED CARE, V28, P285; *COMM SAF MED, 1986, BMJ-BRIT MED J, V292, P614; COX J, 1993, BRIT MED J, V306, P1043, DOI 10.1136/bmj.306.6884.1043; DAVIDSON W, 1995, CAN MED ASSOC J, V152, P1227; DAVIDSON W, 1994, CAN MED ASSOC J, V151, P142; DAVIDSON W, 1994, CAN MED ASSOC J, V150, P917; Demlo L K, 1983, Eval Health Prof, V6, P161, DOI 10.1177/016327878300600204; FENNER H, 1992, J RHEUMATOL, V19, P98; FERGUSON JA, 1990, CAN J AGING, V9, P278, DOI 10.1017/S0714980800010710; FERRY ME, 1985, J AM GERIATR SOC, V33, P616, DOI 10.1111/j.1532-5415.1985.tb06318.x; FRIES JF, 1992, SCAND J RHEUMATOL, P21; GABRIEL SE, 1993, ARTHRITIS RHEUM-US, V36, P447, DOI 10.1002/art.1780360404; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GILLEY J, 1994, BRIT MED J, V308, P731, DOI 10.1136/bmj.308.6931.731; GOEREE R, 1995, CAN MED ASSOC J, V152, P1445; Grad R, 1997, MED EDUC, V31, P132, DOI 10.1111/j.1365-2923.1997.tb02472.x; GREENE JM, 1992, ARCH INTERN MED, V152, P1995, DOI 10.1001/archinte.152.10.1995; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GUESS HA, 1988, J CLIN EPIDEMIOL, V41, P35, DOI 10.1016/0895-4356(88)90007-8; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; HARDO PG, 1993, BRIT J CLIN PRACT, V47, P241; HARTZEMA AG, 1983, MED CARE, V21, P990, DOI 10.1097/00005650-198310000-00005; HAWKEY CJ, 1994, SCAND J GASTROENTERO, V29, P42, DOI 10.3109/00365529409105361; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; HENRY DA, 1987, BRIT MED J, V295, P1227, DOI 10.1136/bmj.295.6608.1227; HOCHBERG MC, 1992, J RHEUMATOL, V19, P63; HOGAN DB, 1994, CAN MED ASSOC J, V151, P315; Holt W S Jr, 1992, Fam Med, V24, P524; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KEYS J, 1992, J ROY SOC MED, V85, P442; KOPELOW ML, 1992, ACAD MED, V67, pS19, DOI 10.1097/00001888-199210000-00026; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVINE JS, 1995, ANN INTERN MED, V123, P309, DOI 10.7326/0003-4819-123-4-199508150-00010; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LICHTENSTEIN DR, 1995, ARTHRITIS RHEUM, V38, P5, DOI 10.1002/art.1780380103; MILES DL, 1977, HEALTH SERV RES, V12, P3; Monette J, 1997, EVAL HEALTH PROF, V20, P115, DOI 10.1177/016327879702000201; NUMO R, 1992, SCAND J RHEUMATOL, P25; PEL M, 1995, EUR J OBSTET GYN R B, V61, P129, DOI 10.1016/0301-2115(95)02129-U; PITTS J, 1989, J ROY COLL GEN PRACT, V39, P65; RENAUD M, 1980, AM J PUBLIC HEALTH, V70, P1068, DOI 10.2105/AJPH.70.10.1068; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; RODRIGUEZ LAG, 1992, EPIDEMIOLOGY, V3, P337, DOI 10.1097/00001648-199207000-00008; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; SOUCIE J, 1994, CAN MED ASSOC J, V151, P139; Tamblyn R M, 1997, Clin Perform Qual Health Care, V5, P104; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; Tamblyn RM, 1997, TEACH LEARN MED, V9, P25, DOI 10.1080/10401339709539809; Tannenbaum H, 1996, CAN MED ASSOC J, V155, P77; TUGWELL P, 1979, CLIN INVEST MED, V2, P113; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; VERHULST SJ, 1993, ACAD MED, V68, pS61, DOI 10.1097/00001888-199302000-00033; WALT RP, 1992, NEW ENGL J MED, V327, P1575; WHEELER B, 1994, CAN MED ASSOC J, V151, P139; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	77	121	125	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					429	438		10.7326/0003-4819-127-6-199709150-00003	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9312999				2022-12-28	WOS:A1997XV77900003
J	Li, JM; Chory, J				Li, JM; Chory, J			A putative leucine-rich repeat receptor kinase involved in brassinosteroid signal transduction	CELL			English	Article							ARABIDOPSIS-THALIANA; PROTEIN-KINASE; CELL-SURFACE; HUMAN SPERM; TRANSMEMBRANE PROTEIN; TYROSINE KINASE; BINDING SITES; GENE; PHOSPHATASE; RESISTANCE	Brassinosteroids are a class of growth-promoting regulators that play a key role throughout plant development. Despite their importance, nothing is known of the mechanism of action of these steroid hormones. We describe the identification of 18 Arabidopsis dwarf mutants that are unable to respond to exogenously added brassinosteroid, a phenotype that might be expected for brassinosteroid signaling mutants. All 18 mutations define alleles of a single previously described gene, BRI1. We cloned BRI1 and examined its expression pattern. It encodes a ubiquitously expressed putative receptor kinase. The extracellular domain contains 25 tandem leucine-rich repeats that resemble repeats found in animal hormone receptors, plant disease resistance genes, and genes involved in unknown signaling pathways controlling plant development.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA	Salk Institute			Li, Jianming/O-1772-2014	Li, Jianming/0000-0003-3231-0778				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BarbierBrygoo H, 1997, TRENDS PLANT SCI, V2, P214, DOI 10.1016/S1360-1385(97)89546-5; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Bishop GJ, 1996, PLANT CELL, V8, P959, DOI 10.1105/tpc.8.6.959; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHOI S, 1995, WEEDS WORLD, V2, P17; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1973, DOI 10.1271/bbb.59.1973; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hong SW, 1997, PLANT PHYSIOL, V113, P1203, DOI 10.1104/pp.113.4.1203; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; Kauschmann A, 1996, PLANT J, V9, P701, DOI 10.1046/j.1365-313X.1996.9050701.x; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KWON HB, 1986, DEV BIOL, V117, P354, DOI 10.1016/0012-1606(86)90305-2; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LEWIN DI, 1996, J NIH RES, V8, P29; Li JM, 1997, P NATL ACAD SCI USA, V94, P3554, DOI 10.1073/pnas.94.8.3554; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.arplant.39.1.23; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MENDOZA C, 1995, BIOCHEM BIOPH RES CO, V210, P518, DOI 10.1006/bbrc.1995.1690; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Nakhla AM, 1997, J BIOL CHEM, V272, P6838, DOI 10.1074/jbc.272.11.6838; Nomura T, 1997, PLANT PHYSIOL, V113, P31, DOI 10.1104/pp.113.1.31; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHULZ B, 1995, PLANT MOL BIOL MANUA; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; TAKAHASHI T, 1995, GENE DEV, V9, P97, DOI 10.1101/gad.9.1.97; TESARIK J, 1993, ENDOCRINOLOGY, V133, P328, DOI 10.1210/en.133.1.328; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERKNAAP E, 1996, PLANT PHYSIOL, V112, P1397; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WISTROM CA, 1993, DEV BIOL, V159, P679	61	1172	1267	4	188	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					929	938		10.1016/S0092-8674(00)80357-8	http://dx.doi.org/10.1016/S0092-8674(00)80357-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298904	Bronze			2022-12-28	WOS:A1997XV56300013
J	Mebatsion, T; Finke, S; Weiland, F; Conzelmann, KK				Mebatsion, T; Finke, S; Weiland, F; Conzelmann, KK			A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells	CELL			English	Article							RABIES VIRUS GLYCOPROTEIN; HUMAN CD4; RECEPTOR; FUSION; PARTICLES; COFACTOR; ENTRY; CCR5; RETROVIRUS; CLONING	We show that a cellular virus receptor functions in the envelope of a virus, allowing selective infection of cells displaying the receptor ligand. A G-deficient rabies virus (RV) pseudotyped with CD4- and CXCR4-derived proteins selectively infected cells expressing HIV-1 envelope protein. Envelope protein or CD4 antibodies blocked virus entry. Pseudotype virus formation was most efficient with chimeric receptor proteins possessing the cytoplasmic tail of the RV G spike protein (CXCR4-RV and CD4-RV). While CXCR4-RV was incorporated when expressed alone, CD4-RV incorporation required CXCR4-RV as a carrier protein, indicating a mechanism by which oligomeric surface proteins are sorted into the RV envelope. Viral vectors bearing virus receptors in their envelope may be useful reagents for targeting virus-infected cells in vivo.	FED RES CTR VIRUS DIS ANIM,DEPT CLIN VIROL,D-72076 TUBINGEN,GERMANY				Conzelmann, Karl-Klaus/L-7239-2013	Finke, Stefan/0000-0001-8716-2341; Conzelmann, Karl-Klaus/0000-0002-8614-3656				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Conzelmann KK, 1996, TRENDS MICROBIOL, V4, P386, DOI 10.1016/0966-842X(96)10062-7; CONZELMANN KK, 1994, J VIROL, V68, P713, DOI 10.1128/JVI.68.2.713-719.1994; CONZELMANN KK, 1990, VIROLOGY, V175, P485, DOI 10.1016/0042-6822(90)90433-R; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Franci C, 1996, J IMMUNOL, V157, P5606; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mebatsion T, 1996, P NATL ACAD SCI USA, V93, P7310, DOI 10.1073/pnas.93.14.7310; Mebatsion T, 1996, P NATL ACAD SCI USA, V93, P11366, DOI 10.1073/pnas.93.21.11366; Mebatsion T, 1996, CELL, V84, P941, DOI 10.1016/S0092-8674(00)81072-7; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; SCHUBERT M, 1992, J VIROL, V66, P1579, DOI 10.1128/JVI.66.3.1579-1589.1992; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wagner RR., 1996, FIELDS VIROLOGY, V1, P1121; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WIMMER E, 1994, CELLULAR RECEPTORS A; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YOUNG JAT, 1990, SCIENCE, V250, P1421, DOI 10.1126/science.2175047	39	114	122	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					841	847		10.1016/S0092-8674(00)80349-9	http://dx.doi.org/10.1016/S0092-8674(00)80349-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298896	Bronze			2022-12-28	WOS:A1997XV56300005
J	Elliot, JL; Stansberry, JA; Olkin, CB; Agner, MA; Davies, ME				Elliot, JL; Stansberry, JA; Olkin, CB; Agner, MA; Davies, ME			Triton's distorted atmosphere	SCIENCE			English	Article							STELLAR OCCULTATION; MODEL; VOYAGER-2; DYNAMICS; NEPTUNE; 28-SGR; CYCLE	A stellar-occultation light curve for Triton shows asymmetry that can be understood if Triton's middle atmosphere is distorted from spherical symmetry. Although a globally oblate model can explain the data, the inferred atmospheric flattening is so large that it could be caused only by an unrealistic internal mass distribution or highly supersonic zonal winds, Cyclostrophic winds confined to a jet near Triton's northern or southern limbs (or both) could also be responsible for the details of the light curve, but such winds are required to be slightly supersonic. Hazes and clouds in the atmosphere are unlikely to have caused the asymmetry in the fight curve.	MIT, DEPT PHYS, CAMBRIDGE, MA 02139 USA; LOWELL OBSERV, FLAGSTAFF, AZ 86001 USA; RAND CORP, SANTA MONICA, CA 90407 USA	Massachusetts Institute of Technology (MIT); RAND Corporation	Elliot, JL (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, BLDG 54-422, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.		Olkin, Catherine/AAF-5160-2019	Olkin, Catherine/0000-0002-5846-716X; Stansberry, John/0000-0003-2434-5225				Bevington P. R, 1969, DATA REDUCTION ERROR; BROADFOOT AL, 1989, SCIENCE, V246, P1459, DOI 10.1126/science.246.4936.1459; DAVIES ME, 1991, J GEOPHYS RES, V96, P15; ELLIOT JL, 1977, ASTROPHYS J, V217, P661, DOI 10.1086/155612; ELLIOT JL, 1992, ASTRON J, V103, P991, DOI 10.1086/116121; ELLIOT JL, 1976, SKY TELESCOPE, V52, P23; HANSEN CJ, 1992, ICARUS, V99, P273, DOI 10.1016/0019-1035(92)90146-X; HILLIER J, 1994, ICARUS, V109, P284, DOI 10.1006/icar.1994.1094; Holton J. R., 2013, INT GEOPHYS SERIES, V88; HUBBARD WB, 1988, ASTROPHYS J, V325, P490, DOI 10.1086/166019; HUBBARD WB, 1993, ASTRON ASTROPHYS, V269, P541; INGERSOLL AP, 1990, NATURE, V344, P315, DOI 10.1038/344315a0; IWMSA, COMMUNICATION; KRASNOPOLSKY VA, 1993, J GEOPHYS RES-PLANET, V98, P3065, DOI 10.1029/92JE02680; LELLOUCH E, 1986, NATURE, V324, P227, DOI 10.1038/324227a0; NICHOLSON PD, 1995, ICARUS, V113, P57, DOI 10.1006/icar.1995.1005; OLKIN CB, IN PRESS ICARUS; POLLACK JB, 1990, SCIENCE, V250, P440, DOI 10.1126/science.250.4979.440; SICARDY B, 1990, NATURE, V343, P350, DOI 10.1038/343350a0; SMITH BA, 1989, SCIENCE, V246, P1422, DOI 10.1126/science.246.4936.1422; SODERBLOM LA, 1990, SCIENCE, V250, P410, DOI 10.1126/science.250.4979.410; SPENCER JR, 1992, ICARUS, V99, P261, DOI 10.1016/0019-1035(92)90145-W; STONE EC, 1989, SCIENCE, V246, P1417, DOI 10.1126/science.246.4936.1417; Strobel DF, 1996, ICARUS, V120, P266, DOI 10.1006/icar.1996.0050; Strobel DF, 1995, SPACE SCI S, P1107; YELLE RV, 1991, ICARUS, V89, P347, DOI 10.1016/0019-1035(91)90182-S; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	27	13	13	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					436	439		10.1126/science.278.5337.436	http://dx.doi.org/10.1126/science.278.5337.436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334297				2022-12-28	WOS:A1997YB35500037
J	Murphy, GG; Glanzman, DL				Murphy, GG; Glanzman, DL			Mediation of classical conditioning in Aplysia californica by long-term potentiation of sensorimotor synapses	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; ASPARTATE RECEPTOR ANTAGONIST; SENSORY NEURONS; PRESYNAPTIC FACILITATION; CELLULAR MECHANISM; SYNAPTIC TRANSMISSION; SENSITIZATION; INTERNEURONS; HIPPOCAMPUS; TRANSMITTER	Long-term potentiation (LTP) is considered an important neuronal mechanism of learning and memory. Currently, however, there is no direct experimental link between LTP of an identified synapse and learning. A cellular analog of classical conditioning in Aplysia was used to determine whether this form of invertebrate learning involves N-methyl-D-aspartate (NMDA)-type LTP. The NMDA receptor-antagonist DL-2-amino-5-phosphonovalerate significantly disrupted synaptic enhancement after associative training but did not disrupt synaptic enhancement after nonassociative training. Thus, classical conditioning in Aplysia appears to be mediated, in part, by LTP due to activation of NMDA-related receptors.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INTERDEPT GRAD PROGRAM NEUROSCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS029563, R01NS029563] Funding Source: NIH RePORTER; NIMH NIH HHS [F31-MH11136] Funding Source: Medline; NINDS NIH HHS [NS29563] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMS TW, 1991, J NEUROSCI, V11, P2655; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; BYRNE J, 1974, J NEUROPHYSIOL, V37, P1041, DOI 10.1152/jn.1974.37.5.1041; CAREW TJ, 1984, J NEUROSCI, V4, P1217; CAREW TJ, 1981, J NEUROSCI, V1, P1426; CAREW TJ, 1983, SCIENCE, V219, P397, DOI 10.1126/science.6681571; CASTELLUCCI VF, 1974, P NATL ACAD SCI USA, V71, P5004, DOI 10.1073/pnas.71.12.5004; CLARK GA, 1994, LEARN MEMORY, V1, P243; CLEARY LJ, 1995, LEARN MEMORY, V2, P133, DOI 10.1101/lm.2.3-4.133; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; DAVIS S, 1992, J NEUROSCI, V12, P21; ELIOT LS, 1994, J NEUROSCI, V14, P368; FROST WN, 1988, J NEUROBIOL, V19, P297, DOI 10.1002/neu.480190402; FROST WN, 1995, J NEUROPHYSIOL, V73, P2413, DOI 10.1152/jn.1995.73.6.2413; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1995, TRENDS NEUROSCI, V18, P30, DOI 10.1016/0166-2236(95)93947-V; GLANZMAN DL, 1994, J NEUROBIOL, V25, P666, DOI 10.1002/neu.480250608; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HAWKINS RD, 1989, J NEUROSCI, V9, P4236; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P304, DOI 10.1152/jn.1981.45.2.304; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P315, DOI 10.1152/jn.1981.45.2.315; HEBB DO, 1949, ORG BEHAVIOR; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P113, DOI 10.1098/rspb.1994.0016; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P215, DOI 10.1098/rspb.1994.0031; Lin XY, 1997, J NEUROPHYSIOL, V77, P667, DOI 10.1152/jn.1997.77.2.667; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACKEY SL, 1989, J NEUROSCI, V9, P4227; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Murphy G.P., UNPUB; Murphy GG, 1996, P NATL ACAD SCI USA, V93, P9931, DOI 10.1073/pnas.93.18.9931; OCORR KA, 1985, P NATL ACAD SCI USA, V82, P2548, DOI 10.1073/pnas.82.8.2548; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; TRUDEAU LE, 1993, J NEUROPHYSIOL, V70, P1221, DOI 10.1152/jn.1993.70.3.1221; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; WALTERS ET, 1983, BRAIN RES, V280, P165, DOI 10.1016/0006-8993(83)91186-1; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	49	109	113	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					467	471		10.1126/science.278.5337.467	http://dx.doi.org/10.1126/science.278.5337.467			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334306				2022-12-28	WOS:A1997YB35500046
J	Fleming, DT; McQuillan, GM; Johnson, RE; Nahmias, AJ; Aral, SO; Lee, FK; StLouis, ME				Fleming, DT; McQuillan, GM; Johnson, RE; Nahmias, AJ; Aral, SO; Lee, FK; StLouis, ME			Herpes simplex virus type 2 in the United States, 1976 TO 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUALLY-TRANSMITTED DISEASES; GENITAL HERPES; RISK-FACTORS; INFECTION; TRANSMISSION; WOMEN; SEROCONVERSION; ANTIBODIES; REACTIVATION; PREVALENCE	Background Herpes simplex virus type 2 (HSV-2) infection is usually transmitted sexually and can cause recurrent, painful genital ulcers. In neonates the infection is potentially lethal. We investigated the seroprevalence and correlates of HSV-2 infection in the United States and identified changes in HSV-2 seroprevalence since the late 1970s. Methods Serum samples and questionnaire data were collected during the National Health and Nutrition Examination Surveys (NHANES) II (1976 to 1980) and III (1988 to 1994). HSV-2 antibody was assessed with an immunodot assay specific for glycoprotein gG-2 of HSV-2. Results From 1988 to 1994, the seroprevalence of HSV-2 in persons 12 years of age or older in the United States was 21.9 percent (95 percent confidence interval, 20.2 to 23.6 percent), corresponding to 45 million infected people in the noninstitutionalized civilian population. The seroprevalence was higher among women (25.6 percent) than men (17.8 percent) and higher among blacks (45.9 percent) than whites (17.6 percent). Less than 10 percent of all those who were seropositive reported a history of genital herpes infection. In a multivariate model, the independent predictors of HSV-2 seropositivity were female sex, black race or Mexican-American ethnic background, older age, less education, poverty, cocaine use, and a greater lifetime number of sexual partners. As compared with the period from 1976 to 1980, the age-adjusted seroprevalence of HSV-2 rose 30 percent (95 percent confidence interval, 15.8 to 45.8 percent). The seroprevalence quintupled among white teenagers and doubled among whites in their twenties. Among blacks and older whites, the increases were smaller. Conclusions Since the late 1970s, the prevalence of HSV-2 infection has increased by 30 percent, and HSV-2 is now detectable in roughly one of five persons 12 years of age or older nationwide. Improvements in the prevention of HSV-2 infection are needed, particularly since genital ulcers may facilitate the transmission of the human immunodeficiency virus. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,NATL CTR HIV STD & TB PREVENT,DIV STD PREVENT,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333; EMORY UNIV,SCH MED,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Emory University								ANDERSON JE, 1992, SEX TRANSM DIS, V19, P320, DOI 10.1097/00007435-199211000-00004; ARAL SO, 1991, JAMA-J AM MED ASSOC, V266, P2570, DOI 10.1001/jama.266.18.2570; ARAL SO, 1994, CHLAMYDIAL INFECT, P17; Becker TM, 1996, SEX TRANSM DIS, V23, P138, DOI 10.1097/00007435-199603000-00009; Bourne N, 1996, J INFECT DIS, V173, P800, DOI 10.1093/infdis/173.4.800; *BUR CENS, 1991, CURR POP REP SER P, V60; CAMERON DW, 1989, LANCET, V2, P403; Carmack MA, 1996, J INFECT DIS, V174, P899, DOI 10.1093/infdis/174.5.899; CATES W, 1992, FAM PLANN PERSPECT, V24, P75, DOI 10.2307/2135469; *CDCP DIV STD PREV, 1996, SEX TRANSM DIS SURV, P30; COLEMAN RM, 1983, J CLIN MICROBIOL, V18, P287, DOI 10.1128/JCM.18.2.287-291.1983; COREY L, 1994, SEX TRANSM DIS, V21, pS38; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; ELANDTJOHNSON RC, 1980, SURVIVAL MODELS DATA, P69; ENG TR, 1997, HIDDEN EPIDEMIC CONF, P1; EZZATI T, 1993, 1992 P SURV RES METH, P339; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; FRENKEL LM, 1993, ANN INTERN MED, V118, P414, DOI 10.7326/0003-4819-118-6-199303150-00003; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; *I MED, 1985, DIS IMP US, V1, P280; *INT WORK GROUP VA, 1996, AIDS, V10; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P87; KASSLER WJ, 1994, AIDS, V8, P351, DOI 10.1097/00002030-199403000-00009; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; KOST K, 1992, FAM PLANN PERSPECT, V24, P244, DOI 10.2307/2135853; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; LAUMANN EO, 1994, SOCIAL ORG SEXUALITY, P172; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; MCDOWELL A, 1981, DHHS PUBLICATION; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MOHADJER L, 1996, NATL HLTH NUTR EXAMI, V3; MORAN JS, 1989, PUBLIC HEALTH REP, V104, P560; MOSHER WD, 1990, FAM PLANN PERSPECT, V22, P198, DOI 10.2307/2135493; MOSHER WD, 1991, FAM PLANN PERSPECT, V23, P107; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P667, DOI 10.1056/NEJM197309272891305; NAHMIAS AJ, 1996, GENITAL NEONATAL HER, P93; *NAT CTR HLTH STAT, 1994, DHHS PUBL; OBERLE MW, 1989, AM J TROP MED HYG, V41, P224, DOI 10.4269/ajtmh.1989.41.224; OLEARY A, 1995, WOMEN RISK ISSUES PR, P13; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; PROBER CG, 1992, CLIN INFECT DIS, V15, P1031, DOI 10.1093/clind/15.6.1031; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SEIDMAN SN, 1992, AM J PUBLIC HEALTH, V82, P1297, DOI 10.2105/AJPH.82.9.1297; Shah BV, 1996, SUDAAN USERS MANUAL; SONENSTEIN FL, 1989, FAM PLANN PERSPECT, V21, P152, DOI 10.2307/2135805; Stanberry L. R., 1996, GENITAL NEONATAL HER, P109; STRAUS SE, 1994, LANCET, V343, P1460, DOI 10.1016/S0140-6736(94)92581-X; STRAUS SE, 1996, 36 INT C ANT AG CHEM, P178; TELZAK EE, 1993, ANN INTERN MED, V119, P1181, DOI 10.7326/0003-4819-119-12-199312150-00005; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; WALD A, 1996, 36 INT C ANT AG CHEM; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1993, MMWR-MORBID MORTAL W, V42, P589; 1991, MMWR-MORBID MORTAL W, V39, P929	58	868	907	0	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1105	1111		10.1056/NEJM199710163371601	http://dx.doi.org/10.1056/NEJM199710163371601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329932	Bronze			2022-12-28	WOS:A1997YA91200001
J	Yan, SD; Fu, J; Soto, C; Chen, X; Zhu, HJ; AlMohanna, F; Collison, K; Zhu, AP; Stern, E; Saido, T; Tohyama, M; Ogawa, S; Roher, A; Stern, D				Yan, SD; Fu, J; Soto, C; Chen, X; Zhu, HJ; AlMohanna, F; Collison, K; Zhu, AP; Stern, E; Saido, T; Tohyama, M; Ogawa, S; Roher, A; Stern, D			An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease	NATURE			English	Article							PRECURSOR PROTEIN; IN-VITRO; PRESENILIN-1; ACCUMULATION; APOPTOSIS; SECRETION; NEURONS; CELLS; GENERATION; EXPRESSION	Amyloid-beta is a neurotoxic peptide which Is implicated In the pathogenesis of Alzheimer's disease. It binds an intracellular polypeptide known as ERAB, thought to be a hydroxysteroid dehydrogenase enzyme, which Is expressed in normal tissues, but is overexpressed In neurons affected In Alzheimer's disease, ERAB immunoprecipitates with amyloid-beta, and when cell cultures are exposed to amyloid-beta, ERAB inside the cell is rapidly redistributed to the plasma membrane, The toxic effect of amyloid-beta on these cells is prevented by blocking ERAB and is enhanced by overexpression of ERAB. By Interacting with intracellular amyloid-beta, ERAB may therefore contribute to the neuronal dysfunction associated with Alzheimer's disease.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG & PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT CELLULAR BIOPHYS,NEW YORK,NY 10032; NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; KING FAISAL SPECIALIST HOSP & RES CTR,RIYADH 11211,SAUDI ARABIA; OSAKA UNIV,SCH MED,DEPT ANAT & NEUROSCI,SUITA,OSAKA 565,JAPAN; SUN HLTH RES INST,HALDEMAN LAB ALZHEIMERS DIS RES,SUN CITY,AZ 85372	Columbia University; Columbia University; New York University; King Faisal Specialist Hospital & Research Center; Osaka University; Banner Research; Banner Health; Banner Sun Health Research Institute	Yan, SD (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Fu, Jin/A-3510-2012	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; 				BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ELKHOURY J, 1996, NATURE, V382, P685; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRACKOWIAK J, 1995, BRAIN RES, V676, P225, DOI 10.1016/0006-8993(94)01465-T; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Roses AD, 1996, NAT MED, V2, P267, DOI 10.1038/nm0396-267; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; SCHEMBRI MA, 1995, J BACTERIOL, V177, P4501, DOI 10.1128/jb.177.15.4501-4507.1995; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TIERNARI P, 1997, P NATL ACAD SCI USA, V94, P4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Urmoneit B, 1997, LAB INVEST, V77, P157; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7784; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	48	319	354	2	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					689	695						7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338779				2022-12-28	WOS:A1997YA95900043
J	ShattuckEidens, D; Oliphant, A; McClure, M; McBride, C; Gupte, J; Rubano, T; Pruss, D; Tavtigian, SV; Teng, DHF; Adey, N; Staebell, M; Gumpper, K; Lundstrom, R; Hulick, M; Kelly, M; Holmen, J; Lingenfelter, B; Manley, S; Fujimura, F; Luce, M; Ward, B; CannonAlbright, L; Steele, L; Offit, K; Gilewski, T; Norton, L; Brown, K; Schulz, C; Hampel, H; Schluger, A; Giulotto, E; Zoli, W; Ravaioli, A; Nevanlinna, H; Pyrhonen, S; Rowley, P; Loader, S; Osborne, MP; Daly, M; Tepler, I; Weinstein, PL; Scalia, JL; Michaelson, R; Scott, RJ; Radice, P; Pierotti, MA; Garber, JE; Isaacs, C; Peshkin, B; Lippman, ME; Dosik, MH; Caligo, MA; Greenstein, RM; Pilarski, R; Weber, B; Burgemeister, R; Frank, TS; Skolnick, MH; Thomas, A				ShattuckEidens, D; Oliphant, A; McClure, M; McBride, C; Gupte, J; Rubano, T; Pruss, D; Tavtigian, SV; Teng, DHF; Adey, N; Staebell, M; Gumpper, K; Lundstrom, R; Hulick, M; Kelly, M; Holmen, J; Lingenfelter, B; Manley, S; Fujimura, F; Luce, M; Ward, B; CannonAlbright, L; Steele, L; Offit, K; Gilewski, T; Norton, L; Brown, K; Schulz, C; Hampel, H; Schluger, A; Giulotto, E; Zoli, W; Ravaioli, A; Nevanlinna, H; Pyrhonen, S; Rowley, P; Loader, S; Osborne, MP; Daly, M; Tepler, I; Weinstein, PL; Scalia, JL; Michaelson, R; Scott, RJ; Radice, P; Pierotti, MA; Garber, JE; Isaacs, C; Peshkin, B; Lippman, ME; Dosik, MH; Caligo, MA; Greenstein, RM; Pilarski, R; Weber, B; Burgemeister, R; Frank, TS; Skolnick, MH; Thomas, A			BRCA 1 sequence analysis in women at high risk for susceptibility mutations - Risk factor analysis and implications for genetic testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER FAMILIES; PROTEIN TRUNCATION TEST; OVARIAN-CANCER; STRONG CANDIDATE; POLYMORPHISMS; FREQUENCY	Context.-A mutation in the BRCA1 gene may confer substantial risk for breast and/or ovarian cancer, However, knowledge regarding all possible mutations and the relationship between risk factors and mutations is incomplete. Objectives.-To identify BRCA1 mutations and to determine factors that best predict presence of a deleterious BRCA1 mutation in patients with breast and/or ovarian cancer. Design.-A complete sequence analysis of the BRCA1 coding sequence and flanking intronic regions was performed in 798 women in a collaborative effort involving institutions from the United States, Italy, Germany, Finland, and Switzerland. Participants.-Institutions selected 798 persons representing families (1 person for each family) thought to be at elevated a priori risk of BRCA1 mutation due to potential risk factors, such as multiple cases of breast cancer, early age of breast cancer diagnosis, and cases of ovarian cancer, No participant was from a family in which genetic markers showed linkage to the BRCA1 locus. Major Outcome Measures.-Sequence variants detected in this sample are presented along with analyses designed to determine predictive characteristics of those testing positive for BRCA1 mutations. Results.-In 102 women (12.8%), clearly deleterious mutations were detected. Fifty new genetic alterations were found including 24 deleterious mutations, 24 variants of unknown significance, and 2 rare polymorphisms. In a subset of 71 Ashkenazi Jewish women, only 2 distinct deleterious mutations were found: 185delAG in 17 cases and 5382insC in 7 cases. A bias in prior reports for mutations in exon 11 was revealed, Characteristics of a patient's specific diagnosis (unilateral or bilateral breast cancer, with or without ovarian cancer), early age at diagnosis, Ashkenazi Jewish ethnicity, and family history of cancer were positively associated with the probability of her carrying a deleterious BRCA1 mutation. Conclusions.-Using logistic regression analysis, we provide a method for evaluating the probability of a woman's carrying a deleterious BRCA1 mutation for a wide range of cases, which can be an important tool for clinicians as they incorporate genetic susceptibility testing into their medical practice.	MYRIAD GENET INC, SALT LAKE CITY, UT 84108 USA; MYRIAD GENET LABS INC, SALT LAKE CITY, UT USA; UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY USA; UNIV PAVIA, DEPT GENET & MICROBIOL, I-27100 PAVIA, ITALY; OSPED GB MORGAGNI L PIERANTONE, DEPT MED ONCOL, FORLI, ITALY; IST ONCOL ROMAGNOLO, FORLI, ITALY; OSPED INFERMI RIMINI, DEPT ONCOL, RIMINI, ITALY; UNIV HELSINKI, CENT HOSP, DEPT OBSTET & GYNECOL, FIN-00290 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, DEPT ONCOL, HELSINKI, FINLAND; UNIV ROCHESTER, ROCHESTER, NY USA; STRANG CANC PREVENT CTR, NEW YORK, NY USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; BENNETT CANC CTR, STAMFORD, CT USA; CANC CTR ST BARNABAS, LIVINGSTON, NJ USA; KANTONSSPITAL, DEPT FORSCH, CH-4031 BASEL, SWITZERLAND; IST NAZL STUDIO & CURA TUMORI, I-20133 MILAN, ITALY; DANA FARBER CANC INST, BOSTON, MA 02115 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; N SHORE HEMATOL ONCOL ASSOCIATES PC, SETAUKET, NY USA; IST ANAT PATOL, PISA, ITALY; UNIV CONNECTICUT, HLTH SCI CTR, DIV HUMAN GENET, FARMINGTON, CT USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA	Myriad Genetics, Inc; Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Memorial Sloan Kettering Cancer Center; University of Pavia; Hospital of Rimini; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Rochester; Fox Chase Cancer Center; Kantonsspital Aarau AG (KSA); University of Basel; Fondazione IRCCS Istituto Nazionale Tumori Milan; Harvard University; Dana-Farber Cancer Institute; Georgetown University; University of Connecticut; University of Pennsylvania			Radice, Paolo/O-3119-2013; Scott, Rodney J/B-2827-2013; Pilarski, Robert/E-3871-2011; Hampel, Heather/AAV-4041-2020; Pilarski, Robert/X-3256-2019; Caligo, Adelaide Maria/K-4289-2018	Radice, Paolo/0000-0001-6298-4111; Scott, Rodney J/0000-0001-7724-3404; Hampel, Heather/0000-0001-7558-9794; Caligo, Adelaide Maria/0000-0003-0589-1829; Pierotti, Marco Alessandro/0000-0002-7431-8332; GIULOTTO, ELENA/0000-0002-4705-2049; albright, lisa/0000-0003-2602-3668; Thomas, Alun/0000-0001-5650-7044	NCI NIH HHS [CA-55914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 1997, CANC FACTS FIG 1997; Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Barker DF, 1996, GENET EPIDEMIOL, V13, P595; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Berman DB, 1996, AM J HUM GENET, V58, P1166; Brown MA, 1996, ONCOGENE, V12, P2507; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; COHEN MM, 1994, AM J HUM GENET, V55, pR1; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; Puget N, 1997, CANCER RES, V57, P828; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Serova O, 1996, AM J HUM GENET, V58, P42; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TAVTIGIAN SV, 1997, GEN MOTORS CANC RES; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	29	312	318	1	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1242	1250		10.1001/jama.278.15.1242	http://dx.doi.org/10.1001/jama.278.15.1242			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333265				2022-12-28	WOS:A1997XZ70900029
J	Malmberg, AB; Chen, C; Tonegawa, S; Basbaum, AI				Malmberg, AB; Chen, C; Tonegawa, S; Basbaum, AI			Preserved acute pain and reduced neuropathic pain in mice lacking PKC gamma	SCIENCE			English	Article							PROTEIN-KINASE-C; RAT SPINAL-CORD; SENSORY NEURONS; DORSAL HORN; MUTANT MICE; NERVE INJURY; SUBSTANTIA GELATINOSA; JOINT INFLAMMATION; PERSISTENT PAIN; INCREASES	In normal animals, peripheral nerve injury produces a persistent, neuropathic pain state in which pain is exaggerated and can be produced by nonpainful stimuli. Here, mice that lack protein kinase C gamma (PKC gamma) displayed normal responses to acute pain stimuli, but they almost completely failed to develop a neuropathic pain syndrome after partial sciatic nerve section, and the neurochemical changes that occurred in the spinal cord after nerve injury were blunted. Also, PKC gamma was shown to be restricted to a small subset of dorsal horn neurons, thus identifying a potential biochemical target for the prevention and therapy of persistent pain.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 92143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 92143 USA; MIT, CTR CANC RES, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Malmberg, AB (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 92143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014627, P50NS021445, P01NS021445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008377] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08377] Funding Source: Medline; NINDS NIH HHS [NS 21445, NS 14627] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbadie C, 1996, NEUROSCIENCE, V70, P201, DOI 10.1016/0306-4522(95)00343-H; ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BENNETT GJ, 1980, J COMP NEUROL, V194, P809, DOI 10.1002/cne.901940407; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CODERRE TJ, 1992, NEUROSCI LETT, V140, P181, DOI 10.1016/0304-3940(92)90097-Q; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; CODERRE TJ, 1989, J NEUROPHYSIOL, V62, P48, DOI 10.1152/jn.1989.62.1.48; Dubner R, 1994, TXB PAIN, P225; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HARGREAVES KM, 1990, AM J PHYSIOL, V258, pE235, DOI 10.1152/ajpendo.1990.258.2.E235; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNT SP, 1992, SENSORY NEURONS DIVE, P60; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; KNYIHARCSILLIK E, 1981, PROG HISTOCHEM CYTOC, V14, P1; LANGFORD LA, 1979, J COMP NEUROL, V184, P193, DOI 10.1002/cne.901840111; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; Lin Q, 1996, J NEUROSCI, V16, P3026; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; Malmberg AB, 1997, J NEUROSCI, V17, P7462; MAO J, 1993, J NEUROPHYSIOL, V70, P470, DOI 10.1152/jn.1993.70.2.470; MAO JR, 1995, NEUROSCI LETT, V198, P75, DOI 10.1016/0304-3940(95)11975-3; MAO JR, 1992, BRAIN RES, V588, P144, DOI 10.1016/0006-8993(92)91354-H; MORI M, 1990, J COMP NEUROL, V299, P167, DOI 10.1002/cne.902990204; NAHIN RL, 1994, PAIN, V58, P95, DOI 10.1016/0304-3959(94)90189-9; PALECEK J, 1994, J NEUROPHYSIOL, V71, P529, DOI 10.1152/jn.1994.71.2.529; REES H, 1995, J PHYSIOL-LONDON, V484, P437, DOI 10.1113/jphysiol.1995.sp020676; Schafer M, 1997, EUR J PHARMACOL, V323, P1, DOI 10.1016/S0014-2999(97)00057-5; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; SLUKA KA, 1993, NEUROREPORT, V5, P109, DOI 10.1097/00001756-199311180-00003; SLUKA KA, 1993, PAIN, V55, P217, DOI 10.1016/0304-3959(93)90150-N; WAKISAKA S, 1991, NEUROSCI LETT, V124, P200, DOI 10.1016/0304-3940(91)90093-9; WOOLF CJ, 1983, J COMP NEUROL, V221, P313, DOI 10.1002/cne.902210307	39	530	565	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					279	283		10.1126/science.278.5336.279	http://dx.doi.org/10.1126/science.278.5336.279			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323205				2022-12-28	WOS:A1997YA56400042
J	Imamura, T; Takase, M; Nishihara, A; Oeda, E; Hanai, J; Kawabata, M; Miyazono, K				Imamura, T; Takase, M; Nishihara, A; Oeda, E; Hanai, J; Kawabata, M; Miyazono, K			Smad6 inhibits signalling by the TGF-beta superfamily	NATURE			English	Article							MAD-RELATED PROTEIN; SIGNALING PATHWAYS; RECEPTORS	SMBD proteins(1) have been identified as signalling mediators of the TGF-beta superfamily, which is involved in a range of biological activities including cell growth, morphogenesis, development and immune responses(2,3). Smad1, Smad2, Smad3 and Smad5 are ligand-specific Smad1 and Smad5 transduce signals from bone morphogenetic proteins(4-7), and Smad2 and Smad3 mediate signalling by TGF-beta and activin(8,9), whereas Smad4 acts as a common signalling component(10). For example, Smad2 is phosphorylated by the TGF-beta type I receptor upon ligand binding, forms a heteromer with Smad4 and then translocates into the nucleus where it activates transcription(10,11). Here we report the isolation of Smad6 in the mouse. Smad6 is quite different in structure from the other SMAD proteins, and forms stable associations with type I receptors. Smad6 interferes with the phosphorylation of Smad2 and the subsequent heteromerization with Smad4, but does not inhibit the activity of Smad3, Smad6 also inhibits the phosphorylation of Smad1 that is induced by the bone morphogenetic protein type IB receptor. These data indicate that signals of the TGF-beta superfamily are regulated both positively and negatively by members of the SMAD family.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; JAPAN SOC PROMOT SCI,RES FUTURE PROGRAM,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science								Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NAKAO A, IN PRESS EMBO J; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	16	840	885	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					622	626		10.1038/39355	http://dx.doi.org/10.1038/39355			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335505				2022-12-28	WOS:A1997YA00800065
J	Kramer, BS; Klausner, RD				Kramer, BS; Klausner, RD			Grappling with cancer - Defeatism versus the reality of progress	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES				Kramer, BS (corresponding author), NCI,BETHESDA,MD 20892, USA.							*AM CANC SOC, 1997, CANC FACTS FIG 1997; Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; Cole P, 1996, CANCER, V78, P2045, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2045::AID-CNCR3>3.0.CO;2-N; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0	5	30	32	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					931	934		10.1056/NEJM199709253371312	http://dx.doi.org/10.1056/NEJM199709253371312			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX302	9302311				2022-12-28	WOS:A1997XX30200012
J	Ruzicka, T; Bieber, T; Schopf, E; Rubins, A; Dobozy, A; Bos, JD; Jablonska, S; Ahmed, I; ThestrupPedersen, K; Daniel, F; Finzi, A; Reitamo, S				Ruzicka, T; Bieber, T; Schopf, E; Rubins, A; Dobozy, A; Bos, JD; Jablonska, S; Ahmed, I; ThestrupPedersen, K; Daniel, F; Finzi, A; Reitamo, S			A short-term trial of tacrolimus ointment for atopic dermatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTACT-DERMATITIS; DOUBLE-BLIND; CYCLOSPORINE; EFFICACY; FK-506; FK506	Background Tracrolimus (FK 506) is an effective immunosuppressant drug for the prevention of rejection after organ transplantation, and preliminary studies suggest that topical application of tacrolimus is effective in the treatment of atopic dermatitis. Methods We conducted a randomized, double-blind, multicenter study that compared 0.03 percent, 0.1 percent, and 0.3 percent tacrolimus ointment with vehicle alone in patients with moderate-to-severe atopic dermatitis. The ointment was applied twice daily to a defined, symptomatic area of 200 to 1000 cm(2) of skin for three weeks, The primary end paint was the change in the summary score for erythema, edema, and pruritus between the first and last days of treatment. Results After three weeks of treatment, the median percentage decrease in the summary scare for dermatitis on the trunk and extremities was 66.7 percent for the 54 patients receiving 0.03 percent tacrolimus, 83.3 percent far the 54 patients receiving 0.1 percent tacrolimus, 75.0 percent for the 51 patients receiving 0.3 percent tacrolimus, and 22.5 percent for the 54 patients receiving vehicle alone (P < 0.001). The results for the face and neck were similar, The differences among the three tacrolimus groups were not statistically significant. A sensation of burning at the site of application was The only adverse event that was significantly more frequent with tacrolimus than with vehicle alone (P < 0.001). Throughout the study, most patients in all three tacrolimus groups had blood concentrations of tacrolimus below 0.25 ng per milliliter. The highest concentration was 4.9 ng per milliliter, which was reported in the group receiving 0.3 percent tacrolimus. Conclusions The short-term application of tacrolimus ointment Is effective in the treatment of atopic dermatitis, with the sensation of burning being the main side effect. (C) 1997, Massachusetts Medical Society.	UNIV MUNICH,DEPT DERMATOL,D-8000 MUNICH,GERMANY; UNIV FREIBURG,DEPT DERMATOL,D-7800 FREIBURG,GERMANY; LATVIAN MED ACAD,DEPT DERMATOL,RIGA,LATVIA; ALBERT SZENT GYORGYI MED UNIV,DEPT DERMATOL,H-6701 SZEGED,HUNGARY; UNIV AMSTERDAM,DEPT DERMATOL,NL-1105 AZ AMSTERDAM,NETHERLANDS; DERMATOL CLIN,WARSAW,POLAND; GEORGE ELLIOT HOSP,NUNEATON,WARWICK,ENGLAND; MARSELISBORG HOSP,AARHUS,DENMARK; ST JOSEPH HOSP,PARIS,FRANCE; UNIV MILAN,MILAN,ITALY; UNIV HELSINKI,CENT HOSP,HELSINKI,FINLAND	University of Munich; University of Freiburg; Riga Stradins University; Szeged University; University of Amsterdam; Aarhus University; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; University of Milan; University of Helsinki; Helsinki University Central Hospital	Ruzicka, T (corresponding author), UNIV DUSSELDORF,DEPT DERMATOL,MOORENSTR 5,D-40225 DUSSELDORF,GERMANY.			Rubins, Andris/0000-0001-6071-6316				[Anonymous], 1996, Arch Dermatol, V132, P419; BELTRANI VS, 1996, ATOPIC DERMATITIS PA, P1; Boguniewicz M., 1996, ATOPIC DERMATITIS PA, P185; DEPROST Y, 1989, ARCH DERMATOL, V125, P570, DOI 10.1001/archderm.125.4.570; DERIE MA, 1991, ACTA DERM-VENEREOL, V71, P452; Fung John J., 1996, P183; GOTO T, 1991, TRANSPL P, V23, P2713; GRANLUND H, 1995, BRIT J DERMATOL, V132, P106, DOI 10.1111/j.1365-2133.1995.tb08633.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.1093/biomet/41.1-2.133; Kawashima M, 1996, LANCET, V348, P1240, DOI 10.1016/S0140-6736(05)65512-2; Kershner RP, 1996, TRANSPLANTATION, V62, P920, DOI 10.1097/00007890-199610150-00009; LAUERMA AI, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91757-Y; MEINGASSNER JG, 1992, J INVEST DERMATOL, V98, P851, DOI 10.1111/1523-1747.ep12456939; MERK H, 1991, HDB ATOPIC ECZEMA, P27; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; NAKAGAWA H, 1995, ALLERGY, V50, P368; RAJKA G, 1989, ACTA DERM-VENER    S, V144, P13; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; THOMSON AW, 1986, LANCET, V2, P971; VANJOOST T, 1994, BRIT J DERMATOL, V130, P634	21	409	426	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					816	821		10.1056/NEJM199709183371203	http://dx.doi.org/10.1056/NEJM199709183371203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9295241	Green Published			2022-12-28	WOS:A1997XW28300003
J	Gattinoni, L; Tognoni, G; Brazzi, L; Latini, R				Gattinoni, L; Tognoni, G; Brazzi, L; Latini, R			Ventilation in the prone position	LANCET			English	Letter									IRCCS,OSPED MAGGIORE POLICLIN,IST ANESTESIA & RIANIMAZ,I-20122 MILAN,ITALY; IST MARIO NEGRI,DIPARTIMENTO RIC CARDIOVASC,MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Brazzi, Luca/AAS-4978-2020; Latini, Roberto/AAB-1410-2020	Brazzi, Luca/0000-0001-7059-0622; Latini, Roberto/0000-0002-3729-4650; Gattinoni, Luciano/0000-0001-5380-2494				Webster NR, 1997, LANCET, V349, P1638, DOI 10.1016/S0140-6736(05)62630-X	1	14	14	2	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					815	815		10.1016/S0140-6736(05)62612-8	http://dx.doi.org/10.1016/S0140-6736(05)62612-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9298030	Bronze			2022-12-28	WOS:A1997XW28200068
J	Greenhalgh, T				Greenhalgh, T			How to read a paper: Papers that summarise other papers (systematic reviews and meta-analyses)	BRITISH MEDICAL JOURNAL			English	Article							TRIALS; METAANALYSIS; SCIENCE; QUALITY				Greenhalgh, T (corresponding author), UCL, SCH MED, ROYAL FREE HOSP SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Chalmers I, 1995, SYSTEMATIC REV; *COCHR CTR, 1997, COCHR COLL HDB; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; EYSENCK HJ, 1995, SYSTEMATIC REV, P64, DOI DOI 10.1007/S11121-005-553-Y; GARNER P, 1995, COCHRANE COLLABORA 2; Greenhalgh T., 1997, READ PAPER, P13; KNIPSCHILD P, 1993, LANCET, V341, P1135, DOI 10.1016/0140-6736(93)93140-V; KNIPSCHILD P, 1995, SYSTEMATIC REV, P9; KOUDSTAAL PJ, 1995, COCHRANE DATABASE SY; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; Oxman A, 1995, COCHRANE COLLABORATI; OXMAN AD, 1993, ANN NY ACAD SCI, V703, P125, DOI 10.1111/j.1749-6632.1993.tb26342.x; Pauling L., 1986, LIVE LONGER FEEL BET; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; Thompson SG, 1995, SYSTEMATIC REV, P48; 1995, DRUG THER B, V33, P25	21	269	281	2	117	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					672	675		10.1136/bmj.315.7109.672	http://dx.doi.org/10.1136/bmj.315.7109.672			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310574	Green Published			2022-12-28	WOS:A1997XW69400028
J	Weinert, T				Weinert, T			Cell cycle - A DNA damage checkpoint meets the cell cycle engine	SCIENCE			English	Editorial Material							FISSION YEAST; TYROSINE PHOSPHORYLATION; KINASE; ARREST; PATHWAYS; EXTRACTS; CDC2				Weinert, T (corresponding author), UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721, USA.							Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MURRAY A, 1993, CELL CYCLE; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; YE SY, 1996, EMBO J, V15, P3599; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182	26	114	133	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1450	1451		10.1126/science.277.5331.1450	http://dx.doi.org/10.1126/science.277.5331.1450			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9304216				2022-12-28	WOS:A1997XV42900029
J	Topol, E; Califf, R; Ohman, E; Wilcox, R; Grinfeld, L; Aylward, P; Simes, R; Probst, P; vandeWerf, F; Armstrong, P; Heikkila, J; Vahanian, A; Bode, C; Ostor, E; Ardissino, D; Deckers, J; White, H; Sadowski, Z; SeabraGomes, R; Dalby, A; Betriu, A; Emanuelsson, H; Hartford, M; Follath, D; Hampton, J; Bates, E; Gibler, W; Gore, J; Granger, C; Guerci, A; Hochman, J; Holmes, D; Kleiman, N; Moliterno, D; Morris, D; Smalling, R; Weaver, W; Neuhaus, K; Cheitlin, M; deBono, D; Fisher, L; Frye, R; Jensen, G; Alberts, M; Mahaffey, K; Miller, J; Sloan, M				Topol, E; Califf, R; Ohman, E; Wilcox, R; Grinfeld, L; Aylward, P; Simes, R; Probst, P; vandeWerf, F; Armstrong, P; Heikkila, J; Vahanian, A; Bode, C; Ostor, E; Ardissino, D; Deckers, J; White, H; Sadowski, Z; SeabraGomes, R; Dalby, A; Betriu, A; Emanuelsson, H; Hartford, M; Follath, D; Hampton, J; Bates, E; Gibler, W; Gore, J; Granger, C; Guerci, A; Hochman, J; Holmes, D; Kleiman, N; Moliterno, D; Morris, D; Smalling, R; Weaver, W; Neuhaus, K; Cheitlin, M; deBono, D; Fisher, L; Frye, R; Jensen, G; Alberts, M; Mahaffey, K; Miller, J; Sloan, M			A comparison of reteplase with alteplase for acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT PLASMINOGEN-ACTIVATOR; GUSTO-I TRIAL; CORONARY THROMBOLYSIS; MORTALITY; REPERFUSION; OUTCOMES	Background Reteplase (recombinant plasminogen activator), a mutant of alteplase tissue plasminogen activator, has a longer half-life than its parent molecule and produced superior angiographic results in pilot studies of acute myocardial infarction. In this large clinical trial, we compared the efficacy and safety of these two thrombolytic agents. Methods A total of 15,059 patients from 807 hospitals in 20 countries who presented within 6 hours after the onset of symptoms with ST-segment elevation or bundle-branch block were randomly assigned in a 2:1 ratio to receive reteplase, in two bolus doses of 10 MU each given 30 minutes apart, or an accelerated infusion of alteplase, up to 100 mg infused over a period of 90 minutes. The primary hypothesis was that mortality at 30 days would be significantly lower with reteplase. Results The mortality rate at 30 days was 7.47 percent for reteplase and 7.24 percent for alteplase (adjusted P=0.54; odds ratio, 1.03; 95 percent confidence interval, 0.91 to 1.18). The 95 percent confidence interval for the absolute difference in mortality rates was -1.1 to 0.66 percent. Stroke occurred in 1.64 percent of patients treated with reteplase and in 1.79 percent of those treated with alteplase (P=0.50). The respective rates of the combined end point of death or nonfatal, disabling stroke were 7.89 percent and 7.91 percent (P=0.97; odds ratio, 1.0; 95 percent confidence interval, 0.88 to 1.13). Conclusions As compared with an accelerated infusion of alteplase, reteplase, although easier to administer, did not provide any additional survival benefit in the treatment of acute myocardial infarction. Other results, particularly for the combined end point of death or nonfatal, disabling stroke, were remarkably similar for the two plasminogen activators. (C) 1997, Massachusetts Medical Society.	NOTTINGHAM CLIN TRIALS DATA CTR, NOTTINGHAM, ENGLAND		Topol, E (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL, F25, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.		Ardissino, Diego/AAC-4041-2022; Simes, Robert John/P-1497-2014	Topol, Eric/0000-0002-1478-4729; Anderson, R. David/0000-0003-3490-3286				Betriu A, 1997, NEW ENGL J MED, V336, P1621; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Granger CB, 1996, CIRCULATION, V93, P870, DOI 10.1161/01.CIR.93.5.870; *INT JOINT EFF COM, 1995, LANCET, V346, P329; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LINCOFF AM, 1993, CIRCULATION, V88, P1361, DOI 10.1161/01.CIR.88.3.1361; MARTIN U, 1993, CARDIOVASC DRUG REV, V11, P299, DOI 10.1111/j.1527-3466.1993.tb00193.x; METZ BK, 1996, CIRCULATION S1, V94, P430; MOLITERNO DJ, 1996, CIRCULATION S1, V94, P553; Ohman EM, 1997, CIRCULATION, V95, P846; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; SMALLING RW, 1995, CIRCULATION, V91, P2725, DOI 10.1161/01.CIR.91.11.2725; The GUSTO Angiographic Investigators, 1994, NEW ENGL J MED, V330, P516; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WHITE H, IN PRESS CIRCULATION	17	509	522	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1118	1123						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9340503				2022-12-28	WOS:A1997YA91200003
J	Baorto, DM; Gao, ZM; Malaviya, R; Dustin, ML; vanderMerwe, A; Lublin, DM; Abraham, SN				Baorto, DM; Gao, ZM; Malaviya, R; Dustin, ML; vanderMerwe, A; Lublin, DM; Abraham, SN			Survival of FimH-expressing enterobacteria in macrophages relies on glycolipid traffic	NATURE			English	Article							URINARY-TRACT INFECTIONS; ESCHERICHIA-COLI; TYPE-1 FIMBRIAE; ADHESION; PILI; IDENTIFICATION; COLONIZATION; ENDOCYTOSIS; BACTEREMIA; ACTIVATION	Strains of Escherichia coli persist within the human gut as normal commensals, but are frequent pathogens and can cause recurrent infection(1-3). Here we show that, in contrast to E. coli subjected to opsonic interactions stimulated by the host's immune response, E. coli that bind to the macrophage surface exclusively through the bacterial lectin FimH can survive inside the cell following phagocytosis. This viability is largely due to the attenuation of intracellular free-radical release and of phagosome acidification during FimH-mediated internalization, both of which are triggered by antibody-mediated internalization. This different processing of non-opsonized bacteria is supported by morphological evidence of tight-fitting phagosomes compared with looser, antibody-mediated phagosomes. We propose that non-opsonized FimH-expressing E. coli co-opt internalization of lipid-rich microdomains following binding to the FimH receptor, the glycosylphosphatidylinositol-linked protein CD48, because (1) the sterol-binding agents filipin, nystatin and methyl beta-cyclodextrin specifically block FimH-mediated internalization; (2) CD48 and the protein caveolin both accumulate on macrophage membranes surrounding bacteria; and (3) antibodies against CD48 inhibit FimH-mediated internalization. Our findings bring the traditionally extracellular E. coli into the realm of opportunistic intracellular parasitism and suggest how opportunistic infections with FimH-expressing enterobacteria could occur in a setting deprived of opsonizing antibodies.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND	Washington University (WUSTL); Washington University (WUSTL); University of Oxford			Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; BERGER KH, 1994, METHOD CELL BIOL, V45, P247; BLUEB JL, 1995, BIOCHIM BIOPHYS ACTA, V1244, P79; BRAUNER A, 1994, J INFECTION, V28, P49, DOI 10.1016/S0163-4453(94)94130-0; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; GBARAH A, 1993, INFECT IMMUN, V61, P1687, DOI 10.1128/IAI.61.5.1687-1693.1993; GOETZ MB, 1987, J INFECT DIS, V156, P229, DOI 10.1093/infdis/156.1.229; HAGBERG L, 1981, INFECT IMMUN, V31, P564, DOI 10.1128/IAI.31.2.564-570.1981; KEITH BR, 1990, INFECT IMMUN, V58, P3448, DOI 10.1128/IAI.58.10.3448-3454.1990; KEITH BR, 1986, INFECT IMMUN, V53, P693, DOI 10.1128/IAI.53.3.693-696.1986; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KISIELIUS PV, 1989, INFECT IMMUN, V57, P1656, DOI 10.1128/IAI.57.6.1656-1662.1989; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; LOCK R, 1990, INFECT IMMUN, V58, P37, DOI 10.1128/IAI.58.1.37-42.1990; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MAY AK, 1993, INFECT IMMUN, V61, P1667, DOI 10.1128/IAI.61.5.1667-1673.1993; OFEK I, 1995, ANNU REV MICROBIOL, V49, P239, DOI 10.1146/annurev.mi.49.100195.001323; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SAUKKONEN K, 1991, J EXP MED, V173, P1143, DOI 10.1084/jem.173.5.1143; SAUTER SL, 1993, J BIOL CHEM, V268, P15510; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SENECA H, 1981, J AM GERIATR SOC, V29, P359, DOI 10.1111/j.1532-5415.1981.tb01242.x; STURGILLKOSZYCK.S, 1994, SCIENCE, V263, P637; TEWARI R, 1993, J BIOL CHEM, V268, P3009; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	30	233	238	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					636	639		10.1038/39376	http://dx.doi.org/10.1038/39376			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335508				2022-12-28	WOS:A1997YA00800068
J	Horton, R				Horton, R			Prague: The birth of the reader	LANCET			English	Editorial Material																		Horton R, 1997, LANCET, V349, P872, DOI 10.1016/S0140-6736(97)02336-2; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; HORTON R, IN PRESS J CLIN EPID; *INT COMM MED J ED, 1997, ANN INTERN MED, V126, P36; NYLENNA M, 1994, JAMA-J AM MED ASSOC, V272, P149, DOI 10.1001/jama.272.2.149; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; Sauve S, 1995, ANN ROY COLL PHYSIC, V28, P396; Smith R, 1997, BRIT MED J, V315, P696, DOI 10.1136/bmj.315.7110.696; Snow R, 1997, Afr J Reprod Health, V1, P3; Toulmin Stephen, 1958, USES ARGUMENT	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					898	899		10.1016/S0140-6736(97)22039-8	http://dx.doi.org/10.1016/S0140-6736(97)22039-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314862				2022-12-28	WOS:A1997XY67200002
J	Zeidler, M; Stewart, GE; Barraclough, CR; Bateman, DE; Bates, D; Burn, DJ; Colchester, AC; Durward, W; Fletcher, NA; Hawkins, SA; Mackenzie, JM; Will, RG				Zeidler, M; Stewart, GE; Barraclough, CR; Bateman, DE; Bates, D; Burn, DJ; Colchester, AC; Durward, W; Fletcher, NA; Hawkins, SA; Mackenzie, JM; Will, RG			New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests	LANCET			English	Article							SPONGIFORM ENCEPHALOPATHIES; DECADE 1968-1977; STRAIN VARIATION; FRANCE; TRANSMISSION; WOMAN; CJD; BSE	Background In April, 1996, ten cases of Creutzfeldt-Jakob disease (CJD) with an apparently new clinicopathological phenotype were published and it was suggested that these new variant cases (nvCJD) might be causally linked to bovine spongiform encephalopathy (BSE). There have now been 21 cases of nvCJD in the UK and one case in France. We report clinical features and diagnostic test results of the first 14 cases of nvCJD in the UK. Methods Case ascertainment of CJD was mainly by direct referral from neurologists and neuropathologists. Clinical and investigative details were obtained by interview with patients' relatives and by examination of case notes. Ten cases in this report were examined while alive. Prion protein (PrP) gene analysis was carried out with informed consent from the patient or from a relative. The diagnosis of nvCJD was established histologically. Findings Eight cases were women. Mean age at onset of symptoms was 29 (16-48) years and the median duration of illness was 14 (9-35) months. All patients had early psychiatric symptoms, most often depression, and 13 were seen by a psychiatrist early in the clinical course. Eight patients developed early sensory symptoms which were persistent and often painful. Neurological signs, including ataxia and involuntary movements, developed in all cases and towards the end of the illness, most had akinetic mutism. The electroencephalogram was abnormal in most patients but typical periodic complexes of CJD were not seen in any case. Cerebral imaging was usually normal or showed non-specific abnormalities; in two cases magnetic-resonance imaging scans showed high signal in the thalamus. Interpretation Clinical features in these cases are similar and relatively distinct from other forms of CJD, suggesting that this is a new clinical phenotype consistent with a single strain of infectious agent. There is, however, some overlap with atypical cases of sporadic CJD, and the diagnosis of nvCJD remains dependent on neuropathological confirmation.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Burn, David/ABD-6052-2021	Burn, David/0000-0001-7658-1209				ALPERS M, 1987, P451; BERMAN PH, 1988, PEDIATR NEUROSCI, V14, P42, DOI 10.1159/000120361; BROWN P, 1985, European Journal of Epidemiology, V1, P42, DOI 10.1007/BF00162311; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1984, ANN NEUROL, V16, P295, DOI 10.1002/ana.410160305; BROWN P, 1979, ANN NEUROL, V6, P430, DOI 10.1002/ana.410060510; BROWN P, 1979, ANN NEUROL, V6, P438, DOI 10.1002/ana.410060511; BROWN P, 1988, NOVEL INFECTIOUS AGE, P3; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; CARABALLO-H A J, 1991, Arquivos de Neuro-Psiquiatria, V49, P218; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; *DEP HLTH, 1997, CMOS UPDATE, V13, P4; DESILVA RN, IN PRESS BMJ; Deslys JP, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P465; deVillemeur TB, 1996, NEUROLOGY, V47, P690, DOI 10.1212/WNL.47.3.690; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Hornabrook R W, 1975, P N G Med J, V18, P226; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; HUNTER N, 1994, VET REC, V135, P400, DOI 10.1136/vr.135.17.400; KIMBERLIN RH, 1990, CAN J VET RES, V54, P30; KULCZYCKI J, 1991, EUR J EPIDEMIOL, V7, P501, DOI 10.1007/BF00143129; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MONREAL J, 1981, J NEUROL SCI, V52, P341, DOI 10.1016/0022-510X(81)90015-0; PACKER RJ, 1980, NEUROLOGY, V30, P492, DOI 10.1212/WNL.30.5.492; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; RAVERDY P, 1983, REV NEUROL, V139, P381; TRIMBLE ME, 1996, NEUROLOGY CLIN PRACT, V1, P107; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; WILL RG, 1996, PRION DIS, P119; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6; Zeidler M, 1996, BRIT MED J, V312, P844; ZEIDLER M, 1997, J NEUROL NEUROSUR PS, V62, P206	38	212	219	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					903	907		10.1016/S0140-6736(97)07472-2	http://dx.doi.org/10.1016/S0140-6736(97)07472-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314867				2022-12-28	WOS:A1997XY67200007
J	Zeidler, M; Johnstone, EC; Bamber, RWK; Dickens, CM; Fisher, CJ; Francis, AF; Goldbeck, R; Higgo, R; JohnsonSabine, EC; Lodge, GJ; McGarry, P; Mitchell, S; Tarlo, L; Turner, M; Ryley, P; Will, RG				Zeidler, M; Johnstone, EC; Bamber, RWK; Dickens, CM; Fisher, CJ; Francis, AF; Goldbeck, R; Higgo, R; JohnsonSabine, EC; Lodge, GJ; McGarry, P; Mitchell, S; Tarlo, L; Turner, M; Ryley, P; Will, RG			New variant Crutzfeldt-Jakob disease: psychiatric features	LANCET			English	Article							DELUSIONS	Background An apparently new variant of Creutzfeldt-Jakob disease (CJD), new variant CJD [nvCJD), was identified in the UK in 1996. There have now been 21 cases of nvCJD in the UK and one in France, Psychiatric symptoms are prominent in the initial presentation in these cases. Methods Cases of nvCJD are identified mainly by direct referral horn neurologists and neuropathologists. Detailed clinical information was obtained by review of case notes and interviewing patients' relatives. We report the psychiatric features of the first 14 cases on nvCJD in the UK. Psychiatric notes were examined in ail 13 of these cases who were seen by a psychiatrist. Results Eight cases were women. Ali 14 cases had early psychiatric features and in nine, the first symptom was psychiatric. 13 cases were seen by a psychiatrist and the majority were diagnosed as suffering from depression or depression secondary to organic disease. Two cases suffered from first-rank symptoms suggestive of psychotic illness and transient delusions and auditory or visual hallucinations occurred in the majority. Aii cases were referred to a neurologist as the illness evolved and neurological signs developed. Interpretation Psychiatric symptoms are a consistent early clinical feature in nvCJD. Analysis of the psychiatric symptoms does not suggest specific features that readily allow distinction from more common psychiatric disorders, although the occurrence of associated persistent sensory symptoms may raise the possibility of this diagnosis. Neurological signs, including ataxia, involuntary movements and cognitive impairment developed in ail cases and the evolution of increasing neurological deficits is likely to remain critical to the clinical diagnosis of nvCJD.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh				Dickens, Chris/0000-0001-6326-7544				AZORIN JM, 1993, COMPR PSYCHIAT, V34, P42, DOI 10.1016/0010-440X(93)90034-2; BERRIOS GE, 1984, BRIT J PSYCHIAT, V144, P662, DOI 10.1192/bjp.144.6.662; BROWN P, 1979, ANN NEUROL, V6, P430, DOI 10.1002/ana.410060510; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BURNS A, 1990, BRIT J PSYCHIAT, V157, P72, DOI 10.1192/bjp.157.1.72; CHAPMAN J, 1993, J NEUROL NEUROSUR PS, V56, P1109, DOI 10.1136/jnnp.56.10.1109; CUMMINGS JL, 1985, BRIT J PSYCHIAT, V146, P184, DOI 10.1192/bjp.146.2.184; ESMONDE TFG, 1994, THESIS TRINITY COLL; KESHAVAN MS, 1987, BRIT J PSYCHIAT, V151, P260, DOI 10.1192/bjp.151.2.260; MCMILLAN JF, 1984, THESIS EDINBURGH U U; *NAT CJD SURV UN D, 1995, 4 DEP EP POP SCI LON; STEVENS EM, 1979, J CLIN PSYCHIAT, V40, P445; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; WILL RG, 1984, THESIS CAMBRIDGE U U; WILL RG, 1996, PRION DIS, P119; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2	17	128	135	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					908	910		10.1016/S0140-6736(97)03148-6	http://dx.doi.org/10.1016/S0140-6736(97)03148-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY672	9314868				2022-12-28	WOS:A1997XY67200008
J	Greenhalgh, T; Taylor, R				Greenhalgh, T; Taylor, R			How to read a paper - Papers that go beyond numbers (qualitative research)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-PRACTICE GUIDELINES; MEDICAL LITERATURE; USERS GUIDES; HELP ME; DECISION-ANALYSIS; DIAGNOSTIC-TEST; ARTICLE; WILL; RECOMMENDATIONS; PREVENTION		POSTGRAD MED SCH, EXETER & DEVON RES & DEV SUPPORT UNIT, EXETER EX2 5EQ, DEVON, ENGLAND	University of Exeter	Greenhalgh, T (corresponding author), UCL MED SCH, ROYAL FREE HOSP, SCH MED, WHITTINGTON HOSP, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				ABELL P, 1990, WHAT HAS SOCIOLOGY A; BLACK N, 1994, J EPIDEMIOL COMMUN H, V48, P425, DOI 10.1136/jech.48.5.425-a; BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; Denkin N, 1994, HDB QUALITATIVE RES; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P243, DOI 10.1136/bmj.315.7102.243; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KINMONTH AL, 1995, FAM PRACT, V12, P1, DOI 10.1093/fampra/12.1.1; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; Mays N, 1996, QUALITATIVE RES HLTH; OBRIEN BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	21	404	410	1	119	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	1997	315	7110					740	743		10.1136/bmj.315.7110.740	http://dx.doi.org/10.1136/bmj.315.7110.740			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314762	Green Published			2022-12-28	WOS:A1997XX67400029
J	McDonagh, TA; Morrison, CE; Lawrence, A; Ford, I; TunstallPedoe, H; McMurray, JJV; Dargie, HJ				McDonagh, TA; Morrison, CE; Lawrence, A; Ford, I; TunstallPedoe, H; McMurray, JJV; Dargie, HJ			Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; UNITED-STATES; PREVALENCE; HEALTH; ECHOCARDIOGRAPHY; HYPERTENSION; MORBIDITY; MORTALITY	Background In most previous epidemiological studies on the prevalence of chronic heart failure (CHF) the disorder has been defined on clinical criteria. In a cross-sectional survey of 2000 men and women aged 25-74, randomly sampled from one geographical area, we assessed left-ventricular systolic function by echocardiography. Methods 1640 (83%) of those invited took part. They completed a questionnaire on current medication, history, and symptoms of breathlessness. Blood pressure was measured and electrocardiography (ECG) and echocardiography were done. Left-ventricular ejection fraction was measurable in 1467 (89.5%) participants by the biplane Simpson's rate method. Findings The mean left-ventricular ejection fraction was 47.3%. The prevalence of definite left-ventricular systolic dysfunction (defined as a left-ventricular ejection fraction less than or equal to 30%) was 2.9% overall (43 participants); it increased with age and was higher in men than in women (4.0 vs 2.0%). The left-ventricular systolic dysfunction was symptomatic in 1.5% of participants and asymptomatic in 1.4%. 83% of participants with left-ventricular systolic dysfunction had evidence of ischaemic heart disease (IHD) from history or ECG criteria compared with 21% of those without this abnormality (p<0.001). Hypertension was also more common in those with left-ventricular systolic dysfunction (72 vs 38%, p<0.001), but there was no difference between those with and without left-ventricular systolic dysfunction in the rate of hypertension without IHD. Interpretation Left-ventricular systolic dysfunction was at least twice as common as symptomatic heart failure defined by clinical criteria. The main risk factors are IHD and hypertension in the presence of IHD; screening of such high-risk groups for left-ventricular systolic dysfunction should be considered.	UNIV GLASGOW,WESTERN INFIRM,MRC,CLIN RES INITIAT HEART FAILURE,GLASGOW G11 6NT,LANARK,SCOTLAND; GLASGOW ROYAL INFIRM,SCOTTISH MONICA PROJECT,GLASGOW G4 0SF,LANARK,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DUNDEE DD1 9SY,SCOTLAND; UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow; University of Dundee; University of Glasgow	McDonagh, TA (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT CARDIOL,GLASGOW G11 6NT,LANARK,SCOTLAND.		mcmurray, John/B-2467-2013; Ford, Ian/ABE-6145-2020	mcmurray, John/0000-0002-6317-3975; 				BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; Clarke KW, 1995, J PUBLIC HEALTH MED, V17, P459; *CONSENSUS TRIAL S, 1987, NEW ENGL J MED, V316, P1429; COSTANZO MR, 1995, CIRCULATION, V92, P3593, DOI 10.1161/01.CIR.92.12.3593; ERIKSSON H, 1989, EUR HEART J, V10, P647, DOI 10.1093/oxfordjournals.eurheartj.a059542; FLETCHER CM, 1959, BMJ-BRIT MED J, V2, P257, DOI 10.1136/bmj.2.5147.257; GARDIN JM, 1995, CIRCULATION, V91, P1739, DOI 10.1161/01.CIR.91.6.1739; GHJALI JK, 1990, ARCH INTERN MED, V150, P769; GIBSON TC, 1966, J CHRON DIS, V19, P141, DOI 10.1016/0021-9681(66)90045-2; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; KOSTIS JB, 1995, AM J HYPERTENS, V8, P909, DOI 10.1016/0895-7061(95)00156-J; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; MCKEE PA, 1971, NEW ENGL J MED, V285, P781; MCMURRAY J, 1993, EUR HEART J, V14, P1158, DOI 10.1093/eurheartj/14.9.1158; PARAMESHWAR J, 1992, BRIT J GEN PRACT, V42, P287; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROSE GA, WHO MONOGRAPH SERIES, V56; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SMITH WCS, 1990, J CLIN EPIDEMIOL, V43, P637, DOI 10.1016/0895-4356(90)90033-L; *SOLVD INV, 1991, NEW ENGL J MED, V325, P293; *SOLVD INV, 1992, NEW ENGL J MED, V327, P685; *TASK FORC HEART F, 1995, EUR HEART J, V16, P741; TEERLINK JR, 1991, AM HEART J, V121, P1852, DOI 10.1016/0002-8703(91)90072-P; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Vasan RS, 1997, NEW ENGL J MED, V336, P1350, DOI 10.1056/NEJM199705083361903; WHEELDON NM, 1993, Q J MED, V86, P17	30	454	467	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					829	833		10.1016/S0140-6736(97)03033-X	http://dx.doi.org/10.1016/S0140-6736(97)03033-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310600				2022-12-28	WOS:A1997XX40100008
J	Lam, KP; Kuhn, R; Rajewsky, K				Lam, KP; Kuhn, R; Rajewsky, K			In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death	CELL			English	Article							CD4(+) T-CELLS; ANTIGEN RECEPTOR; HEAVY-CHAIN; RAG-1-DEFICIENT MICE; CLONAL SELECTION; IMMUNE-RESPONSE; LYMPHOCYTES-B; NP ANTIBODIES; EXPRESSION; APOPTOSIS	Gene targeting experiments have demonstrated that the expression of immunoglobulin heavy chain in the pre-B cell receptor (pBCR) and of heavy and light chains in the B cell antigen receptor (BCR) marks checkpoints in early B cell development that the cells have to pass to survive. To investigate whether the persistence of mature B cells in the peripheral immune system also depends on BCR expression, we have generated a transgenic mouse in which the BCR can be inducibly ablated through V region gene deletion. Ablation leads to rapid death of mature B lymphocytes, which is preceded by down-regulation of MHC antigens and up-regulation of CD95 (Fas) and can be delayed by constitutive bcl-2 expression.			Lam, KP (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, D-50931 COLOGNE, GERMANY.		Lam, Kong-Peng/G-5374-2012; Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Lam, Kong-Peng/0000-0002-1316-4333; Rajewsky, Klaus/0000-0002-6633-6370				BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dul JL, 1996, J IMMUNOL, V157, P2969; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagresle C, 1996, J EXP MED, V183, P1377, DOI 10.1084/jem.183.4.1377; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MOMBAERTS P, 1991, P NATL ACAD SCI USA, V88, P3084, DOI 10.1073/pnas.88.8.3084; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SCHWARTZ RS, 1994, IMMUNOL TODAY, V15, P27, DOI 10.1016/0167-5699(94)90022-1; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TAKI S, 1993, SCIENCE, V262, P1268, DOI 10.1126/science.8235657; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; Torres RM, 1997, LAB PROTOCOLS CONDIT; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3	53	913	938	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1073	1083		10.1016/S0092-8674(00)80373-6	http://dx.doi.org/10.1016/S0092-8674(00)80373-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323135	Bronze			2022-12-28	WOS:A1997XX76800013
J	Starks, CM; Back, KW; Chappell, J; Noel, JP				Starks, CM; Back, KW; Chappell, J; Noel, JP			Structural basis for cyclic terpene biosynthesis by tobacco 5-epi-aristolochene synthase	SCIENCE			English	Article							SESQUITERPENE CYCLASE; TAXADIENE SYNTHASE; TAXOL BIOSYNTHESIS; DITERPENE CYCLASE; EXPRESSION; CATALYZES; ALGORITHM; BIOLOGY; MODELS; STEP	Terpene cyclases catalyze the synthesis of cyclic terpenes with 10-, 15-, and 20-carbon acyclic isoprenoid diphosphates as substrates. Plants have been a source of these natural products by providing a homologous set of terpene synthases. The crystal structures of 5-epi-aristolochene synthase, a sesquiterpene cyclase from tobacco, alone and complexed separately with two farnesyl diphosphate analogs were analyzed. These structures reveal an unexpected enzymatic mechanism for the synthesis of the bicyclic product, 5-epi-aristolochene, and provide a basis for understanding the stereochemical selectivity displayed by other cyclases in the biosynthesis of pharmacologically important cyclic terpenes. As such, these structures provide templates for the engineering of novel terpene cyclases.	SALK INST BIOL STUDIES,STRUCT BIOL LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV KENTUCKY,BIOCHEM & MOL BIOL PROGRAM,LEXINGTON,KY 40546	Salk Institute; University of California System; University of California San Diego; University of Kentucky			Noel, Joseph P/A-9459-2009		NIGMS NIH HHS [GM54029, GM07240] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054029] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULLAH MI, 1990, HETEROCYCLES, V30, P317; ALESHIN AE, 1994, J MOL BIOL, V238, P575, DOI 10.1006/jmbi.1994.1316; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BACK KC, UNPUB; BACK KW, 1994, ARCH BIOCHEM BIOPHYS, V315, P527, DOI 10.1006/abbi.1994.1533; Back KW, 1996, P NATL ACAD SCI USA, V93, P6841, DOI 10.1073/pnas.93.13.6841; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BISWAS KM, 1989, J CHEM SOC P1, V11, P1981; BORMAN S, 1996, CHEM ENG NEWS   0701, P27; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P187; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; Cane DE, 1996, BIOCHEMISTRY-US, V35, P12369, DOI 10.1021/bi961344y; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1, DOI 10.1145/224057.224059; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GUEDES MEM, 1982, PHYTOCHEMISTRY, V21, P2987, DOI 10.1016/0031-9422(80)85086-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; Morse MA, 1996, CANCER LETT, V104, P211, DOI 10.1016/0304-3835(96)04252-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1991, CCP4 SERC DAR LAB; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201	31	552	597	0	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1815	1820		10.1126/science.277.5333.1815	http://dx.doi.org/10.1126/science.277.5333.1815			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295271				2022-12-28	WOS:A1997XX29800045
J	Wortley, PM; Fleming, PL				Wortley, PM; Fleming, PL			AIDS in women in the United States - Recent trends	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS DRUG-USERS; CRACK COCAINE USE; NEW-YORK-CITY; HIV-INFECTION; RISK-FACTORS; SAN-FRANCISCO; CONDOM USE; EPIDEMIC; BEHAVIOR	Context.-The effect of the acquired immunodeficiency syndrome (AIDS) epidemic Objective.-To describe AIDS incidence trends in women. Design.-We analyzed national surveillance data on women 13 years of age and older with AIDS reported through June 1996. Data were adjusted for reporting delay, unreported risk, and the 1993 change in AIDS surveillance case definition to assess overall trends and examine trends by age group and birth cohort. Setting.-Surveillance conducted by the Centers for Disease Control and Prevention in collaboration with state and local health departments. Results.-In 1995, women accounted for 19% of AIDS cases in adults; AIDS incidence rates per 100 000 women were highest in black women (50.1), women in the Northeast (22.3), heterosexual contacts (5.5), and women living in metropolitan statistical areas with more than 1 million residents (15.9). Greatest increases in rates between 1991 and 1995 by region and mode of transmission were in the South and in heterosexual contacts. Greatest increases in AIDS incidence rates were observed in heterosexually infected women born between 1970 and 1974, ie, women who were 14 to 18 years old in 1988. Conclusions.-These trends predict continued growth of the number of AIDS cases in women, especially in those in the South and those infected heterosexually, and suggest that successive cohorts or young women may be at risk for human immunodeficiency virus infection as they reach adolescence and young adulthood. Prevention programs must reach young women before they initiate sexual activity and drug use.			Wortley, PM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HIV STD & TB PREVENT, DIV HIV AIDS PREVENT, ATLANTA, GA 30333 USA.							*A GUTTM I, 1994, SEX AM TEEN; BACCHETTI P, 1991, BIOMETRICS, V47, P947, DOI 10.2307/2532651; BATTJES RJ, 1994, AIDS, V8, P681, DOI 10.1097/00002030-199405000-00016; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; CDC, 1991, MMWR-MORBID MORTAL W, V40, P314; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P323; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P151; *CDCP, 1996, HIV AIDS SURV REP, P8; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P121; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DIAZ T, 1993, JAMA-J AM MED ASSOC, V269, P2845, DOI 10.1001/jama.1993.03500220031012; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; Guinan M E, 1995, J Am Med Womens Assoc (1972), V50, P74; Gwinn M, 1996, CLIN OBSTET GYNECOL, V39, P292, DOI 10.1097/00003081-199606000-00005; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HEWITT M, 1989, DEFINING RURAL AREAS, P1; HSER YI, 1987, AM J DRUG ALCOHOL AB, V13, P231, DOI 10.3109/00952998709001512; HU DJ, 1994, ARCH INTERN MED, V154, P654, DOI 10.1001/archinte.154.6.654; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KARON JM, 1991, J ACQ IMMUN DEF SYND, V4, P1179; KARON JM, 1993, PROJECTIONS NUMBERS; KARON JM, 1989, MATH STATISTICAL APP, P58; KARON JM, 1993, IN PRESS J ACQUIR IM; KLEVENS RM, 1996, P 11 INT C AIDS JUL; Males M, 1996, AM J PUBLIC HEALTH, V86, P565, DOI 10.2105/AJPH.86.4.565; MICHAEL RT, 1994, SEX AM DEFINITIVE SU, P42; MILLER K, IN PRESS FAM PLANN P; *NAT CTR HLTH STAT, 1994, BIRTHS TEEN MOMS AG; NOVICK DM, 1989, J MED VIROL, V29, P181, DOI 10.1002/jmv.1890290307; NWANYANWU OC, 1993, AM J DRUG ALCOHOL AB, V19, P399, DOI 10.3109/00952999309001630; OTTEN MW, 1994, AIDS, V8, P549, DOI 10.1097/00002030-199404000-00020; Paone D, 1995, J Am Med Womens Assoc (1972), V50, P109; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; SCHMID GP, 1987, JAMA-J AM MED ASSOC, V258, P3265, DOI 10.1001/jama.258.22.3265; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SINGH BK, 1993, INT J ADDICT, V28, P735, DOI 10.3109/10826089309062170; *US BUR CENS, 1990 1994 STAT POP E; *US BUR CENS, APR 1 90 JUL 1 94 CO; VANICHSENI S, 1993, AIDS, V7, P887, DOI 10.1097/00002030-199306000-00020; WATTERS JK, 1994, J ACQ IMMUN DEF SYND, V7, P1276; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P13; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P1	51	135	138	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					911	916		10.1001/jama.278.11.911	http://dx.doi.org/10.1001/jama.278.11.911			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302243				2022-12-28	WOS:A1997XV64000029
J	Huber, AH; Nelson, WJ; Weis, WI				Huber, AH; Nelson, WJ; Weis, WI			Three-dimensional structure of the armadillo repeat region of beta-catenin	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; CELL-ADHESION MOLECULE; E-CADHERIN; XENOPUS EMBRYOS; ALPHA-CATENIN; ANOMALOUS DIFFRACTION; NUCLEAR-LOCALIZATION; CYTOPLASMIC DOMAIN	beta-catenin is essential for cadherin-based cell adhesion and Wnt/Wingless growth factor signaling. In these roles, it binds to cadherins, Tcf-family transcription factors, and the tumor suppressor gene product Adenomatous Polyposis Coli (APC). A core region of beta-catenin, composed of 12 copies of a 42 amino acid sequence motif known as an armadillo repeat, mediates these interactions. The three-dimensional structure of a protease-resistant fragment of beta-catenin containing the armadillo repeat region has been determined. The 12 repeats form a superhelix of helices that features a long, positively charged groove. Although unrelated in sequence, the beta-catenin binding regions of cadherins, Tcfs, and APC are acidic and are proposed to interact with this groove.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hirschl D, 1996, FEBS LETT, V383, P31, DOI 10.1016/0014-5793(96)00215-3; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNIGHT S, 1989, THESIS SWEDISH U AGR; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nicholls A., 1992, GRASP GRAPHICAL REPR; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TUNNISSEN AMW, 1994, NATURE, V467, P750; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	57	554	577	1	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					871	882		10.1016/S0092-8674(00)80352-9	http://dx.doi.org/10.1016/S0092-8674(00)80352-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298899	Bronze			2022-12-28	WOS:A1997XV56300008
J	Loeb, LA				Loeb, LA			Carcinogenesis - Transient expression of a mutator phenotype in cancer cells	SCIENCE			English	Editorial Material							MICROSATELLITE INSTABILITY; DNA-REPLICATION; MUTATIONS; TUMORS				Loeb, LA (corresponding author), UNIV WASHINGTON,DEPT PATHOL,JOSEPH GOTTSTEIN MEM CANC RES LAB,SEATTLE,WA 98195, USA.							BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FOSTER PL, 1992, GENETICS, V131, P783; HALL BG, 1995, P NATL ACAD SCI USA, V92, P5669, DOI 10.1073/pnas.92.12.5669; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1994, CANCER RES, V54, P5059; LOEB LA, 1974, CANCER RES, V34, P2311; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; Perucho M, 1996, BIOL CHEM, V377, P675; Richards B, 1997, SCIENCE, V277, P1523, DOI 10.1126/science.277.5331.1523; STRAUSS BS, 1992, CANCER RES, V52, P249; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122	16	37	38	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1449	1450		10.1126/science.277.5331.1449	http://dx.doi.org/10.1126/science.277.5331.1449			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9304215				2022-12-28	WOS:A1997XV42900028
J	Herbert, J				Herbert, J			Fortnighly review - Stress, the brain, and mental illness	BRITISH MEDICAL JOURNAL			English	Review							MAJOR-DEPRESSION; CUSHINGS-SYNDROME; C-FOS; DEHYDROEPIANDROSTERONE; SEROTONIN; EXPRESSION; CORTISOL; RECEPTOR; CORTICOSTEROIDS; POLYMORPHISM		UNIV CAMBRIDGE,MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE CB2 3DY,ENGLAND	University of Cambridge	Herbert, J (corresponding author), UNIV CAMBRIDGE,DEPT ANAT,DOWNING ST,CAMBRIDGE CB2 3DY,ENGLAND.							APPLEY MH, 1986, DYNAMICS STRESS PHYS; BALDWIN HA, 1990, BEHAVIORAL ASPECTS N, P1; BLAUER KL, 1991, ENDOCRINOLOGY, V129, P3174, DOI 10.1210/endo-129-6-3174; Brown G.W., 1993, STRESS SYNAPSE SYNDR, P23; Brown GW, 1989, LIFE EVENTS ILLNESS; Brown M. R., 1991, STRESS NEUROBIOLOGY; BUSTER JE, 1993, AM J OBSTET GYNECOL, V169, P1536; CHALMERS DT, 1993, J NEUROSCI, V13, P914; CHEN X, 1995, NEUROSCIENCE, V64, P675, DOI 10.1016/0306-4522(94)00532-A; CLARK DA, 1994, AM J PSYCHIAT, V151, P205; Collier DA, 1996, MOL PSYCHIATR, V1, P453; DE GOEIJ DCE, 1991, NEUROENDOCRINOLOGY, V53, P150, DOI 10.1159/000125712; DEAKIN J F W, 1991, Journal of Psychopharmacology, V5, P305, DOI 10.1177/026988119100500414; DEAKIN JFW, 1990, PSYCHOPHARMACOLOGY, V101, P85, DOI 10.1007/BF02253723; Farde L, 1997, NATURE, V385, P590, DOI 10.1038/385590a0; FINLAYJONES R, 1989, LIFE EVENTS ILLNESS; FISHER S, 1988, HDB LIFE STRESS COGN; Friedman MJ, 1995, NEUROBIOLOGICAL CLIN; Goodyer IM, 1996, PSYCHOL MED, V26, P245, DOI 10.1017/S0033291700034644; HERBERT J, 1995, LANCET, V345, P1193, DOI 10.1016/S0140-6736(95)91987-2; HERBERT J, 1993, PROG NEUROBIOL, V41, P723, DOI 10.1016/0301-0082(93)90033-O; HERBERT J, 1996, ANN REV SEX RES, V7, P1; HOLMES MC, 1995, MOL BRAIN RES, V28, P186, DOI 10.1016/0169-328X(94)00207-U; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; KELLY WF, 1983, BRIT J PSYCHIAT, V142, P16, DOI 10.1192/bjp.142.1.16; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; LEWIS DA, 1983, J AFFECT DISORDERS, V5, P319, DOI 10.1016/0165-0327(83)90022-8; LOOSEN PT, 1994, ENDOCRINOLOGIST, V4, P373, DOI 10.1097/00019616-199409000-00008; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MANN JJ, 1995, CLIN NEUROPHARMACOL, V18, pS57; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; NEMEROFF CB, 1984, SCIENCE, V226, P1342, DOI 10.1126/science.6334362; ODWYER AM, 1995, J AFFECT DISORDERS, V33, P123, DOI 10.1016/0165-0327(94)00082-K; Ogilvie AD, 1996, LANCET, V347, P731, DOI 10.1016/S0140-6736(96)90079-3; OKEANE V, 1992, J AFFECT DISORDERS, V26, P143, DOI 10.1016/0165-0327(92)90009-U; ORENTREICH N, 1992, J CLIN ENDOCR METAB, V75, P1002, DOI 10.1210/jc.75.4.1002; Paykel E. S., 1992, HDB AFFECTIVE DISORD, P149; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; Sapolsky RM, 1992, STRESS AGING BRAIN M; Selye H., 1978, STRESS LIFE; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMITH KA, 1997, LANCET, V347, P915; TARBUCK AF, 1995, PSYCHOL MED, V25, P285, DOI 10.1017/S0033291700036187; WOLKOWITZ OM, 1994, PSYCHONEUROENDOCRINO, V19, P233, DOI 10.1016/0306-4530(94)90064-7; YOUNG AH, 1994, BRIT J PSYCHIAT, V165, P271, DOI 10.1192/bjp.165.2.271; YOUNG SN, 1985, PSYCHOPHARMACOLOGY, V87, P173, DOI 10.1007/BF00431803; ZUMOFF B, 1983, J CLIN ENDOCR METAB, V56, P668, DOI 10.1210/jcem-56-4-668	47	83	89	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					530	535		10.1136/bmj.315.7107.530	http://dx.doi.org/10.1136/bmj.315.7107.530			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU506	9329310	Green Published			2022-12-28	WOS:A1997XU50600025
J	Wiklund, RA; Rosenbaum, SH				Wiklund, RA; Rosenbaum, SH			Medical progress - Anesthesiology .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LARYNGEAL MASK AIRWAY; TRANSIENT RADICULAR IRRITATION; SPINAL-ANESTHESIA; PULSE OXIMETRY; GENERAL-ANESTHESIA; RANDOMIZED EVALUATION; REGIONAL ANESTHESIA; ROPIVACAINE; ANALGESIA; BUPIVACAINE				Wiklund, RA (corresponding author), YALE UNIV, SCH MED, DEPT ANESTHESIOL, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.							ABRAM SE, 1993, REGION ANESTH, V18, P66; AHO M, 1992, ANESTH ANALG, V75, P940; *AM SOC AN, 1997, ASA 1997 DIR MEMB; Benumof JL, 1996, ANESTHESIOLOGY, V84, P686, DOI 10.1097/00000542-199603000-00024; BLOOR BC, 1993, ANAESTHETIC PHARM RE, V1, P221; BRAIN AIJ, 1983, BRIT J ANAESTH, V55, P801, DOI 10.1093/bja/55.8.801; COUSINS MJ, 1971, SURG GYNECOL OBSTETR, V133, P59; DAVIS PJ, 1995, ANESTHESIOLOGY, V83, P956, DOI 10.1097/00000542-199511000-00007; DEJONG RH, 1995, REGION ANESTH, V20, P474; DELAUNAY L, 1993, REGION ANESTH, V18, P176; Eddleston JM, 1996, BRIT J ANAESTH, V76, P66, DOI 10.1093/bja/76.1.66; EICHHORN JH, 1993, ANESTHESIOLOGY, V78, P423; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; EMANUELSSON BMK, 1995, ANESTH ANALG, V81, P1163, DOI 10.1097/00000539-199512000-00008; FORREST JB, 1990, ANESTHESIOLOGY, V72, P262, DOI 10.1097/00000542-199002000-00009; GELMAN S, 1987, CAN J PHYSIOL PHARM, V65, P1762, DOI 10.1139/y87-276; HAMPL KF, 1995, ANESTH ANALG, V81, P1148, DOI 10.1097/00000539-199512000-00006; HARRISON DM, 1988, ANESTHESIOLOGY, V68, P454, DOI 10.1097/00000542-198803000-00025; HAYASHI Y, 1993, BRIT J ANAESTH, V71, P108, DOI 10.1093/bja/71.1.108; HUGHES JA, 1992, ANAESTHESIA, V47, P354, DOI 10.1111/j.1365-2044.1992.tb02183.x; JACKSON C, 1993, ANAESTH PHARM REV, V1, P288; KEHLET H, 1993, ANESTH ANALG, V77, P1048; KING AE, 1988, NEUROSCIENCE, V27, P231, DOI 10.1016/0306-4522(88)90233-3; KITAHATA LM, 1974, ANESTHESIOLOGY, V41, P39, DOI 10.1097/00000542-197407000-00008; LEWIS JH, 1983, ANN INTERN MED, V98, P984, DOI 10.7326/0003-4819-98-6-984; MANGANO DT, 1992, ANESTHESIOLOGY, V76, P342, DOI 10.1097/00000542-199203000-00004; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; MODIG J, 1983, ANESTH ANALG, V62, P174; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P445, DOI 10.1097/00000542-199303000-00007; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P436, DOI 10.1097/00000542-199303000-00006; MUJAIS SK, 1986, SEMIN NEPHROL, V6, P251; Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739; ORKIN FK, 1993, ANESTHESIOLOGY, V78, P417; PATEL RI, 1993, ANESTHESIOLOGY, V79, pA22; PENNANT JH, 1993, ANESTHESIOLOGY, V79, P144; PIERCE EC, 1989, JAMA-J AM MED ASSOC, V262, P773, DOI 10.1001/jama.1989.03430060067018; PITKANEN M, 1992, REGION ANESTH, V17, P183; PLUMMER JL, 1992, PAIN, V49, P145, DOI 10.1016/0304-3959(92)90201-L; Pollock JE, 1996, ANESTHESIOLOGY, V84, P1361, DOI 10.1097/00000542-199606000-00012; RIGLER ML, 1991, ANESTH ANALG, V72, P275; SCOTT NB, 1988, BRIT J SURG, V75, P299; SEVERINGHAUS JW, 1992, ANESTHESIOLOGY, V76, P1018; SWEDLOW DB, 1986, SEMIN ANESTH PERIO M, V5, P194; TARKKILA P, 1995, BRIT J ANAESTH, V74, P328, DOI 10.1093/bja/74.3.328; VANKLEEF JW, 1994, ANESTH ANALG, V78, P1125; WARNER MA, 1993, ANESTHESIOLOGY, V78, P56, DOI 10.1097/00000542-199301000-00010; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004; ZIMMERMAN H, 1991, HEPATOLOGY, V13, P1251, DOI 10.1002/hep.1840130634	51	8	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1215	1219		10.1056/NEJM199710233371707	http://dx.doi.org/10.1056/NEJM199710233371707			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337382				2022-12-28	WOS:A1997YB71800007
J	Schiodt, FV; Rochling, FA; Casey, DL; Lee, WM				Schiodt, FV; Rochling, FA; Casey, DL; Lee, WM			Acetaminophen toxicity in an urban county hospital	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC MISADVENTURE; INDUCED HEPATOTOXICITY; MEDICAL PROGRESS; N-ACETYLCYSTEINE; LIVER; ALCOHOL; ETHANOL; FAILURE; ASSOCIATION	Background The prevalence and characteristics of acetaminophen associated liver injury in hospitalized patients are not well defined. Methods We identified patients hospitalized for excessive acetaminophen ingestion at an urban county hospital over a 40-month period (1992 to 1995) and reviewed their medical records to determine the incidence and clinical features of the ingestions and their outcomes. Results Of the 71 patients studied, 50 were classified as having taken acetaminophen during suicide attempts and 21 as having accidentally poisoned themselves while attempting to relieve pain, The suicidal patients had ingested almost twice as much acetaminophen as those in the accidental-overdose group (median, 20 vs. 12 g; P=0.009), Among the patients for whom data were available, 63 percent of those in the accidental-overdose group and 25 percent of those in the suicidal group were chronic alcohol abusers (P=0.009). The patients in the accidental-overdose group more often had severe liver necrosis (aminotransferase levels, >3500 IU per liter; 52 percent vs, 14 percent; P=0.002) and were more likely to have hepatic coma (33 percent vs. 6 percent, P=0.006). There were four deaths (19 percent) in the accidental-overdose group and one (2 percent) in the suicidal group (P=0.04). Five patients - three in the accidental-overdose group and two in the suicidal group - had ingested 4 g of acetaminophen or less. Acetaminophen ingestion accounted for 12 percent of all patients hospitalized with overdoses (71 of 589) and 40 percent of patients with acute liver failure (10 of 25) during the study period. Conclusions In an urban county hospital, patients hospitalized with acetaminophen toxicity related to accidental misuse had higher rates of morbidity and mortality than those who attempted suicide, even though the latter had taken more acetaminophen. A higher frequency of chronic alcohol abuse among the patients with accidental overdoses may be one explanation. (C) 1997, Massachusetts Medical Society.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,LIVER DIV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Altman D.G., 1991, PRACTICAL STAT MED R; BLACK M, 1984, ANNU REV MED, V35, P577, DOI 10.1146/annurev.me.35.020184.003045; BLACK M, 1986, ANN INTERN MED, V104, P427, DOI 10.7326/0003-4819-104-3-427; BROTODIHARDJO AE, 1992, MED J AUSTRALIA, V157, P382, DOI 10.5694/j.1326-5377.1992.tb137246.x; FRENCH SW, 1993, EXP MOL PATHOL, V58, P61, DOI 10.1006/exmp.1993.1006; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HUGHES R D, 1991, Gut, pS86; Johnston SC, 1997, MEDICINE, V76, P185, DOI 10.1097/00005792-199705000-00004; KUMAR S, 1991, ARCH INTERN MED, V151, P1189, DOI 10.1001/archinte.151.6.1189; LEE WM, 1994, NEW ENGL J MED, V330, P584; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; LICHT H, 1980, ANN INTERN MED, V92, P511, DOI 10.7326/0003-4819-92-4-511_1; Litovitz TL, 1996, AM J EMERG MED, V14, P487, DOI 10.1016/S0735-6757(96)90160-6; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; MAKIN AJ, 1997, ACUTE LIVER FAILURE, P32; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MUTIMER DJ, 1994, GUT, V35, P809, DOI 10.1136/gut.35.6.809; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; RAMOND MJ, 1992, NEW ENGL J MED, V326, P507, DOI 10.1056/NEJM199202203260802; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; TAKAHASHI T, 1993, HEPATOLOGY, V17, P236, DOI 10.1016/0270-9139(93)90083-Y; VALE JA, 1995, LANCET, V346, P547, DOI 10.1016/S0140-6736(95)91385-8; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; WOOTTON FT, 1990, SOUTHERN MED J, V83, P1047, DOI 10.1097/00007611-199009000-00017; Zimmerman HJ, 1995, HEPATOLOGY, V22, P1898; ZIMMERMAN HJ, 1995, HEPATOLOGY, V22, P767, DOI 10.1002/hep.1840220312	28	296	301	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1112	1117		10.1056/NEJM199710163371602	http://dx.doi.org/10.1056/NEJM199710163371602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329933				2022-12-28	WOS:A1997YA91200002
J	SoderbergNaucler, C; Fish, KN; Nelson, JA				SoderbergNaucler, C; Fish, KN; Nelson, JA			Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors	CELL			English	Article							VERSUS-HOST DISEASE; GRANULOCYTE-MACROPHAGE PROGENITORS; MARROW TRANSPLANT RECIPIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; BONE-MARROW; MURINE CYTOMEGALOVIRUS; GENE-EXPRESSION; IN-VIVO; INFECTION; LYMPHOCYTES	Reactivation of human cytomegalovirus (HCMV) results in severe disease in AIDS patients and immunocompromised patients receiving blood transfusions or organ or bone marrow grafts. Although the site of HCMV latency is unknown, blood cells have been implicated as a viral reservoir. In this study, we demonstrate HCMV reactivation in vitro from seven consecutive healthy donors through allogeneic stimulation of peripheral blood mononuclear cells (PBMCs). HCMV replication was detected at 17 days poststimulation, and virus was recovered after long-term culture from a macrophage expressing dendritic cell markers. Thus, these observations demonstrate that PBMCs harbor latent HCMV, which reactivates in a myeloid lineage cell upon allogeneic stimulation.	OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL,PORTLAND,OR 97201	Oregon Health & Science University			Fish, Kenneth/AAX-3067-2020	Fish, Kenneth/0000-0003-1774-3815	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21640] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS DO, 1992, MACROPHAGE, P77; BOSTROM L, 1990, BONE MARROW TRANSPL, V5, P321; Britt W. J., 1996, FIELDS VIROLOGY, P2493; BRITT WJ, 1992, J VIROL, V66, P6747, DOI 10.1128/JVI.66.11.6747-6754.1992; BRUNING JH, 1986, TRANSPLANTATION, V41, P695, DOI 10.1097/00007890-198606000-00005; BRYTTING M, 1995, TRANSPLANTATION, V60, P961; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; CHOU SW, 1986, NEW ENGL J MED, V314, P1418, DOI 10.1056/NEJM198605293142205; DOCKE WD, 1994, LANCET, V343, P238; Fish KN, 1996, J VIROL, V70, P1855, DOI 10.1128/JVI.70.3.1855-1862.1996; FISH KN, 1995, J VIROL, V69, P3737, DOI 10.1128/JVI.69.6.3737-3743.1995; FLECKENSTEIN B, 1982, GENE, V18, P39, DOI 10.1016/0378-1119(82)90054-3; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GNANN JW, 1988, AM J PATHOL, V132, P239; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HAMILTON JD, 1995, TRANSPLANTATION, V39, P290; IBANEZ CE, 1991, J VIROL, V65, P6581, DOI 10.1128/JVI.65.12.6581-6588.1991; JORDAN MC, 1982, J CLIN INVEST, V70, P762, DOI 10.1172/JCI110672; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KOFFRON AJ, 1995, SCAND J INF DIS S, V99, P612; Kondo K, 1996, P NATL ACAD SCI USA, V93, P11137, DOI 10.1073/pnas.93.20.11137; KONDO K, 1994, P NATL ACAD SCI USA, V91, P11879, DOI 10.1073/pnas.91.25.11879; LONNQVIST B, 1984, TRANSPLANTATION, V38, P465, DOI 10.1097/00007890-198411000-00004; MACIEJEWSKI JP, 1992, BLOOD, V80, P170; Mandanas RA, 1996, AM J HEMATOL, V51, P104; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; MELNICK JL, 1995, BIOESSAYS, V17, P899, DOI 10.1002/bies.950171012; Mendelson M, 1996, J GEN VIROL, V77, P3099, DOI 10.1099/0022-1317-77-12-3099; MERCER JA, 1988, J VIROL, V62, P987, DOI 10.1128/JVI.62.3.987-997.1988; MEYERS JD, 1986, AM J MED, V81, P27, DOI 10.1016/0002-9343(86)90511-5; MINTON EJ, 1994, J VIROL, V68, P4017, DOI 10.1128/JVI.68.6.4017-4021.1994; MYERSON D, 1984, HUM PATHOL, V15, P430, DOI 10.1016/S0046-8177(84)80076-3; NOVASSAGH M, 1996, BLOOD, V88, P1277; OLDING LB, 1975, J EXP MED, V141, P561, DOI 10.1084/jem.141.3.561; Pollock JL, 1997, VIROLOGY, V227, P168, DOI 10.1006/viro.1996.8303; REDDEHASE MJ, 1994, J EXP MED, V179, P185, DOI 10.1084/jem.179.1.185; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; Roizman B, 1996, FIELDS VIROLOGY, P2231; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHMADER KE, 1992, J INFECT DIS, V166, P1403, DOI 10.1093/infdis/166.6.1403; SCHRIER RD, 1990, J VIROL, V64, P3280, DOI 10.1128/JVI.64.7.3280-3288.1990; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SIMMONS P, 1990, P NATL ACAD SCI USA, V87, P1386, DOI 10.1073/pnas.87.4.1386; Sinzger C, 1996, J INFECT DIS, V173, P240, DOI 10.1093/infdis/173.1.240; SINZGER C, 1993, J INFECT DIS, V167, P1427, DOI 10.1093/infdis/167.6.1427; SODERBERG C, 1993, J VIROL, V67, P3166; Soderberg C, 1996, TRANSPLANTATION, V61, P600; STENBERG RM, 1989, J VIROL, V63, P2699, DOI 10.1128/JVI.63.6.2699-2708.1989; STODDART CA, 1994, J VIROL, V68, P6243, DOI 10.1128/JVI.68.10.6243-6253.1994; TAYLORWIEDEMAN J, 1994, J VIROL, V68, P1597, DOI 10.1128/JVI.68.3.1597-1604.1994; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; TEGTMEIER GE, 1989, ARCH PATHOL LAB MED, V113, P236; TOROKSTORB B, 1992, ANN HEMATOL SA, V64, P128; vandenBerg AP, 1996, CLIN TRANSPLANT, V10, P224; VONLAER D, 1995, BLOOD, V86, P4086, DOI 10.1182/blood.V86.11.4086.bloodjournal86114086; VONLAER D, 1995, J INFECT DIS, V172, P365, DOI 10.1093/infdis/172.2.365; YAGYU K, 1993, TRANSPLANT P, V25, P1152; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	59	531	547	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					119	126		10.1016/S0092-8674(01)80014-3	http://dx.doi.org/10.1016/S0092-8674(01)80014-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335340	Bronze			2022-12-28	WOS:A1997XZ80900014
J	Cassell, EJ				Cassell, EJ			Why should doctors read medical books?	ANNALS OF INTERNAL MEDICINE			English	Article											Cassell, EJ (corresponding author), CORNELL UNIV, COLL MED, 1550 YORK AVE, NEW YORK, NY 10021 USA.							Brody H., 1987, STORIES SICKNESS; Byock I., 1997, DYING WELL; CURSCHMANN H, 1901, TYPHOID FEVER TYPHUS; Hawkins Anne Hunsaker, 1999, RECONSTRUCTING ILLNE; Kleinman A., 1988, ILLNESS NARRATIVES; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Osler W, 1892, PRINCIPLES PRACTICE; PORTENOY R., 1996, PAIN MANAGEMENT THEO; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SHELLEY WB, 1992, ADV DERMATOLOGIC DIA; Smith HW., 1951, KIDNEY STRUCTURE FUN, P552; Toombs S. K., 1992, MEANING ILLNESS PHEN; Waller A, 1996, HDB PALLIATIVE CARE	14	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					576	578		10.7326/0003-4819-127-7-199710010-00024	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00024			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313033				2022-12-28	WOS:A1997XY73300022
J	Nightingale, SL				Nightingale, SL			New guidance for prescription drug TV and radio advertising proposed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-28	WOS:A1997XX30300006
J	Staessen, JA; Byttebier, G; Buntinx, F; Celis, H; OBrien, ET; Fagard, R				Staessen, JA; Byttebier, G; Buntinx, F; Celis, H; OBrien, ET; Fagard, R			Antihypertensive treatment based on conventional or ambulatory blood pressure measurement - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR STRUCTURE; WHITE COAT HYPERTENSION; PROGNOSTIC VALUE; HEART; ECHOCARDIOGRAPHY; ACCURACY; PROTOCOL	Context.-Ambulatory blood pressure (ABP) monitoring is used increasingly in clinical practice, but how it affects treatment of blood pressure has not been determined. Objective.-To compare conventional blood pressure (CBP) measurement and ABP measurement in the management of hypertensive patients. Design.-Multicenter, randomized, parallel-group trial. Setting.-Family practices and outpatient clinics at regional and university hospitals. Participants.-A total of 419 patients (greater than or equal to 18 years), whose untreated diastolic blood pressure (DBP) on CBP measurement averaged 95 mm Hg or higher, randomized to CBP or ABP arms. Interventions.-Antihypertensive drug treatment was adjusted in a stepwise fashion based on either the average daytime (from 10 AM to 8 PM) ambulatory DBP (n=213) or the average of 3 sitting DBP readings (n=206). If the DBP guiding treatment was above (>89 mm Hg), at (80-89 mm Hg), or below (<80 mm Hg) target, 1 physician blinded to the patients' randomization intensified antihypertensive treatment, left it unchanged, or reduced it, respectively. Main Outcome Measures.-The CBP and ABP levels, intensity of drug treatment, electrocardiographic and echocardiographic left ventricular mass, symptoms reported by questionnaire, and cost. Results.-At the end of the study (median follow-up, 182 days; 5th to 95th percentile interval, 85-258 days), more ABP than CBP patients had stopped antihypertensive drug treatment (26.3% vs 7.3%; P<.001), and fewer ABP patients had progressed to sustained multiple-drug treatment (27.2% vs 42.7%; P<.001). The final CBP and 24-hour ABP averaged 144.1/89.9 mm Hg and 129.4/79.5 mm Hg in the ABP group and 140.3/89.6 mm Hg and 128.0/79.1 mm Hg in the CBP group. Left ventricular mass and reported symptoms were similar in the 2 groups. The potential savings in the ABP group in terms of less intensive drug treatment and fewer physician visits were offset by the costs of ABP monitoring. Conclusions.-Adjustment of antihypertensive treatment based on ABP monitoring instead of CBP measurement led to less intensive drug treatment with presentation of blood pressure control, general well-being, and inhibition of left ventricular enlargement but did not reduce the overall costs of antihypertensive treatment.	KATHOLIEKE UNIV LEUVEN, DEPT MOL CARDIOVASC ONDERZOEK, B-3001 LOUVAIN, BELGIUM; KATHOLIEKE UNIV LEUVEN, ACAD CENTRUM HUISARTSGENEESKUNDE, B-3001 LOUVAIN, BELGIUM; BEAUMONT HOSP, HYPERTENS UNIT, DUBLIN 9, IRELAND; ZENECA NV, DESTELBERGEN, BELGIUM	KU Leuven; KU Leuven			Staessen, Jan A/A-1065-2011; Buntinx, Frank/E-4950-2011	Staessen, Jan A/0000-0002-3026-1637; 				*41 WORLD MED ASS, 1990, B PAN AM HLTH ORG, V24, P606; ALTMAN DG, 1991, PRACTICAL STAT MED R, P368; BIELEN E, 1991, AM HEART J, V121, P1743, DOI 10.1016/0002-8703(91)90021-9; BIELEN EC, 1992, AM J CARDIOL, V69, P1200, DOI 10.1016/0002-9149(92)90936-S; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; CLEMENT DL, 1994, J HYPERTENS, V12, P857; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONWAY J, 1988, J HYPERTENS, V6, P111; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1993, AM J HYPERTENS, V6, pS211; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; Fagard R, 1996, J HYPERTENS, V14, P557, DOI 10.1097/00004872-199605000-00003; FAGARD R, 1993, AM J HYPERTENS, V6, P648, DOI 10.1093/ajh/6.8.648; Fagard RH, 1997, HYPERTENSION, V29, P22, DOI 10.1161/01.HYP.29.1.22; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; IMAI Y, 1993, HYPERTENSION, V22, P900, DOI 10.1161/01.HYP.22.6.900; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; Mancia G, 1995, J HYPERTENS, V13, P1377; MANCIA G, 1983, LANCET, V2, P695; MANN S, 1985, CLIN EXP HYPERTENS A, V7, P279, DOI 10.3109/10641968509073547; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; OBRIEN E, 1991, J HYPERTENS, V9, P573, DOI 10.1097/00004872-199106000-00016; OBRIEN E, 1991, J HYPERTENS, V9, P355, DOI 10.1097/00004872-199104000-00007; PALATINI P, 1990, J HYPERTENS, V8, pS65; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; Pickering, 1996, Blood Press Monit, V1, P151; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1992, J HYPERTENS, V10, P401, DOI 10.1097/00004872-199205000-00001; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SASSANO P, 1987, CURR THER RES CLIN E, V41, P305; *SCI COMM, 1990, J HYPERTENS       S6, V8, pS135; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; Staessen, 1996, Blood Press Monit, V1, P13; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAESSEN J, 1993, ACTA CARDIOL, V48, P25; Staessen JA, 1996, NEPHROL DIAL TRANSPL, V11, P241, DOI 10.1093/oxfordjournals.ndt.a027247; STAESSEN JA, 1994, J HYPERTENS, V12, pS1; Staessen JA, 1996, JAMA-J AM MED ASSOC, V275, P1563, DOI 10.1001/jama.275.20.1563; THIJS L, 1992, J HYPERTENS, V10, P1103, DOI 10.1097/00004872-199210000-00001; Verdecchia P, 1997, HYPERTENSION, V29, P1218, DOI 10.1161/01.HYP.29.6.1218; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; WAEBER B, 1987, LANCET, V2, P732; WHITE WB, 1990, AM J CARDIOL, V65, P60, DOI 10.1016/0002-9149(90)90026-W; *WHO, 1996, HYP CONTR REP WHO EX; WIINBERG N, 1995, AM J HYPERTENS, V8, P978, DOI 10.1016/0895-7061(95)00216-2; ZANCHETTI A, 1993, HYPERTENSION, V22, P392; ZARUKE KB, 1997, AM J HYPERTENS, V10, P58	50	231	234	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1065	1072		10.1001/jama.278.13.1065	http://dx.doi.org/10.1001/jama.278.13.1065			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315764				2022-12-28	WOS:A1997XX30300029
J	Hirschfeld, RMA; Russell, JM				Hirschfeld, RMA; Russell, JM			Current concepts - Assessment and treatment of suicidal patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MENTAL-DISORDERS; GENERAL POPULATION; RISK-FACTORS; PREVALENCE; COMORBIDITY; YOUNG; OUTPATIENTS; BEHAVIORS; IDEATION; YOUTH				Hirschfeld, RMA (corresponding author), UNIV TEXAS, MED BRANCH, DEPT PSYCHIAT & BEHAV SCI, ROOM 1-200, GRAVES BLDG, GALVESTON, TX 77555 USA.							ANDREWS JA, 1992, J AM ACAD CHILD PSY, V31, P655, DOI 10.1097/00004583-199207000-00012; ASNIS GM, 1993, AM J PSYCHIAT, V150, P108; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BEAUMONT G, 1989, BRIT J PSYCHIAT, V155, P27, DOI 10.1192/S0007125000297456; Beautrais AL, 1996, AM J PSYCHIAT, V153, P1009; BIRKHEAD GS, 1993, PUBLIC HEALTH REP, V108, P323; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; BRENT DA, 1987, JAMA-J AM MED ASSOC, V257, P3369, DOI 10.1001/jama.257.24.3369; Dannenberg AL, 1996, JAMA-J AM MED ASSOC, V276, P1743, DOI 10.1001/jama.276.21.1743; FAWCETT J, 1993, PSYCHIAT ANN, V23, P244, DOI 10.3928/0048-5713-19930501-05; HAGNELL O, 1981, NEUROPSYCHOBIOLOGY, V7, P248, DOI 10.1159/000117857; HENDIN H, 1997, SEDUCED DEATH; HENRIKSSON MM, 1993, AM J PSYCHIAT, V150, P935; HENRY JA, 1994, POSTGRAD MED J, V70, pS9; HIRSCHFELD RMA, 1988, REV PSYCHIATRY, V7, P307; HIRSCHFELD RMA, 1996, PRIM PSYCHIAT, V3, P26; KRAGHSORENSEN P, 1993, ACTA PSYCHIAT SCAND, V87, P57, DOI 10.1111/j.1600-0447.1993.tb05376.x; LESAGE AD, 1994, AM J PSYCHIAT, V151, P1063; MACKENZIE TB, 1987, INT J PSYCHIAT MED, V17, P3; MATTHEWS K, 1994, BRIT J GEN PRACT, V44, P345; MOLCHO A, 1992, J CLIN PSYCHOPHARM, V12, pS13; MOSCICKI EK, 1988, YALE J BIOL MED, V61, P259; Moscicki Eve K., 1994, Annals of Epidemiology, V4, P152; MURPHY GE, 1975, ANN INTERN MED, V82, P301, DOI 10.7326/0003-4819-82-3-301; *NAT CTR HLTH STAT, 1996, DEATH RAT 72 SEL CAU; PAYKEL ES, 1974, BRIT J PSYCHIAT, V124, P460, DOI 10.1192/bjp.124.5.460; PETERS KD, 1997, MON VITAL STAT RE S2, V45; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; RAMSAY R, 1985, SUICIDE LIFE-THREAT, V15, P151; RETTERSTOL N, 1993, ACTA PSYCHIAT SCAND, V87, P28, DOI 10.1111/j.1600-0447.1993.tb05370.x; RICH CL, 1992, ACTA PSYCHIAT SCAND, V86, P335, DOI 10.1111/j.1600-0447.1992.tb03276.x; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; RUNESON B, 1989, ACTA PSYCHIAT SCAND, V79, P490, DOI 10.1111/j.1600-0447.1989.tb10292.x; SCHWAB JJ, 1972, DIS NERV SYST, V33, P745; SINGH GK, 1996, MON VITAL STAT REP S, V45; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; WHITFIELD CL, 1986, PRINCIPLES AMBULATOR, P245; ZIMMERMAN M, 1995, J GEN INTERN MED, V10, P573, DOI 10.1007/BF02640368; 1996, DUQUESNE LAW REV, P35	41	171	179	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					910	915		10.1056/NEJM199709253371307	http://dx.doi.org/10.1056/NEJM199709253371307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX302	9302306				2022-12-28	WOS:A1997XX30200007
J	Kutay, U; Bischoff, FR; Kostka, S; Kraft, R; Gorlich, D				Kutay, U; Bischoff, FR; Kostka, S; Kraft, R; Gorlich, D			Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; SEGREGATION GENE CSE1; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; CHROMOSOME SEGREGATION; HNRNP A1; RAN-GTP; RAN/TC4 HOMOLOG; YEAST; LOCALIZATION	NLS proteins are transported into the nucleus by the importin alpha/beta heterodimer. Importin alpha binds the NLS, while importin beta mediates translocation through the nuclear pore complex. After translocation, RanGTP, whose predicted concentration is high in the nucleus and low in the cytoplasm, binds importin beta and displaces importin alpha. Importin alpha must then be returned to the cytoplasm, leaving the NLS protein behind. Here, we report that the previously identified CAS protein mediates importin alpha re-export. CAS binds strongly to importin alpha only in the presence of RanGTP, forming an importin alpha/CAS/RanGTP complex. Importin alpha is released from this complex in the cytoplasm by the combined action of RanBP1 and RanGAP1. CAS binds preferentially to NLS-free importin alpha, explaining why import substrates stay in the nucleus.	UNIV HEIDELBERG, ZENTRUM MOL BIOL, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, ABT MOL BIOL MITOSE, D-69120 HEIDELBERG, GERMANY; ZENTRUM MOL MED, D-13122 BERLIN, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)			Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DEANE R, 1997, IN PRESS MOL CELL BI; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fridell RA, 1997, J CELL SCI, V110, P1325; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; IZAURRALDE E, 1997, IN PRESS EMBO J; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	72	517	528	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1061	1071		10.1016/S0092-8674(00)80372-4	http://dx.doi.org/10.1016/S0092-8674(00)80372-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323134	Bronze			2022-12-28	WOS:A1997XX76800012
J	Miles, M				Miles, M			Scanning probe microscopy - Probing the future	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPY; DNA; RESOLUTION; SURFACE				Miles, M (corresponding author), UNIV BRISTOL,DEPT PHYS,HH WILLS PHYS LAB,BRISTOL BS8 1TL,AVON,ENGLAND.							Allison DP, 1997, GENOMICS, V41, P379, DOI 10.1006/geno.1997.4686; BAMMERLIN M, 1997, PROBE MICROSC, V1, P1; Berger R, 1996, APPL PHYS LETT, V69, P40, DOI 10.1063/1.118111; Berger R, 1997, SCIENCE, V276, P2021, DOI 10.1126/science.276.5321.2021; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1982, HELV PHYS ACTA, V55, P726; Chen C. J., 1993, INTRO SCANNING TUNNE; CLEMMER CR, 1991, SCIENCE, V251, P640, DOI 10.1126/science.1992517; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; GIESSIBL FJ, 1995, SCIENCE, V267, P68, DOI 10.1126/science.267.5194.68; HALLETT P, 1995, BIOPHYS J, V68, P1604, DOI 10.1016/S0006-3495(95)80333-4; Kasas S, 1997, BIOCHEMISTRY-US, V36, P461, DOI 10.1021/bi9624402; KITAMURA S, 1995, JPN J APPL PHYS 2, V34, pL145, DOI 10.1143/JJAP.34.L145; Lantz MA, 1997, PHYS REV B, V55, P10776, DOI 10.1103/PhysRevB.55.10776; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; McMaster TJ, 1996, BIOPHYS J, V70, P2432, DOI 10.1016/S0006-3495(96)79813-2; McMaster TJ, 1996, J VAC SCI TECHNOL B, V14, P1438, DOI 10.1116/1.589115; MOU JX, 1995, FEBS LETT, V371, P279, DOI 10.1016/0014-5793(95)00906-P; MULLER DJ, 1995, J MOL BIOL, V249, P239, DOI 10.1006/jmbi.1995.0292; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rippe K, 1997, J MOL BIOL, V270, P125, DOI 10.1006/jmbi.1997.1079; SIDLES JA, 1995, REV MOD PHYS, V67, P249, DOI 10.1103/RevModPhys.67.249; Stowe TD, 1997, APPL PHYS LETT, V71, P288, DOI 10.1063/1.119522; Thalhammer S, 1997, J STRUCT BIOL, V119, P232, DOI 10.1006/jsbi.1997.3869; Walters DA, 1996, REV SCI INSTRUM, V67, P3583, DOI 10.1063/1.1147177; Wiesendanger R., 1994, SCANNING PROBE MICRO; WILDER K, 1997, NAV RES REV, V49, P35	27	30	32	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1845	&		10.1126/science.277.5333.1845	http://dx.doi.org/10.1126/science.277.5333.1845			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324770				2022-12-28	WOS:A1997XX29800052
J	Ullman, KS; Powers, MA; Forbes, DJ				Ullman, KS; Powers, MA; Forbes, DJ			Nuclear export receptors: From importin to exportin	CELL			English	Review							TRANSPORT				Ullman, KS (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL 0347,LA JOLLA,CA 92093, USA.			Ullman, Katharine/0000-0003-3693-2830	NIGMS NIH HHS [R01 GM033279] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033279] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Goldfarb DS, 1997, SCIENCE, V276, P1814, DOI 10.1126/science.276.5320.1814; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; NEVILLE M, 1997, IN PRESS CURR BIOL; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	21	232	238	4	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					967	970		10.1016/S0092-8674(00)80361-X	http://dx.doi.org/10.1016/S0092-8674(00)80361-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323123	Bronze			2022-12-28	WOS:A1997XX76800001
J	Staessen, JA; Fagard, R; Thijs, L; Celis, H; Arabidze, GG; Birkenhager, WH; Bulpitt, CJ; deLeeuw, PW; Dollery, CT; Fletcher, AE; Forette, F; Leonetti, G; Nachev, C; OBrien, ET; Rosenfeld, J; Rodicio, JL; Tuomilehto, J; Zanchetti, A				Staessen, JA; Fagard, R; Thijs, L; Celis, H; Arabidze, GG; Birkenhager, WH; Bulpitt, CJ; deLeeuw, PW; Dollery, CT; Fletcher, AE; Forette, F; Leonetti, G; Nachev, C; OBrien, ET; Rosenfeld, J; Rodicio, JL; Tuomilehto, J; Zanchetti, A			Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension	LANCET			English	Article							ELDERLY PROGRAM SHEP; CALCIUM-ANTAGONISTS; SWEDISH TRIAL; MORTALITY; MORBIDITY; PRESSURE; STOP; RISK	Background Isolated systolic hypertension occurs in about 15% of people aged 60 years or older. In 1989, the European Working Party on High Blood Pressure whether active treatment investigated cardiovascular complications hypertension. Fatal and non-fatal stroke combined was the primary endpoint. Methods All patients (greater than or equal to 60 years) were initially started on masked placebo. At three run-in visits 1 month apart, their average sitting systolic blood pressure was 160-219 mm Hg with a diastolic blood pressure lower than 95 mm Hg. After stratification for centre, sex, and previous cardiovascular complications, 4695 patients were randomly assigned to nitrendipine 10-40 mg daily, with the possible addition of enalapril 5-20 mg daily and hydrochlorothiazide 12.5-25.0 mg daily, or matching placebos. Patients withdrawing from double-blind treatment were still followed up. We compared occurrence of major endpoints by intention to treat. Findings At a median of 2 years' follow-up, sitting systolic acid diastolic blood pressures had fallen by 13 mm Hg and 2 mm Hg in the placebo group (n=2297) and by 23 mm Hg and 7 mm Hg in the active treatment group (n=2398). The between-group differences were systolic 10.1 mm Hg (95% CI 8.8-11.4) and diastolic, 4.5 mm Hg (3.9-5.1). Active treatment reduced the total rate of stroke from 13.7 to 7.9 endpoints per 1000 patient-years (42% reduction; p=0.003). Non-fatal stroke decreased by 44% (p=0.007). In the active treatment. group, all fatal and non-fatal cardiac endpoints, including sudden death, declined by 26% (p=0.03). Non-fatal cardiac endpoints decreased by 33% (p=0.03) and all fatal and non-fatal cardiovascular endpoints by 31% (p<0.001). Cardiovascular mortality was slightly lower on active treatment (-27%, p=0.07), but all-cause mortality was not influenced (-14%; p=0.22). Interpretation Among elderly patients with isolated systolic hypertension, antihypertensive drug treatment starting with nitrendipine reduces the rate of cardiovascular complications. Treatment of 1000 patients for 5 years with this type of regimen may prevent 29 strokes or 53 major cardiovascular endpoints.	AL MYASNIKOV CARDIOL INST, MOSCOW, RUSSIA; ERASMUS UNIV ROTTERDAM, ROTTERDAM, NETHERLANDS; ROYAL POSTGRAD MED SCH, DEPT MED, LONDON, ENGLAND; UNIV HOSP MAASTRICHT, DEPT INTERNAL MED, MAASTRICHT, NETHERLANDS; UNIV LONDON, LONDON WC1E 7HU, ENGLAND; LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON, ENGLAND; UNIV PARIS 05, HOP BROCA, DEPT GERIATR, PARIS, FRANCE; UNIV MILAN, OSPED MAGGIORE, I-20122 MILAN, ITALY; IST AUXOL ITALIANO, MILAN, ITALY; ALEXANDROVS UNIV HOSP, DEPT INTERNAL MED, SOFIA, BULGARIA; BEAUMONT HOSP, DUBLIN, IRELAND; HOSP 12 DE OCTUBRE, E-28041 MADRID, SPAIN; SACKLER SCH MED, TEL AVIV, ISRAEL; NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, HELSINKI, FINLAND	National Medical Research Center of Cardiology; Erasmus University Rotterdam; Imperial College London; Maastricht University; Maastricht University Medical Centre (MUMC); University of London; University of London; London School of Hygiene & Tropical Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Broca - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Milan; IRCCS Istituto Auxologico Italiano; Medical University Sofia; Hospital Universitario 12 de Octubre; Tel Aviv University; Sackler Faculty of Medicine; Finland National Institute for Health & Welfare	Staessen, JA (corresponding author), UNIV LEUVEN, DEPT MOL & CARDIOVASC RES, KLIN LAB HYPERTENS, LOUVAIN, BELGIUM.		Staessen, Jan A/A-1065-2011; de Leeuw, Peter W./J-4552-2016	Staessen, Jan A/0000-0002-3026-1637; de Leeuw, Peter W./0000-0002-4949-5812; Thijs, Lutgarde/0000-0002-8108-2356; zanchetti, alberto/0000-0003-4796-7959				*41 WORLD MED ASS, 1990, B PAN AM HLTH ORG, V24, P606; AMERY A, 1985, LANCET, V1, P1349; Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1981, MED J AUSTRALIA, V2, P398; Celis H, 1996, FAM PRACT, V13, P138, DOI 10.1093/fampra/13.2.138; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FLETCHER A, 1993, LANCET, V342, P653, DOI 10.1016/0140-6736(93)91762-B; Furberg CD, 1996, AM J HYPERTENS, V9, P122, DOI 10.1016/0895-7061(96)00014-3; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOA KL, 1987, DRUGS, V33, P123, DOI 10.2165/00003495-198733020-00003; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Hamet P, 1996, J HYPERTENS, V14, pS123, DOI 10.1097/00004872-199609002-00021; KAPLAN NM, 1992, AM J HYPERTENS, V5, P331, DOI 10.1093/ajh/5.5.331; KURAMOTO K, 1981, JPN CIRC J, V45, P833, DOI 10.1253/jcj.45.833; LEVER AF, 1995, J HYPERTENS, V13, P571, DOI 10.1097/00004872-199506000-00001; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MENARD J, 1992, AM J HYPERTENS, V5, P325, DOI 10.1093/ajh/5.5.325; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAESSEN J, 1991, J HUM HYPERTENS, V5, P469; STAESSEN JA, 1994, HYPERTENSION, V23, P269, DOI 10.1161/01.HYP.23.2.269; SWALES JD, 1994, LANCET, V344, P380; THIJS L, 1992, J HYPERTENS, V10, P1103, DOI 10.1097/00004872-199210000-00001; WANG J, 1966, J HUM HYPERTENS, V10, P735; ZANCHETTI A, 1993, HYPERTENSION, V22, P392; ZANCHETTI A, 1995, J HYPERTENS, V13, pS119, DOI 10.1097/00004872-199508001-00020; 1977, INT CLASSIFICATION D, V1	34	2302	2414	1	61	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 13	1997	350	9080					757	764		10.1016/S0140-6736(97)05381-6	http://dx.doi.org/10.1016/S0140-6736(97)05381-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297994				2022-12-28	WOS:A1997XW28200009
J	Ames, JB; Ishima, R; Tanaka, T; Gordon, JI; Stryer, L; Ikura, M				Ames, JB; Ishima, R; Tanaka, T; Gordon, JI; Stryer, L; Ikura, M			Molecular mechanics of calcium-myristoyl switches	NATURE			English	Article							RHODOPSIN KINASE; RECOVERIN; PROTEIN; BINDING; SYSTEM; RESOLUTION; TERMINUS; FAMILY	Many eukaryotic cellular and viral proteins have a covalently attached myristoyl group at the amino terminus. One such protein is recovering a calcium sensor in retinal rod cells, which controls the lifetime of photoexited rhodopsin by inhibiting rhodopsin kinase(1-6). Recoverin has a relative molecular mass of 23,000 (M-r 23K), and contains an amino-terminal myristoyl group (or related acyl group) and four EF hands(7). The binding of two Ca2+ ions to rccoverin leads to its translocation from the cytosol to the disc membraned(8,9). In the Ca2+-free state, the myristoyl group is sequestered in a deep hydrophobic box, where it is clamped by multiple residues contributed by three of the EF hands(10). We have used nuclear magnetic resonance to show that Ca2+ induces the unclamping and extrusion of the myristoyl group, enabling it to interact with a lipid bilayer membrane. The transition is also accompanied by a 45-degree rotation of the amino-terminal domain relative to the carboxy-terminal domain, and many hydrophobic residues are exposed. The conservation of the myristoyl binding site and two swivels in recoverin homologues from yeast to humans indicates that calcium-myristoyl switches are ancient devices for controlling calcium-sensitive processes.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; UNIV TORONTO,ONTARIO CANC INST,DIV MOL & STRUCT BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Stanford University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba; University of Tsukuba; Washington University (WUSTL)				Ikura, Mitsuhiko/0000-0002-9524-1303				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KELLER MPG, 1993, NEURON, V10, P523; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	29	412	417	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					198	202		10.1038/38310	http://dx.doi.org/10.1038/38310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296500				2022-12-28	WOS:A1997XV75700053
J	Lijam, N; Paylor, R; McDonald, MP; Crawley, JN; Deng, CX; Herrup, K; Stevens, KE; Maccaferri, G; McBain, CJ; Sussman, DJ; WynshawBoris, A				Lijam, N; Paylor, R; McDonald, MP; Crawley, JN; Deng, CX; Herrup, K; Stevens, KE; Maccaferri, G; McBain, CJ; Sussman, DJ; WynshawBoris, A			Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1	CELL			English	Article							SEGMENT-POLARITY GENE; PREPULSE INHIBITION; ACOUSTIC STARTLE; SCHIZOPHRENIC-PATIENTS; INBRED STRAINS; ANIMAL-MODEL; DROSOPHILA; STIMULATION; DEFICITS; HABITUATION	Mice completely deficient for Dvl1, one of three mouse homologs of the Drosophila segment polarity gene Dishevelled, were created by gene targeting. Dv1-deficient mice are viable, fertile, and structurally normal. Surprisingly, these mice exhibited reduced social interaction, including differences in whisker trimming, deficits in nest-building, less huddling contact during home cage sleeping, and subordinate responses in a social dominance test. Sensorimotor gating was abnormal, as measured by deficits in prepulse inhibition of acoustic and tactile startle. Thus, Dv1 mutants may provide a model for aspects of several human psychiatric disorders. These results are consistent with an interpretation that common genetic mechanisms underlie abnormal social behavior and sensorimotor gating deficits and implicate Dvl1 in processes underlying complex behaviors.	NIMH,SECT BEHAV NEUROPHARMACOL,EXPT THERAPEUT BRANCH,BETHESDA,MD 20892; NIDDK,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NICHHD,LAB CELLULAR & MOL NEUROPHYSIOL,NATL INST HLTH,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV COLORADO,HLTH SCI CTR,DEPT PSYCHIAT,DENVER,CO 80262; UNIV MARYLAND,SCH MED,DIV HUMAN GENET,BALTIMORE,MD 21201	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University System of Maryland; University of Maryland Baltimore	Lijam, N (corresponding author), NATL HUMAN GENOME RES INST,LAB GENET DIS RES,BETHESDA,MD 20892, USA.		deng, chuxia/N-6713-2016; Herrup, Karl/C-5313-2014	Herrup, Karl/0000-0001-7786-5844; McDonald, Michael P./0000-0002-9642-964X	NCI NIH HHS [CA63929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA063929, R01CA063929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKSHI VP, 1994, J PHARMACOL EXP THER, V271, P787; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BRAFF D, 1978, PSYCHOPHYSIOLOGY, V15, P339, DOI 10.1111/j.1469-8986.1978.tb01390.x; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; CADENHEAD KS, 1993, AM J PSYCHIAT, V150, P1862; Castellanos FX, 1996, BIOL PSYCHIAT, V39, P33, DOI 10.1016/0006-3223(95)00101-8; CIARANELLO AL, 1995, ANNU REV NEUROSCI, V18, P101, DOI 10.1146/annurev.ne.18.030195.000533; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; DAVIS M, 1982, J NEUROSCI, V2, P791; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; GEYER MA, 1987, SCHIZOPHRENIA BULL, V13, P643, DOI 10.1093/schbul/13.4.643; GEYER MA, 1993, BIOL PSYCHIAT, V34, P361, DOI 10.1016/0006-3223(93)90180-L; GRAHAM FK, 1975, PSYCHOPHYSIOLOGY, V12, P238, DOI 10.1111/j.1469-8986.1975.tb01284.x; GRANT E. C, 1963, BEHAVIOUR, V21, P246, DOI 10.1163/156853963X00185; GRILLON C, 1992, BIOL PSYCHIAT, V32, P939, DOI 10.1016/0006-3223(92)90183-Z; Hahn ME, 1996, BEHAV GENET, V26, P463, DOI 10.1007/BF02359750; HARLOW E, 1988, J HERED, V43, P77; ISON JR, 1973, PHYSIOL BEHAV, V10, P1036; JOHANSSON C, 1995, PHARMACOL BIOCHEM BE, V52, P649, DOI 10.1016/0091-3057(95)00160-X; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; LIJAM N, 1996, GENOME RES, V5, P116; LINDZEY G, 1961, NATURE, V191, P474, DOI 10.1038/191474a0; LONG SY, 1972, ANIM BEHAV, V20, P10, DOI 10.1016/S0003-3472(72)80167-2; Luna L.G., 1992, HISTOPATHOLOGICAL ME; Maccaferri G, 1996, J NEUROSCI, V16, P5334; MANSBACH RS, 1988, PSYCHOPHARMACOLOGY, V94, P507, DOI 10.1007/BF00212846; MCDOWD JM, 1993, SCHIZOPHRENIA BULL, V19, P733, DOI 10.1093/schbul/19.4.733; MESSERI P, 1975, PHYSIOL BEHAV, V14, P53, DOI 10.1016/0031-9384(75)90141-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Murphy KC, 1996, J MOL NEUROSCI, V7, P147, DOI 10.1007/BF02736794; Paylor R, 1997, PSYCHOPHARMACOLOGY, V132, P169, DOI 10.1007/s002130050333; Paylor R, 1996, BEHAV NEUROSCI, V110, P1415, DOI 10.1037/0735-7044.110.6.1415; PICKAR D, 1995, LANCET, V345, P557, DOI 10.1016/S0140-6736(95)90469-7; Pizzuti A, 1996, AM J HUM GENET, V58, P722; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; Steitz SA, 1996, IN VITRO CELL DEV-AN, V32, P441, DOI 10.1007/BF02723007; STROZIK E, 1981, LAB ANIM, V15, P309, DOI 10.1258/002367781780953040; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; SWERDLOW NR, 1995, J NEUROL NEUROSUR PS, V58, P192, DOI 10.1136/jnnp.58.2.192; SWERDLOW NR, 1994, ARCH GEN PSYCHIAT, V51, P139; SWERDLOW NR, 1993, BIOL PSYCHIAT, V33, P298, DOI 10.1016/0006-3223(93)90300-3; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; WILKINSON LS, 1994, NEUROPSYCHOPHARMACOL, V10, P61, DOI 10.1038/npp.1994.8; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	51	373	393	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					895	905		10.1016/S0092-8674(00)80354-2	http://dx.doi.org/10.1016/S0092-8674(00)80354-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298901	Bronze			2022-12-28	WOS:A1997XV56300010
J	Panning, B; Dausman, J; Jaenisch, R				Panning, B; Dausman, J; Jaenisch, R			X chromosome inactivation is mediated by Xist RNA stabilization	CELL			English	Article							MOUSE DEVELOPMENT; EMBRYONIC-CELLS; GENE-EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; METHYLATION; REQUIREMENT; BLASTOCYST; NUCLEUS; PROTEIN	Low level Xist expression can be detected from both active X chromosomes (Xa) in female embryonic stem cells prior to X inactivation. After differentiation, Xist is expressed at high levels only from the inactive X chromosome (Xi). Differentiating female cells increase Xist expression from the Xi prior to silencing low level Xist expression from the Xa. The transition from low level to high level expression is regulated by the stabilization of Xist transcripts at the Xi. We suggest that these developmentally modulated changes in Xist expression are regulated by several different mechanisms: factors that stabilize Xist transcripts at the Xi, an activity that blocks this stabilization at the Xa, and a mechanism that silences low level Xist expression from the Xa.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	Panning, B (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NCI NIH HHS [R35-CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; ANDREWS GK, 1982, DEV BIOL, V89, P111, DOI 10.1016/0012-1606(82)90299-8; BARR ML, 1959, SCIENCE, V130, P679, DOI 10.1126/science.130.3377.679; BARR ML, 1962, ACTA CYTOL, V6, P34; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BURGOYNE PS, 1993, DEVELOPMENT, V117, P341; CATTANACH BM, 1975, ANNU REV GENET, V9, P1, DOI 10.1146/annurev.ge.09.120175.000245; CLEMSON CM, 1996, J CELL BIOL, V132, P1; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CRUZ YP, 1993, IN VITRO CELL DEV, V29, P671; GARDNER RL, 1971, NATURE, V231, P385, DOI 10.1038/231385a0; HENDRICH BD, 1997, NUCLEIC ACIDS RES, V13, P2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; LOCK LF, 1986, MOL CELL BIOL, V6, P914, DOI 10.1128/MCB.6.3.914; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; LYON MF, 1961, NATURE, V190, P327; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MATTEI JF, 1981, HUM GENET, V56, P409, DOI 10.1007/BF00274703; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; MOORE MJ, 1993, RNA WORLD, P305; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; PANNING B, 1996, GENE DEV, V10, P1191; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219	48	248	257	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					907	916		10.1016/S0092-8674(00)80355-4	http://dx.doi.org/10.1016/S0092-8674(00)80355-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298902	Bronze			2022-12-28	WOS:A1997XV56300011
J	Greenhalgh, T				Greenhalgh, T			How to read a paper - Papers that report diagnostic or screening tests	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL LITERATURE; USERS GUIDES; ARTICLE				Greenhalgh, T (corresponding author), UCL, SCH MED, WHITTINGTON HOSP, ROYAL FREE HOSP SCH MED, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				ANDERSSON DKG, 1993, DIABETIC MED, V10, P167, DOI 10.1111/j.1464-5491.1993.tb00036.x; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CATALONA WJ, 1994, J UROLOGY, V152, P2037, DOI 10.1016/S0022-5347(17)32300-5; FAGAN TJ, 1975, NEW ENGL J MED, V293, P257; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GUYATT GH, 1990, AM J MED, V88, P205, DOI 10.1016/0002-9343(90)90143-2; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; MANT D, 1995, CRITICAL READING PRI, P183; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; READ MC, 1995, JAMA-J AM MED ASSOC, V274, P645; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P51; Verkerk P H, 1993, Ned Tijdschr Geneeskd, V137, P2199; *WHO STUD GROUP, 1985, WHO TECH REP SER, V727; 1996, BANDOLIER, V3, P6	15	271	290	1	36	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					540	543		10.1136/bmj.315.7107.540	http://dx.doi.org/10.1136/bmj.315.7107.540			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329312	Green Published			2022-12-28	WOS:A1997XU50600029
J	Barcellos, LF; Thomson, G; Carrington, M; Schafer, J; Begovich, AB; Lin, P; Xu, XH; Min, BQ; Marti, D; Klitz, W				Barcellos, LF; Thomson, G; Carrington, M; Schafer, J; Begovich, AB; Lin, P; Xu, XH; Min, BQ; Marti, D; Klitz, W			Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis - Evidence of a new susceptibility locus in Caucasian and Chinese patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASIC-PROTEIN GENE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; APOLIPOPROTEIN-E; LINKAGE DISEQUILIBRIUM; ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; SHANGHAI CHINESE; HLA; POLYMORPHISM; COMPLEX	Context.-Susceptibility to multiple sclerosis (MS) involves a genetically complex autoimmune component. However, except for genes in the HLA system, specific susceptibility loci are unknown or unconfirmed. Objective.-To investigate several loci spanning 3 candidate regions for a role in multiple sclerosis (MS) susceptibility in 2 ethnic groups using both single-locus and haplotype analyses. The 3 regions include HLA on chromosome 6p21.3, APOE on chromosome 19q13.2, and MBP (myelin basic protein) on chromosome 18q23. Design.-Case-control association testing. Subjects.-A total of 120 Caucasian patients with MS and 107 unrelated control individuals from California, and 32 patients and 32 unrelated control individuals from Beijing, China. All patients with MS were diagnosed as having clinically definite disease according to published criteria. Main Outcome Measures.-chi(2) Testing of loci and individual alleles and haplotypes. Haplotype frequencies were estimated with standard maximum likelihood methods. Results.-The HLA effect is due to the class II DR2 haplotype, DRB1*1501-DQA1*0102-DRB1*0602; contributions to MS susceptibility from additional DRB1-DQB1 alleles or other HLA region loci were not observed. Variation within the MBP locus on chromosome 18q23 showed no effect in MS. The distribution of haplotypes from 5 loci within the chromosome 19q13.2 region, including D19S178, D19S574, APOE, APOC2, and D19S219, differed between patient and control samples. D19S574 showed a significant effect (P=.015) in Caucasian patients with MS due to the increased frequency of a single allele (P=.002). The APOE variation, prominent in other neurological diseases, showed no influence on MS susceptibility, despite its location within the chromosome 19q13.2 region. interaction effects between DR2 and chromosome 19q13.2 or MBP in MS susceptibility were not apparent. Conclusions.-The significant chromosome 19q13.2 single-locus and multilocus haplotype associations with MS in Caucasian and Chinese patient samples indicate an effect from a nearby disease susceptibility locus. These initial observations are an encouraging step toward the description of non-HLA genetic susceptibility to MS.	UNIV CALIF BERKELEY, DEPT INTEGRAT BIOL, BERKELEY, CA 94720 USA; ROCHE MOL SYST INC, DEPT HUMAN GENET, ALAMEDA, CA USA; CHILDRENS HOSP, OAKLAND RES INST, OAKLAND, CA 94609 USA; NCI, INTRAMURAL RES SUPPORT PROGRAM, SAIC FREDERICK, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21701 USA; UNIV CALIF DAVIS, DEPT NEUROL, DAVIS, CA USA; BEIJING UNION MED COLL HOSP, DEPT NEUROL, BEIJING 100730, PEOPLES R CHINA	University of California System; University of California Berkeley; Roche Holding; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Davis; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035326] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; ALLEN M, 1994, HUM IMMUNOL, V39, P41, DOI 10.1016/0198-8859(94)90099-X; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Baur M.P., 1980, HISTOCOMPATIBILITY T, P955; BenNun A, 1996, J NEUROL, V243, pS14, DOI 10.1007/BF00873697; BIAN HJ, 1992, NEUROEPIDEMIOLOGY, V11, P52, DOI 10.1159/000110911; CARRINGTON M, 1994, HUM MOL GENET, V3, P218, DOI 10.1093/hmg/3.1.218; CARRINGTON M, 1994, HUM IMMUNOL, V41, P234, DOI 10.1016/0198-8859(94)90041-8; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CLERGETDARPOUX F, 1992, ANN HUM GENET, V56, P145, DOI 10.1111/j.1469-1809.1992.tb01140.x; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; GOODKIN DE, 1991, ARCH NEUROL-CHICAGO, V48, P805, DOI 10.1001/archneur.1991.00530200041016; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HAINES JL, 1993, AM J HUM GENET, V53, P266; HASHIMOTO LL, 1993, J NEUROIMMUNOL, V44, P77, DOI 10.1016/0165-5728(93)90270-9; HILLERT J, 1994, ANN NEUROL, V36, pS15, DOI 10.1002/ana.410360706; HILTON AA, 1995, J NEUROCHEM, V65, P309; Ibsen SN, 1996, ACTA NEUROL SCAND, V93, P236; Imanish T, 1992, HLA 1991, V1, P1065; KAMBOH MI, 1995, HUM BIOL, V67, P195; KELLARWOOD HF, 1995, J NEUROIMMUNOL, V58, P183, DOI 10.1016/0165-5728(95)00015-T; KELLY MA, 1995, J CLIN PATHOL-CL MOL, V48, pM111; KELLY MA, 1995, HUM IMMUNOL, V42, P203, DOI 10.1016/0198-8859(94)00094-7; KLITZ W, 1995, AM J HUM GENET, V57, P1436; Kuokkanen S, 1996, NAT GENET, V13, P477, DOI 10.1038/ng0896-477; KURTZKE JF, 1983, MULTIPLE SCLEROSIS P, P47; LONG JC, 1995, AM J HUM GENET, V56, P799; MARTIN M, 1995, HUM MOL GENET, V4, P423, DOI 10.1093/hmg/4.3.423; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NILLESEN WM, 1992, NUCLEIC ACIDS RES, V18, P428; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAMACHANDRAN S, 1995, TISSUE ANTIGENS, V46, P140, DOI 10.1111/j.1399-0039.1995.tb02492.x; RISCH N, 1990, AM J HUM GENET, V46, P242; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; RISCH N, 1987, AM J HUM GENET, V40, P1; RISCH N, 1992, AM J HUM GENET, V51, P673; ROTH MP, 1994, J NEUROIMMUNOL, V51, P93, DOI 10.1016/0165-5728(94)90133-3; ROTH MP, 1995, J NEUROIMMUNOL, V61, P117, DOI 10.1016/0165-5728(95)00078-G; ROTH MP, 1995, HUM IMMUNOL, V43, P276, DOI 10.1016/0198-8859(95)91033-T; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SADOVNICK AD, 1993, ANN NEUROL, V33, P281, DOI 10.1002/ana.410330309; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SERJEANTSON SW, 1992, EUR J IMMUNOGENET, V19, P11, DOI 10.1111/j.1744-313X.1992.tb00043.x; SPURKLAND A, 1994, HUM IMMUNOL, V39, P299, DOI 10.1016/0198-8859(94)90273-9; TIENARI PJ, 1992, LANCET, V340, P987, DOI 10.1016/0140-6736(92)93007-A; VANDEVYVER C, 1994, J NEUROIMMUNOL, V52, P97, DOI 10.1016/0165-5728(94)90167-8; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISS KM, 1993, GENETIC VARIATION HU, P180; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WOOD NW, 1994, J NEUROL NEUROSUR PS, V57, P1191, DOI 10.1136/jnnp.57.10.1191	57	67	69	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1256	1261		10.1001/jama.278.15.1256	http://dx.doi.org/10.1001/jama.278.15.1256			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333267				2022-12-28	WOS:A1997XZ70900031
J	Bolognia, JL; Edelson, RL				Bolognia, JL; Edelson, RL			Spread of antibiotic-resistant bacteria from acne patients to personal contacts - a problem beyond the skin?	LANCET			English	Editorial Material							STAPHYLOCOCCI; ERYTHROMYCIN; THERAPY				Bolognia, JL (corresponding author), YALE UNIV,SCH MED,DEPT DERMATOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Edelson, Richard/AAD-4826-2019					CRAWFORD WW, 1979, J INVEST DERMATOL, V72, P187, DOI 10.1111/1523-1747.ep12676385; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; HARKAWAY KS, 1992, BRIT J DERMATOL, V126, P586; LEYDEN JJ, 1983, J AM ACAD DERMATOL, V8, P41, DOI 10.1016/S0190-9622(83)70005-8; LYEDEN JJ, 1997, J GERIATR DERMATO SA, V5, pA1; Miller YW, 1996, J ANTIMICROB CHEMOTH, V38, P829; MURRAY PR, 1994, MED MICROBIOLOGY, V176, P292	7	10	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					972	973		10.1016/S0140-6736(05)64063-9	http://dx.doi.org/10.1016/S0140-6736(05)64063-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329508				2022-12-28	WOS:A1997XZ71000004
J	Messina, M; Barnes, S; Setchell, KD				Messina, M; Barnes, S; Setchell, KD			Phyto-oestrogens and breast cancer	LANCET			English	Editorial Material							RISK-FACTORS		UNIV ALABAMA,DEPT BIOCHEM & PHARMACOL,BIRMINGHAM,AL; CHILDRENS HOSP & MED CTR,DEPT CLIN MASS SPECTROMETRY,CINCINNATI,OH	University of Alabama System; University of Alabama Birmingham; Cincinnati Children's Hospital Medical Center	Messina, M (corresponding author), NUTR MATTERS INC,1543 LINCOLN ST,PORT TOWNSEND,WA 98368, USA.							Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; CASSIDY A, 1995, BRIT J NUTR, V74, P587, DOI 10.1079/BJN19950160; COLDITZ GA, 1995, CANCER EPIDEM BIOMAR, V4, P567; DeStefani E, 1997, NUTR CANCER, V28, P14, DOI 10.1080/01635589709514547; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; GREENSTEIN J, 1996, AM J EPIDEMIOL, pS36; HIROSE K, 1995, JPN J CANCER RES, V86, P146, DOI 10.1111/j.1349-7006.1995.tb03032.x; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; MAYR U, 1992, TOXICOLOGY, V74, P135, DOI 10.1016/0300-483X(92)90134-Z; Murrill WB, 1996, CARCINOGENESIS, V17, P1451, DOI 10.1093/carcin/17.7.1451; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; Wu AH, 1996, CANCER EPIDEM BIOMAR, V5, P901; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263	16	84	88	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					971	972		10.1016/S0140-6736(05)64062-7	http://dx.doi.org/10.1016/S0140-6736(05)64062-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329507				2022-12-28	WOS:A1997XZ71000003
J	Boussiotis, VA; Freeman, GJ; Berezovskaya, A; Barber, DL; Nadler, LM				Boussiotis, VA; Freeman, GJ; Berezovskaya, A; Barber, DL; Nadler, LM			Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; CBL PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; C-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; SUPPRESSOR ACTIVITY; INSULIN-RECEPTOR; MAMMALIAN-CELLS	In the absence of costimulation, T cells activated through their antigen receptor become unresponsive (anergic) and do not transcribe the gene encoding interleukin-2 (IL-2) when restimulated with antigen. Anergic alloantigen-specific human T cells contained phosphorylated Cbl that coimmunoprecipitated with Fyn. The adapter protein CrkL was associated with both phosphorylated Cbl and the guanidine nucleotide-releasing factor G3G, which catalyzes guanosine triphosphate (GTP) exchange on Rap1. Active Rap1 (GTP-bound form) was present in anergic cells, Forced expression of low amounts of Rap1-GTP in Jurkat T cells recapitulated the anergic defect and blocked T cell antigen receptor (TCR)- and CD28-mediated IL-2 gene transcription. Therefore, Rap1 functions as a negative regulator of TCR-mediated IL-2 gene transcription and may be responsible for the specific defect in IL-2 production in T cell anergy.	HARVARD UNIV, SCH MED, BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; ONTARIO CANC INST, DIV CELLULAR & MOL BIOL, TORONTO, ON M5G 2M9, CANADA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Boussiotis, VA (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT ADULT ONCOL, BOSTON, MA 02115 USA.		Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Barber, Dwayne/0000-0001-5528-8150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039671] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54785] Funding Source: Medline; NIAID NIH HHS [AI39671, AI 35225] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; BOUSSIOTIS VA, UNPUB; Brownell HL, 1996, DNA CELL BIOL, V15, P443, DOI 10.1089/dna.1996.15.443; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JONGEWARD GD, 1995, GENETICS, V139, P1553; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MIGITA K, 1995, J IMMUNOL, V155, P5083; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAHL HL, 1991, EXP HEMATOL, V19, P1038; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PIZON V, 1988, ONCOGENE, V3, P201; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; QIAN DP, 1993, J BIOL CHEM, V268, P4488; QUILL H, 1987, J IMMUNOL, V138, P3704; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SREEDQUIST KA, 1996, J BIOL CHEM, V271, P8453; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	77	388	395	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					124	128		10.1126/science.278.5335.124	http://dx.doi.org/10.1126/science.278.5335.124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311917				2022-12-28	WOS:A1997XZ12400053
J	MacCoun, R; Reuter, P				MacCoun, R; Reuter, P			Interpreting Dutch cannabis policy: Reasoning by analogy in the legalization debate	SCIENCE			English	Article							DRUG PROHIBITION	The Dutch depenalization and subsequent de facto legalization of cannabis since 1976 is used here to highlight the strengths and limitations of reasoning by analogy as a guide for projecting the effects of relaxing drug prohibitions. While the Dutch case and other analogies have flaws, they appear to converge in suggesting that reductions in criminal penalties have limited effects on drug use-at least for marijuana-but that commercial access is associated with growth in the drug-using population.	UNIV MARYLAND,SCH PUBL AFFAIRS,COLLEGE PK,MD 20742; UNIV MARYLAND,DEPT CRIMINOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	MacCoun, R (corresponding author), UNIV CALIF BERKELEY,RICHARD & RHODA GOLDMAN SCH PUBL POLICY,BERKELEY,CA 94720, USA.		MacCoun, Robert/N-1765-2019; MacCoun, Robert/D-1702-2011	MacCoun, Robert/0000-0003-0929-4423; 				Brown Jodi M., 1996, CORRECTIONAL POPULAT; COHEN P, 1997, CANNABIS USE AMSTERD; Cohen P., 1996, CANNABIS USE STEPPIN; COHEN P, COMMUNICATION; Cook T.C., 1979, QUASIEXPERIMENTATION; DEZWART WM, 1997, KERNGEGEVENS ROKEN D; DRIESSEN FM, 1989, ALCOHOL DRUGS ANDERE, V15, P2; *DRUG ENF ADM, ILL DRUG WHOL RET PR; DUKE SB, 1993, LONGEST RUNNING WAR; *EUR MON CTR DRUG, 1996, 1995 EUR MON CTR DRU; EVERINGHAM S, UNPUB 1993 NATL HOUS; *GEN ACC OFF, 1997, TGGD977 GAO; Goldstein A., 1994, ADDICTION BIOL DRUG; Hartnoll R., 1994, MULTICITY STUDY DRUG; Jansen A.C.M., 1991, CANNABIS AMSTERDAM G; Johnston LD, 1981, MARIJUANA DECRIMINAL; Johnston LD, 1995, NATL SURVEY RESULTS; KANDEL DB, 1991, MILBANK Q, V69, P365, DOI 10.2307/3350102; Kaplan J., 1970, MARIJUANA NEW PROHIB; KLEBER HD, 1994, NEW ENGL J MED, V330, P361, DOI 10.1056/NEJM199402033300514; Kleiman M, 1992, EXCESS DRUG POLICY R; KORF DJ, 1988, TIJDSCHR ALCOHOL DRU, V14, P81; LANGEMEIJER MPS, IN PRESS ILLICIT DRU; Leuw E, 1994, PROHIBITION LEGALIZA, P23; MacCoun R, 1996, J POLICY ANAL MANAG, V15, P330, DOI 10.1002/(SICI)1520-6688(199622)15:3<330::AID-PAM1>3.0.CO;2-J; MACCOUN R, IN PRESS DRUG WAR LE; MACCOUN RJ, 1993, PSYCHOL BULL, V113, P497, DOI 10.1037/0033-2909.113.3.497; MACCOUN RJ, 1993, J DRUG ISSUES, V23, P615, DOI 10.1177/002204269302300404; MACCOUN RJ, 1993, PSYCHOACTIVE DRUGS H, P103; MACCOUN RJ, 1995, POLICIES STRATEGIES; MEYENFELDT LH, 1996, EUROPEAN DRUG POLICI, P97; *MIN FOR AFF MIN H, 1995, DRUGS POL NETH CONT; *MIN JUST, DUTCH DRUGS POL; MIRON JA, 1995, J ECON PERSPECT, V9, P175, DOI 10.1257/jep.9.4.175; MIRON JA, 1991, AM ECON REV, V81, P242; NADELMANN E, 1989, SCIENCE, V245, P739; *NORW MIN HLTH SOC, 1997, NEW TRENDS DRUG AB N; *OFF NAT DRUG CONT, 1997, NAT DRUG CONTR STRAT; *OFF NAT DRUG CONT, 1993, STAT LOC SPEND DRUG; RHODES W, 1995, WHAT AM USERS SPEND; SANDWIJK JP, 1995, LICIT ILLICIT DRUG U, V2; SANDWIJK JP, 1991, LICIT ILLICIT DRUG U; SINGLE E W, 1989, Journal of Public Health Policy, V10, P456, DOI 10.2307/3342518; *SUBST AB MENT HLT, 1994, MED EX DAT STAT 1 B, V14; *SUBST AB MENT HLT, NAT HOUS SURV DRUG A; UCHTENHAGEN A, 1997, PROGRAMME MED PRESCR; *UN, 1981, 2 UN SURV CRIME TREN; WILSON JQ, 1991, COMMENTARY, V89, P21; Wisotsky Steven., 1992, SOC SUSPECTS WAR DRU; 1997, MMWR-MORBID MORTAL W, V45, P392	50	91	94	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					47	52		10.1126/science.278.5335.47	http://dx.doi.org/10.1126/science.278.5335.47			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311925				2022-12-28	WOS:A1997XZ12400030
J	Dantonel, JC; Murthy, KGK; Manley, JL; Tora, L				Dantonel, JC; Murthy, KGK; Manley, JL; Tora, L			Transcription factor TFIID recruits factor CPSF for formation of 3' end of mRNA	NATURE			English	Article							RNA-POLYMERASE-II; POLYADENYLATION SPECIFICITY FACTOR; ESTROGEN-RECEPTOR; GLOBIN GENE; ACTIVATION; TERMINATION; CLEAVAGE; SUBUNIT; COMPLEX; PROTEIN	Initiation of transcription by RNA polymerase II from a promoter region on DNA requires the assembly of several initiation factors to form a preinitiation complex, Assembly of this complex(1,2) is initiated by the binding of the transcription factor TFIID, composed of the TATA-box binding protein (TBP) and TBP-associated factors (TAF(II)s), to the promoter, We have now characterized an immunopurified TFIID complex which we unexpectedly find contains the cleavage-polyadenylation specificity factor (CPSF), one of the factors required for formation of the 3' end of messenger RNA(3,4). CPSF is brought to the preinitiation complex by TFIID, but after transcription starts, CPSF dissociates from TFIID and becomes associated with the elongating polymerase, We also show that overexpression of recombinant TBP in HeLa cells decreases polyadenylation without affecting the correct initiation of transcription of the reporter gene, This indicates that, owing to incomplete assembly of TFIID on recombinant TBP, CPSF is not brought to the promoter and therefore polyadenylation becomes less efficient. Our observations have thus revealed a link between transcription initiation and elongation by RNA polymerase II and processing of the 3' end of mRNA.	ULP,COLL FRANCE,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 STRASBOURG,FRANCE; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Columbia University			Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Besse Sylvie, 1995, Gene Expression, V4, P143; BIENROTH S, 1991, J BIOL CHEM, V266, P768; BOAM DS, 1995, J BIOL CHEM, V270, P487; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; GERARD M, 1991, J BIOL CHEM, V266, P20940; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LAVIGNE AC, 1996, J BIOL CHEM, V271, P774; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	30	249	250	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					399	402		10.1038/38763	http://dx.doi.org/10.1038/38763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311784				2022-12-28	WOS:A1997XX67500057
J	Ladenson, PW; Braverman, LE; Mazzaferri, EL; BruckerDavis, F; Cooper, DS; Garber, JR; Wondisford, FE; Davies, TF; DeGroot, LJ; Daniels, GH; Ross, DS; Weintraub, BD				Ladenson, PW; Braverman, LE; Mazzaferri, EL; BruckerDavis, F; Cooper, DS; Garber, JR; Wondisford, FE; Davies, TF; DeGroot, LJ; Daniels, GH; Ross, DS; Weintraub, BD			Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HAMSTER OVARY CELLS; SERUM THYROGLOBULIN; STIMULATING HORMONE; CANCER; I-131; BIOACTIVITY; DIAGNOSIS	Background To detect recurrent disease in patients who have had differentiated thyroid cancer, periodic withdrawal of thyroid hormone therapy may be required to raise serum thyrotropin concentrations to stimulate thyroid tissue so that radioiodine (iodine-131) scanning can be performed. However, withdrawal of thyroid hormone therapy causes hypothyroidism. Administration of recombinant human thyrotropin stimulates thyroid tissue without requiring the discontinuation of thyroid hormone thera py. Methods One hundred twenty-seven patients with thyroid cancer underwent whole-body radioiodine scanning by two techniques: first after receiving two doses of thyrotropin while thyroid hormone therapy was continued, and second after the withdrawal of thyroid hormone therapy. The scans were evaluated by reviewers unaware of the conditions of scanning. The serum thyroglobulin concentrations and the prevalence of symptoms of hypothyroidism and mood disorders were also determined. Results Sixty-two of the 127 patients had positive whole-body radioiodine scans by one or both techniques. The scans obtained after stimulation with thyrotropin were equivalent to the scans obtained after withdrawal of thyroid hormone in 41 of these patients (66 percent), superior in 3 (5 percent), and inferior in 18 (29 percent). When the 65 patients with concordant negative scans were included, the two scans were equivalent in 106 patients (83 percent). Eight patients (13 percent of those with at least one positive scan) were treated with radioiodine on the basis of superior scans done after withdrawal of thyroid hormone. Serum thyroglobulin concentrations increased in 15 of 35 tested patients: 14 after withdrawal of thyroid hormone and 13 after administration of thyrotropin. Patients had more symptoms of hypothyroidism (P<0.001) and dysphoric mood states (P<0.001) after withdrawal of thyroid hormone than after administration of thyrotropin. Conclusions Thyrotropin stimulates radioiodine uptake for scanning in patients with thyroid cancer, but the sensitivity of scanning after the administration of thyrotropin is less than that after the withdrawal of thyroid hormone. Thyrotropin scanning is associated with fewer symptoms and dysphoric mood states. (C) 1997, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DIV ENDOCRINOL & METAB, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, THYROID TUMOR CTR, BALTIMORE, MD USA; UNIV MASSACHUSETTS, MED CTR, DIV ENDOCRINOL & METAB, WORCESTER, MA USA; OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; NIDDKD, NIH, BETHESDA, MD 20892 USA; SINAI HOSP, DIV ENDOCRINOL & METAB, BALTIMORE, MD 21215 USA; BETH ISRAEL HOSP, THYROID UNIT, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV ENDOCRINOL & METAB, BOSTON, MA 02215 USA; UNIV CHICAGO, MED CTR, THYROID STUDY UNIT, CHICAGO, IL 60637 USA; MASSACHUSETTS GEN HOSP, THYROID UNIT, BOSTON, MA 02114 USA; MT SINAI MED CTR, DIV ENDOCRINOL & METAB, NEW YORK, NY 10029 USA	Johns Hopkins University; Johns Hopkins University; University of Massachusetts System; University of Massachusetts Worcester; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Sinai Hospital of Baltimore; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Chicago; University of Chicago Medical Center; Harvard University; Massachusetts General Hospital; Icahn School of Medicine at Mount Sinai			Sgouros, George/A-6767-2008	Braverman, Lewis/0000-0003-1263-1099				*AM CANC SOC, 1995, CANC FACTS FIG; BENOTTI J, 1965, CLIN CHEM, V11, P932; BENUA RS, 1964, J NUCL MED, V5, P796; BILLEWICZ WZ, 1969, Q J MED, V38, P255; BRAVERMAN LE, 1992, J CLIN ENDOCR METAB, V74, P1135, DOI 10.1210/jc.74.5.1135; COLE ES, 1993, BIO-TECHNOL, V11, P1014, DOI 10.1038/nbt0993-1014; GOLDBERG LD, 1981, JAMA-J AM MED ASSOC, V245, P953, DOI 10.1001/jama.245.9.953; GOLDMAN JM, 1980, J CLIN ENDOCR METAB, V50, P734, DOI 10.1210/jcem-50-4-734; Guimaraes V, 1996, THYROID, V6, P69, DOI 10.1089/thy.1996.6.69; HUBER GK, 1991, J CLIN ENDOCR METAB, V72, P1328, DOI 10.1210/jcem-72-6-1328; MALOOF F, 1956, J CLIN ENDOCR METAB, V16, P1; MAXON HR, 1990, ENDOCRIN METAB CLIN, V19, P685, DOI 10.1016/S0889-8529(18)30317-7; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; MAZZAFERRI EL, 1995, AM J MED, V98, P215; MEIER CA, 1994, J CLIN ENDOCR METAB, V78, P188, DOI 10.1210/jc.78.1.188; OZATA M, 1994, J CLIN ENDOCR METAB, V79, P98, DOI 10.1210/jc.79.1.98; PACINI F, 1980, CLIN ENDOCRINOL, V13, P107, DOI 10.1111/j.1365-2265.1980.tb01030.x; PARK HM, 1994, THYROID, V4, P49, DOI 10.1089/thy.1994.4.49; Park S.-G., 1996, Journal of Nuclear Medicine, V37, p15P; Ringel MD, 1996, J CLIN ENDOCR METAB, V81, P1724, DOI 10.1210/jc.81.5.1724; ROBBINS J, 1991, ANN INTERN MED, V115, P133, DOI 10.7326/0003-4819-115-2-133; Sfakianakis G N, 1975, Ohio State Med J, V71, P79; SHACHAM S, 1983, J PERS ASSESS, V47, P305, DOI 10.1207/s15327752jpa4703_14; STURGEON CT, 1953, J CLIN ENDOCR METAB, V13, P1391, DOI 10.1210/jcem-13-11-1391; SZKUDLINSKI MW, 1993, ENDOCRINOLOGY, V133, P1490, DOI 10.1210/en.133.4.1490; THOTAKURA NR, 1991, ENDOCRINOLOGY, V128, P341, DOI 10.1210/endo-128-1-341	26	313	325	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					888	896		10.1056/NEJM199709253371304	http://dx.doi.org/10.1056/NEJM199709253371304			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX302	9302303				2022-12-28	WOS:A1997XX30200004
J	Delbanco, TL; Oparil, S				Delbanco, TL; Oparil, S			A 42-year-old man with hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SINGLE-DRUG THERAPY; BLOOD-PRESSURE; ANTIHYPERTENSIVE THERAPY; MYOCARDIAL-INFARCTION; RISK; POPULATION; CALCIUM; SODIUM; MEN		UNIV ALABAMA, SCH MED, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham								ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1997, LANCET, V349, P594, DOI 10.1016/S0140-6736(96)08359-6; *AM SOC HYPT, 1995, AM J HYPERTENS, V5, P207; [Anonymous], 1996, JAMA, V276, P241; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Braun S, 1996, J AM COLL CARDIOL, V28, P7, DOI 10.1016/0735-1097(96)00109-X; BULPITT CJ, 1985, HDB HYPERTENSION, V6, P291; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CALHOUN DA, 1993, HYPERTENSION, V22, P801, DOI 10.1161/01.HYP.22.6.801; CAMPESE VM, 1991, HYPERTENSION, V18, P805, DOI 10.1161/01.HYP.18.6.805; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; EISENBERG DM, 1993, ANN INTERN MED, V118, P964, DOI 10.7326/0003-4819-118-12-199306150-00009; Epstein M, 1996, ARCH INTERN MED, V156, P1969, DOI 10.1001/archinte.156.17.1969; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Grimm RH, 1997, HYPERTENSION, V29, P8, DOI 10.1161/01.HYP.29.1.8; HARBURG E, 1973, J CHRON DIS, V26, P595, DOI 10.1016/0021-9681(73)90064-7; Jamerson Kenneth, 1996, American Journal of Medicine, V101, p22S, DOI 10.1016/S0002-9343(96)00265-3; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; JONES JK, 1995, BMJ-BRIT MED J, V311, P293, DOI 10.1136/bmj.311.7000.293; KEIL JE, 1977, AM J PUBLIC HEALTH, V67, P634, DOI 10.2105/AJPH.67.7.634; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; LANGFORD HG, 1985, HYPERTENSION BLACKS, P49; Lindquist TL, 1997, HYPERTENSION, V29, P1; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MATERSON BJ, 1995, AM J HYPERTENS, V8, P189, DOI 10.1016/0895-7061(94)00196-I; MBUYAMBAKABANGU JR, 1994, J HUM HYPERTENS, V8, P163; McCarron DA, 1997, ARCH INTERN MED, V157, P169, DOI 10.1001/archinte.157.2.169; MCCARRON DA, 1982, SCIENCE, V217, P267, DOI 10.1126/science.7089566; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; Miller NH, 1997, CIRCULATION, V95, P1085; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; Oparil S, 1996, CARDIOVASC RISK FACT, V6, P222; OPARIL S, IN PRESS SCI AM MED; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; SETARO JF, 1992, NEW ENGL J MED, V327, P543; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; Sudhir K, 1997, HYPERTENSION, V29, P1083, DOI 10.1161/01.HYP.29.5.1083; *US REN DAT SYST, 1996, USRDS 1996; WARD R, 1990, HYPERTENSION PATHOPH, P81; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624	47	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1015	1021						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307351				2022-12-28	WOS:A1997XX01200034
J	Mercer, BM; Miodovnik, M; Thurnau, GR; Goldenberg, RL; Das, AF; Ramsey, RD; Rabello, YA; Meis, PJ; Moawad, AH; Iams, JD; VanDorsten, JP; Paul, RH; Bottoms, SF; Merenstein, G; Thom, EA; Roberts, JM; McNellis, D				Mercer, BM; Miodovnik, M; Thurnau, GR; Goldenberg, RL; Das, AF; Ramsey, RD; Rabello, YA; Meis, PJ; Moawad, AH; Iams, JD; VanDorsten, JP; Paul, RH; Bottoms, SF; Merenstein, G; Thom, EA; Roberts, JM; McNellis, D			Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; ANTIMICROBIAL THERAPY; DOUBLE-BLIND; INTRAAMNIOTIC INFECTION; EXPECTANT MANAGEMENT; CLINICAL-TRIALS; GRAM STAIN; AMNIOCENTESIS; PROPHYLAXIS; AMPICILLIN	Context.-Intrauterine infection is thought to be one cause of preterm premature rupture of the membranes (PPROM). Antibiotic therapy has been shown to prolong pregnancy, but the effect on infant morbidity has been inconsistent. Objective.-To determine if antibiotic treatment during expectant management of PPROM will reduce infant morbidity. Design.-Randomized, double-blind, placebo-controlled trial. Setting.-University hospitals of the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Patients.-A total of 614 of 804 eligible gravidas with PPROM between 24 weeks' and 0 days' and 32 weeks' and 0 days' gestation who were considered candidates for pregnancy prolongation and had not received corticosteroids for fetal maturation or antibiotic treatment within 1 week of randomization. Interventions.-Intravenous ampicillin (2-g dose every 6 hours) and erythromycin (250-mg dose every 6 hours) for 48 hours followed by oral amoxicillin (250-mg dose every 8 hours) and erythromycin base (333-mg dose every 8 hours) for 5 days vs a matching placebo regimen, Group B streptococcus (GBS) carriers were identified and treated, Tocolysis and corticosteroids were prohibited after randomization. Main Outcome Measures.-The composite primary outcome included pregnancies complicated by at least one of the following: fetal or infant death, respiratory distress, severe intraventricular hemorrhage, stage 2 or 3 necrotizing enterocolitis, or sepsis within 72 hours of birth, These perinatal morbidities were also evaluated individually and pregnancy prolongation was assessed. Results.-In the total study population, the primary outcome (44.1% vs 52.9%; P=.04), respiratory distress (40.5% vs 48.7%; P=.04), and necrotizing enterocolitis (2.3% vs 5.8%; P=.03) were less frequent with antibiotics. In the GBS-negative cohort, the antibiotic group had less frequent primary outcome (44.5% vs 54.5%; P=.03), respiratory distress (40.8% vs 50.6%; P=.03), overall sepsis (8.4% vs 15.6%; P=.01), pneumonia (2.9% vs 7.0%; P=.04), and other morbidities. Among GBS-negative women, significant pregnancy prolongation was seen with antibiotics (P<.001). Conclusions.-We recommend that women with expectantly managed PPROM remote from term receive antibiotics to reduce infant morbidity.	UNIV CINCINNATI,CINCINNATI,OH 45221; UNIV OKLAHOMA,OKLAHOMA CITY,OK; UNIV ALABAMA,BIRMINGHAM,AL; GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052; UNIV SO CALIF,LOS ANGELES,CA 90089; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC; UNIV CHICAGO,CHICAGO,IL 60637; OHIO STATE UNIV,COLUMBUS,OH 43210; MED UNIV S CAROLINA,CHARLESTON,SC 29425; WAYNE STATE UNIV,DETROIT,MI 48202; UNIV COLORADO,DENVER,CO 80202; UNIV PITTSBURGH,PITTSBURGH,PA 15260; NICHHD,BETHESDA,MD 20892	University System of Ohio; University of Cincinnati; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Alabama System; University of Alabama Birmingham; George Washington University; University of Southern California; Wake Forest University; Wake Forest Baptist Medical Center; University of Chicago; University System of Ohio; Ohio State University; Medical University of South Carolina; Wayne State University; University of Colorado System; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mercer, BM (corresponding author), UNIV TENNESSEE,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,853 JEFFERSON AVE,SUITE E102,MEMPHIS,TN 38103, USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027915, U10HD027917] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021434] Funding Source: NIH RePORTER; NICHD NIH HHS [U10-HD-21434, U10-HD-27915, U10-HD-27917] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALGER LS, 1988, AM J OBSTET GYNECOL, V159, P397, DOI 10.1016/S0002-9378(88)80093-0; AMON E, 1988, AM J OBSTET GYNECOL, V159, P539, DOI 10.1016/S0002-9378(88)80002-4; Blanco J., 1993, American Journal of Obstetrics and Gynecology, V168, P378; BROEKHUIZEN FF, 1985, OBSTET GYNECOL, V66, P316; CHRISTMAS JT, 1992, OBSTET GYNECOL, V80, P759; *COMM INF DIS COMM, 1992, PEDIATRICS, V90, P775; COTTON DB, 1984, OBSTET GYNECOL, V63, P38; DEBODINANCE P, 1990, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V19, P533; DUNLOP PDM, 1986, J OBSTET GYNAECOL, V7, P92, DOI 10.3109/01443618609112279; ERNEST JM, 1994, AM J OBSTET GYNECOL, V170, P516, DOI 10.1016/S0002-9378(94)70220-9; GARITE TJ, 1982, OBSTET GYNECOL, V59, P539; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; GOCHAY DW, 1992, OBSTET GYNECOL, V80, P102; GORDON M, 1974, CONTROVERSY OBSTETRI, V2, P42; HILLIER SL, 1993, OBSTET GYNECOL, V81, P941; JOHNSTON MM, 1990, AM J OBSTET GYNECOL, V163, P743, DOI 10.1016/0002-9378(90)91060-P; KURKI T, 1992, AM J PERINAT, V9, P11, DOI 10.1055/s-2007-994661; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEWIS DF, 1995, OBSTET GYNECOL, V86, P392, DOI 10.1016/0029-7844(95)00181-P; LOCKWOOD CJ, 1993, AM J OBSTET GYNECOL, V169, P970, DOI 10.1016/0002-9378(93)90037-J; MCCAUL JF, 1992, INT J GYNECOL OBSTET, V38, P19, DOI 10.1016/0020-7292(92)90724-W; MCGREGOR J A, 1988, Obstetrical and Gynecological Survey, V43, P1; MCGREGOR JA, 1991, AM J OBSTET GYNECOL, V165, P632, DOI 10.1016/0002-9378(91)90299-7; MEIS PJ, 1987, AM J OBSTET GYNECOL, V156, P1165, DOI 10.1016/0002-9378(87)90133-5; MERCER BM, 1992, AM J OBSTET GYNECOL, V166, P794, DOI 10.1016/0002-9378(92)91336-9; MERCER BM, 1995, LANCET, V346, P1271, DOI 10.1016/S0140-6736(95)91868-X; MORALES WJ, 1989, OBSTET GYNECOL, V73, P721; *NIH, 1995, AM J OBSTET GYNECOL, V173, P246; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OWEN J, 1993, AM J OBSTET GYNECOL, V169, P976, DOI 10.1016/0002-9378(93)90038-K; *PREV EARL ONS GRO, 1996, COMM OP ACOG COMM OB, P1; ROMERO R, 1991, CLIN OBSTET GYNECOL, V34, P769, DOI 10.1097/00003081-199112000-00013; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P114, DOI 10.1016/0002-9378(88)90503-0; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P661, DOI 10.1016/S0002-9378(88)80030-9; Schuchat A., 1996, MMWR RECOMM REP, V45, P1; VINTZILEOS AM, 1986, OBSTET GYNECOL, V67, P579; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7	37	347	376	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					989	995		10.1001/jama.278.12.989	http://dx.doi.org/10.1001/jama.278.12.989			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307346				2022-12-28	WOS:A1997XX01200029
J	Cumming, BG; Parker, AJ				Cumming, BG; Parker, AJ			Responses of primary visual cortical neurons to binocular disparity without depth perception	NATURE			English	Article							HUMAN STEREO VISION; CORTEX; MONKEY	The identification of brain regions that are associated with the conscious perception of visual stimuli is a major goal in neuroscience(1). Here we present a test of whether the signals on neurons in cortical area V1 correspond directly to our conscious perception of binocular stereoscopic depth. Depth perception requires that image features on one retina are first matched with appropriate features on the other retina. The mechanisms that perform this matching can be examined by using random-dot stereograms(2), in which the left and right eyes view randomly positioned but binocularly correlated dots. We exploit the fact that anticorrelated random-dot stereograms (in which dots in one eye are matched geometrically to dots of the opposite contrast in the other eye) do not give rise to the perception of depth(3) because the matching process does not find a consistent solution. Anticorrelated random-dot stereograms contain binocular features that could excite neurons that have not solved the correspondence problem. We demonstrate that disparity-selective neurons in V1 signal the disparity of anticorrelated random-dot stereograms, indicating that they do not unambiguously signal stereoscopic depth. Hence single V1 neurons cannot account for the conscious perception of stereopsis, although combining the outputs of many V1 neurons could solve the matching problem. The accompanying paper(4) suggests an additional function for disparity signals from V1: they may be important for the rapid involuntary control of vergence eye movements (eye movements that bring the images on the two foveae into register).			Cumming, BG (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Parker, Andrew J/I-7867-2013	Parker, Andrew J/0000-0001-5800-0407	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; GRIMSON WEL, 1981, PHILOS T ROY SOC B, V292, P217, DOI 10.1098/rstb.1981.0031; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; Masson GS, 1997, NATURE, V389, P283, DOI 10.1038/38496; NIKARA T, 1968, EXP BRAIN RES, V6, P353; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; POGGIO GF, 1984, ANNU REV NEUROSCI, V7, P379, DOI 10.1146/annurev.ne.07.030184.002115; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; POGGIO GF, 1995, CEREB CORTEX, V3, P193; QIAN N, 1994, NEURAL COMPUT, V6, P390, DOI 10.1162/neco.1994.6.3.390; SKOTTUN BC, 1991, VISION RES, V31, P1079, DOI 10.1016/0042-6989(91)90033-2	17	310	315	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					280	283		10.1038/38487	http://dx.doi.org/10.1038/38487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305841				2022-12-28	WOS:A1997XW77200046
J	Luger, K; Mader, AW; Richmond, RK; Sargent, DF; Richmond, TJ				Luger, K; Mader, AW; Richmond, RK; Sargent, DF; Richmond, TJ			Crystal structure of the nucleosome core particle at 2.8 angstrom resolution	NATURE			English	Article							X-RAY-DIFFRACTION; CHROMATIN; DNA; TRANSCRIPTION; HISTONE; PROTEIN; MODEL; BINDING; YEAST; INTEGRATION	The X-ray crystal structure of the nucleosome cave particle of chromatin shows in atomic detail how the histone protein octamer is assembled and how 146 base pairs of DNA are organized into a superhelix around it. Both histone/histone and histone/DNA interactions depend on the histone fold domains and additional, well ordered structure elements extending from this motif. Histone amino-terminal tails pass over and between the gyres of the DNA superhelix to contact neighbouring particles. The lack of uniformity between multiple histone/DNA-binding sites causes the DNA to deviate from ideal superhelix geometry.	ETH HONGGERBERG, ETHZ, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich				SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Blank TA, 1996, J MOL BIOL, V260, P1, DOI 10.1006/jmbi.1996.0377; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BRUNGER A, 1992, X PLOR V3 1 MANUAL; CAMERINIOTERO RD, 1977, P NATL ACAD SCI USA, V74, P5519, DOI 10.1073/pnas.74.12.5519; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; FINCH JT, 1979, FEBS P M, V51, P193; Flaus A, 1996, P NATL ACAD SCI USA, V93, P1370, DOI 10.1073/pnas.93.4.1370; FLAUS A, IN PRESS J MOL BIOL; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Harp JM, 1996, ACTA CRYSTALLOGR D, V52, P283, DOI 10.1107/S0907444995009139; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LUGER K, IN PRESS J MOL BIOL; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHALLORAN TV, 1987, J MOL BIOL, V194, P705, DOI 10.1016/0022-2836(87)90248-8; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1989, METHOD ENZYMOL, V170, P420; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Starich MR, 1996, J MOL BIOL, V255, P187, DOI 10.1006/jmbi.1996.0016; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; van Holde K.E., 1988, CHROMATIN; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YANG TP, 1982, P NATL ACAD SCI-BIOL, V79, P6593, DOI 10.1073/pnas.79.21.6593	51	6531	6744	11	640	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					251	260		10.1038/38444	http://dx.doi.org/10.1038/38444			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305837				2022-12-28	WOS:A1997XW77200038
J	Sapolsky, RM				Sapolsky, RM			The importance of a well-groomed child	SCIENCE			English	Editorial Material							NEUROENDOCRINE				Sapolsky, RM (corresponding author), STANFORD UNIV,DEPT BIOL,STANFORD,CA 94305, USA.							Francis D, 1996, ANN NY ACAD SCI, V794, P136, DOI 10.1111/j.1749-6632.1996.tb32517.x; GAULIN S, 1995, COGNITIVE NEUROSCIEN; JACOBS LF, 1994, BRAIN BEHAV EVOLUT, V44, P125, DOI 10.1159/000113584; LEVINE S, 1957, SCIENCE, V126, P405, DOI 10.1126/science.126.3270.405; Levine S., 1975, SOC STRESS DIS, P43; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEANEY MJ, UNPUB; SCHANBERG SM, 1984, P SOC EXP BIOL MED, V175, P135	9	60	60	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1620	1621		10.1126/science.277.5332.1620	http://dx.doi.org/10.1126/science.277.5332.1620			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9312858				2022-12-28	WOS:A1997XV68400036
